data_5gvq_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 5gvq _Structure_validation_residue.Date_analyzed 2017-04-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.613 0 N-CA-C 111.463 -0.655 . . . . 0.0 111.463 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.7 m -60.09 -23.26 63.66 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 114.879 1.437 . . . . 0.0 114.879 -171.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.7 m -60.7 -23.73 65.1 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.539 1.135 . . . . 0.0 113.427 174.744 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -85.88 -7.08 81.62 Favored Glycine 0 CA--C 1.538 1.484 0 C-N-CA 125.038 1.304 . . . . 0.0 115.169 176.46 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 50.6 m -78.44 -8.9 59.02 Favored 'General case' 0 N--CA 1.478 0.93 0 CA-C-N 119.048 1.424 . . . . 0.0 114.7 -173.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 9.2 t -148.42 155.7 41.55 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 125.275 1.43 . . . . 0.0 111.513 175.099 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -74.43 155.1 48.32 Favored Glycine 0 CA--C 1.543 1.838 0 C-N-CA 124.09 0.852 . . . . 0.0 114.054 -179.411 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -72.56 161.2 44.72 Favored 'Trans proline' 0 CA--C 1.54 0.805 0 C-N-CA 123.821 3.014 . . . . 0.0 112.627 176.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.2 tp -145.64 147.97 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 C-N-CA 124.871 1.269 . . . . 0.0 111.359 175.242 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 22.9 m -72.6 -23.33 60.93 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.928 0.891 . . . . 0.0 113.356 178.596 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -63.84 133.16 52.87 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 125.032 1.333 . . . . 0.0 113.396 -172.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 5.9 mmp_? -88.92 150.74 22.71 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 125.525 1.53 . . . . 0.0 111.142 175.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -140.05 130.9 26.0 Favored 'General case' 0 CA--C 1.547 0.832 0 N-CA-C 113.776 1.028 . . . . 0.0 113.776 -175.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 40.4 mt-30 -80.9 -10.64 59.69 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 115.387 1.625 . . . . 0.0 115.387 -175.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 47.7 m-20 -91.96 -34.04 14.62 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-N 119.828 1.195 . . . . 0.0 111.645 171.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -77.7 -13.85 59.78 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 124.389 1.076 . . . . 0.0 112.832 169.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 29.9 m -94.56 136.07 35.29 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 124.36 1.064 . . . . 0.0 110.002 169.158 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 4.7 m -103.13 147.67 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 C-N-CA 124.765 1.226 . . . . 0.0 109.912 170.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 30.3 t80 -95.11 142.22 27.81 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 126.265 1.826 . . . . 0.0 109.277 169.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 22.8 t -132.18 107.05 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 C-N-CA 125.699 1.6 . . . . 0.0 109.15 176.352 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -103.4 145.47 16.22 Favored Glycine 0 CA--C 1.529 0.923 0 C-N-CA 124.452 1.025 . . . . 0.0 112.747 177.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.12 32.14 6.91 Favored Glycine 0 CA--C 1.534 1.225 0 C-N-CA 124.489 1.042 . . . . 0.0 113.897 175.209 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 85.2 mt -74.06 145.57 44.34 Favored 'General case' 0 C--O 1.234 0.267 0 C-N-CA 125.382 1.473 . . . . 0.0 111.312 -175.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -85.02 158.05 20.57 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 123.14 0.576 . . . . 0.0 112.479 174.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -58.51 -20.85 49.44 Favored 'General case' 0 CA--C 1.545 0.785 0 N-CA-C 114.462 1.282 . . . . 0.0 114.462 178.127 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.4 mtmm -79.66 -11.69 59.85 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 114.36 1.244 . . . . 0.0 114.36 174.16 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 67.0 t -74.48 142.82 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 124.583 1.153 . . . . 0.0 111.519 178.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 90.6 p -137.82 162.96 32.6 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 125.418 1.487 . . . . 0.0 111.941 174.116 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -58.15 -44.45 99.27 Favored Pre-proline 0 CA--C 1.548 0.874 0 O-C-N 121.0 -1.062 . . . . 0.0 112.963 176.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_exo -58.9 -31.82 96.18 Favored 'Trans proline' 0 C--N 1.354 0.856 0 C-N-CA 122.544 2.163 . . . . 0.0 114.275 171.483 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 21.1 tp -65.85 -53.58 38.08 Favored 'General case' 0 C--N 1.344 0.361 0 CA-C-N 119.261 0.937 . . . . 0.0 109.67 173.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 24.7 mt -55.47 -42.3 74.14 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 119.497 -0.287 . . . . 0.0 111.458 -178.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.8 t90 -57.68 -62.49 1.76 Allowed 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.221 0.608 . . . . 0.0 111.176 177.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -65.03 -30.03 70.97 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 113.881 1.067 . . . . 0.0 113.881 -176.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.2 tp -71.06 -37.32 72.5 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.123 0.969 . . . . 0.0 111.823 176.086 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.3 m-85 -87.71 -10.6 50.71 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 124.861 1.264 . . . . 0.0 113.439 -175.801 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 24.4 mt -54.03 -21.96 9.5 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 124.373 1.069 . . . . 0.0 113.847 169.23 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 41.8 mt-30 -64.11 -31.15 72.24 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 125.224 1.41 . . . . 0.0 112.608 174.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -78.17 -46.13 21.35 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 123.509 0.723 . . . . 0.0 112.362 176.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 178.81 -172.64 44.93 Favored Glycine 0 CA--C 1.536 1.404 0 C-N-CA 124.835 1.207 . . . . 0.0 112.969 -179.086 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -67.86 110.84 2.24 Favored 'Trans proline' 0 CA--C 1.537 0.632 0 C-N-CA 123.689 2.926 . . . . 0.0 111.736 -178.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 87.7 t -85.7 134.04 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 124.962 1.305 . . . . 0.0 110.016 174.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 4.4 t -109.12 -33.86 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 C-N-CA 126.458 1.903 . . . . 0.0 112.068 -172.48 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 10.9 t30 -160.38 157.65 28.21 Favored 'General case' 0 CA--C 1.552 1.028 0 C-N-CA 125.91 1.684 . . . . 0.0 110.975 -171.034 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 7.5 p -140.03 152.53 46.31 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 126.314 1.846 . . . . 0.0 111.37 174.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 47.3 t-80 -142.46 133.88 26.41 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 123.467 0.707 . . . . 0.0 111.424 174.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 82.9 mtp -133.73 106.21 11.76 Favored Pre-proline 0 N--CA 1.471 0.615 0 C-N-CA 124.215 1.006 . . . . 0.0 109.338 169.501 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_exo -57.27 140.95 94.42 Favored 'Trans proline' 0 CA--C 1.538 0.704 0 C-N-CA 123.278 2.652 . . . . 0.0 113.292 178.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 44.3 mmtm -111.48 145.01 39.78 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 125.204 1.402 . . . . 0.0 112.812 -173.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -67.82 144.0 55.53 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 125.952 1.701 . . . . 0.0 112.636 174.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 18.0 ptp180 -86.86 7.53 26.76 Favored 'General case' 0 N--CA 1.478 0.967 0 N-CA-C 115.927 1.825 . . . . 0.0 115.927 -174.117 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 38.2 t -131.31 -37.36 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 124.972 1.309 . . . . 0.0 111.389 -174.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 73.0 p -115.04 -14.58 11.82 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 125.791 1.637 . . . . 0.0 112.555 -176.259 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.43 4.09 50.11 Favored Glycine 0 CA--C 1.538 1.493 0 C-N-CA 125.117 1.341 . . . . 0.0 115.502 176.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 71.9 mm-40 -77.37 162.79 26.98 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 124.677 1.191 . . . . 0.0 110.846 177.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 17.8 p80 -68.96 152.89 44.7 Favored 'General case' 0 N--CA 1.472 0.637 0 O-C-N 120.853 -1.154 . . . . 0.0 112.343 176.417 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 47.5 mt-30 -85.3 18.01 2.84 Favored 'General case' 0 CA--C 1.549 0.907 0 N-CA-C 114.355 1.242 . . . . 0.0 114.355 -172.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.6 2.69 84.55 Favored Glycine 0 CA--C 1.535 1.305 0 C-N-CA 125.022 1.296 . . . . 0.0 115.002 179.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -144.74 159.74 42.36 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 124.732 1.213 . . . . 0.0 112.443 177.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -150.95 -178.13 25.48 Favored Glycine 0 CA--C 1.529 0.953 0 C-N-CA 125.853 1.692 . . . . 0.0 113.264 -176.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -144.78 148.22 33.82 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 126.026 1.73 . . . . 0.0 111.595 -176.586 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 20.2 t -134.65 127.91 50.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 C-N-CA 124.841 1.256 . . . . 0.0 109.762 175.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 44.8 tt0 -108.51 127.25 53.76 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.252 1.021 . . . . 0.0 111.765 -177.762 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -100.24 162.69 12.8 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 125.552 1.541 . . . . 0.0 112.493 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.6 tp -62.22 -32.64 73.33 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 123.02 0.528 . . . . 0.0 112.398 177.282 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.0 m -144.99 157.26 44.19 Favored 'General case' 0 N--CA 1.47 0.525 0 C-N-CA 124.104 0.962 . . . . 0.0 111.768 -178.602 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -61.55 -36.78 81.56 Favored 'General case' 0 N--CA 1.472 0.671 0 O-C-N 121.576 -0.703 . . . . 0.0 112.777 -178.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -64.9 -23.51 67.25 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 113.592 0.96 . . . . 0.0 113.592 179.221 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -80.55 -33.62 36.08 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 124.215 1.006 . . . . 0.0 111.668 172.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -71.26 -44.75 64.68 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 123.835 0.854 . . . . 0.0 111.741 174.468 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -61.39 -30.19 70.4 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.826 1.25 . . . . 0.0 112.253 179.269 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 59.9 t80 -78.24 -36.45 47.0 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.336 1.054 . . . . 0.0 113.044 173.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.15 -38.4 88.85 Favored 'General case' 0 CA--C 1.539 0.544 0 O-C-N 121.115 -0.991 . . . . 0.0 111.211 176.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 59.7 mt -61.24 -35.91 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 C-N-CA 124.988 1.315 . . . . 0.0 111.308 173.475 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -69.01 -37.34 78.63 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 124.138 0.975 . . . . 0.0 113.102 176.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 19.1 pt -99.16 -14.74 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 N-CA-C 116.143 1.905 . . . . 0.0 116.143 -172.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 12.2 mmt -112.28 -2.66 14.78 Favored 'General case' 0 N--CA 1.483 1.203 0 N-CA-C 115.149 1.537 . . . . 0.0 115.149 -176.37 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -81.88 145.25 30.46 Favored 'General case' 0 N--CA 1.475 0.812 0 O-C-N 120.863 -1.148 . . . . 0.0 113.863 -176.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 28.5 ttm 60.33 13.42 3.98 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 127.316 2.246 . . . . 0.0 115.115 -179.237 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 18.0 mt -87.3 152.04 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 C-N-CA 127.96 2.504 . . . . 0.0 111.645 -179.297 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 43.6 mtpt -104.64 72.07 1.02 Allowed 'General case' 0 N--CA 1.473 0.678 0 C-N-CA 124.467 1.107 . . . . 0.0 112.634 -171.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 31.4 tp -57.34 125.01 20.9 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.747 0.819 . . . . 0.0 109.73 173.3 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 63.6 m-85 46.44 28.69 0.77 Allowed 'General case' 0 CA--C 1.561 1.381 0 N-CA-C 116.326 1.973 . . . . 0.0 116.326 -168.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.77 27.46 53.77 Favored Glycine 0 CA--C 1.541 1.709 0 O-C-N 120.124 -1.61 . . . . 0.0 115.751 177.047 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 33.0 ttmt -143.4 120.41 6.75 Favored Pre-proline 0 CA--C 1.543 0.709 0 C-N-CA 128.453 2.701 . . . . 0.0 107.646 -175.739 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -71.27 127.66 13.68 Favored 'Trans proline' 0 CA--C 1.537 0.636 0 C-N-CA 123.059 2.506 . . . . 0.0 113.458 -168.227 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 21.5 pt -97.91 143.28 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 125.127 1.371 . . . . 0.0 112.156 174.663 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 47.9 tpt85 -108.38 127.68 54.1 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 126.246 1.818 . . . . 0.0 109.013 173.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 19.7 t -124.81 135.47 63.88 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 124.418 1.087 . . . . 0.0 111.064 -173.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 38.5 t-20 -159.29 175.42 13.41 Favored 'General case' 0 CA--C 1.55 0.959 0 C-N-CA 125.182 1.393 . . . . 0.0 111.122 -179.18 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.9 mmmm -62.9 140.16 58.8 Favored 'General case' 0 N--CA 1.48 1.055 0 O-C-N 120.614 -1.304 . . . . 0.0 109.99 172.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -72.33 -4.27 28.85 Favored 'General case' 0 CA--C 1.55 0.95 0 N-CA-C 113.652 0.982 . . . . 0.0 113.652 177.174 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 62.6 p -86.72 -5.61 59.07 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 127.029 2.132 . . . . 0.0 113.361 169.408 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -134.66 177.9 7.42 Favored 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 126.312 1.845 . . . . 0.0 112.404 -175.008 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -120.49 -69.99 0.81 Allowed 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 124.75 1.22 . . . . 0.0 111.467 176.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 49.4 t30 -142.79 160.78 39.66 Favored 'General case' 0 CA--C 1.547 0.846 0 C-N-CA 125.247 1.419 . . . . 0.0 111.329 177.534 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 36.1 ttpt -71.74 134.12 46.03 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 124.426 1.091 . . . . 0.0 111.526 -178.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 21.9 t-20 -103.21 -25.52 13.32 Favored 'General case' 0 CA--C 1.546 0.812 0 N-CA-C 114.355 1.243 . . . . 0.0 114.355 -175.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 96.0 mt -132.78 157.24 45.46 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 125.781 1.632 . . . . 0.0 111.782 -175.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 2.5 t -149.71 165.41 32.46 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 124.472 1.109 . . . . 0.0 112.022 176.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -177.79 178.37 48.43 Favored Glycine 0 CA--C 1.54 1.625 0 C-N-CA 124.455 1.026 . . . . 0.0 114.224 -178.46 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 98.7 Cg_endo -71.31 160.41 48.88 Favored 'Trans proline' 0 CA--C 1.541 0.855 0 C-N-CA 124.125 3.217 . . . . 0.0 112.975 -179.284 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 20.2 m -71.94 -16.71 62.1 Favored 'General case' 0 N--CA 1.477 0.887 0 N-CA-C 114.422 1.268 . . . . 0.0 114.422 -177.16 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.3 t -150.51 161.44 42.54 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 125.7 1.6 . . . . 0.0 111.466 177.049 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.299 0 C-N-CA 125.632 1.587 . . . . 0.0 113.864 -179.573 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.638 0 N-CA-C 112.089 -0.404 . . . . 0.0 112.089 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 66.7 p -63.17 -14.62 51.0 Favored 'General case' 0 N--CA 1.479 0.998 0 N-CA-C 115.123 1.527 . . . . 0.0 115.123 -174.74 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.1 m -67.35 -14.9 63.34 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 125.219 1.408 . . . . 0.0 114.055 171.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -64.47 152.52 49.79 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 124.011 0.815 . . . . 0.0 112.995 174.241 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.8 m -59.59 -25.99 65.07 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 114.997 1.48 . . . . 0.0 114.997 -169.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 17.2 m -83.4 -6.83 59.58 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 124.878 1.271 . . . . 0.0 114.123 177.178 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 57.96 50.53 65.11 Favored Glycine 0 CA--C 1.542 1.749 0 C-N-CA 124.956 1.265 . . . . 0.0 113.986 -171.35 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -68.81 150.81 74.15 Favored 'Trans proline' 0 CA--C 1.54 0.795 0 C-N-CA 123.237 2.625 . . . . 0.0 113.738 -169.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 18.6 tt -87.69 152.62 3.38 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.681 0 C-N-CA 125.645 1.578 . . . . 0.0 111.623 175.398 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 52.4 p -81.67 -1.25 46.12 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 125.286 1.434 . . . . 0.0 114.787 179.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . 0.292 10.8 pt-20 50.26 29.74 3.93 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 127.706 2.402 . . . . 0.0 116.416 174.038 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.93 156.54 39.59 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 126.348 1.859 . . . . 0.0 112.5 -179.103 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 33.8 t-20 50.07 52.6 14.38 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 126.125 1.77 . . . . 0.0 114.062 177.534 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 24.0 mp0 -58.9 -24.36 62.24 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 124.683 1.193 . . . . 0.0 112.838 177.345 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -69.04 -23.63 64.08 Favored 'General case' 0 N--CA 1.471 0.619 0 O-C-N 120.982 -1.074 . . . . 0.0 113.501 174.062 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -85.42 1.75 47.37 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 123.966 0.906 . . . . 0.0 112.702 169.282 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 25.2 m -100.68 135.44 42.12 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.424 1.09 . . . . 0.0 109.699 170.049 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.9 m -102.59 148.28 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 C-N-CA 124.355 1.062 . . . . 0.0 110.53 172.186 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 32.5 t80 -95.44 142.77 27.42 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 126.374 1.869 . . . . 0.0 109.3 169.319 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 22.1 t -131.96 113.12 21.43 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 C-N-CA 125.75 1.62 . . . . 0.0 109.147 177.073 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -110.65 145.78 17.39 Favored Glycine 0 CA--C 1.531 1.037 0 C-N-CA 124.494 1.045 . . . . 0.0 113.104 178.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 97.23 30.75 7.21 Favored Glycine 0 CA--C 1.534 1.238 0 C-N-CA 124.763 1.173 . . . . 0.0 113.905 176.313 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 86.9 mt -73.67 145.39 45.32 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 125.316 1.446 . . . . 0.0 111.345 -173.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -84.53 157.58 21.23 Favored 'General case' 0 CA--C 1.542 0.64 0 N-CA-C 112.441 0.534 . . . . 0.0 112.441 175.288 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -58.71 -20.59 50.22 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 114.485 1.291 . . . . 0.0 114.485 178.05 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.1 mtmm -81.25 -7.86 59.65 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 114.42 1.267 . . . . 0.0 114.42 174.463 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 85.7 t -77.3 138.55 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 C-N-CA 124.519 1.128 . . . . 0.0 111.498 178.086 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 52.6 m -135.07 163.25 30.31 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 124.876 1.27 . . . . 0.0 111.522 172.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -56.15 -42.64 97.22 Favored Pre-proline 0 CA--C 1.548 0.881 0 O-C-N 120.774 -1.204 . . . . 0.0 114.038 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 66.7 Cg_exo -60.92 -28.54 86.49 Favored 'Trans proline' 0 C--N 1.354 0.831 0 C-N-CA 122.236 1.958 . . . . 0.0 114.099 174.005 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 27.2 tp -67.88 -51.49 47.48 Favored 'General case' 0 C--N 1.344 0.328 0 CA-C-N 118.591 0.632 . . . . 0.0 109.981 172.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 20.6 mt -61.54 -23.17 65.76 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 112.801 0.667 . . . . 0.0 112.801 178.952 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.5 t90 -73.2 -66.13 0.72 Allowed 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 123.348 0.659 . . . . 0.0 111.101 171.208 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 39.0 mt-10 -66.12 -29.99 70.4 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 -172.313 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.1 tp -69.13 -33.22 73.11 Favored 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 123.794 0.837 . . . . 0.0 111.872 175.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 19.1 m-85 -90.98 -11.2 39.68 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.996 1.318 . . . . 0.0 113.422 -175.101 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 47.2 mt -55.46 -18.51 7.2 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 114.024 1.12 . . . . 0.0 114.024 169.501 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 40.8 mt-30 -65.18 -32.81 74.68 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 125.261 1.424 . . . . 0.0 112.684 173.464 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.23 -45.48 19.74 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 123.581 0.752 . . . . 0.0 112.608 177.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.86 -172.33 43.94 Favored Glycine 0 CA--C 1.537 1.438 0 C-N-CA 124.759 1.171 . . . . 0.0 112.997 179.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -67.71 110.68 2.17 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 123.745 2.964 . . . . 0.0 111.58 -179.076 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 65.2 t -86.33 131.85 33.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 C-N-CA 124.848 1.259 . . . . 0.0 109.667 174.01 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 7.8 t -107.3 -33.71 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 C-N-CA 126.58 1.952 . . . . 0.0 111.715 -171.248 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 19.9 t30 -160.89 165.51 29.97 Favored 'General case' 0 CA--C 1.553 1.088 0 C-N-CA 126.135 1.774 . . . . 0.0 111.016 -175.323 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 4.4 p -141.15 156.61 45.93 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 126.233 1.813 . . . . 0.0 111.348 174.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 2.6 t60 -142.32 136.7 29.96 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 123.952 0.901 . . . . 0.0 110.886 174.755 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 88.2 mtp -138.98 102.82 7.5 Favored Pre-proline 0 N--CA 1.472 0.645 0 C-N-CA 124.117 0.967 . . . . 0.0 109.273 169.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_exo -55.73 137.39 78.22 Favored 'Trans proline' 0 CA--C 1.537 0.671 0 C-N-CA 123.412 2.741 . . . . 0.0 113.301 177.341 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 44.4 mmtm -107.72 146.77 31.66 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 125.251 1.421 . . . . 0.0 112.681 -174.31 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -71.36 150.44 45.06 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 125.527 1.531 . . . . 0.0 112.672 175.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 39.9 ptt180 -89.58 -1.5 58.04 Favored 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 -173.002 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 3.5 m -135.01 -31.55 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 C-N-CA 124.687 1.195 . . . . 0.0 113.289 -178.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.4 p -103.72 -20.32 14.0 Favored 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 125.021 1.329 . . . . 0.0 111.905 179.302 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.99 0.52 35.05 Favored Glycine 0 CA--C 1.539 1.586 0 C-N-CA 125.431 1.491 . . . . 0.0 116.094 172.15 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -75.67 170.57 15.92 Favored 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 124.654 1.182 . . . . 0.0 111.257 171.46 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 24.7 p80 -67.46 156.92 35.43 Favored 'General case' 0 CA--C 1.54 0.585 0 O-C-N 121.085 -1.009 . . . . 0.0 112.141 170.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 47.1 mt-30 -86.54 18.41 3.33 Favored 'General case' 0 CA--C 1.549 0.94 0 N-CA-C 114.277 1.214 . . . . 0.0 114.277 -173.704 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.59 0.96 81.35 Favored Glycine 0 CA--C 1.536 1.355 0 C-N-CA 125.263 1.411 . . . . 0.0 114.977 -179.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 47.3 p90 -145.3 161.25 40.04 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 124.963 1.305 . . . . 0.0 112.616 179.247 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -152.62 -176.09 24.84 Favored Glycine 0 CA--C 1.531 1.035 0 C-N-CA 126.013 1.768 . . . . 0.0 112.801 -178.19 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 62.9 m-85 -144.59 151.47 39.09 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.809 1.644 . . . . 0.0 111.536 -179.402 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 17.9 t -132.93 128.23 56.4 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 124.666 1.187 . . . . 0.0 109.802 176.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 50.9 tt0 -102.69 119.8 39.47 Favored 'General case' 0 N--CA 1.464 0.246 0 C-N-CA 124.658 1.183 . . . . 0.0 110.552 -176.11 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -97.02 162.24 13.47 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 124.745 1.218 . . . . 0.0 112.256 175.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.9 tp -63.34 -34.66 78.18 Favored 'General case' 0 CA--C 1.54 0.585 0 N-CA-C 112.55 0.574 . . . . 0.0 112.55 176.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 16.8 m -144.28 157.62 44.18 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 124.577 1.151 . . . . 0.0 111.927 -176.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -62.85 -33.42 75.21 Favored 'General case' 0 N--CA 1.473 0.708 0 O-C-N 121.503 -0.748 . . . . 0.0 112.872 -179.58 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -67.45 -23.96 65.57 Favored 'General case' 0 N--CA 1.473 0.694 0 O-C-N 121.102 -0.998 . . . . 0.0 113.558 177.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 51.0 m-20 -81.4 -33.25 32.37 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 124.16 0.984 . . . . 0.0 111.552 172.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.18 -44.97 71.1 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 123.83 0.852 . . . . 0.0 111.395 173.285 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -56.99 -36.4 70.34 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 124.781 1.232 . . . . 0.0 112.44 175.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 26.5 t80 -70.91 -38.14 72.98 Favored 'General case' 0 CA--C 1.536 0.427 0 O-C-N 121.891 -0.505 . . . . 0.0 111.979 175.32 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -65.94 -36.51 83.55 Favored 'General case' 0 CA--C 1.538 0.504 0 O-C-N 120.896 -1.127 . . . . 0.0 111.621 176.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 61.9 mt -63.35 -34.88 69.84 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 124.129 0.971 . . . . 0.0 110.74 172.309 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -67.89 -42.92 80.45 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 123.996 0.918 . . . . 0.0 112.681 176.661 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 16.5 pt -90.42 -38.39 10.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -175.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 15.7 mmt -90.2 0.15 57.33 Favored 'General case' 0 N--CA 1.479 0.995 0 N-CA-C 114.642 1.349 . . . . 0.0 114.642 -169.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -84.43 136.07 34.0 Favored 'General case' 0 CA--C 1.541 0.596 0 O-C-N 121.442 -0.786 . . . . 0.0 112.045 178.271 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 1.7 mmt 59.03 13.97 3.16 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 126.087 1.755 . . . . 0.0 115.25 -170.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.3 mt -71.21 154.02 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 C-N-CA 124.671 1.188 . . . . 0.0 109.777 168.132 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 47.2 mtpt -113.7 71.01 0.73 Allowed 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 125.125 1.37 . . . . 0.0 112.154 -175.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 25.2 tp -57.99 126.91 29.5 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 123.978 0.911 . . . . 0.0 109.888 174.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 46.89 28.55 0.86 Allowed 'General case' 0 CA--C 1.56 1.358 0 N-CA-C 116.268 1.951 . . . . 0.0 116.268 -168.708 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 77.57 29.09 56.19 Favored Glycine 0 CA--C 1.54 1.6 0 O-C-N 120.071 -1.643 . . . . 0.0 115.418 177.101 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 34.8 ttmt -143.21 119.77 6.69 Favored Pre-proline 0 CA--C 1.543 0.708 0 C-N-CA 128.267 2.627 . . . . 0.0 107.842 -175.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -70.18 132.86 23.5 Favored 'Trans proline' 0 CA--C 1.536 0.613 0 C-N-CA 122.972 2.448 . . . . 0.0 113.528 -168.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 17.8 pt -105.72 151.91 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 C-N-CA 125.722 1.609 . . . . 0.0 112.163 175.376 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 24.2 mmt180 -115.11 140.33 49.15 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 125.307 1.443 . . . . 0.0 110.512 169.585 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 30.4 t -133.34 139.08 49.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 C-N-CA 125.253 1.421 . . . . 0.0 110.718 -173.877 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 40.2 t-20 -161.65 179.2 8.35 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 125.952 1.701 . . . . 0.0 110.252 179.59 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 13.8 mmmm -55.92 147.82 18.61 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 125.373 1.469 . . . . 0.0 111.298 170.016 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -76.08 -33.08 59.54 Favored 'General case' 0 CA--C 1.549 0.909 0 O-C-N 121.973 -0.455 . . . . 0.0 111.967 169.059 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 20.4 m -77.33 -44.07 30.79 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 124.149 0.98 . . . . 0.0 113.374 176.642 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . 40.64 75.76 0.08 Allowed 'General case' 0 CA--C 1.551 0.999 0 C-N-CA 128.284 2.634 . . . . 0.0 115.759 176.233 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 14.7 p80 -130.74 16.17 5.3 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 126.427 1.891 . . . . 0.0 113.743 -174.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -61.65 141.04 58.07 Favored 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 124.538 1.135 . . . . 0.0 112.579 -174.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 62.3 tttp -147.77 146.01 29.01 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 126.272 1.829 . . . . 0.0 110.968 -175.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 79.4 m-20 -79.93 54.52 1.9 Allowed 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 124.879 1.272 . . . . 0.0 111.259 173.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 41.5 tp -72.98 147.58 45.04 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 125.601 1.56 . . . . 0.0 112.147 -174.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 87.1 p -135.32 167.32 21.24 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 125.948 1.699 . . . . 0.0 112.513 -179.385 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -170.4 -171.64 36.01 Favored Glycine 0 CA--C 1.539 1.544 0 C-N-CA 124.73 1.157 . . . . 0.0 113.554 -179.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -59.93 152.57 63.46 Favored 'Trans proline' 0 CA--C 1.539 0.752 0 C-N-CA 124.119 3.213 . . . . 0.0 114.36 -178.353 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 35.4 m -67.07 149.8 50.07 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 124.69 1.196 . . . . 0.0 113.039 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 61.3 p -78.69 -15.37 58.55 Favored 'General case' 0 N--CA 1.476 0.857 0 N-CA-C 114.467 1.284 . . . . 0.0 114.467 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.209 0 C-N-CA 126.026 1.774 . . . . 0.0 113.05 177.672 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.642 0 N-CA-C 111.836 -0.506 . . . . 0.0 111.836 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 77.0 p -145.82 159.05 43.75 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.292 1.437 . . . . 0.0 112.481 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 38.8 m -72.76 147.43 45.57 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 124.411 1.084 . . . . 0.0 113.136 -177.233 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.8 156.33 18.54 Favored Glycine 0 CA--C 1.534 1.271 0 C-N-CA 124.99 1.281 . . . . 0.0 112.805 176.339 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 50.8 p -84.72 -27.93 26.66 Favored 'General case' 0 N--CA 1.476 0.825 0 N-CA-C 114.105 1.15 . . . . 0.0 114.105 -176.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 90.8 p -156.27 161.8 40.19 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.423 1.489 . . . . 0.0 112.585 177.747 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 170.4 171.17 35.54 Favored Glycine 0 CA--C 1.54 1.641 0 C-N-CA 125.049 1.309 . . . . 0.0 113.175 174.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_exo -61.56 133.99 48.73 Favored 'Trans proline' 0 CA--C 1.537 0.646 0 C-N-CA 123.425 2.75 . . . . 0.0 112.7 178.408 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.0 tp -154.29 154.21 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 124.941 1.296 . . . . 0.0 111.324 -178.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 59.3 p -85.25 3.0 41.49 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 125.683 1.593 . . . . 0.0 114.496 177.193 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -72.52 158.48 35.62 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 125.755 1.622 . . . . 0.0 113.126 -177.215 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 89.9 mtt180 -64.32 163.23 13.37 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 126.007 1.723 . . . . 0.0 113.243 -178.451 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 77.9 m-20 -69.31 98.19 1.03 Allowed 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.752 1.221 . . . . 0.0 112.785 -169.994 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.4 tt0 -70.04 -18.87 63.31 Favored 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 124.091 0.956 . . . . 0.0 113.005 -179.395 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -63.21 -34.66 78.13 Favored 'General case' 0 N--CA 1.472 0.666 0 O-C-N 120.908 -1.12 . . . . 0.0 112.963 174.343 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -95.28 10.77 34.91 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.517 1.527 . . . . 0.0 112.661 173.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 53.1 m -99.55 136.48 39.41 Favored 'General case' 0 N--CA 1.47 0.548 0 O-C-N 121.272 -0.893 . . . . 0.0 109.598 172.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.2 m -102.21 147.74 8.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 C-N-CA 124.418 1.087 . . . . 0.0 110.283 171.337 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 16.5 t80 -95.66 141.98 28.51 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 126.354 1.862 . . . . 0.0 109.097 169.18 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 22.6 t -132.01 108.78 14.46 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 125.626 1.57 . . . . 0.0 109.143 178.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -103.77 145.62 16.18 Favored Glycine 0 CA--C 1.529 0.956 0 C-N-CA 124.436 1.017 . . . . 0.0 112.87 177.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 97.5 33.41 5.91 Favored Glycine 0 CA--C 1.533 1.192 0 C-N-CA 124.677 1.132 . . . . 0.0 113.899 174.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 83.0 mt -76.49 145.97 38.8 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 125.286 1.434 . . . . 0.0 111.346 -174.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -85.23 157.8 20.51 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 123.506 0.723 . . . . 0.0 112.196 174.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.44 -20.7 47.11 Favored 'General case' 0 CA--C 1.547 0.83 0 N-CA-C 114.599 1.333 . . . . 0.0 114.599 178.317 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.0 mtmm -80.45 -11.03 59.73 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 114.374 1.25 . . . . 0.0 114.374 174.255 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.3 t -75.01 138.12 21.63 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 124.31 1.044 . . . . 0.0 111.324 177.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 56.7 m -136.42 162.64 32.49 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 125.169 1.388 . . . . 0.0 111.36 172.765 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -55.8 -43.21 99.09 Favored Pre-proline 0 CA--C 1.549 0.916 0 N-CA-C 114.022 1.119 . . . . 0.0 114.022 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -62.67 -28.26 76.6 Favored 'Trans proline' 0 C--N 1.355 0.873 0 C-N-CA 122.224 1.95 . . . . 0.0 113.999 174.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 20.6 tp -66.31 -54.15 28.1 Favored 'General case' 0 C--N 1.345 0.374 0 CA-C-N 118.634 0.652 . . . . 0.0 109.461 172.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 25.8 mt -55.33 -42.09 73.32 Favored 'General case' 0 N--CA 1.464 0.273 0 O-C-N 123.218 0.324 . . . . 0.0 111.37 -178.429 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 3.0 t90 -57.31 -62.79 1.52 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.379 0.672 . . . . 0.0 111.262 178.418 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 -65.22 -29.04 69.81 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 113.801 1.037 . . . . 0.0 113.801 -176.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.8 tp -72.03 -36.96 69.81 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 124.229 1.012 . . . . 0.0 111.863 175.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 11.0 m-85 -87.3 -10.5 52.13 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 124.779 1.231 . . . . 0.0 113.378 -176.082 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 25.5 mt -53.91 -20.47 6.08 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 124.53 1.132 . . . . 0.0 113.899 168.878 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 76.3 mt-30 -62.42 -33.45 74.81 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 125.672 1.589 . . . . 0.0 112.581 173.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.71 -46.11 17.68 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 123.777 0.831 . . . . 0.0 112.715 178.135 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -179.51 -171.86 43.0 Favored Glycine 0 CA--C 1.535 1.341 0 C-N-CA 124.279 0.943 . . . . 0.0 113.16 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -67.97 108.75 1.77 Allowed 'Trans proline' 0 CA--C 1.537 0.648 0 C-N-CA 123.757 2.971 . . . . 0.0 111.463 -179.033 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 75.4 t -84.33 132.84 30.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 C-N-CA 124.746 1.218 . . . . 0.0 109.831 174.202 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.8 t -109.3 -33.6 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 126.329 1.852 . . . . 0.0 111.922 -171.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 18.6 t30 -161.0 164.74 30.76 Favored 'General case' 0 CA--C 1.555 1.135 0 C-N-CA 126.028 1.731 . . . . 0.0 111.037 -174.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 3.7 p -141.92 153.79 44.63 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 126.339 1.856 . . . . 0.0 111.636 175.746 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 3.7 t60 -142.43 133.34 25.71 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 123.815 0.846 . . . . 0.0 111.109 175.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 84.9 mtp -135.29 103.28 10.52 Favored Pre-proline 0 N--CA 1.472 0.651 0 C-N-CA 124.072 0.949 . . . . 0.0 109.257 169.273 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 81.1 Cg_exo -54.58 138.12 74.42 Favored 'Trans proline' 0 CA--C 1.536 0.585 0 C-N-CA 123.276 2.651 . . . . 0.0 112.832 176.275 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 45.0 mmtm -104.3 154.26 20.02 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 125.018 1.327 . . . . 0.0 112.439 -176.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -80.51 143.67 33.12 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 125.843 1.657 . . . . 0.0 112.017 175.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 39.7 ptt180 -86.67 5.2 37.19 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 116.019 1.859 . . . . 0.0 116.019 -174.211 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 23.8 t -132.16 -37.88 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 124.91 1.284 . . . . 0.0 111.479 -175.047 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 74.9 p -107.95 -21.5 12.8 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 126.052 1.741 . . . . 0.0 112.511 -177.487 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 73.63 1.87 59.18 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 125.072 1.32 . . . . 0.0 116.034 173.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 3.4 pt20 -76.06 172.38 12.88 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 118.506 1.153 . . . . 0.0 110.871 169.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 29.0 p80 -68.04 158.43 32.95 Favored 'General case' 0 N--CA 1.471 0.577 0 O-C-N 120.946 -1.096 . . . . 0.0 112.355 171.29 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 82.4 mt-30 -80.51 14.04 2.22 Favored 'General case' 0 CA--C 1.552 1.027 0 C-N-CA 124.872 1.269 . . . . 0.0 114.424 -176.082 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.54 0.91 81.53 Favored Glycine 0 CA--C 1.537 1.444 0 C-N-CA 125.207 1.384 . . . . 0.0 114.884 -177.134 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 42.0 p90 -144.4 161.01 40.09 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.1 1.36 . . . . 0.0 112.249 178.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -150.7 -175.38 22.63 Favored Glycine 0 CA--C 1.528 0.882 0 C-N-CA 125.718 1.628 . . . . 0.0 113.176 -179.258 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -145.08 151.67 38.88 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 125.767 1.627 . . . . 0.0 111.937 -178.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 20.5 t -133.89 128.15 53.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 124.716 1.206 . . . . 0.0 110.001 175.301 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 51.3 tt0 -101.18 122.36 43.49 Favored 'General case' 0 N--CA 1.466 0.337 0 C-N-CA 125.03 1.332 . . . . 0.0 110.731 -177.511 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 81.9 m-85 -98.42 162.11 13.33 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 125.058 1.343 . . . . 0.0 112.306 175.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.6 tp -62.39 -34.2 76.25 Favored 'General case' 0 CA--C 1.541 0.622 0 CA-C-N 115.86 -0.609 . . . . 0.0 112.56 176.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.8 m -144.06 155.67 44.07 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 124.497 1.119 . . . . 0.0 112.164 -176.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -63.26 -31.12 72.19 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 123.958 0.903 . . . . 0.0 113.107 -178.596 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -69.63 -23.87 63.55 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 121.119 -0.988 . . . . 0.0 113.535 175.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 46.7 m-20 -81.34 -32.4 33.02 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 123.822 0.849 . . . . 0.0 111.401 172.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -67.69 -44.03 78.72 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 123.436 0.694 . . . . 0.0 111.076 172.057 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -57.43 -34.31 68.81 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.482 1.113 . . . . 0.0 112.933 173.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 17.3 t80 -72.43 -37.35 68.61 Favored 'General case' 0 CA--C 1.537 0.449 0 O-C-N 121.554 -0.716 . . . . 0.0 111.963 175.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.5 -36.3 82.39 Favored 'General case' 0 CA--C 1.536 0.441 0 O-C-N 120.731 -1.23 . . . . 0.0 111.529 176.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 64.8 mt -62.95 -34.23 65.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 124.003 0.921 . . . . 0.0 111.004 172.138 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -68.47 -43.14 77.62 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 124.054 0.942 . . . . 0.0 112.584 176.586 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 19.5 pt -91.73 -38.39 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 114.926 1.454 . . . . 0.0 114.926 -174.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 15.1 mmt -90.84 0.73 57.39 Favored 'General case' 0 N--CA 1.479 0.984 0 N-CA-C 114.768 1.396 . . . . 0.0 114.768 -169.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -85.04 135.87 33.82 Favored 'General case' 0 CA--C 1.538 0.49 0 O-C-N 121.528 -0.733 . . . . 0.0 112.203 179.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 26.3 ttm 59.88 11.81 2.75 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 126.149 1.779 . . . . 0.0 114.848 -171.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.5 mt -69.96 150.7 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 124.874 1.27 . . . . 0.0 109.793 168.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 44.7 mtpt -108.86 70.52 0.74 Allowed 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 124.713 1.205 . . . . 0.0 112.364 -174.808 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 25.3 tp -58.55 124.1 18.49 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 123.789 0.835 . . . . 0.0 109.659 174.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 45.38 31.09 0.79 Allowed 'General case' 0 CA--C 1.56 1.358 0 N-CA-C 116.082 1.882 . . . . 0.0 116.082 -168.5 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 82.23 17.55 69.01 Favored Glycine 0 CA--C 1.542 1.726 0 O-C-N 120.272 -1.517 . . . . 0.0 116.691 173.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 94.3 mttt -131.96 123.94 19.32 Favored Pre-proline 0 CA--C 1.54 0.569 0 C-N-CA 128.22 2.608 . . . . 0.0 108.088 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -71.49 123.09 9.2 Favored 'Trans proline' 0 CA--C 1.538 0.679 0 C-N-CA 123.343 2.695 . . . . 0.0 112.351 -169.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 15.6 pt -91.12 147.92 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 125.135 1.374 . . . . 0.0 111.818 175.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 9.6 mmm180 -114.72 132.42 56.43 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 125.412 1.485 . . . . 0.0 110.379 175.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.2 t -128.19 137.18 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 C-N-CA 124.278 1.031 . . . . 0.0 111.135 -170.976 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 5.7 p30 -157.2 175.32 14.2 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 126.526 1.93 . . . . 0.0 110.536 176.617 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.5 mmmp? -64.63 138.83 58.62 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 123.864 0.866 . . . . 0.0 110.298 174.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -67.4 -32.14 72.84 Favored 'General case' 0 CA--C 1.55 0.97 0 O-C-N 121.837 -0.539 . . . . 0.0 110.565 168.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 37.4 m -118.23 95.94 5.11 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 126.105 1.762 . . . . 0.0 108.982 166.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -90.96 150.76 21.35 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 124.721 1.208 . . . . 0.0 112.051 178.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 11.1 p80 -147.82 176.31 10.24 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 125.173 1.389 . . . . 0.0 112.486 -178.168 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 59.6 t-20 -59.82 134.47 57.06 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 125.501 1.521 . . . . 0.0 112.761 -172.815 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 45.0 mmtm -86.8 -17.35 33.67 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 125.215 1.406 . . . . 0.0 113.851 -178.533 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -73.22 146.41 45.5 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 123.779 0.832 . . . . 0.0 112.571 -177.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 47.6 tp -92.83 -28.35 16.59 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 125.561 1.544 . . . . 0.0 113.118 177.011 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 84.3 p -84.43 166.51 17.26 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 113.729 1.011 . . . . 0.0 113.729 -178.177 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -166.38 176.33 41.63 Favored Glycine 0 CA--C 1.54 1.642 0 C-N-CA 125.299 1.428 . . . . 0.0 112.982 178.838 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -69.5 146.95 63.43 Favored 'Trans proline' 0 CA--C 1.539 0.757 0 C-N-CA 123.684 2.923 . . . . 0.0 112.907 -176.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 19.1 m -92.79 -4.18 53.47 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 124.872 1.269 . . . . 0.0 114.36 -177.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 9.1 t -72.84 152.87 41.31 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.47 1.108 . . . . 0.0 112.924 -177.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.174 0 C-N-CA 125.693 1.616 . . . . 0.0 112.79 -178.721 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.52 0 N-CA-C 111.734 -0.546 . . . . 0.0 111.734 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 37.2 m -69.19 153.44 43.69 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 124.581 1.153 . . . . 0.0 113.333 -179.033 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.6 t -73.16 162.01 29.92 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 124.126 0.971 . . . . 0.0 112.406 173.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -171.3 -178.1 41.53 Favored Glycine 0 CA--C 1.534 1.261 0 C-N-CA 124.86 1.219 . . . . 0.0 113.723 -178.363 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.7 m 55.38 27.82 10.58 Favored 'General case' 0 N--CA 1.48 1.033 0 C-N-CA 125.787 1.635 . . . . 0.0 114.998 179.513 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 13.2 t -151.27 153.51 34.99 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.321 1.448 . . . . 0.0 111.945 -179.01 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 83.99 133.64 2.46 Favored Glycine 0 CA--C 1.545 1.926 0 C-N-CA 125.923 1.725 . . . . 0.0 113.91 -179.182 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -79.8 168.45 19.3 Favored 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 123.888 3.059 . . . . 0.0 112.676 177.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -69.2 147.96 11.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 123.997 0.919 . . . . 0.0 112.233 170.242 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.6 m -74.72 -26.66 59.95 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -179.161 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -151.98 146.18 25.4 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 125.783 1.633 . . . . 0.0 110.599 178.548 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.0 tpm_? -138.37 139.68 39.1 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 124.956 1.302 . . . . 0.0 111.012 179.084 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 83.8 m-20 -87.49 146.35 25.86 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 124.217 1.007 . . . . 0.0 112.766 -177.372 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 31.8 tp60 -145.78 -40.79 0.22 Allowed 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 125.123 1.369 . . . . 0.0 111.368 169.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -69.33 -33.45 73.15 Favored 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 113.471 0.915 . . . . 0.0 113.471 178.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.3 5.54 34.03 Favored 'General case' 0 CA--C 1.545 0.77 0 C-N-CA 124.795 1.238 . . . . 0.0 113.055 171.206 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 18.7 m -99.57 137.57 37.88 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 124.293 1.037 . . . . 0.0 109.185 172.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 14.3 m -105.66 148.56 9.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 C-N-CA 124.685 1.194 . . . . 0.0 110.322 173.24 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 32.1 t80 -95.43 141.77 28.58 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 126.245 1.818 . . . . 0.0 109.392 169.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 22.0 t -131.53 109.9 16.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 C-N-CA 125.636 1.574 . . . . 0.0 109.166 175.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -105.47 147.78 16.34 Favored Glycine 0 CA--C 1.53 0.972 0 C-N-CA 124.445 1.021 . . . . 0.0 112.714 177.056 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.36 31.37 7.21 Favored Glycine 0 CA--C 1.534 1.277 0 C-N-CA 124.767 1.175 . . . . 0.0 114.24 173.837 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 89.1 mt -73.95 150.21 40.92 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 125.511 1.525 . . . . 0.0 111.598 -172.101 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -89.74 156.38 18.57 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 123.784 0.833 . . . . 0.0 111.973 175.594 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.53 -20.39 45.69 Favored 'General case' 0 CA--C 1.546 0.795 0 N-CA-C 114.818 1.414 . . . . 0.0 114.818 -179.799 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.6 mtmm -81.17 -11.23 59.48 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 124.666 1.186 . . . . 0.0 114.15 175.132 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 75.4 t -72.15 140.98 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 C-N-CA 124.395 1.078 . . . . 0.0 111.632 179.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 92.3 p -135.27 162.08 33.58 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.188 1.395 . . . . 0.0 112.16 175.111 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -59.82 -39.86 73.83 Favored Pre-proline 0 CA--C 1.547 0.831 0 O-C-N 120.814 -1.179 . . . . 0.0 113.551 177.43 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -61.96 -30.9 84.08 Favored 'Trans proline' 0 C--N 1.352 0.754 0 C-N-CA 122.537 2.158 . . . . 0.0 113.94 170.369 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 27.1 tp -68.07 -50.37 55.52 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 119.114 0.87 . . . . 0.0 109.893 174.009 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 19.9 mt -61.1 -23.05 65.21 Favored 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 112.985 0.735 . . . . 0.0 112.985 178.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.6 t90 -73.54 -66.62 0.67 Allowed 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 123.159 0.584 . . . . 0.0 111.006 170.745 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -65.01 -30.33 71.3 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 114.221 1.193 . . . . 0.0 114.221 -172.365 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.9 tp -69.53 -32.56 71.45 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 123.762 0.825 . . . . 0.0 111.917 175.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -91.18 -10.83 40.29 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 125.194 1.397 . . . . 0.0 113.313 -175.175 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 50.7 mt -55.12 -18.63 5.9 Favored 'General case' 0 N--CA 1.475 0.808 0 C-N-CA 124.477 1.111 . . . . 0.0 113.945 169.377 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 41.2 mt-30 -64.82 -33.06 75.09 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 125.367 1.467 . . . . 0.0 112.737 173.272 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.25 -45.1 20.46 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 123.543 0.737 . . . . 0.0 112.624 177.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.46 -172.78 44.71 Favored Glycine 0 CA--C 1.535 1.284 0 C-N-CA 124.672 1.13 . . . . 0.0 112.996 179.321 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -67.48 111.28 2.27 Favored 'Trans proline' 0 CA--C 1.537 0.626 0 C-N-CA 123.658 2.905 . . . . 0.0 111.633 -179.197 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 67.0 t -86.25 134.23 27.85 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 C-N-CA 124.863 1.265 . . . . 0.0 109.856 174.187 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 8.0 t -109.32 -33.37 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.703 0 C-N-CA 126.633 1.973 . . . . 0.0 111.959 -171.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 20.0 t30 -160.8 161.35 31.99 Favored 'General case' 0 CA--C 1.554 1.128 0 C-N-CA 125.926 1.691 . . . . 0.0 111.205 -175.265 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 5.0 p -137.97 155.1 49.22 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 125.928 1.691 . . . . 0.0 111.864 171.569 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 47.3 t-80 -142.33 133.72 26.42 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 123.848 0.859 . . . . 0.0 111.197 175.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 87.5 mtp -134.21 107.24 11.27 Favored Pre-proline 0 N--CA 1.471 0.613 0 C-N-CA 124.04 0.936 . . . . 0.0 109.638 169.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -57.82 140.34 93.39 Favored 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 123.305 2.67 . . . . 0.0 113.179 177.384 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 43.3 mmtm -112.89 146.82 38.27 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.249 1.42 . . . . 0.0 113.076 -172.624 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 27.3 t70 -67.14 143.46 56.6 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 125.827 1.651 . . . . 0.0 112.447 172.479 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 9.7 ptm180 -85.84 6.66 27.18 Favored 'General case' 0 N--CA 1.479 1.02 0 N-CA-C 116.0 1.852 . . . . 0.0 116.0 -174.018 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 35.6 t -131.36 -37.48 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.104 0 C-N-CA 124.942 1.297 . . . . 0.0 111.405 -174.307 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 72.5 p -113.97 -14.66 12.42 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 125.846 1.659 . . . . 0.0 112.544 -176.574 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.21 4.96 52.34 Favored Glycine 0 CA--C 1.538 1.489 0 C-N-CA 125.146 1.355 . . . . 0.0 115.393 176.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 72.9 mm-40 -77.49 162.14 27.39 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 124.611 1.165 . . . . 0.0 110.805 177.226 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 18.7 p80 -69.18 153.54 43.53 Favored 'General case' 0 N--CA 1.473 0.681 0 O-C-N 120.948 -1.095 . . . . 0.0 112.473 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 46.3 mt-30 -84.94 17.36 2.9 Favored 'General case' 0 CA--C 1.549 0.927 0 N-CA-C 114.344 1.239 . . . . 0.0 114.344 -173.456 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 87.12 1.69 84.22 Favored Glycine 0 CA--C 1.535 1.289 0 C-N-CA 125.071 1.32 . . . . 0.0 114.953 -179.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 41.3 p90 -144.79 161.01 40.31 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 124.917 1.287 . . . . 0.0 112.427 177.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -152.12 -178.15 26.53 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 125.968 1.747 . . . . 0.0 113.003 -177.467 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -142.81 149.03 38.08 Favored 'General case' 0 C--O 1.237 0.421 0 C-N-CA 126.025 1.73 . . . . 0.0 111.573 -178.5 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 14.4 t -132.91 127.81 55.91 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 124.637 1.175 . . . . 0.0 109.953 176.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 57.3 tt0 -103.63 120.2 40.42 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 124.789 1.236 . . . . 0.0 110.845 -175.842 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -96.83 161.95 13.63 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 124.638 1.175 . . . . 0.0 112.387 176.001 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.8 tp -63.25 -34.42 77.63 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 123.224 0.61 . . . . 0.0 112.448 176.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.0 m -143.65 156.27 44.5 Favored 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 124.393 1.077 . . . . 0.0 112.012 -177.391 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 49.6 tt0 -64.09 -30.85 71.89 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 123.847 0.859 . . . . 0.0 113.27 -178.302 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -69.58 -24.55 63.71 Favored 'General case' 0 N--CA 1.474 0.733 0 O-C-N 121.173 -0.955 . . . . 0.0 113.396 176.159 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 52.5 m-20 -79.83 -33.57 40.15 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 123.925 0.89 . . . . 0.0 111.333 172.326 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -67.55 -45.2 76.34 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 123.57 0.748 . . . . 0.0 111.491 172.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -56.86 -36.0 69.54 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 124.474 1.11 . . . . 0.0 112.672 175.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 24.0 t80 -71.56 -37.83 71.03 Favored 'General case' 0 CA--C 1.538 0.493 0 O-C-N 121.719 -0.613 . . . . 0.0 111.973 175.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.0 -36.93 84.63 Favored 'General case' 0 CA--C 1.537 0.452 0 O-C-N 120.916 -1.115 . . . . 0.0 111.696 176.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 55.8 mt -63.81 -33.99 65.36 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 C-N-CA 124.053 0.941 . . . . 0.0 110.783 172.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -67.62 -43.62 79.96 Favored 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 123.865 0.866 . . . . 0.0 112.713 175.546 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 18.2 pt -91.09 -34.38 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 N-CA-C 115.282 1.586 . . . . 0.0 115.282 -174.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 15.0 mmt -95.05 -1.16 52.8 Favored 'General case' 0 N--CA 1.479 1.023 0 N-CA-C 114.615 1.339 . . . . 0.0 114.615 -171.257 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -82.84 146.27 29.01 Favored 'General case' 0 CA--C 1.539 0.553 0 O-C-N 121.395 -0.815 . . . . 0.0 111.206 174.159 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 84.6 mmm 60.24 5.96 0.92 Allowed 'General case' 0 N--CA 1.479 1.012 0 C-N-CA 125.929 1.692 . . . . 0.0 115.468 -172.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.4 mt -71.78 157.42 6.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 C-N-CA 125.862 1.665 . . . . 0.0 111.236 172.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 50.8 mtpt -118.83 71.23 0.84 Allowed 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 125.815 1.646 . . . . 0.0 112.028 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 32.9 tp -57.65 126.75 28.72 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.049 0.939 . . . . 0.0 110.301 176.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 53.6 m-85 46.27 27.58 0.59 Allowed 'General case' 0 CA--C 1.559 1.311 0 N-CA-C 116.398 1.999 . . . . 0.0 116.398 -168.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 78.78 27.56 56.51 Favored Glycine 0 CA--C 1.542 1.768 0 O-C-N 120.103 -1.623 . . . . 0.0 115.715 177.542 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -135.71 121.03 13.61 Favored Pre-proline 0 CA--C 1.542 0.64 0 C-N-CA 128.316 2.647 . . . . 0.0 107.63 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -68.61 127.91 16.27 Favored 'Trans proline' 0 CA--C 1.536 0.577 0 C-N-CA 123.002 2.468 . . . . 0.0 112.745 -171.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 27.5 pt -101.39 159.21 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 125.418 1.487 . . . . 0.0 112.051 175.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 86.9 mmt-85 -127.48 134.95 49.79 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 125.747 1.619 . . . . 0.0 110.167 174.003 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 30.9 t -130.01 138.58 53.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 124.257 1.023 . . . . 0.0 111.366 -172.605 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 40.8 t-20 -159.0 177.29 11.3 Favored 'General case' 0 CA--C 1.548 0.883 0 C-N-CA 125.987 1.715 . . . . 0.0 110.228 178.039 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.3 mmmp? -58.11 146.91 31.62 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 124.715 1.206 . . . . 0.0 110.69 169.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -80.01 -16.09 55.87 Favored 'General case' 0 CA--C 1.55 0.958 0 N-CA-C 112.494 0.553 . . . . 0.0 112.494 169.485 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 59.7 p -88.84 -55.26 3.77 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 125.322 1.449 . . . . 0.0 112.317 170.519 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . 56.85 40.49 28.92 Favored 'General case' 0 CA--C 1.549 0.928 0 C-N-CA 127.413 2.285 . . . . 0.0 115.495 176.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 84.1 m-70 -114.61 145.85 41.51 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 125.215 1.406 . . . . 0.0 111.122 169.156 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 26.2 m120 -82.91 152.74 25.41 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.147 0.979 . . . . 0.0 112.353 -177.246 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 66.1 mttm -81.98 44.63 0.85 Allowed 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 125.752 1.621 . . . . 0.0 112.291 177.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 51.3 t30 -76.4 158.65 31.19 Favored 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 125.303 1.441 . . . . 0.0 112.734 -172.1 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 64.5 tp -141.6 135.23 29.82 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 126.14 1.776 . . . . 0.0 110.397 177.655 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 17.4 m -69.52 -27.17 64.94 Favored 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 114.207 1.188 . . . . 0.0 114.207 -174.524 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 160.16 -172.68 36.67 Favored Glycine 0 CA--C 1.54 1.617 0 C-N-CA 125.174 1.368 . . . . 0.0 113.354 178.083 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -67.76 -23.53 41.81 Favored 'Trans proline' 0 CA--C 1.54 0.8 0 C-N-CA 123.578 2.852 . . . . 0.0 114.645 178.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 44.2 m 54.4 28.19 9.16 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 126.197 1.799 . . . . 0.0 114.899 -178.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 59.1 p -89.06 -13.18 39.26 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.519 1.528 . . . . 0.0 114.524 -177.51 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.24 0 C-N-CA 125.705 1.622 . . . . 0.0 113.656 178.096 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.563 0 N-CA-C 111.582 -0.607 . . . . 0.0 111.582 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 69.5 p -152.65 159.6 43.2 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.825 1.25 . . . . 0.0 112.655 178.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.2 m 50.63 48.46 22.61 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 116.14 1.904 . . . . 0.0 116.14 169.238 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -72.02 130.79 17.12 Favored Glycine 0 CA--C 1.534 1.226 0 O-C-N 120.978 -1.076 . . . . 0.0 110.98 168.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 68.6 p -88.45 -6.13 57.83 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 124.845 1.258 . . . . 0.0 114.116 -178.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 25.8 m -60.29 140.31 57.15 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 125.371 1.468 . . . . 0.0 112.775 -178.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 68.15 59.45 6.35 Favored Glycine 0 CA--C 1.542 1.777 0 CA-C-O 118.739 -1.034 . . . . 0.0 113.602 -174.266 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo -63.33 155.43 62.03 Favored 'Trans proline' 0 CA--C 1.539 0.76 0 C-N-CA 123.61 2.874 . . . . 0.0 112.62 178.638 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 71.1 mt -95.76 131.07 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 C-N-CA 125.346 1.458 . . . . 0.0 110.742 -175.429 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 67.6 p -97.75 -10.38 24.97 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 124.894 1.277 . . . . 0.0 113.966 174.884 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -94.25 -20.29 19.95 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 114.477 1.288 . . . . 0.0 114.477 -169.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 32.8 ttp-105 -140.1 143.07 36.07 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 124.781 1.232 . . . . 0.0 112.832 -169.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 15.9 p-10 -65.14 -8.14 15.59 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 125.565 1.546 . . . . 0.0 114.997 -179.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 65.0 tt0 -57.26 -29.56 63.93 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.264 1.025 . . . . 0.0 111.932 169.534 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -79.99 -26.95 39.71 Favored 'General case' 0 CA--C 1.543 0.706 0 O-C-N 121.358 -0.839 . . . . 0.0 112.91 174.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -78.09 -5.79 52.63 Favored 'General case' 0 CA--C 1.545 0.768 0 C-N-CA 124.596 1.159 . . . . 0.0 112.627 169.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 26.4 m -102.64 134.58 45.77 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 125.036 1.335 . . . . 0.0 110.18 177.009 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 18.1 m -100.73 147.79 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.64 0 C-N-CA 124.361 1.064 . . . . 0.0 110.368 170.729 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 51.8 t80 -95.49 141.3 29.18 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 126.419 1.888 . . . . 0.0 109.676 169.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 23.1 t -132.01 107.07 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 C-N-CA 125.521 1.529 . . . . 0.0 109.123 176.147 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -103.26 147.17 16.74 Favored Glycine 0 CA--C 1.53 0.974 0 C-N-CA 124.58 1.086 . . . . 0.0 112.813 177.174 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 92.76 36.93 5.92 Favored Glycine 0 N--CA 1.472 1.071 0 C-N-CA 124.13 0.871 . . . . 0.0 113.64 173.637 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 83.7 mt -75.06 150.28 38.92 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 125.44 1.496 . . . . 0.0 111.424 -175.09 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -88.84 156.27 19.04 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 123.786 0.834 . . . . 0.0 111.783 174.126 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.28 -20.28 41.4 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 114.774 1.398 . . . . 0.0 114.774 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.5 mtmm -82.02 -11.27 58.91 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 124.758 1.223 . . . . 0.0 114.135 175.028 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 62.4 t -74.0 141.03 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.926 0 C-N-CA 124.337 1.055 . . . . 0.0 111.265 176.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 9.4 t -144.11 167.2 22.97 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 124.358 1.063 . . . . 0.0 111.612 170.42 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -56.17 -43.28 99.19 Favored Pre-proline 0 CA--C 1.549 0.918 0 O-C-N 120.996 -1.065 . . . . 0.0 113.816 -177.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -62.52 -29.42 78.54 Favored 'Trans proline' 0 C--N 1.354 0.828 0 C-N-CA 122.311 2.008 . . . . 0.0 113.719 174.387 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 18.5 tp -67.08 -53.69 28.58 Favored 'General case' 0 C--N 1.344 0.355 0 CA-C-N 118.574 0.625 . . . . 0.0 109.54 173.264 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 22.6 mt -55.37 -42.14 73.53 Favored 'General case' 0 C--O 1.224 -0.277 0 O-C-N 123.216 0.322 . . . . 0.0 111.38 -178.303 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.9 t90 -58.35 -62.56 1.75 Allowed 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.089 0.555 . . . . 0.0 111.397 178.346 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -65.34 -29.41 70.14 Favored 'General case' 0 CA--C 1.539 0.557 0 N-CA-C 113.851 1.056 . . . . 0.0 113.851 -176.75 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.2 tp -71.76 -36.85 70.52 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.023 0.929 . . . . 0.0 111.762 175.458 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -87.0 -10.38 53.29 Favored 'General case' 0 N--CA 1.469 0.516 0 C-N-CA 124.731 1.212 . . . . 0.0 113.679 -176.18 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 25.5 mt -54.13 -20.57 6.88 Favored 'General case' 0 CA--C 1.547 0.851 0 N-CA-C 113.941 1.089 . . . . 0.0 113.941 168.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 43.2 mt-30 -63.35 -33.75 76.22 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 125.072 1.349 . . . . 0.0 112.682 173.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -77.32 -46.78 21.83 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 123.511 0.724 . . . . 0.0 112.443 178.487 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -179.93 -172.66 44.17 Favored Glycine 0 CA--C 1.535 1.337 0 C-N-CA 124.926 1.251 . . . . 0.0 112.675 -179.157 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -67.58 110.79 2.17 Favored 'Trans proline' 0 CA--C 1.538 0.678 0 C-N-CA 123.584 2.856 . . . . 0.0 111.526 -179.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 66.1 t -85.79 133.38 29.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.805 1.242 . . . . 0.0 109.975 174.846 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.1 t -109.78 -33.6 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 C-N-CA 126.43 1.892 . . . . 0.0 111.899 -171.573 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 17.8 t30 -160.6 162.4 32.8 Favored 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 126.005 1.722 . . . . 0.0 111.056 -174.332 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 7.2 p -140.75 153.24 45.8 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 126.453 1.901 . . . . 0.0 111.33 174.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 49.2 t-80 -142.39 131.14 22.76 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 123.261 0.624 . . . . 0.0 111.355 174.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 81.5 mtp -132.45 106.35 13.22 Favored Pre-proline 0 N--CA 1.471 0.583 0 C-N-CA 124.041 0.936 . . . . 0.0 109.614 169.67 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_exo -56.99 143.05 93.72 Favored 'Trans proline' 0 CA--C 1.537 0.632 0 C-N-CA 123.233 2.622 . . . . 0.0 112.837 176.464 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 45.4 mmtm -108.8 153.87 22.88 Favored 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 124.78 1.232 . . . . 0.0 113.421 -172.478 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -79.41 144.35 34.19 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 126.944 2.098 . . . . 0.0 112.436 178.356 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 53.6 ptt85 -87.23 8.2 25.1 Favored 'General case' 0 N--CA 1.479 1.015 0 N-CA-C 115.722 1.749 . . . . 0.0 115.722 -174.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 32.2 t -132.06 -37.94 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 124.767 1.227 . . . . 0.0 111.391 -173.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 61.0 p -116.67 -18.3 10.33 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 125.62 1.568 . . . . 0.0 112.647 -175.669 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.71 8.74 64.17 Favored Glycine 0 CA--C 1.54 1.633 0 C-N-CA 124.864 1.221 . . . . 0.0 114.999 -177.44 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 39.4 mt-30 -67.01 171.29 5.64 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.118 1.367 . . . . 0.0 110.801 170.014 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 26.8 p80 -73.94 157.76 35.65 Favored 'General case' 0 N--CA 1.473 0.717 0 O-C-N 120.351 -1.468 . . . . 0.0 112.202 169.859 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 81.8 mt-30 -79.05 12.53 2.18 Favored 'General case' 0 CA--C 1.552 1.029 0 N-CA-C 114.488 1.292 . . . . 0.0 114.488 -177.65 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 87.87 1.52 82.41 Favored Glycine 0 CA--C 1.535 1.303 0 C-N-CA 124.987 1.28 . . . . 0.0 114.89 -177.084 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -144.65 160.72 40.71 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.952 1.301 . . . . 0.0 112.323 178.177 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -151.29 -178.24 25.89 Favored Glycine 0 CA--C 1.529 0.951 0 C-N-CA 125.955 1.74 . . . . 0.0 113.377 -178.231 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -143.29 149.45 37.86 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 126.141 1.776 . . . . 0.0 111.631 -178.329 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 26.1 t -132.93 128.56 56.86 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 124.593 1.157 . . . . 0.0 109.612 174.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -104.45 122.43 45.51 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 124.507 1.123 . . . . 0.0 110.977 -178.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -96.26 163.81 12.93 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 125.066 1.347 . . . . 0.0 112.176 176.229 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.5 tp -63.38 -33.47 75.6 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 112.276 0.473 . . . . 0.0 112.276 175.005 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 8.8 m -142.48 158.03 44.12 Favored 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 122.843 1.306 . . . . 0.0 112.655 -176.727 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 53.5 mp0 -67.99 -29.67 68.75 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 125.735 1.614 . . . . 0.0 113.505 -174.123 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -74.35 -26.95 60.45 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 124.001 0.92 . . . . 0.0 112.811 175.469 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 47.9 m-20 -73.47 -34.0 65.13 Favored 'General case' 0 CA--C 1.538 0.498 0 O-C-N 121.49 -0.757 . . . . 0.0 111.003 172.001 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -66.87 -47.65 71.2 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 123.022 0.529 . . . . 0.0 111.205 170.411 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -56.31 -35.87 68.03 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.877 0.871 . . . . 0.0 112.899 176.135 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 60.8 t80 -75.69 -36.79 59.94 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.413 0.685 . . . . 0.0 112.829 176.5 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -61.81 -38.81 89.5 Favored 'General case' 0 CA--C 1.539 0.538 0 O-C-N 121.056 -1.027 . . . . 0.0 111.549 177.3 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 57.4 mt -61.85 -37.93 79.36 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 C-N-CA 124.92 1.288 . . . . 0.0 111.042 175.018 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 61.4 tttp -65.45 -35.5 81.09 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 124.312 1.045 . . . . 0.0 113.144 177.315 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 19.7 pt -102.1 -14.18 8.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 N-CA-C 115.908 1.818 . . . . 0.0 115.908 -172.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 6.0 mmt -113.13 -4.08 13.85 Favored 'General case' 0 N--CA 1.485 1.286 0 N-CA-C 115.518 1.673 . . . . 0.0 115.518 -176.013 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -80.9 145.75 31.16 Favored 'General case' 0 N--CA 1.477 0.904 0 O-C-N 120.818 -1.176 . . . . 0.0 113.699 -174.47 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 25.5 mmt 58.26 9.58 1.05 Allowed 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 127.938 2.495 . . . . 0.0 115.832 -175.114 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 17.8 mt -83.2 148.16 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 C-N-CA 126.964 2.106 . . . . 0.0 111.983 -176.294 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 42.3 mtpt -99.93 69.77 1.57 Allowed 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.369 1.068 . . . . 0.0 112.448 -169.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 35.7 tp -57.42 123.39 15.31 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 123.64 0.776 . . . . 0.0 109.427 173.66 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 45.97 27.18 0.47 Allowed 'General case' 0 CA--C 1.562 1.419 0 N-CA-C 116.473 2.027 . . . . 0.0 116.473 -168.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 84.97 18.12 61.83 Favored Glycine 0 CA--C 1.544 1.871 0 O-C-N 120.222 -1.549 . . . . 0.0 116.743 176.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -131.52 122.11 18.67 Favored Pre-proline 0 CA--C 1.545 0.778 0 C-N-CA 128.34 2.656 . . . . 0.0 107.991 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -72.51 110.06 2.9 Favored 'Trans proline' 0 CA--C 1.538 0.681 0 C-N-CA 123.212 2.608 . . . . 0.0 112.614 -169.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 19.1 pt -78.72 141.29 15.63 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 C-N-CA 124.079 0.952 . . . . 0.0 111.085 174.47 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 4.8 mpt_? -108.97 128.57 55.06 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 125.712 1.605 . . . . 0.0 108.809 175.07 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 19.3 t -125.5 137.34 57.99 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 124.419 1.088 . . . . 0.0 110.979 -171.663 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 -163.14 177.85 8.75 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 125.18 1.392 . . . . 0.0 110.97 -177.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 26.3 mmmt -69.4 140.92 54.2 Favored 'General case' 0 N--CA 1.475 0.817 0 O-C-N 120.826 -1.171 . . . . 0.0 110.138 175.011 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -72.7 -11.1 60.49 Favored 'General case' 0 CA--C 1.551 1.005 0 O-C-N 121.41 -0.806 . . . . 0.0 112.472 169.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 70.7 p -87.9 -1.87 58.25 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 126.857 2.063 . . . . 0.0 114.436 170.351 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -64.97 149.73 49.25 Favored 'General case' 0 CA--C 1.547 0.833 0 CA-C-N 119.171 0.896 . . . . 0.0 113.07 -177.714 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 25.0 p80 -150.94 176.15 11.38 Favored 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 125.126 1.371 . . . . 0.0 112.649 -170.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -136.83 36.91 2.62 Favored 'General case' 0 CA--C 1.549 0.918 0 C-N-CA 124.011 0.925 . . . . 0.0 110.675 168.144 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -92.69 -41.88 9.92 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 125.14 1.376 . . . . 0.0 112.626 -174.248 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 -112.52 141.79 45.85 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.029 1.332 . . . . 0.0 111.258 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 59.9 tp -152.72 -45.94 0.1 Allowed 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 124.979 1.312 . . . . 0.0 112.263 177.615 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 23.9 m -70.37 159.27 34.45 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.985 1.314 . . . . 0.0 113.275 179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -160.5 174.15 37.16 Favored Glycine 0 CA--C 1.541 1.675 0 C-N-CA 124.812 1.196 . . . . 0.0 113.684 177.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -73.56 161.41 42.27 Favored 'Trans proline' 0 CA--C 1.541 0.84 0 C-N-CA 124.116 3.21 . . . . 0.0 113.438 -176.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 6.8 t 62.0 169.4 0.12 Allowed 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 126.945 2.098 . . . . 0.0 115.457 -178.117 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 79.8 p -129.23 -0.14 5.14 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 126.823 2.049 . . . . 0.0 113.746 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.264 0 C-N-CA 125.612 1.577 . . . . 0.0 113.806 178.64 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.66 0 N-CA-C 112.101 -0.4 . . . . 0.0 112.101 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 35.8 t -138.36 148.28 44.37 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.328 1.451 . . . . 0.0 112.024 -179.424 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 41.2 m -125.89 45.25 2.66 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 126.161 1.784 . . . . 0.0 109.217 169.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 73.04 35.51 57.65 Favored Glycine 0 CA--C 1.533 1.21 0 N-CA-C 110.814 -0.915 . . . . 0.0 110.814 -167.384 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.1 p -120.21 -33.1 3.99 Favored 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 125.981 1.713 . . . . 0.0 112.888 -172.036 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 48.2 m -79.3 -9.12 59.51 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 123.948 0.899 . . . . 0.0 113.096 169.141 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.82 166.39 33.78 Favored Glycine 0 CA--C 1.541 1.672 0 C-N-CA 125.513 1.53 . . . . 0.0 112.847 173.385 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -88.26 174.0 4.55 Favored 'Trans proline' 0 CA--C 1.54 0.783 0 C-N-CA 124.429 3.419 . . . . 0.0 114.345 -169.703 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 7.0 tp -88.15 154.95 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 C-N-CA 124.724 1.21 . . . . 0.0 110.776 168.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 16.4 m -72.65 -7.79 52.06 Favored 'General case' 0 N--CA 1.477 0.919 0 N-CA-C 114.216 1.191 . . . . 0.0 114.216 174.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -79.57 79.83 6.01 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.625 1.57 . . . . 0.0 111.555 -177.505 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 38.8 ttm180 48.64 -94.55 0.03 OUTLIER 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 127.411 2.284 . . . . 0.0 113.769 175.023 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -136.16 27.6 3.18 Favored 'General case' 0 CA--C 1.549 0.916 0 C-N-CA 126.205 1.802 . . . . 0.0 112.311 179.444 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -62.97 -17.24 61.82 Favored 'General case' 0 N--CA 1.478 0.941 0 O-C-N 120.635 -1.29 . . . . 0.0 113.545 -175.658 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -55.96 -27.14 51.21 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 124.893 1.277 . . . . 0.0 112.82 168.402 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -79.58 -3.74 48.37 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 113.654 0.983 . . . . 0.0 113.654 177.696 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.2 m -103.39 133.48 48.37 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 124.175 0.99 . . . . 0.0 109.903 173.069 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 13.9 m -104.76 148.38 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 C-N-CA 124.69 1.196 . . . . 0.0 110.697 172.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 34.9 t80 -95.82 143.08 27.35 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 126.642 1.977 . . . . 0.0 109.81 169.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.7 t -131.43 111.71 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 125.523 1.529 . . . . 0.0 109.222 173.378 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -106.29 149.33 16.63 Favored Glycine 0 CA--C 1.528 0.902 0 C-N-CA 124.623 1.106 . . . . 0.0 112.649 176.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.24 35.46 7.03 Favored Glycine 0 CA--C 1.532 1.112 0 C-N-CA 124.192 0.901 . . . . 0.0 113.644 174.423 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 85.9 mt -74.87 150.15 39.29 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 125.505 1.522 . . . . 0.0 111.273 -174.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -88.89 156.81 18.69 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 123.739 0.816 . . . . 0.0 111.802 174.588 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.74 -20.38 48.63 Favored 'General case' 0 CA--C 1.546 0.827 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.5 mtmm -81.73 -11.89 58.84 Favored 'General case' 0 N--CA 1.476 0.832 0 C-N-CA 124.717 1.207 . . . . 0.0 114.172 174.882 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 88.2 t -72.17 137.2 24.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 124.191 0.996 . . . . 0.0 111.113 177.004 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 57.0 m -134.36 163.77 28.92 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 124.811 1.244 . . . . 0.0 111.501 172.218 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -56.0 -42.78 97.9 Favored Pre-proline 0 CA--C 1.549 0.909 0 O-C-N 120.888 -1.132 . . . . 0.0 113.846 179.306 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_exo -60.59 -28.82 87.3 Favored 'Trans proline' 0 C--N 1.354 0.825 0 C-N-CA 122.252 1.968 . . . . 0.0 114.046 173.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 26.2 tp -68.21 -50.93 50.9 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 118.82 0.737 . . . . 0.0 110.135 172.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 20.5 mt -62.04 -22.12 65.47 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 178.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.5 t90 -74.27 -66.8 0.68 Allowed 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 123.255 0.622 . . . . 0.0 110.949 170.006 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.8 mt-10 -65.37 -29.95 70.73 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 114.386 1.254 . . . . 0.0 114.386 -171.91 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.7 tp -69.04 -35.22 76.35 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.535 0.734 . . . . 0.0 111.579 175.117 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -89.34 -10.85 45.13 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.123 1.369 . . . . 0.0 113.444 -174.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 44.5 mt -54.86 -19.8 7.34 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 124.529 1.132 . . . . 0.0 113.874 169.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 40.5 mt-30 -66.4 -31.54 72.36 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 125.413 1.485 . . . . 0.0 112.638 173.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -77.08 -46.55 23.24 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.23 0.612 . . . . 0.0 112.182 176.504 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.45 -173.68 45.55 Favored Glycine 0 CA--C 1.537 1.416 0 C-N-CA 125.399 1.476 . . . . 0.0 112.492 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -66.76 112.62 2.49 Favored 'Trans proline' 0 CA--C 1.538 0.68 0 C-N-CA 123.579 2.852 . . . . 0.0 111.766 -179.302 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 75.6 t -87.14 134.46 27.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 125.006 1.322 . . . . 0.0 109.794 174.602 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.9 t -109.14 -33.8 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 126.527 1.931 . . . . 0.0 111.847 -171.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 21.3 t30 -160.84 163.24 32.23 Favored 'General case' 0 CA--C 1.554 1.107 0 C-N-CA 125.851 1.66 . . . . 0.0 111.05 -175.08 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 4.0 p -140.06 154.54 47.1 Favored 'General case' 0 N--CA 1.481 1.079 0 C-N-CA 126.429 1.892 . . . . 0.0 111.295 174.173 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 47.9 t-80 -142.18 132.0 24.28 Favored 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 123.445 0.698 . . . . 0.0 111.142 175.531 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 87.6 mtp -133.28 106.61 12.22 Favored Pre-proline 0 N--CA 1.472 0.671 0 C-N-CA 123.876 0.871 . . . . 0.0 109.649 169.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_exo -57.8 140.28 93.15 Favored 'Trans proline' 0 CA--C 1.538 0.689 0 C-N-CA 123.283 2.655 . . . . 0.0 113.101 177.535 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -112.86 146.18 39.36 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 125.209 1.404 . . . . 0.0 112.822 -173.371 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -66.66 139.12 57.84 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 125.479 1.512 . . . . 0.0 111.618 170.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 34.0 ptt-85 -82.74 5.56 20.98 Favored 'General case' 0 N--CA 1.48 1.034 0 N-CA-C 115.908 1.818 . . . . 0.0 115.908 -173.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 23.3 t -131.4 -38.79 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 C-N-CA 125.558 1.543 . . . . 0.0 111.277 -173.894 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 33.7 p -106.24 -16.79 14.49 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 124.771 1.228 . . . . 0.0 112.321 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 71.39 3.52 53.78 Favored Glycine 0 CA--C 1.537 1.448 0 C-N-CA 124.811 1.196 . . . . 0.0 115.221 177.753 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 71.9 mm-40 -80.08 162.65 24.68 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.703 1.201 . . . . 0.0 110.947 178.253 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 18.0 p80 -68.91 153.21 44.2 Favored 'General case' 0 N--CA 1.471 0.602 0 O-C-N 120.986 -1.071 . . . . 0.0 112.621 177.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 45.9 mt-30 -85.06 17.04 3.11 Favored 'General case' 0 CA--C 1.549 0.92 0 N-CA-C 114.251 1.204 . . . . 0.0 114.251 -173.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 87.52 1.5 83.35 Favored Glycine 0 CA--C 1.535 1.333 0 C-N-CA 125.06 1.314 . . . . 0.0 114.97 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -145.13 161.66 38.93 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 124.899 1.279 . . . . 0.0 112.603 178.19 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -153.54 -177.36 26.96 Favored Glycine 0 CA--C 1.531 1.039 0 C-N-CA 125.963 1.744 . . . . 0.0 113.065 -177.417 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 80.8 m-85 -144.22 150.79 38.52 Favored 'General case' 0 C--O 1.237 0.438 0 C-N-CA 126.048 1.739 . . . . 0.0 111.574 -178.116 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 20.1 t -132.51 130.11 59.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 124.889 1.276 . . . . 0.0 109.642 176.085 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 63.2 tt0 -106.72 119.67 39.94 Favored 'General case' 0 N--CA 1.465 0.324 0 C-N-CA 124.814 1.246 . . . . 0.0 110.582 -176.858 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -96.17 162.58 13.47 Favored 'General case' 0 C--O 1.234 0.272 0 C-N-CA 124.959 1.304 . . . . 0.0 112.441 177.353 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.5 tp -64.13 -34.81 78.91 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 123.052 0.541 . . . . 0.0 112.298 176.636 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.7 m -141.76 157.89 44.48 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-O 122.601 1.191 . . . . 0.0 112.324 -177.23 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 60.3 mp0 -65.18 -35.75 82.07 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 125.117 1.367 . . . . 0.0 112.871 -175.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -67.89 -25.77 65.67 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 113.218 0.822 . . . . 0.0 113.218 177.035 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 55.2 m-20 -76.02 -33.9 59.66 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 123.781 0.832 . . . . 0.0 111.357 173.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -70.83 -45.85 63.8 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.841 0.857 . . . . 0.0 111.386 173.213 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -55.91 -34.83 65.94 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 124.134 0.974 . . . . 0.0 112.31 174.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 60.3 t80 -78.09 -36.44 48.17 Favored 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 123.756 0.823 . . . . 0.0 112.902 177.117 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.11 -36.58 82.16 Favored 'General case' 0 CA--C 1.539 0.554 0 O-C-N 120.921 -1.112 . . . . 0.0 111.485 176.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 57.9 mt -63.23 -34.23 65.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 124.732 1.213 . . . . 0.0 111.31 174.022 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 62.1 tttp -70.03 -36.59 75.17 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.354 1.061 . . . . 0.0 113.023 176.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 14.1 pt -101.58 -13.97 8.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 N-CA-C 116.135 1.902 . . . . 0.0 116.135 -171.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 13.5 mmt -113.12 -2.28 14.19 Favored 'General case' 0 N--CA 1.484 1.25 0 N-CA-C 115.247 1.573 . . . . 0.0 115.247 -176.228 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -82.53 140.89 33.05 Favored 'General case' 0 N--CA 1.476 0.844 0 O-C-N 120.868 -1.145 . . . . 0.0 114.037 -174.353 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . 0.253 7.9 mmt 56.33 22.26 6.16 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 127.537 2.335 . . . . 0.0 115.201 -177.44 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 20.9 mt -90.0 149.32 4.08 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 127.786 2.435 . . . . 0.0 111.257 177.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 42.9 mtpt -100.61 70.54 1.45 Allowed 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 124.188 0.995 . . . . 0.0 112.498 -169.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 31.3 tp -57.43 123.55 15.87 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.723 0.809 . . . . 0.0 109.709 174.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 59.0 m-85 45.85 27.44 0.47 Allowed 'General case' 0 CA--C 1.561 1.387 0 N-CA-C 116.487 2.032 . . . . 0.0 116.487 -168.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 83.58 21.5 57.97 Favored Glycine 0 CA--C 1.544 1.858 0 O-C-N 120.068 -1.645 . . . . 0.0 116.522 177.038 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -135.02 121.71 14.77 Favored Pre-proline 0 CA--C 1.544 0.731 0 C-N-CA 128.546 2.738 . . . . 0.0 107.803 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -72.2 119.57 6.24 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 123.055 2.504 . . . . 0.0 112.207 -169.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 18.4 pt -88.33 141.41 14.34 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 C-N-CA 124.341 1.056 . . . . 0.0 111.696 176.199 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 36.6 tpt85 -104.32 127.79 52.02 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 125.828 1.651 . . . . 0.0 108.948 173.441 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.8 t -122.55 136.33 59.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 123.818 0.847 . . . . 0.0 110.697 -175.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -160.44 -178.53 6.98 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 123.987 0.915 . . . . 0.0 112.122 177.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 7.8 mmmm -63.62 141.88 58.6 Favored 'General case' 0 N--CA 1.477 0.903 0 O-C-N 121.186 -0.946 . . . . 0.0 110.37 172.9 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -66.13 -30.7 71.24 Favored 'General case' 0 CA--C 1.545 0.755 0 O-C-N 121.807 -0.558 . . . . 0.0 111.947 172.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 38.2 m -119.3 83.16 1.99 Allowed 'General case' 0 N--CA 1.469 0.505 0 C-N-CA 126.07 1.748 . . . . 0.0 109.392 168.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -78.38 46.13 0.61 Allowed 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 125.172 1.389 . . . . 0.0 113.321 -177.227 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 11.7 m-70 -123.62 146.32 48.27 Favored 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 126.859 2.063 . . . . 0.0 111.444 -175.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 35.8 t30 -116.87 119.49 35.53 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 124.865 1.266 . . . . 0.0 110.322 173.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 12.5 mptt -110.03 9.94 24.17 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 126.205 1.802 . . . . 0.0 113.486 178.291 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 47.6 t30 -66.82 154.64 40.36 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 124.142 0.977 . . . . 0.0 111.642 172.052 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 83.9 mt -79.9 154.48 28.31 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 124.655 1.182 . . . . 0.0 112.908 -176.405 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 11.8 t -151.79 159.0 44.06 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 125.554 1.542 . . . . 0.0 111.484 175.778 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 65.74 73.68 0.58 Allowed Glycine 0 CA--C 1.541 1.688 0 C-N-CA 125.533 1.539 . . . . 0.0 114.322 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_exo -61.17 153.07 67.46 Favored 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 123.697 2.931 . . . . 0.0 114.242 -179.452 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 10.6 t -76.0 154.58 35.67 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 124.132 0.973 . . . . 0.0 112.249 175.025 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.5 t -150.09 157.94 43.65 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 125.372 1.469 . . . . 0.0 111.861 178.823 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.33 0 C-N-CA 125.738 1.637 . . . . 0.0 113.734 -179.145 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.428 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.0 t -139.67 172.33 12.95 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 125.344 1.458 . . . . 0.0 111.343 178.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 40.4 m 52.26 34.01 13.79 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.443 1.497 . . . . 0.0 113.987 -176.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 81.0 1.55 90.0 Favored Glycine 0 CA--C 1.538 1.524 0 C-N-CA 125.168 1.366 . . . . 0.0 115.707 -177.619 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 36.3 t -75.99 134.35 40.18 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 119.349 1.574 . . . . 0.0 112.386 177.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.0 p -81.96 -7.0 59.58 Favored 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 125.344 1.458 . . . . 0.0 113.827 173.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -68.73 153.44 52.93 Favored Glycine 0 CA--C 1.543 1.783 0 C-N-CA 124.171 0.891 . . . . 0.0 114.291 -177.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -79.12 170.87 17.12 Favored 'Trans proline' 0 CA--C 1.542 0.908 0 C-N-CA 124.128 3.219 . . . . 0.0 112.972 177.535 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 20.6 tt -139.29 146.39 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 C-N-CA 125.533 1.533 . . . . 0.0 110.607 169.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.0 m -77.93 -13.95 59.71 Favored 'General case' 0 N--CA 1.474 0.743 0 N-CA-C 114.221 1.193 . . . . 0.0 114.221 -177.277 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 58.63 -28.93 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.35 0 C-N-CA 128.798 2.839 . . . . 0.0 117.884 -177.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -61.03 139.95 57.95 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 125.402 1.481 . . . . 0.0 114.265 -173.22 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . 0.26 0.7 OUTLIER 46.1 27.88 0.58 Allowed 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 127.803 2.441 . . . . 0.0 116.821 174.347 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.5 tp-100 -67.74 -19.25 65.11 Favored 'General case' 0 CA--C 1.544 0.746 0 O-C-N 120.81 -1.181 . . . . 0.0 113.512 -172.259 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 18.5 m-20 -67.32 -23.05 65.6 Favored 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 124.342 1.057 . . . . 0.0 113.117 169.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.43 1.51 51.06 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 124.874 1.269 . . . . 0.0 113.03 171.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 17.5 m -100.63 137.0 39.61 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 124.427 1.091 . . . . 0.0 109.258 169.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.9 m -106.2 145.83 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.556 1.142 . . . . 0.0 110.349 172.229 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -95.81 142.7 27.77 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 126.083 1.753 . . . . 0.0 109.527 169.575 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 24.2 t -130.02 115.91 35.07 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 C-N-CA 125.553 1.541 . . . . 0.0 109.094 174.274 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -109.56 150.28 17.3 Favored Glycine 0 CA--C 1.531 1.037 0 C-N-CA 124.511 1.053 . . . . 0.0 113.045 176.557 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 93.04 32.99 7.54 Favored Glycine 0 CA--C 1.533 1.177 0 C-N-CA 124.782 1.182 . . . . 0.0 114.01 175.488 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 87.0 mt -78.72 153.26 31.03 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 125.219 1.408 . . . . 0.0 112.029 -170.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -90.97 155.66 18.55 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 124.151 0.98 . . . . 0.0 111.997 176.453 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.51 -20.23 44.17 Favored 'General case' 0 CA--C 1.547 0.832 0 N-CA-C 114.988 1.477 . . . . 0.0 114.988 -179.112 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.4 mtmm -81.6 -9.04 59.77 Favored 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 124.763 1.225 . . . . 0.0 114.119 175.194 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.3 t -78.99 138.65 19.7 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 124.857 1.263 . . . . 0.0 111.275 178.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 6.7 t -147.05 167.75 23.29 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 123.601 0.76 . . . . 0.0 112.43 171.058 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -48.81 -45.56 72.32 Favored Pre-proline 0 CA--C 1.545 0.751 0 N-CA-C 115.923 1.823 . . . . 0.0 115.923 178.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -69.55 -26.64 28.36 Favored 'Trans proline' 0 C--N 1.354 0.831 0 CA-C-N 122.021 1.757 . . . . 0.0 112.978 177.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 18.3 tp -66.46 -53.86 30.62 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 118.589 0.631 . . . . 0.0 109.486 170.001 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 25.9 mt -55.42 -42.12 73.7 Favored 'General case' 0 N--CA 1.464 0.257 0 C-N-CA 122.769 0.428 . . . . 0.0 111.601 -176.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.8 t90 -57.96 -61.81 2.27 Favored 'General case' 0 C--N 1.331 -0.236 0 C-N-CA 123.236 0.614 . . . . 0.0 111.109 179.328 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -64.41 -30.19 71.23 Favored 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 113.699 1.0 . . . . 0.0 113.699 -178.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 7.4 tp -70.73 -35.91 72.93 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 123.95 0.9 . . . . 0.0 111.879 176.037 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 14.8 m-85 -89.2 -10.64 46.3 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 124.816 1.247 . . . . 0.0 113.596 -175.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 27.8 mt -54.38 -20.73 7.91 Favored 'General case' 0 CA--C 1.547 0.844 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 168.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -61.85 -34.14 75.44 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 125.055 1.342 . . . . 0.0 112.566 173.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -78.9 -45.6 20.23 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 123.559 0.744 . . . . 0.0 112.666 178.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 178.48 -172.46 44.85 Favored Glycine 0 CA--C 1.536 1.403 0 C-N-CA 124.815 1.197 . . . . 0.0 112.813 -178.377 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -67.81 110.22 2.08 Favored 'Trans proline' 0 CA--C 1.538 0.68 0 C-N-CA 123.663 2.908 . . . . 0.0 111.783 -178.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 63.9 t -85.18 134.3 27.39 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 C-N-CA 124.916 1.287 . . . . 0.0 109.825 174.07 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 5.7 t -108.69 -34.31 2.63 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 126.235 1.814 . . . . 0.0 111.805 -172.611 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 21.3 t30 -160.79 160.82 31.69 Favored 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 125.995 1.718 . . . . 0.0 110.863 -174.343 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 12.2 p -137.31 156.42 48.27 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 125.9 1.68 . . . . 0.0 111.535 172.644 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 47.3 t-80 -142.11 134.25 27.58 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 123.461 0.704 . . . . 0.0 111.442 175.493 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 29.5 mmm -133.41 105.56 12.1 Favored Pre-proline 0 N--CA 1.471 0.604 0 C-N-CA 124.57 1.148 . . . . 0.0 109.336 172.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_exo -59.24 134.95 62.43 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 123.177 2.585 . . . . 0.0 112.523 176.259 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 41.4 mmtm -109.9 148.63 31.22 Favored 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 125.225 1.41 . . . . 0.0 112.65 -173.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -66.93 148.61 51.72 Favored 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 125.231 1.412 . . . . 0.0 112.395 170.15 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 17.6 ptp180 -87.12 -1.35 57.82 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 116.645 2.091 . . . . 0.0 116.645 -172.568 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 3.5 m -135.54 -31.53 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 C-N-CA 124.619 1.168 . . . . 0.0 113.355 -178.697 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 69.2 p -103.9 -18.41 14.63 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 124.995 1.318 . . . . 0.0 111.898 179.336 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 71.43 -0.54 32.9 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 125.381 1.467 . . . . 0.0 116.243 170.911 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -79.33 164.16 24.3 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 125.305 1.442 . . . . 0.0 111.412 173.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 24.4 p80 -69.69 157.03 38.05 Favored 'General case' 0 N--CA 1.471 0.607 0 O-C-N 121.216 -0.928 . . . . 0.0 113.199 -178.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 45.2 mt-30 -85.71 16.8 3.7 Favored 'General case' 0 CA--C 1.551 1.007 0 N-CA-C 114.518 1.303 . . . . 0.0 114.518 -173.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 89.49 0.24 79.69 Favored Glycine 0 CA--C 1.536 1.352 0 C-N-CA 125.395 1.474 . . . . 0.0 115.112 179.536 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -145.63 156.72 43.84 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 125.411 1.484 . . . . 0.0 112.235 179.126 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -145.87 178.18 23.76 Favored Glycine 0 CA--C 1.532 1.124 0 C-N-CA 126.437 1.97 . . . . 0.0 112.92 -175.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 76.0 m-85 -141.85 150.27 41.38 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 125.537 1.535 . . . . 0.0 112.251 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 22.6 t -134.32 130.64 54.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 C-N-CA 125.043 1.337 . . . . 0.0 109.977 175.704 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -107.96 122.67 47.31 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 124.917 1.287 . . . . 0.0 111.073 -176.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -99.05 161.07 13.82 Favored 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 125.29 1.436 . . . . 0.0 112.581 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 14.4 tp -62.84 -34.44 77.34 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 123.305 0.642 . . . . 0.0 112.206 178.395 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.7 m -141.07 154.94 46.19 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 124.453 1.101 . . . . 0.0 111.831 -178.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 12.5 tm-20 -64.42 -31.96 73.38 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 124.479 1.111 . . . . 0.0 113.221 -177.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -69.42 -26.26 64.53 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 113.154 0.798 . . . . 0.0 113.154 176.046 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 41.6 m-20 -77.26 -33.22 55.98 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 123.707 0.803 . . . . 0.0 111.412 173.405 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.7 -43.67 71.96 Favored 'General case' 0 CA--C 1.539 0.545 0 O-C-N 121.832 -0.543 . . . . 0.0 111.355 172.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -61.58 -28.76 69.57 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 124.088 0.955 . . . . 0.0 112.853 178.082 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 61.6 t80 -79.88 -34.21 39.34 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.172 0.989 . . . . 0.0 112.9 173.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.57 -37.15 86.56 Favored 'General case' 0 CA--C 1.537 0.457 0 O-C-N 121.119 -0.988 . . . . 0.0 111.091 176.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 65.2 mt -61.31 -39.85 84.09 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 C-N-CA 125.159 1.384 . . . . 0.0 111.224 172.707 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 62.4 tttp -62.88 -38.16 89.79 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 124.051 0.94 . . . . 0.0 112.618 178.184 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 44.9 pt -96.07 -29.5 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 115.334 1.605 . . . . 0.0 115.334 -175.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 5.7 mmt -98.07 -0.75 43.93 Favored 'General case' 0 N--CA 1.482 1.156 0 N-CA-C 115.194 1.553 . . . . 0.0 115.194 -173.24 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -83.9 140.29 32.06 Favored 'General case' 0 CA--C 1.539 0.546 0 O-C-N 121.066 -1.021 . . . . 0.0 111.7 178.396 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 28.1 ttm 60.05 13.41 3.75 Favored 'General case' 0 CA--C 1.552 1.021 0 C-N-CA 125.448 1.499 . . . . 0.0 114.84 -173.316 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 1.5 mt -71.04 159.38 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 C-N-CA 125.659 1.583 . . . . 0.0 110.46 169.014 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 50.8 mtpt -119.9 69.52 0.85 Allowed 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 125.69 1.596 . . . . 0.0 112.214 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 40.2 tp -57.49 127.17 30.66 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 124.113 0.965 . . . . 0.0 109.949 174.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 64.1 m-85 46.17 27.37 0.54 Allowed 'General case' 0 CA--C 1.561 1.384 0 N-CA-C 116.325 1.972 . . . . 0.0 116.325 -168.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 78.99 23.56 63.57 Favored Glycine 0 CA--C 1.542 1.745 0 O-C-N 120.096 -1.627 . . . . 0.0 116.053 176.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -131.12 120.01 18.04 Favored Pre-proline 0 CA--C 1.542 0.654 0 C-N-CA 128.154 2.581 . . . . 0.0 107.915 179.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -69.78 130.33 19.13 Favored 'Trans proline' 0 CA--C 1.536 0.602 0 C-N-CA 122.979 2.452 . . . . 0.0 112.891 -171.397 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 27.3 pt -103.95 161.8 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 125.498 1.519 . . . . 0.0 112.27 179.301 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 89.6 mmt-85 -128.82 139.29 52.24 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 125.292 1.437 . . . . 0.0 110.714 170.343 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.4 t -133.74 136.31 54.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 124.404 1.082 . . . . 0.0 111.386 -169.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -157.07 172.9 17.84 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 125.795 1.638 . . . . 0.0 111.49 179.269 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.9 mmmm -60.26 142.27 54.86 Favored 'General case' 0 N--CA 1.481 1.115 0 O-C-N 121.323 -0.861 . . . . 0.0 109.225 171.432 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -67.94 -20.21 65.04 Favored 'General case' 0 CA--C 1.548 0.883 0 N-CA-C 113.302 0.853 . . . . 0.0 113.302 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 70.8 m -122.76 46.72 2.09 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 126.276 1.831 . . . . 0.0 111.729 173.582 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.72 156.62 36.54 Favored 'General case' 0 CA--C 1.547 0.838 0 N-CA-C 114.098 1.147 . . . . 0.0 114.098 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -138.44 158.37 44.4 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 126.294 1.838 . . . . 0.0 111.368 177.247 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -77.26 146.93 36.58 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 123.59 0.756 . . . . 0.0 111.076 171.356 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -75.84 118.85 19.07 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.884 0.874 . . . . 0.0 111.3 179.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 -93.41 -22.65 18.78 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 124.661 1.185 . . . . 0.0 112.929 173.425 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 47.1 tp -69.78 150.19 47.15 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 125.275 1.43 . . . . 0.0 112.293 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 20.4 m -67.02 167.28 12.1 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 125.502 1.521 . . . . 0.0 114.1 178.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -74.9 -169.58 24.33 Favored Glycine 0 CA--C 1.546 1.978 0 C-N-CA 124.703 1.145 . . . . 0.0 113.413 168.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -64.79 152.17 83.07 Favored 'Trans proline' 0 CA--C 1.541 0.839 0 C-N-CA 123.463 2.775 . . . . 0.0 112.613 178.317 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 85.5 p -79.26 -21.74 45.71 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -176.029 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 34.2 m 54.18 27.7 8.11 Favored 'General case' 0 N--CA 1.478 0.941 0 C-N-CA 125.766 1.626 . . . . 0.0 114.433 -174.205 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.251 0 C-N-CA 125.655 1.598 . . . . 0.0 113.84 178.789 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.588 0 N-CA-C 111.741 -0.543 . . . . 0.0 111.741 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 49.6 m -63.59 141.72 58.66 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 124.634 1.174 . . . . 0.0 112.837 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 21.0 m -72.07 -27.37 62.63 Favored 'General case' 0 N--CA 1.476 0.868 0 N-CA-C 113.563 0.949 . . . . 0.0 113.563 -178.851 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 154.62 -175.63 32.66 Favored Glycine 0 CA--C 1.535 1.314 0 C-N-CA 125.319 1.438 . . . . 0.0 113.215 178.322 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.2 t -152.63 133.72 14.19 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 125.602 1.561 . . . . 0.0 109.928 174.225 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 92.5 p -131.73 150.91 52.0 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 124.492 1.117 . . . . 0.0 113.869 -175.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 75.24 93.18 0.17 Allowed Glycine 0 CA--C 1.54 1.625 0 C-N-CA 124.904 1.24 . . . . 0.0 113.637 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -57.83 150.33 63.62 Favored 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 123.809 3.006 . . . . 0.0 113.177 174.654 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 8.1 tt -72.92 152.63 7.61 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 N-CA-C 113.496 0.924 . . . . 0.0 113.496 -171.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 64.4 p -98.88 -0.94 41.35 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 125.969 1.708 . . . . 0.0 114.634 176.495 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -126.14 133.75 51.51 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.413 1.485 . . . . 0.0 112.108 -176.308 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 28.2 mtm180 45.35 -136.68 0.6 Allowed 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 125.865 1.666 . . . . 0.0 111.835 -171.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 18.6 m120 -131.6 40.76 3.37 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 126.242 1.817 . . . . 0.0 110.43 177.128 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 16.7 mm100 -58.54 -22.96 57.13 Favored 'General case' 0 CA--C 1.547 0.841 0 N-CA-C 114.693 1.368 . . . . 0.0 114.693 -168.906 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -75.48 -19.19 59.57 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 114.025 1.12 . . . . 0.0 114.025 175.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -117.67 12.45 13.99 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 126.097 1.759 . . . . 0.0 112.062 172.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 31.8 m -109.18 137.13 47.55 Favored 'General case' 0 N--CA 1.468 0.428 0 C-N-CA 125.165 1.386 . . . . 0.0 108.664 173.472 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.3 m -98.26 146.56 7.86 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 123.348 0.659 . . . . 0.0 110.193 171.056 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 12.0 t80 -95.08 141.8 28.29 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 125.561 1.544 . . . . 0.0 108.42 168.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.6 t -130.63 111.99 21.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 125.37 1.468 . . . . 0.0 109.059 177.575 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -107.36 145.81 16.1 Favored Glycine 0 CA--C 1.53 1.022 0 C-N-CA 124.368 0.985 . . . . 0.0 112.681 177.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 99.54 30.17 6.66 Favored Glycine 0 CA--C 1.537 1.411 0 C-N-CA 124.985 1.278 . . . . 0.0 114.352 176.019 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 85.2 mt -77.3 144.69 37.91 Favored 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 125.415 1.486 . . . . 0.0 111.699 -172.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -85.07 158.91 20.31 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 123.721 0.809 . . . . 0.0 112.519 176.063 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.48 -21.63 52.27 Favored 'General case' 0 CA--C 1.547 0.832 0 N-CA-C 114.534 1.309 . . . . 0.0 114.534 177.687 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.0 mtmm -80.0 -12.73 59.68 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 114.271 1.212 . . . . 0.0 114.271 174.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 66.8 t -71.4 140.16 18.68 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 C-N-CA 124.056 0.942 . . . . 0.0 111.235 178.329 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 91.3 p -134.57 161.43 35.1 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 125.093 1.357 . . . . 0.0 112.135 175.728 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -59.59 -39.63 72.89 Favored Pre-proline 0 CA--C 1.546 0.8 0 O-C-N 120.878 -1.139 . . . . 0.0 113.512 177.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_exo -62.29 -31.17 81.94 Favored 'Trans proline' 0 C--N 1.353 0.798 0 C-N-CA 122.587 2.192 . . . . 0.0 114.005 170.337 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 27.5 tp -67.38 -50.46 59.61 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 119.199 0.909 . . . . 0.0 109.862 173.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 20.2 mt -61.32 -22.6 65.04 Favored 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 113.118 0.785 . . . . 0.0 113.118 178.616 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.6 t90 -74.02 -66.69 0.68 Allowed 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 123.153 0.581 . . . . 0.0 110.851 171.293 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 39.0 mt-10 -64.74 -30.78 71.8 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 114.064 1.135 . . . . 0.0 114.064 -172.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.0 tp -69.13 -31.88 70.87 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 123.687 0.795 . . . . 0.0 112.148 175.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -92.59 -10.47 37.37 Favored 'General case' 0 CA--C 1.537 0.481 0 C-N-CA 125.227 1.411 . . . . 0.0 113.465 -175.102 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 50.4 mt -55.33 -18.07 5.88 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.395 1.078 . . . . 0.0 113.852 169.268 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 40.7 mt-30 -64.43 -33.24 75.41 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 125.456 1.502 . . . . 0.0 112.764 172.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.25 -45.88 18.89 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 123.469 0.707 . . . . 0.0 112.661 177.68 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.93 -171.6 43.08 Favored Glycine 0 CA--C 1.535 1.334 0 C-N-CA 124.307 0.956 . . . . 0.0 113.098 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -67.96 107.88 1.6 Allowed 'Trans proline' 0 CA--C 1.537 0.658 0 C-N-CA 123.698 2.932 . . . . 0.0 111.441 -179.586 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 64.3 t -82.62 133.63 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 C-N-CA 124.717 1.207 . . . . 0.0 109.602 172.678 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 9.1 t -109.03 -33.25 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 126.238 1.815 . . . . 0.0 111.71 -171.789 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 20.6 t30 -161.59 160.91 29.48 Favored 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 126.095 1.758 . . . . 0.0 110.926 -175.134 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 4.0 p -136.74 153.92 50.72 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 125.709 1.603 . . . . 0.0 111.845 171.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 15.9 t-80 -142.36 132.31 24.41 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 123.699 0.8 . . . . 0.0 111.301 177.672 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 88.6 mtp -134.39 104.2 11.26 Favored Pre-proline 0 N--CA 1.473 0.693 0 C-N-CA 124.149 0.979 . . . . 0.0 109.509 171.438 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_exo -55.62 129.7 36.48 Favored 'Trans proline' 0 CA--C 1.536 0.579 0 C-N-CA 123.31 2.673 . . . . 0.0 113.581 -179.507 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 45.6 mmtm -94.44 148.6 22.07 Favored 'General case' 0 N--CA 1.473 0.678 0 C-N-CA 124.937 1.295 . . . . 0.0 112.162 -177.181 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -80.79 147.39 30.51 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.922 1.689 . . . . 0.0 113.55 -175.275 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 17.4 ptp180 -89.01 6.33 40.17 Favored 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 115.729 1.751 . . . . 0.0 115.729 -175.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 26.3 t -131.51 -38.56 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 124.958 1.303 . . . . 0.0 111.256 -175.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.0 p -113.06 -20.76 11.38 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 125.569 1.548 . . . . 0.0 112.704 -176.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 74.01 0.57 56.65 Favored Glycine 0 CA--C 1.54 1.596 0 C-N-CA 124.977 1.275 . . . . 0.0 115.66 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 21.8 mm100 -74.67 170.95 14.78 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 124.945 1.298 . . . . 0.0 111.062 172.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 22.2 p80 -70.45 151.48 45.1 Favored 'General case' 0 N--CA 1.473 0.693 0 O-C-N 120.523 -1.36 . . . . 0.0 111.453 169.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 83.0 mt-30 -88.12 25.56 1.57 Allowed 'General case' 0 CA--C 1.549 0.906 0 N-CA-C 114.498 1.296 . . . . 0.0 114.498 -174.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.74 4.93 84.7 Favored Glycine 0 CA--C 1.535 1.298 0 C-N-CA 124.771 1.176 . . . . 0.0 115.289 175.539 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 39.3 p90 -144.36 161.17 39.66 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 124.623 1.169 . . . . 0.0 112.422 176.676 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -152.45 -177.29 25.95 Favored Glycine 0 CA--C 1.53 0.97 0 C-N-CA 125.578 1.561 . . . . 0.0 113.136 -177.518 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -142.37 149.01 38.82 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 126.12 1.768 . . . . 0.0 111.717 -178.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 14.9 t -132.53 122.26 47.1 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.854 0 C-N-CA 124.448 1.099 . . . . 0.0 110.215 175.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 47.6 tt0 -97.39 120.64 38.12 Favored 'General case' 0 N--CA 1.467 0.386 0 C-N-CA 125.083 1.353 . . . . 0.0 110.399 -175.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 -99.0 159.8 14.71 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 124.702 1.201 . . . . 0.0 112.298 176.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 14.3 tp -61.87 -34.38 75.91 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 123.302 0.641 . . . . 0.0 112.383 177.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 19.4 m -143.32 155.42 44.45 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.635 1.174 . . . . 0.0 112.071 -177.312 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -60.78 -34.01 73.84 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.501 1.12 . . . . 0.0 113.142 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -68.49 -22.89 64.52 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 177.011 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 53.2 m-20 -82.62 -31.16 28.98 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 123.926 0.891 . . . . 0.0 111.577 172.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -68.89 -42.52 76.83 Favored 'General case' 0 CA--C 1.544 0.721 0 O-C-N 121.654 -0.654 . . . . 0.0 111.09 170.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -59.8 -28.08 67.14 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 124.307 1.043 . . . . 0.0 112.942 173.206 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 6.8 t80 -73.6 -41.42 62.89 Favored 'General case' 0 CA--C 1.536 0.432 0 O-C-N 121.232 -0.918 . . . . 0.0 111.635 172.46 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -68.46 -37.17 79.95 Favored 'General case' 0 CA--C 1.535 0.404 0 O-C-N 120.885 -1.134 . . . . 0.0 112.109 -178.651 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 77.8 mt -59.26 -37.35 68.41 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 124.063 0.945 . . . . 0.0 110.793 171.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 3.3 ttmp? -70.11 -37.58 75.38 Favored 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 124.969 1.308 . . . . 0.0 113.275 -177.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 19.5 pt -94.99 -36.38 6.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 N-CA-C 115.423 1.638 . . . . 0.0 115.423 -179.447 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 14.2 mmt -94.05 -0.25 55.54 Favored 'General case' 0 N--CA 1.481 1.098 0 N-CA-C 114.931 1.456 . . . . 0.0 114.931 -169.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -82.69 139.76 33.49 Favored 'General case' 0 CA--C 1.539 0.55 0 O-C-N 121.206 -0.934 . . . . 0.0 111.799 177.242 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 28.0 ttm 60.35 12.26 3.33 Favored 'General case' 0 CA--C 1.55 0.962 0 C-N-CA 125.555 1.542 . . . . 0.0 114.99 -173.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.1 mt -72.02 158.63 6.1 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.598 0 C-N-CA 125.64 1.576 . . . . 0.0 110.311 169.017 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 49.7 mtpt -117.91 71.52 0.83 Allowed 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 125.379 1.472 . . . . 0.0 112.125 -177.564 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 27.7 tp -58.65 126.97 29.86 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 123.819 0.848 . . . . 0.0 109.961 175.413 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 67.2 m-85 45.82 29.9 0.78 Allowed 'General case' 0 CA--C 1.561 1.393 0 N-CA-C 116.105 1.891 . . . . 0.0 116.105 -168.669 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.94 19.95 69.0 Favored Glycine 0 CA--C 1.541 1.67 0 O-C-N 120.271 -1.518 . . . . 0.0 116.308 174.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -132.36 124.57 19.29 Favored Pre-proline 0 CA--C 1.54 0.587 0 C-N-CA 128.186 2.595 . . . . 0.0 108.036 179.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -70.57 131.09 19.41 Favored 'Trans proline' 0 CA--C 1.537 0.645 0 C-N-CA 123.364 2.71 . . . . 0.0 113.074 -169.772 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 21.2 pt -102.0 162.77 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.618 1.567 . . . . 0.0 112.218 176.608 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 89.4 mmt-85 -129.02 140.39 51.65 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 125.342 1.457 . . . . 0.0 111.035 170.509 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 20.9 t -132.58 136.58 55.77 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 C-N-CA 124.598 1.159 . . . . 0.0 111.494 -172.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -158.05 174.14 15.67 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 126.189 1.796 . . . . 0.0 111.068 179.12 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 11.8 mmmm -59.25 139.54 56.87 Favored 'General case' 0 N--CA 1.476 0.865 0 C-N-CA 123.644 0.778 . . . . 0.0 109.781 171.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -73.9 -5.39 40.83 Favored 'General case' 0 CA--C 1.553 1.086 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 175.176 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 88.3 p -112.33 13.59 20.35 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 127.47 2.308 . . . . 0.0 114.121 172.18 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -54.04 -25.73 22.92 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 115.357 1.614 . . . . 0.0 115.357 -169.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 21.4 m80 -62.85 -17.84 62.02 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.388 1.475 . . . . 0.0 113.828 176.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 17.2 t30 -66.97 -14.87 63.3 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.78 1.232 . . . . 0.0 114.127 -179.371 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 80.8 tttt -51.23 -22.73 2.86 Favored 'General case' 0 N--CA 1.481 1.078 0 C-N-CA 126.482 1.913 . . . . 0.0 114.377 176.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -56.32 -28.43 58.88 Favored 'General case' 0 CA--C 1.55 0.95 0 C-N-CA 124.804 1.242 . . . . 0.0 113.728 171.717 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 93.7 mt -108.07 104.92 14.46 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 125.688 1.595 . . . . 0.0 108.769 170.28 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 80.2 p -96.81 -11.81 24.43 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 115.453 1.649 . . . . 0.0 115.453 -169.451 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -163.05 174.77 39.4 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 124.57 1.081 . . . . 0.0 113.5 -179.087 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -57.69 134.58 63.88 Favored 'Trans proline' 0 CA--C 1.536 0.617 0 C-N-CA 123.194 2.596 . . . . 0.0 112.845 -178.409 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 23.2 m 53.11 32.39 12.99 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 125.394 1.478 . . . . 0.0 114.806 -178.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 23.3 t -60.39 139.31 57.74 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 124.242 1.017 . . . . 0.0 112.184 177.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.256 0 C-N-CA 125.561 1.553 . . . . 0.0 113.907 -178.93 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.654 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 31.6 m -67.74 154.08 42.3 Favored 'General case' 0 N--CA 1.477 0.889 0 C-N-CA 124.518 1.127 . . . . 0.0 113.276 -179.308 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 26.2 m -63.8 143.27 57.98 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 124.68 1.192 . . . . 0.0 112.584 178.104 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 163.83 -151.79 21.36 Favored Glycine 0 CA--C 1.534 1.265 0 C-N-CA 124.23 0.919 . . . . 0.0 113.304 -177.445 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.0 m 57.99 26.44 13.47 Favored 'General case' 0 N--CA 1.479 1.008 0 N-CA-C 115.639 1.718 . . . . 0.0 115.639 175.081 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 9.9 t -149.81 145.28 26.51 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 124.994 1.318 . . . . 0.0 111.581 175.662 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -93.94 -166.57 37.27 Favored Glycine 0 CA--C 1.541 1.695 0 C-N-CA 125.298 1.428 . . . . 0.0 114.204 178.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -59.31 150.0 77.39 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 123.863 3.042 . . . . 0.0 113.169 173.508 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 1.7 pp -131.55 160.17 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 C-N-CA 125.423 1.489 . . . . 0.0 112.98 -176.112 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 57.3 p -79.56 -16.21 56.32 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.887 1.275 . . . . 0.0 114.086 178.645 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -79.78 58.8 2.92 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 125.648 1.579 . . . . 0.0 111.623 178.391 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 63.7 ttt180 -70.1 119.82 14.87 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 125.522 1.529 . . . . 0.0 110.796 -177.133 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -119.29 142.1 48.39 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.86 1.264 . . . . 0.0 111.952 -173.592 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 25.6 tp60 -60.24 -31.09 69.86 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 124.112 0.965 . . . . 0.0 112.205 176.525 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 21.3 m-20 -67.35 -17.55 64.8 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.206 1.402 . . . . 0.0 113.903 178.017 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -85.52 -4.58 59.2 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 123.88 0.872 . . . . 0.0 113.062 173.205 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 31.5 m -102.74 138.23 39.92 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 124.679 1.192 . . . . 0.0 109.429 170.679 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.0 m -104.14 146.61 11.35 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.686 0 C-N-CA 124.528 1.131 . . . . 0.0 109.899 170.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 18.9 t80 -95.68 143.6 26.81 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 125.85 1.66 . . . . 0.0 109.607 169.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 24.3 t -130.97 111.37 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 C-N-CA 125.68 1.592 . . . . 0.0 109.04 176.659 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -108.39 146.01 16.42 Favored Glycine 0 CA--C 1.53 1.015 0 C-N-CA 124.487 1.041 . . . . 0.0 112.762 177.82 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 98.57 31.31 6.46 Favored Glycine 0 CA--C 1.534 1.278 0 C-N-CA 124.571 1.082 . . . . 0.0 114.223 175.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 76.2 mt -73.17 171.37 13.09 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.678 1.591 . . . . 0.0 111.977 -176.597 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -130.96 164.41 25.4 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 124.117 0.967 . . . . 0.0 112.186 179.031 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -59.81 -17.7 38.06 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -169.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -84.18 -16.08 44.71 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 125.211 1.404 . . . . 0.0 113.637 176.141 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.1 t -71.72 139.3 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.8 0 C-N-CA 124.655 1.182 . . . . 0.0 110.892 178.358 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 89.4 p -137.06 161.91 34.8 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 124.964 1.306 . . . . 0.0 112.216 176.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -59.48 -39.93 75.83 Favored Pre-proline 0 CA--C 1.546 0.806 0 O-C-N 120.854 -1.154 . . . . 0.0 113.346 177.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 75.4 Cg_exo -61.76 -31.57 85.86 Favored 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 122.577 2.184 . . . . 0.0 113.959 169.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 27.8 tp -67.81 -50.69 55.46 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 119.24 0.927 . . . . 0.0 109.959 174.252 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 18.0 mt -61.08 -24.39 66.19 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 178.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.7 t90 -72.79 -66.03 0.72 Allowed 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 123.16 0.584 . . . . 0.0 111.123 171.074 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -64.78 -30.56 71.57 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 -172.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.6 tp -69.28 -33.2 72.86 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 123.81 0.844 . . . . 0.0 111.934 175.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -90.87 -10.51 42.37 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 125.227 1.411 . . . . 0.0 113.397 -175.493 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 47.6 mt -55.77 -18.68 8.95 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 169.307 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 40.9 mt-30 -64.24 -32.74 74.44 Favored 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 125.264 1.425 . . . . 0.0 112.634 172.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -78.89 -44.54 22.54 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 123.205 0.602 . . . . 0.0 112.593 177.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 177.34 -172.67 45.51 Favored Glycine 0 CA--C 1.537 1.414 0 C-N-CA 124.678 1.132 . . . . 0.0 112.868 -178.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -67.85 109.26 1.86 Allowed 'Trans proline' 0 CA--C 1.539 0.749 0 C-N-CA 123.768 2.979 . . . . 0.0 111.764 -179.037 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 70.3 t -84.89 135.23 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 C-N-CA 124.974 1.31 . . . . 0.0 109.907 173.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.2 t -110.5 -33.4 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 126.356 1.862 . . . . 0.0 111.931 -171.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 19.9 t30 -160.78 159.73 30.36 Favored 'General case' 0 CA--C 1.553 1.067 0 C-N-CA 125.826 1.65 . . . . 0.0 111.217 -174.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 6.1 p -136.93 155.61 49.52 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 125.942 1.697 . . . . 0.0 111.882 171.495 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 -142.36 133.8 26.47 Favored 'General case' 0 N--CA 1.468 0.426 0 C-N-CA 123.734 0.814 . . . . 0.0 111.122 175.295 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 86.0 mtp -134.7 105.59 10.76 Favored Pre-proline 0 N--CA 1.47 0.566 0 C-N-CA 124.171 0.989 . . . . 0.0 109.561 169.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -57.53 137.81 83.15 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 123.153 2.568 . . . . 0.0 112.64 177.61 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 45.3 mmtm -103.21 152.45 21.46 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 124.967 1.307 . . . . 0.0 112.726 -174.612 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -78.11 143.66 37.14 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 126.164 1.786 . . . . 0.0 111.768 176.177 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 40.3 ptt180 -84.46 3.41 36.38 Favored 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 115.91 1.819 . . . . 0.0 115.91 -176.041 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 19.9 t -132.91 -40.3 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 125.546 1.539 . . . . 0.0 111.184 -174.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 68.8 p -102.19 -20.67 14.59 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 124.837 1.255 . . . . 0.0 112.438 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 73.62 -1.58 44.07 Favored Glycine 0 CA--C 1.54 1.624 0 C-N-CA 124.735 1.16 . . . . 0.0 115.94 172.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 7.7 pt20 -83.67 174.53 10.43 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.983 1.313 . . . . 0.0 110.824 169.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 33.1 p80 -68.08 157.23 35.72 Favored 'General case' 0 N--CA 1.473 0.688 0 O-C-N 120.827 -1.17 . . . . 0.0 113.471 -179.172 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 -81.07 15.93 1.7 Allowed 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 124.942 1.297 . . . . 0.0 114.296 -177.295 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 87.54 2.67 82.01 Favored Glycine 0 CA--C 1.536 1.381 0 O-C-N 120.651 -1.281 . . . . 0.0 115.056 -178.529 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 39.8 p90 -143.6 161.37 38.67 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 124.778 1.231 . . . . 0.0 112.739 176.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -151.61 -177.86 25.8 Favored Glycine 0 CA--C 1.53 0.992 0 C-N-CA 125.956 1.741 . . . . 0.0 113.128 -177.756 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -143.63 149.51 37.42 Favored 'General case' 0 C--O 1.237 0.407 0 C-N-CA 126.034 1.733 . . . . 0.0 111.655 -178.286 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 15.8 t -133.74 127.95 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.826 0 C-N-CA 124.923 1.289 . . . . 0.0 109.974 175.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -106.53 125.33 50.87 Favored 'General case' 0 N--CA 1.465 0.323 0 C-N-CA 124.703 1.201 . . . . 0.0 111.31 -175.894 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -101.92 160.43 14.5 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 125.083 1.353 . . . . 0.0 112.549 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.7 tp -61.37 -35.46 77.52 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 123.391 0.676 . . . . 0.0 112.242 177.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 13.2 m -141.41 154.56 45.68 Favored 'General case' 0 N--CA 1.468 0.446 0 C-N-CA 124.749 1.22 . . . . 0.0 111.877 -178.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 54.7 mt-10 -62.38 -33.99 75.82 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 124.361 1.065 . . . . 0.0 113.025 -176.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -68.22 -25.6 65.28 Favored 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 113.381 0.882 . . . . 0.0 113.381 176.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -77.67 -33.55 53.33 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 123.814 0.845 . . . . 0.0 111.354 173.563 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.61 -43.67 72.27 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 123.331 0.652 . . . . 0.0 111.362 172.103 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -60.04 -31.17 69.72 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 124.369 1.067 . . . . 0.0 112.648 178.308 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 63.1 t80 -79.9 -34.59 38.9 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 124.225 1.01 . . . . 0.0 113.114 174.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.45 -37.61 87.96 Favored 'General case' 0 CA--C 1.535 0.398 0 O-C-N 121.084 -1.01 . . . . 0.0 111.149 176.499 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 61.9 mt -61.48 -41.28 89.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 C-N-CA 124.834 1.254 . . . . 0.0 111.074 172.627 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 25.6 ttmm -61.73 -38.67 88.81 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.99 0.916 . . . . 0.0 112.448 179.09 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 45.9 pt -94.24 -32.72 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 N-CA-C 115.183 1.549 . . . . 0.0 115.183 -177.124 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 10.7 mmt -96.72 -0.69 47.87 Favored 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 115.351 1.612 . . . . 0.0 115.351 -171.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 26.5 t0 -83.78 139.08 32.93 Favored 'General case' 0 CA--C 1.538 0.512 0 O-C-N 121.341 -0.849 . . . . 0.0 111.943 178.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 23.6 mtp 58.21 13.38 2.3 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 126.177 1.791 . . . . 0.0 115.318 -171.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 1.7 mt -70.13 155.24 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 C-N-CA 125.429 1.492 . . . . 0.0 110.002 168.833 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 46.2 mtpt -113.28 71.42 0.74 Allowed 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.916 1.286 . . . . 0.0 112.568 -176.011 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 23.4 tp -58.47 127.48 32.34 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 123.888 0.875 . . . . 0.0 109.905 174.647 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 84.4 m-85 47.01 28.61 0.91 Allowed 'General case' 0 CA--C 1.561 1.378 0 N-CA-C 116.217 1.932 . . . . 0.0 116.217 -168.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 76.32 32.55 51.44 Favored Glycine 0 CA--C 1.54 1.594 0 O-C-N 120.153 -1.592 . . . . 0.0 115.013 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 80.0 tttt -145.57 118.91 5.34 Favored Pre-proline 0 CA--C 1.542 0.638 0 C-N-CA 128.274 2.63 . . . . 0.0 107.848 -172.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -69.79 123.35 10.0 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 122.623 2.216 . . . . 0.0 112.521 -169.52 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 17.7 pt -95.92 146.75 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 C-N-CA 125.371 1.468 . . . . 0.0 111.379 173.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 38.9 mmm-85 -111.14 137.87 48.27 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 124.51 1.124 . . . . 0.0 110.797 170.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 26.5 t -131.46 136.42 57.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.69 0 C-N-CA 124.407 1.083 . . . . 0.0 111.13 -173.077 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -156.05 171.64 19.77 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 125.81 1.644 . . . . 0.0 111.509 178.339 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.0 mmmm -59.55 140.83 55.97 Favored 'General case' 0 N--CA 1.479 0.978 0 O-C-N 121.449 -0.782 . . . . 0.0 109.035 171.48 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -70.69 -4.13 22.05 Favored 'General case' 0 CA--C 1.55 0.971 0 CA-C-N 119.317 0.962 . . . . 0.0 113.398 177.722 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 37.3 p -89.83 -16.8 29.38 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.149 2.18 . . . . 0.0 113.707 169.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -71.74 -10.67 60.12 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 114.584 1.327 . . . . 0.0 114.584 -170.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 27.5 m80 -72.15 -16.45 61.98 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.213 1.005 . . . . 0.0 113.236 174.395 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 41.7 t-20 -81.64 152.72 27.01 Favored 'General case' 0 CA--C 1.549 0.926 0 C-N-CA 124.818 1.247 . . . . 0.0 112.309 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 73.5 mmtt 60.97 166.89 0.09 Allowed 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 128.133 2.573 . . . . 0.0 115.385 -178.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 48.4 t30 -149.27 161.38 42.15 Favored 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 126.119 1.767 . . . . 0.0 110.608 177.332 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 62.5 tp -79.02 130.48 35.57 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 124.413 1.085 . . . . 0.0 111.204 175.324 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 48.0 m -124.08 -0.09 8.42 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 124.826 1.25 . . . . 0.0 114.351 -179.237 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -73.93 153.13 46.63 Favored Glycine 0 CA--C 1.542 1.746 0 O-C-N 121.365 -0.835 . . . . 0.0 113.62 179.222 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -72.58 151.23 52.39 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 123.667 2.912 . . . . 0.0 112.628 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 68.3 p -87.45 -18.57 29.61 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 124.805 1.242 . . . . 0.0 114.253 179.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 9.3 t -153.07 162.66 41.06 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 125.798 1.639 . . . . 0.0 111.654 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.147 0 C-N-CA 125.633 1.587 . . . . 0.0 112.843 -179.077 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.636 0 N-CA-C 112.085 -0.406 . . . . 0.0 112.085 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 38.2 t -148.58 152.56 36.99 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.179 1.392 . . . . 0.0 111.809 178.166 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 72.3 p -75.67 -23.33 56.23 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 124.728 1.211 . . . . 0.0 113.175 170.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 69.35 7.39 57.4 Favored Glycine 0 CA--C 1.539 1.593 0 C-N-CA 124.805 1.193 . . . . 0.0 115.069 -175.084 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 72.3 m -57.16 126.95 29.53 Favored 'General case' 0 N--CA 1.472 0.634 0 CA-C-N 118.73 1.265 . . . . 0.0 112.642 -173.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 7.4 m 59.31 13.53 3.17 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 125.951 1.7 . . . . 0.0 115.293 -178.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -72.84 135.68 21.97 Favored Glycine 0 CA--C 1.543 1.797 0 O-C-N 121.209 -0.932 . . . . 0.0 113.43 -176.678 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -78.88 -23.82 7.64 Favored 'Trans proline' 0 CA--C 1.541 0.861 0 C-N-CA 123.406 2.738 . . . . 0.0 114.217 -177.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 8.3 tp -148.74 145.41 18.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.43 1.492 . . . . 0.0 111.364 178.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 67.8 p -111.73 -8.89 14.14 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 125.696 1.599 . . . . 0.0 113.95 177.609 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 40.9 mt-10 -87.1 -22.91 25.1 Favored 'General case' 0 N--CA 1.478 0.93 0 N-CA-C 113.96 1.096 . . . . 0.0 113.96 -173.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 10.0 mmm180 -143.1 154.16 43.65 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 126.877 2.071 . . . . 0.0 110.553 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -75.46 43.09 0.23 Allowed 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 125.683 1.593 . . . . 0.0 113.194 174.328 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 35.9 tt0 -67.52 -16.23 64.09 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 124.862 1.265 . . . . 0.0 113.391 -170.241 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -72.71 -23.05 60.81 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 124.587 1.155 . . . . 0.0 113.018 169.45 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.7 -2.82 58.84 Favored 'General case' 0 CA--C 1.545 0.75 0 C-N-CA 124.156 0.982 . . . . 0.0 112.37 170.36 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 20.4 m -100.17 142.6 31.42 Favored 'General case' 0 N--CA 1.47 0.536 0 C-N-CA 124.595 1.158 . . . . 0.0 109.64 171.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 18.1 m -110.41 148.35 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 124.871 1.268 . . . . 0.0 110.415 171.155 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 22.1 t80 -95.82 143.11 27.33 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 126.012 1.725 . . . . 0.0 109.346 169.298 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.8 t -132.26 106.48 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 C-N-CA 125.724 1.61 . . . . 0.0 109.086 177.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -101.22 145.99 17.17 Favored Glycine 0 CA--C 1.53 1.023 0 C-N-CA 124.296 0.95 . . . . 0.0 112.543 176.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.88 33.66 5.99 Favored Glycine 0 CA--C 1.533 1.203 0 C-N-CA 124.474 1.035 . . . . 0.0 113.936 173.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 85.3 mt -74.98 151.28 38.81 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 125.312 1.445 . . . . 0.0 111.402 -174.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -90.48 157.44 17.56 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 123.979 0.912 . . . . 0.0 111.955 175.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -59.06 -20.13 50.45 Favored 'General case' 0 CA--C 1.547 0.851 0 N-CA-C 114.712 1.375 . . . . 0.0 114.712 179.404 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.4 mtmm -82.46 -7.48 59.64 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 124.861 1.264 . . . . 0.0 114.183 174.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.9 t -77.93 138.82 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 C-N-CA 124.461 1.105 . . . . 0.0 111.479 177.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 51.8 m -136.55 162.12 34.0 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 125.212 1.405 . . . . 0.0 111.459 173.039 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -56.54 -40.03 81.99 Favored Pre-proline 0 CA--C 1.547 0.856 0 N-CA-C 114.572 1.323 . . . . 0.0 114.572 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -65.75 -28.5 51.61 Favored 'Trans proline' 0 C--N 1.353 0.798 0 C-N-CA 122.28 1.987 . . . . 0.0 113.617 173.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 20.4 tp -66.28 -53.08 41.02 Favored 'General case' 0 C--N 1.343 0.321 0 CA-C-N 118.645 0.657 . . . . 0.0 109.33 173.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 22.7 mt -55.47 -41.49 73.03 Favored 'General case' 0 N--CA 1.464 0.252 0 O-C-N 123.315 0.384 . . . . 0.0 111.281 -179.039 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.8 t90 -58.16 -62.96 1.45 Allowed 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 123.373 0.669 . . . . 0.0 111.32 177.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.8 mt-10 -64.62 -29.52 70.53 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 113.892 1.071 . . . . 0.0 113.892 -176.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.5 tp -72.37 -35.86 68.58 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 124.174 0.989 . . . . 0.0 112.101 176.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -88.51 -10.66 48.21 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.86 1.264 . . . . 0.0 113.446 -176.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 25.1 mt -52.69 -21.23 3.78 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 114.125 1.157 . . . . 0.0 114.125 169.161 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 42.2 mt-30 -63.61 -32.6 74.12 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 125.389 1.476 . . . . 0.0 112.756 174.524 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.02 -45.82 19.41 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 123.501 0.72 . . . . 0.0 112.559 176.817 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -178.57 -174.54 44.9 Favored Glycine 0 CA--C 1.535 1.319 0 C-N-CA 124.356 0.979 . . . . 0.0 113.176 178.394 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -66.68 113.12 2.62 Favored 'Trans proline' 0 CA--C 1.538 0.677 0 C-N-CA 123.651 2.901 . . . . 0.0 111.549 -179.277 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 85.1 t -87.64 134.92 26.61 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 125.046 1.338 . . . . 0.0 109.959 175.984 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.3 t -110.03 -33.54 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 126.81 2.044 . . . . 0.0 111.94 -171.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 19.6 t30 -160.63 159.65 30.68 Favored 'General case' 0 CA--C 1.552 1.039 0 C-N-CA 125.961 1.704 . . . . 0.0 110.911 -174.503 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 6.7 p -137.45 154.81 49.86 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 125.812 1.645 . . . . 0.0 111.614 171.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 43.1 t-80 -142.43 133.94 26.55 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 123.599 0.76 . . . . 0.0 111.291 175.643 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 84.0 mtp -134.52 105.45 10.95 Favored Pre-proline 0 N--CA 1.47 0.575 0 C-N-CA 124.136 0.974 . . . . 0.0 109.137 169.615 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_exo -58.09 139.98 92.42 Favored 'Trans proline' 0 CA--C 1.536 0.579 0 C-N-CA 122.882 2.388 . . . . 0.0 113.017 178.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 44.0 mmtm -108.7 149.74 28.55 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 125.228 1.411 . . . . 0.0 112.468 -174.568 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -67.87 138.33 55.98 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 125.525 1.53 . . . . 0.0 111.917 172.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 53.6 ptt85 -80.02 7.87 8.2 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 115.947 1.832 . . . . 0.0 115.947 -173.106 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 31.8 t -132.13 -37.44 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 124.942 1.297 . . . . 0.0 111.433 -174.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 65.6 p -114.91 -14.23 11.91 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 125.69 1.596 . . . . 0.0 112.697 -175.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.29 6.54 57.92 Favored Glycine 0 CA--C 1.537 1.453 0 C-N-CA 125.075 1.322 . . . . 0.0 115.542 174.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 71.1 mm-40 -79.18 159.33 27.43 Favored 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 124.67 1.188 . . . . 0.0 110.662 176.121 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 15.9 p80 -68.03 150.89 47.88 Favored 'General case' 0 N--CA 1.473 0.699 0 O-C-N 120.892 -1.13 . . . . 0.0 112.266 177.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 28.8 mt-30 -86.23 19.05 2.84 Favored 'General case' 0 CA--C 1.549 0.94 0 N-CA-C 114.316 1.228 . . . . 0.0 114.316 -172.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.27 3.3 78.96 Favored Glycine 0 CA--C 1.534 1.254 0 C-N-CA 125.097 1.332 . . . . 0.0 115.131 179.478 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 46.4 p90 -145.59 159.84 42.54 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 124.822 1.249 . . . . 0.0 112.566 178.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -150.78 -176.25 23.53 Favored Glycine 0 CA--C 1.529 0.946 0 C-N-CA 125.792 1.663 . . . . 0.0 113.396 -178.176 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -144.71 149.02 34.88 Favored 'General case' 0 C--O 1.237 0.414 0 C-N-CA 126.21 1.804 . . . . 0.0 111.63 -178.106 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.3 t -132.8 127.01 55.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 C-N-CA 124.42 1.088 . . . . 0.0 110.028 175.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -103.45 119.71 39.42 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 124.784 1.234 . . . . 0.0 111.049 -177.031 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -95.54 163.13 13.34 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 125.111 1.364 . . . . 0.0 112.366 176.459 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 12.7 tp -63.37 -32.79 74.31 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 123.325 0.65 . . . . 0.0 112.376 175.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.6 m -145.08 157.6 44.06 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 122.662 1.22 . . . . 0.0 112.903 -175.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -64.46 -32.66 74.39 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.872 1.269 . . . . 0.0 113.404 -175.413 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -70.31 -26.87 63.98 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 123.848 0.859 . . . . 0.0 113.036 176.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 59.6 m-20 -75.74 -33.42 60.26 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 123.849 0.86 . . . . 0.0 111.129 173.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -67.11 -45.86 75.94 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 122.932 0.493 . . . . 0.0 111.359 170.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -55.29 -36.23 65.92 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 123.599 0.76 . . . . 0.0 112.592 174.229 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 21.4 t80 -73.93 -37.8 64.48 Favored 'General case' 0 CA--C 1.535 0.388 0 O-C-N 121.669 -0.644 . . . . 0.0 112.163 177.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -65.17 -35.95 82.71 Favored 'General case' 0 CA--C 1.537 0.446 0 O-C-N 120.682 -1.261 . . . . 0.0 111.52 176.525 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 63.6 mt -63.77 -34.53 68.61 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 124.277 1.031 . . . . 0.0 111.033 172.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 63.1 tttp -67.95 -41.71 82.04 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 124.062 0.945 . . . . 0.0 112.523 176.784 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 19.2 pt -92.69 -38.28 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 N-CA-C 115.041 1.497 . . . . 0.0 115.041 -175.29 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 15.2 mmt -91.51 0.56 57.49 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 114.863 1.431 . . . . 0.0 114.863 -169.794 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -85.82 137.34 32.85 Favored 'General case' 0 CA--C 1.538 0.514 0 O-C-N 121.44 -0.787 . . . . 0.0 112.057 179.64 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 24.1 mmt 59.61 9.59 1.63 Allowed 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 126.238 1.815 . . . . 0.0 115.059 -170.794 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.5 mt -68.01 152.42 9.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 C-N-CA 124.981 1.312 . . . . 0.0 110.061 169.291 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.0 mtpt -112.78 70.21 0.71 Allowed 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 125.05 1.34 . . . . 0.0 112.289 -176.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 31.9 tp -57.64 125.02 21.1 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.068 0.947 . . . . 0.0 109.926 175.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 57.2 m-85 46.0 28.77 0.66 Allowed 'General case' 0 CA--C 1.561 1.382 0 N-CA-C 116.289 1.959 . . . . 0.0 116.289 -168.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.5 26.71 56.39 Favored Glycine 0 CA--C 1.542 1.745 0 O-C-N 120.183 -1.573 . . . . 0.0 115.903 176.688 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -137.18 120.44 11.74 Favored Pre-proline 0 CA--C 1.542 0.673 0 C-N-CA 128.268 2.627 . . . . 0.0 107.813 -179.364 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -70.19 127.1 13.79 Favored 'Trans proline' 0 CA--C 1.536 0.615 0 C-N-CA 122.878 2.385 . . . . 0.0 112.497 -170.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 17.1 pt -98.86 145.34 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 C-N-CA 125.496 1.519 . . . . 0.0 112.215 177.082 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 46.4 tpt85 -114.02 129.18 56.62 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 126.389 1.876 . . . . 0.0 109.522 178.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -128.15 135.79 61.84 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 124.156 0.983 . . . . 0.0 111.787 -171.03 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -153.93 173.73 15.56 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 126.135 1.774 . . . . 0.0 110.613 175.904 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 22.6 mmmt -57.75 143.33 42.33 Favored 'General case' 0 N--CA 1.479 1.014 0 C-N-CA 123.809 0.844 . . . . 0.0 109.298 170.86 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -70.27 -13.74 62.3 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 113.106 0.78 . . . . 0.0 113.106 179.312 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 23.1 t -139.6 128.84 23.94 Favored 'General case' 0 N--CA 1.467 0.38 0 C-N-CA 125.967 1.707 . . . . 0.0 108.338 166.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -134.26 22.46 3.76 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.688 1.195 . . . . 0.0 112.607 -171.369 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 92.6 m-70 -89.0 38.86 0.91 Allowed 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 125.271 1.429 . . . . 0.0 113.575 -172.185 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 49.5 p-10 -76.41 47.59 0.48 Allowed 'General case' 0 CA--C 1.551 1.009 0 C-N-CA 125.615 1.566 . . . . 0.0 112.73 176.134 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -69.52 -15.35 63.23 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 126.769 2.028 . . . . 0.0 114.354 -169.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -133.73 137.57 45.3 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 126.031 1.732 . . . . 0.0 109.927 169.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 10.7 mp -99.9 141.06 33.23 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 124.419 1.088 . . . . 0.0 111.426 -177.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 11.0 t -85.47 154.22 21.95 Favored 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 124.599 1.16 . . . . 0.0 112.704 177.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 178.08 49.16 0.07 OUTLIER Glycine 0 CA--C 1.542 1.729 0 CA-C-O 118.485 -1.175 . . . . 0.0 115.235 175.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 80.0 Cg_endo -66.85 -21.41 50.64 Favored 'Trans proline' 0 CA--C 1.542 0.889 0 C-N-CA 123.206 2.604 . . . . 0.0 113.934 -176.038 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 19.6 m -78.01 -13.14 59.98 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 124.867 1.267 . . . . 0.0 114.161 -179.634 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 55.5 m -73.94 148.15 42.44 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.45 1.1 . . . . 0.0 112.953 -178.171 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.178 0 CA-C-O 118.214 -1.326 . . . . 0.0 112.772 179.429 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.684 0 N-CA-C 112.041 -0.424 . . . . 0.0 112.041 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 47.1 p -76.0 156.17 34.31 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 124.617 1.167 . . . . 0.0 113.243 177.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 63.4 p -86.95 161.67 18.11 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 125.337 1.455 . . . . 0.0 112.975 177.166 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 72.26 -161.02 54.25 Favored Glycine 0 CA--C 1.537 1.458 0 C-N-CA 124.191 0.9 . . . . 0.0 114.033 -178.273 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 56.0 p -74.47 152.32 39.45 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 124.807 1.243 . . . . 0.0 113.152 179.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 88.5 p -145.33 164.47 31.36 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 125.155 1.382 . . . . 0.0 112.549 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -177.91 173.02 45.66 Favored Glycine 0 CA--C 1.539 1.571 0 C-N-CA 124.579 1.085 . . . . 0.0 113.491 179.161 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -73.97 163.52 36.67 Favored 'Trans proline' 0 CA--C 1.539 0.771 0 C-N-CA 123.828 3.019 . . . . 0.0 113.266 -178.505 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.3 tp -72.35 152.68 7.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 124.238 1.015 . . . . 0.0 111.867 173.595 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.5 m -75.54 -9.74 58.84 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 114.869 1.433 . . . . 0.0 114.869 -177.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -132.89 129.67 38.68 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 124.364 1.066 . . . . 0.0 112.984 -172.256 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 21.1 mtm180 55.34 -168.88 0.08 Allowed 'General case' 0 N--CA 1.482 1.127 0 C-N-CA 126.763 2.025 . . . . 0.0 114.07 177.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -85.95 30.09 0.69 Allowed 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 126.025 1.73 . . . . 0.0 113.38 176.375 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -66.32 -13.72 60.96 Favored 'General case' 0 CA--C 1.542 0.65 0 N-CA-C 115.58 1.696 . . . . 0.0 115.58 -169.329 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.03 -22.62 62.12 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-N 119.604 1.093 . . . . 0.0 112.729 168.436 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -88.65 -1.18 57.93 Favored 'General case' 0 CA--C 1.548 0.883 0 C-N-CA 125.077 1.351 . . . . 0.0 112.658 169.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.5 m -100.09 134.78 42.51 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.346 1.058 . . . . 0.0 110.212 171.66 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.6 m -106.11 147.42 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 124.468 1.107 . . . . 0.0 110.333 171.236 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 33.5 t80 -95.42 143.71 26.54 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 125.833 1.653 . . . . 0.0 109.324 169.546 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 20.0 t -130.61 112.68 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 C-N-CA 125.531 1.532 . . . . 0.0 109.127 175.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -110.52 145.49 17.29 Favored Glycine 0 CA--C 1.53 0.972 0 C-N-CA 124.493 1.044 . . . . 0.0 112.805 178.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 95.73 33.51 6.38 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 124.471 1.034 . . . . 0.0 113.843 175.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 84.0 mt -73.68 152.83 40.34 Favored 'General case' 0 C--O 1.234 0.271 0 C-N-CA 125.496 1.518 . . . . 0.0 111.428 -174.49 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -92.33 157.48 16.61 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 123.677 0.791 . . . . 0.0 111.953 174.018 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -58.6 -20.82 50.54 Favored 'General case' 0 CA--C 1.546 0.823 0 O-C-N 120.543 -1.348 . . . . 0.0 114.58 179.112 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 60.5 mtpt -77.42 -12.89 60.01 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 114.302 1.223 . . . . 0.0 114.302 174.4 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 78.9 t -74.62 141.19 16.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.911 0 C-N-CA 124.509 1.124 . . . . 0.0 111.689 -178.655 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 94.1 p -136.08 163.51 30.16 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 125.315 1.446 . . . . 0.0 111.969 175.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -59.27 -43.63 97.0 Favored Pre-proline 0 CA--C 1.546 0.807 0 O-C-N 120.745 -1.222 . . . . 0.0 113.025 176.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_exo -57.64 -31.03 90.78 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 122.509 2.139 . . . . 0.0 114.146 171.232 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 27.7 tp -68.71 -51.28 43.32 Favored 'General case' 0 C--N 1.343 0.322 0 CA-C-N 119.072 0.851 . . . . 0.0 110.261 173.459 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 21.3 mt -61.29 -22.56 64.97 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 113.094 0.776 . . . . 0.0 113.094 178.633 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.6 t90 -73.61 -67.5 0.59 Allowed 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 123.233 0.613 . . . . 0.0 110.83 170.404 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.8 mt-10 -64.72 -30.13 71.14 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 114.206 1.187 . . . . 0.0 114.206 -172.11 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.0 tp -69.65 -33.3 72.4 Favored 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 123.711 0.804 . . . . 0.0 111.969 175.46 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 18.3 m-85 -90.43 -10.96 41.88 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.048 1.339 . . . . 0.0 113.306 -175.125 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 49.2 mt -54.89 -19.11 5.88 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 124.517 1.127 . . . . 0.0 114.038 169.648 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 41.2 mt-30 -65.0 -32.72 74.59 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 125.443 1.497 . . . . 0.0 112.678 173.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -78.91 -45.49 20.44 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.44 0.696 . . . . 0.0 112.451 176.897 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.18 -173.8 45.84 Favored Glycine 0 CA--C 1.536 1.354 0 C-N-CA 124.852 1.215 . . . . 0.0 112.855 177.776 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -66.1 113.83 2.77 Favored 'Trans proline' 0 CA--C 1.537 0.656 0 C-N-CA 123.614 2.876 . . . . 0.0 111.795 -179.005 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 93.9 t -87.32 135.23 25.76 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.179 1.391 . . . . 0.0 109.792 174.753 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.2 t -109.71 -34.13 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 126.614 1.965 . . . . 0.0 111.746 -171.691 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 20.4 t30 -160.68 163.35 32.51 Favored 'General case' 0 CA--C 1.554 1.119 0 C-N-CA 126.023 1.729 . . . . 0.0 111.066 -175.05 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.7 p -142.04 153.58 44.32 Favored 'General case' 0 N--CA 1.48 1.075 0 C-N-CA 126.484 1.913 . . . . 0.0 111.207 175.534 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -142.06 129.74 21.55 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 123.642 0.777 . . . . 0.0 111.528 177.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 87.9 mtp -134.79 102.2 11.38 Favored Pre-proline 0 N--CA 1.472 0.669 0 C-N-CA 124.15 0.98 . . . . 0.0 109.482 169.614 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_exo -61.86 126.82 19.78 Favored 'Trans proline' 0 CA--C 1.537 0.675 0 C-N-CA 122.948 2.432 . . . . 0.0 113.307 -178.432 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 44.2 mmtm -92.67 150.78 20.47 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 124.77 1.228 . . . . 0.0 113.054 -175.358 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -67.67 137.92 55.93 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.839 1.256 . . . . 0.0 111.317 169.164 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 39.3 ptt180 -80.76 6.52 12.71 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 116.107 1.892 . . . . 0.0 116.107 -172.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.5 t -131.12 -37.2 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 C-N-CA 125.068 1.347 . . . . 0.0 111.424 -175.38 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 69.7 p -107.8 -17.26 14.12 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 125.732 1.613 . . . . 0.0 112.484 -178.444 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 72.48 7.45 68.61 Favored Glycine 0 CA--C 1.538 1.512 0 C-N-CA 124.963 1.268 . . . . 0.0 115.8 171.197 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -94.91 163.54 13.29 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 125.589 1.555 . . . . 0.0 111.477 176.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 14.9 p80 -68.74 157.53 36.15 Favored 'General case' 0 N--CA 1.472 0.632 0 O-C-N 121.391 -0.818 . . . . 0.0 112.712 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 37.9 mt-30 -99.41 23.9 8.75 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 124.797 1.239 . . . . 0.0 113.473 -170.963 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.65 3.65 77.28 Favored Glycine 0 CA--C 1.535 1.301 0 C-N-CA 125.199 1.38 . . . . 0.0 115.251 178.408 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -145.86 161.17 40.61 Favored 'General case' 0 CA--C 1.539 0.551 0 CA-C-N 118.713 1.257 . . . . 0.0 112.994 179.339 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -154.4 -175.74 25.92 Favored Glycine 0 CA--C 1.531 1.088 0 C-N-CA 125.983 1.754 . . . . 0.0 113.118 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 71.1 m-85 -144.4 152.49 40.77 Favored 'General case' 0 C--O 1.236 0.381 0 C-N-CA 126.101 1.76 . . . . 0.0 111.471 179.219 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 15.9 t -132.64 131.57 59.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 124.864 1.266 . . . . 0.0 109.73 175.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 61.3 tt0 -107.81 120.21 41.63 Favored 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 124.831 1.252 . . . . 0.0 110.674 -177.512 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -96.65 162.94 13.23 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 125.012 1.325 . . . . 0.0 112.412 177.478 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.8 tp -64.02 -35.25 80.09 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 123.107 0.563 . . . . 0.0 112.224 176.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.1 m -140.12 153.82 46.81 Favored 'General case' 0 N--CA 1.468 0.426 0 C-N-CA 124.649 1.18 . . . . 0.0 112.152 -176.549 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -58.42 -32.42 68.64 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 125.443 1.497 . . . . 0.0 112.785 178.186 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 14.1 mm-40 -67.97 -34.3 76.29 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.659 1.184 . . . . 0.0 112.437 178.244 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 58.4 m-20 -75.75 -31.08 59.42 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 124.105 0.962 . . . . 0.0 111.353 176.559 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -70.64 -46.57 63.06 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 123.708 0.803 . . . . 0.0 111.16 173.239 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -56.52 -36.11 68.82 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 124.002 0.921 . . . . 0.0 112.558 174.726 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 25.6 t80 -71.51 -38.23 71.14 Favored 'General case' 0 CA--C 1.537 0.448 0 O-C-N 121.777 -0.577 . . . . 0.0 112.145 175.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -65.6 -36.56 84.09 Favored 'General case' 0 CA--C 1.537 0.462 0 O-C-N 120.784 -1.197 . . . . 0.0 111.72 176.517 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 59.4 mt -63.77 -34.0 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 123.991 0.916 . . . . 0.0 110.858 172.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -68.17 -42.9 79.33 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.966 0.906 . . . . 0.0 112.616 176.208 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 18.0 pt -91.22 -37.51 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 N-CA-C 114.916 1.451 . . . . 0.0 114.916 -175.045 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 15.4 mmt -91.76 0.12 57.51 Favored 'General case' 0 N--CA 1.479 1.02 0 N-CA-C 114.705 1.372 . . . . 0.0 114.705 -169.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -84.72 139.63 31.86 Favored 'General case' 0 CA--C 1.539 0.545 0 O-C-N 121.571 -0.705 . . . . 0.0 111.918 178.218 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 20.4 mmt 58.31 10.47 1.31 Allowed 'General case' 0 CA--C 1.55 0.946 0 N-CA-C 115.408 1.633 . . . . 0.0 115.408 -170.291 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.5 mt -70.28 152.44 8.98 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 124.638 1.175 . . . . 0.0 110.285 169.403 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.1 mtpt -112.06 69.98 0.7 Allowed 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 125.145 1.378 . . . . 0.0 112.345 -176.666 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 29.6 tp -57.73 124.2 18.33 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.156 0.982 . . . . 0.0 110.092 176.302 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 44.3 m-85 45.33 31.06 0.77 Allowed 'General case' 0 CA--C 1.56 1.354 0 N-CA-C 116.2 1.926 . . . . 0.0 116.2 -168.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 78.96 27.77 55.72 Favored Glycine 0 CA--C 1.54 1.64 0 O-C-N 120.234 -1.541 . . . . 0.0 115.811 175.58 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -138.84 120.6 10.2 Favored Pre-proline 0 CA--C 1.541 0.62 0 C-N-CA 128.325 2.65 . . . . 0.0 107.82 -179.575 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -69.65 123.42 10.12 Favored 'Trans proline' 0 CA--C 1.536 0.597 0 C-N-CA 122.964 2.443 . . . . 0.0 112.202 -171.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 17.8 pt -95.71 146.53 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 125.314 1.445 . . . . 0.0 111.524 175.361 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 43.2 mmm-85 -109.88 137.24 47.95 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 124.858 1.263 . . . . 0.0 110.73 170.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 24.4 t -130.65 137.56 55.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 124.6 1.16 . . . . 0.0 111.063 -175.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 38.0 t-20 -161.42 178.0 9.56 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 126.1 1.76 . . . . 0.0 110.247 179.09 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 12.5 mmmm -57.17 140.84 48.35 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 125.337 1.455 . . . . 0.0 110.666 171.437 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -67.36 -25.74 66.13 Favored 'General case' 0 CA--C 1.546 0.811 0 N-CA-C 113.491 0.923 . . . . 0.0 113.491 178.517 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 67.3 m -123.93 52.06 1.49 Allowed 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 125.835 1.654 . . . . 0.0 111.529 176.127 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -62.13 154.76 26.16 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 124.248 1.019 . . . . 0.0 113.563 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 73.5 m-70 -77.97 152.64 33.05 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 124.54 1.136 . . . . 0.0 112.766 178.212 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 51.6 p-10 -121.78 21.28 10.79 Favored 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 126.2 1.8 . . . . 0.0 113.149 178.575 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 64.6 mtpt -66.64 145.22 55.82 Favored 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 125.51 1.524 . . . . 0.0 112.339 -174.316 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 50.7 p-10 -133.32 21.64 4.03 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 125.687 1.595 . . . . 0.0 113.89 -173.017 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 52.8 tp -63.33 137.78 58.3 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.654 1.182 . . . . 0.0 112.131 -177.382 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 58.2 p -86.16 7.36 25.29 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.811 1.644 . . . . 0.0 115.053 -175.753 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 84.28 -176.06 51.42 Favored Glycine 0 CA--C 1.542 1.729 0 C-N-CA 125.114 1.34 . . . . 0.0 114.022 -175.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -71.25 154.42 61.56 Favored 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 123.794 2.996 . . . . 0.0 112.97 -177.213 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 51.8 p -80.65 -22.32 40.62 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 124.76 1.224 . . . . 0.0 113.933 176.275 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 46.9 m 60.87 166.43 0.08 Allowed 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 127.458 2.303 . . . . 0.0 115.582 -177.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.213 0 C-N-CA 125.259 1.409 . . . . 0.0 112.825 -178.718 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.648 0 N-CA-C 111.835 -0.506 . . . . 0.0 111.835 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 58.2 p -78.64 -15.89 57.98 Favored 'General case' 0 N--CA 1.477 0.908 0 N-CA-C 114.514 1.302 . . . . 0.0 114.514 -178.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 89.4 p -144.05 160.58 40.63 Favored 'General case' 0 N--CA 1.473 0.678 0 C-N-CA 125.877 1.671 . . . . 0.0 112.188 176.289 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 170.24 -177.39 43.53 Favored Glycine 0 CA--C 1.535 1.32 0 C-N-CA 124.874 1.226 . . . . 0.0 113.08 -179.466 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 46.7 m -72.3 145.86 47.55 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 124.187 0.995 . . . . 0.0 112.467 177.661 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.5 m -137.89 153.01 49.58 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.435 1.494 . . . . 0.0 111.926 -179.515 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -73.93 171.22 52.45 Favored Glycine 0 CA--C 1.543 1.806 0 C-N-CA 124.015 0.817 . . . . 0.0 113.829 174.462 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -78.43 70.34 7.29 Favored 'Trans proline' 0 CA--C 1.545 1.052 0 C-N-CA 124.427 3.418 . . . . 0.0 111.854 -179.179 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -72.85 -22.94 20.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 N-CA-C 114.12 1.156 . . . . 0.0 114.12 -178.849 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.6 m 59.79 -38.68 0.08 Allowed 'General case' 0 N--CA 1.481 1.123 0 C-N-CA 129.159 2.984 . . . . 0.0 117.232 -178.724 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -80.9 31.73 0.31 Allowed 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 126.089 1.756 . . . . 0.0 113.838 -173.46 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 91.4 mmt-85 -140.16 -55.41 0.54 Allowed 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 125.913 1.685 . . . . 0.0 111.979 177.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . 0.276 1.0 OUTLIER 48.79 24.33 0.81 Allowed 'General case' 0 CA--C 1.55 0.955 0 C-N-CA 127.573 2.349 . . . . 0.0 116.862 178.325 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -68.27 -14.85 63.29 Favored 'General case' 0 N--CA 1.476 0.83 0 N-CA-C 114.096 1.147 . . . . 0.0 114.096 -174.541 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 25.9 m-20 -88.82 -24.37 22.6 Favored 'General case' 0 CA--C 1.541 0.617 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 172.187 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.71 -14.06 43.58 Favored 'General case' 0 CA--C 1.545 0.781 0 O-C-N 121.398 -0.814 . . . . 0.0 112.383 170.624 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 27.4 m -90.55 137.93 31.96 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 124.372 1.069 . . . . 0.0 109.863 168.29 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.9 m -103.98 149.09 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.657 0 C-N-CA 124.536 1.135 . . . . 0.0 110.334 169.699 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -94.97 143.3 26.59 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 126.192 1.797 . . . . 0.0 108.595 168.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 23.2 t -132.49 109.59 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 C-N-CA 125.629 1.572 . . . . 0.0 109.231 178.328 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -106.72 143.23 15.76 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 124.274 0.94 . . . . 0.0 113.014 179.372 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 100.87 32.15 5.45 Favored Glycine 0 CA--C 1.535 1.294 0 C-N-CA 124.921 1.248 . . . . 0.0 114.135 175.303 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 83.0 mt -76.49 145.33 39.23 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 125.322 1.449 . . . . 0.0 111.508 -173.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -85.06 157.54 20.7 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 123.486 0.715 . . . . 0.0 112.342 175.597 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -57.79 -20.92 38.89 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 114.749 1.389 . . . . 0.0 114.749 178.576 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.8 mtmm -81.39 -8.22 59.7 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 124.711 1.204 . . . . 0.0 114.232 174.46 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.6 t -78.31 141.37 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 C-N-CA 124.537 1.135 . . . . 0.0 111.241 176.554 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 43.4 m -144.08 165.16 28.57 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 125.225 1.41 . . . . 0.0 110.676 169.36 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -54.74 -41.18 88.65 Favored Pre-proline 0 CA--C 1.547 0.836 0 N-CA-C 114.839 1.422 . . . . 0.0 114.839 -177.028 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -62.45 -28.02 77.64 Favored 'Trans proline' 0 C--N 1.354 0.843 0 C-N-CA 122.187 1.925 . . . . 0.0 113.608 175.873 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 20.5 tp -66.82 -55.19 15.97 Favored 'General case' 0 C--N 1.344 0.343 0 CA-C-N 118.393 0.542 . . . . 0.0 109.586 171.919 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 34.1 mt -55.89 -42.61 76.22 Favored 'General case' 0 N--CA 1.464 0.256 0 O-C-N 123.241 0.338 . . . . 0.0 111.388 -176.672 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 3.1 t90 -56.39 -62.32 1.8 Allowed 'General case' 0 CA--C 1.53 0.199 0 C-N-CA 123.552 0.741 . . . . 0.0 111.27 178.959 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -65.25 -29.53 70.32 Favored 'General case' 0 N--CA 1.471 0.593 0 N-CA-C 113.645 0.98 . . . . 0.0 113.645 -177.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.8 tp -72.22 -36.26 69.09 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 124.081 0.952 . . . . 0.0 112.104 176.535 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 -88.32 -10.82 48.23 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 124.904 1.281 . . . . 0.0 113.286 -176.241 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 23.3 mt -52.89 -21.7 4.6 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 114.041 1.126 . . . . 0.0 114.041 169.138 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 -64.2 -32.08 73.53 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 125.338 1.455 . . . . 0.0 112.738 175.287 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.23 -45.53 19.62 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.45 0.7 . . . . 0.0 112.521 176.654 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -179.05 -173.65 44.52 Favored Glycine 0 CA--C 1.536 1.378 0 C-N-CA 124.538 1.066 . . . . 0.0 113.008 177.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -66.57 112.6 2.44 Favored 'Trans proline' 0 CA--C 1.537 0.675 0 C-N-CA 123.647 2.898 . . . . 0.0 111.616 -179.302 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 74.5 t -87.84 133.91 29.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 125.098 1.359 . . . . 0.0 109.901 175.649 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.7 t -111.88 -32.58 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 126.314 1.845 . . . . 0.0 112.329 -169.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 14.6 t30 -160.21 162.08 33.69 Favored 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 126.171 1.788 . . . . 0.0 110.68 -174.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 1.5 p -143.28 153.18 42.51 Favored 'General case' 0 N--CA 1.482 1.159 0 C-N-CA 126.313 1.845 . . . . 0.0 111.417 176.492 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 4.3 t60 -142.91 134.48 26.44 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 123.914 0.886 . . . . 0.0 111.187 175.358 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 82.2 mtp -136.07 105.15 9.56 Favored Pre-proline 0 N--CA 1.469 0.484 0 C-N-CA 124.099 0.959 . . . . 0.0 108.776 168.672 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_exo -53.62 139.92 66.31 Favored 'Trans proline' 0 CA--C 1.537 0.657 0 C-N-CA 123.397 2.732 . . . . 0.0 112.965 176.5 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 44.7 mmtm -112.22 157.96 20.27 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 125.069 1.348 . . . . 0.0 113.294 -172.499 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -76.52 151.98 36.19 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 127.024 2.13 . . . . 0.0 112.225 174.094 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 40.4 ptt180 -90.7 0.86 57.27 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 116.462 2.023 . . . . 0.0 116.462 -172.666 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 3.6 m -136.28 -31.66 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 C-N-CA 124.362 1.065 . . . . 0.0 113.461 -178.756 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.3 p -106.97 -20.36 13.34 Favored 'General case' 0 N--CA 1.468 0.437 0 C-N-CA 124.7 1.2 . . . . 0.0 111.866 179.23 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 69.09 8.86 59.19 Favored Glycine 0 CA--C 1.541 1.682 0 C-N-CA 124.674 1.131 . . . . 0.0 115.329 -178.73 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 39.5 mt-30 -65.99 160.76 22.94 Favored 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 125.253 1.421 . . . . 0.0 110.683 171.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 25.2 p80 -74.82 156.86 36.04 Favored 'General case' 0 N--CA 1.474 0.77 0 O-C-N 120.569 -1.332 . . . . 0.0 112.514 173.364 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 78.8 mt-30 -81.55 14.55 2.49 Favored 'General case' 0 CA--C 1.552 1.035 0 N-CA-C 114.59 1.33 . . . . 0.0 114.59 -174.672 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 87.85 0.46 83.6 Favored Glycine 0 CA--C 1.535 1.333 0 C-N-CA 125.256 1.407 . . . . 0.0 115.011 -179.34 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 39.3 p90 -143.43 161.37 38.58 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.063 1.345 . . . . 0.0 112.273 177.276 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -149.21 -174.93 21.15 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 125.737 1.637 . . . . 0.0 113.109 -178.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -145.88 149.98 35.27 Favored 'General case' 0 C--O 1.236 0.364 0 C-N-CA 125.973 1.709 . . . . 0.0 111.402 -179.378 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.2 t -134.4 126.42 48.83 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 124.672 1.189 . . . . 0.0 109.981 176.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -100.66 121.39 41.56 Favored 'General case' 0 N--CA 1.467 0.376 0 C-N-CA 124.791 1.236 . . . . 0.0 110.935 -176.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -97.33 160.81 14.11 Favored 'General case' 0 C--O 1.235 0.299 0 C-N-CA 124.246 1.018 . . . . 0.0 112.465 175.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 14.6 tp -62.13 -34.3 76.11 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 123.325 0.65 . . . . 0.0 112.478 176.435 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 18.4 m -143.23 156.36 44.73 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 124.515 1.126 . . . . 0.0 112.139 -177.448 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 74.8 tt0 -62.91 -32.84 74.21 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 124.122 0.969 . . . . 0.0 113.092 -179.422 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -68.4 -23.86 64.69 Favored 'General case' 0 N--CA 1.474 0.728 0 O-C-N 121.23 -0.919 . . . . 0.0 113.439 176.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 51.7 m-20 -80.99 -32.6 34.22 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 123.932 0.893 . . . . 0.0 111.438 172.564 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -68.26 -44.56 75.33 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 123.47 0.708 . . . . 0.0 111.447 172.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -57.6 -33.47 68.25 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.438 1.095 . . . . 0.0 112.659 174.128 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 16.0 t80 -72.72 -36.78 67.87 Favored 'General case' 0 CA--C 1.536 0.442 0 O-C-N 121.638 -0.664 . . . . 0.0 111.912 175.329 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -68.11 -35.0 77.44 Favored 'General case' 0 CA--C 1.54 0.572 0 O-C-N 120.622 -1.299 . . . . 0.0 111.445 175.561 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 70.8 mt -64.24 -29.71 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 124.189 0.995 . . . . 0.0 111.384 171.171 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 25.1 ttmm -71.95 -48.02 48.15 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 124.213 1.005 . . . . 0.0 112.322 174.059 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 19.7 pt -89.34 -39.84 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 115.156 1.539 . . . . 0.0 115.156 -172.998 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 15.2 mmt -89.38 0.81 56.55 Favored 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 114.407 1.262 . . . . 0.0 114.407 -170.359 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -86.94 136.26 33.0 Favored 'General case' 0 CA--C 1.538 0.504 0 C-N-CA 123.399 0.68 . . . . 0.0 111.717 178.392 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 21.0 mtp 60.36 10.62 2.5 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 126.084 1.754 . . . . 0.0 115.494 -169.545 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.8 mt -70.6 151.26 9.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 124.639 1.176 . . . . 0.0 109.9 168.727 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 46.7 mtpt -110.58 70.74 0.73 Allowed 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 124.982 1.313 . . . . 0.0 112.194 -175.692 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 25.3 tp -58.34 124.13 18.45 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 123.878 0.871 . . . . 0.0 109.618 175.158 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 61.5 m-85 45.39 31.26 0.83 Allowed 'General case' 0 CA--C 1.561 1.38 0 N-CA-C 116.058 1.873 . . . . 0.0 116.058 -168.486 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 82.36 17.4 69.04 Favored Glycine 0 CA--C 1.541 1.685 0 O-C-N 120.268 -1.52 . . . . 0.0 116.655 173.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 94.0 mttt -131.58 123.31 19.3 Favored Pre-proline 0 CA--C 1.542 0.639 0 C-N-CA 128.113 2.565 . . . . 0.0 108.081 -179.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -71.34 127.06 12.89 Favored 'Trans proline' 0 CA--C 1.535 0.559 0 C-N-CA 123.329 2.686 . . . . 0.0 112.524 -169.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 16.7 pt -97.08 150.51 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 C-N-CA 125.272 1.429 . . . . 0.0 112.149 176.605 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 23.9 mmt180 -115.4 140.58 49.01 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.948 1.299 . . . . 0.0 111.17 170.323 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 19.8 t -131.5 135.15 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 124.974 1.31 . . . . 0.0 111.063 -172.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -154.68 174.52 14.89 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.061 1.344 . . . . 0.0 111.968 177.243 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 11.9 mmmm -56.34 136.78 53.36 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 124.021 0.929 . . . . 0.0 109.599 171.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -69.92 -16.9 63.29 Favored 'General case' 0 CA--C 1.547 0.864 0 CA-C-N 119.847 1.203 . . . . 0.0 112.889 177.29 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 75.4 p -70.36 -10.03 57.9 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 126.53 1.932 . . . . 0.0 114.028 169.571 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -126.14 162.27 25.75 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 125.838 1.655 . . . . 0.0 112.977 -176.239 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -95.3 -8.71 35.11 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 124.619 1.168 . . . . 0.0 113.68 178.47 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 -152.13 165.14 35.71 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 126.055 1.742 . . . . 0.0 111.525 -176.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 74.7 tttt -70.96 147.82 48.3 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 124.538 1.135 . . . . 0.0 111.072 171.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -74.53 149.53 40.18 Favored 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 123.769 0.828 . . . . 0.0 112.223 177.796 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 23.9 tp -134.15 -0.99 2.97 Favored 'General case' 0 CA--C 1.553 1.089 0 C-N-CA 126.176 1.79 . . . . 0.0 112.968 175.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 52.3 m -122.71 159.84 27.13 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 125.464 1.506 . . . . 0.0 113.392 -169.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -165.78 178.57 40.48 Favored Glycine 0 CA--C 1.54 1.635 0 C-N-CA 124.888 1.232 . . . . 0.0 113.34 178.817 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -70.59 159.4 52.91 Favored 'Trans proline' 0 CA--C 1.541 0.829 0 C-N-CA 123.907 3.071 . . . . 0.0 112.973 -178.279 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 67.2 p -76.54 -14.48 60.01 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 114.539 1.311 . . . . 0.0 114.539 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 9.9 t -148.89 159.78 43.86 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.853 1.661 . . . . 0.0 111.572 177.854 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.198 0 C-N-CA 125.542 1.544 . . . . 0.0 112.823 -178.382 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.585 0 N-CA-C 111.601 -0.6 . . . . 0.0 111.601 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.3 m -64.04 -13.99 51.07 Favored 'General case' 0 N--CA 1.481 1.085 0 N-CA-C 115.106 1.521 . . . . 0.0 115.106 -173.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 43.0 p -73.28 -14.11 61.25 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 125.797 1.639 . . . . 0.0 114.295 171.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -69.4 155.13 53.4 Favored Glycine 0 CA--C 1.537 1.467 0 C-N-CA 124.519 1.057 . . . . 0.0 113.994 178.05 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 92.9 p -149.02 165.71 30.84 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 125.331 1.452 . . . . 0.0 112.565 -178.039 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 22.8 m -77.3 -9.83 59.06 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 124.437 1.095 . . . . 0.0 113.891 176.084 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 170.65 -174.46 44.55 Favored Glycine 0 CA--C 1.539 1.538 0 C-N-CA 125.552 1.548 . . . . 0.0 112.783 -178.356 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -78.32 46.6 2.15 Favored 'Trans proline' 0 CA--C 1.549 1.232 0 C-N-CA 125.065 3.843 . . . . 0.0 112.79 -178.422 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 1.6 pp -96.85 158.94 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 C-N-CA 126.123 1.769 . . . . 0.0 113.376 -175.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 18.8 m -89.98 11.27 21.07 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 125.004 1.322 . . . . 0.0 114.451 -174.023 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 16.7 tt0 56.96 36.48 27.83 Favored 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 126.147 1.779 . . . . 0.0 114.036 179.749 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 17.7 ptp180 -146.22 160.01 42.55 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 125.877 1.671 . . . . 0.0 112.465 178.092 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 12.2 p30 -144.26 162.61 35.95 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.415 1.486 . . . . 0.0 112.53 -173.469 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 85.4 mt-30 -136.08 6.39 3.1 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.116 1.367 . . . . 0.0 113.673 176.438 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 23.8 p-10 -105.72 -37.29 6.78 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 126.175 1.79 . . . . 0.0 112.287 176.279 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.13 -2.9 58.77 Favored 'General case' 0 CA--C 1.547 0.863 0 C-N-CA 124.68 1.192 . . . . 0.0 112.833 169.188 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 79.0 m -105.8 132.06 52.38 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 125.027 1.331 . . . . 0.0 109.381 169.134 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.0 m -101.85 149.89 6.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 124.953 1.301 . . . . 0.0 110.792 174.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 13.6 t80 -95.6 144.57 25.93 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 126.255 1.822 . . . . 0.0 109.487 169.398 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 24.0 t -132.01 113.47 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 125.618 1.567 . . . . 0.0 109.332 174.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -109.06 149.31 17.06 Favored Glycine 0 CA--C 1.53 1.031 0 C-N-CA 124.554 1.073 . . . . 0.0 113.334 178.054 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 92.9 34.61 6.75 Favored Glycine 0 CA--C 1.533 1.206 0 C-N-CA 124.718 1.151 . . . . 0.0 113.794 175.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 88.4 mt -83.47 144.97 29.21 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 125.275 1.43 . . . . 0.0 112.005 -172.23 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -82.86 157.32 23.16 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 123.94 0.896 . . . . 0.0 112.444 177.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -58.29 -21.18 47.93 Favored 'General case' 0 CA--C 1.546 0.799 0 N-CA-C 114.66 1.355 . . . . 0.0 114.66 178.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.0 mtmm -79.49 -13.07 59.81 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 174.509 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.1 t -75.4 138.56 20.65 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.898 0 C-N-CA 124.426 1.09 . . . . 0.0 111.302 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 9.4 t -144.39 167.22 23.0 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 123.973 0.909 . . . . 0.0 112.151 173.198 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -54.17 -43.84 97.71 Favored Pre-proline 0 CA--C 1.549 0.908 0 N-CA-C 114.137 1.162 . . . . 0.0 114.137 -179.253 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -62.93 -29.98 76.53 Favored 'Trans proline' 0 C--N 1.353 0.808 0 C-N-CA 122.23 1.953 . . . . 0.0 113.463 175.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 21.3 tp -67.4 -54.43 20.53 Favored 'General case' 0 C--N 1.343 0.311 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 172.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 24.6 mt -56.11 -42.01 76.17 Favored 'General case' 0 N--CA 1.463 0.204 0 C-N-CA 122.692 0.397 . . . . 0.0 111.737 -176.383 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.8 t90 -57.96 -62.05 2.09 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 123.211 0.605 . . . . 0.0 111.276 178.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -64.61 -29.84 70.86 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 113.685 0.995 . . . . 0.0 113.685 -177.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.2 tp -70.72 -36.32 73.15 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.021 0.928 . . . . 0.0 112.065 176.187 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 11.6 m-85 -88.86 -10.91 46.26 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 124.92 1.288 . . . . 0.0 113.512 -175.709 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 26.4 mt -53.77 -20.97 6.37 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 114.03 1.122 . . . . 0.0 114.03 169.324 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 -64.14 -32.28 73.79 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.284 1.433 . . . . 0.0 112.712 175.176 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.66 -44.55 20.7 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 123.525 0.73 . . . . 0.0 112.684 177.129 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.54 -172.78 44.66 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 124.485 1.041 . . . . 0.0 113.07 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -67.92 109.38 1.9 Allowed 'Trans proline' 0 CA--C 1.537 0.664 0 C-N-CA 123.704 2.936 . . . . 0.0 111.663 -179.082 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 68.9 t -84.48 133.63 28.83 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 124.896 1.278 . . . . 0.0 109.8 174.199 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 5.6 t -109.85 -33.65 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 126.162 1.785 . . . . 0.0 111.968 -171.683 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 19.5 t30 -160.64 163.23 32.71 Favored 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 125.962 1.705 . . . . 0.0 110.929 -173.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 5.2 p -140.2 156.94 46.31 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 126.449 1.9 . . . . 0.0 111.295 175.59 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 4.8 t60 -141.66 142.37 33.38 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 123.832 0.853 . . . . 0.0 111.111 171.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 30.7 mmm -139.55 102.84 7.13 Favored Pre-proline 0 N--CA 1.469 0.521 0 C-N-CA 125.127 1.371 . . . . 0.0 108.356 170.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_exo -56.28 132.38 51.52 Favored 'Trans proline' 0 CA--C 1.537 0.632 0 C-N-CA 123.105 2.537 . . . . 0.0 112.701 177.234 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 42.8 mmtm -104.63 141.68 36.0 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.959 1.304 . . . . 0.0 111.698 -177.396 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -69.48 140.1 53.97 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 125.212 1.405 . . . . 0.0 112.261 177.424 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 53.2 ptt85 -83.98 6.14 23.01 Favored 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 115.887 1.81 . . . . 0.0 115.887 -173.688 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 25.0 t -132.41 -37.7 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 124.988 1.315 . . . . 0.0 111.41 -175.207 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 73.4 p -108.4 -20.67 13.04 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 126.05 1.74 . . . . 0.0 112.614 -177.491 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 74.07 1.85 60.72 Favored Glycine 0 CA--C 1.539 1.568 0 C-N-CA 125.018 1.294 . . . . 0.0 116.003 172.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -78.54 168.99 18.96 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-N 118.513 1.156 . . . . 0.0 111.315 171.195 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 18.5 p80 -67.64 156.04 37.77 Favored 'General case' 0 CA--C 1.54 0.581 0 O-C-N 121.029 -1.044 . . . . 0.0 112.037 170.664 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 46.6 mt-30 -87.88 17.04 5.15 Favored 'General case' 0 CA--C 1.55 0.978 0 N-CA-C 114.493 1.294 . . . . 0.0 114.493 -172.047 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.3 1.12 81.86 Favored Glycine 0 CA--C 1.536 1.371 0 C-N-CA 125.223 1.392 . . . . 0.0 115.002 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 45.6 p90 -145.66 156.28 43.55 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 125.268 1.427 . . . . 0.0 112.19 178.165 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -142.87 -178.17 18.52 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 126.784 2.135 . . . . 0.0 112.755 -176.918 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 65.4 m-85 -144.03 151.71 40.04 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 125.705 1.602 . . . . 0.0 111.896 177.364 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 19.4 t -134.84 131.99 53.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 C-N-CA 124.72 1.208 . . . . 0.0 110.132 176.518 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -108.35 127.35 53.8 Favored 'General case' 0 N--CA 1.467 0.377 0 C-N-CA 124.772 1.229 . . . . 0.0 111.613 -176.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -103.73 160.67 14.57 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 125.241 1.416 . . . . 0.0 112.475 178.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 14.8 tp -61.97 -32.61 73.07 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 123.361 0.664 . . . . 0.0 112.387 178.29 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.4 m -143.8 155.3 44.1 Favored 'General case' 0 N--CA 1.468 0.45 0 C-N-CA 124.258 1.023 . . . . 0.0 111.868 -179.435 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 12.8 tm-20 -62.66 -32.06 73.05 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 124.388 1.075 . . . . 0.0 113.221 -178.321 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -69.3 -25.23 64.14 Favored 'General case' 0 CA--C 1.542 0.648 0 N-CA-C 113.346 0.869 . . . . 0.0 113.346 176.52 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 -79.75 -32.53 41.07 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 123.875 0.87 . . . . 0.0 111.465 173.416 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.68 -42.83 73.61 Favored 'General case' 0 CA--C 1.539 0.545 0 O-C-N 121.875 -0.516 . . . . 0.0 111.263 172.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -62.16 -26.8 68.53 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 123.929 0.891 . . . . 0.0 112.704 176.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 30.3 t80 -78.68 -34.54 46.13 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 123.705 0.802 . . . . 0.0 112.838 173.657 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -65.38 -34.23 77.81 Favored 'General case' 0 CA--C 1.536 0.434 0 O-C-N 120.541 -1.349 . . . . 0.0 111.146 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 61.8 mt -65.42 -33.85 66.47 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 C-N-CA 124.605 1.162 . . . . 0.0 111.625 173.27 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 50.5 tttm -65.03 -41.97 94.78 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.207 1.003 . . . . 0.0 112.053 174.576 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 20.0 pt -93.98 -37.77 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 N-CA-C 114.809 1.411 . . . . 0.0 114.809 -174.318 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 13.8 mmt -90.85 -1.25 57.86 Favored 'General case' 0 N--CA 1.479 1.011 0 N-CA-C 114.948 1.462 . . . . 0.0 114.948 -169.742 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -81.17 138.86 35.84 Favored 'General case' 0 CA--C 1.54 0.565 0 O-C-N 120.929 -1.107 . . . . 0.0 111.863 178.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 22.3 mmt 61.5 5.45 1.22 Allowed 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 126.443 1.897 . . . . 0.0 115.345 -170.55 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 1.6 mt -68.69 142.36 16.34 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 C-N-CA 124.405 1.082 . . . . 0.0 111.894 178.711 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 42.5 mtpt -98.27 64.89 1.65 Allowed 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 125.0 1.32 . . . . 0.0 112.35 -171.478 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 27.1 tp -59.35 123.74 17.75 Favored 'General case' 0 CA--C 1.542 0.663 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 174.233 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 63.0 m-85 45.27 31.65 0.85 Allowed 'General case' 0 CA--C 1.562 1.418 0 N-CA-C 115.848 1.796 . . . . 0.0 115.848 -168.022 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 84.61 12.66 74.68 Favored Glycine 0 CA--C 1.542 1.753 0 N-CA-C 117.045 1.578 . . . . 0.0 117.045 173.175 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -127.27 117.85 21.72 Favored Pre-proline 0 CA--C 1.54 0.575 0 C-N-CA 127.892 2.477 . . . . 0.0 108.49 -178.026 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -71.89 121.86 7.98 Favored 'Trans proline' 0 CA--C 1.536 0.609 0 C-N-CA 123.617 2.878 . . . . 0.0 111.761 -171.623 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 4.9 pt -86.94 168.49 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 125.681 1.592 . . . . 0.0 112.524 -176.804 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 73.6 mmt-85 -120.82 132.92 55.28 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 125.571 1.548 . . . . 0.0 109.961 171.348 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 15.2 t -131.07 133.94 62.1 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 123.95 0.9 . . . . 0.0 111.376 -176.659 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -157.65 171.73 19.8 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.888 1.675 . . . . 0.0 111.252 179.658 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.1 mmmm -58.82 144.04 45.47 Favored 'General case' 0 N--CA 1.48 1.072 0 O-C-N 121.3 -0.875 . . . . 0.0 109.444 170.58 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -66.85 -29.89 69.92 Favored 'General case' 0 CA--C 1.547 0.848 0 CA-C-N 119.142 0.883 . . . . 0.0 112.862 -178.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 5.9 t -85.16 -61.19 1.83 Allowed 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 124.69 1.196 . . . . 0.0 111.505 169.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . 53.28 18.57 1.29 Allowed 'General case' 0 CA--C 1.552 1.034 0 C-N-CA 126.05 1.74 . . . . 0.0 114.921 -169.657 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -139.68 18.62 2.51 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.067 1.347 . . . . 0.0 113.388 -174.549 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 58.8 t-20 -65.93 134.72 53.58 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 124.898 1.279 . . . . 0.0 112.015 -177.202 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 57.5 mtmt -94.1 -6.73 44.37 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.785 1.634 . . . . 0.0 114.157 -179.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -62.22 149.17 42.48 Favored 'General case' 0 CA--C 1.549 0.922 0 C-N-CA 124.557 1.143 . . . . 0.0 112.672 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 16.9 tp 53.62 47.66 23.36 Favored 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 125.98 1.712 . . . . 0.0 113.173 -179.267 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 56.8 p -71.14 -36.25 72.01 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 124.282 1.033 . . . . 0.0 112.688 173.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -89.62 173.97 40.81 Favored Glycine 0 CA--C 1.542 1.748 0 C-N-CA 125.221 1.391 . . . . 0.0 113.3 169.69 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -62.33 148.52 93.12 Favored 'Trans proline' 0 CA--C 1.537 0.655 0 C-N-CA 123.539 2.826 . . . . 0.0 113.73 179.164 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 60.8 p -67.82 -18.91 64.99 Favored 'General case' 0 N--CA 1.477 0.889 0 C-N-CA 124.183 0.993 . . . . 0.0 113.649 173.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 61.5 p -85.84 -4.16 59.09 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 126.271 1.828 . . . . 0.0 114.295 173.449 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.236 0 C-N-CA 125.596 1.57 . . . . 0.0 114.082 -179.544 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.548 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 27.8 m 53.03 38.0 26.18 Favored 'General case' 0 N--CA 1.48 1.065 0 C-N-CA 125.026 1.33 . . . . 0.0 113.439 -174.462 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 60.9 p -140.28 162.93 34.12 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 126.489 1.916 . . . . 0.0 112.043 -171.075 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 61.64 25.38 65.34 Favored Glycine 0 CA--C 1.538 1.517 0 C-N-CA 123.919 0.771 . . . . 0.0 114.648 178.287 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.2 m 56.91 22.17 6.89 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 126.158 1.783 . . . . 0.0 114.826 -170.21 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 8.3 t -79.76 162.65 25.02 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.78 1.232 . . . . 0.0 112.122 174.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 77.77 -128.81 9.08 Favored Glycine 0 CA--C 1.543 1.787 0 CA-C-O 118.578 -1.123 . . . . 0.0 112.609 -176.637 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -68.82 157.83 60.27 Favored 'Trans proline' 0 CA--C 1.541 0.826 0 C-N-CA 123.454 2.769 . . . . 0.0 113.507 -175.244 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -69.81 153.65 8.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 C-N-CA 125.102 1.361 . . . . 0.0 113.401 179.34 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 64.5 p -92.47 -4.21 53.99 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 125.575 1.55 . . . . 0.0 115.018 -175.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -138.57 147.77 43.41 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 125.678 1.591 . . . . 0.0 111.303 -178.657 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 26.6 mmt85 -78.68 86.36 4.65 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.191 1.396 . . . . 0.0 110.166 177.209 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 10.9 m120 55.7 -94.47 0.04 OUTLIER 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 126.29 1.836 . . . . 0.0 113.71 -171.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 61.69 -4.27 0.18 Allowed 'General case' 0 CA--C 1.552 1.028 0 C-N-CA 126.575 1.95 . . . . 0.0 115.228 -170.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 24.6 p-10 -92.43 -41.08 10.51 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 127.667 2.387 . . . . 0.0 111.845 172.92 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -80.18 -3.34 48.6 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 124.66 1.184 . . . . 0.0 112.991 169.649 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.2 m -92.47 133.28 36.07 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 124.158 0.983 . . . . 0.0 109.734 169.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.4 m -105.38 147.32 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 C-N-CA 124.948 1.299 . . . . 0.0 110.768 172.948 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 28.1 t80 -95.4 142.43 27.78 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 126.16 1.784 . . . . 0.0 109.644 169.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 25.0 t -133.34 108.22 12.13 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 C-N-CA 125.812 1.645 . . . . 0.0 109.374 178.161 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -102.96 150.97 17.95 Favored Glycine 0 CA--C 1.53 1.023 0 C-N-CA 124.353 0.978 . . . . 0.0 112.942 175.889 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.54 34.25 7.52 Favored Glycine 0 CA--C 1.532 1.152 0 C-N-CA 124.591 1.091 . . . . 0.0 113.959 173.216 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 88.9 mt -81.29 144.93 31.18 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 125.394 1.478 . . . . 0.0 111.763 -173.112 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -82.43 156.14 24.29 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 123.821 0.848 . . . . 0.0 112.246 177.413 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.84 -20.28 49.22 Favored 'General case' 0 CA--C 1.546 0.823 0 N-CA-C 114.804 1.409 . . . . 0.0 114.804 179.038 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.5 mtmm -82.24 -8.53 59.64 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 124.883 1.273 . . . . 0.0 114.178 174.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 55.1 t -78.23 140.07 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 C-N-CA 124.884 1.274 . . . . 0.0 111.13 177.508 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 9.5 t -144.49 167.29 22.85 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 123.912 0.885 . . . . 0.0 112.104 171.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 7.8 mt-10 -54.29 -43.9 98.02 Favored Pre-proline 0 CA--C 1.547 0.838 0 CA-C-O 117.682 -1.152 . . . . 0.0 114.106 -179.292 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -62.69 -30.85 79.02 Favored 'Trans proline' 0 C--N 1.354 0.82 0 C-N-CA 122.216 1.944 . . . . 0.0 113.389 175.144 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 20.8 tp -67.29 -54.24 22.57 Favored 'General case' 0 C--N 1.343 0.322 0 CA-C-N 118.218 0.463 . . . . 0.0 109.754 173.197 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 34.4 mt -55.18 -42.99 73.9 Favored 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 122.62 0.368 . . . . 0.0 111.567 -177.365 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.7 t90 -57.22 -61.34 2.54 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 123.407 0.683 . . . . 0.0 111.348 178.684 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -65.54 -29.86 70.54 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 113.745 1.017 . . . . 0.0 113.745 -177.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.6 tp -71.53 -36.18 70.94 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 124.162 0.985 . . . . 0.0 111.873 176.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -88.57 -11.9 44.26 Favored 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 124.746 1.218 . . . . 0.0 113.299 -176.245 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 24.1 mt -52.84 -22.37 5.35 Favored 'General case' 0 N--CA 1.477 0.904 0 N-CA-C 114.058 1.133 . . . . 0.0 114.058 169.037 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 41.4 mt-30 -63.29 -32.04 73.35 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 125.225 1.41 . . . . 0.0 112.662 175.584 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.54 -44.88 20.3 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 123.563 0.745 . . . . 0.0 112.677 176.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.64 -173.56 45.33 Favored Glycine 0 CA--C 1.536 1.377 0 C-N-CA 124.631 1.11 . . . . 0.0 112.97 179.099 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -66.71 112.13 2.34 Favored 'Trans proline' 0 CA--C 1.538 0.676 0 C-N-CA 123.66 2.907 . . . . 0.0 111.677 -178.939 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 69.3 t -87.28 131.92 33.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 C-N-CA 124.953 1.301 . . . . 0.0 109.686 174.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.8 t -106.44 -34.11 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 126.671 1.988 . . . . 0.0 111.746 -171.961 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 24.3 t30 -160.66 165.83 29.89 Favored 'General case' 0 CA--C 1.554 1.109 0 C-N-CA 125.973 1.709 . . . . 0.0 110.832 -174.741 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 8.4 p -139.69 160.36 40.06 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 126.391 1.876 . . . . 0.0 111.026 173.619 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 5.6 t60 -142.23 143.17 32.77 Favored 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 123.688 0.795 . . . . 0.0 111.047 171.734 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 2.6 mmm -141.39 104.42 5.99 Favored Pre-proline 0 N--CA 1.468 0.469 0 C-N-CA 125.321 1.448 . . . . 0.0 108.673 170.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_exo -56.18 134.93 67.25 Favored 'Trans proline' 0 CA--C 1.539 0.768 0 C-N-CA 123.181 2.588 . . . . 0.0 112.049 171.451 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 42.7 mmtm -110.45 146.3 36.16 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 124.83 1.252 . . . . 0.0 113.19 -172.149 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -68.82 144.87 54.17 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 125.822 1.649 . . . . 0.0 112.324 171.458 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 11.9 ptp85 -88.87 7.24 35.32 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 115.995 1.85 . . . . 0.0 115.995 -174.449 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 39.3 t -130.24 -37.38 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.15 0 C-N-CA 125.008 1.323 . . . . 0.0 111.291 -174.68 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 73.1 p -113.29 -15.44 12.69 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 125.888 1.675 . . . . 0.0 112.437 -177.212 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.83 4.35 53.94 Favored Glycine 0 CA--C 1.537 1.422 0 C-N-CA 125.041 1.305 . . . . 0.0 115.412 177.067 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 72.6 mm-40 -78.22 164.89 24.53 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 124.705 1.202 . . . . 0.0 110.945 177.615 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 25.4 p80 -68.04 154.68 41.14 Favored 'General case' 0 N--CA 1.471 0.608 0 O-C-N 120.922 -1.111 . . . . 0.0 112.338 175.247 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 47.7 mt-30 -84.54 20.72 1.64 Allowed 'General case' 0 CA--C 1.55 0.977 0 N-CA-C 114.396 1.258 . . . . 0.0 114.396 -173.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.95 -1.21 86.72 Favored Glycine 0 CA--C 1.535 1.283 0 C-N-CA 125.257 1.408 . . . . 0.0 114.936 -179.331 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -144.89 152.26 39.98 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.209 1.404 . . . . 0.0 111.949 177.44 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -142.31 -178.94 18.81 Favored Glycine 0 CA--C 1.534 1.244 0 C-N-CA 126.846 2.165 . . . . 0.0 112.284 -176.652 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 51.7 m-85 -142.94 152.72 42.32 Favored 'General case' 0 C--O 1.236 0.371 0 C-N-CA 125.321 1.449 . . . . 0.0 111.688 178.588 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.3 t -133.55 133.87 57.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 124.714 1.205 . . . . 0.0 109.561 176.135 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 59.8 tt0 -109.77 119.71 40.21 Favored 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 124.687 1.195 . . . . 0.0 110.896 -176.056 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -96.01 163.15 13.25 Favored 'General case' 0 C--O 1.234 0.25 0 C-N-CA 124.688 1.195 . . . . 0.0 112.693 177.163 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.9 tp -64.44 -34.7 78.79 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 123.246 0.618 . . . . 0.0 112.415 177.055 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 18.6 m -144.03 156.83 44.54 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 124.629 1.172 . . . . 0.0 112.042 -176.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 50.3 tt0 -62.58 -33.31 74.71 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 124.003 0.921 . . . . 0.0 113.027 -179.094 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -68.44 -24.47 64.73 Favored 'General case' 0 CA--C 1.542 0.67 0 O-C-N 121.23 -0.919 . . . . 0.0 113.469 177.343 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -80.24 -33.27 38.09 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 123.848 0.859 . . . . 0.0 111.376 172.591 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -68.64 -44.76 73.49 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.305 0.642 . . . . 0.0 111.521 172.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 33.6 t70 -57.27 -35.19 69.45 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.515 1.126 . . . . 0.0 112.524 175.635 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 23.6 t80 -71.42 -38.41 71.4 Favored 'General case' 0 CA--C 1.536 0.439 0 O-C-N 121.725 -0.609 . . . . 0.0 111.985 175.052 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -65.8 -37.08 85.3 Favored 'General case' 0 CA--C 1.537 0.466 0 O-C-N 120.795 -1.19 . . . . 0.0 111.537 176.537 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 64.5 mt -63.42 -33.26 60.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 124.097 0.959 . . . . 0.0 110.936 172.484 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 63.2 tttp -69.66 -43.68 72.08 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 124.117 0.967 . . . . 0.0 112.478 176.635 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 18.3 pt -89.21 -42.67 14.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 114.5 1.296 . . . . 0.0 114.5 -175.574 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 15.3 mmt -86.69 0.82 53.88 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 114.772 1.397 . . . . 0.0 114.772 -169.254 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -84.37 132.27 34.61 Favored 'General case' 0 CA--C 1.538 0.5 0 O-C-N 121.433 -0.792 . . . . 0.0 112.336 -178.338 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 24.4 ttm 59.01 17.7 5.66 Favored 'General case' 0 CA--C 1.549 0.921 0 C-N-CA 126.698 1.999 . . . . 0.0 114.539 -169.87 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.8 mt -73.71 140.66 17.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 124.52 1.128 . . . . 0.0 111.072 171.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 42.7 mtpt -97.63 63.99 1.77 Allowed 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 124.58 1.152 . . . . 0.0 112.622 -172.153 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 37.3 tp -58.14 122.23 12.61 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 123.899 0.88 . . . . 0.0 109.422 174.55 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 57.8 m-85 44.91 31.69 0.72 Allowed 'General case' 0 CA--C 1.56 1.345 0 N-CA-C 116.008 1.855 . . . . 0.0 116.008 -168.578 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 83.49 15.53 70.98 Favored Glycine 0 CA--C 1.541 1.705 0 O-C-N 120.168 -1.583 . . . . 0.0 116.957 173.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 59.3 mttp -126.45 121.1 23.49 Favored Pre-proline 0 CA--C 1.539 0.54 0 C-N-CA 127.638 2.375 . . . . 0.0 108.457 176.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -71.14 108.83 2.42 Favored 'Trans proline' 0 CA--C 1.537 0.643 0 C-N-CA 123.807 3.005 . . . . 0.0 111.27 -174.201 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 5.8 pt -77.61 147.12 7.46 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 C-N-CA 124.694 1.197 . . . . 0.0 110.245 179.124 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 40.1 mmm-85 -113.2 133.36 55.1 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 123.947 0.899 . . . . 0.0 110.671 175.064 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.8 t -128.46 136.78 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 124.2 1.0 . . . . 0.0 111.326 -169.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -158.66 -178.21 7.09 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 124.853 1.261 . . . . 0.0 111.281 173.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 10.1 mmmm -60.89 144.14 53.51 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 124.499 1.12 . . . . 0.0 110.167 172.505 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -68.24 -29.33 68.13 Favored 'General case' 0 CA--C 1.549 0.937 0 O-C-N 121.615 -0.678 . . . . 0.0 112.07 174.511 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 26.3 m -117.98 119.15 33.95 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 125.743 1.617 . . . . 0.0 109.252 167.387 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -134.51 175.22 9.73 Favored 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 125.302 1.441 . . . . 0.0 112.62 -170.292 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 90.4 m-70 56.82 40.0 29.26 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 125.969 1.707 . . . . 0.0 114.395 178.407 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 46.6 t30 -69.27 160.46 31.17 Favored 'General case' 0 CA--C 1.551 1.018 0 C-N-CA 124.513 1.125 . . . . 0.0 112.094 175.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 40.0 ttpt -61.89 142.77 57.19 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 125.496 1.518 . . . . 0.0 112.127 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 4.9 p-10 -117.07 166.89 11.68 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.782 1.633 . . . . 0.0 112.766 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 54.8 tp -114.92 145.42 42.23 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.925 1.69 . . . . 0.0 110.496 174.519 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 25.0 m -69.89 -31.47 69.29 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 123.84 0.856 . . . . 0.0 113.213 179.484 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 170.06 154.96 9.74 Favored Glycine 0 CA--C 1.539 1.569 0 C-N-CA 125.969 1.747 . . . . 0.0 112.243 172.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -67.76 143.53 61.96 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 123.098 2.532 . . . . 0.0 111.799 178.058 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 22.5 m 53.41 28.2 7.24 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 125.441 1.496 . . . . 0.0 114.935 -179.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 68.4 p -79.3 -11.38 59.94 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 114.857 1.429 . . . . 0.0 114.857 -175.671 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.265 0 C-N-CA 125.699 1.619 . . . . 0.0 113.816 177.775 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.632 0 N-CA-C 111.821 -0.512 . . . . 0.0 111.821 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.4 m 61.89 167.75 0.11 Allowed 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 126.676 1.99 . . . . 0.0 115.401 -176.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 71.5 m -74.83 158.87 32.7 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 124.435 1.094 . . . . 0.0 112.505 175.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.34 164.53 44.56 Favored Glycine 0 CA--C 1.537 1.432 0 CA-C-O 121.791 0.662 . . . . 0.0 113.478 172.71 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 13.3 p -68.0 -22.06 65.01 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 116.119 1.896 . . . . 0.0 116.119 -169.974 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 60.4 p 55.34 -175.27 0.04 OUTLIER 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 127.128 2.171 . . . . 0.0 113.818 -174.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -165.59 156.65 28.73 Favored Glycine 0 CA--C 1.538 1.51 0 O-C-N 120.343 -1.473 . . . . 0.0 115.801 174.468 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -80.51 54.07 5.06 Favored 'Trans proline' 0 CA--C 1.547 1.146 0 C-N-CA 124.984 3.789 . . . . 0.0 112.772 -177.294 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 17.3 tt -69.34 141.19 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 C-N-CA 125.102 1.361 . . . . 0.0 111.709 176.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 61.7 m -109.56 -12.81 14.64 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 125.068 1.347 . . . . 0.0 112.927 174.424 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 21.9 mp0 -83.06 -14.99 52.71 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 125.352 1.461 . . . . 0.0 112.907 -177.13 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 27.4 ttm180 -143.8 141.17 30.25 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 127.482 2.313 . . . . 0.0 108.525 170.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 55.9 m-20 -89.12 10.66 21.03 Favored 'General case' 0 CA--C 1.545 0.773 0 N-CA-C 113.576 0.954 . . . . 0.0 113.576 -178.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 63.4 tt0 -66.26 -38.04 86.89 Favored 'General case' 0 N--CA 1.472 0.627 0 O-C-N 120.707 -1.245 . . . . 0.0 112.977 -173.689 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -73.89 -24.41 59.71 Favored 'General case' 0 N--CA 1.473 0.714 0 O-C-N 121.309 -0.869 . . . . 0.0 112.197 173.243 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -84.89 5.06 30.45 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 125.513 1.525 . . . . 0.0 113.106 169.631 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 53.7 m -112.02 139.39 47.57 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 125.089 1.355 . . . . 0.0 109.172 174.578 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 4.3 m -104.94 146.17 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 C-N-CA 124.152 0.981 . . . . 0.0 110.012 174.214 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 50.3 t80 -95.44 140.36 30.42 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 125.784 1.634 . . . . 0.0 109.318 169.464 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 26.1 t -131.68 110.96 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.542 0 C-N-CA 125.673 1.589 . . . . 0.0 109.208 178.507 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -107.23 149.04 16.56 Favored Glycine 0 CA--C 1.531 1.032 0 C-N-CA 124.572 1.082 . . . . 0.0 112.826 176.125 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.65 33.6 6.67 Favored Glycine 0 CA--C 1.533 1.213 0 C-N-CA 124.482 1.039 . . . . 0.0 113.953 174.2 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 84.9 mt -74.41 152.06 39.57 Favored 'General case' 0 C--O 1.234 0.259 0 C-N-CA 125.459 1.504 . . . . 0.0 111.505 -174.522 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -90.69 156.31 18.19 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 123.885 0.874 . . . . 0.0 111.854 174.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.3 -20.53 43.65 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 114.823 1.416 . . . . 0.0 114.823 -179.543 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.5 mtmm -81.38 -12.18 59.06 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 124.687 1.195 . . . . 0.0 114.093 175.067 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 64.4 t -73.36 141.92 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 124.576 1.15 . . . . 0.0 111.572 178.316 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 6.2 t -144.29 166.88 23.82 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 123.949 0.899 . . . . 0.0 111.671 169.237 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -53.15 -42.68 92.27 Favored Pre-proline 0 CA--C 1.545 0.786 0 N-CA-C 115.498 1.666 . . . . 0.0 115.498 -179.37 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -70.53 -25.01 25.5 Favored 'Trans proline' 0 C--N 1.353 0.804 0 CA-C-N 122.142 1.801 . . . . 0.0 112.997 176.487 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 17.6 tp -65.74 -53.83 35.38 Favored 'General case' 0 C--N 1.343 0.32 0 CA-C-N 118.707 0.685 . . . . 0.0 109.273 170.265 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 25.8 mt -54.94 -41.95 71.7 Favored 'General case' 0 N--CA 1.464 0.269 0 O-C-N 123.265 0.353 . . . . 0.0 111.261 -179.067 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 3.0 t90 -57.87 -62.42 1.82 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 123.371 0.669 . . . . 0.0 111.35 177.823 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -64.67 -29.48 70.47 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 113.844 1.053 . . . . 0.0 113.844 -177.33 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.0 tp -71.79 -36.61 70.35 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 124.328 1.051 . . . . 0.0 111.918 176.425 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 -88.36 -10.42 49.43 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.071 1.349 . . . . 0.0 113.424 -176.392 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 25.0 mt -53.66 -21.42 6.89 Favored 'General case' 0 CA--C 1.546 0.804 0 N-CA-C 113.948 1.092 . . . . 0.0 113.948 168.884 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 42.3 mt-30 -63.25 -32.28 73.65 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 125.182 1.393 . . . . 0.0 112.618 174.02 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -78.58 -44.35 24.3 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.36 0.664 . . . . 0.0 112.519 177.151 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 177.36 -173.02 45.86 Favored Glycine 0 CA--C 1.535 1.316 0 C-N-CA 124.578 1.085 . . . . 0.0 113.04 -178.584 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -67.63 110.08 2.01 Favored 'Trans proline' 0 CA--C 1.537 0.671 0 C-N-CA 123.774 2.983 . . . . 0.0 111.719 -178.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 80.8 t -85.72 135.11 25.66 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 C-N-CA 124.896 1.278 . . . . 0.0 109.973 174.363 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.9 t -110.17 -34.01 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 C-N-CA 126.262 1.825 . . . . 0.0 111.897 -172.038 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 21.3 t30 -160.94 160.88 31.37 Favored 'General case' 0 CA--C 1.553 1.064 0 C-N-CA 125.775 1.63 . . . . 0.0 110.978 -174.864 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 6.7 p -137.57 154.41 49.8 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 125.816 1.647 . . . . 0.0 111.875 172.124 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 18.1 t-80 -142.29 130.58 22.23 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 123.659 0.784 . . . . 0.0 111.553 177.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 83.3 mtp -134.09 102.49 12.06 Favored Pre-proline 0 N--CA 1.471 0.62 0 C-N-CA 124.575 1.15 . . . . 0.0 109.562 170.013 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo -61.86 128.72 25.16 Favored 'Trans proline' 0 CA--C 1.538 0.704 0 C-N-CA 123.016 2.478 . . . . 0.0 113.135 -178.44 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 45.2 mmtm -92.47 151.41 20.22 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 124.506 1.122 . . . . 0.0 113.686 -172.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -66.39 142.2 57.68 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 126.471 1.908 . . . . 0.0 112.338 172.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 9.7 ptm180 -83.84 8.14 15.8 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 115.944 1.831 . . . . 0.0 115.944 -174.237 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 35.1 t -131.33 -37.88 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 124.857 1.263 . . . . 0.0 111.494 -173.761 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 63.5 p -116.34 -17.53 10.71 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 125.411 1.484 . . . . 0.0 112.555 -176.236 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.77 9.27 65.4 Favored Glycine 0 CA--C 1.539 1.542 0 C-N-CA 124.77 1.176 . . . . 0.0 114.944 -178.369 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 39.2 mt-30 -70.63 162.91 28.09 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 125.205 1.402 . . . . 0.0 110.934 173.149 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 12.8 p80 -72.38 155.19 40.41 Favored 'General case' 0 N--CA 1.473 0.693 0 O-C-N 120.727 -1.233 . . . . 0.0 111.525 169.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 37.8 mt-30 -95.92 22.14 7.77 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 124.225 1.01 . . . . 0.0 113.715 -171.361 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.94 3.4 83.1 Favored Glycine 0 CA--C 1.533 1.206 0 C-N-CA 125.018 1.294 . . . . 0.0 115.148 179.199 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 46.3 p90 -144.25 160.37 41.09 Favored 'General case' 0 CA--C 1.54 0.596 0 CA-C-N 118.795 1.298 . . . . 0.0 112.934 178.682 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -154.63 -177.37 27.9 Favored Glycine 0 CA--C 1.532 1.112 0 C-N-CA 125.889 1.709 . . . . 0.0 113.456 -178.777 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 89.5 m-85 -143.16 149.39 37.99 Favored 'General case' 0 C--O 1.236 0.378 0 C-N-CA 126.107 1.763 . . . . 0.0 111.617 -178.312 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 16.4 t -132.25 126.47 55.89 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 C-N-CA 124.564 1.146 . . . . 0.0 110.211 174.785 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 72.0 tt0 -102.34 123.16 45.64 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 125.383 1.473 . . . . 0.0 110.575 -176.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -100.81 161.5 13.56 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 125.226 1.411 . . . . 0.0 112.335 178.374 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.6 tp -62.33 -34.17 76.1 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 123.216 0.606 . . . . 0.0 112.351 177.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.2 m -142.17 155.64 45.31 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 124.499 1.12 . . . . 0.0 112.016 -177.141 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 13.6 tm-20 -64.12 -33.42 75.74 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.401 1.081 . . . . 0.0 113.28 -177.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -69.26 -26.5 64.8 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 113.189 0.811 . . . . 0.0 113.189 176.851 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 42.0 m-20 -76.93 -33.89 57.7 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 123.71 0.804 . . . . 0.0 111.375 173.202 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.9 -43.82 70.98 Favored 'General case' 0 CA--C 1.54 0.567 0 O-C-N 121.955 -0.466 . . . . 0.0 111.454 173.697 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -61.48 -30.27 70.5 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 123.888 0.875 . . . . 0.0 112.706 178.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 61.8 t80 -77.99 -35.03 50.54 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.047 0.939 . . . . 0.0 113.063 173.905 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.8 -37.8 88.15 Favored 'General case' 0 CA--C 1.537 0.46 0 O-C-N 121.053 -1.03 . . . . 0.0 111.155 175.543 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 53.7 mt -64.11 -35.73 74.66 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 124.808 1.243 . . . . 0.0 111.185 173.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -65.81 -40.52 91.94 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 123.961 0.904 . . . . 0.0 112.473 176.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 46.3 pt -92.06 -35.88 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 N-CA-C 114.85 1.426 . . . . 0.0 114.85 -175.95 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 9.9 mmt -91.77 0.75 57.47 Favored 'General case' 0 N--CA 1.479 1.025 0 N-CA-C 115.134 1.531 . . . . 0.0 115.134 -171.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -84.82 136.82 33.51 Favored 'General case' 0 CA--C 1.538 0.519 0 O-C-N 121.391 -0.818 . . . . 0.0 112.249 179.426 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 25.5 ttm 59.71 12.25 2.83 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 126.184 1.794 . . . . 0.0 114.729 -172.103 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.3 mt -69.81 151.68 9.57 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 C-N-CA 125.149 1.379 . . . . 0.0 109.927 168.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 47.4 mtpt -111.54 69.5 0.69 Allowed 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 124.994 1.317 . . . . 0.0 112.472 -175.521 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 31.4 tp -57.69 125.1 21.5 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 124.103 0.961 . . . . 0.0 109.99 174.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 54.3 m-85 46.21 27.93 0.61 Allowed 'General case' 0 CA--C 1.561 1.378 0 N-CA-C 116.366 1.987 . . . . 0.0 116.366 -168.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 80.11 25.59 57.25 Favored Glycine 0 CA--C 1.541 1.709 0 O-C-N 120.176 -1.577 . . . . 0.0 115.998 176.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -135.94 120.44 13.06 Favored Pre-proline 0 CA--C 1.543 0.694 0 C-N-CA 128.293 2.637 . . . . 0.0 107.814 -179.79 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -70.54 125.01 11.29 Favored 'Trans proline' 0 CA--C 1.538 0.684 0 C-N-CA 122.897 2.398 . . . . 0.0 112.381 -171.337 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 18.9 pt -95.33 144.72 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 C-N-CA 125.168 1.387 . . . . 0.0 111.848 176.187 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 44.9 tpt85 -111.41 128.04 55.86 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 126.145 1.778 . . . . 0.0 109.19 176.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.7 t -127.88 138.99 53.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 124.175 0.99 . . . . 0.0 111.34 -170.569 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 31.7 t-20 -157.48 175.96 13.28 Favored 'General case' 0 CA--C 1.549 0.911 0 C-N-CA 125.467 1.507 . . . . 0.0 111.125 -179.242 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 4.8 mmmm -62.61 141.93 58.26 Favored 'General case' 0 N--CA 1.477 0.919 0 O-C-N 120.945 -1.097 . . . . 0.0 109.719 169.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -73.82 -11.41 60.37 Favored 'General case' 0 CA--C 1.55 0.952 0 N-CA-C 112.33 0.492 . . . . 0.0 112.33 170.04 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 64.5 p -89.03 -73.63 0.5 Allowed 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.49 1.516 . . . . 0.0 110.739 168.593 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . 52.55 30.04 7.96 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 126.593 1.957 . . . . 0.0 113.618 -173.046 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 20.9 m170 -78.17 143.97 36.77 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 125.696 1.598 . . . . 0.0 111.775 -178.139 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 48.0 t30 -85.35 81.88 8.57 Favored 'General case' 0 CA--C 1.545 0.75 0 O-C-N 121.142 -0.974 . . . . 0.0 110.165 170.794 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 56.8 pttt -131.92 -7.97 3.51 Favored 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 116.824 2.157 . . . . 0.0 116.824 -169.505 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 44.6 t30 -70.84 148.81 47.44 Favored 'General case' 0 CA--C 1.548 0.872 0 CA-C-N 119.554 1.07 . . . . 0.0 111.256 171.348 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.2 pp -146.45 165.0 30.7 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.957 1.303 . . . . 0.0 113.523 -177.969 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 30.8 p -85.89 -37.43 19.14 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 124.972 1.309 . . . . 0.0 113.545 -179.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 54.64 50.46 57.41 Favored Glycine 0 CA--C 1.545 1.915 0 C-N-CA 125.511 1.529 . . . . 0.0 115.997 175.76 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -68.05 152.27 76.74 Favored 'Trans proline' 0 CA--C 1.541 0.831 0 C-N-CA 123.498 2.799 . . . . 0.0 113.029 -177.204 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 19.7 m -80.55 -17.55 51.15 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 124.391 1.076 . . . . 0.0 113.9 178.424 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 27.0 m -71.87 149.26 45.34 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 125.051 1.34 . . . . 0.0 113.325 -176.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.278 0 C-N-CA 125.241 1.4 . . . . 0.0 113.44 175.141 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.602 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.4 m 53.05 35.54 19.8 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 124.983 1.313 . . . . 0.0 113.157 -171.505 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 12.5 m -73.84 157.04 37.09 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 125.825 1.65 . . . . 0.0 113.697 -169.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -159.51 142.35 8.22 Favored Glycine 0 CA--C 1.533 1.217 0 C-N-CA 124.879 1.228 . . . . 0.0 112.362 174.375 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 73.9 p -116.07 -1.93 12.36 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 125.554 1.542 . . . . 0.0 115.087 -169.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 12.2 m -69.77 -26.15 64.15 Favored 'General case' 0 N--CA 1.475 0.801 0 N-CA-C 115.1 1.518 . . . . 0.0 115.1 -169.635 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 47.48 51.48 16.22 Favored Glycine 0 CA--C 1.544 1.868 0 C-N-CA 126.045 1.783 . . . . 0.0 116.692 -178.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_exo -68.63 115.72 4.06 Favored 'Trans proline' 0 C--N 1.354 0.867 0 CA-C-N 121.66 2.73 . . . . 0.0 113.088 -169.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 46.1 pt -140.58 155.22 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 125.921 1.688 . . . . 0.0 111.746 174.782 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 71.5 p -105.48 0.65 26.92 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 125.587 1.555 . . . . 0.0 114.108 177.785 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -68.59 -38.82 80.96 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.847 1.259 . . . . 0.0 113.757 -171.045 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 35.9 mtm180 -138.31 149.03 45.26 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.895 1.678 . . . . 0.0 111.981 -171.45 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 10.3 p-10 -75.85 -4.37 40.39 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 114.653 1.353 . . . . 0.0 114.653 -177.542 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.2 mp0 -70.66 -9.07 56.24 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 124.333 1.053 . . . . 0.0 113.609 174.533 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -99.73 -20.75 16.1 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 124.6 1.16 . . . . 0.0 112.607 168.39 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -83.78 -17.47 41.01 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.525 1.13 . . . . 0.0 112.381 168.635 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.9 m -95.68 137.44 34.73 Favored 'General case' 0 N--CA 1.466 0.344 0 C-N-CA 125.312 1.445 . . . . 0.0 109.414 170.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.9 m -106.71 147.93 11.58 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 C-N-CA 124.77 1.228 . . . . 0.0 110.225 171.287 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 9.5 t80 -95.19 143.03 26.94 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 125.879 1.672 . . . . 0.0 108.639 169.142 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 25.4 t -130.77 109.82 17.43 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 C-N-CA 125.139 1.375 . . . . 0.0 109.204 174.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -102.76 151.4 18.09 Favored Glycine 0 CA--C 1.53 1.008 0 C-N-CA 124.647 1.118 . . . . 0.0 112.691 175.723 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.45 35.4 6.97 Favored Glycine 0 CA--C 1.533 1.171 0 C-N-CA 124.474 1.035 . . . . 0.0 113.985 174.603 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 90.2 mt -82.93 146.48 28.8 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.382 1.473 . . . . 0.0 111.94 -173.076 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -83.96 157.1 22.01 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 123.872 0.869 . . . . 0.0 112.355 175.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -58.4 -21.03 49.14 Favored 'General case' 0 CA--C 1.547 0.839 0 N-CA-C 114.718 1.377 . . . . 0.0 114.718 178.392 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.8 mtmm -80.66 -10.2 59.75 Favored 'General case' 0 N--CA 1.477 0.901 0 N-CA-C 114.269 1.211 . . . . 0.0 114.269 175.055 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 93.2 t -75.18 138.94 19.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 C-N-CA 124.429 1.092 . . . . 0.0 111.56 178.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 92.5 p -136.99 162.09 34.26 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 125.178 1.391 . . . . 0.0 112.414 178.672 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -54.73 -46.38 99.4 Favored Pre-proline 0 N--CA 1.478 0.969 0 O-C-N 120.786 -1.196 . . . . 0.0 113.158 174.652 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_exo -57.78 -33.2 96.54 Favored 'Trans proline' 0 C--N 1.354 0.819 0 C-N-CA 122.406 2.071 . . . . 0.0 114.058 173.196 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 28.1 tp -67.43 -51.08 55.95 Favored 'General case' 0 C--N 1.343 0.291 0 CA-C-N 118.687 0.676 . . . . 0.0 110.163 173.491 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 21.2 mt -61.7 -23.06 65.87 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 113.338 0.866 . . . . 0.0 113.338 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.3 t90 -74.41 -66.16 0.77 Allowed 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 123.01 0.524 . . . . 0.0 110.965 170.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -65.02 -30.35 71.32 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 114.172 1.175 . . . . 0.0 114.172 -172.543 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.2 tp -68.81 -34.37 75.41 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 123.673 0.789 . . . . 0.0 111.655 175.114 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -90.03 -10.66 44.04 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 125.156 1.382 . . . . 0.0 113.812 -174.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 47.7 mt -56.23 -17.69 8.22 Favored 'General case' 0 CA--C 1.545 0.765 0 N-CA-C 113.873 1.064 . . . . 0.0 113.873 169.031 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 -64.03 -34.84 78.93 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 125.177 1.391 . . . . 0.0 112.624 171.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -77.84 -46.26 21.99 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.371 0.669 . . . . 0.0 112.451 179.31 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.27 -172.06 44.03 Favored Glycine 0 CA--C 1.537 1.411 0 C-N-CA 125.013 1.292 . . . . 0.0 112.594 -178.899 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -68.03 110.21 2.13 Favored 'Trans proline' 0 CA--C 1.537 0.655 0 C-N-CA 123.608 2.872 . . . . 0.0 111.698 -179.319 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 61.8 t -84.86 133.64 28.84 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 124.872 1.269 . . . . 0.0 109.785 173.766 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 5.2 t -109.44 -33.65 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 C-N-CA 126.38 1.872 . . . . 0.0 111.923 -171.767 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 17.4 t30 -160.52 161.35 32.71 Favored 'General case' 0 CA--C 1.553 1.072 0 C-N-CA 125.974 1.71 . . . . 0.0 110.968 -173.554 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 7.7 p -140.98 154.59 46.11 Favored 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 126.409 1.883 . . . . 0.0 111.343 174.563 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 42.0 t-80 -142.38 134.45 27.37 Favored 'General case' 0 N--CA 1.473 0.678 0 C-N-CA 123.386 0.674 . . . . 0.0 112.478 175.362 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 36.4 mmm -132.34 102.54 14.15 Favored Pre-proline 0 CA--C 1.543 0.676 0 C-N-CA 125.139 1.375 . . . . 0.0 110.471 175.191 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -60.11 144.31 99.49 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 123.533 2.822 . . . . 0.0 113.46 177.763 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 26.1 mmtp -113.47 159.84 19.09 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 125.313 1.445 . . . . 0.0 113.545 -174.046 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -87.95 136.82 32.79 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.751 1.62 . . . . 0.0 112.332 170.973 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 10.0 ptp180 -82.7 8.85 10.96 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 115.649 1.722 . . . . 0.0 115.649 -173.672 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 39.3 t -130.67 -37.1 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 C-N-CA 125.066 1.346 . . . . 0.0 111.265 -175.051 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 66.9 p -114.27 -15.82 12.11 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 125.502 1.521 . . . . 0.0 112.569 -176.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 71.06 6.39 60.43 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 124.933 1.254 . . . . 0.0 115.151 176.405 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 74.4 mm-40 -79.97 162.71 24.76 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.99 1.316 . . . . 0.0 110.777 177.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 10.0 p80 -71.46 155.15 40.93 Favored 'General case' 0 CA--C 1.539 0.534 0 O-C-N 121.317 -0.865 . . . . 0.0 112.381 176.077 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 28.0 mm-40 -84.63 13.54 5.56 Favored 'General case' 0 CA--C 1.548 0.876 0 N-CA-C 114.431 1.271 . . . . 0.0 114.431 -170.256 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.0 -0.13 87.51 Favored Glycine 0 CA--C 1.536 1.355 0 C-N-CA 125.165 1.364 . . . . 0.0 114.701 -178.156 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 45.2 p90 -144.2 157.67 44.16 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 125.19 1.396 . . . . 0.0 112.299 177.283 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -144.98 -179.53 21.38 Favored Glycine 0 CA--C 1.534 1.243 0 C-N-CA 126.996 2.236 . . . . 0.0 112.317 -176.444 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -142.58 150.14 39.96 Favored 'General case' 0 C--O 1.237 0.438 0 C-N-CA 125.594 1.558 . . . . 0.0 112.114 179.557 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.3 t -134.6 129.5 52.33 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 125.05 1.34 . . . . 0.0 109.825 176.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 62.1 tt0 -108.85 123.3 48.84 Favored 'General case' 0 N--CA 1.466 0.37 0 C-N-CA 124.414 1.086 . . . . 0.0 111.575 -177.038 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -97.5 161.51 13.75 Favored 'General case' 0 C--O 1.234 0.277 0 C-N-CA 125.209 1.404 . . . . 0.0 112.51 178.128 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 14.7 tp -62.51 -33.8 75.6 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 123.199 0.6 . . . . 0.0 112.32 177.115 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 17.0 m -141.88 155.5 45.52 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 124.422 1.089 . . . . 0.0 112.049 -177.751 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 13.9 tm-20 -62.85 -33.38 75.14 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 124.487 1.115 . . . . 0.0 113.119 -179.565 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -68.4 -25.75 65.21 Favored 'General case' 0 CA--C 1.541 0.633 0 N-CA-C 113.208 0.818 . . . . 0.0 113.208 177.27 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 46.6 m-20 -78.46 -33.1 48.61 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 123.895 0.878 . . . . 0.0 111.491 173.526 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -70.63 -44.07 67.95 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 123.197 0.599 . . . . 0.0 111.474 173.916 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -62.94 -27.57 69.47 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 124.157 0.983 . . . . 0.0 112.846 178.396 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 67.9 t80 -79.73 -35.37 38.99 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 124.3 1.04 . . . . 0.0 112.801 172.351 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.22 -38.99 93.34 Favored 'General case' 0 CA--C 1.538 0.499 0 O-C-N 121.054 -1.029 . . . . 0.0 111.072 177.736 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 70.4 mt -58.24 -38.64 69.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 C-N-CA 125.481 1.512 . . . . 0.0 111.372 172.792 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -67.84 -34.7 77.22 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.314 1.046 . . . . 0.0 113.168 179.249 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 20.2 pt -101.62 -14.22 8.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 115.899 1.815 . . . . 0.0 115.899 -173.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 7.9 mmt -111.6 -3.39 15.11 Favored 'General case' 0 N--CA 1.483 1.195 0 N-CA-C 115.453 1.649 . . . . 0.0 115.453 -176.037 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -82.49 142.23 32.04 Favored 'General case' 0 N--CA 1.475 0.795 0 O-C-N 120.674 -1.266 . . . . 0.0 113.9 -173.4 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 26.4 ttm 60.65 16.98 7.06 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 127.801 2.44 . . . . 0.0 115.21 -176.133 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 23.1 mt -91.39 142.04 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 126.453 1.901 . . . . 0.0 111.999 -174.685 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 40.6 mtpt -93.67 67.58 3.9 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.466 1.106 . . . . 0.0 113.003 -168.102 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 38.5 tp -58.46 121.25 10.44 Favored 'General case' 0 CA--C 1.542 0.662 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 173.755 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 52.9 m-85 44.77 30.04 0.5 Allowed 'General case' 0 CA--C 1.56 1.358 0 N-CA-C 116.152 1.908 . . . . 0.0 116.152 -168.688 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 87.38 12.4 67.46 Favored Glycine 0 CA--C 1.543 1.806 0 N-CA-C 117.345 1.698 . . . . 0.0 117.345 174.433 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 60.3 mttp -125.01 121.92 25.44 Favored Pre-proline 0 CA--C 1.541 0.62 0 C-N-CA 127.569 2.348 . . . . 0.0 108.57 176.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -72.86 112.82 3.6 Favored 'Trans proline' 0 CA--C 1.533 0.471 0 C-N-CA 123.957 3.104 . . . . 0.0 111.599 -171.239 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 8.2 pt -80.72 145.89 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 C-N-CA 123.861 0.865 . . . . 0.0 111.3 -177.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -114.45 127.97 56.1 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 125.665 1.586 . . . . 0.0 109.482 177.707 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 6.3 t -127.68 134.89 64.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 124.095 0.958 . . . . 0.0 111.838 -169.258 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -158.58 172.39 18.38 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.872 1.669 . . . . 0.0 111.565 179.472 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 4.2 mmmm -58.28 140.92 52.42 Favored 'General case' 0 N--CA 1.483 1.212 0 O-C-N 121.346 -0.846 . . . . 0.0 109.371 171.068 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -61.6 -30.21 70.54 Favored 'General case' 0 CA--C 1.544 0.741 0 N-CA-C 114.524 1.305 . . . . 0.0 114.524 -169.17 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 17.9 m -134.86 57.92 1.79 Allowed 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 124.514 1.126 . . . . 0.0 110.748 169.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -51.8 142.97 13.96 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 124.934 1.293 . . . . 0.0 113.918 -175.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 16.2 p80 -142.95 143.6 32.04 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 125.564 1.546 . . . . 0.0 112.001 -174.573 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 6.8 t-20 -152.63 9.71 0.47 Allowed 'General case' 0 CA--C 1.552 1.025 0 N-CA-C 114.191 1.182 . . . . 0.0 114.191 -178.017 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -80.68 141.23 35.11 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 124.878 1.271 . . . . 0.0 113.1 -169.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 12.5 p-10 -145.37 152.01 39.18 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 126.357 1.863 . . . . 0.0 110.78 169.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 7.8 tt -76.08 -47.29 25.12 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.721 0.808 . . . . 0.0 111.504 -178.737 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 8.1 t -152.88 174.71 13.75 Favored 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 125.803 1.641 . . . . 0.0 110.867 176.688 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -77.82 169.33 54.61 Favored Glycine 0 CA--C 1.543 1.832 0 C-N-CA 124.346 0.974 . . . . 0.0 113.594 172.33 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -69.71 155.71 65.39 Favored 'Trans proline' 0 CA--C 1.541 0.831 0 C-N-CA 123.637 2.891 . . . . 0.0 112.533 176.614 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 22.9 m -68.88 148.97 49.44 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 124.325 1.05 . . . . 0.0 112.837 178.732 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 40.5 m -69.01 150.96 47.08 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 124.401 1.08 . . . . 0.0 112.871 178.026 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.28 0 C-N-CA 125.146 1.355 . . . . 0.0 113.643 175.802 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.576 0 N-CA-C 111.95 -0.46 . . . . 0.0 111.95 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 53.2 p -76.87 160.53 29.16 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 124.865 1.266 . . . . 0.0 113.22 177.539 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 46.2 t -70.52 145.75 50.65 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 124.025 0.93 . . . . 0.0 112.554 178.156 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.44 -12.04 60.57 Favored Glycine 0 CA--C 1.539 1.554 0 C-N-CA 124.257 0.932 . . . . 0.0 114.516 173.321 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 45.8 m -80.8 5.25 16.48 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 125.06 1.344 . . . . 0.0 114.182 177.09 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 89.7 p -68.92 -21.56 64.2 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 114.864 1.431 . . . . 0.0 114.864 -176.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 174.72 -171.33 44.49 Favored Glycine 0 CA--C 1.539 1.56 0 C-N-CA 124.756 1.169 . . . . 0.0 113.794 178.756 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -65.31 -23.91 58.53 Favored 'Trans proline' 0 CA--C 1.54 0.795 0 C-N-CA 123.591 2.86 . . . . 0.0 115.124 -176.513 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 16.8 tt -145.23 129.05 11.87 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 125.363 1.465 . . . . 0.0 111.697 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 21.7 m -100.9 -15.25 17.62 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 124.914 1.286 . . . . 0.0 112.888 170.246 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 21.4 tt0 -85.0 33.54 0.54 Allowed 'General case' 0 CA--C 1.55 0.943 0 C-N-CA 125.97 1.708 . . . . 0.0 112.526 -178.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 17.8 ptp180 -80.15 44.0 0.65 Allowed 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 126.944 2.098 . . . . 0.0 114.012 -172.107 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 64.4 t-20 -65.83 107.39 1.8 Allowed 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 124.898 1.279 . . . . 0.0 112.094 -174.397 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 31.4 tp60 -85.22 -20.78 29.63 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.142 0.977 . . . . 0.0 113.031 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -69.88 -24.69 63.45 Favored 'General case' 0 N--CA 1.474 0.765 0 O-C-N 120.726 -1.234 . . . . 0.0 112.489 172.486 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -75.24 -0.01 18.06 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 123.959 0.904 . . . . 0.0 113.082 168.904 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 37.4 m -105.18 134.75 47.76 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 124.806 1.243 . . . . 0.0 109.298 169.284 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.0 m -99.05 147.93 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 123.915 0.886 . . . . 0.0 110.327 171.895 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 28.4 t80 -95.29 142.14 28.05 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.737 1.615 . . . . 0.0 109.067 169.193 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 31.3 t -133.21 108.65 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 C-N-CA 125.602 1.561 . . . . 0.0 109.443 178.331 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -102.75 151.78 18.14 Favored Glycine 0 CA--C 1.53 1.024 0 C-N-CA 124.475 1.036 . . . . 0.0 112.997 175.393 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.66 35.26 6.95 Favored Glycine 0 CA--C 1.532 1.143 0 C-N-CA 124.347 0.975 . . . . 0.0 113.924 172.485 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 91.1 mt -79.11 145.39 33.78 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 125.398 1.479 . . . . 0.0 111.542 -174.024 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -82.25 156.41 24.37 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 123.444 0.698 . . . . 0.0 112.184 175.052 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.59 -20.5 47.61 Favored 'General case' 0 CA--C 1.546 0.807 0 N-CA-C 114.632 1.345 . . . . 0.0 114.632 178.126 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.8 mtmm -81.59 -9.69 59.61 Favored 'General case' 0 N--CA 1.476 0.87 0 C-N-CA 124.919 1.288 . . . . 0.0 114.279 174.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 84.9 t -74.78 138.61 20.68 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.908 0 C-N-CA 124.404 1.082 . . . . 0.0 111.437 177.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 51.8 m -135.14 162.64 31.92 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 124.782 1.233 . . . . 0.0 111.698 173.473 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -57.32 -38.9 73.03 Favored Pre-proline 0 CA--C 1.546 0.821 0 N-CA-C 114.6 1.333 . . . . 0.0 114.6 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -64.76 -28.49 59.69 Favored 'Trans proline' 0 C--N 1.353 0.786 0 C-N-CA 122.281 1.987 . . . . 0.0 113.605 173.066 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 27.1 tp -68.22 -50.43 54.14 Favored 'General case' 0 C--N 1.343 0.309 0 CA-C-N 118.626 0.648 . . . . 0.0 109.791 172.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 20.6 mt -61.36 -23.01 65.46 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 112.972 0.73 . . . . 0.0 112.972 178.529 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.7 t90 -74.22 -66.15 0.76 Allowed 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 123.281 0.632 . . . . 0.0 111.002 171.038 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -64.82 -30.3 71.3 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 114.222 1.193 . . . . 0.0 114.222 -172.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.0 tp -69.23 -34.16 74.41 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 123.842 0.857 . . . . 0.0 111.799 175.504 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -90.1 -10.71 43.67 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.124 1.37 . . . . 0.0 113.337 -175.1 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 46.5 mt -55.21 -19.35 7.81 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 113.853 1.057 . . . . 0.0 113.853 169.313 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 41.0 mt-30 -64.96 -32.57 74.35 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 125.269 1.427 . . . . 0.0 112.592 173.163 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -78.36 -44.08 26.0 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 123.311 0.645 . . . . 0.0 112.639 177.629 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 177.34 -173.68 46.39 Favored Glycine 0 CA--C 1.538 1.517 0 C-N-CA 125.181 1.372 . . . . 0.0 112.498 -179.733 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -66.89 111.22 2.12 Favored 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 123.651 2.9 . . . . 0.0 111.827 -179.431 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 67.1 t -86.51 135.57 24.82 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 C-N-CA 125.12 1.368 . . . . 0.0 109.78 173.8 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 7.8 t -110.32 -33.64 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 C-N-CA 126.172 1.789 . . . . 0.0 111.939 -171.657 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 21.6 t30 -160.92 161.24 31.64 Favored 'General case' 0 CA--C 1.553 1.072 0 C-N-CA 125.752 1.621 . . . . 0.0 111.074 -175.381 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 4.7 p -137.36 155.18 49.71 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 125.938 1.695 . . . . 0.0 111.801 171.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 51.2 t-80 -142.15 132.69 25.28 Favored 'General case' 0 N--CA 1.466 0.357 0 C-N-CA 123.67 0.788 . . . . 0.0 110.838 176.105 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 89.5 mtp -133.89 107.61 11.65 Favored Pre-proline 0 N--CA 1.469 0.515 0 C-N-CA 124.113 0.965 . . . . 0.0 109.493 169.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_exo -57.57 142.64 95.59 Favored 'Trans proline' 0 CA--C 1.537 0.661 0 C-N-CA 123.082 2.521 . . . . 0.0 112.897 176.234 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 43.3 mmtm -114.59 159.41 20.47 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 125.218 1.407 . . . . 0.0 113.247 -172.598 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -77.33 141.48 39.87 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.797 1.639 . . . . 0.0 111.418 169.357 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 53.1 ptt85 -83.72 6.39 21.25 Favored 'General case' 0 N--CA 1.479 0.98 0 N-CA-C 115.982 1.845 . . . . 0.0 115.982 -173.582 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 32.4 t -131.31 -37.54 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 124.95 1.3 . . . . 0.0 111.471 -174.128 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 68.5 p -113.42 -14.01 12.79 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 125.764 1.626 . . . . 0.0 112.54 -176.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.26 5.67 55.02 Favored Glycine 0 CA--C 1.536 1.403 0 C-N-CA 125.09 1.328 . . . . 0.0 115.452 175.223 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 72.1 mm-40 -76.43 159.36 30.51 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 124.701 1.2 . . . . 0.0 110.717 176.727 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 22.7 p80 -72.23 155.56 40.09 Favored 'General case' 0 N--CA 1.473 0.715 0 O-C-N 120.931 -1.106 . . . . 0.0 113.023 179.841 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 81.9 mt-30 -80.68 11.91 3.5 Favored 'General case' 0 CA--C 1.552 1.052 0 N-CA-C 114.492 1.293 . . . . 0.0 114.492 -174.846 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.76 1.59 79.99 Favored Glycine 0 CA--C 1.538 1.489 0 C-N-CA 125.122 1.344 . . . . 0.0 114.912 -178.049 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 40.2 p90 -144.74 162.03 37.74 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.035 1.334 . . . . 0.0 112.341 178.459 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -153.04 -176.2 25.3 Favored Glycine 0 CA--C 1.532 1.114 0 C-N-CA 125.947 1.737 . . . . 0.0 113.186 -177.943 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 81.9 m-85 -144.03 149.73 37.14 Favored 'General case' 0 C--O 1.237 0.437 0 C-N-CA 126.073 1.749 . . . . 0.0 111.585 -178.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 14.9 t -132.99 126.41 53.58 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 124.582 1.153 . . . . 0.0 110.13 176.416 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -102.83 122.42 44.49 Favored 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 125.218 1.407 . . . . 0.0 110.718 -175.643 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -101.33 159.63 15.1 Favored 'General case' 0 C--O 1.234 0.258 0 C-N-CA 124.839 1.256 . . . . 0.0 112.613 179.206 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 14.6 tp -62.63 -35.12 78.58 Favored 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 123.442 0.697 . . . . 0.0 112.504 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.4 m -140.96 157.03 45.92 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.659 1.183 . . . . 0.0 110.944 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 58.5 tt0 -64.72 -35.33 80.72 Favored 'General case' 0 N--CA 1.471 0.58 0 O-C-N 121.499 -0.75 . . . . 0.0 112.863 -176.519 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -64.67 -24.57 67.62 Favored 'General case' 0 N--CA 1.473 0.721 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 177.657 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 52.1 m-20 -78.24 -33.78 49.54 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 123.9 0.88 . . . . 0.0 111.73 173.298 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -70.07 -43.21 71.64 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 123.075 0.55 . . . . 0.0 111.379 171.706 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -60.35 -32.02 70.87 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 124.669 1.188 . . . . 0.0 112.505 179.499 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 63.4 t80 -78.82 -35.22 44.44 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 124.213 1.005 . . . . 0.0 113.036 173.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.38 -36.74 84.7 Favored 'General case' 0 CA--C 1.537 0.466 0 O-C-N 120.978 -1.076 . . . . 0.0 111.211 176.553 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 56.2 mt -62.74 -36.92 77.58 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 124.718 1.207 . . . . 0.0 111.318 172.813 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -66.51 -40.07 89.01 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 124.274 1.029 . . . . 0.0 112.255 178.639 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 21.9 pt -91.41 -40.72 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 N-CA-C 114.409 1.263 . . . . 0.0 114.409 -176.934 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 12.5 mmt -88.16 1.46 54.35 Favored 'General case' 0 N--CA 1.48 1.063 0 N-CA-C 115.144 1.535 . . . . 0.0 115.144 -169.708 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -83.43 134.63 34.86 Favored 'General case' 0 CA--C 1.539 0.548 0 O-C-N 121.316 -0.865 . . . . 0.0 112.311 -179.064 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 24.6 ttm 58.8 15.0 3.52 Favored 'General case' 0 CA--C 1.549 0.914 0 C-N-CA 126.985 2.114 . . . . 0.0 114.686 -169.58 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.9 mt -72.54 137.9 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 C-N-CA 124.33 1.052 . . . . 0.0 111.189 173.999 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 41.6 mtpt -95.03 64.43 2.79 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 124.566 1.146 . . . . 0.0 112.395 -169.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 28.0 tp -58.99 120.39 9.01 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 123.595 0.758 . . . . 0.0 109.167 174.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 57.7 m-85 44.75 31.17 0.62 Allowed 'General case' 0 CA--C 1.562 1.411 0 N-CA-C 115.949 1.833 . . . . 0.0 115.949 -168.286 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 87.87 8.81 72.24 Favored Glycine 0 CA--C 1.542 1.76 0 N-CA-C 117.461 1.744 . . . . 0.0 117.461 173.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 60.1 mttp -119.42 119.38 31.71 Favored Pre-proline 0 CA--C 1.54 0.585 0 C-N-CA 127.497 2.319 . . . . 0.0 108.78 177.698 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -72.65 98.46 0.97 Allowed 'Trans proline' 0 CA--C 1.538 0.723 0 C-N-CA 124.152 3.234 . . . . 0.0 111.672 -173.409 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 6.5 pt -66.65 148.51 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 C-N-CA 124.44 1.096 . . . . 0.0 111.124 -177.266 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 33.5 mmt-85 -111.68 127.67 55.84 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.571 1.148 . . . . 0.0 109.95 178.826 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 17.0 t -128.0 137.21 58.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 124.054 0.942 . . . . 0.0 111.501 -169.518 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 30.6 t-20 -159.76 174.97 13.71 Favored 'General case' 0 CA--C 1.55 0.96 0 C-N-CA 125.501 1.52 . . . . 0.0 111.051 177.549 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 6.5 mmmm -62.0 141.04 58.29 Favored 'General case' 0 N--CA 1.48 1.052 0 O-C-N 120.849 -1.157 . . . . 0.0 109.704 172.191 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -70.75 -13.26 61.99 Favored 'General case' 0 CA--C 1.552 1.032 0 N-CA-C 113.699 1.0 . . . . 0.0 113.699 178.417 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 74.0 m -123.33 39.6 3.92 Favored 'General case' 0 N--CA 1.479 0.983 0 C-N-CA 126.328 1.851 . . . . 0.0 112.501 173.088 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -61.39 -25.32 67.1 Favored 'General case' 0 CA--C 1.548 0.882 0 N-CA-C 115.269 1.581 . . . . 0.0 115.269 -174.12 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 97.2 m-70 -83.49 132.52 34.94 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.037 0.935 . . . . 0.0 112.045 179.455 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 56.6 t30 -80.97 158.3 25.24 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 123.941 0.896 . . . . 0.0 112.582 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 63.9 tttm -65.56 -26.62 67.95 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 124.845 1.258 . . . . 0.0 113.732 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -137.8 149.92 46.77 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.325 1.45 . . . . 0.0 111.779 176.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 35.8 tp -95.78 -19.55 19.55 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 114.217 1.191 . . . . 0.0 114.217 -173.377 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 50.8 m -74.25 141.2 45.38 Favored 'General case' 0 N--CA 1.473 0.72 0 O-C-N 121.233 -0.917 . . . . 0.0 113.263 -172.342 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -78.88 170.43 54.72 Favored Glycine 0 CA--C 1.543 1.788 0 C-N-CA 124.327 0.965 . . . . 0.0 113.989 174.492 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -75.63 -18.19 17.61 Favored 'Trans proline' 0 CA--C 1.543 0.961 0 C-N-CA 123.863 3.042 . . . . 0.0 113.828 -179.777 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 85.3 p -149.7 176.05 11.03 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 125.998 1.719 . . . . 0.0 112.025 -178.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 58.4 p -74.96 -5.9 46.41 Favored 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 114.616 1.339 . . . . 0.0 114.616 175.44 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.298 0 C-N-CA 125.734 1.635 . . . . 0.0 113.721 -179.885 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.604 0 N-CA-C 111.438 -0.665 . . . . 0.0 111.438 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.7 m -69.99 151.43 45.59 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 124.523 1.129 . . . . 0.0 113.301 -178.468 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 67.5 p -90.23 -1.07 57.89 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 125.426 1.49 . . . . 0.0 114.988 -177.613 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -69.41 172.12 39.07 Favored Glycine 0 CA--C 1.539 1.55 0 C-N-CA 124.962 1.268 . . . . 0.0 114.98 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 47.3 t -144.89 154.19 42.36 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 125.501 1.52 . . . . 0.0 112.325 -177.503 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 18.0 m -81.03 -4.59 55.68 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 125.132 1.373 . . . . 0.0 113.468 172.04 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.2 -179.2 46.1 Favored Glycine 0 CA--C 1.544 1.853 0 C-N-CA 124.455 1.026 . . . . 0.0 113.683 170.481 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -69.82 143.33 50.2 Favored 'Trans proline' 0 CA--C 1.542 0.886 0 C-N-CA 123.183 2.589 . . . . 0.0 111.348 175.879 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.0 tp -80.94 148.14 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 124.096 0.959 . . . . 0.0 112.019 -177.762 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 17.4 m -66.56 -12.91 59.99 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 114.342 1.238 . . . . 0.0 114.342 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -79.69 -12.85 59.79 Favored 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 124.596 1.159 . . . . 0.0 113.405 176.381 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 23.8 mmt180 -90.63 153.39 20.35 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 125.378 1.471 . . . . 0.0 111.492 177.019 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 64.3 t-20 -81.18 84.27 6.6 Favored 'General case' 0 CA--C 1.537 0.459 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 175.34 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -66.62 -17.03 64.62 Favored 'General case' 0 CA--C 1.539 0.557 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -171.762 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -85.71 -25.23 26.59 Favored 'General case' 0 CA--C 1.543 0.68 0 CA-C-N 119.308 0.958 . . . . 0.0 112.939 174.136 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -94.59 2.04 55.64 Favored 'General case' 0 CA--C 1.546 0.802 0 C-N-CA 124.756 1.222 . . . . 0.0 112.704 168.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 36.0 m -101.94 136.96 40.87 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 124.988 1.315 . . . . 0.0 109.374 172.365 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.2 m -101.52 148.05 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 C-N-CA 123.96 0.904 . . . . 0.0 110.362 171.788 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 25.3 t80 -95.34 141.33 29.03 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 126.018 1.727 . . . . 0.0 108.848 169.019 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 20.2 t -129.07 115.87 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 C-N-CA 125.532 1.533 . . . . 0.0 108.875 175.667 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -113.37 145.63 18.36 Favored Glycine 0 CA--C 1.531 1.034 0 C-N-CA 124.573 1.082 . . . . 0.0 112.793 178.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.7 33.27 6.8 Favored Glycine 0 CA--C 1.533 1.213 0 C-N-CA 124.404 1.002 . . . . 0.0 113.738 176.541 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 84.4 mt -72.36 151.96 42.36 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 125.482 1.513 . . . . 0.0 111.405 -174.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -91.75 157.3 16.99 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 123.561 0.744 . . . . 0.0 111.967 174.426 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -58.38 -20.93 48.06 Favored 'General case' 0 N--CA 1.475 0.824 0 O-C-N 120.607 -1.308 . . . . 0.0 114.478 179.124 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 27.3 mtpp -76.27 -15.52 59.99 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 124.77 1.228 . . . . 0.0 114.233 174.479 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 93.8 t -73.19 141.56 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 124.553 1.141 . . . . 0.0 111.868 -177.137 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 96.4 p -136.74 162.72 32.41 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.316 1.447 . . . . 0.0 112.36 175.268 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -59.65 -40.41 79.01 Favored Pre-proline 0 CA--C 1.546 0.817 0 O-C-N 120.79 -1.194 . . . . 0.0 113.59 177.519 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_exo -62.04 -30.52 83.04 Favored 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 122.474 2.116 . . . . 0.0 113.839 170.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 26.4 tp -68.57 -50.57 50.74 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 119.031 0.832 . . . . 0.0 109.906 173.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 20.5 mt -60.91 -22.35 64.26 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 113.026 0.75 . . . . 0.0 113.026 178.341 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.7 t90 -74.42 -66.87 0.68 Allowed 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 123.123 0.569 . . . . 0.0 110.863 170.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -65.14 -29.7 70.56 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 114.218 1.192 . . . . 0.0 114.218 -172.239 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.7 tp -69.99 -33.31 71.88 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 123.692 0.797 . . . . 0.0 111.845 175.586 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -90.24 -10.96 42.35 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 124.945 1.298 . . . . 0.0 113.409 -175.067 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 49.4 mt -55.13 -18.14 5.2 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 124.437 1.095 . . . . 0.0 113.889 169.21 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 75.4 mt-30 -63.52 -34.4 77.71 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 125.785 1.634 . . . . 0.0 112.606 172.948 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.92 -45.15 19.07 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 123.657 0.783 . . . . 0.0 112.61 178.421 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.71 -172.98 44.76 Favored Glycine 0 CA--C 1.535 1.286 0 C-N-CA 124.595 1.093 . . . . 0.0 112.932 178.491 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -67.09 111.17 2.15 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 123.719 2.946 . . . . 0.0 111.715 -179.101 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 82.9 t -84.99 134.8 26.19 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 124.96 1.304 . . . . 0.0 109.67 173.364 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 4.1 t -108.04 -33.96 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 126.222 1.809 . . . . 0.0 111.656 -173.202 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 4.7 t30 -161.61 158.27 25.92 Favored 'General case' 0 CA--C 1.553 1.063 0 C-N-CA 125.956 1.702 . . . . 0.0 111.465 -174.468 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 5.9 p -133.8 153.88 51.41 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 125.773 1.629 . . . . 0.0 112.389 171.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 2.6 t60 -141.03 130.83 24.27 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.283 1.033 . . . . 0.0 111.088 178.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 86.4 mtp -134.57 102.51 11.51 Favored Pre-proline 0 N--CA 1.472 0.655 0 C-N-CA 124.336 1.054 . . . . 0.0 109.461 169.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -60.95 127.36 22.09 Favored 'Trans proline' 0 CA--C 1.537 0.634 0 C-N-CA 123.172 2.581 . . . . 0.0 113.076 -178.703 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 44.9 mmtm -92.47 150.45 20.77 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 124.596 1.158 . . . . 0.0 113.124 -174.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -65.25 138.0 57.94 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 125.49 1.516 . . . . 0.0 112.018 172.343 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 16.6 ptm180 -80.41 8.73 7.02 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 116.013 1.857 . . . . 0.0 116.013 -173.121 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 35.0 t -132.47 -37.26 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.116 0 C-N-CA 124.954 1.302 . . . . 0.0 111.447 -175.136 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.8 p -115.84 -14.17 11.34 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 125.736 1.614 . . . . 0.0 112.641 -175.583 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 69.84 8.2 60.37 Favored Glycine 0 CA--C 1.536 1.391 0 C-N-CA 125.039 1.304 . . . . 0.0 115.483 175.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 74.0 mm-40 -80.92 162.82 23.75 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.79 1.236 . . . . 0.0 110.994 176.989 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 6.9 p80 -70.17 153.65 42.86 Favored 'General case' 0 N--CA 1.473 0.7 0 O-C-N 120.883 -1.135 . . . . 0.0 111.866 174.126 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 37.7 mt-30 -98.09 21.88 10.19 Favored 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 124.414 1.086 . . . . 0.0 113.618 -170.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.77 3.14 86.17 Favored Glycine 0 CA--C 1.535 1.286 0 C-N-CA 124.938 1.256 . . . . 0.0 115.089 179.835 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -141.92 158.93 43.2 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 118.794 1.297 . . . . 0.0 113.077 177.437 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -154.63 -178.32 28.85 Favored Glycine 0 CA--C 1.53 1.007 0 C-N-CA 125.797 1.665 . . . . 0.0 113.016 -178.616 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -144.34 151.57 39.52 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 125.622 1.569 . . . . 0.0 112.036 -178.265 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 13.6 t -134.34 121.08 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 124.796 1.239 . . . . 0.0 110.052 176.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -97.1 118.6 33.88 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 124.901 1.28 . . . . 0.0 110.705 -178.503 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 -95.54 162.08 13.79 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 125.034 1.334 . . . . 0.0 112.252 176.957 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 12.8 tp -64.31 -33.99 77.11 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 123.37 0.668 . . . . 0.0 112.369 177.62 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.6 m -140.58 154.8 46.63 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 124.681 1.193 . . . . 0.0 112.495 -177.495 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -65.38 -30.56 71.4 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 124.693 1.197 . . . . 0.0 112.643 -176.486 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -72.07 -26.33 62.13 Favored 'General case' 0 CA--C 1.542 0.668 0 O-C-N 121.352 -0.843 . . . . 0.0 113.262 175.037 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 61.6 m-20 -75.74 -34.05 60.28 Favored 'General case' 0 N--CA 1.469 0.511 0 O-C-N 121.569 -0.707 . . . . 0.0 111.009 172.86 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -67.51 -45.84 74.63 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 123.341 0.656 . . . . 0.0 111.227 171.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -56.67 -36.38 69.5 Favored 'General case' 0 CA--C 1.543 0.697 0 O-C-N 121.259 -0.901 . . . . 0.0 112.772 174.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -69.46 -38.76 77.9 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 123.441 0.697 . . . . 0.0 111.915 174.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.4 -36.83 83.83 Favored 'General case' 0 CA--C 1.538 0.499 0 O-C-N 120.631 -1.293 . . . . 0.0 111.82 176.242 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 55.9 mt -64.33 -32.31 57.07 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 123.85 0.86 . . . . 0.0 110.752 172.738 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -67.02 -47.84 70.21 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 124.228 1.011 . . . . 0.0 112.301 175.217 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 19.3 pt -90.09 -37.24 9.36 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 114.884 1.438 . . . . 0.0 114.884 -172.071 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 14.3 mmt -92.22 0.43 57.46 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 114.52 1.304 . . . . 0.0 114.52 -170.192 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -83.83 136.97 33.92 Favored 'General case' 0 CA--C 1.54 0.565 0 O-C-N 121.605 -0.684 . . . . 0.0 111.98 178.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 22.8 mtp 58.67 14.07 2.95 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 126.106 1.763 . . . . 0.0 115.405 -171.487 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.4 mt -72.25 152.47 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.625 0 C-N-CA 125.197 1.399 . . . . 0.0 110.193 169.195 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.2 mtpt -111.33 69.63 0.69 Allowed 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 124.975 1.31 . . . . 0.0 112.456 -176.11 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 29.1 tp -57.71 124.39 18.96 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 124.05 0.94 . . . . 0.0 110.062 175.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 44.5 m-85 45.62 30.04 0.73 Allowed 'General case' 0 CA--C 1.559 1.314 0 N-CA-C 116.321 1.971 . . . . 0.0 116.321 -169.136 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.73 26.69 55.82 Favored Glycine 0 CA--C 1.542 1.723 0 O-C-N 120.188 -1.57 . . . . 0.0 115.94 175.857 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -137.4 120.94 11.74 Favored Pre-proline 0 CA--C 1.542 0.644 0 C-N-CA 128.222 2.609 . . . . 0.0 107.783 179.603 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -69.92 122.4 9.03 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 122.864 2.376 . . . . 0.0 112.223 -172.142 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 18.2 pt -94.2 146.27 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 125.259 1.424 . . . . 0.0 111.264 174.08 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 38.1 mmm-85 -110.43 139.27 45.82 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 124.699 1.2 . . . . 0.0 110.596 170.054 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 25.7 t -130.2 138.73 53.18 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 C-N-CA 124.523 1.129 . . . . 0.0 111.035 -175.042 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 41.2 t-20 -159.5 -179.14 7.66 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 126.247 1.819 . . . . 0.0 110.057 178.737 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 12.1 mmmm -58.78 148.23 30.48 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 124.928 1.291 . . . . 0.0 111.28 170.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.02 -24.07 43.91 Favored 'General case' 0 CA--C 1.547 0.861 0 O-C-N 121.893 -0.504 . . . . 0.0 112.034 168.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 40.4 p -71.21 -70.15 0.33 Allowed 'General case' 0 N--CA 1.47 0.568 0 C-N-CA 125.691 1.596 . . . . 0.0 111.615 171.349 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . 55.61 -21.51 0.01 OUTLIER 'General case' 0 CA--C 1.553 1.08 0 C-N-CA 130.492 3.517 . . . . 0.0 119.21 172.649 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -78.88 -4.92 52.07 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 125.078 1.351 . . . . 0.0 113.789 177.009 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 46.0 t30 -131.76 147.66 52.51 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.33 1.852 . . . . 0.0 110.421 173.661 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -74.29 -49.08 24.59 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 125.077 1.351 . . . . 0.0 112.434 -179.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -158.09 158.68 35.19 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 125.04 1.336 . . . . 0.0 112.347 -179.329 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 10.4 mp -82.19 155.96 24.67 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 123.985 0.914 . . . . 0.0 109.716 168.627 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 68.4 m -138.54 144.56 39.97 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 124.795 1.238 . . . . 0.0 112.079 -177.743 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -80.1 173.89 54.99 Favored Glycine 0 CA--C 1.543 1.785 0 C-N-CA 124.39 0.995 . . . . 0.0 114.034 174.366 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -69.57 159.83 52.06 Favored 'Trans proline' 0 CA--C 1.542 0.889 0 C-N-CA 123.899 3.066 . . . . 0.0 112.638 176.334 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 29.3 t -148.03 156.34 42.53 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.037 1.335 . . . . 0.0 112.06 178.272 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.6 t -78.31 -19.83 52.74 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 124.702 1.201 . . . . 0.0 112.722 172.216 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.27 0 C-N-CA 125.66 1.6 . . . . 0.0 113.744 178.879 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.564 0 N-CA-C 111.554 -0.619 . . . . 0.0 111.554 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 36.3 m -70.02 155.38 40.68 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 124.611 1.164 . . . . 0.0 113.213 -179.449 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 73.0 m -71.37 151.36 44.17 Favored 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 123.684 0.794 . . . . 0.0 112.17 174.306 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -153.42 156.71 26.92 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 124.359 0.98 . . . . 0.0 113.553 178.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 82.0 p -143.88 162.71 35.41 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 126.669 1.988 . . . . 0.0 111.744 -173.268 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 21.9 m -65.74 107.0 1.64 Allowed 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 123.476 0.711 . . . . 0.0 112.604 -179.076 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.86 -177.22 51.89 Favored Glycine 0 CA--C 1.542 1.729 0 C-N-CA 125.181 1.372 . . . . 0.0 112.965 169.191 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -65.87 150.99 85.38 Favored 'Trans proline' 0 CA--C 1.54 0.783 0 C-N-CA 123.096 2.531 . . . . 0.0 111.959 173.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 21.5 pt -73.76 152.36 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 123.799 0.84 . . . . 0.0 112.328 178.654 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 77.9 p -112.68 -36.99 5.02 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 124.221 1.008 . . . . 0.0 113.675 177.065 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -143.14 -21.81 0.63 Allowed 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 115.54 1.682 . . . . 0.0 115.54 -173.29 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 15.6 tpt180 -149.86 170.62 18.36 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 125.027 1.331 . . . . 0.0 110.873 -172.155 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 8.7 m120 -69.57 70.16 0.29 Allowed 'General case' 0 CA--C 1.545 0.76 0 CA-C-O 122.523 1.154 . . . . 0.0 112.542 172.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 35.8 mt-30 -68.3 -6.52 24.51 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 126.257 1.823 . . . . 0.0 113.088 177.036 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 14.0 p-10 -79.61 -24.98 41.6 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 126.997 2.119 . . . . 0.0 112.838 169.201 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -116.77 -1.43 12.07 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.863 1.665 . . . . 0.0 113.324 175.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 24.2 m -98.41 134.08 41.91 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 124.8 1.24 . . . . 0.0 109.779 172.019 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.3 m -100.84 148.57 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 124.595 1.158 . . . . 0.0 110.282 172.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 22.0 t80 -95.4 142.38 27.85 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 126.542 1.937 . . . . 0.0 109.243 169.505 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 23.4 t -131.45 108.88 15.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 C-N-CA 125.778 1.631 . . . . 0.0 109.07 177.172 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -106.19 144.69 15.86 Favored Glycine 0 CA--C 1.529 0.947 0 C-N-CA 124.44 1.019 . . . . 0.0 112.856 178.648 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 97.36 32.79 6.19 Favored Glycine 0 CA--C 1.533 1.205 0 C-N-CA 124.488 1.042 . . . . 0.0 113.936 175.207 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 84.6 mt -73.45 152.52 40.73 Favored 'General case' 0 C--O 1.234 0.269 0 C-N-CA 125.431 1.493 . . . . 0.0 111.352 -175.346 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -92.15 157.87 16.49 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 123.842 0.857 . . . . 0.0 112.004 174.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -58.68 -20.94 52.75 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 114.489 1.292 . . . . 0.0 114.489 178.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 60.2 mtpt -76.17 -15.53 60.04 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 114.222 1.193 . . . . 0.0 114.222 174.201 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 64.8 t -73.85 141.68 15.87 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 C-N-CA 124.471 1.108 . . . . 0.0 111.763 -177.506 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 95.1 p -136.66 163.09 31.39 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.537 1.535 . . . . 0.0 111.851 174.01 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -58.79 -44.61 99.17 Favored Pre-proline 0 CA--C 1.547 0.85 0 O-C-N 120.949 -1.094 . . . . 0.0 113.119 177.352 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_exo -59.29 -30.69 93.54 Favored 'Trans proline' 0 C--N 1.355 0.896 0 C-N-CA 122.38 2.053 . . . . 0.0 114.108 172.088 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 21.2 tp -66.67 -53.84 29.56 Favored 'General case' 0 C--N 1.345 0.37 0 CA-C-N 119.076 0.853 . . . . 0.0 109.655 173.919 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 28.0 mt -54.74 -42.33 71.49 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 122.518 0.327 . . . . 0.0 111.475 -179.221 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 3.0 t90 -57.48 -62.29 1.88 Allowed 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 123.283 0.633 . . . . 0.0 111.173 178.056 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -65.04 -29.5 70.4 Favored 'General case' 0 N--CA 1.471 0.575 0 N-CA-C 113.835 1.05 . . . . 0.0 113.835 -177.272 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.5 tp -72.23 -36.22 69.05 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 124.215 1.006 . . . . 0.0 111.96 176.628 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 12.0 m-85 -88.58 -10.43 48.79 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.842 1.257 . . . . 0.0 113.334 -176.51 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 24.2 mt -53.71 -21.72 7.65 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 124.323 1.049 . . . . 0.0 113.795 168.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 41.4 mt-30 -63.51 -32.11 73.47 Favored 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 125.167 1.387 . . . . 0.0 112.623 174.164 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -78.52 -44.32 24.63 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 123.218 0.607 . . . . 0.0 112.58 176.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 177.52 -172.47 45.22 Favored Glycine 0 CA--C 1.536 1.391 0 C-N-CA 124.609 1.099 . . . . 0.0 112.851 -179.51 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -67.25 109.29 1.73 Allowed 'Trans proline' 0 CA--C 1.537 0.652 0 C-N-CA 123.722 2.948 . . . . 0.0 111.646 -178.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 72.3 t -84.81 133.33 29.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 C-N-CA 124.805 1.242 . . . . 0.0 109.826 173.584 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 4.5 t -107.71 -34.53 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 C-N-CA 126.248 1.819 . . . . 0.0 111.761 -172.723 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 17.0 t30 -161.34 164.17 30.25 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 126.057 1.743 . . . . 0.0 111.357 -174.035 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 4.2 p -141.62 154.42 45.38 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 126.39 1.876 . . . . 0.0 111.86 176.165 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 3.4 t60 -142.38 135.51 28.66 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 123.955 0.902 . . . . 0.0 111.179 175.055 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 83.9 mtp -136.52 103.08 9.45 Favored Pre-proline 0 N--CA 1.471 0.585 0 C-N-CA 124.435 1.094 . . . . 0.0 109.433 169.525 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_exo -55.74 130.31 39.75 Favored 'Trans proline' 0 CA--C 1.535 0.572 0 C-N-CA 123.277 2.651 . . . . 0.0 113.639 -179.352 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 45.1 mmtm -96.23 147.9 23.28 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 125.015 1.326 . . . . 0.0 111.981 -177.762 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -76.82 141.9 40.5 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.338 1.455 . . . . 0.0 112.938 -178.796 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 33.1 ptt-85 -81.34 4.03 22.13 Favored 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 115.686 1.736 . . . . 0.0 115.686 -176.616 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 20.3 t -132.29 -39.61 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.989 0 C-N-CA 125.285 1.434 . . . . 0.0 111.261 -174.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 33.2 p -107.24 -17.26 14.19 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 124.42 1.088 . . . . 0.0 112.523 -178.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 71.1 1.91 44.12 Favored Glycine 0 CA--C 1.539 1.541 0 C-N-CA 124.947 1.26 . . . . 0.0 115.538 178.395 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 67.4 mm-40 -82.1 168.33 17.86 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 124.911 1.285 . . . . 0.0 110.905 177.324 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 18.3 p80 -67.85 148.74 50.76 Favored 'General case' 0 N--CA 1.473 0.681 0 O-C-N 120.772 -1.205 . . . . 0.0 111.459 171.111 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 86.3 mt-30 -88.31 25.53 1.62 Allowed 'General case' 0 CA--C 1.548 0.874 0 N-CA-C 114.254 1.205 . . . . 0.0 114.254 -174.874 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.57 4.54 82.94 Favored Glycine 0 CA--C 1.534 1.259 0 C-N-CA 124.901 1.239 . . . . 0.0 115.253 176.295 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -144.52 159.61 42.49 Favored 'General case' 0 CA--C 1.538 0.501 0 CA-C-N 118.686 1.243 . . . . 0.0 112.652 177.527 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -150.82 -175.94 23.26 Favored Glycine 0 CA--C 1.53 0.983 0 C-N-CA 125.943 1.735 . . . . 0.0 113.039 -178.2 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -145.98 150.73 36.58 Favored 'General case' 0 C--O 1.237 0.421 0 C-N-CA 125.894 1.678 . . . . 0.0 111.62 -178.538 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.3 t -134.24 126.29 49.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.724 1.21 . . . . 0.0 109.805 176.376 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.9 tt0 -101.88 120.59 40.63 Favored 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 124.622 1.169 . . . . 0.0 111.086 -177.363 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -96.9 162.19 13.51 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 124.756 1.223 . . . . 0.0 112.367 177.593 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 12.9 tp -63.4 -34.9 78.75 Favored 'General case' 0 CA--C 1.542 0.662 0 CA-C-N 115.903 -0.59 . . . . 0.0 112.337 176.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 6.6 m -144.17 156.24 44.24 Favored 'General case' 0 N--CA 1.472 0.625 0 CA-C-O 122.587 1.184 . . . . 0.0 112.674 -177.304 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -62.52 -31.98 72.84 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.208 1.403 . . . . 0.0 113.51 -176.236 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -72.05 -27.04 62.44 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 113.2 0.815 . . . . 0.0 113.2 176.793 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 47.4 m-20 -75.98 -34.51 59.77 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 123.732 0.813 . . . . 0.0 111.077 172.511 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -68.24 -47.12 68.64 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 123.936 0.894 . . . . 0.0 111.426 172.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -57.21 -35.72 69.99 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 124.284 1.034 . . . . 0.0 112.642 175.499 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 54.1 t80 -73.8 -35.15 64.88 Favored 'General case' 0 CA--C 1.536 0.41 0 O-C-N 121.736 -0.603 . . . . 0.0 112.584 175.645 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -65.31 -37.84 88.36 Favored 'General case' 0 CA--C 1.539 0.522 0 O-C-N 121.118 -0.989 . . . . 0.0 111.211 174.483 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 65.0 mt -63.25 -34.28 66.05 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 124.404 1.082 . . . . 0.0 110.965 172.377 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 41.5 ttmt -68.43 -44.12 75.66 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 123.835 0.854 . . . . 0.0 112.636 176.411 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 43.4 pt -91.05 -34.86 6.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 N-CA-C 115.063 1.505 . . . . 0.0 115.063 -173.644 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 9.9 mmt -93.51 1.32 56.81 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 114.834 1.42 . . . . 0.0 114.834 -172.279 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -85.22 137.24 33.12 Favored 'General case' 0 CA--C 1.54 0.565 0 O-C-N 121.614 -0.679 . . . . 0.0 111.927 178.776 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 22.4 mtp 58.92 14.44 3.32 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 126.111 1.764 . . . . 0.0 115.358 -171.107 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.2 mt -72.37 153.85 7.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 C-N-CA 125.285 1.434 . . . . 0.0 110.053 168.815 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.6 mtpt -113.89 70.04 0.72 Allowed 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 125.008 1.323 . . . . 0.0 112.619 -175.46 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 30.1 tp -57.75 124.93 20.85 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 124.1 0.96 . . . . 0.0 110.135 175.59 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 47.7 m-85 45.45 30.02 0.67 Allowed 'General case' 0 CA--C 1.559 1.322 0 N-CA-C 116.21 1.93 . . . . 0.0 116.21 -169.054 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.02 26.93 57.28 Favored Glycine 0 CA--C 1.542 1.726 0 O-C-N 120.139 -1.601 . . . . 0.0 115.916 176.13 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -136.93 120.43 11.98 Favored Pre-proline 0 CA--C 1.541 0.608 0 C-N-CA 128.264 2.626 . . . . 0.0 107.792 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -69.66 124.2 10.89 Favored 'Trans proline' 0 CA--C 1.537 0.646 0 C-N-CA 122.923 2.415 . . . . 0.0 112.35 -171.802 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 18.1 pt -95.84 145.05 9.03 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 C-N-CA 125.468 1.507 . . . . 0.0 111.404 174.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 37.3 mmm-85 -111.51 138.05 48.54 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 124.692 1.197 . . . . 0.0 110.75 170.993 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 23.7 t -130.63 137.46 56.05 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 124.376 1.071 . . . . 0.0 111.198 -172.82 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 32.0 t-20 -161.16 -178.89 7.04 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 126.347 1.859 . . . . 0.0 110.073 177.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 11.8 mmmm -63.77 145.73 55.22 Favored 'General case' 0 N--CA 1.477 0.905 0 O-C-N 120.577 -1.327 . . . . 0.0 111.433 175.211 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -74.33 0.36 14.62 Favored 'General case' 0 CA--C 1.551 1.006 0 N-CA-C 113.58 0.956 . . . . 0.0 113.58 171.568 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 15.3 p -110.13 3.53 20.28 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 127.618 2.367 . . . . 0.0 113.605 176.288 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -65.96 19.46 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.153 0 N-CA-C 117.105 2.261 . . . . 0.0 117.105 -168.643 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 24.2 m80 -87.59 -10.36 51.73 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 125.947 1.699 . . . . 0.0 114.517 -170.172 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 27.6 t30 -79.88 126.57 31.17 Favored 'General case' 0 CA--C 1.54 0.586 0 CA-C-N 119.124 0.875 . . . . 0.0 111.075 178.323 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 65.4 pttt -73.33 150.51 41.81 Favored 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 123.696 0.798 . . . . 0.0 112.473 177.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -141.44 158.48 43.81 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.829 1.251 . . . . 0.0 112.491 -178.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 88.4 mt -81.06 163.07 23.48 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 124.497 1.119 . . . . 0.0 111.2 169.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 59.1 p -75.23 -21.98 58.22 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 124.344 1.057 . . . . 0.0 113.774 175.557 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 171.62 175.74 40.15 Favored Glycine 0 CA--C 1.54 1.656 0 C-N-CA 125.305 1.431 . . . . 0.0 113.508 177.348 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_endo -73.05 166.69 29.35 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 124.18 3.253 . . . . 0.0 112.787 176.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 83.1 p -145.29 170.24 16.69 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 125.049 1.34 . . . . 0.0 112.53 175.567 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 64.7 p -82.28 -1.09 48.35 Favored 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 125.339 1.456 . . . . 0.0 114.65 177.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.304 0 C-N-CA 125.677 1.608 . . . . 0.0 114.113 -179.552 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 1.458 0 N-CA-C 111.792 -0.523 . . . . 0.0 111.792 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 38.2 m -72.67 157.76 36.92 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.406 1.082 . . . . 0.0 112.985 176.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 42.8 p -79.52 -21.9 44.65 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 125.381 1.472 . . . . 0.0 114.693 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 81.02 12.08 82.99 Favored Glycine 0 CA--C 1.54 1.612 0 C-N-CA 124.143 0.878 . . . . 0.0 114.362 -169.579 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 59.8 m -61.37 155.62 21.01 Favored 'General case' 0 N--CA 1.476 0.839 0 CA-C-N 118.708 1.254 . . . . 0.0 112.808 175.015 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 60.7 p -68.42 -23.19 64.6 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 114.842 1.423 . . . . 0.0 114.842 -174.749 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 173.22 178.88 43.52 Favored Glycine 0 CA--C 1.539 1.561 0 C-N-CA 124.727 1.156 . . . . 0.0 113.817 174.602 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -61.45 150.11 86.6 Favored 'Trans proline' 0 CA--C 1.539 0.755 0 C-N-CA 123.971 3.114 . . . . 0.0 113.698 177.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 29.8 pt -84.98 142.34 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 124.266 1.026 . . . . 0.0 112.304 174.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 22.6 m -74.89 -28.65 60.72 Favored 'General case' 0 N--CA 1.475 0.819 0 N-CA-C 113.839 1.051 . . . . 0.0 113.839 -173.606 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -85.15 143.72 28.64 Favored 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 124.254 1.022 . . . . 0.0 111.829 174.181 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 10.4 mmp_? -97.88 123.36 41.82 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 124.533 1.133 . . . . 0.0 111.342 -173.323 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 75.5 m-20 -102.99 86.65 2.75 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 124.382 1.073 . . . . 0.0 111.92 -172.285 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 57.5 tt0 -61.41 -33.79 74.29 Favored 'General case' 0 N--CA 1.476 0.854 0 O-C-N 121.136 -0.978 . . . . 0.0 112.47 178.568 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -72.34 -12.65 61.22 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 113.782 1.03 . . . . 0.0 113.782 175.412 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -110.39 11.73 23.21 Favored 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 125.234 1.414 . . . . 0.0 111.654 168.75 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 59.1 m -99.12 133.54 43.26 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 124.307 1.043 . . . . 0.0 109.431 173.32 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 13.9 m -100.17 146.58 8.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 C-N-CA 124.114 0.966 . . . . 0.0 109.938 170.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 12.0 t80 -95.0 142.42 27.5 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 125.496 1.518 . . . . 0.0 108.53 169.08 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.5 t -131.75 106.48 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 C-N-CA 125.383 1.473 . . . . 0.0 109.063 179.176 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -102.91 144.56 16.07 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 124.216 0.912 . . . . 0.0 112.593 177.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 97.84 32.03 6.4 Favored Glycine 0 CA--C 1.534 1.23 0 C-N-CA 124.48 1.038 . . . . 0.0 113.863 174.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 83.3 mt -73.97 145.27 44.78 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 125.222 1.409 . . . . 0.0 111.203 -175.277 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -84.38 157.3 21.48 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 123.063 0.545 . . . . 0.0 112.45 174.864 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -58.51 -20.41 45.66 Favored 'General case' 0 CA--C 1.546 0.809 0 N-CA-C 114.591 1.33 . . . . 0.0 114.591 178.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.4 mtmm -79.7 -12.05 59.82 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 114.341 1.238 . . . . 0.0 114.341 174.044 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.6 t -76.2 142.46 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 C-N-CA 124.815 1.246 . . . . 0.0 111.588 178.023 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 6.3 t -144.24 166.79 24.05 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 124.067 0.947 . . . . 0.0 111.71 169.061 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -52.78 -43.01 92.33 Favored Pre-proline 0 CA--C 1.547 0.842 0 N-CA-C 115.495 1.665 . . . . 0.0 115.495 -179.146 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -70.64 -25.12 24.88 Favored 'Trans proline' 0 C--N 1.353 0.792 0 CA-C-N 121.921 1.722 . . . . 0.0 113.024 176.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 17.6 tp -65.04 -54.07 35.93 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 170.159 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 26.5 mt -54.91 -42.73 72.55 Favored 'General case' 0 C--O 1.224 -0.259 0 O-C-N 123.305 0.378 . . . . 0.0 111.316 -178.675 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.8 t90 -57.64 -62.7 1.6 Allowed 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 123.272 0.629 . . . . 0.0 111.349 178.692 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -64.44 -30.42 71.46 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 113.857 1.058 . . . . 0.0 113.857 -177.392 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.0 tp -71.11 -35.27 71.72 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 124.173 0.989 . . . . 0.0 112.106 176.433 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 -89.51 -10.77 44.99 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 124.863 1.265 . . . . 0.0 113.361 -176.291 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 26.9 mt -53.96 -20.92 6.93 Favored 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 113.92 1.081 . . . . 0.0 113.92 169.172 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 45.0 mt-30 -59.54 -40.16 86.34 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 124.845 1.258 . . . . 0.0 111.89 173.242 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -74.63 -45.45 44.76 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 123.772 0.829 . . . . 0.0 112.899 179.566 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -177.71 -173.09 42.87 Favored Glycine 0 CA--C 1.537 1.44 0 C-N-CA 124.158 0.885 . . . . 0.0 113.595 -177.567 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -67.66 108.65 1.68 Allowed 'Trans proline' 0 CA--C 1.535 0.565 0 C-N-CA 124.072 3.181 . . . . 0.0 111.505 178.392 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 67.3 t -83.99 132.33 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 C-N-CA 124.195 0.998 . . . . 0.0 109.863 173.579 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 15.6 t -107.05 -35.43 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.72 0 C-N-CA 126.797 2.039 . . . . 0.0 111.725 -171.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 14.7 t30 -161.13 157.87 26.64 Favored 'General case' 0 CA--C 1.552 1.029 0 C-N-CA 125.917 1.687 . . . . 0.0 110.777 -171.697 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 11.1 p -136.82 155.59 49.6 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 125.844 1.658 . . . . 0.0 111.584 171.834 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 4.1 t60 -141.74 130.36 22.71 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 124.116 0.967 . . . . 0.0 110.484 177.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 86.3 mtp -135.54 107.18 10.01 Favored Pre-proline 0 N--CA 1.468 0.451 0 C-N-CA 123.991 0.916 . . . . 0.0 109.292 169.388 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_exo -55.89 146.18 69.32 Favored 'Trans proline' 0 CA--C 1.539 0.763 0 C-N-CA 123.709 2.939 . . . . 0.0 113.217 173.196 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 21.6 mmtp -121.95 159.77 26.24 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 125.318 1.447 . . . . 0.0 113.483 -168.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -79.85 152.27 29.78 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 126.403 1.881 . . . . 0.0 112.066 170.299 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 11.9 ptp85 -92.85 0.18 57.36 Favored 'General case' 0 N--CA 1.478 0.945 0 N-CA-C 116.551 2.056 . . . . 0.0 116.551 -173.07 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 3.3 m -135.29 -31.63 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.22 0 C-N-CA 124.488 1.115 . . . . 0.0 113.456 -178.501 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 80.7 p -104.96 -20.51 13.52 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 124.781 1.233 . . . . 0.0 111.65 179.067 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 69.92 7.71 59.7 Favored Glycine 0 CA--C 1.54 1.607 0 C-N-CA 125.113 1.34 . . . . 0.0 115.262 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 58.3 mm-40 -70.11 161.32 30.41 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 124.682 1.193 . . . . 0.0 111.12 173.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 25.4 p80 -75.7 158.74 31.93 Favored 'General case' 0 N--CA 1.472 0.636 0 O-C-N 120.997 -1.064 . . . . 0.0 112.765 175.449 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 82.2 mt-30 -81.3 12.62 3.43 Favored 'General case' 0 CA--C 1.551 1.008 0 N-CA-C 114.595 1.332 . . . . 0.0 114.595 -174.658 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.02 1.48 82.09 Favored Glycine 0 CA--C 1.536 1.362 0 C-N-CA 125.138 1.351 . . . . 0.0 114.941 -178.7 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -144.91 160.73 40.85 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 125.193 1.397 . . . . 0.0 112.138 178.271 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -151.61 -175.03 22.96 Favored Glycine 0 CA--C 1.529 0.942 0 C-N-CA 125.591 1.567 . . . . 0.0 112.918 -179.465 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -144.5 151.73 39.56 Favored 'General case' 0 C--O 1.238 0.452 0 C-N-CA 125.573 1.549 . . . . 0.0 111.582 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 17.1 t -134.22 125.05 47.21 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 124.639 1.176 . . . . 0.0 110.073 175.437 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 78.3 tt0 -100.69 124.88 46.91 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 124.756 1.222 . . . . 0.0 111.298 -178.415 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -98.87 161.42 13.65 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 125.258 1.423 . . . . 0.0 112.274 174.667 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.5 tp -63.38 -33.53 75.75 Favored 'General case' 0 CA--C 1.541 0.63 0 CA-C-N 116.0 -0.545 . . . . 0.0 112.267 176.742 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 12.8 m -143.31 154.46 43.81 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 124.467 1.107 . . . . 0.0 112.129 -175.23 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -63.69 -35.73 81.52 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.565 1.146 . . . . 0.0 113.215 -176.052 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 2.9 pm0 -65.01 -26.12 68.14 Favored 'General case' 0 CA--C 1.541 0.625 0 N-CA-C 113.693 0.997 . . . . 0.0 113.693 174.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 46.9 m-20 -79.51 -31.9 42.28 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.639 0.776 . . . . 0.0 111.783 173.336 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.89 -43.67 71.32 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 123.203 0.601 . . . . 0.0 111.337 172.274 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -57.71 -34.26 69.27 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 124.334 1.054 . . . . 0.0 112.583 174.641 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 20.2 t80 -71.93 -37.68 69.98 Favored 'General case' 0 CA--C 1.537 0.479 0 O-C-N 121.597 -0.689 . . . . 0.0 111.985 174.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.77 -36.12 81.68 Favored 'General case' 0 CA--C 1.537 0.477 0 O-C-N 120.843 -1.161 . . . . 0.0 111.452 176.388 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 74.8 mt -62.88 -34.33 65.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 C-N-CA 124.085 0.954 . . . . 0.0 111.022 171.633 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 63.3 tttp -68.4 -42.67 78.68 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 124.007 0.923 . . . . 0.0 112.498 176.937 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 18.8 pt -91.78 -39.71 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 N-CA-C 114.771 1.397 . . . . 0.0 114.771 -175.258 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 15.1 mmt -90.06 1.01 56.82 Favored 'General case' 0 N--CA 1.48 1.051 0 N-CA-C 114.808 1.41 . . . . 0.0 114.808 -169.512 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -86.15 133.65 33.85 Favored 'General case' 0 CA--C 1.537 0.46 0 O-C-N 121.5 -0.75 . . . . 0.0 112.52 -178.301 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 86.2 mmm 56.79 16.67 2.81 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 126.482 1.913 . . . . 0.0 114.968 -170.048 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.0 mt -69.51 150.78 10.2 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 C-N-CA 124.707 1.203 . . . . 0.0 109.534 167.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 44.6 mtpt -108.72 70.04 0.73 Allowed 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 124.719 1.207 . . . . 0.0 112.163 -177.241 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 30.5 tp -57.48 125.1 21.37 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 124.104 0.961 . . . . 0.0 109.665 174.222 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 63.6 m-85 46.81 29.44 1.0 Allowed 'General case' 0 CA--C 1.56 1.354 0 N-CA-C 116.253 1.946 . . . . 0.0 116.253 -168.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 78.71 28.31 55.16 Favored Glycine 0 CA--C 1.54 1.631 0 O-C-N 120.224 -1.547 . . . . 0.0 115.689 176.447 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 33.9 ttmt -144.06 120.06 6.31 Favored Pre-proline 0 CA--C 1.544 0.74 0 C-N-CA 128.157 2.583 . . . . 0.0 107.853 -174.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -71.05 130.16 17.34 Favored 'Trans proline' 0 CA--C 1.537 0.649 0 C-N-CA 122.894 2.396 . . . . 0.0 113.294 -168.741 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 17.8 pt -102.06 143.91 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 C-N-CA 125.623 1.569 . . . . 0.0 111.966 175.828 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 46.0 tpt85 -112.58 130.09 56.14 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.967 1.707 . . . . 0.0 109.738 178.738 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 17.5 t -129.3 132.69 66.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 C-N-CA 124.342 1.057 . . . . 0.0 112.167 -170.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 52.5 p-10 -156.48 -178.85 7.65 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 126.27 1.828 . . . . 0.0 111.251 174.77 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 11.5 mmmm -67.5 138.83 56.85 Favored 'General case' 0 N--CA 1.478 0.959 0 O-C-N 121.068 -1.02 . . . . 0.0 111.078 178.011 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -71.92 -5.7 36.57 Favored 'General case' 0 CA--C 1.551 0.994 0 N-CA-C 113.595 0.961 . . . . 0.0 113.595 173.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 84.2 p -115.59 11.78 15.93 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 126.768 2.027 . . . . 0.0 113.927 175.564 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -56.2 138.04 50.82 Favored 'General case' 0 CA--C 1.545 0.784 0 N-CA-C 114.493 1.294 . . . . 0.0 114.493 -170.212 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 7.9 p80 -157.06 -36.37 0.08 Allowed 'General case' 0 N--CA 1.476 0.865 0 C-N-CA 125.039 1.336 . . . . 0.0 113.601 177.602 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 14.5 p-10 -90.57 152.88 20.72 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.591 1.556 . . . . 0.0 113.321 -175.43 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -130.48 11.29 5.32 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 125.699 1.6 . . . . 0.0 113.941 -176.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 13.3 p-10 -73.86 146.26 44.25 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 125.031 1.332 . . . . 0.0 113.473 -175.511 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 59.8 tp -96.89 -43.11 7.62 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.74 1.216 . . . . 0.0 111.794 170.296 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 46.4 m 58.57 179.21 0.07 Allowed 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 126.865 2.066 . . . . 0.0 115.45 177.349 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -170.3 178.91 42.79 Favored Glycine 0 CA--C 1.541 1.703 0 C-N-CA 125.371 1.462 . . . . 0.0 112.906 -178.431 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -69.02 144.65 58.73 Favored 'Trans proline' 0 CA--C 1.539 0.772 0 C-N-CA 123.682 2.921 . . . . 0.0 112.814 -177.115 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 64.3 p -83.28 -7.3 59.61 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 125.052 1.341 . . . . 0.0 114.436 -179.634 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 18.2 m -74.45 -12.74 60.58 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 114.721 1.378 . . . . 0.0 114.721 -176.791 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.266 0 C-N-CA 125.492 1.52 . . . . 0.0 113.718 -179.779 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.613 0 N-CA-C 111.463 -0.655 . . . . 0.0 111.463 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.7 m -60.09 -23.26 63.66 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 114.879 1.437 . . . . 0.0 114.879 -171.417 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.7 m -60.7 -23.73 65.1 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.539 1.135 . . . . 0.0 113.427 174.744 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -85.88 -7.08 81.62 Favored Glycine 0 CA--C 1.538 1.484 0 C-N-CA 125.038 1.304 . . . . 0.0 115.169 176.46 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 50.6 m -78.44 -8.9 59.02 Favored 'General case' 0 N--CA 1.478 0.93 0 CA-C-N 119.048 1.424 . . . . 0.0 114.7 -173.533 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 9.2 t -148.42 155.7 41.55 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 125.275 1.43 . . . . 0.0 111.513 175.099 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -74.43 155.1 48.32 Favored Glycine 0 CA--C 1.543 1.838 0 C-N-CA 124.09 0.852 . . . . 0.0 114.054 -179.411 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -72.56 161.2 44.72 Favored 'Trans proline' 0 CA--C 1.54 0.805 0 C-N-CA 123.821 3.014 . . . . 0.0 112.627 176.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.406 HG13 ' H ' ' A' ' 11' ' ' GLU . 10.2 tp -145.64 147.97 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 C-N-CA 124.871 1.269 . . . . 0.0 111.359 175.242 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 22.9 m -72.6 -23.33 60.93 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.928 0.891 . . . . 0.0 113.356 178.596 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.406 ' H ' HG13 ' A' ' 9' ' ' ILE . 38.7 tt0 -63.84 133.16 52.87 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 125.032 1.333 . . . . 0.0 113.396 -172.487 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 5.9 mmp_? -88.92 150.74 22.71 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 125.525 1.53 . . . . 0.0 111.142 175.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -140.05 130.9 26.0 Favored 'General case' 0 CA--C 1.547 0.832 0 N-CA-C 113.776 1.028 . . . . 0.0 113.776 -175.51 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 40.4 mt-30 -80.9 -10.64 59.69 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 115.387 1.625 . . . . 0.0 115.387 -175.625 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 47.7 m-20 -91.96 -34.04 14.62 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-N 119.828 1.195 . . . . 0.0 111.645 171.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -77.7 -13.85 59.78 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 124.389 1.076 . . . . 0.0 112.832 169.475 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 29.9 m -94.56 136.07 35.29 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 124.36 1.064 . . . . 0.0 110.002 169.158 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 4.7 m -103.13 147.67 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 C-N-CA 124.765 1.226 . . . . 0.0 109.912 170.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 30.3 t80 -95.11 142.22 27.81 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 126.265 1.826 . . . . 0.0 109.277 169.825 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 22.8 t -132.18 107.05 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 C-N-CA 125.699 1.6 . . . . 0.0 109.15 176.352 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -103.4 145.47 16.22 Favored Glycine 0 CA--C 1.529 0.923 0 C-N-CA 124.452 1.025 . . . . 0.0 112.747 177.52 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.12 32.14 6.91 Favored Glycine 0 CA--C 1.534 1.225 0 C-N-CA 124.489 1.042 . . . . 0.0 113.897 175.209 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 85.2 mt -74.06 145.57 44.34 Favored 'General case' 0 C--O 1.234 0.267 0 C-N-CA 125.382 1.473 . . . . 0.0 111.312 -175.788 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -85.02 158.05 20.57 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 123.14 0.576 . . . . 0.0 112.479 174.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -58.51 -20.85 49.44 Favored 'General case' 0 CA--C 1.545 0.785 0 N-CA-C 114.462 1.282 . . . . 0.0 114.462 178.127 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.4 mtmm -79.66 -11.69 59.85 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 114.36 1.244 . . . . 0.0 114.36 174.16 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 67.0 t -74.48 142.82 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 124.583 1.153 . . . . 0.0 111.519 178.114 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 90.6 p -137.82 162.96 32.6 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 125.418 1.487 . . . . 0.0 111.941 174.116 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -58.15 -44.45 99.27 Favored Pre-proline 0 CA--C 1.548 0.874 0 O-C-N 121.0 -1.062 . . . . 0.0 112.963 176.625 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_exo -58.9 -31.82 96.18 Favored 'Trans proline' 0 C--N 1.354 0.856 0 C-N-CA 122.544 2.163 . . . . 0.0 114.275 171.483 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 21.1 tp -65.85 -53.58 38.08 Favored 'General case' 0 C--N 1.344 0.361 0 CA-C-N 119.261 0.937 . . . . 0.0 109.67 173.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 24.7 mt -55.47 -42.3 74.14 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 119.497 -0.287 . . . . 0.0 111.458 -178.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.8 t90 -57.68 -62.49 1.76 Allowed 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.221 0.608 . . . . 0.0 111.176 177.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -65.03 -30.03 70.97 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 113.881 1.067 . . . . 0.0 113.881 -176.585 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.2 tp -71.06 -37.32 72.5 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.123 0.969 . . . . 0.0 111.823 176.086 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.3 m-85 -87.71 -10.6 50.71 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 124.861 1.264 . . . . 0.0 113.439 -175.801 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 24.4 mt -54.03 -21.96 9.5 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 124.373 1.069 . . . . 0.0 113.847 169.23 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 41.8 mt-30 -64.11 -31.15 72.24 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 125.224 1.41 . . . . 0.0 112.608 174.729 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -78.17 -46.13 21.35 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 123.509 0.723 . . . . 0.0 112.362 176.58 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 178.81 -172.64 44.93 Favored Glycine 0 CA--C 1.536 1.404 0 C-N-CA 124.835 1.207 . . . . 0.0 112.969 -179.086 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -67.86 110.84 2.24 Favored 'Trans proline' 0 CA--C 1.537 0.632 0 C-N-CA 123.689 2.926 . . . . 0.0 111.736 -178.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 87.7 t -85.7 134.04 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 124.962 1.305 . . . . 0.0 110.016 174.776 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 4.4 t -109.12 -33.86 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 C-N-CA 126.458 1.903 . . . . 0.0 112.068 -172.48 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 10.9 t30 -160.38 157.65 28.21 Favored 'General case' 0 CA--C 1.552 1.028 0 C-N-CA 125.91 1.684 . . . . 0.0 110.975 -171.034 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 7.5 p -140.03 152.53 46.31 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 126.314 1.846 . . . . 0.0 111.37 174.139 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 47.3 t-80 -142.46 133.88 26.41 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 123.467 0.707 . . . . 0.0 111.424 174.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 82.9 mtp -133.73 106.21 11.76 Favored Pre-proline 0 N--CA 1.471 0.615 0 C-N-CA 124.215 1.006 . . . . 0.0 109.338 169.501 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_exo -57.27 140.95 94.42 Favored 'Trans proline' 0 CA--C 1.538 0.704 0 C-N-CA 123.278 2.652 . . . . 0.0 113.292 178.783 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 44.3 mmtm -111.48 145.01 39.78 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 125.204 1.402 . . . . 0.0 112.812 -173.166 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -67.82 144.0 55.53 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 125.952 1.701 . . . . 0.0 112.636 174.852 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 18.0 ptp180 -86.86 7.53 26.76 Favored 'General case' 0 N--CA 1.478 0.967 0 N-CA-C 115.927 1.825 . . . . 0.0 115.927 -174.117 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 38.2 t -131.31 -37.36 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 124.972 1.309 . . . . 0.0 111.389 -174.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 73.0 p -115.04 -14.58 11.82 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 125.791 1.637 . . . . 0.0 112.555 -176.259 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.43 4.09 50.11 Favored Glycine 0 CA--C 1.538 1.493 0 C-N-CA 125.117 1.341 . . . . 0.0 115.502 176.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 71.9 mm-40 -77.37 162.79 26.98 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 124.677 1.191 . . . . 0.0 110.846 177.21 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 17.8 p80 -68.96 152.89 44.7 Favored 'General case' 0 N--CA 1.472 0.637 0 O-C-N 120.853 -1.154 . . . . 0.0 112.343 176.417 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 47.5 mt-30 -85.3 18.01 2.84 Favored 'General case' 0 CA--C 1.549 0.907 0 N-CA-C 114.355 1.242 . . . . 0.0 114.355 -172.45 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.6 2.69 84.55 Favored Glycine 0 CA--C 1.535 1.305 0 C-N-CA 125.022 1.296 . . . . 0.0 115.002 179.31 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -144.74 159.74 42.36 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 124.732 1.213 . . . . 0.0 112.443 177.231 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -150.95 -178.13 25.48 Favored Glycine 0 CA--C 1.529 0.953 0 C-N-CA 125.853 1.692 . . . . 0.0 113.264 -176.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -144.78 148.22 33.82 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 126.026 1.73 . . . . 0.0 111.595 -176.586 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 20.2 t -134.65 127.91 50.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 C-N-CA 124.841 1.256 . . . . 0.0 109.762 175.321 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 44.8 tt0 -108.51 127.25 53.76 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.252 1.021 . . . . 0.0 111.765 -177.762 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -100.24 162.69 12.8 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 125.552 1.541 . . . . 0.0 112.493 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.6 tp -62.22 -32.64 73.33 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 123.02 0.528 . . . . 0.0 112.398 177.282 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.0 m -144.99 157.26 44.19 Favored 'General case' 0 N--CA 1.47 0.525 0 C-N-CA 124.104 0.962 . . . . 0.0 111.768 -178.602 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -61.55 -36.78 81.56 Favored 'General case' 0 N--CA 1.472 0.671 0 O-C-N 121.576 -0.703 . . . . 0.0 112.777 -178.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -64.9 -23.51 67.25 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 113.592 0.96 . . . . 0.0 113.592 179.221 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -80.55 -33.62 36.08 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 124.215 1.006 . . . . 0.0 111.668 172.848 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -71.26 -44.75 64.68 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 123.835 0.854 . . . . 0.0 111.741 174.468 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -61.39 -30.19 70.4 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.826 1.25 . . . . 0.0 112.253 179.269 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 59.9 t80 -78.24 -36.45 47.0 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.336 1.054 . . . . 0.0 113.044 173.046 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.15 -38.4 88.85 Favored 'General case' 0 CA--C 1.539 0.544 0 O-C-N 121.115 -0.991 . . . . 0.0 111.211 176.776 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 59.7 mt -61.24 -35.91 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 C-N-CA 124.988 1.315 . . . . 0.0 111.308 173.475 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -69.01 -37.34 78.63 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 124.138 0.975 . . . . 0.0 113.102 176.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 19.1 pt -99.16 -14.74 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 N-CA-C 116.143 1.905 . . . . 0.0 116.143 -172.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 12.2 mmt -112.28 -2.66 14.78 Favored 'General case' 0 N--CA 1.483 1.203 0 N-CA-C 115.149 1.537 . . . . 0.0 115.149 -176.37 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -81.88 145.25 30.46 Favored 'General case' 0 N--CA 1.475 0.812 0 O-C-N 120.863 -1.148 . . . . 0.0 113.863 -176.562 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 28.5 ttm 60.33 13.42 3.98 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 127.316 2.246 . . . . 0.0 115.115 -179.237 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 18.0 mt -87.3 152.04 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 C-N-CA 127.96 2.504 . . . . 0.0 111.645 -179.297 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 43.6 mtpt -104.64 72.07 1.02 Allowed 'General case' 0 N--CA 1.473 0.678 0 C-N-CA 124.467 1.107 . . . . 0.0 112.634 -171.336 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 31.4 tp -57.34 125.01 20.9 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.747 0.819 . . . . 0.0 109.73 173.3 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 63.6 m-85 46.44 28.69 0.77 Allowed 'General case' 0 CA--C 1.561 1.381 0 N-CA-C 116.326 1.973 . . . . 0.0 116.326 -168.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.77 27.46 53.77 Favored Glycine 0 CA--C 1.541 1.709 0 O-C-N 120.124 -1.61 . . . . 0.0 115.751 177.047 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 33.0 ttmt -143.4 120.41 6.75 Favored Pre-proline 0 CA--C 1.543 0.709 0 C-N-CA 128.453 2.701 . . . . 0.0 107.646 -175.739 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -71.27 127.66 13.68 Favored 'Trans proline' 0 CA--C 1.537 0.636 0 C-N-CA 123.059 2.506 . . . . 0.0 113.458 -168.227 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 21.5 pt -97.91 143.28 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 125.127 1.371 . . . . 0.0 112.156 174.663 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 47.9 tpt85 -108.38 127.68 54.1 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 126.246 1.818 . . . . 0.0 109.013 173.64 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 19.7 t -124.81 135.47 63.88 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 124.418 1.087 . . . . 0.0 111.064 -173.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 38.5 t-20 -159.29 175.42 13.41 Favored 'General case' 0 CA--C 1.55 0.959 0 C-N-CA 125.182 1.393 . . . . 0.0 111.122 -179.18 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.9 mmmm -62.9 140.16 58.8 Favored 'General case' 0 N--CA 1.48 1.055 0 O-C-N 120.614 -1.304 . . . . 0.0 109.99 172.575 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -72.33 -4.27 28.85 Favored 'General case' 0 CA--C 1.55 0.95 0 N-CA-C 113.652 0.982 . . . . 0.0 113.652 177.174 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 62.6 p -86.72 -5.61 59.07 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 127.029 2.132 . . . . 0.0 113.361 169.408 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -134.66 177.9 7.42 Favored 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 126.312 1.845 . . . . 0.0 112.404 -175.008 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -120.49 -69.99 0.81 Allowed 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 124.75 1.22 . . . . 0.0 111.467 176.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 49.4 t30 -142.79 160.78 39.66 Favored 'General case' 0 CA--C 1.547 0.846 0 C-N-CA 125.247 1.419 . . . . 0.0 111.329 177.534 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 36.1 ttpt -71.74 134.12 46.03 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 124.426 1.091 . . . . 0.0 111.526 -178.755 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 21.9 t-20 -103.21 -25.52 13.32 Favored 'General case' 0 CA--C 1.546 0.812 0 N-CA-C 114.355 1.243 . . . . 0.0 114.355 -175.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 96.0 mt -132.78 157.24 45.46 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 125.781 1.632 . . . . 0.0 111.782 -175.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 2.5 t -149.71 165.41 32.46 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 124.472 1.109 . . . . 0.0 112.022 176.183 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -177.79 178.37 48.43 Favored Glycine 0 CA--C 1.54 1.625 0 C-N-CA 124.455 1.026 . . . . 0.0 114.224 -178.46 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 98.7 Cg_endo -71.31 160.41 48.88 Favored 'Trans proline' 0 CA--C 1.541 0.855 0 C-N-CA 124.125 3.217 . . . . 0.0 112.975 -179.284 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 20.2 m -71.94 -16.71 62.1 Favored 'General case' 0 N--CA 1.477 0.887 0 N-CA-C 114.422 1.268 . . . . 0.0 114.422 -177.16 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.3 t -150.51 161.44 42.54 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 125.7 1.6 . . . . 0.0 111.466 177.049 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.299 0 C-N-CA 125.632 1.587 . . . . 0.0 113.864 -179.573 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.638 0 N-CA-C 112.089 -0.404 . . . . 0.0 112.089 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 66.7 p -63.17 -14.62 51.0 Favored 'General case' 0 N--CA 1.479 0.998 0 N-CA-C 115.123 1.527 . . . . 0.0 115.123 -174.74 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.1 m -67.35 -14.9 63.34 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 125.219 1.408 . . . . 0.0 114.055 171.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -64.47 152.52 49.79 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 124.011 0.815 . . . . 0.0 112.995 174.241 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.8 m -59.59 -25.99 65.07 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 114.997 1.48 . . . . 0.0 114.997 -169.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 17.2 m -83.4 -6.83 59.58 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 124.878 1.271 . . . . 0.0 114.123 177.178 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 57.96 50.53 65.11 Favored Glycine 0 CA--C 1.542 1.749 0 C-N-CA 124.956 1.265 . . . . 0.0 113.986 -171.35 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -68.81 150.81 74.15 Favored 'Trans proline' 0 CA--C 1.54 0.795 0 C-N-CA 123.237 2.625 . . . . 0.0 113.738 -169.75 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 18.6 tt -87.69 152.62 3.38 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.681 0 C-N-CA 125.645 1.578 . . . . 0.0 111.623 175.398 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 52.4 p -81.67 -1.25 46.12 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 125.286 1.434 . . . . 0.0 114.787 179.271 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . 0.292 10.8 pt-20 50.26 29.74 3.93 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 127.706 2.402 . . . . 0.0 116.416 174.038 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.93 156.54 39.59 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 126.348 1.859 . . . . 0.0 112.5 -179.103 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 33.8 t-20 50.07 52.6 14.38 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 126.125 1.77 . . . . 0.0 114.062 177.534 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 24.0 mp0 -58.9 -24.36 62.24 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 124.683 1.193 . . . . 0.0 112.838 177.345 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -69.04 -23.63 64.08 Favored 'General case' 0 N--CA 1.471 0.619 0 O-C-N 120.982 -1.074 . . . . 0.0 113.501 174.062 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -85.42 1.75 47.37 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 123.966 0.906 . . . . 0.0 112.702 169.282 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 25.2 m -100.68 135.44 42.12 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.424 1.09 . . . . 0.0 109.699 170.049 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.9 m -102.59 148.28 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 C-N-CA 124.355 1.062 . . . . 0.0 110.53 172.186 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 32.5 t80 -95.44 142.77 27.42 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 126.374 1.869 . . . . 0.0 109.3 169.319 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 22.1 t -131.96 113.12 21.43 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 C-N-CA 125.75 1.62 . . . . 0.0 109.147 177.073 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -110.65 145.78 17.39 Favored Glycine 0 CA--C 1.531 1.037 0 C-N-CA 124.494 1.045 . . . . 0.0 113.104 178.551 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 97.23 30.75 7.21 Favored Glycine 0 CA--C 1.534 1.238 0 C-N-CA 124.763 1.173 . . . . 0.0 113.905 176.313 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 86.9 mt -73.67 145.39 45.32 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 125.316 1.446 . . . . 0.0 111.345 -173.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -84.53 157.58 21.23 Favored 'General case' 0 CA--C 1.542 0.64 0 N-CA-C 112.441 0.534 . . . . 0.0 112.441 175.288 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -58.71 -20.59 50.22 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 114.485 1.291 . . . . 0.0 114.485 178.05 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.1 mtmm -81.25 -7.86 59.65 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 114.42 1.267 . . . . 0.0 114.42 174.463 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 85.7 t -77.3 138.55 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 C-N-CA 124.519 1.128 . . . . 0.0 111.498 178.086 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 52.6 m -135.07 163.25 30.31 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 124.876 1.27 . . . . 0.0 111.522 172.787 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -56.15 -42.64 97.22 Favored Pre-proline 0 CA--C 1.548 0.881 0 O-C-N 120.774 -1.204 . . . . 0.0 114.038 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 66.7 Cg_exo -60.92 -28.54 86.49 Favored 'Trans proline' 0 C--N 1.354 0.831 0 C-N-CA 122.236 1.958 . . . . 0.0 114.099 174.005 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 27.2 tp -67.88 -51.49 47.48 Favored 'General case' 0 C--N 1.344 0.328 0 CA-C-N 118.591 0.632 . . . . 0.0 109.981 172.572 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 20.6 mt -61.54 -23.17 65.76 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 112.801 0.667 . . . . 0.0 112.801 178.952 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.5 t90 -73.2 -66.13 0.72 Allowed 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 123.348 0.659 . . . . 0.0 111.101 171.208 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 39.0 mt-10 -66.12 -29.99 70.4 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 -172.313 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.1 tp -69.13 -33.22 73.11 Favored 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 123.794 0.837 . . . . 0.0 111.872 175.325 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 19.1 m-85 -90.98 -11.2 39.68 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.996 1.318 . . . . 0.0 113.422 -175.101 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 47.2 mt -55.46 -18.51 7.2 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 114.024 1.12 . . . . 0.0 114.024 169.501 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 40.8 mt-30 -65.18 -32.81 74.68 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 125.261 1.424 . . . . 0.0 112.684 173.464 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.23 -45.48 19.74 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 123.581 0.752 . . . . 0.0 112.608 177.737 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.86 -172.33 43.94 Favored Glycine 0 CA--C 1.537 1.438 0 C-N-CA 124.759 1.171 . . . . 0.0 112.997 179.626 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -67.71 110.68 2.17 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 123.745 2.964 . . . . 0.0 111.58 -179.076 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 65.2 t -86.33 131.85 33.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 C-N-CA 124.848 1.259 . . . . 0.0 109.667 174.01 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 7.8 t -107.3 -33.71 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 C-N-CA 126.58 1.952 . . . . 0.0 111.715 -171.248 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 19.9 t30 -160.89 165.51 29.97 Favored 'General case' 0 CA--C 1.553 1.088 0 C-N-CA 126.135 1.774 . . . . 0.0 111.016 -175.323 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 4.4 p -141.15 156.61 45.93 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 126.233 1.813 . . . . 0.0 111.348 174.348 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 2.6 t60 -142.32 136.7 29.96 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 123.952 0.901 . . . . 0.0 110.886 174.755 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 88.2 mtp -138.98 102.82 7.5 Favored Pre-proline 0 N--CA 1.472 0.645 0 C-N-CA 124.117 0.967 . . . . 0.0 109.273 169.73 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_exo -55.73 137.39 78.22 Favored 'Trans proline' 0 CA--C 1.537 0.671 0 C-N-CA 123.412 2.741 . . . . 0.0 113.301 177.341 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 44.4 mmtm -107.72 146.77 31.66 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 125.251 1.421 . . . . 0.0 112.681 -174.31 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -71.36 150.44 45.06 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 125.527 1.531 . . . . 0.0 112.672 175.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 39.9 ptt180 -89.58 -1.5 58.04 Favored 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 -173.002 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 3.5 m -135.01 -31.55 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 C-N-CA 124.687 1.195 . . . . 0.0 113.289 -178.823 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.4 p -103.72 -20.32 14.0 Favored 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 125.021 1.329 . . . . 0.0 111.905 179.302 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.99 0.52 35.05 Favored Glycine 0 CA--C 1.539 1.586 0 C-N-CA 125.431 1.491 . . . . 0.0 116.094 172.15 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -75.67 170.57 15.92 Favored 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 124.654 1.182 . . . . 0.0 111.257 171.46 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 24.7 p80 -67.46 156.92 35.43 Favored 'General case' 0 CA--C 1.54 0.585 0 O-C-N 121.085 -1.009 . . . . 0.0 112.141 170.699 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 47.1 mt-30 -86.54 18.41 3.33 Favored 'General case' 0 CA--C 1.549 0.94 0 N-CA-C 114.277 1.214 . . . . 0.0 114.277 -173.704 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.59 0.96 81.35 Favored Glycine 0 CA--C 1.536 1.355 0 C-N-CA 125.263 1.411 . . . . 0.0 114.977 -179.439 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 47.3 p90 -145.3 161.25 40.04 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 124.963 1.305 . . . . 0.0 112.616 179.247 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -152.62 -176.09 24.84 Favored Glycine 0 CA--C 1.531 1.035 0 C-N-CA 126.013 1.768 . . . . 0.0 112.801 -178.19 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 62.9 m-85 -144.59 151.47 39.09 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.809 1.644 . . . . 0.0 111.536 -179.402 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 17.9 t -132.93 128.23 56.4 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 124.666 1.187 . . . . 0.0 109.802 176.589 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 50.9 tt0 -102.69 119.8 39.47 Favored 'General case' 0 N--CA 1.464 0.246 0 C-N-CA 124.658 1.183 . . . . 0.0 110.552 -176.11 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -97.02 162.24 13.47 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 124.745 1.218 . . . . 0.0 112.256 175.514 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.9 tp -63.34 -34.66 78.18 Favored 'General case' 0 CA--C 1.54 0.585 0 N-CA-C 112.55 0.574 . . . . 0.0 112.55 176.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 16.8 m -144.28 157.62 44.18 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 124.577 1.151 . . . . 0.0 111.927 -176.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -62.85 -33.42 75.21 Favored 'General case' 0 N--CA 1.473 0.708 0 O-C-N 121.503 -0.748 . . . . 0.0 112.872 -179.58 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -67.45 -23.96 65.57 Favored 'General case' 0 N--CA 1.473 0.694 0 O-C-N 121.102 -0.998 . . . . 0.0 113.558 177.695 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 51.0 m-20 -81.4 -33.25 32.37 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 124.16 0.984 . . . . 0.0 111.552 172.805 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.18 -44.97 71.1 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 123.83 0.852 . . . . 0.0 111.395 173.285 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -56.99 -36.4 70.34 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 124.781 1.232 . . . . 0.0 112.44 175.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 26.5 t80 -70.91 -38.14 72.98 Favored 'General case' 0 CA--C 1.536 0.427 0 O-C-N 121.891 -0.505 . . . . 0.0 111.979 175.32 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -65.94 -36.51 83.55 Favored 'General case' 0 CA--C 1.538 0.504 0 O-C-N 120.896 -1.127 . . . . 0.0 111.621 176.676 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 61.9 mt -63.35 -34.88 69.84 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 124.129 0.971 . . . . 0.0 110.74 172.309 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -67.89 -42.92 80.45 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 123.996 0.918 . . . . 0.0 112.681 176.661 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 16.5 pt -90.42 -38.39 10.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -175.781 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' MET . . . . . 0.488 ' HA ' HD12 ' A' ' 80' ' ' ILE . 15.7 mmt -90.2 0.15 57.33 Favored 'General case' 0 N--CA 1.479 0.995 0 N-CA-C 114.642 1.349 . . . . 0.0 114.642 -169.853 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -84.43 136.07 34.0 Favored 'General case' 0 CA--C 1.541 0.596 0 O-C-N 121.442 -0.786 . . . . 0.0 112.045 178.271 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 1.7 mmt 59.03 13.97 3.16 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 126.087 1.755 . . . . 0.0 115.25 -170.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.488 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.3 mt -71.21 154.02 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 C-N-CA 124.671 1.188 . . . . 0.0 109.777 168.132 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 47.2 mtpt -113.7 71.01 0.73 Allowed 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 125.125 1.37 . . . . 0.0 112.154 -175.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 25.2 tp -57.99 126.91 29.5 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 123.978 0.911 . . . . 0.0 109.888 174.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 46.89 28.55 0.86 Allowed 'General case' 0 CA--C 1.56 1.358 0 N-CA-C 116.268 1.951 . . . . 0.0 116.268 -168.708 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 77.57 29.09 56.19 Favored Glycine 0 CA--C 1.54 1.6 0 O-C-N 120.071 -1.643 . . . . 0.0 115.418 177.101 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 34.8 ttmt -143.21 119.77 6.69 Favored Pre-proline 0 CA--C 1.543 0.708 0 C-N-CA 128.267 2.627 . . . . 0.0 107.842 -175.112 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -70.18 132.86 23.5 Favored 'Trans proline' 0 CA--C 1.536 0.613 0 C-N-CA 122.972 2.448 . . . . 0.0 113.528 -168.852 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 17.8 pt -105.72 151.91 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 C-N-CA 125.722 1.609 . . . . 0.0 112.163 175.376 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 24.2 mmt180 -115.11 140.33 49.15 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 125.307 1.443 . . . . 0.0 110.512 169.585 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 30.4 t -133.34 139.08 49.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 C-N-CA 125.253 1.421 . . . . 0.0 110.718 -173.877 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 40.2 t-20 -161.65 179.2 8.35 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 125.952 1.701 . . . . 0.0 110.252 179.59 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 13.8 mmmm -55.92 147.82 18.61 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 125.373 1.469 . . . . 0.0 111.298 170.016 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -76.08 -33.08 59.54 Favored 'General case' 0 CA--C 1.549 0.909 0 O-C-N 121.973 -0.455 . . . . 0.0 111.967 169.059 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 20.4 m -77.33 -44.07 30.79 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 124.149 0.98 . . . . 0.0 113.374 176.642 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . 40.64 75.76 0.08 Allowed 'General case' 0 CA--C 1.551 0.999 0 C-N-CA 128.284 2.634 . . . . 0.0 115.759 176.233 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 14.7 p80 -130.74 16.17 5.3 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 126.427 1.891 . . . . 0.0 113.743 -174.737 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -61.65 141.04 58.07 Favored 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 124.538 1.135 . . . . 0.0 112.579 -174.764 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 62.3 tttp -147.77 146.01 29.01 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 126.272 1.829 . . . . 0.0 110.968 -175.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 79.4 m-20 -79.93 54.52 1.9 Allowed 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 124.879 1.272 . . . . 0.0 111.259 173.632 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 41.5 tp -72.98 147.58 45.04 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 125.601 1.56 . . . . 0.0 112.147 -174.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 87.1 p -135.32 167.32 21.24 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 125.948 1.699 . . . . 0.0 112.513 -179.385 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -170.4 -171.64 36.01 Favored Glycine 0 CA--C 1.539 1.544 0 C-N-CA 124.73 1.157 . . . . 0.0 113.554 -179.406 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -59.93 152.57 63.46 Favored 'Trans proline' 0 CA--C 1.539 0.752 0 C-N-CA 124.119 3.213 . . . . 0.0 114.36 -178.353 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 35.4 m -67.07 149.8 50.07 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 124.69 1.196 . . . . 0.0 113.039 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 61.3 p -78.69 -15.37 58.55 Favored 'General case' 0 N--CA 1.476 0.857 0 N-CA-C 114.467 1.284 . . . . 0.0 114.467 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.209 0 C-N-CA 126.026 1.774 . . . . 0.0 113.05 177.672 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.642 0 N-CA-C 111.836 -0.506 . . . . 0.0 111.836 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 77.0 p -145.82 159.05 43.75 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.292 1.437 . . . . 0.0 112.481 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 38.8 m -72.76 147.43 45.57 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 124.411 1.084 . . . . 0.0 113.136 -177.233 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.8 156.33 18.54 Favored Glycine 0 CA--C 1.534 1.271 0 C-N-CA 124.99 1.281 . . . . 0.0 112.805 176.339 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 50.8 p -84.72 -27.93 26.66 Favored 'General case' 0 N--CA 1.476 0.825 0 N-CA-C 114.105 1.15 . . . . 0.0 114.105 -176.602 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 90.8 p -156.27 161.8 40.19 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.423 1.489 . . . . 0.0 112.585 177.747 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 170.4 171.17 35.54 Favored Glycine 0 CA--C 1.54 1.641 0 C-N-CA 125.049 1.309 . . . . 0.0 113.175 174.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_exo -61.56 133.99 48.73 Favored 'Trans proline' 0 CA--C 1.537 0.646 0 C-N-CA 123.425 2.75 . . . . 0.0 112.7 178.408 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.0 tp -154.29 154.21 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 124.941 1.296 . . . . 0.0 111.324 -178.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 59.3 p -85.25 3.0 41.49 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 125.683 1.593 . . . . 0.0 114.496 177.193 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -72.52 158.48 35.62 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 125.755 1.622 . . . . 0.0 113.126 -177.215 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 89.9 mtt180 -64.32 163.23 13.37 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 126.007 1.723 . . . . 0.0 113.243 -178.451 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 77.9 m-20 -69.31 98.19 1.03 Allowed 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.752 1.221 . . . . 0.0 112.785 -169.994 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.4 tt0 -70.04 -18.87 63.31 Favored 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 124.091 0.956 . . . . 0.0 113.005 -179.395 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -63.21 -34.66 78.13 Favored 'General case' 0 N--CA 1.472 0.666 0 O-C-N 120.908 -1.12 . . . . 0.0 112.963 174.343 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -95.28 10.77 34.91 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.517 1.527 . . . . 0.0 112.661 173.625 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 53.1 m -99.55 136.48 39.41 Favored 'General case' 0 N--CA 1.47 0.548 0 O-C-N 121.272 -0.893 . . . . 0.0 109.598 172.778 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.2 m -102.21 147.74 8.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 C-N-CA 124.418 1.087 . . . . 0.0 110.283 171.337 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 16.5 t80 -95.66 141.98 28.51 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 126.354 1.862 . . . . 0.0 109.097 169.18 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 22.6 t -132.01 108.78 14.46 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 125.626 1.57 . . . . 0.0 109.143 178.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -103.77 145.62 16.18 Favored Glycine 0 CA--C 1.529 0.956 0 C-N-CA 124.436 1.017 . . . . 0.0 112.87 177.755 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 97.5 33.41 5.91 Favored Glycine 0 CA--C 1.533 1.192 0 C-N-CA 124.677 1.132 . . . . 0.0 113.899 174.526 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 83.0 mt -76.49 145.97 38.8 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 125.286 1.434 . . . . 0.0 111.346 -174.803 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -85.23 157.8 20.51 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 123.506 0.723 . . . . 0.0 112.196 174.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.44 -20.7 47.11 Favored 'General case' 0 CA--C 1.547 0.83 0 N-CA-C 114.599 1.333 . . . . 0.0 114.599 178.317 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.0 mtmm -80.45 -11.03 59.73 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 114.374 1.25 . . . . 0.0 114.374 174.255 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.3 t -75.01 138.12 21.63 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 124.31 1.044 . . . . 0.0 111.324 177.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 56.7 m -136.42 162.64 32.49 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 125.169 1.388 . . . . 0.0 111.36 172.765 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -55.8 -43.21 99.09 Favored Pre-proline 0 CA--C 1.549 0.916 0 N-CA-C 114.022 1.119 . . . . 0.0 114.022 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -62.67 -28.26 76.6 Favored 'Trans proline' 0 C--N 1.355 0.873 0 C-N-CA 122.224 1.95 . . . . 0.0 113.999 174.707 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 20.6 tp -66.31 -54.15 28.1 Favored 'General case' 0 C--N 1.345 0.374 0 CA-C-N 118.634 0.652 . . . . 0.0 109.461 172.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 25.8 mt -55.33 -42.09 73.32 Favored 'General case' 0 N--CA 1.464 0.273 0 O-C-N 123.218 0.324 . . . . 0.0 111.37 -178.429 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 3.0 t90 -57.31 -62.79 1.52 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.379 0.672 . . . . 0.0 111.262 178.418 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 -65.22 -29.04 69.81 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 113.801 1.037 . . . . 0.0 113.801 -176.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.8 tp -72.03 -36.96 69.81 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 124.229 1.012 . . . . 0.0 111.863 175.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 11.0 m-85 -87.3 -10.5 52.13 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 124.779 1.231 . . . . 0.0 113.378 -176.082 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 25.5 mt -53.91 -20.47 6.08 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 124.53 1.132 . . . . 0.0 113.899 168.878 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 76.3 mt-30 -62.42 -33.45 74.81 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 125.672 1.589 . . . . 0.0 112.581 173.824 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.71 -46.11 17.68 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 123.777 0.831 . . . . 0.0 112.715 178.135 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -179.51 -171.86 43.0 Favored Glycine 0 CA--C 1.535 1.341 0 C-N-CA 124.279 0.943 . . . . 0.0 113.16 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -67.97 108.75 1.77 Allowed 'Trans proline' 0 CA--C 1.537 0.648 0 C-N-CA 123.757 2.971 . . . . 0.0 111.463 -179.033 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 75.4 t -84.33 132.84 30.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 C-N-CA 124.746 1.218 . . . . 0.0 109.831 174.202 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.8 t -109.3 -33.6 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 126.329 1.852 . . . . 0.0 111.922 -171.65 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 18.6 t30 -161.0 164.74 30.76 Favored 'General case' 0 CA--C 1.555 1.135 0 C-N-CA 126.028 1.731 . . . . 0.0 111.037 -174.702 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 3.7 p -141.92 153.79 44.63 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 126.339 1.856 . . . . 0.0 111.636 175.746 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 3.7 t60 -142.43 133.34 25.71 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 123.815 0.846 . . . . 0.0 111.109 175.607 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 84.9 mtp -135.29 103.28 10.52 Favored Pre-proline 0 N--CA 1.472 0.651 0 C-N-CA 124.072 0.949 . . . . 0.0 109.257 169.273 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 81.1 Cg_exo -54.58 138.12 74.42 Favored 'Trans proline' 0 CA--C 1.536 0.585 0 C-N-CA 123.276 2.651 . . . . 0.0 112.832 176.275 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 45.0 mmtm -104.3 154.26 20.02 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 125.018 1.327 . . . . 0.0 112.439 -176.301 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -80.51 143.67 33.12 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 125.843 1.657 . . . . 0.0 112.017 175.688 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 39.7 ptt180 -86.67 5.2 37.19 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 116.019 1.859 . . . . 0.0 116.019 -174.211 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 23.8 t -132.16 -37.88 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 124.91 1.284 . . . . 0.0 111.479 -175.047 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 74.9 p -107.95 -21.5 12.8 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 126.052 1.741 . . . . 0.0 112.511 -177.487 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 73.63 1.87 59.18 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 125.072 1.32 . . . . 0.0 116.034 173.676 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 3.4 pt20 -76.06 172.38 12.88 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 118.506 1.153 . . . . 0.0 110.871 169.713 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 29.0 p80 -68.04 158.43 32.95 Favored 'General case' 0 N--CA 1.471 0.577 0 O-C-N 120.946 -1.096 . . . . 0.0 112.355 171.29 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 82.4 mt-30 -80.51 14.04 2.22 Favored 'General case' 0 CA--C 1.552 1.027 0 C-N-CA 124.872 1.269 . . . . 0.0 114.424 -176.082 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.54 0.91 81.53 Favored Glycine 0 CA--C 1.537 1.444 0 C-N-CA 125.207 1.384 . . . . 0.0 114.884 -177.134 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 42.0 p90 -144.4 161.01 40.09 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.1 1.36 . . . . 0.0 112.249 178.71 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -150.7 -175.38 22.63 Favored Glycine 0 CA--C 1.528 0.882 0 C-N-CA 125.718 1.628 . . . . 0.0 113.176 -179.258 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -145.08 151.67 38.88 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 125.767 1.627 . . . . 0.0 111.937 -178.818 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 20.5 t -133.89 128.15 53.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 124.716 1.206 . . . . 0.0 110.001 175.301 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 51.3 tt0 -101.18 122.36 43.49 Favored 'General case' 0 N--CA 1.466 0.337 0 C-N-CA 125.03 1.332 . . . . 0.0 110.731 -177.511 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 81.9 m-85 -98.42 162.11 13.33 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 125.058 1.343 . . . . 0.0 112.306 175.548 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.6 tp -62.39 -34.2 76.25 Favored 'General case' 0 CA--C 1.541 0.622 0 CA-C-N 115.86 -0.609 . . . . 0.0 112.56 176.384 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.8 m -144.06 155.67 44.07 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 124.497 1.119 . . . . 0.0 112.164 -176.934 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -63.26 -31.12 72.19 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 123.958 0.903 . . . . 0.0 113.107 -178.596 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -69.63 -23.87 63.55 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 121.119 -0.988 . . . . 0.0 113.535 175.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 46.7 m-20 -81.34 -32.4 33.02 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 123.822 0.849 . . . . 0.0 111.401 172.416 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -67.69 -44.03 78.72 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 123.436 0.694 . . . . 0.0 111.076 172.057 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -57.43 -34.31 68.81 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.482 1.113 . . . . 0.0 112.933 173.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 17.3 t80 -72.43 -37.35 68.61 Favored 'General case' 0 CA--C 1.537 0.449 0 O-C-N 121.554 -0.716 . . . . 0.0 111.963 175.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.5 -36.3 82.39 Favored 'General case' 0 CA--C 1.536 0.441 0 O-C-N 120.731 -1.23 . . . . 0.0 111.529 176.356 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 64.8 mt -62.95 -34.23 65.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 124.003 0.921 . . . . 0.0 111.004 172.138 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -68.47 -43.14 77.62 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 124.054 0.942 . . . . 0.0 112.584 176.586 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 19.5 pt -91.73 -38.39 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 114.926 1.454 . . . . 0.0 114.926 -174.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' MET . . . . . 0.482 ' HA ' HD12 ' A' ' 80' ' ' ILE . 15.1 mmt -90.84 0.73 57.39 Favored 'General case' 0 N--CA 1.479 0.984 0 N-CA-C 114.768 1.396 . . . . 0.0 114.768 -169.851 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -85.04 135.87 33.82 Favored 'General case' 0 CA--C 1.538 0.49 0 O-C-N 121.528 -0.733 . . . . 0.0 112.203 179.067 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 26.3 ttm 59.88 11.81 2.75 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 126.149 1.779 . . . . 0.0 114.848 -171.547 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.482 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.5 mt -69.96 150.7 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 124.874 1.27 . . . . 0.0 109.793 168.673 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 44.7 mtpt -108.86 70.52 0.74 Allowed 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 124.713 1.205 . . . . 0.0 112.364 -174.808 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 25.3 tp -58.55 124.1 18.49 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 123.789 0.835 . . . . 0.0 109.659 174.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 45.38 31.09 0.79 Allowed 'General case' 0 CA--C 1.56 1.358 0 N-CA-C 116.082 1.882 . . . . 0.0 116.082 -168.5 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 82.23 17.55 69.01 Favored Glycine 0 CA--C 1.542 1.726 0 O-C-N 120.272 -1.517 . . . . 0.0 116.691 173.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 94.3 mttt -131.96 123.94 19.32 Favored Pre-proline 0 CA--C 1.54 0.569 0 C-N-CA 128.22 2.608 . . . . 0.0 108.088 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -71.49 123.09 9.2 Favored 'Trans proline' 0 CA--C 1.538 0.679 0 C-N-CA 123.343 2.695 . . . . 0.0 112.351 -169.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 15.6 pt -91.12 147.92 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 125.135 1.374 . . . . 0.0 111.818 175.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 9.6 mmm180 -114.72 132.42 56.43 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 125.412 1.485 . . . . 0.0 110.379 175.363 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.2 t -128.19 137.18 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 C-N-CA 124.278 1.031 . . . . 0.0 111.135 -170.976 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 5.7 p30 -157.2 175.32 14.2 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 126.526 1.93 . . . . 0.0 110.536 176.617 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.5 mmmp? -64.63 138.83 58.62 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 123.864 0.866 . . . . 0.0 110.298 174.473 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -67.4 -32.14 72.84 Favored 'General case' 0 CA--C 1.55 0.97 0 O-C-N 121.837 -0.539 . . . . 0.0 110.565 168.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 37.4 m -118.23 95.94 5.11 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 126.105 1.762 . . . . 0.0 108.982 166.807 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -90.96 150.76 21.35 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 124.721 1.208 . . . . 0.0 112.051 178.521 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 11.1 p80 -147.82 176.31 10.24 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 125.173 1.389 . . . . 0.0 112.486 -178.168 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 59.6 t-20 -59.82 134.47 57.06 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 125.501 1.521 . . . . 0.0 112.761 -172.815 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 45.0 mmtm -86.8 -17.35 33.67 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 125.215 1.406 . . . . 0.0 113.851 -178.533 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -73.22 146.41 45.5 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 123.779 0.832 . . . . 0.0 112.571 -177.548 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 47.6 tp -92.83 -28.35 16.59 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 125.561 1.544 . . . . 0.0 113.118 177.011 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 84.3 p -84.43 166.51 17.26 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 113.729 1.011 . . . . 0.0 113.729 -178.177 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -166.38 176.33 41.63 Favored Glycine 0 CA--C 1.54 1.642 0 C-N-CA 125.299 1.428 . . . . 0.0 112.982 178.838 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -69.5 146.95 63.43 Favored 'Trans proline' 0 CA--C 1.539 0.757 0 C-N-CA 123.684 2.923 . . . . 0.0 112.907 -176.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 19.1 m -92.79 -4.18 53.47 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 124.872 1.269 . . . . 0.0 114.36 -177.459 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 9.1 t -72.84 152.87 41.31 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.47 1.108 . . . . 0.0 112.924 -177.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.174 0 C-N-CA 125.693 1.616 . . . . 0.0 112.79 -178.721 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.52 0 N-CA-C 111.734 -0.546 . . . . 0.0 111.734 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 37.2 m -69.19 153.44 43.69 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 124.581 1.153 . . . . 0.0 113.333 -179.033 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.6 t -73.16 162.01 29.92 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 124.126 0.971 . . . . 0.0 112.406 173.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -171.3 -178.1 41.53 Favored Glycine 0 CA--C 1.534 1.261 0 C-N-CA 124.86 1.219 . . . . 0.0 113.723 -178.363 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.7 m 55.38 27.82 10.58 Favored 'General case' 0 N--CA 1.48 1.033 0 C-N-CA 125.787 1.635 . . . . 0.0 114.998 179.513 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 13.2 t -151.27 153.51 34.99 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.321 1.448 . . . . 0.0 111.945 -179.01 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 83.99 133.64 2.46 Favored Glycine 0 CA--C 1.545 1.926 0 C-N-CA 125.923 1.725 . . . . 0.0 113.91 -179.182 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -79.8 168.45 19.3 Favored 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 123.888 3.059 . . . . 0.0 112.676 177.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -69.2 147.96 11.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 123.997 0.919 . . . . 0.0 112.233 170.242 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.6 m -74.72 -26.66 59.95 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -179.161 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -151.98 146.18 25.4 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 125.783 1.633 . . . . 0.0 110.599 178.548 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.0 tpm_? -138.37 139.68 39.1 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 124.956 1.302 . . . . 0.0 111.012 179.084 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 83.8 m-20 -87.49 146.35 25.86 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 124.217 1.007 . . . . 0.0 112.766 -177.372 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 31.8 tp60 -145.78 -40.79 0.22 Allowed 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 125.123 1.369 . . . . 0.0 111.368 169.516 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -69.33 -33.45 73.15 Favored 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 113.471 0.915 . . . . 0.0 113.471 178.006 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.3 5.54 34.03 Favored 'General case' 0 CA--C 1.545 0.77 0 C-N-CA 124.795 1.238 . . . . 0.0 113.055 171.206 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 18.7 m -99.57 137.57 37.88 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 124.293 1.037 . . . . 0.0 109.185 172.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 14.3 m -105.66 148.56 9.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 C-N-CA 124.685 1.194 . . . . 0.0 110.322 173.24 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 32.1 t80 -95.43 141.77 28.58 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 126.245 1.818 . . . . 0.0 109.392 169.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 22.0 t -131.53 109.9 16.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 C-N-CA 125.636 1.574 . . . . 0.0 109.166 175.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -105.47 147.78 16.34 Favored Glycine 0 CA--C 1.53 0.972 0 C-N-CA 124.445 1.021 . . . . 0.0 112.714 177.056 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.36 31.37 7.21 Favored Glycine 0 CA--C 1.534 1.277 0 C-N-CA 124.767 1.175 . . . . 0.0 114.24 173.837 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 89.1 mt -73.95 150.21 40.92 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 125.511 1.525 . . . . 0.0 111.598 -172.101 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -89.74 156.38 18.57 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 123.784 0.833 . . . . 0.0 111.973 175.594 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.53 -20.39 45.69 Favored 'General case' 0 CA--C 1.546 0.795 0 N-CA-C 114.818 1.414 . . . . 0.0 114.818 -179.799 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.6 mtmm -81.17 -11.23 59.48 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 124.666 1.186 . . . . 0.0 114.15 175.132 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 75.4 t -72.15 140.98 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 C-N-CA 124.395 1.078 . . . . 0.0 111.632 179.19 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 92.3 p -135.27 162.08 33.58 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.188 1.395 . . . . 0.0 112.16 175.111 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -59.82 -39.86 73.83 Favored Pre-proline 0 CA--C 1.547 0.831 0 O-C-N 120.814 -1.179 . . . . 0.0 113.551 177.43 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -61.96 -30.9 84.08 Favored 'Trans proline' 0 C--N 1.352 0.754 0 C-N-CA 122.537 2.158 . . . . 0.0 113.94 170.369 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 27.1 tp -68.07 -50.37 55.52 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 119.114 0.87 . . . . 0.0 109.893 174.009 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 19.9 mt -61.1 -23.05 65.21 Favored 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 112.985 0.735 . . . . 0.0 112.985 178.579 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.6 t90 -73.54 -66.62 0.67 Allowed 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 123.159 0.584 . . . . 0.0 111.006 170.745 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -65.01 -30.33 71.3 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 114.221 1.193 . . . . 0.0 114.221 -172.365 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.9 tp -69.53 -32.56 71.45 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 123.762 0.825 . . . . 0.0 111.917 175.709 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -91.18 -10.83 40.29 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 125.194 1.397 . . . . 0.0 113.313 -175.175 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 50.7 mt -55.12 -18.63 5.9 Favored 'General case' 0 N--CA 1.475 0.808 0 C-N-CA 124.477 1.111 . . . . 0.0 113.945 169.377 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 41.2 mt-30 -64.82 -33.06 75.09 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 125.367 1.467 . . . . 0.0 112.737 173.272 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.25 -45.1 20.46 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 123.543 0.737 . . . . 0.0 112.624 177.57 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.46 -172.78 44.71 Favored Glycine 0 CA--C 1.535 1.284 0 C-N-CA 124.672 1.13 . . . . 0.0 112.996 179.321 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -67.48 111.28 2.27 Favored 'Trans proline' 0 CA--C 1.537 0.626 0 C-N-CA 123.658 2.905 . . . . 0.0 111.633 -179.197 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 67.0 t -86.25 134.23 27.85 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 C-N-CA 124.863 1.265 . . . . 0.0 109.856 174.187 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 8.0 t -109.32 -33.37 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.703 0 C-N-CA 126.633 1.973 . . . . 0.0 111.959 -171.416 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 20.0 t30 -160.8 161.35 31.99 Favored 'General case' 0 CA--C 1.554 1.128 0 C-N-CA 125.926 1.691 . . . . 0.0 111.205 -175.265 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 5.0 p -137.97 155.1 49.22 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 125.928 1.691 . . . . 0.0 111.864 171.569 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 47.3 t-80 -142.33 133.72 26.42 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 123.848 0.859 . . . . 0.0 111.197 175.66 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 87.5 mtp -134.21 107.24 11.27 Favored Pre-proline 0 N--CA 1.471 0.613 0 C-N-CA 124.04 0.936 . . . . 0.0 109.638 169.868 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -57.82 140.34 93.39 Favored 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 123.305 2.67 . . . . 0.0 113.179 177.384 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 43.3 mmtm -112.89 146.82 38.27 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.249 1.42 . . . . 0.0 113.076 -172.624 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 27.3 t70 -67.14 143.46 56.6 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 125.827 1.651 . . . . 0.0 112.447 172.479 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 9.7 ptm180 -85.84 6.66 27.18 Favored 'General case' 0 N--CA 1.479 1.02 0 N-CA-C 116.0 1.852 . . . . 0.0 116.0 -174.018 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 35.6 t -131.36 -37.48 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.104 0 C-N-CA 124.942 1.297 . . . . 0.0 111.405 -174.307 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 72.5 p -113.97 -14.66 12.42 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 125.846 1.659 . . . . 0.0 112.544 -176.574 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.21 4.96 52.34 Favored Glycine 0 CA--C 1.538 1.489 0 C-N-CA 125.146 1.355 . . . . 0.0 115.393 176.72 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 72.9 mm-40 -77.49 162.14 27.39 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 124.611 1.165 . . . . 0.0 110.805 177.226 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 18.7 p80 -69.18 153.54 43.53 Favored 'General case' 0 N--CA 1.473 0.681 0 O-C-N 120.948 -1.095 . . . . 0.0 112.473 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 46.3 mt-30 -84.94 17.36 2.9 Favored 'General case' 0 CA--C 1.549 0.927 0 N-CA-C 114.344 1.239 . . . . 0.0 114.344 -173.456 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 87.12 1.69 84.22 Favored Glycine 0 CA--C 1.535 1.289 0 C-N-CA 125.071 1.32 . . . . 0.0 114.953 -179.863 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 41.3 p90 -144.79 161.01 40.31 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 124.917 1.287 . . . . 0.0 112.427 177.768 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -152.12 -178.15 26.53 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 125.968 1.747 . . . . 0.0 113.003 -177.467 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -142.81 149.03 38.08 Favored 'General case' 0 C--O 1.237 0.421 0 C-N-CA 126.025 1.73 . . . . 0.0 111.573 -178.5 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 14.4 t -132.91 127.81 55.91 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 124.637 1.175 . . . . 0.0 109.953 176.488 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 57.3 tt0 -103.63 120.2 40.42 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 124.789 1.236 . . . . 0.0 110.845 -175.842 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -96.83 161.95 13.63 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 124.638 1.175 . . . . 0.0 112.387 176.001 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.8 tp -63.25 -34.42 77.63 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 123.224 0.61 . . . . 0.0 112.448 176.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.0 m -143.65 156.27 44.5 Favored 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 124.393 1.077 . . . . 0.0 112.012 -177.391 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 49.6 tt0 -64.09 -30.85 71.89 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 123.847 0.859 . . . . 0.0 113.27 -178.302 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -69.58 -24.55 63.71 Favored 'General case' 0 N--CA 1.474 0.733 0 O-C-N 121.173 -0.955 . . . . 0.0 113.396 176.159 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 52.5 m-20 -79.83 -33.57 40.15 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 123.925 0.89 . . . . 0.0 111.333 172.326 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -67.55 -45.2 76.34 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 123.57 0.748 . . . . 0.0 111.491 172.725 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -56.86 -36.0 69.54 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 124.474 1.11 . . . . 0.0 112.672 175.599 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 24.0 t80 -71.56 -37.83 71.03 Favored 'General case' 0 CA--C 1.538 0.493 0 O-C-N 121.719 -0.613 . . . . 0.0 111.973 175.773 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.0 -36.93 84.63 Favored 'General case' 0 CA--C 1.537 0.452 0 O-C-N 120.916 -1.115 . . . . 0.0 111.696 176.586 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 55.8 mt -63.81 -33.99 65.36 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 C-N-CA 124.053 0.941 . . . . 0.0 110.783 172.633 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -67.62 -43.62 79.96 Favored 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 123.865 0.866 . . . . 0.0 112.713 175.546 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 18.2 pt -91.09 -34.38 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 N-CA-C 115.282 1.586 . . . . 0.0 115.282 -174.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' MET . . . . . 0.477 ' HA ' HD12 ' A' ' 80' ' ' ILE . 15.0 mmt -95.05 -1.16 52.8 Favored 'General case' 0 N--CA 1.479 1.023 0 N-CA-C 114.615 1.339 . . . . 0.0 114.615 -171.257 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -82.84 146.27 29.01 Favored 'General case' 0 CA--C 1.539 0.553 0 O-C-N 121.395 -0.815 . . . . 0.0 111.206 174.159 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 84.6 mmm 60.24 5.96 0.92 Allowed 'General case' 0 N--CA 1.479 1.012 0 C-N-CA 125.929 1.692 . . . . 0.0 115.468 -172.533 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.477 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.4 mt -71.78 157.42 6.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 C-N-CA 125.862 1.665 . . . . 0.0 111.236 172.72 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 50.8 mtpt -118.83 71.23 0.84 Allowed 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 125.815 1.646 . . . . 0.0 112.028 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 32.9 tp -57.65 126.75 28.72 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.049 0.939 . . . . 0.0 110.301 176.633 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 53.6 m-85 46.27 27.58 0.59 Allowed 'General case' 0 CA--C 1.559 1.311 0 N-CA-C 116.398 1.999 . . . . 0.0 116.398 -168.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 78.78 27.56 56.51 Favored Glycine 0 CA--C 1.542 1.768 0 O-C-N 120.103 -1.623 . . . . 0.0 115.715 177.542 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -135.71 121.03 13.61 Favored Pre-proline 0 CA--C 1.542 0.64 0 C-N-CA 128.316 2.647 . . . . 0.0 107.63 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -68.61 127.91 16.27 Favored 'Trans proline' 0 CA--C 1.536 0.577 0 C-N-CA 123.002 2.468 . . . . 0.0 112.745 -171.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 27.5 pt -101.39 159.21 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 125.418 1.487 . . . . 0.0 112.051 175.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 86.9 mmt-85 -127.48 134.95 49.79 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 125.747 1.619 . . . . 0.0 110.167 174.003 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 30.9 t -130.01 138.58 53.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 124.257 1.023 . . . . 0.0 111.366 -172.605 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 40.8 t-20 -159.0 177.29 11.3 Favored 'General case' 0 CA--C 1.548 0.883 0 C-N-CA 125.987 1.715 . . . . 0.0 110.228 178.039 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.3 mmmp? -58.11 146.91 31.62 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 124.715 1.206 . . . . 0.0 110.69 169.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -80.01 -16.09 55.87 Favored 'General case' 0 CA--C 1.55 0.958 0 N-CA-C 112.494 0.553 . . . . 0.0 112.494 169.485 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 59.7 p -88.84 -55.26 3.77 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 125.322 1.449 . . . . 0.0 112.317 170.519 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . 56.85 40.49 28.92 Favored 'General case' 0 CA--C 1.549 0.928 0 C-N-CA 127.413 2.285 . . . . 0.0 115.495 176.592 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 84.1 m-70 -114.61 145.85 41.51 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 125.215 1.406 . . . . 0.0 111.122 169.156 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 26.2 m120 -82.91 152.74 25.41 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.147 0.979 . . . . 0.0 112.353 -177.246 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 66.1 mttm -81.98 44.63 0.85 Allowed 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 125.752 1.621 . . . . 0.0 112.291 177.59 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 51.3 t30 -76.4 158.65 31.19 Favored 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 125.303 1.441 . . . . 0.0 112.734 -172.1 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 64.5 tp -141.6 135.23 29.82 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 126.14 1.776 . . . . 0.0 110.397 177.655 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 17.4 m -69.52 -27.17 64.94 Favored 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 114.207 1.188 . . . . 0.0 114.207 -174.524 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 160.16 -172.68 36.67 Favored Glycine 0 CA--C 1.54 1.617 0 C-N-CA 125.174 1.368 . . . . 0.0 113.354 178.083 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -67.76 -23.53 41.81 Favored 'Trans proline' 0 CA--C 1.54 0.8 0 C-N-CA 123.578 2.852 . . . . 0.0 114.645 178.907 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 44.2 m 54.4 28.19 9.16 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 126.197 1.799 . . . . 0.0 114.899 -178.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 59.1 p -89.06 -13.18 39.26 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.519 1.528 . . . . 0.0 114.524 -177.51 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.24 0 C-N-CA 125.705 1.622 . . . . 0.0 113.656 178.096 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.563 0 N-CA-C 111.582 -0.607 . . . . 0.0 111.582 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 69.5 p -152.65 159.6 43.2 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.825 1.25 . . . . 0.0 112.655 178.612 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.2 m 50.63 48.46 22.61 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 116.14 1.904 . . . . 0.0 116.14 169.238 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -72.02 130.79 17.12 Favored Glycine 0 CA--C 1.534 1.226 0 O-C-N 120.978 -1.076 . . . . 0.0 110.98 168.614 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 68.6 p -88.45 -6.13 57.83 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 124.845 1.258 . . . . 0.0 114.116 -178.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 25.8 m -60.29 140.31 57.15 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 125.371 1.468 . . . . 0.0 112.775 -178.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 68.15 59.45 6.35 Favored Glycine 0 CA--C 1.542 1.777 0 CA-C-O 118.739 -1.034 . . . . 0.0 113.602 -174.266 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo -63.33 155.43 62.03 Favored 'Trans proline' 0 CA--C 1.539 0.76 0 C-N-CA 123.61 2.874 . . . . 0.0 112.62 178.638 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 71.1 mt -95.76 131.07 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 C-N-CA 125.346 1.458 . . . . 0.0 110.742 -175.429 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 67.6 p -97.75 -10.38 24.97 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 124.894 1.277 . . . . 0.0 113.966 174.884 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -94.25 -20.29 19.95 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 114.477 1.288 . . . . 0.0 114.477 -169.745 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 32.8 ttp-105 -140.1 143.07 36.07 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 124.781 1.232 . . . . 0.0 112.832 -169.783 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 15.9 p-10 -65.14 -8.14 15.59 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 125.565 1.546 . . . . 0.0 114.997 -179.515 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 65.0 tt0 -57.26 -29.56 63.93 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.264 1.025 . . . . 0.0 111.932 169.534 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -79.99 -26.95 39.71 Favored 'General case' 0 CA--C 1.543 0.706 0 O-C-N 121.358 -0.839 . . . . 0.0 112.91 174.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -78.09 -5.79 52.63 Favored 'General case' 0 CA--C 1.545 0.768 0 C-N-CA 124.596 1.159 . . . . 0.0 112.627 169.887 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 26.4 m -102.64 134.58 45.77 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 125.036 1.335 . . . . 0.0 110.18 177.009 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 18.1 m -100.73 147.79 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.64 0 C-N-CA 124.361 1.064 . . . . 0.0 110.368 170.729 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 51.8 t80 -95.49 141.3 29.18 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 126.419 1.888 . . . . 0.0 109.676 169.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 23.1 t -132.01 107.07 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 C-N-CA 125.521 1.529 . . . . 0.0 109.123 176.147 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -103.26 147.17 16.74 Favored Glycine 0 CA--C 1.53 0.974 0 C-N-CA 124.58 1.086 . . . . 0.0 112.813 177.174 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 92.76 36.93 5.92 Favored Glycine 0 N--CA 1.472 1.071 0 C-N-CA 124.13 0.871 . . . . 0.0 113.64 173.637 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 83.7 mt -75.06 150.28 38.92 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 125.44 1.496 . . . . 0.0 111.424 -175.09 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -88.84 156.27 19.04 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 123.786 0.834 . . . . 0.0 111.783 174.126 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.28 -20.28 41.4 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 114.774 1.398 . . . . 0.0 114.774 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.5 mtmm -82.02 -11.27 58.91 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 124.758 1.223 . . . . 0.0 114.135 175.028 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 62.4 t -74.0 141.03 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.926 0 C-N-CA 124.337 1.055 . . . . 0.0 111.265 176.711 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 9.4 t -144.11 167.2 22.97 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 124.358 1.063 . . . . 0.0 111.612 170.42 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -56.17 -43.28 99.19 Favored Pre-proline 0 CA--C 1.549 0.918 0 O-C-N 120.996 -1.065 . . . . 0.0 113.816 -177.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -62.52 -29.42 78.54 Favored 'Trans proline' 0 C--N 1.354 0.828 0 C-N-CA 122.311 2.008 . . . . 0.0 113.719 174.387 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 18.5 tp -67.08 -53.69 28.58 Favored 'General case' 0 C--N 1.344 0.355 0 CA-C-N 118.574 0.625 . . . . 0.0 109.54 173.264 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 22.6 mt -55.37 -42.14 73.53 Favored 'General case' 0 C--O 1.224 -0.277 0 O-C-N 123.216 0.322 . . . . 0.0 111.38 -178.303 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.9 t90 -58.35 -62.56 1.75 Allowed 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.089 0.555 . . . . 0.0 111.397 178.346 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -65.34 -29.41 70.14 Favored 'General case' 0 CA--C 1.539 0.557 0 N-CA-C 113.851 1.056 . . . . 0.0 113.851 -176.75 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.2 tp -71.76 -36.85 70.52 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.023 0.929 . . . . 0.0 111.762 175.458 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -87.0 -10.38 53.29 Favored 'General case' 0 N--CA 1.469 0.516 0 C-N-CA 124.731 1.212 . . . . 0.0 113.679 -176.18 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 25.5 mt -54.13 -20.57 6.88 Favored 'General case' 0 CA--C 1.547 0.851 0 N-CA-C 113.941 1.089 . . . . 0.0 113.941 168.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 43.2 mt-30 -63.35 -33.75 76.22 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 125.072 1.349 . . . . 0.0 112.682 173.416 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -77.32 -46.78 21.83 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 123.511 0.724 . . . . 0.0 112.443 178.487 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -179.93 -172.66 44.17 Favored Glycine 0 CA--C 1.535 1.337 0 C-N-CA 124.926 1.251 . . . . 0.0 112.675 -179.157 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -67.58 110.79 2.17 Favored 'Trans proline' 0 CA--C 1.538 0.678 0 C-N-CA 123.584 2.856 . . . . 0.0 111.526 -179.203 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 66.1 t -85.79 133.38 29.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.805 1.242 . . . . 0.0 109.975 174.846 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.1 t -109.78 -33.6 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 C-N-CA 126.43 1.892 . . . . 0.0 111.899 -171.573 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 17.8 t30 -160.6 162.4 32.8 Favored 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 126.005 1.722 . . . . 0.0 111.056 -174.332 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 7.2 p -140.75 153.24 45.8 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 126.453 1.901 . . . . 0.0 111.33 174.736 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 49.2 t-80 -142.39 131.14 22.76 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 123.261 0.624 . . . . 0.0 111.355 174.629 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 81.5 mtp -132.45 106.35 13.22 Favored Pre-proline 0 N--CA 1.471 0.583 0 C-N-CA 124.041 0.936 . . . . 0.0 109.614 169.67 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_exo -56.99 143.05 93.72 Favored 'Trans proline' 0 CA--C 1.537 0.632 0 C-N-CA 123.233 2.622 . . . . 0.0 112.837 176.464 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 45.4 mmtm -108.8 153.87 22.88 Favored 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 124.78 1.232 . . . . 0.0 113.421 -172.478 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -79.41 144.35 34.19 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 126.944 2.098 . . . . 0.0 112.436 178.356 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 53.6 ptt85 -87.23 8.2 25.1 Favored 'General case' 0 N--CA 1.479 1.015 0 N-CA-C 115.722 1.749 . . . . 0.0 115.722 -174.624 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 32.2 t -132.06 -37.94 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 124.767 1.227 . . . . 0.0 111.391 -173.543 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 61.0 p -116.67 -18.3 10.33 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 125.62 1.568 . . . . 0.0 112.647 -175.669 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.71 8.74 64.17 Favored Glycine 0 CA--C 1.54 1.633 0 C-N-CA 124.864 1.221 . . . . 0.0 114.999 -177.44 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 39.4 mt-30 -67.01 171.29 5.64 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.118 1.367 . . . . 0.0 110.801 170.014 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 26.8 p80 -73.94 157.76 35.65 Favored 'General case' 0 N--CA 1.473 0.717 0 O-C-N 120.351 -1.468 . . . . 0.0 112.202 169.859 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 81.8 mt-30 -79.05 12.53 2.18 Favored 'General case' 0 CA--C 1.552 1.029 0 N-CA-C 114.488 1.292 . . . . 0.0 114.488 -177.65 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 87.87 1.52 82.41 Favored Glycine 0 CA--C 1.535 1.303 0 C-N-CA 124.987 1.28 . . . . 0.0 114.89 -177.084 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -144.65 160.72 40.71 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.952 1.301 . . . . 0.0 112.323 178.177 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -151.29 -178.24 25.89 Favored Glycine 0 CA--C 1.529 0.951 0 C-N-CA 125.955 1.74 . . . . 0.0 113.377 -178.231 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -143.29 149.45 37.86 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 126.141 1.776 . . . . 0.0 111.631 -178.329 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 26.1 t -132.93 128.56 56.86 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 124.593 1.157 . . . . 0.0 109.612 174.986 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -104.45 122.43 45.51 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 124.507 1.123 . . . . 0.0 110.977 -178.223 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -96.26 163.81 12.93 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 125.066 1.347 . . . . 0.0 112.176 176.229 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.5 tp -63.38 -33.47 75.6 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 112.276 0.473 . . . . 0.0 112.276 175.005 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 8.8 m -142.48 158.03 44.12 Favored 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 122.843 1.306 . . . . 0.0 112.655 -176.727 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 53.5 mp0 -67.99 -29.67 68.75 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 125.735 1.614 . . . . 0.0 113.505 -174.123 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -74.35 -26.95 60.45 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 124.001 0.92 . . . . 0.0 112.811 175.469 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 47.9 m-20 -73.47 -34.0 65.13 Favored 'General case' 0 CA--C 1.538 0.498 0 O-C-N 121.49 -0.757 . . . . 0.0 111.003 172.001 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -66.87 -47.65 71.2 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 123.022 0.529 . . . . 0.0 111.205 170.411 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -56.31 -35.87 68.03 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.877 0.871 . . . . 0.0 112.899 176.135 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 60.8 t80 -75.69 -36.79 59.94 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.413 0.685 . . . . 0.0 112.829 176.5 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -61.81 -38.81 89.5 Favored 'General case' 0 CA--C 1.539 0.538 0 O-C-N 121.056 -1.027 . . . . 0.0 111.549 177.3 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 57.4 mt -61.85 -37.93 79.36 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 C-N-CA 124.92 1.288 . . . . 0.0 111.042 175.018 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 61.4 tttp -65.45 -35.5 81.09 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 124.312 1.045 . . . . 0.0 113.144 177.315 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 19.7 pt -102.1 -14.18 8.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 N-CA-C 115.908 1.818 . . . . 0.0 115.908 -172.762 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 6.0 mmt -113.13 -4.08 13.85 Favored 'General case' 0 N--CA 1.485 1.286 0 N-CA-C 115.518 1.673 . . . . 0.0 115.518 -176.013 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -80.9 145.75 31.16 Favored 'General case' 0 N--CA 1.477 0.904 0 O-C-N 120.818 -1.176 . . . . 0.0 113.699 -174.47 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 25.5 mmt 58.26 9.58 1.05 Allowed 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 127.938 2.495 . . . . 0.0 115.832 -175.114 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 17.8 mt -83.2 148.16 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 C-N-CA 126.964 2.106 . . . . 0.0 111.983 -176.294 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 42.3 mtpt -99.93 69.77 1.57 Allowed 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.369 1.068 . . . . 0.0 112.448 -169.492 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 35.7 tp -57.42 123.39 15.31 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 123.64 0.776 . . . . 0.0 109.427 173.66 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 45.97 27.18 0.47 Allowed 'General case' 0 CA--C 1.562 1.419 0 N-CA-C 116.473 2.027 . . . . 0.0 116.473 -168.817 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 84.97 18.12 61.83 Favored Glycine 0 CA--C 1.544 1.871 0 O-C-N 120.222 -1.549 . . . . 0.0 116.743 176.737 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -131.52 122.11 18.67 Favored Pre-proline 0 CA--C 1.545 0.778 0 C-N-CA 128.34 2.656 . . . . 0.0 107.991 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -72.51 110.06 2.9 Favored 'Trans proline' 0 CA--C 1.538 0.681 0 C-N-CA 123.212 2.608 . . . . 0.0 112.614 -169.543 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 19.1 pt -78.72 141.29 15.63 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 C-N-CA 124.079 0.952 . . . . 0.0 111.085 174.47 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 4.8 mpt_? -108.97 128.57 55.06 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 125.712 1.605 . . . . 0.0 108.809 175.07 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 19.3 t -125.5 137.34 57.99 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 124.419 1.088 . . . . 0.0 110.979 -171.663 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 -163.14 177.85 8.75 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 125.18 1.392 . . . . 0.0 110.97 -177.472 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 26.3 mmmt -69.4 140.92 54.2 Favored 'General case' 0 N--CA 1.475 0.817 0 O-C-N 120.826 -1.171 . . . . 0.0 110.138 175.011 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -72.7 -11.1 60.49 Favored 'General case' 0 CA--C 1.551 1.005 0 O-C-N 121.41 -0.806 . . . . 0.0 112.472 169.902 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 70.7 p -87.9 -1.87 58.25 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 126.857 2.063 . . . . 0.0 114.436 170.351 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -64.97 149.73 49.25 Favored 'General case' 0 CA--C 1.547 0.833 0 CA-C-N 119.171 0.896 . . . . 0.0 113.07 -177.714 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 25.0 p80 -150.94 176.15 11.38 Favored 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 125.126 1.371 . . . . 0.0 112.649 -170.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -136.83 36.91 2.62 Favored 'General case' 0 CA--C 1.549 0.918 0 C-N-CA 124.011 0.925 . . . . 0.0 110.675 168.144 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -92.69 -41.88 9.92 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 125.14 1.376 . . . . 0.0 112.626 -174.248 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 -112.52 141.79 45.85 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.029 1.332 . . . . 0.0 111.258 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 59.9 tp -152.72 -45.94 0.1 Allowed 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 124.979 1.312 . . . . 0.0 112.263 177.615 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 23.9 m -70.37 159.27 34.45 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.985 1.314 . . . . 0.0 113.275 179.83 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -160.5 174.15 37.16 Favored Glycine 0 CA--C 1.541 1.675 0 C-N-CA 124.812 1.196 . . . . 0.0 113.684 177.881 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -73.56 161.41 42.27 Favored 'Trans proline' 0 CA--C 1.541 0.84 0 C-N-CA 124.116 3.21 . . . . 0.0 113.438 -176.797 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 6.8 t 62.0 169.4 0.12 Allowed 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 126.945 2.098 . . . . 0.0 115.457 -178.117 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 79.8 p -129.23 -0.14 5.14 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 126.823 2.049 . . . . 0.0 113.746 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.264 0 C-N-CA 125.612 1.577 . . . . 0.0 113.806 178.64 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.66 0 N-CA-C 112.101 -0.4 . . . . 0.0 112.101 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 35.8 t -138.36 148.28 44.37 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.328 1.451 . . . . 0.0 112.024 -179.424 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 41.2 m -125.89 45.25 2.66 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 126.161 1.784 . . . . 0.0 109.217 169.871 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 73.04 35.51 57.65 Favored Glycine 0 CA--C 1.533 1.21 0 N-CA-C 110.814 -0.915 . . . . 0.0 110.814 -167.384 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.1 p -120.21 -33.1 3.99 Favored 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 125.981 1.713 . . . . 0.0 112.888 -172.036 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 48.2 m -79.3 -9.12 59.51 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 123.948 0.899 . . . . 0.0 113.096 169.141 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.82 166.39 33.78 Favored Glycine 0 CA--C 1.541 1.672 0 C-N-CA 125.513 1.53 . . . . 0.0 112.847 173.385 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -88.26 174.0 4.55 Favored 'Trans proline' 0 CA--C 1.54 0.783 0 C-N-CA 124.429 3.419 . . . . 0.0 114.345 -169.703 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 7.0 tp -88.15 154.95 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 C-N-CA 124.724 1.21 . . . . 0.0 110.776 168.307 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 16.4 m -72.65 -7.79 52.06 Favored 'General case' 0 N--CA 1.477 0.919 0 N-CA-C 114.216 1.191 . . . . 0.0 114.216 174.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -79.57 79.83 6.01 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.625 1.57 . . . . 0.0 111.555 -177.505 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 38.8 ttm180 48.64 -94.55 0.03 OUTLIER 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 127.411 2.284 . . . . 0.0 113.769 175.023 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -136.16 27.6 3.18 Favored 'General case' 0 CA--C 1.549 0.916 0 C-N-CA 126.205 1.802 . . . . 0.0 112.311 179.444 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -62.97 -17.24 61.82 Favored 'General case' 0 N--CA 1.478 0.941 0 O-C-N 120.635 -1.29 . . . . 0.0 113.545 -175.658 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -55.96 -27.14 51.21 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 124.893 1.277 . . . . 0.0 112.82 168.402 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -79.58 -3.74 48.37 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 113.654 0.983 . . . . 0.0 113.654 177.696 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.2 m -103.39 133.48 48.37 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 124.175 0.99 . . . . 0.0 109.903 173.069 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 13.9 m -104.76 148.38 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 C-N-CA 124.69 1.196 . . . . 0.0 110.697 172.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 34.9 t80 -95.82 143.08 27.35 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 126.642 1.977 . . . . 0.0 109.81 169.769 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.7 t -131.43 111.71 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 125.523 1.529 . . . . 0.0 109.222 173.378 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -106.29 149.33 16.63 Favored Glycine 0 CA--C 1.528 0.902 0 C-N-CA 124.623 1.106 . . . . 0.0 112.649 176.834 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.24 35.46 7.03 Favored Glycine 0 CA--C 1.532 1.112 0 C-N-CA 124.192 0.901 . . . . 0.0 113.644 174.423 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 85.9 mt -74.87 150.15 39.29 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 125.505 1.522 . . . . 0.0 111.273 -174.89 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -88.89 156.81 18.69 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 123.739 0.816 . . . . 0.0 111.802 174.588 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.74 -20.38 48.63 Favored 'General case' 0 CA--C 1.546 0.827 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.5 mtmm -81.73 -11.89 58.84 Favored 'General case' 0 N--CA 1.476 0.832 0 C-N-CA 124.717 1.207 . . . . 0.0 114.172 174.882 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 88.2 t -72.17 137.2 24.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 124.191 0.996 . . . . 0.0 111.113 177.004 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 57.0 m -134.36 163.77 28.92 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 124.811 1.244 . . . . 0.0 111.501 172.218 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -56.0 -42.78 97.9 Favored Pre-proline 0 CA--C 1.549 0.909 0 O-C-N 120.888 -1.132 . . . . 0.0 113.846 179.306 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_exo -60.59 -28.82 87.3 Favored 'Trans proline' 0 C--N 1.354 0.825 0 C-N-CA 122.252 1.968 . . . . 0.0 114.046 173.751 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 26.2 tp -68.21 -50.93 50.9 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 118.82 0.737 . . . . 0.0 110.135 172.502 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 20.5 mt -62.04 -22.12 65.47 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 178.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.5 t90 -74.27 -66.8 0.68 Allowed 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 123.255 0.622 . . . . 0.0 110.949 170.006 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.8 mt-10 -65.37 -29.95 70.73 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 114.386 1.254 . . . . 0.0 114.386 -171.91 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.7 tp -69.04 -35.22 76.35 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.535 0.734 . . . . 0.0 111.579 175.117 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -89.34 -10.85 45.13 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.123 1.369 . . . . 0.0 113.444 -174.208 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 44.5 mt -54.86 -19.8 7.34 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 124.529 1.132 . . . . 0.0 113.874 169.393 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 40.5 mt-30 -66.4 -31.54 72.36 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 125.413 1.485 . . . . 0.0 112.638 173.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -77.08 -46.55 23.24 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.23 0.612 . . . . 0.0 112.182 176.504 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.45 -173.68 45.55 Favored Glycine 0 CA--C 1.537 1.416 0 C-N-CA 125.399 1.476 . . . . 0.0 112.492 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -66.76 112.62 2.49 Favored 'Trans proline' 0 CA--C 1.538 0.68 0 C-N-CA 123.579 2.852 . . . . 0.0 111.766 -179.302 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 75.6 t -87.14 134.46 27.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 125.006 1.322 . . . . 0.0 109.794 174.602 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.9 t -109.14 -33.8 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 126.527 1.931 . . . . 0.0 111.847 -171.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 21.3 t30 -160.84 163.24 32.23 Favored 'General case' 0 CA--C 1.554 1.107 0 C-N-CA 125.851 1.66 . . . . 0.0 111.05 -175.08 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 4.0 p -140.06 154.54 47.1 Favored 'General case' 0 N--CA 1.481 1.079 0 C-N-CA 126.429 1.892 . . . . 0.0 111.295 174.173 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 47.9 t-80 -142.18 132.0 24.28 Favored 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 123.445 0.698 . . . . 0.0 111.142 175.531 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 87.6 mtp -133.28 106.61 12.22 Favored Pre-proline 0 N--CA 1.472 0.671 0 C-N-CA 123.876 0.871 . . . . 0.0 109.649 169.569 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_exo -57.8 140.28 93.15 Favored 'Trans proline' 0 CA--C 1.538 0.689 0 C-N-CA 123.283 2.655 . . . . 0.0 113.101 177.535 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -112.86 146.18 39.36 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 125.209 1.404 . . . . 0.0 112.822 -173.371 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -66.66 139.12 57.84 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 125.479 1.512 . . . . 0.0 111.618 170.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 34.0 ptt-85 -82.74 5.56 20.98 Favored 'General case' 0 N--CA 1.48 1.034 0 N-CA-C 115.908 1.818 . . . . 0.0 115.908 -173.831 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 23.3 t -131.4 -38.79 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 C-N-CA 125.558 1.543 . . . . 0.0 111.277 -173.894 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 33.7 p -106.24 -16.79 14.49 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 124.771 1.228 . . . . 0.0 112.321 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 71.39 3.52 53.78 Favored Glycine 0 CA--C 1.537 1.448 0 C-N-CA 124.811 1.196 . . . . 0.0 115.221 177.753 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 71.9 mm-40 -80.08 162.65 24.68 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.703 1.201 . . . . 0.0 110.947 178.253 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 18.0 p80 -68.91 153.21 44.2 Favored 'General case' 0 N--CA 1.471 0.602 0 O-C-N 120.986 -1.071 . . . . 0.0 112.621 177.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 45.9 mt-30 -85.06 17.04 3.11 Favored 'General case' 0 CA--C 1.549 0.92 0 N-CA-C 114.251 1.204 . . . . 0.0 114.251 -173.638 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 87.52 1.5 83.35 Favored Glycine 0 CA--C 1.535 1.333 0 C-N-CA 125.06 1.314 . . . . 0.0 114.97 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -145.13 161.66 38.93 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 124.899 1.279 . . . . 0.0 112.603 178.19 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -153.54 -177.36 26.96 Favored Glycine 0 CA--C 1.531 1.039 0 C-N-CA 125.963 1.744 . . . . 0.0 113.065 -177.417 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 80.8 m-85 -144.22 150.79 38.52 Favored 'General case' 0 C--O 1.237 0.438 0 C-N-CA 126.048 1.739 . . . . 0.0 111.574 -178.116 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 20.1 t -132.51 130.11 59.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 124.889 1.276 . . . . 0.0 109.642 176.085 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 63.2 tt0 -106.72 119.67 39.94 Favored 'General case' 0 N--CA 1.465 0.324 0 C-N-CA 124.814 1.246 . . . . 0.0 110.582 -176.858 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -96.17 162.58 13.47 Favored 'General case' 0 C--O 1.234 0.272 0 C-N-CA 124.959 1.304 . . . . 0.0 112.441 177.353 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.5 tp -64.13 -34.81 78.91 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 123.052 0.541 . . . . 0.0 112.298 176.636 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.7 m -141.76 157.89 44.48 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-O 122.601 1.191 . . . . 0.0 112.324 -177.23 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 60.3 mp0 -65.18 -35.75 82.07 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 125.117 1.367 . . . . 0.0 112.871 -175.313 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -67.89 -25.77 65.67 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 113.218 0.822 . . . . 0.0 113.218 177.035 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 55.2 m-20 -76.02 -33.9 59.66 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 123.781 0.832 . . . . 0.0 111.357 173.572 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -70.83 -45.85 63.8 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.841 0.857 . . . . 0.0 111.386 173.213 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -55.91 -34.83 65.94 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 124.134 0.974 . . . . 0.0 112.31 174.793 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 60.3 t80 -78.09 -36.44 48.17 Favored 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 123.756 0.823 . . . . 0.0 112.902 177.117 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.11 -36.58 82.16 Favored 'General case' 0 CA--C 1.539 0.554 0 O-C-N 120.921 -1.112 . . . . 0.0 111.485 176.829 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 57.9 mt -63.23 -34.23 65.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 124.732 1.213 . . . . 0.0 111.31 174.022 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 62.1 tttp -70.03 -36.59 75.17 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.354 1.061 . . . . 0.0 113.023 176.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 14.1 pt -101.58 -13.97 8.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 N-CA-C 116.135 1.902 . . . . 0.0 116.135 -171.789 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 13.5 mmt -113.12 -2.28 14.19 Favored 'General case' 0 N--CA 1.484 1.25 0 N-CA-C 115.247 1.573 . . . . 0.0 115.247 -176.228 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -82.53 140.89 33.05 Favored 'General case' 0 N--CA 1.476 0.844 0 O-C-N 120.868 -1.145 . . . . 0.0 114.037 -174.353 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . 0.253 7.9 mmt 56.33 22.26 6.16 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 127.537 2.335 . . . . 0.0 115.201 -177.44 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 20.9 mt -90.0 149.32 4.08 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 127.786 2.435 . . . . 0.0 111.257 177.152 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 42.9 mtpt -100.61 70.54 1.45 Allowed 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 124.188 0.995 . . . . 0.0 112.498 -169.848 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 31.3 tp -57.43 123.55 15.87 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.723 0.809 . . . . 0.0 109.709 174.259 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 59.0 m-85 45.85 27.44 0.47 Allowed 'General case' 0 CA--C 1.561 1.387 0 N-CA-C 116.487 2.032 . . . . 0.0 116.487 -168.847 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 83.58 21.5 57.97 Favored Glycine 0 CA--C 1.544 1.858 0 O-C-N 120.068 -1.645 . . . . 0.0 116.522 177.038 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -135.02 121.71 14.77 Favored Pre-proline 0 CA--C 1.544 0.731 0 C-N-CA 128.546 2.738 . . . . 0.0 107.803 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -72.2 119.57 6.24 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 123.055 2.504 . . . . 0.0 112.207 -169.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 18.4 pt -88.33 141.41 14.34 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 C-N-CA 124.341 1.056 . . . . 0.0 111.696 176.199 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 36.6 tpt85 -104.32 127.79 52.02 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 125.828 1.651 . . . . 0.0 108.948 173.441 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.8 t -122.55 136.33 59.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 123.818 0.847 . . . . 0.0 110.697 -175.495 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -160.44 -178.53 6.98 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 123.987 0.915 . . . . 0.0 112.122 177.854 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 7.8 mmmm -63.62 141.88 58.6 Favored 'General case' 0 N--CA 1.477 0.903 0 O-C-N 121.186 -0.946 . . . . 0.0 110.37 172.9 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -66.13 -30.7 71.24 Favored 'General case' 0 CA--C 1.545 0.755 0 O-C-N 121.807 -0.558 . . . . 0.0 111.947 172.698 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 38.2 m -119.3 83.16 1.99 Allowed 'General case' 0 N--CA 1.469 0.505 0 C-N-CA 126.07 1.748 . . . . 0.0 109.392 168.866 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -78.38 46.13 0.61 Allowed 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 125.172 1.389 . . . . 0.0 113.321 -177.227 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 11.7 m-70 -123.62 146.32 48.27 Favored 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 126.859 2.063 . . . . 0.0 111.444 -175.864 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 35.8 t30 -116.87 119.49 35.53 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 124.865 1.266 . . . . 0.0 110.322 173.884 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 12.5 mptt -110.03 9.94 24.17 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 126.205 1.802 . . . . 0.0 113.486 178.291 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 47.6 t30 -66.82 154.64 40.36 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 124.142 0.977 . . . . 0.0 111.642 172.052 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 83.9 mt -79.9 154.48 28.31 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 124.655 1.182 . . . . 0.0 112.908 -176.405 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 11.8 t -151.79 159.0 44.06 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 125.554 1.542 . . . . 0.0 111.484 175.778 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 65.74 73.68 0.58 Allowed Glycine 0 CA--C 1.541 1.688 0 C-N-CA 125.533 1.539 . . . . 0.0 114.322 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_exo -61.17 153.07 67.46 Favored 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 123.697 2.931 . . . . 0.0 114.242 -179.452 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 10.6 t -76.0 154.58 35.67 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 124.132 0.973 . . . . 0.0 112.249 175.025 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.5 t -150.09 157.94 43.65 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 125.372 1.469 . . . . 0.0 111.861 178.823 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.33 0 C-N-CA 125.738 1.637 . . . . 0.0 113.734 -179.145 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.428 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.0 t -139.67 172.33 12.95 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 125.344 1.458 . . . . 0.0 111.343 178.407 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 40.4 m 52.26 34.01 13.79 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.443 1.497 . . . . 0.0 113.987 -176.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 81.0 1.55 90.0 Favored Glycine 0 CA--C 1.538 1.524 0 C-N-CA 125.168 1.366 . . . . 0.0 115.707 -177.619 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 36.3 t -75.99 134.35 40.18 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 119.349 1.574 . . . . 0.0 112.386 177.781 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.0 p -81.96 -7.0 59.58 Favored 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 125.344 1.458 . . . . 0.0 113.827 173.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -68.73 153.44 52.93 Favored Glycine 0 CA--C 1.543 1.783 0 C-N-CA 124.171 0.891 . . . . 0.0 114.291 -177.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -79.12 170.87 17.12 Favored 'Trans proline' 0 CA--C 1.542 0.908 0 C-N-CA 124.128 3.219 . . . . 0.0 112.972 177.535 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 20.6 tt -139.29 146.39 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 C-N-CA 125.533 1.533 . . . . 0.0 110.607 169.888 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.0 m -77.93 -13.95 59.71 Favored 'General case' 0 N--CA 1.474 0.743 0 N-CA-C 114.221 1.193 . . . . 0.0 114.221 -177.277 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 58.63 -28.93 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.35 0 C-N-CA 128.798 2.839 . . . . 0.0 117.884 -177.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -61.03 139.95 57.95 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 125.402 1.481 . . . . 0.0 114.265 -173.22 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . 0.26 0.7 OUTLIER 46.1 27.88 0.58 Allowed 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 127.803 2.441 . . . . 0.0 116.821 174.347 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.5 tp-100 -67.74 -19.25 65.11 Favored 'General case' 0 CA--C 1.544 0.746 0 O-C-N 120.81 -1.181 . . . . 0.0 113.512 -172.259 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 18.5 m-20 -67.32 -23.05 65.6 Favored 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 124.342 1.057 . . . . 0.0 113.117 169.912 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.43 1.51 51.06 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 124.874 1.269 . . . . 0.0 113.03 171.345 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 17.5 m -100.63 137.0 39.61 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 124.427 1.091 . . . . 0.0 109.258 169.661 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.9 m -106.2 145.83 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.556 1.142 . . . . 0.0 110.349 172.229 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -95.81 142.7 27.77 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 126.083 1.753 . . . . 0.0 109.527 169.575 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 24.2 t -130.02 115.91 35.07 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 C-N-CA 125.553 1.541 . . . . 0.0 109.094 174.274 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -109.56 150.28 17.3 Favored Glycine 0 CA--C 1.531 1.037 0 C-N-CA 124.511 1.053 . . . . 0.0 113.045 176.557 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 93.04 32.99 7.54 Favored Glycine 0 CA--C 1.533 1.177 0 C-N-CA 124.782 1.182 . . . . 0.0 114.01 175.488 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 87.0 mt -78.72 153.26 31.03 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 125.219 1.408 . . . . 0.0 112.029 -170.787 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -90.97 155.66 18.55 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 124.151 0.98 . . . . 0.0 111.997 176.453 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.51 -20.23 44.17 Favored 'General case' 0 CA--C 1.547 0.832 0 N-CA-C 114.988 1.477 . . . . 0.0 114.988 -179.112 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.4 mtmm -81.6 -9.04 59.77 Favored 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 124.763 1.225 . . . . 0.0 114.119 175.194 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.3 t -78.99 138.65 19.7 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 124.857 1.263 . . . . 0.0 111.275 178.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 6.7 t -147.05 167.75 23.29 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 123.601 0.76 . . . . 0.0 112.43 171.058 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -48.81 -45.56 72.32 Favored Pre-proline 0 CA--C 1.545 0.751 0 N-CA-C 115.923 1.823 . . . . 0.0 115.923 178.753 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -69.55 -26.64 28.36 Favored 'Trans proline' 0 C--N 1.354 0.831 0 CA-C-N 122.021 1.757 . . . . 0.0 112.978 177.556 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 18.3 tp -66.46 -53.86 30.62 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 118.589 0.631 . . . . 0.0 109.486 170.001 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 25.9 mt -55.42 -42.12 73.7 Favored 'General case' 0 N--CA 1.464 0.257 0 C-N-CA 122.769 0.428 . . . . 0.0 111.601 -176.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.8 t90 -57.96 -61.81 2.27 Favored 'General case' 0 C--N 1.331 -0.236 0 C-N-CA 123.236 0.614 . . . . 0.0 111.109 179.328 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -64.41 -30.19 71.23 Favored 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 113.699 1.0 . . . . 0.0 113.699 -178.487 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 7.4 tp -70.73 -35.91 72.93 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 123.95 0.9 . . . . 0.0 111.879 176.037 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 14.8 m-85 -89.2 -10.64 46.3 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 124.816 1.247 . . . . 0.0 113.596 -175.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 27.8 mt -54.38 -20.73 7.91 Favored 'General case' 0 CA--C 1.547 0.844 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 168.66 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -61.85 -34.14 75.44 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 125.055 1.342 . . . . 0.0 112.566 173.408 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -78.9 -45.6 20.23 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 123.559 0.744 . . . . 0.0 112.666 178.717 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 178.48 -172.46 44.85 Favored Glycine 0 CA--C 1.536 1.403 0 C-N-CA 124.815 1.197 . . . . 0.0 112.813 -178.377 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -67.81 110.22 2.08 Favored 'Trans proline' 0 CA--C 1.538 0.68 0 C-N-CA 123.663 2.908 . . . . 0.0 111.783 -178.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 63.9 t -85.18 134.3 27.39 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 C-N-CA 124.916 1.287 . . . . 0.0 109.825 174.07 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 5.7 t -108.69 -34.31 2.63 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 126.235 1.814 . . . . 0.0 111.805 -172.611 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 21.3 t30 -160.79 160.82 31.69 Favored 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 125.995 1.718 . . . . 0.0 110.863 -174.343 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 12.2 p -137.31 156.42 48.27 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 125.9 1.68 . . . . 0.0 111.535 172.644 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 47.3 t-80 -142.11 134.25 27.58 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 123.461 0.704 . . . . 0.0 111.442 175.493 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 29.5 mmm -133.41 105.56 12.1 Favored Pre-proline 0 N--CA 1.471 0.604 0 C-N-CA 124.57 1.148 . . . . 0.0 109.336 172.293 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_exo -59.24 134.95 62.43 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 123.177 2.585 . . . . 0.0 112.523 176.259 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 41.4 mmtm -109.9 148.63 31.22 Favored 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 125.225 1.41 . . . . 0.0 112.65 -173.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -66.93 148.61 51.72 Favored 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 125.231 1.412 . . . . 0.0 112.395 170.15 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 17.6 ptp180 -87.12 -1.35 57.82 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 116.645 2.091 . . . . 0.0 116.645 -172.568 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 3.5 m -135.54 -31.53 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 C-N-CA 124.619 1.168 . . . . 0.0 113.355 -178.697 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 69.2 p -103.9 -18.41 14.63 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 124.995 1.318 . . . . 0.0 111.898 179.336 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 71.43 -0.54 32.9 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 125.381 1.467 . . . . 0.0 116.243 170.911 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -79.33 164.16 24.3 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 125.305 1.442 . . . . 0.0 111.412 173.763 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 24.4 p80 -69.69 157.03 38.05 Favored 'General case' 0 N--CA 1.471 0.607 0 O-C-N 121.216 -0.928 . . . . 0.0 113.199 -178.402 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 45.2 mt-30 -85.71 16.8 3.7 Favored 'General case' 0 CA--C 1.551 1.007 0 N-CA-C 114.518 1.303 . . . . 0.0 114.518 -173.888 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 89.49 0.24 79.69 Favored Glycine 0 CA--C 1.536 1.352 0 C-N-CA 125.395 1.474 . . . . 0.0 115.112 179.536 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -145.63 156.72 43.84 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 125.411 1.484 . . . . 0.0 112.235 179.126 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -145.87 178.18 23.76 Favored Glycine 0 CA--C 1.532 1.124 0 C-N-CA 126.437 1.97 . . . . 0.0 112.92 -175.431 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 76.0 m-85 -141.85 150.27 41.38 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 125.537 1.535 . . . . 0.0 112.251 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 22.6 t -134.32 130.64 54.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 C-N-CA 125.043 1.337 . . . . 0.0 109.977 175.704 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -107.96 122.67 47.31 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 124.917 1.287 . . . . 0.0 111.073 -176.67 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -99.05 161.07 13.82 Favored 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 125.29 1.436 . . . . 0.0 112.581 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 14.4 tp -62.84 -34.44 77.34 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 123.305 0.642 . . . . 0.0 112.206 178.395 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.7 m -141.07 154.94 46.19 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 124.453 1.101 . . . . 0.0 111.831 -178.185 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 12.5 tm-20 -64.42 -31.96 73.38 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 124.479 1.111 . . . . 0.0 113.221 -177.703 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -69.42 -26.26 64.53 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 113.154 0.798 . . . . 0.0 113.154 176.046 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 41.6 m-20 -77.26 -33.22 55.98 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 123.707 0.803 . . . . 0.0 111.412 173.405 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.7 -43.67 71.96 Favored 'General case' 0 CA--C 1.539 0.545 0 O-C-N 121.832 -0.543 . . . . 0.0 111.355 172.868 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -61.58 -28.76 69.57 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 124.088 0.955 . . . . 0.0 112.853 178.082 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 61.6 t80 -79.88 -34.21 39.34 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.172 0.989 . . . . 0.0 112.9 173.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.57 -37.15 86.56 Favored 'General case' 0 CA--C 1.537 0.457 0 O-C-N 121.119 -0.988 . . . . 0.0 111.091 176.584 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 65.2 mt -61.31 -39.85 84.09 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 C-N-CA 125.159 1.384 . . . . 0.0 111.224 172.707 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 62.4 tttp -62.88 -38.16 89.79 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 124.051 0.94 . . . . 0.0 112.618 178.184 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 44.9 pt -96.07 -29.5 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 115.334 1.605 . . . . 0.0 115.334 -175.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' MET . . . . . 0.481 ' HA ' HD12 ' A' ' 80' ' ' ILE . 5.7 mmt -98.07 -0.75 43.93 Favored 'General case' 0 N--CA 1.482 1.156 0 N-CA-C 115.194 1.553 . . . . 0.0 115.194 -173.24 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -83.9 140.29 32.06 Favored 'General case' 0 CA--C 1.539 0.546 0 O-C-N 121.066 -1.021 . . . . 0.0 111.7 178.396 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 28.1 ttm 60.05 13.41 3.75 Favored 'General case' 0 CA--C 1.552 1.021 0 C-N-CA 125.448 1.499 . . . . 0.0 114.84 -173.316 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.481 HD12 ' HA ' ' A' ' 77' ' ' MET . 1.5 mt -71.04 159.38 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 C-N-CA 125.659 1.583 . . . . 0.0 110.46 169.014 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 50.8 mtpt -119.9 69.52 0.85 Allowed 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 125.69 1.596 . . . . 0.0 112.214 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 40.2 tp -57.49 127.17 30.66 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 124.113 0.965 . . . . 0.0 109.949 174.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 64.1 m-85 46.17 27.37 0.54 Allowed 'General case' 0 CA--C 1.561 1.384 0 N-CA-C 116.325 1.972 . . . . 0.0 116.325 -168.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 78.99 23.56 63.57 Favored Glycine 0 CA--C 1.542 1.745 0 O-C-N 120.096 -1.627 . . . . 0.0 116.053 176.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -131.12 120.01 18.04 Favored Pre-proline 0 CA--C 1.542 0.654 0 C-N-CA 128.154 2.581 . . . . 0.0 107.915 179.455 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -69.78 130.33 19.13 Favored 'Trans proline' 0 CA--C 1.536 0.602 0 C-N-CA 122.979 2.452 . . . . 0.0 112.891 -171.397 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 27.3 pt -103.95 161.8 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 125.498 1.519 . . . . 0.0 112.27 179.301 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 89.6 mmt-85 -128.82 139.29 52.24 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 125.292 1.437 . . . . 0.0 110.714 170.343 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.4 t -133.74 136.31 54.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 124.404 1.082 . . . . 0.0 111.386 -169.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -157.07 172.9 17.84 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 125.795 1.638 . . . . 0.0 111.49 179.269 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.9 mmmm -60.26 142.27 54.86 Favored 'General case' 0 N--CA 1.481 1.115 0 O-C-N 121.323 -0.861 . . . . 0.0 109.225 171.432 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -67.94 -20.21 65.04 Favored 'General case' 0 CA--C 1.548 0.883 0 N-CA-C 113.302 0.853 . . . . 0.0 113.302 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 70.8 m -122.76 46.72 2.09 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 126.276 1.831 . . . . 0.0 111.729 173.582 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.72 156.62 36.54 Favored 'General case' 0 CA--C 1.547 0.838 0 N-CA-C 114.098 1.147 . . . . 0.0 114.098 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -138.44 158.37 44.4 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 126.294 1.838 . . . . 0.0 111.368 177.247 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -77.26 146.93 36.58 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 123.59 0.756 . . . . 0.0 111.076 171.356 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -75.84 118.85 19.07 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.884 0.874 . . . . 0.0 111.3 179.562 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 -93.41 -22.65 18.78 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 124.661 1.185 . . . . 0.0 112.929 173.425 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 47.1 tp -69.78 150.19 47.15 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 125.275 1.43 . . . . 0.0 112.293 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 20.4 m -67.02 167.28 12.1 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 125.502 1.521 . . . . 0.0 114.1 178.745 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -74.9 -169.58 24.33 Favored Glycine 0 CA--C 1.546 1.978 0 C-N-CA 124.703 1.145 . . . . 0.0 113.413 168.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -64.79 152.17 83.07 Favored 'Trans proline' 0 CA--C 1.541 0.839 0 C-N-CA 123.463 2.775 . . . . 0.0 112.613 178.317 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 85.5 p -79.26 -21.74 45.71 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -176.029 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 34.2 m 54.18 27.7 8.11 Favored 'General case' 0 N--CA 1.478 0.941 0 C-N-CA 125.766 1.626 . . . . 0.0 114.433 -174.205 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.251 0 C-N-CA 125.655 1.598 . . . . 0.0 113.84 178.789 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.588 0 N-CA-C 111.741 -0.543 . . . . 0.0 111.741 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 49.6 m -63.59 141.72 58.66 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 124.634 1.174 . . . . 0.0 112.837 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 21.0 m -72.07 -27.37 62.63 Favored 'General case' 0 N--CA 1.476 0.868 0 N-CA-C 113.563 0.949 . . . . 0.0 113.563 -178.851 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 154.62 -175.63 32.66 Favored Glycine 0 CA--C 1.535 1.314 0 C-N-CA 125.319 1.438 . . . . 0.0 113.215 178.322 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.2 t -152.63 133.72 14.19 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 125.602 1.561 . . . . 0.0 109.928 174.225 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 92.5 p -131.73 150.91 52.0 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 124.492 1.117 . . . . 0.0 113.869 -175.763 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 75.24 93.18 0.17 Allowed Glycine 0 CA--C 1.54 1.625 0 C-N-CA 124.904 1.24 . . . . 0.0 113.637 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -57.83 150.33 63.62 Favored 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 123.809 3.006 . . . . 0.0 113.177 174.654 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 8.1 tt -72.92 152.63 7.61 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 N-CA-C 113.496 0.924 . . . . 0.0 113.496 -171.163 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 64.4 p -98.88 -0.94 41.35 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 125.969 1.708 . . . . 0.0 114.634 176.495 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -126.14 133.75 51.51 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.413 1.485 . . . . 0.0 112.108 -176.308 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 28.2 mtm180 45.35 -136.68 0.6 Allowed 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 125.865 1.666 . . . . 0.0 111.835 -171.493 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 18.6 m120 -131.6 40.76 3.37 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 126.242 1.817 . . . . 0.0 110.43 177.128 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 16.7 mm100 -58.54 -22.96 57.13 Favored 'General case' 0 CA--C 1.547 0.841 0 N-CA-C 114.693 1.368 . . . . 0.0 114.693 -168.906 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -75.48 -19.19 59.57 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 114.025 1.12 . . . . 0.0 114.025 175.497 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -117.67 12.45 13.99 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 126.097 1.759 . . . . 0.0 112.062 172.784 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 31.8 m -109.18 137.13 47.55 Favored 'General case' 0 N--CA 1.468 0.428 0 C-N-CA 125.165 1.386 . . . . 0.0 108.664 173.472 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.3 m -98.26 146.56 7.86 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 123.348 0.659 . . . . 0.0 110.193 171.056 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 12.0 t80 -95.08 141.8 28.29 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 125.561 1.544 . . . . 0.0 108.42 168.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.6 t -130.63 111.99 21.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 125.37 1.468 . . . . 0.0 109.059 177.575 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -107.36 145.81 16.1 Favored Glycine 0 CA--C 1.53 1.022 0 C-N-CA 124.368 0.985 . . . . 0.0 112.681 177.618 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 99.54 30.17 6.66 Favored Glycine 0 CA--C 1.537 1.411 0 C-N-CA 124.985 1.278 . . . . 0.0 114.352 176.019 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 85.2 mt -77.3 144.69 37.91 Favored 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 125.415 1.486 . . . . 0.0 111.699 -172.581 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -85.07 158.91 20.31 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 123.721 0.809 . . . . 0.0 112.519 176.063 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.48 -21.63 52.27 Favored 'General case' 0 CA--C 1.547 0.832 0 N-CA-C 114.534 1.309 . . . . 0.0 114.534 177.687 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.0 mtmm -80.0 -12.73 59.68 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 114.271 1.212 . . . . 0.0 114.271 174.474 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 66.8 t -71.4 140.16 18.68 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 C-N-CA 124.056 0.942 . . . . 0.0 111.235 178.329 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 91.3 p -134.57 161.43 35.1 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 125.093 1.357 . . . . 0.0 112.135 175.728 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -59.59 -39.63 72.89 Favored Pre-proline 0 CA--C 1.546 0.8 0 O-C-N 120.878 -1.139 . . . . 0.0 113.512 177.484 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_exo -62.29 -31.17 81.94 Favored 'Trans proline' 0 C--N 1.353 0.798 0 C-N-CA 122.587 2.192 . . . . 0.0 114.005 170.337 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 27.5 tp -67.38 -50.46 59.61 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 119.199 0.909 . . . . 0.0 109.862 173.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 20.2 mt -61.32 -22.6 65.04 Favored 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 113.118 0.785 . . . . 0.0 113.118 178.616 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.6 t90 -74.02 -66.69 0.68 Allowed 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 123.153 0.581 . . . . 0.0 110.851 171.293 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 39.0 mt-10 -64.74 -30.78 71.8 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 114.064 1.135 . . . . 0.0 114.064 -172.631 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.0 tp -69.13 -31.88 70.87 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 123.687 0.795 . . . . 0.0 112.148 175.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -92.59 -10.47 37.37 Favored 'General case' 0 CA--C 1.537 0.481 0 C-N-CA 125.227 1.411 . . . . 0.0 113.465 -175.102 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 50.4 mt -55.33 -18.07 5.88 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.395 1.078 . . . . 0.0 113.852 169.268 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 40.7 mt-30 -64.43 -33.24 75.41 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 125.456 1.502 . . . . 0.0 112.764 172.585 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.25 -45.88 18.89 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 123.469 0.707 . . . . 0.0 112.661 177.68 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.93 -171.6 43.08 Favored Glycine 0 CA--C 1.535 1.334 0 C-N-CA 124.307 0.956 . . . . 0.0 113.098 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -67.96 107.88 1.6 Allowed 'Trans proline' 0 CA--C 1.537 0.658 0 C-N-CA 123.698 2.932 . . . . 0.0 111.441 -179.586 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 64.3 t -82.62 133.63 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 C-N-CA 124.717 1.207 . . . . 0.0 109.602 172.678 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 9.1 t -109.03 -33.25 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 126.238 1.815 . . . . 0.0 111.71 -171.789 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 20.6 t30 -161.59 160.91 29.48 Favored 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 126.095 1.758 . . . . 0.0 110.926 -175.134 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 4.0 p -136.74 153.92 50.72 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 125.709 1.603 . . . . 0.0 111.845 171.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 15.9 t-80 -142.36 132.31 24.41 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 123.699 0.8 . . . . 0.0 111.301 177.672 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 88.6 mtp -134.39 104.2 11.26 Favored Pre-proline 0 N--CA 1.473 0.693 0 C-N-CA 124.149 0.979 . . . . 0.0 109.509 171.438 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_exo -55.62 129.7 36.48 Favored 'Trans proline' 0 CA--C 1.536 0.579 0 C-N-CA 123.31 2.673 . . . . 0.0 113.581 -179.507 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 45.6 mmtm -94.44 148.6 22.07 Favored 'General case' 0 N--CA 1.473 0.678 0 C-N-CA 124.937 1.295 . . . . 0.0 112.162 -177.181 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -80.79 147.39 30.51 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.922 1.689 . . . . 0.0 113.55 -175.275 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 17.4 ptp180 -89.01 6.33 40.17 Favored 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 115.729 1.751 . . . . 0.0 115.729 -175.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 26.3 t -131.51 -38.56 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 124.958 1.303 . . . . 0.0 111.256 -175.417 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.0 p -113.06 -20.76 11.38 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 125.569 1.548 . . . . 0.0 112.704 -176.779 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 74.01 0.57 56.65 Favored Glycine 0 CA--C 1.54 1.596 0 C-N-CA 124.977 1.275 . . . . 0.0 115.66 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 21.8 mm100 -74.67 170.95 14.78 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 124.945 1.298 . . . . 0.0 111.062 172.867 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 22.2 p80 -70.45 151.48 45.1 Favored 'General case' 0 N--CA 1.473 0.693 0 O-C-N 120.523 -1.36 . . . . 0.0 111.453 169.774 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 83.0 mt-30 -88.12 25.56 1.57 Allowed 'General case' 0 CA--C 1.549 0.906 0 N-CA-C 114.498 1.296 . . . . 0.0 114.498 -174.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.74 4.93 84.7 Favored Glycine 0 CA--C 1.535 1.298 0 C-N-CA 124.771 1.176 . . . . 0.0 115.289 175.539 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 39.3 p90 -144.36 161.17 39.66 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 124.623 1.169 . . . . 0.0 112.422 176.676 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -152.45 -177.29 25.95 Favored Glycine 0 CA--C 1.53 0.97 0 C-N-CA 125.578 1.561 . . . . 0.0 113.136 -177.518 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -142.37 149.01 38.82 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 126.12 1.768 . . . . 0.0 111.717 -178.922 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 14.9 t -132.53 122.26 47.1 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.854 0 C-N-CA 124.448 1.099 . . . . 0.0 110.215 175.547 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 47.6 tt0 -97.39 120.64 38.12 Favored 'General case' 0 N--CA 1.467 0.386 0 C-N-CA 125.083 1.353 . . . . 0.0 110.399 -175.242 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 -99.0 159.8 14.71 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 124.702 1.201 . . . . 0.0 112.298 176.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 14.3 tp -61.87 -34.38 75.91 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 123.302 0.641 . . . . 0.0 112.383 177.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 19.4 m -143.32 155.42 44.45 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.635 1.174 . . . . 0.0 112.071 -177.312 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -60.78 -34.01 73.84 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.501 1.12 . . . . 0.0 113.142 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -68.49 -22.89 64.52 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 177.011 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 53.2 m-20 -82.62 -31.16 28.98 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 123.926 0.891 . . . . 0.0 111.577 172.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -68.89 -42.52 76.83 Favored 'General case' 0 CA--C 1.544 0.721 0 O-C-N 121.654 -0.654 . . . . 0.0 111.09 170.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -59.8 -28.08 67.14 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 124.307 1.043 . . . . 0.0 112.942 173.206 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 6.8 t80 -73.6 -41.42 62.89 Favored 'General case' 0 CA--C 1.536 0.432 0 O-C-N 121.232 -0.918 . . . . 0.0 111.635 172.46 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -68.46 -37.17 79.95 Favored 'General case' 0 CA--C 1.535 0.404 0 O-C-N 120.885 -1.134 . . . . 0.0 112.109 -178.651 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 77.8 mt -59.26 -37.35 68.41 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 124.063 0.945 . . . . 0.0 110.793 171.38 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 3.3 ttmp? -70.11 -37.58 75.38 Favored 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 124.969 1.308 . . . . 0.0 113.275 -177.348 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 19.5 pt -94.99 -36.38 6.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 N-CA-C 115.423 1.638 . . . . 0.0 115.423 -179.447 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' MET . . . . . 0.48 ' HA ' HD12 ' A' ' 80' ' ' ILE . 14.2 mmt -94.05 -0.25 55.54 Favored 'General case' 0 N--CA 1.481 1.098 0 N-CA-C 114.931 1.456 . . . . 0.0 114.931 -169.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -82.69 139.76 33.49 Favored 'General case' 0 CA--C 1.539 0.55 0 O-C-N 121.206 -0.934 . . . . 0.0 111.799 177.242 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 28.0 ttm 60.35 12.26 3.33 Favored 'General case' 0 CA--C 1.55 0.962 0 C-N-CA 125.555 1.542 . . . . 0.0 114.99 -173.821 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.48 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.1 mt -72.02 158.63 6.1 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.598 0 C-N-CA 125.64 1.576 . . . . 0.0 110.311 169.017 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 49.7 mtpt -117.91 71.52 0.83 Allowed 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 125.379 1.472 . . . . 0.0 112.125 -177.564 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 27.7 tp -58.65 126.97 29.86 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 123.819 0.848 . . . . 0.0 109.961 175.413 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 67.2 m-85 45.82 29.9 0.78 Allowed 'General case' 0 CA--C 1.561 1.393 0 N-CA-C 116.105 1.891 . . . . 0.0 116.105 -168.669 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.94 19.95 69.0 Favored Glycine 0 CA--C 1.541 1.67 0 O-C-N 120.271 -1.518 . . . . 0.0 116.308 174.729 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -132.36 124.57 19.29 Favored Pre-proline 0 CA--C 1.54 0.587 0 C-N-CA 128.186 2.595 . . . . 0.0 108.036 179.633 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -70.57 131.09 19.41 Favored 'Trans proline' 0 CA--C 1.537 0.645 0 C-N-CA 123.364 2.71 . . . . 0.0 113.074 -169.772 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 21.2 pt -102.0 162.77 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.618 1.567 . . . . 0.0 112.218 176.608 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 89.4 mmt-85 -129.02 140.39 51.65 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 125.342 1.457 . . . . 0.0 111.035 170.509 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 20.9 t -132.58 136.58 55.77 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 C-N-CA 124.598 1.159 . . . . 0.0 111.494 -172.402 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -158.05 174.14 15.67 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 126.189 1.796 . . . . 0.0 111.068 179.12 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 11.8 mmmm -59.25 139.54 56.87 Favored 'General case' 0 N--CA 1.476 0.865 0 C-N-CA 123.644 0.778 . . . . 0.0 109.781 171.883 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -73.9 -5.39 40.83 Favored 'General case' 0 CA--C 1.553 1.086 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 175.176 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 88.3 p -112.33 13.59 20.35 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 127.47 2.308 . . . . 0.0 114.121 172.18 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -54.04 -25.73 22.92 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 115.357 1.614 . . . . 0.0 115.357 -169.859 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 21.4 m80 -62.85 -17.84 62.02 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.388 1.475 . . . . 0.0 113.828 176.761 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 17.2 t30 -66.97 -14.87 63.3 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.78 1.232 . . . . 0.0 114.127 -179.371 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 80.8 tttt -51.23 -22.73 2.86 Favored 'General case' 0 N--CA 1.481 1.078 0 C-N-CA 126.482 1.913 . . . . 0.0 114.377 176.739 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -56.32 -28.43 58.88 Favored 'General case' 0 CA--C 1.55 0.95 0 C-N-CA 124.804 1.242 . . . . 0.0 113.728 171.717 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 93.7 mt -108.07 104.92 14.46 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 125.688 1.595 . . . . 0.0 108.769 170.28 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 80.2 p -96.81 -11.81 24.43 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 115.453 1.649 . . . . 0.0 115.453 -169.451 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -163.05 174.77 39.4 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 124.57 1.081 . . . . 0.0 113.5 -179.087 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -57.69 134.58 63.88 Favored 'Trans proline' 0 CA--C 1.536 0.617 0 C-N-CA 123.194 2.596 . . . . 0.0 112.845 -178.409 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 23.2 m 53.11 32.39 12.99 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 125.394 1.478 . . . . 0.0 114.806 -178.973 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 23.3 t -60.39 139.31 57.74 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 124.242 1.017 . . . . 0.0 112.184 177.657 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.256 0 C-N-CA 125.561 1.553 . . . . 0.0 113.907 -178.93 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.654 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 31.6 m -67.74 154.08 42.3 Favored 'General case' 0 N--CA 1.477 0.889 0 C-N-CA 124.518 1.127 . . . . 0.0 113.276 -179.308 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 26.2 m -63.8 143.27 57.98 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 124.68 1.192 . . . . 0.0 112.584 178.104 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 163.83 -151.79 21.36 Favored Glycine 0 CA--C 1.534 1.265 0 C-N-CA 124.23 0.919 . . . . 0.0 113.304 -177.445 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.0 m 57.99 26.44 13.47 Favored 'General case' 0 N--CA 1.479 1.008 0 N-CA-C 115.639 1.718 . . . . 0.0 115.639 175.081 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 9.9 t -149.81 145.28 26.51 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 124.994 1.318 . . . . 0.0 111.581 175.662 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -93.94 -166.57 37.27 Favored Glycine 0 CA--C 1.541 1.695 0 C-N-CA 125.298 1.428 . . . . 0.0 114.204 178.744 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -59.31 150.0 77.39 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 123.863 3.042 . . . . 0.0 113.169 173.508 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 1.7 pp -131.55 160.17 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 C-N-CA 125.423 1.489 . . . . 0.0 112.98 -176.112 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 57.3 p -79.56 -16.21 56.32 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.887 1.275 . . . . 0.0 114.086 178.645 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -79.78 58.8 2.92 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 125.648 1.579 . . . . 0.0 111.623 178.391 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 63.7 ttt180 -70.1 119.82 14.87 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 125.522 1.529 . . . . 0.0 110.796 -177.133 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -119.29 142.1 48.39 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.86 1.264 . . . . 0.0 111.952 -173.592 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 25.6 tp60 -60.24 -31.09 69.86 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 124.112 0.965 . . . . 0.0 112.205 176.525 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 21.3 m-20 -67.35 -17.55 64.8 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.206 1.402 . . . . 0.0 113.903 178.017 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -85.52 -4.58 59.2 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 123.88 0.872 . . . . 0.0 113.062 173.205 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 31.5 m -102.74 138.23 39.92 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 124.679 1.192 . . . . 0.0 109.429 170.679 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.0 m -104.14 146.61 11.35 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.686 0 C-N-CA 124.528 1.131 . . . . 0.0 109.899 170.156 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 18.9 t80 -95.68 143.6 26.81 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 125.85 1.66 . . . . 0.0 109.607 169.779 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 24.3 t -130.97 111.37 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 C-N-CA 125.68 1.592 . . . . 0.0 109.04 176.659 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -108.39 146.01 16.42 Favored Glycine 0 CA--C 1.53 1.015 0 C-N-CA 124.487 1.041 . . . . 0.0 112.762 177.82 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 98.57 31.31 6.46 Favored Glycine 0 CA--C 1.534 1.278 0 C-N-CA 124.571 1.082 . . . . 0.0 114.223 175.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 76.2 mt -73.17 171.37 13.09 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.678 1.591 . . . . 0.0 111.977 -176.597 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -130.96 164.41 25.4 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 124.117 0.967 . . . . 0.0 112.186 179.031 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -59.81 -17.7 38.06 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -169.541 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -84.18 -16.08 44.71 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 125.211 1.404 . . . . 0.0 113.637 176.141 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.1 t -71.72 139.3 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.8 0 C-N-CA 124.655 1.182 . . . . 0.0 110.892 178.358 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 89.4 p -137.06 161.91 34.8 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 124.964 1.306 . . . . 0.0 112.216 176.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -59.48 -39.93 75.83 Favored Pre-proline 0 CA--C 1.546 0.806 0 O-C-N 120.854 -1.154 . . . . 0.0 113.346 177.404 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 75.4 Cg_exo -61.76 -31.57 85.86 Favored 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 122.577 2.184 . . . . 0.0 113.959 169.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 27.8 tp -67.81 -50.69 55.46 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 119.24 0.927 . . . . 0.0 109.959 174.252 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 18.0 mt -61.08 -24.39 66.19 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 178.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.7 t90 -72.79 -66.03 0.72 Allowed 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 123.16 0.584 . . . . 0.0 111.123 171.074 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -64.78 -30.56 71.57 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 -172.624 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.6 tp -69.28 -33.2 72.86 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 123.81 0.844 . . . . 0.0 111.934 175.721 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -90.87 -10.51 42.37 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 125.227 1.411 . . . . 0.0 113.397 -175.493 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 47.6 mt -55.77 -18.68 8.95 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 169.307 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 40.9 mt-30 -64.24 -32.74 74.44 Favored 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 125.264 1.425 . . . . 0.0 112.634 172.367 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -78.89 -44.54 22.54 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 123.205 0.602 . . . . 0.0 112.593 177.731 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 177.34 -172.67 45.51 Favored Glycine 0 CA--C 1.537 1.414 0 C-N-CA 124.678 1.132 . . . . 0.0 112.868 -178.72 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -67.85 109.26 1.86 Allowed 'Trans proline' 0 CA--C 1.539 0.749 0 C-N-CA 123.768 2.979 . . . . 0.0 111.764 -179.037 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 70.3 t -84.89 135.23 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 C-N-CA 124.974 1.31 . . . . 0.0 109.907 173.836 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.2 t -110.5 -33.4 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 126.356 1.862 . . . . 0.0 111.931 -171.816 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 19.9 t30 -160.78 159.73 30.36 Favored 'General case' 0 CA--C 1.553 1.067 0 C-N-CA 125.826 1.65 . . . . 0.0 111.217 -174.382 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 6.1 p -136.93 155.61 49.52 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 125.942 1.697 . . . . 0.0 111.882 171.495 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 -142.36 133.8 26.47 Favored 'General case' 0 N--CA 1.468 0.426 0 C-N-CA 123.734 0.814 . . . . 0.0 111.122 175.295 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 86.0 mtp -134.7 105.59 10.76 Favored Pre-proline 0 N--CA 1.47 0.566 0 C-N-CA 124.171 0.989 . . . . 0.0 109.561 169.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -57.53 137.81 83.15 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 123.153 2.568 . . . . 0.0 112.64 177.61 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 45.3 mmtm -103.21 152.45 21.46 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 124.967 1.307 . . . . 0.0 112.726 -174.612 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -78.11 143.66 37.14 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 126.164 1.786 . . . . 0.0 111.768 176.177 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 40.3 ptt180 -84.46 3.41 36.38 Favored 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 115.91 1.819 . . . . 0.0 115.91 -176.041 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 19.9 t -132.91 -40.3 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 125.546 1.539 . . . . 0.0 111.184 -174.702 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 68.8 p -102.19 -20.67 14.59 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 124.837 1.255 . . . . 0.0 112.438 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 73.62 -1.58 44.07 Favored Glycine 0 CA--C 1.54 1.624 0 C-N-CA 124.735 1.16 . . . . 0.0 115.94 172.763 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 7.7 pt20 -83.67 174.53 10.43 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.983 1.313 . . . . 0.0 110.824 169.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 33.1 p80 -68.08 157.23 35.72 Favored 'General case' 0 N--CA 1.473 0.688 0 O-C-N 120.827 -1.17 . . . . 0.0 113.471 -179.172 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 -81.07 15.93 1.7 Allowed 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 124.942 1.297 . . . . 0.0 114.296 -177.295 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 87.54 2.67 82.01 Favored Glycine 0 CA--C 1.536 1.381 0 O-C-N 120.651 -1.281 . . . . 0.0 115.056 -178.529 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 39.8 p90 -143.6 161.37 38.67 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 124.778 1.231 . . . . 0.0 112.739 176.699 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -151.61 -177.86 25.8 Favored Glycine 0 CA--C 1.53 0.992 0 C-N-CA 125.956 1.741 . . . . 0.0 113.128 -177.756 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -143.63 149.51 37.42 Favored 'General case' 0 C--O 1.237 0.407 0 C-N-CA 126.034 1.733 . . . . 0.0 111.655 -178.286 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 15.8 t -133.74 127.95 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.826 0 C-N-CA 124.923 1.289 . . . . 0.0 109.974 175.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -106.53 125.33 50.87 Favored 'General case' 0 N--CA 1.465 0.323 0 C-N-CA 124.703 1.201 . . . . 0.0 111.31 -175.894 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -101.92 160.43 14.5 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 125.083 1.353 . . . . 0.0 112.549 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.7 tp -61.37 -35.46 77.52 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 123.391 0.676 . . . . 0.0 112.242 177.773 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 13.2 m -141.41 154.56 45.68 Favored 'General case' 0 N--CA 1.468 0.446 0 C-N-CA 124.749 1.22 . . . . 0.0 111.877 -178.718 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 54.7 mt-10 -62.38 -33.99 75.82 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 124.361 1.065 . . . . 0.0 113.025 -176.636 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -68.22 -25.6 65.28 Favored 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 113.381 0.882 . . . . 0.0 113.381 176.906 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -77.67 -33.55 53.33 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 123.814 0.845 . . . . 0.0 111.354 173.563 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.61 -43.67 72.27 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 123.331 0.652 . . . . 0.0 111.362 172.103 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -60.04 -31.17 69.72 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 124.369 1.067 . . . . 0.0 112.648 178.308 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 63.1 t80 -79.9 -34.59 38.9 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 124.225 1.01 . . . . 0.0 113.114 174.607 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.45 -37.61 87.96 Favored 'General case' 0 CA--C 1.535 0.398 0 O-C-N 121.084 -1.01 . . . . 0.0 111.149 176.499 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 61.9 mt -61.48 -41.28 89.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 C-N-CA 124.834 1.254 . . . . 0.0 111.074 172.627 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 25.6 ttmm -61.73 -38.67 88.81 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.99 0.916 . . . . 0.0 112.448 179.09 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 45.9 pt -94.24 -32.72 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 N-CA-C 115.183 1.549 . . . . 0.0 115.183 -177.124 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' MET . . . . . 0.474 ' HA ' HD12 ' A' ' 80' ' ' ILE . 10.7 mmt -96.72 -0.69 47.87 Favored 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 115.351 1.612 . . . . 0.0 115.351 -171.874 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 26.5 t0 -83.78 139.08 32.93 Favored 'General case' 0 CA--C 1.538 0.512 0 O-C-N 121.341 -0.849 . . . . 0.0 111.943 178.614 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 23.6 mtp 58.21 13.38 2.3 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 126.177 1.791 . . . . 0.0 115.318 -171.783 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.474 HD12 ' HA ' ' A' ' 77' ' ' MET . 1.7 mt -70.13 155.24 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 C-N-CA 125.429 1.492 . . . . 0.0 110.002 168.833 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 46.2 mtpt -113.28 71.42 0.74 Allowed 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.916 1.286 . . . . 0.0 112.568 -176.011 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 23.4 tp -58.47 127.48 32.34 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 123.888 0.875 . . . . 0.0 109.905 174.647 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 84.4 m-85 47.01 28.61 0.91 Allowed 'General case' 0 CA--C 1.561 1.378 0 N-CA-C 116.217 1.932 . . . . 0.0 116.217 -168.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 76.32 32.55 51.44 Favored Glycine 0 CA--C 1.54 1.594 0 O-C-N 120.153 -1.592 . . . . 0.0 115.013 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 80.0 tttt -145.57 118.91 5.34 Favored Pre-proline 0 CA--C 1.542 0.638 0 C-N-CA 128.274 2.63 . . . . 0.0 107.848 -172.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -69.79 123.35 10.0 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 122.623 2.216 . . . . 0.0 112.521 -169.52 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 17.7 pt -95.92 146.75 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 C-N-CA 125.371 1.468 . . . . 0.0 111.379 173.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 38.9 mmm-85 -111.14 137.87 48.27 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 124.51 1.124 . . . . 0.0 110.797 170.743 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 26.5 t -131.46 136.42 57.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.69 0 C-N-CA 124.407 1.083 . . . . 0.0 111.13 -173.077 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -156.05 171.64 19.77 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 125.81 1.644 . . . . 0.0 111.509 178.339 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.0 mmmm -59.55 140.83 55.97 Favored 'General case' 0 N--CA 1.479 0.978 0 O-C-N 121.449 -0.782 . . . . 0.0 109.035 171.48 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -70.69 -4.13 22.05 Favored 'General case' 0 CA--C 1.55 0.971 0 CA-C-N 119.317 0.962 . . . . 0.0 113.398 177.722 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 37.3 p -89.83 -16.8 29.38 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.149 2.18 . . . . 0.0 113.707 169.76 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -71.74 -10.67 60.12 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 114.584 1.327 . . . . 0.0 114.584 -170.746 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 27.5 m80 -72.15 -16.45 61.98 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.213 1.005 . . . . 0.0 113.236 174.395 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 41.7 t-20 -81.64 152.72 27.01 Favored 'General case' 0 CA--C 1.549 0.926 0 C-N-CA 124.818 1.247 . . . . 0.0 112.309 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 73.5 mmtt 60.97 166.89 0.09 Allowed 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 128.133 2.573 . . . . 0.0 115.385 -178.684 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 48.4 t30 -149.27 161.38 42.15 Favored 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 126.119 1.767 . . . . 0.0 110.608 177.332 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 62.5 tp -79.02 130.48 35.57 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 124.413 1.085 . . . . 0.0 111.204 175.324 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 48.0 m -124.08 -0.09 8.42 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 124.826 1.25 . . . . 0.0 114.351 -179.237 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -73.93 153.13 46.63 Favored Glycine 0 CA--C 1.542 1.746 0 O-C-N 121.365 -0.835 . . . . 0.0 113.62 179.222 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -72.58 151.23 52.39 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 123.667 2.912 . . . . 0.0 112.628 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 68.3 p -87.45 -18.57 29.61 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 124.805 1.242 . . . . 0.0 114.253 179.049 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 9.3 t -153.07 162.66 41.06 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 125.798 1.639 . . . . 0.0 111.654 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.147 0 C-N-CA 125.633 1.587 . . . . 0.0 112.843 -179.077 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.636 0 N-CA-C 112.085 -0.406 . . . . 0.0 112.085 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 38.2 t -148.58 152.56 36.99 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.179 1.392 . . . . 0.0 111.809 178.166 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 72.3 p -75.67 -23.33 56.23 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 124.728 1.211 . . . . 0.0 113.175 170.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 69.35 7.39 57.4 Favored Glycine 0 CA--C 1.539 1.593 0 C-N-CA 124.805 1.193 . . . . 0.0 115.069 -175.084 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 72.3 m -57.16 126.95 29.53 Favored 'General case' 0 N--CA 1.472 0.634 0 CA-C-N 118.73 1.265 . . . . 0.0 112.642 -173.856 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 7.4 m 59.31 13.53 3.17 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 125.951 1.7 . . . . 0.0 115.293 -178.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -72.84 135.68 21.97 Favored Glycine 0 CA--C 1.543 1.797 0 O-C-N 121.209 -0.932 . . . . 0.0 113.43 -176.678 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -78.88 -23.82 7.64 Favored 'Trans proline' 0 CA--C 1.541 0.861 0 C-N-CA 123.406 2.738 . . . . 0.0 114.217 -177.599 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.4 HG13 ' H ' ' A' ' 11' ' ' GLU . 8.3 tp -148.74 145.41 18.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.43 1.492 . . . . 0.0 111.364 178.934 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 67.8 p -111.73 -8.89 14.14 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 125.696 1.599 . . . . 0.0 113.95 177.609 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.4 ' H ' HG13 ' A' ' 9' ' ' ILE . 40.9 mt-10 -87.1 -22.91 25.1 Favored 'General case' 0 N--CA 1.478 0.93 0 N-CA-C 113.96 1.096 . . . . 0.0 113.96 -173.516 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 10.0 mmm180 -143.1 154.16 43.65 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 126.877 2.071 . . . . 0.0 110.553 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -75.46 43.09 0.23 Allowed 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 125.683 1.593 . . . . 0.0 113.194 174.328 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 35.9 tt0 -67.52 -16.23 64.09 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 124.862 1.265 . . . . 0.0 113.391 -170.241 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -72.71 -23.05 60.81 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 124.587 1.155 . . . . 0.0 113.018 169.45 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.7 -2.82 58.84 Favored 'General case' 0 CA--C 1.545 0.75 0 C-N-CA 124.156 0.982 . . . . 0.0 112.37 170.36 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 20.4 m -100.17 142.6 31.42 Favored 'General case' 0 N--CA 1.47 0.536 0 C-N-CA 124.595 1.158 . . . . 0.0 109.64 171.029 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 18.1 m -110.41 148.35 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 124.871 1.268 . . . . 0.0 110.415 171.155 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 22.1 t80 -95.82 143.11 27.33 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 126.012 1.725 . . . . 0.0 109.346 169.298 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.8 t -132.26 106.48 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 C-N-CA 125.724 1.61 . . . . 0.0 109.086 177.742 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -101.22 145.99 17.17 Favored Glycine 0 CA--C 1.53 1.023 0 C-N-CA 124.296 0.95 . . . . 0.0 112.543 176.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.88 33.66 5.99 Favored Glycine 0 CA--C 1.533 1.203 0 C-N-CA 124.474 1.035 . . . . 0.0 113.936 173.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 85.3 mt -74.98 151.28 38.81 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 125.312 1.445 . . . . 0.0 111.402 -174.784 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -90.48 157.44 17.56 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 123.979 0.912 . . . . 0.0 111.955 175.509 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -59.06 -20.13 50.45 Favored 'General case' 0 CA--C 1.547 0.851 0 N-CA-C 114.712 1.375 . . . . 0.0 114.712 179.404 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.4 mtmm -82.46 -7.48 59.64 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 124.861 1.264 . . . . 0.0 114.183 174.691 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.9 t -77.93 138.82 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 C-N-CA 124.461 1.105 . . . . 0.0 111.479 177.493 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 51.8 m -136.55 162.12 34.0 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 125.212 1.405 . . . . 0.0 111.459 173.039 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -56.54 -40.03 81.99 Favored Pre-proline 0 CA--C 1.547 0.856 0 N-CA-C 114.572 1.323 . . . . 0.0 114.572 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -65.75 -28.5 51.61 Favored 'Trans proline' 0 C--N 1.353 0.798 0 C-N-CA 122.28 1.987 . . . . 0.0 113.617 173.752 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 20.4 tp -66.28 -53.08 41.02 Favored 'General case' 0 C--N 1.343 0.321 0 CA-C-N 118.645 0.657 . . . . 0.0 109.33 173.429 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 22.7 mt -55.47 -41.49 73.03 Favored 'General case' 0 N--CA 1.464 0.252 0 O-C-N 123.315 0.384 . . . . 0.0 111.281 -179.039 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.8 t90 -58.16 -62.96 1.45 Allowed 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 123.373 0.669 . . . . 0.0 111.32 177.53 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.8 mt-10 -64.62 -29.52 70.53 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 113.892 1.071 . . . . 0.0 113.892 -176.766 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.5 tp -72.37 -35.86 68.58 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 124.174 0.989 . . . . 0.0 112.101 176.416 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -88.51 -10.66 48.21 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.86 1.264 . . . . 0.0 113.446 -176.658 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 25.1 mt -52.69 -21.23 3.78 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 114.125 1.157 . . . . 0.0 114.125 169.161 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 42.2 mt-30 -63.61 -32.6 74.12 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 125.389 1.476 . . . . 0.0 112.756 174.524 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.02 -45.82 19.41 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 123.501 0.72 . . . . 0.0 112.559 176.817 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -178.57 -174.54 44.9 Favored Glycine 0 CA--C 1.535 1.319 0 C-N-CA 124.356 0.979 . . . . 0.0 113.176 178.394 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -66.68 113.12 2.62 Favored 'Trans proline' 0 CA--C 1.538 0.677 0 C-N-CA 123.651 2.901 . . . . 0.0 111.549 -179.277 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 85.1 t -87.64 134.92 26.61 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 125.046 1.338 . . . . 0.0 109.959 175.984 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.3 t -110.03 -33.54 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 126.81 2.044 . . . . 0.0 111.94 -171.574 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 19.6 t30 -160.63 159.65 30.68 Favored 'General case' 0 CA--C 1.552 1.039 0 C-N-CA 125.961 1.704 . . . . 0.0 110.911 -174.503 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 6.7 p -137.45 154.81 49.86 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 125.812 1.645 . . . . 0.0 111.614 171.652 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 43.1 t-80 -142.43 133.94 26.55 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 123.599 0.76 . . . . 0.0 111.291 175.643 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 84.0 mtp -134.52 105.45 10.95 Favored Pre-proline 0 N--CA 1.47 0.575 0 C-N-CA 124.136 0.974 . . . . 0.0 109.137 169.615 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_exo -58.09 139.98 92.42 Favored 'Trans proline' 0 CA--C 1.536 0.579 0 C-N-CA 122.882 2.388 . . . . 0.0 113.017 178.814 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 44.0 mmtm -108.7 149.74 28.55 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 125.228 1.411 . . . . 0.0 112.468 -174.568 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -67.87 138.33 55.98 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 125.525 1.53 . . . . 0.0 111.917 172.419 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 53.6 ptt85 -80.02 7.87 8.2 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 115.947 1.832 . . . . 0.0 115.947 -173.106 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 31.8 t -132.13 -37.44 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 124.942 1.297 . . . . 0.0 111.433 -174.802 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 65.6 p -114.91 -14.23 11.91 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 125.69 1.596 . . . . 0.0 112.697 -175.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.29 6.54 57.92 Favored Glycine 0 CA--C 1.537 1.453 0 C-N-CA 125.075 1.322 . . . . 0.0 115.542 174.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 71.1 mm-40 -79.18 159.33 27.43 Favored 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 124.67 1.188 . . . . 0.0 110.662 176.121 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 15.9 p80 -68.03 150.89 47.88 Favored 'General case' 0 N--CA 1.473 0.699 0 O-C-N 120.892 -1.13 . . . . 0.0 112.266 177.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 28.8 mt-30 -86.23 19.05 2.84 Favored 'General case' 0 CA--C 1.549 0.94 0 N-CA-C 114.316 1.228 . . . . 0.0 114.316 -172.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.27 3.3 78.96 Favored Glycine 0 CA--C 1.534 1.254 0 C-N-CA 125.097 1.332 . . . . 0.0 115.131 179.478 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 46.4 p90 -145.59 159.84 42.54 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 124.822 1.249 . . . . 0.0 112.566 178.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -150.78 -176.25 23.53 Favored Glycine 0 CA--C 1.529 0.946 0 C-N-CA 125.792 1.663 . . . . 0.0 113.396 -178.176 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -144.71 149.02 34.88 Favored 'General case' 0 C--O 1.237 0.414 0 C-N-CA 126.21 1.804 . . . . 0.0 111.63 -178.106 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.3 t -132.8 127.01 55.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 C-N-CA 124.42 1.088 . . . . 0.0 110.028 175.546 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -103.45 119.71 39.42 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 124.784 1.234 . . . . 0.0 111.049 -177.031 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -95.54 163.13 13.34 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 125.111 1.364 . . . . 0.0 112.366 176.459 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 12.7 tp -63.37 -32.79 74.31 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 123.325 0.65 . . . . 0.0 112.376 175.465 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.6 m -145.08 157.6 44.06 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 122.662 1.22 . . . . 0.0 112.903 -175.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -64.46 -32.66 74.39 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.872 1.269 . . . . 0.0 113.404 -175.413 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -70.31 -26.87 63.98 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 123.848 0.859 . . . . 0.0 113.036 176.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 59.6 m-20 -75.74 -33.42 60.26 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 123.849 0.86 . . . . 0.0 111.129 173.623 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -67.11 -45.86 75.94 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 122.932 0.493 . . . . 0.0 111.359 170.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -55.29 -36.23 65.92 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 123.599 0.76 . . . . 0.0 112.592 174.229 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 21.4 t80 -73.93 -37.8 64.48 Favored 'General case' 0 CA--C 1.535 0.388 0 O-C-N 121.669 -0.644 . . . . 0.0 112.163 177.718 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -65.17 -35.95 82.71 Favored 'General case' 0 CA--C 1.537 0.446 0 O-C-N 120.682 -1.261 . . . . 0.0 111.52 176.525 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 63.6 mt -63.77 -34.53 68.61 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 124.277 1.031 . . . . 0.0 111.033 172.53 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 63.1 tttp -67.95 -41.71 82.04 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 124.062 0.945 . . . . 0.0 112.523 176.784 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 19.2 pt -92.69 -38.28 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 N-CA-C 115.041 1.497 . . . . 0.0 115.041 -175.29 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' MET . . . . . 0.481 ' HA ' HD12 ' A' ' 80' ' ' ILE . 15.2 mmt -91.51 0.56 57.49 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 114.863 1.431 . . . . 0.0 114.863 -169.794 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -85.82 137.34 32.85 Favored 'General case' 0 CA--C 1.538 0.514 0 O-C-N 121.44 -0.787 . . . . 0.0 112.057 179.64 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 24.1 mmt 59.61 9.59 1.63 Allowed 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 126.238 1.815 . . . . 0.0 115.059 -170.794 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.481 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.5 mt -68.01 152.42 9.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 C-N-CA 124.981 1.312 . . . . 0.0 110.061 169.291 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.0 mtpt -112.78 70.21 0.71 Allowed 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 125.05 1.34 . . . . 0.0 112.289 -176.853 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 31.9 tp -57.64 125.02 21.1 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.068 0.947 . . . . 0.0 109.926 175.194 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 57.2 m-85 46.0 28.77 0.66 Allowed 'General case' 0 CA--C 1.561 1.382 0 N-CA-C 116.289 1.959 . . . . 0.0 116.289 -168.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.5 26.71 56.39 Favored Glycine 0 CA--C 1.542 1.745 0 O-C-N 120.183 -1.573 . . . . 0.0 115.903 176.688 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -137.18 120.44 11.74 Favored Pre-proline 0 CA--C 1.542 0.673 0 C-N-CA 128.268 2.627 . . . . 0.0 107.813 -179.364 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -70.19 127.1 13.79 Favored 'Trans proline' 0 CA--C 1.536 0.615 0 C-N-CA 122.878 2.385 . . . . 0.0 112.497 -170.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 17.1 pt -98.86 145.34 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 C-N-CA 125.496 1.519 . . . . 0.0 112.215 177.082 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 46.4 tpt85 -114.02 129.18 56.62 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 126.389 1.876 . . . . 0.0 109.522 178.515 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -128.15 135.79 61.84 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 124.156 0.983 . . . . 0.0 111.787 -171.03 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -153.93 173.73 15.56 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 126.135 1.774 . . . . 0.0 110.613 175.904 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 22.6 mmmt -57.75 143.33 42.33 Favored 'General case' 0 N--CA 1.479 1.014 0 C-N-CA 123.809 0.844 . . . . 0.0 109.298 170.86 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -70.27 -13.74 62.3 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 113.106 0.78 . . . . 0.0 113.106 179.312 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 23.1 t -139.6 128.84 23.94 Favored 'General case' 0 N--CA 1.467 0.38 0 C-N-CA 125.967 1.707 . . . . 0.0 108.338 166.755 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -134.26 22.46 3.76 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.688 1.195 . . . . 0.0 112.607 -171.369 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 92.6 m-70 -89.0 38.86 0.91 Allowed 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 125.271 1.429 . . . . 0.0 113.575 -172.185 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 49.5 p-10 -76.41 47.59 0.48 Allowed 'General case' 0 CA--C 1.551 1.009 0 C-N-CA 125.615 1.566 . . . . 0.0 112.73 176.134 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -69.52 -15.35 63.23 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 126.769 2.028 . . . . 0.0 114.354 -169.659 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -133.73 137.57 45.3 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 126.031 1.732 . . . . 0.0 109.927 169.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 10.7 mp -99.9 141.06 33.23 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 124.419 1.088 . . . . 0.0 111.426 -177.522 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 11.0 t -85.47 154.22 21.95 Favored 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 124.599 1.16 . . . . 0.0 112.704 177.856 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 178.08 49.16 0.07 OUTLIER Glycine 0 CA--C 1.542 1.729 0 CA-C-O 118.485 -1.175 . . . . 0.0 115.235 175.836 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 80.0 Cg_endo -66.85 -21.41 50.64 Favored 'Trans proline' 0 CA--C 1.542 0.889 0 C-N-CA 123.206 2.604 . . . . 0.0 113.934 -176.038 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 19.6 m -78.01 -13.14 59.98 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 124.867 1.267 . . . . 0.0 114.161 -179.634 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 55.5 m -73.94 148.15 42.44 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.45 1.1 . . . . 0.0 112.953 -178.171 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.178 0 CA-C-O 118.214 -1.326 . . . . 0.0 112.772 179.429 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.684 0 N-CA-C 112.041 -0.424 . . . . 0.0 112.041 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 47.1 p -76.0 156.17 34.31 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 124.617 1.167 . . . . 0.0 113.243 177.833 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 63.4 p -86.95 161.67 18.11 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 125.337 1.455 . . . . 0.0 112.975 177.166 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 72.26 -161.02 54.25 Favored Glycine 0 CA--C 1.537 1.458 0 C-N-CA 124.191 0.9 . . . . 0.0 114.033 -178.273 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 56.0 p -74.47 152.32 39.45 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 124.807 1.243 . . . . 0.0 113.152 179.703 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 88.5 p -145.33 164.47 31.36 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 125.155 1.382 . . . . 0.0 112.549 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -177.91 173.02 45.66 Favored Glycine 0 CA--C 1.539 1.571 0 C-N-CA 124.579 1.085 . . . . 0.0 113.491 179.161 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -73.97 163.52 36.67 Favored 'Trans proline' 0 CA--C 1.539 0.771 0 C-N-CA 123.828 3.019 . . . . 0.0 113.266 -178.505 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.3 tp -72.35 152.68 7.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 124.238 1.015 . . . . 0.0 111.867 173.595 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.5 m -75.54 -9.74 58.84 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 114.869 1.433 . . . . 0.0 114.869 -177.759 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -132.89 129.67 38.68 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 124.364 1.066 . . . . 0.0 112.984 -172.256 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 21.1 mtm180 55.34 -168.88 0.08 Allowed 'General case' 0 N--CA 1.482 1.127 0 C-N-CA 126.763 2.025 . . . . 0.0 114.07 177.793 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -85.95 30.09 0.69 Allowed 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 126.025 1.73 . . . . 0.0 113.38 176.375 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -66.32 -13.72 60.96 Favored 'General case' 0 CA--C 1.542 0.65 0 N-CA-C 115.58 1.696 . . . . 0.0 115.58 -169.329 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.03 -22.62 62.12 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-N 119.604 1.093 . . . . 0.0 112.729 168.436 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -88.65 -1.18 57.93 Favored 'General case' 0 CA--C 1.548 0.883 0 C-N-CA 125.077 1.351 . . . . 0.0 112.658 169.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.5 m -100.09 134.78 42.51 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.346 1.058 . . . . 0.0 110.212 171.66 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.6 m -106.11 147.42 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 124.468 1.107 . . . . 0.0 110.333 171.236 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 33.5 t80 -95.42 143.71 26.54 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 125.833 1.653 . . . . 0.0 109.324 169.546 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 20.0 t -130.61 112.68 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 C-N-CA 125.531 1.532 . . . . 0.0 109.127 175.62 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -110.52 145.49 17.29 Favored Glycine 0 CA--C 1.53 0.972 0 C-N-CA 124.493 1.044 . . . . 0.0 112.805 178.576 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 95.73 33.51 6.38 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 124.471 1.034 . . . . 0.0 113.843 175.875 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 84.0 mt -73.68 152.83 40.34 Favored 'General case' 0 C--O 1.234 0.271 0 C-N-CA 125.496 1.518 . . . . 0.0 111.428 -174.49 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -92.33 157.48 16.61 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 123.677 0.791 . . . . 0.0 111.953 174.018 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -58.6 -20.82 50.54 Favored 'General case' 0 CA--C 1.546 0.823 0 O-C-N 120.543 -1.348 . . . . 0.0 114.58 179.112 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 60.5 mtpt -77.42 -12.89 60.01 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 114.302 1.223 . . . . 0.0 114.302 174.4 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 78.9 t -74.62 141.19 16.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.911 0 C-N-CA 124.509 1.124 . . . . 0.0 111.689 -178.655 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 94.1 p -136.08 163.51 30.16 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 125.315 1.446 . . . . 0.0 111.969 175.0 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -59.27 -43.63 97.0 Favored Pre-proline 0 CA--C 1.546 0.807 0 O-C-N 120.745 -1.222 . . . . 0.0 113.025 176.732 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_exo -57.64 -31.03 90.78 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 122.509 2.139 . . . . 0.0 114.146 171.232 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 27.7 tp -68.71 -51.28 43.32 Favored 'General case' 0 C--N 1.343 0.322 0 CA-C-N 119.072 0.851 . . . . 0.0 110.261 173.459 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 21.3 mt -61.29 -22.56 64.97 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 113.094 0.776 . . . . 0.0 113.094 178.633 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.6 t90 -73.61 -67.5 0.59 Allowed 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 123.233 0.613 . . . . 0.0 110.83 170.404 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.8 mt-10 -64.72 -30.13 71.14 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 114.206 1.187 . . . . 0.0 114.206 -172.11 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.0 tp -69.65 -33.3 72.4 Favored 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 123.711 0.804 . . . . 0.0 111.969 175.46 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 18.3 m-85 -90.43 -10.96 41.88 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.048 1.339 . . . . 0.0 113.306 -175.125 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 49.2 mt -54.89 -19.11 5.88 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 124.517 1.127 . . . . 0.0 114.038 169.648 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 41.2 mt-30 -65.0 -32.72 74.59 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 125.443 1.497 . . . . 0.0 112.678 173.81 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -78.91 -45.49 20.44 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.44 0.696 . . . . 0.0 112.451 176.897 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.18 -173.8 45.84 Favored Glycine 0 CA--C 1.536 1.354 0 C-N-CA 124.852 1.215 . . . . 0.0 112.855 177.776 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -66.1 113.83 2.77 Favored 'Trans proline' 0 CA--C 1.537 0.656 0 C-N-CA 123.614 2.876 . . . . 0.0 111.795 -179.005 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 93.9 t -87.32 135.23 25.76 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.179 1.391 . . . . 0.0 109.792 174.753 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.2 t -109.71 -34.13 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 126.614 1.965 . . . . 0.0 111.746 -171.691 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 20.4 t30 -160.68 163.35 32.51 Favored 'General case' 0 CA--C 1.554 1.119 0 C-N-CA 126.023 1.729 . . . . 0.0 111.066 -175.05 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.7 p -142.04 153.58 44.32 Favored 'General case' 0 N--CA 1.48 1.075 0 C-N-CA 126.484 1.913 . . . . 0.0 111.207 175.534 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -142.06 129.74 21.55 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 123.642 0.777 . . . . 0.0 111.528 177.861 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 87.9 mtp -134.79 102.2 11.38 Favored Pre-proline 0 N--CA 1.472 0.669 0 C-N-CA 124.15 0.98 . . . . 0.0 109.482 169.614 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_exo -61.86 126.82 19.78 Favored 'Trans proline' 0 CA--C 1.537 0.675 0 C-N-CA 122.948 2.432 . . . . 0.0 113.307 -178.432 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 44.2 mmtm -92.67 150.78 20.47 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 124.77 1.228 . . . . 0.0 113.054 -175.358 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -67.67 137.92 55.93 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.839 1.256 . . . . 0.0 111.317 169.164 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 39.3 ptt180 -80.76 6.52 12.71 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 116.107 1.892 . . . . 0.0 116.107 -172.788 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.5 t -131.12 -37.2 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 C-N-CA 125.068 1.347 . . . . 0.0 111.424 -175.38 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 69.7 p -107.8 -17.26 14.12 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 125.732 1.613 . . . . 0.0 112.484 -178.444 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 72.48 7.45 68.61 Favored Glycine 0 CA--C 1.538 1.512 0 C-N-CA 124.963 1.268 . . . . 0.0 115.8 171.197 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -94.91 163.54 13.29 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 125.589 1.555 . . . . 0.0 111.477 176.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 14.9 p80 -68.74 157.53 36.15 Favored 'General case' 0 N--CA 1.472 0.632 0 O-C-N 121.391 -0.818 . . . . 0.0 112.712 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 37.9 mt-30 -99.41 23.9 8.75 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 124.797 1.239 . . . . 0.0 113.473 -170.963 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.65 3.65 77.28 Favored Glycine 0 CA--C 1.535 1.301 0 C-N-CA 125.199 1.38 . . . . 0.0 115.251 178.408 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -145.86 161.17 40.61 Favored 'General case' 0 CA--C 1.539 0.551 0 CA-C-N 118.713 1.257 . . . . 0.0 112.994 179.339 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -154.4 -175.74 25.92 Favored Glycine 0 CA--C 1.531 1.088 0 C-N-CA 125.983 1.754 . . . . 0.0 113.118 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 71.1 m-85 -144.4 152.49 40.77 Favored 'General case' 0 C--O 1.236 0.381 0 C-N-CA 126.101 1.76 . . . . 0.0 111.471 179.219 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 15.9 t -132.64 131.57 59.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 124.864 1.266 . . . . 0.0 109.73 175.551 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 61.3 tt0 -107.81 120.21 41.63 Favored 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 124.831 1.252 . . . . 0.0 110.674 -177.512 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -96.65 162.94 13.23 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 125.012 1.325 . . . . 0.0 112.412 177.478 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.8 tp -64.02 -35.25 80.09 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 123.107 0.563 . . . . 0.0 112.224 176.391 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.1 m -140.12 153.82 46.81 Favored 'General case' 0 N--CA 1.468 0.426 0 C-N-CA 124.649 1.18 . . . . 0.0 112.152 -176.549 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -58.42 -32.42 68.64 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 125.443 1.497 . . . . 0.0 112.785 178.186 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 14.1 mm-40 -67.97 -34.3 76.29 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.659 1.184 . . . . 0.0 112.437 178.244 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 58.4 m-20 -75.75 -31.08 59.42 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 124.105 0.962 . . . . 0.0 111.353 176.559 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -70.64 -46.57 63.06 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 123.708 0.803 . . . . 0.0 111.16 173.239 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -56.52 -36.11 68.82 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 124.002 0.921 . . . . 0.0 112.558 174.726 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 25.6 t80 -71.51 -38.23 71.14 Favored 'General case' 0 CA--C 1.537 0.448 0 O-C-N 121.777 -0.577 . . . . 0.0 112.145 175.703 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -65.6 -36.56 84.09 Favored 'General case' 0 CA--C 1.537 0.462 0 O-C-N 120.784 -1.197 . . . . 0.0 111.72 176.517 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 59.4 mt -63.77 -34.0 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 123.991 0.916 . . . . 0.0 110.858 172.646 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -68.17 -42.9 79.33 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.966 0.906 . . . . 0.0 112.616 176.208 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 18.0 pt -91.22 -37.51 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 N-CA-C 114.916 1.451 . . . . 0.0 114.916 -175.045 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' MET . . . . . 0.48 ' HA ' HD12 ' A' ' 80' ' ' ILE . 15.4 mmt -91.76 0.12 57.51 Favored 'General case' 0 N--CA 1.479 1.02 0 N-CA-C 114.705 1.372 . . . . 0.0 114.705 -169.887 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -84.72 139.63 31.86 Favored 'General case' 0 CA--C 1.539 0.545 0 O-C-N 121.571 -0.705 . . . . 0.0 111.918 178.218 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 20.4 mmt 58.31 10.47 1.31 Allowed 'General case' 0 CA--C 1.55 0.946 0 N-CA-C 115.408 1.633 . . . . 0.0 115.408 -170.291 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.48 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.5 mt -70.28 152.44 8.98 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 124.638 1.175 . . . . 0.0 110.285 169.403 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.1 mtpt -112.06 69.98 0.7 Allowed 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 125.145 1.378 . . . . 0.0 112.345 -176.666 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 29.6 tp -57.73 124.2 18.33 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.156 0.982 . . . . 0.0 110.092 176.302 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 44.3 m-85 45.33 31.06 0.77 Allowed 'General case' 0 CA--C 1.56 1.354 0 N-CA-C 116.2 1.926 . . . . 0.0 116.2 -168.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 78.96 27.77 55.72 Favored Glycine 0 CA--C 1.54 1.64 0 O-C-N 120.234 -1.541 . . . . 0.0 115.811 175.58 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -138.84 120.6 10.2 Favored Pre-proline 0 CA--C 1.541 0.62 0 C-N-CA 128.325 2.65 . . . . 0.0 107.82 -179.575 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -69.65 123.42 10.12 Favored 'Trans proline' 0 CA--C 1.536 0.597 0 C-N-CA 122.964 2.443 . . . . 0.0 112.202 -171.649 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 17.8 pt -95.71 146.53 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 125.314 1.445 . . . . 0.0 111.524 175.361 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 43.2 mmm-85 -109.88 137.24 47.95 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 124.858 1.263 . . . . 0.0 110.73 170.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 24.4 t -130.65 137.56 55.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 124.6 1.16 . . . . 0.0 111.063 -175.884 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 38.0 t-20 -161.42 178.0 9.56 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 126.1 1.76 . . . . 0.0 110.247 179.09 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 12.5 mmmm -57.17 140.84 48.35 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 125.337 1.455 . . . . 0.0 110.666 171.437 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -67.36 -25.74 66.13 Favored 'General case' 0 CA--C 1.546 0.811 0 N-CA-C 113.491 0.923 . . . . 0.0 113.491 178.517 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 67.3 m -123.93 52.06 1.49 Allowed 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 125.835 1.654 . . . . 0.0 111.529 176.127 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -62.13 154.76 26.16 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 124.248 1.019 . . . . 0.0 113.563 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 73.5 m-70 -77.97 152.64 33.05 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 124.54 1.136 . . . . 0.0 112.766 178.212 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 51.6 p-10 -121.78 21.28 10.79 Favored 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 126.2 1.8 . . . . 0.0 113.149 178.575 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 64.6 mtpt -66.64 145.22 55.82 Favored 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 125.51 1.524 . . . . 0.0 112.339 -174.316 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 50.7 p-10 -133.32 21.64 4.03 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 125.687 1.595 . . . . 0.0 113.89 -173.017 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 52.8 tp -63.33 137.78 58.3 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.654 1.182 . . . . 0.0 112.131 -177.382 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 58.2 p -86.16 7.36 25.29 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.811 1.644 . . . . 0.0 115.053 -175.753 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 84.28 -176.06 51.42 Favored Glycine 0 CA--C 1.542 1.729 0 C-N-CA 125.114 1.34 . . . . 0.0 114.022 -175.791 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -71.25 154.42 61.56 Favored 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 123.794 2.996 . . . . 0.0 112.97 -177.213 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 51.8 p -80.65 -22.32 40.62 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 124.76 1.224 . . . . 0.0 113.933 176.275 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 46.9 m 60.87 166.43 0.08 Allowed 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 127.458 2.303 . . . . 0.0 115.582 -177.913 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.213 0 C-N-CA 125.259 1.409 . . . . 0.0 112.825 -178.718 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.648 0 N-CA-C 111.835 -0.506 . . . . 0.0 111.835 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 58.2 p -78.64 -15.89 57.98 Favored 'General case' 0 N--CA 1.477 0.908 0 N-CA-C 114.514 1.302 . . . . 0.0 114.514 -178.863 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 89.4 p -144.05 160.58 40.63 Favored 'General case' 0 N--CA 1.473 0.678 0 C-N-CA 125.877 1.671 . . . . 0.0 112.188 176.289 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 170.24 -177.39 43.53 Favored Glycine 0 CA--C 1.535 1.32 0 C-N-CA 124.874 1.226 . . . . 0.0 113.08 -179.466 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 46.7 m -72.3 145.86 47.55 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 124.187 0.995 . . . . 0.0 112.467 177.661 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.5 m -137.89 153.01 49.58 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.435 1.494 . . . . 0.0 111.926 -179.515 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -73.93 171.22 52.45 Favored Glycine 0 CA--C 1.543 1.806 0 C-N-CA 124.015 0.817 . . . . 0.0 113.829 174.462 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -78.43 70.34 7.29 Favored 'Trans proline' 0 CA--C 1.545 1.052 0 C-N-CA 124.427 3.418 . . . . 0.0 111.854 -179.179 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -72.85 -22.94 20.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 N-CA-C 114.12 1.156 . . . . 0.0 114.12 -178.849 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.6 m 59.79 -38.68 0.08 Allowed 'General case' 0 N--CA 1.481 1.123 0 C-N-CA 129.159 2.984 . . . . 0.0 117.232 -178.724 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -80.9 31.73 0.31 Allowed 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 126.089 1.756 . . . . 0.0 113.838 -173.46 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 91.4 mmt-85 -140.16 -55.41 0.54 Allowed 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 125.913 1.685 . . . . 0.0 111.979 177.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . 0.276 1.0 OUTLIER 48.79 24.33 0.81 Allowed 'General case' 0 CA--C 1.55 0.955 0 C-N-CA 127.573 2.349 . . . . 0.0 116.862 178.325 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -68.27 -14.85 63.29 Favored 'General case' 0 N--CA 1.476 0.83 0 N-CA-C 114.096 1.147 . . . . 0.0 114.096 -174.541 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 25.9 m-20 -88.82 -24.37 22.6 Favored 'General case' 0 CA--C 1.541 0.617 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 172.187 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.71 -14.06 43.58 Favored 'General case' 0 CA--C 1.545 0.781 0 O-C-N 121.398 -0.814 . . . . 0.0 112.383 170.624 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 27.4 m -90.55 137.93 31.96 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 124.372 1.069 . . . . 0.0 109.863 168.29 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.9 m -103.98 149.09 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.657 0 C-N-CA 124.536 1.135 . . . . 0.0 110.334 169.699 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -94.97 143.3 26.59 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 126.192 1.797 . . . . 0.0 108.595 168.866 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 23.2 t -132.49 109.59 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 C-N-CA 125.629 1.572 . . . . 0.0 109.231 178.328 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -106.72 143.23 15.76 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 124.274 0.94 . . . . 0.0 113.014 179.372 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 100.87 32.15 5.45 Favored Glycine 0 CA--C 1.535 1.294 0 C-N-CA 124.921 1.248 . . . . 0.0 114.135 175.303 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 83.0 mt -76.49 145.33 39.23 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 125.322 1.449 . . . . 0.0 111.508 -173.87 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -85.06 157.54 20.7 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 123.486 0.715 . . . . 0.0 112.342 175.597 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -57.79 -20.92 38.89 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 114.749 1.389 . . . . 0.0 114.749 178.576 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.8 mtmm -81.39 -8.22 59.7 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 124.711 1.204 . . . . 0.0 114.232 174.46 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.6 t -78.31 141.37 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 C-N-CA 124.537 1.135 . . . . 0.0 111.241 176.554 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 43.4 m -144.08 165.16 28.57 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 125.225 1.41 . . . . 0.0 110.676 169.36 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -54.74 -41.18 88.65 Favored Pre-proline 0 CA--C 1.547 0.836 0 N-CA-C 114.839 1.422 . . . . 0.0 114.839 -177.028 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -62.45 -28.02 77.64 Favored 'Trans proline' 0 C--N 1.354 0.843 0 C-N-CA 122.187 1.925 . . . . 0.0 113.608 175.873 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 20.5 tp -66.82 -55.19 15.97 Favored 'General case' 0 C--N 1.344 0.343 0 CA-C-N 118.393 0.542 . . . . 0.0 109.586 171.919 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 34.1 mt -55.89 -42.61 76.22 Favored 'General case' 0 N--CA 1.464 0.256 0 O-C-N 123.241 0.338 . . . . 0.0 111.388 -176.672 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 3.1 t90 -56.39 -62.32 1.8 Allowed 'General case' 0 CA--C 1.53 0.199 0 C-N-CA 123.552 0.741 . . . . 0.0 111.27 178.959 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -65.25 -29.53 70.32 Favored 'General case' 0 N--CA 1.471 0.593 0 N-CA-C 113.645 0.98 . . . . 0.0 113.645 -177.87 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.8 tp -72.22 -36.26 69.09 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 124.081 0.952 . . . . 0.0 112.104 176.535 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 -88.32 -10.82 48.23 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 124.904 1.281 . . . . 0.0 113.286 -176.241 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 23.3 mt -52.89 -21.7 4.6 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 114.041 1.126 . . . . 0.0 114.041 169.138 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 -64.2 -32.08 73.53 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 125.338 1.455 . . . . 0.0 112.738 175.287 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.23 -45.53 19.62 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.45 0.7 . . . . 0.0 112.521 176.654 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -179.05 -173.65 44.52 Favored Glycine 0 CA--C 1.536 1.378 0 C-N-CA 124.538 1.066 . . . . 0.0 113.008 177.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -66.57 112.6 2.44 Favored 'Trans proline' 0 CA--C 1.537 0.675 0 C-N-CA 123.647 2.898 . . . . 0.0 111.616 -179.302 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 74.5 t -87.84 133.91 29.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 125.098 1.359 . . . . 0.0 109.901 175.649 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.7 t -111.88 -32.58 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 126.314 1.845 . . . . 0.0 112.329 -169.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 14.6 t30 -160.21 162.08 33.69 Favored 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 126.171 1.788 . . . . 0.0 110.68 -174.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 1.5 p -143.28 153.18 42.51 Favored 'General case' 0 N--CA 1.482 1.159 0 C-N-CA 126.313 1.845 . . . . 0.0 111.417 176.492 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 4.3 t60 -142.91 134.48 26.44 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 123.914 0.886 . . . . 0.0 111.187 175.358 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 82.2 mtp -136.07 105.15 9.56 Favored Pre-proline 0 N--CA 1.469 0.484 0 C-N-CA 124.099 0.959 . . . . 0.0 108.776 168.672 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_exo -53.62 139.92 66.31 Favored 'Trans proline' 0 CA--C 1.537 0.657 0 C-N-CA 123.397 2.732 . . . . 0.0 112.965 176.5 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 44.7 mmtm -112.22 157.96 20.27 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 125.069 1.348 . . . . 0.0 113.294 -172.499 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -76.52 151.98 36.19 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 127.024 2.13 . . . . 0.0 112.225 174.094 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 40.4 ptt180 -90.7 0.86 57.27 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 116.462 2.023 . . . . 0.0 116.462 -172.666 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 3.6 m -136.28 -31.66 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 C-N-CA 124.362 1.065 . . . . 0.0 113.461 -178.756 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.3 p -106.97 -20.36 13.34 Favored 'General case' 0 N--CA 1.468 0.437 0 C-N-CA 124.7 1.2 . . . . 0.0 111.866 179.23 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 69.09 8.86 59.19 Favored Glycine 0 CA--C 1.541 1.682 0 C-N-CA 124.674 1.131 . . . . 0.0 115.329 -178.73 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 39.5 mt-30 -65.99 160.76 22.94 Favored 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 125.253 1.421 . . . . 0.0 110.683 171.813 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 25.2 p80 -74.82 156.86 36.04 Favored 'General case' 0 N--CA 1.474 0.77 0 O-C-N 120.569 -1.332 . . . . 0.0 112.514 173.364 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 78.8 mt-30 -81.55 14.55 2.49 Favored 'General case' 0 CA--C 1.552 1.035 0 N-CA-C 114.59 1.33 . . . . 0.0 114.59 -174.672 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 87.85 0.46 83.6 Favored Glycine 0 CA--C 1.535 1.333 0 C-N-CA 125.256 1.407 . . . . 0.0 115.011 -179.34 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 39.3 p90 -143.43 161.37 38.58 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.063 1.345 . . . . 0.0 112.273 177.276 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -149.21 -174.93 21.15 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 125.737 1.637 . . . . 0.0 113.109 -178.838 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -145.88 149.98 35.27 Favored 'General case' 0 C--O 1.236 0.364 0 C-N-CA 125.973 1.709 . . . . 0.0 111.402 -179.378 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.2 t -134.4 126.42 48.83 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 124.672 1.189 . . . . 0.0 109.981 176.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -100.66 121.39 41.56 Favored 'General case' 0 N--CA 1.467 0.376 0 C-N-CA 124.791 1.236 . . . . 0.0 110.935 -176.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -97.33 160.81 14.11 Favored 'General case' 0 C--O 1.235 0.299 0 C-N-CA 124.246 1.018 . . . . 0.0 112.465 175.783 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 14.6 tp -62.13 -34.3 76.11 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 123.325 0.65 . . . . 0.0 112.478 176.435 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 18.4 m -143.23 156.36 44.73 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 124.515 1.126 . . . . 0.0 112.139 -177.448 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 74.8 tt0 -62.91 -32.84 74.21 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 124.122 0.969 . . . . 0.0 113.092 -179.422 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -68.4 -23.86 64.69 Favored 'General case' 0 N--CA 1.474 0.728 0 O-C-N 121.23 -0.919 . . . . 0.0 113.439 176.835 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 51.7 m-20 -80.99 -32.6 34.22 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 123.932 0.893 . . . . 0.0 111.438 172.564 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -68.26 -44.56 75.33 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 123.47 0.708 . . . . 0.0 111.447 172.525 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -57.6 -33.47 68.25 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.438 1.095 . . . . 0.0 112.659 174.128 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 16.0 t80 -72.72 -36.78 67.87 Favored 'General case' 0 CA--C 1.536 0.442 0 O-C-N 121.638 -0.664 . . . . 0.0 111.912 175.329 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -68.11 -35.0 77.44 Favored 'General case' 0 CA--C 1.54 0.572 0 O-C-N 120.622 -1.299 . . . . 0.0 111.445 175.561 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 70.8 mt -64.24 -29.71 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 124.189 0.995 . . . . 0.0 111.384 171.171 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 25.1 ttmm -71.95 -48.02 48.15 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 124.213 1.005 . . . . 0.0 112.322 174.059 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 19.7 pt -89.34 -39.84 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 115.156 1.539 . . . . 0.0 115.156 -172.998 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' MET . . . . . 0.478 ' HA ' HD12 ' A' ' 80' ' ' ILE . 15.2 mmt -89.38 0.81 56.55 Favored 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 114.407 1.262 . . . . 0.0 114.407 -170.359 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -86.94 136.26 33.0 Favored 'General case' 0 CA--C 1.538 0.504 0 C-N-CA 123.399 0.68 . . . . 0.0 111.717 178.392 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 21.0 mtp 60.36 10.62 2.5 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 126.084 1.754 . . . . 0.0 115.494 -169.545 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.478 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.8 mt -70.6 151.26 9.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 124.639 1.176 . . . . 0.0 109.9 168.727 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 46.7 mtpt -110.58 70.74 0.73 Allowed 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 124.982 1.313 . . . . 0.0 112.194 -175.692 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 25.3 tp -58.34 124.13 18.45 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 123.878 0.871 . . . . 0.0 109.618 175.158 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 61.5 m-85 45.39 31.26 0.83 Allowed 'General case' 0 CA--C 1.561 1.38 0 N-CA-C 116.058 1.873 . . . . 0.0 116.058 -168.486 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 82.36 17.4 69.04 Favored Glycine 0 CA--C 1.541 1.685 0 O-C-N 120.268 -1.52 . . . . 0.0 116.655 173.719 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 94.0 mttt -131.58 123.31 19.3 Favored Pre-proline 0 CA--C 1.542 0.639 0 C-N-CA 128.113 2.565 . . . . 0.0 108.081 -179.572 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -71.34 127.06 12.89 Favored 'Trans proline' 0 CA--C 1.535 0.559 0 C-N-CA 123.329 2.686 . . . . 0.0 112.524 -169.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 16.7 pt -97.08 150.51 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 C-N-CA 125.272 1.429 . . . . 0.0 112.149 176.605 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 23.9 mmt180 -115.4 140.58 49.01 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.948 1.299 . . . . 0.0 111.17 170.323 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 19.8 t -131.5 135.15 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 124.974 1.31 . . . . 0.0 111.063 -172.647 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -154.68 174.52 14.89 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.061 1.344 . . . . 0.0 111.968 177.243 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 11.9 mmmm -56.34 136.78 53.36 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 124.021 0.929 . . . . 0.0 109.599 171.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -69.92 -16.9 63.29 Favored 'General case' 0 CA--C 1.547 0.864 0 CA-C-N 119.847 1.203 . . . . 0.0 112.889 177.29 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 75.4 p -70.36 -10.03 57.9 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 126.53 1.932 . . . . 0.0 114.028 169.571 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -126.14 162.27 25.75 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 125.838 1.655 . . . . 0.0 112.977 -176.239 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -95.3 -8.71 35.11 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 124.619 1.168 . . . . 0.0 113.68 178.47 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 -152.13 165.14 35.71 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 126.055 1.742 . . . . 0.0 111.525 -176.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 74.7 tttt -70.96 147.82 48.3 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 124.538 1.135 . . . . 0.0 111.072 171.906 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -74.53 149.53 40.18 Favored 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 123.769 0.828 . . . . 0.0 112.223 177.796 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 23.9 tp -134.15 -0.99 2.97 Favored 'General case' 0 CA--C 1.553 1.089 0 C-N-CA 126.176 1.79 . . . . 0.0 112.968 175.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 52.3 m -122.71 159.84 27.13 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 125.464 1.506 . . . . 0.0 113.392 -169.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -165.78 178.57 40.48 Favored Glycine 0 CA--C 1.54 1.635 0 C-N-CA 124.888 1.232 . . . . 0.0 113.34 178.817 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -70.59 159.4 52.91 Favored 'Trans proline' 0 CA--C 1.541 0.829 0 C-N-CA 123.907 3.071 . . . . 0.0 112.973 -178.279 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 67.2 p -76.54 -14.48 60.01 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 114.539 1.311 . . . . 0.0 114.539 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 9.9 t -148.89 159.78 43.86 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.853 1.661 . . . . 0.0 111.572 177.854 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.198 0 C-N-CA 125.542 1.544 . . . . 0.0 112.823 -178.382 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.585 0 N-CA-C 111.601 -0.6 . . . . 0.0 111.601 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.3 m -64.04 -13.99 51.07 Favored 'General case' 0 N--CA 1.481 1.085 0 N-CA-C 115.106 1.521 . . . . 0.0 115.106 -173.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 43.0 p -73.28 -14.11 61.25 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 125.797 1.639 . . . . 0.0 114.295 171.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -69.4 155.13 53.4 Favored Glycine 0 CA--C 1.537 1.467 0 C-N-CA 124.519 1.057 . . . . 0.0 113.994 178.05 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 92.9 p -149.02 165.71 30.84 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 125.331 1.452 . . . . 0.0 112.565 -178.039 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 22.8 m -77.3 -9.83 59.06 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 124.437 1.095 . . . . 0.0 113.891 176.084 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 170.65 -174.46 44.55 Favored Glycine 0 CA--C 1.539 1.538 0 C-N-CA 125.552 1.548 . . . . 0.0 112.783 -178.356 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -78.32 46.6 2.15 Favored 'Trans proline' 0 CA--C 1.549 1.232 0 C-N-CA 125.065 3.843 . . . . 0.0 112.79 -178.422 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 1.6 pp -96.85 158.94 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 C-N-CA 126.123 1.769 . . . . 0.0 113.376 -175.889 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 18.8 m -89.98 11.27 21.07 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 125.004 1.322 . . . . 0.0 114.451 -174.023 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 16.7 tt0 56.96 36.48 27.83 Favored 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 126.147 1.779 . . . . 0.0 114.036 179.749 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 17.7 ptp180 -146.22 160.01 42.55 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 125.877 1.671 . . . . 0.0 112.465 178.092 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 12.2 p30 -144.26 162.61 35.95 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.415 1.486 . . . . 0.0 112.53 -173.469 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 85.4 mt-30 -136.08 6.39 3.1 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.116 1.367 . . . . 0.0 113.673 176.438 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 23.8 p-10 -105.72 -37.29 6.78 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 126.175 1.79 . . . . 0.0 112.287 176.279 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.13 -2.9 58.77 Favored 'General case' 0 CA--C 1.547 0.863 0 C-N-CA 124.68 1.192 . . . . 0.0 112.833 169.188 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 79.0 m -105.8 132.06 52.38 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 125.027 1.331 . . . . 0.0 109.381 169.134 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.0 m -101.85 149.89 6.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 124.953 1.301 . . . . 0.0 110.792 174.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 13.6 t80 -95.6 144.57 25.93 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 126.255 1.822 . . . . 0.0 109.487 169.398 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 24.0 t -132.01 113.47 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 125.618 1.567 . . . . 0.0 109.332 174.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -109.06 149.31 17.06 Favored Glycine 0 CA--C 1.53 1.031 0 C-N-CA 124.554 1.073 . . . . 0.0 113.334 178.054 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 92.9 34.61 6.75 Favored Glycine 0 CA--C 1.533 1.206 0 C-N-CA 124.718 1.151 . . . . 0.0 113.794 175.667 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 88.4 mt -83.47 144.97 29.21 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 125.275 1.43 . . . . 0.0 112.005 -172.23 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -82.86 157.32 23.16 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 123.94 0.896 . . . . 0.0 112.444 177.888 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -58.29 -21.18 47.93 Favored 'General case' 0 CA--C 1.546 0.799 0 N-CA-C 114.66 1.355 . . . . 0.0 114.66 178.471 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.0 mtmm -79.49 -13.07 59.81 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 174.509 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.1 t -75.4 138.56 20.65 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.898 0 C-N-CA 124.426 1.09 . . . . 0.0 111.302 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 9.4 t -144.39 167.22 23.0 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 123.973 0.909 . . . . 0.0 112.151 173.198 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -54.17 -43.84 97.71 Favored Pre-proline 0 CA--C 1.549 0.908 0 N-CA-C 114.137 1.162 . . . . 0.0 114.137 -179.253 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -62.93 -29.98 76.53 Favored 'Trans proline' 0 C--N 1.353 0.808 0 C-N-CA 122.23 1.953 . . . . 0.0 113.463 175.553 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 21.3 tp -67.4 -54.43 20.53 Favored 'General case' 0 C--N 1.343 0.311 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 172.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 24.6 mt -56.11 -42.01 76.17 Favored 'General case' 0 N--CA 1.463 0.204 0 C-N-CA 122.692 0.397 . . . . 0.0 111.737 -176.383 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.8 t90 -57.96 -62.05 2.09 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 123.211 0.605 . . . . 0.0 111.276 178.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -64.61 -29.84 70.86 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 113.685 0.995 . . . . 0.0 113.685 -177.838 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.2 tp -70.72 -36.32 73.15 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.021 0.928 . . . . 0.0 112.065 176.187 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 11.6 m-85 -88.86 -10.91 46.26 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 124.92 1.288 . . . . 0.0 113.512 -175.709 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 26.4 mt -53.77 -20.97 6.37 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 114.03 1.122 . . . . 0.0 114.03 169.324 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 -64.14 -32.28 73.79 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.284 1.433 . . . . 0.0 112.712 175.176 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.66 -44.55 20.7 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 123.525 0.73 . . . . 0.0 112.684 177.129 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.54 -172.78 44.66 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 124.485 1.041 . . . . 0.0 113.07 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -67.92 109.38 1.9 Allowed 'Trans proline' 0 CA--C 1.537 0.664 0 C-N-CA 123.704 2.936 . . . . 0.0 111.663 -179.082 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 68.9 t -84.48 133.63 28.83 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 124.896 1.278 . . . . 0.0 109.8 174.199 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 5.6 t -109.85 -33.65 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 126.162 1.785 . . . . 0.0 111.968 -171.683 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 19.5 t30 -160.64 163.23 32.71 Favored 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 125.962 1.705 . . . . 0.0 110.929 -173.938 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 5.2 p -140.2 156.94 46.31 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 126.449 1.9 . . . . 0.0 111.295 175.59 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 4.8 t60 -141.66 142.37 33.38 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 123.832 0.853 . . . . 0.0 111.111 171.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 30.7 mmm -139.55 102.84 7.13 Favored Pre-proline 0 N--CA 1.469 0.521 0 C-N-CA 125.127 1.371 . . . . 0.0 108.356 170.87 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_exo -56.28 132.38 51.52 Favored 'Trans proline' 0 CA--C 1.537 0.632 0 C-N-CA 123.105 2.537 . . . . 0.0 112.701 177.234 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 42.8 mmtm -104.63 141.68 36.0 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.959 1.304 . . . . 0.0 111.698 -177.396 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -69.48 140.1 53.97 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 125.212 1.405 . . . . 0.0 112.261 177.424 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 53.2 ptt85 -83.98 6.14 23.01 Favored 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 115.887 1.81 . . . . 0.0 115.887 -173.688 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 25.0 t -132.41 -37.7 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 124.988 1.315 . . . . 0.0 111.41 -175.207 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 73.4 p -108.4 -20.67 13.04 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 126.05 1.74 . . . . 0.0 112.614 -177.491 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 74.07 1.85 60.72 Favored Glycine 0 CA--C 1.539 1.568 0 C-N-CA 125.018 1.294 . . . . 0.0 116.003 172.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -78.54 168.99 18.96 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-N 118.513 1.156 . . . . 0.0 111.315 171.195 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 18.5 p80 -67.64 156.04 37.77 Favored 'General case' 0 CA--C 1.54 0.581 0 O-C-N 121.029 -1.044 . . . . 0.0 112.037 170.664 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 46.6 mt-30 -87.88 17.04 5.15 Favored 'General case' 0 CA--C 1.55 0.978 0 N-CA-C 114.493 1.294 . . . . 0.0 114.493 -172.047 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.3 1.12 81.86 Favored Glycine 0 CA--C 1.536 1.371 0 C-N-CA 125.223 1.392 . . . . 0.0 115.002 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 45.6 p90 -145.66 156.28 43.55 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 125.268 1.427 . . . . 0.0 112.19 178.165 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -142.87 -178.17 18.52 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 126.784 2.135 . . . . 0.0 112.755 -176.918 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 65.4 m-85 -144.03 151.71 40.04 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 125.705 1.602 . . . . 0.0 111.896 177.364 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 19.4 t -134.84 131.99 53.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 C-N-CA 124.72 1.208 . . . . 0.0 110.132 176.518 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -108.35 127.35 53.8 Favored 'General case' 0 N--CA 1.467 0.377 0 C-N-CA 124.772 1.229 . . . . 0.0 111.613 -176.833 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -103.73 160.67 14.57 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 125.241 1.416 . . . . 0.0 112.475 178.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 14.8 tp -61.97 -32.61 73.07 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 123.361 0.664 . . . . 0.0 112.387 178.29 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.4 m -143.8 155.3 44.1 Favored 'General case' 0 N--CA 1.468 0.45 0 C-N-CA 124.258 1.023 . . . . 0.0 111.868 -179.435 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 12.8 tm-20 -62.66 -32.06 73.05 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 124.388 1.075 . . . . 0.0 113.221 -178.321 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -69.3 -25.23 64.14 Favored 'General case' 0 CA--C 1.542 0.648 0 N-CA-C 113.346 0.869 . . . . 0.0 113.346 176.52 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 -79.75 -32.53 41.07 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 123.875 0.87 . . . . 0.0 111.465 173.416 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.68 -42.83 73.61 Favored 'General case' 0 CA--C 1.539 0.545 0 O-C-N 121.875 -0.516 . . . . 0.0 111.263 172.833 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -62.16 -26.8 68.53 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 123.929 0.891 . . . . 0.0 112.704 176.083 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 30.3 t80 -78.68 -34.54 46.13 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 123.705 0.802 . . . . 0.0 112.838 173.657 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -65.38 -34.23 77.81 Favored 'General case' 0 CA--C 1.536 0.434 0 O-C-N 120.541 -1.349 . . . . 0.0 111.146 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 61.8 mt -65.42 -33.85 66.47 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 C-N-CA 124.605 1.162 . . . . 0.0 111.625 173.27 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 50.5 tttm -65.03 -41.97 94.78 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.207 1.003 . . . . 0.0 112.053 174.576 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 20.0 pt -93.98 -37.77 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 N-CA-C 114.809 1.411 . . . . 0.0 114.809 -174.318 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' MET . . . . . 0.488 ' HA ' HD12 ' A' ' 80' ' ' ILE . 13.8 mmt -90.85 -1.25 57.86 Favored 'General case' 0 N--CA 1.479 1.011 0 N-CA-C 114.948 1.462 . . . . 0.0 114.948 -169.742 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -81.17 138.86 35.84 Favored 'General case' 0 CA--C 1.54 0.565 0 O-C-N 120.929 -1.107 . . . . 0.0 111.863 178.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 22.3 mmt 61.5 5.45 1.22 Allowed 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 126.443 1.897 . . . . 0.0 115.345 -170.55 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.488 HD12 ' HA ' ' A' ' 77' ' ' MET . 1.6 mt -68.69 142.36 16.34 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 C-N-CA 124.405 1.082 . . . . 0.0 111.894 178.711 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 42.5 mtpt -98.27 64.89 1.65 Allowed 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 125.0 1.32 . . . . 0.0 112.35 -171.478 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 27.1 tp -59.35 123.74 17.75 Favored 'General case' 0 CA--C 1.542 0.663 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 174.233 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 63.0 m-85 45.27 31.65 0.85 Allowed 'General case' 0 CA--C 1.562 1.418 0 N-CA-C 115.848 1.796 . . . . 0.0 115.848 -168.022 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 84.61 12.66 74.68 Favored Glycine 0 CA--C 1.542 1.753 0 N-CA-C 117.045 1.578 . . . . 0.0 117.045 173.175 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -127.27 117.85 21.72 Favored Pre-proline 0 CA--C 1.54 0.575 0 C-N-CA 127.892 2.477 . . . . 0.0 108.49 -178.026 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -71.89 121.86 7.98 Favored 'Trans proline' 0 CA--C 1.536 0.609 0 C-N-CA 123.617 2.878 . . . . 0.0 111.761 -171.623 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 4.9 pt -86.94 168.49 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 125.681 1.592 . . . . 0.0 112.524 -176.804 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 73.6 mmt-85 -120.82 132.92 55.28 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 125.571 1.548 . . . . 0.0 109.961 171.348 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 15.2 t -131.07 133.94 62.1 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 123.95 0.9 . . . . 0.0 111.376 -176.659 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -157.65 171.73 19.8 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.888 1.675 . . . . 0.0 111.252 179.658 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.1 mmmm -58.82 144.04 45.47 Favored 'General case' 0 N--CA 1.48 1.072 0 O-C-N 121.3 -0.875 . . . . 0.0 109.444 170.58 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -66.85 -29.89 69.92 Favored 'General case' 0 CA--C 1.547 0.848 0 CA-C-N 119.142 0.883 . . . . 0.0 112.862 -178.81 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 5.9 t -85.16 -61.19 1.83 Allowed 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 124.69 1.196 . . . . 0.0 111.505 169.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . 53.28 18.57 1.29 Allowed 'General case' 0 CA--C 1.552 1.034 0 C-N-CA 126.05 1.74 . . . . 0.0 114.921 -169.657 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -139.68 18.62 2.51 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.067 1.347 . . . . 0.0 113.388 -174.549 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 58.8 t-20 -65.93 134.72 53.58 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 124.898 1.279 . . . . 0.0 112.015 -177.202 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 57.5 mtmt -94.1 -6.73 44.37 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.785 1.634 . . . . 0.0 114.157 -179.291 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -62.22 149.17 42.48 Favored 'General case' 0 CA--C 1.549 0.922 0 C-N-CA 124.557 1.143 . . . . 0.0 112.672 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 16.9 tp 53.62 47.66 23.36 Favored 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 125.98 1.712 . . . . 0.0 113.173 -179.267 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 56.8 p -71.14 -36.25 72.01 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 124.282 1.033 . . . . 0.0 112.688 173.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -89.62 173.97 40.81 Favored Glycine 0 CA--C 1.542 1.748 0 C-N-CA 125.221 1.391 . . . . 0.0 113.3 169.69 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -62.33 148.52 93.12 Favored 'Trans proline' 0 CA--C 1.537 0.655 0 C-N-CA 123.539 2.826 . . . . 0.0 113.73 179.164 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 60.8 p -67.82 -18.91 64.99 Favored 'General case' 0 N--CA 1.477 0.889 0 C-N-CA 124.183 0.993 . . . . 0.0 113.649 173.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 61.5 p -85.84 -4.16 59.09 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 126.271 1.828 . . . . 0.0 114.295 173.449 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.236 0 C-N-CA 125.596 1.57 . . . . 0.0 114.082 -179.544 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.548 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 27.8 m 53.03 38.0 26.18 Favored 'General case' 0 N--CA 1.48 1.065 0 C-N-CA 125.026 1.33 . . . . 0.0 113.439 -174.462 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 60.9 p -140.28 162.93 34.12 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 126.489 1.916 . . . . 0.0 112.043 -171.075 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 61.64 25.38 65.34 Favored Glycine 0 CA--C 1.538 1.517 0 C-N-CA 123.919 0.771 . . . . 0.0 114.648 178.287 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.2 m 56.91 22.17 6.89 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 126.158 1.783 . . . . 0.0 114.826 -170.21 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 8.3 t -79.76 162.65 25.02 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.78 1.232 . . . . 0.0 112.122 174.518 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 77.77 -128.81 9.08 Favored Glycine 0 CA--C 1.543 1.787 0 CA-C-O 118.578 -1.123 . . . . 0.0 112.609 -176.637 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -68.82 157.83 60.27 Favored 'Trans proline' 0 CA--C 1.541 0.826 0 C-N-CA 123.454 2.769 . . . . 0.0 113.507 -175.244 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ILE . . . . . 0.418 HD13 ' H ' ' A' ' 9' ' ' ILE . 0.2 OUTLIER -69.81 153.65 8.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 C-N-CA 125.102 1.361 . . . . 0.0 113.401 179.34 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 64.5 p -92.47 -4.21 53.99 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 125.575 1.55 . . . . 0.0 115.018 -175.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -138.57 147.77 43.41 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 125.678 1.591 . . . . 0.0 111.303 -178.657 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 26.6 mmt85 -78.68 86.36 4.65 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.191 1.396 . . . . 0.0 110.166 177.209 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 10.9 m120 55.7 -94.47 0.04 OUTLIER 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 126.29 1.836 . . . . 0.0 113.71 -171.44 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 61.69 -4.27 0.18 Allowed 'General case' 0 CA--C 1.552 1.028 0 C-N-CA 126.575 1.95 . . . . 0.0 115.228 -170.8 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 24.6 p-10 -92.43 -41.08 10.51 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 127.667 2.387 . . . . 0.0 111.845 172.92 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -80.18 -3.34 48.6 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 124.66 1.184 . . . . 0.0 112.991 169.649 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.2 m -92.47 133.28 36.07 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 124.158 0.983 . . . . 0.0 109.734 169.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.4 m -105.38 147.32 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 C-N-CA 124.948 1.299 . . . . 0.0 110.768 172.948 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 28.1 t80 -95.4 142.43 27.78 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 126.16 1.784 . . . . 0.0 109.644 169.825 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 25.0 t -133.34 108.22 12.13 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 C-N-CA 125.812 1.645 . . . . 0.0 109.374 178.161 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -102.96 150.97 17.95 Favored Glycine 0 CA--C 1.53 1.023 0 C-N-CA 124.353 0.978 . . . . 0.0 112.942 175.889 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.54 34.25 7.52 Favored Glycine 0 CA--C 1.532 1.152 0 C-N-CA 124.591 1.091 . . . . 0.0 113.959 173.216 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 88.9 mt -81.29 144.93 31.18 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 125.394 1.478 . . . . 0.0 111.763 -173.112 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -82.43 156.14 24.29 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 123.821 0.848 . . . . 0.0 112.246 177.413 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.84 -20.28 49.22 Favored 'General case' 0 CA--C 1.546 0.823 0 N-CA-C 114.804 1.409 . . . . 0.0 114.804 179.038 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.5 mtmm -82.24 -8.53 59.64 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 124.883 1.273 . . . . 0.0 114.178 174.917 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 55.1 t -78.23 140.07 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 C-N-CA 124.884 1.274 . . . . 0.0 111.13 177.508 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 9.5 t -144.49 167.29 22.85 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 123.912 0.885 . . . . 0.0 112.104 171.677 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 7.8 mt-10 -54.29 -43.9 98.02 Favored Pre-proline 0 CA--C 1.547 0.838 0 CA-C-O 117.682 -1.152 . . . . 0.0 114.106 -179.292 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -62.69 -30.85 79.02 Favored 'Trans proline' 0 C--N 1.354 0.82 0 C-N-CA 122.216 1.944 . . . . 0.0 113.389 175.144 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 20.8 tp -67.29 -54.24 22.57 Favored 'General case' 0 C--N 1.343 0.322 0 CA-C-N 118.218 0.463 . . . . 0.0 109.754 173.197 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 34.4 mt -55.18 -42.99 73.9 Favored 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 122.62 0.368 . . . . 0.0 111.567 -177.365 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.7 t90 -57.22 -61.34 2.54 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 123.407 0.683 . . . . 0.0 111.348 178.684 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -65.54 -29.86 70.54 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 113.745 1.017 . . . . 0.0 113.745 -177.817 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.6 tp -71.53 -36.18 70.94 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 124.162 0.985 . . . . 0.0 111.873 176.451 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -88.57 -11.9 44.26 Favored 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 124.746 1.218 . . . . 0.0 113.299 -176.245 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 24.1 mt -52.84 -22.37 5.35 Favored 'General case' 0 N--CA 1.477 0.904 0 N-CA-C 114.058 1.133 . . . . 0.0 114.058 169.037 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 41.4 mt-30 -63.29 -32.04 73.35 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 125.225 1.41 . . . . 0.0 112.662 175.584 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.54 -44.88 20.3 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 123.563 0.745 . . . . 0.0 112.677 176.873 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.64 -173.56 45.33 Favored Glycine 0 CA--C 1.536 1.377 0 C-N-CA 124.631 1.11 . . . . 0.0 112.97 179.099 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -66.71 112.13 2.34 Favored 'Trans proline' 0 CA--C 1.538 0.676 0 C-N-CA 123.66 2.907 . . . . 0.0 111.677 -178.939 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 69.3 t -87.28 131.92 33.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 C-N-CA 124.953 1.301 . . . . 0.0 109.686 174.827 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.8 t -106.44 -34.11 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 126.671 1.988 . . . . 0.0 111.746 -171.961 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 24.3 t30 -160.66 165.83 29.89 Favored 'General case' 0 CA--C 1.554 1.109 0 C-N-CA 125.973 1.709 . . . . 0.0 110.832 -174.741 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 8.4 p -139.69 160.36 40.06 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 126.391 1.876 . . . . 0.0 111.026 173.619 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 5.6 t60 -142.23 143.17 32.77 Favored 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 123.688 0.795 . . . . 0.0 111.047 171.734 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 2.6 mmm -141.39 104.42 5.99 Favored Pre-proline 0 N--CA 1.468 0.469 0 C-N-CA 125.321 1.448 . . . . 0.0 108.673 170.555 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_exo -56.18 134.93 67.25 Favored 'Trans proline' 0 CA--C 1.539 0.768 0 C-N-CA 123.181 2.588 . . . . 0.0 112.049 171.451 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 42.7 mmtm -110.45 146.3 36.16 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 124.83 1.252 . . . . 0.0 113.19 -172.149 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -68.82 144.87 54.17 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 125.822 1.649 . . . . 0.0 112.324 171.458 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 11.9 ptp85 -88.87 7.24 35.32 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 115.995 1.85 . . . . 0.0 115.995 -174.449 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 39.3 t -130.24 -37.38 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.15 0 C-N-CA 125.008 1.323 . . . . 0.0 111.291 -174.68 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 73.1 p -113.29 -15.44 12.69 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 125.888 1.675 . . . . 0.0 112.437 -177.212 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.83 4.35 53.94 Favored Glycine 0 CA--C 1.537 1.422 0 C-N-CA 125.041 1.305 . . . . 0.0 115.412 177.067 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 72.6 mm-40 -78.22 164.89 24.53 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 124.705 1.202 . . . . 0.0 110.945 177.615 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 25.4 p80 -68.04 154.68 41.14 Favored 'General case' 0 N--CA 1.471 0.608 0 O-C-N 120.922 -1.111 . . . . 0.0 112.338 175.247 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 47.7 mt-30 -84.54 20.72 1.64 Allowed 'General case' 0 CA--C 1.55 0.977 0 N-CA-C 114.396 1.258 . . . . 0.0 114.396 -173.865 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.95 -1.21 86.72 Favored Glycine 0 CA--C 1.535 1.283 0 C-N-CA 125.257 1.408 . . . . 0.0 114.936 -179.331 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -144.89 152.26 39.98 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.209 1.404 . . . . 0.0 111.949 177.44 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -142.31 -178.94 18.81 Favored Glycine 0 CA--C 1.534 1.244 0 C-N-CA 126.846 2.165 . . . . 0.0 112.284 -176.652 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 51.7 m-85 -142.94 152.72 42.32 Favored 'General case' 0 C--O 1.236 0.371 0 C-N-CA 125.321 1.449 . . . . 0.0 111.688 178.588 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.3 t -133.55 133.87 57.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 124.714 1.205 . . . . 0.0 109.561 176.135 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 59.8 tt0 -109.77 119.71 40.21 Favored 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 124.687 1.195 . . . . 0.0 110.896 -176.056 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -96.01 163.15 13.25 Favored 'General case' 0 C--O 1.234 0.25 0 C-N-CA 124.688 1.195 . . . . 0.0 112.693 177.163 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.9 tp -64.44 -34.7 78.79 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 123.246 0.618 . . . . 0.0 112.415 177.055 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 18.6 m -144.03 156.83 44.54 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 124.629 1.172 . . . . 0.0 112.042 -176.807 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 50.3 tt0 -62.58 -33.31 74.71 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 124.003 0.921 . . . . 0.0 113.027 -179.094 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -68.44 -24.47 64.73 Favored 'General case' 0 CA--C 1.542 0.67 0 O-C-N 121.23 -0.919 . . . . 0.0 113.469 177.343 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -80.24 -33.27 38.09 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 123.848 0.859 . . . . 0.0 111.376 172.591 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -68.64 -44.76 73.49 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.305 0.642 . . . . 0.0 111.521 172.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 33.6 t70 -57.27 -35.19 69.45 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.515 1.126 . . . . 0.0 112.524 175.635 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 23.6 t80 -71.42 -38.41 71.4 Favored 'General case' 0 CA--C 1.536 0.439 0 O-C-N 121.725 -0.609 . . . . 0.0 111.985 175.052 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -65.8 -37.08 85.3 Favored 'General case' 0 CA--C 1.537 0.466 0 O-C-N 120.795 -1.19 . . . . 0.0 111.537 176.537 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 64.5 mt -63.42 -33.26 60.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 124.097 0.959 . . . . 0.0 110.936 172.484 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 63.2 tttp -69.66 -43.68 72.08 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 124.117 0.967 . . . . 0.0 112.478 176.635 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 18.3 pt -89.21 -42.67 14.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 114.5 1.296 . . . . 0.0 114.5 -175.574 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' MET . . . . . 0.491 ' HA ' HD12 ' A' ' 80' ' ' ILE . 15.3 mmt -86.69 0.82 53.88 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 114.772 1.397 . . . . 0.0 114.772 -169.254 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -84.37 132.27 34.61 Favored 'General case' 0 CA--C 1.538 0.5 0 O-C-N 121.433 -0.792 . . . . 0.0 112.336 -178.338 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 24.4 ttm 59.01 17.7 5.66 Favored 'General case' 0 CA--C 1.549 0.921 0 C-N-CA 126.698 1.999 . . . . 0.0 114.539 -169.87 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.491 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.8 mt -73.71 140.66 17.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 124.52 1.128 . . . . 0.0 111.072 171.814 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 42.7 mtpt -97.63 63.99 1.77 Allowed 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 124.58 1.152 . . . . 0.0 112.622 -172.153 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 37.3 tp -58.14 122.23 12.61 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 123.899 0.88 . . . . 0.0 109.422 174.55 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 57.8 m-85 44.91 31.69 0.72 Allowed 'General case' 0 CA--C 1.56 1.345 0 N-CA-C 116.008 1.855 . . . . 0.0 116.008 -168.578 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 83.49 15.53 70.98 Favored Glycine 0 CA--C 1.541 1.705 0 O-C-N 120.168 -1.583 . . . . 0.0 116.957 173.528 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 59.3 mttp -126.45 121.1 23.49 Favored Pre-proline 0 CA--C 1.539 0.54 0 C-N-CA 127.638 2.375 . . . . 0.0 108.457 176.857 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -71.14 108.83 2.42 Favored 'Trans proline' 0 CA--C 1.537 0.643 0 C-N-CA 123.807 3.005 . . . . 0.0 111.27 -174.201 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 5.8 pt -77.61 147.12 7.46 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 C-N-CA 124.694 1.197 . . . . 0.0 110.245 179.124 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 40.1 mmm-85 -113.2 133.36 55.1 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 123.947 0.899 . . . . 0.0 110.671 175.064 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.8 t -128.46 136.78 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 124.2 1.0 . . . . 0.0 111.326 -169.737 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -158.66 -178.21 7.09 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 124.853 1.261 . . . . 0.0 111.281 173.653 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 10.1 mmmm -60.89 144.14 53.51 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 124.499 1.12 . . . . 0.0 110.167 172.505 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -68.24 -29.33 68.13 Favored 'General case' 0 CA--C 1.549 0.937 0 O-C-N 121.615 -0.678 . . . . 0.0 112.07 174.511 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 26.3 m -117.98 119.15 33.95 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 125.743 1.617 . . . . 0.0 109.252 167.387 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -134.51 175.22 9.73 Favored 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 125.302 1.441 . . . . 0.0 112.62 -170.292 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 90.4 m-70 56.82 40.0 29.26 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 125.969 1.707 . . . . 0.0 114.395 178.407 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 46.6 t30 -69.27 160.46 31.17 Favored 'General case' 0 CA--C 1.551 1.018 0 C-N-CA 124.513 1.125 . . . . 0.0 112.094 175.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 40.0 ttpt -61.89 142.77 57.19 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 125.496 1.518 . . . . 0.0 112.127 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 4.9 p-10 -117.07 166.89 11.68 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.782 1.633 . . . . 0.0 112.766 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 54.8 tp -114.92 145.42 42.23 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.925 1.69 . . . . 0.0 110.496 174.519 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 25.0 m -69.89 -31.47 69.29 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 123.84 0.856 . . . . 0.0 113.213 179.484 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 170.06 154.96 9.74 Favored Glycine 0 CA--C 1.539 1.569 0 C-N-CA 125.969 1.747 . . . . 0.0 112.243 172.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -67.76 143.53 61.96 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 123.098 2.532 . . . . 0.0 111.799 178.058 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 22.5 m 53.41 28.2 7.24 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 125.441 1.496 . . . . 0.0 114.935 -179.738 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 68.4 p -79.3 -11.38 59.94 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 114.857 1.429 . . . . 0.0 114.857 -175.671 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.265 0 C-N-CA 125.699 1.619 . . . . 0.0 113.816 177.775 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.632 0 N-CA-C 111.821 -0.512 . . . . 0.0 111.821 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.4 m 61.89 167.75 0.11 Allowed 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 126.676 1.99 . . . . 0.0 115.401 -176.904 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 71.5 m -74.83 158.87 32.7 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 124.435 1.094 . . . . 0.0 112.505 175.825 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.34 164.53 44.56 Favored Glycine 0 CA--C 1.537 1.432 0 CA-C-O 121.791 0.662 . . . . 0.0 113.478 172.71 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 13.3 p -68.0 -22.06 65.01 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 116.119 1.896 . . . . 0.0 116.119 -169.974 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 60.4 p 55.34 -175.27 0.04 OUTLIER 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 127.128 2.171 . . . . 0.0 113.818 -174.756 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -165.59 156.65 28.73 Favored Glycine 0 CA--C 1.538 1.51 0 O-C-N 120.343 -1.473 . . . . 0.0 115.801 174.468 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -80.51 54.07 5.06 Favored 'Trans proline' 0 CA--C 1.547 1.146 0 C-N-CA 124.984 3.789 . . . . 0.0 112.772 -177.294 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 17.3 tt -69.34 141.19 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 C-N-CA 125.102 1.361 . . . . 0.0 111.709 176.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 61.7 m -109.56 -12.81 14.64 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 125.068 1.347 . . . . 0.0 112.927 174.424 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 21.9 mp0 -83.06 -14.99 52.71 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 125.352 1.461 . . . . 0.0 112.907 -177.13 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 27.4 ttm180 -143.8 141.17 30.25 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 127.482 2.313 . . . . 0.0 108.525 170.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 55.9 m-20 -89.12 10.66 21.03 Favored 'General case' 0 CA--C 1.545 0.773 0 N-CA-C 113.576 0.954 . . . . 0.0 113.576 -178.827 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 63.4 tt0 -66.26 -38.04 86.89 Favored 'General case' 0 N--CA 1.472 0.627 0 O-C-N 120.707 -1.245 . . . . 0.0 112.977 -173.689 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -73.89 -24.41 59.71 Favored 'General case' 0 N--CA 1.473 0.714 0 O-C-N 121.309 -0.869 . . . . 0.0 112.197 173.243 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -84.89 5.06 30.45 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 125.513 1.525 . . . . 0.0 113.106 169.631 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 53.7 m -112.02 139.39 47.57 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 125.089 1.355 . . . . 0.0 109.172 174.578 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 4.3 m -104.94 146.17 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 C-N-CA 124.152 0.981 . . . . 0.0 110.012 174.214 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 50.3 t80 -95.44 140.36 30.42 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 125.784 1.634 . . . . 0.0 109.318 169.464 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 26.1 t -131.68 110.96 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.542 0 C-N-CA 125.673 1.589 . . . . 0.0 109.208 178.507 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -107.23 149.04 16.56 Favored Glycine 0 CA--C 1.531 1.032 0 C-N-CA 124.572 1.082 . . . . 0.0 112.826 176.125 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.65 33.6 6.67 Favored Glycine 0 CA--C 1.533 1.213 0 C-N-CA 124.482 1.039 . . . . 0.0 113.953 174.2 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 84.9 mt -74.41 152.06 39.57 Favored 'General case' 0 C--O 1.234 0.259 0 C-N-CA 125.459 1.504 . . . . 0.0 111.505 -174.522 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -90.69 156.31 18.19 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 123.885 0.874 . . . . 0.0 111.854 174.798 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.3 -20.53 43.65 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 114.823 1.416 . . . . 0.0 114.823 -179.543 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.5 mtmm -81.38 -12.18 59.06 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 124.687 1.195 . . . . 0.0 114.093 175.067 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 64.4 t -73.36 141.92 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 124.576 1.15 . . . . 0.0 111.572 178.316 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 6.2 t -144.29 166.88 23.82 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 123.949 0.899 . . . . 0.0 111.671 169.237 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -53.15 -42.68 92.27 Favored Pre-proline 0 CA--C 1.545 0.786 0 N-CA-C 115.498 1.666 . . . . 0.0 115.498 -179.37 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -70.53 -25.01 25.5 Favored 'Trans proline' 0 C--N 1.353 0.804 0 CA-C-N 122.142 1.801 . . . . 0.0 112.997 176.487 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 17.6 tp -65.74 -53.83 35.38 Favored 'General case' 0 C--N 1.343 0.32 0 CA-C-N 118.707 0.685 . . . . 0.0 109.273 170.265 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 25.8 mt -54.94 -41.95 71.7 Favored 'General case' 0 N--CA 1.464 0.269 0 O-C-N 123.265 0.353 . . . . 0.0 111.261 -179.067 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 3.0 t90 -57.87 -62.42 1.82 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 123.371 0.669 . . . . 0.0 111.35 177.823 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -64.67 -29.48 70.47 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 113.844 1.053 . . . . 0.0 113.844 -177.33 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.0 tp -71.79 -36.61 70.35 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 124.328 1.051 . . . . 0.0 111.918 176.425 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 -88.36 -10.42 49.43 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.071 1.349 . . . . 0.0 113.424 -176.392 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 25.0 mt -53.66 -21.42 6.89 Favored 'General case' 0 CA--C 1.546 0.804 0 N-CA-C 113.948 1.092 . . . . 0.0 113.948 168.884 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 42.3 mt-30 -63.25 -32.28 73.65 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 125.182 1.393 . . . . 0.0 112.618 174.02 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -78.58 -44.35 24.3 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.36 0.664 . . . . 0.0 112.519 177.151 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 177.36 -173.02 45.86 Favored Glycine 0 CA--C 1.535 1.316 0 C-N-CA 124.578 1.085 . . . . 0.0 113.04 -178.584 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -67.63 110.08 2.01 Favored 'Trans proline' 0 CA--C 1.537 0.671 0 C-N-CA 123.774 2.983 . . . . 0.0 111.719 -178.8 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 80.8 t -85.72 135.11 25.66 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 C-N-CA 124.896 1.278 . . . . 0.0 109.973 174.363 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.9 t -110.17 -34.01 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 C-N-CA 126.262 1.825 . . . . 0.0 111.897 -172.038 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 21.3 t30 -160.94 160.88 31.37 Favored 'General case' 0 CA--C 1.553 1.064 0 C-N-CA 125.775 1.63 . . . . 0.0 110.978 -174.864 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 6.7 p -137.57 154.41 49.8 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 125.816 1.647 . . . . 0.0 111.875 172.124 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 18.1 t-80 -142.29 130.58 22.23 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 123.659 0.784 . . . . 0.0 111.553 177.84 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 83.3 mtp -134.09 102.49 12.06 Favored Pre-proline 0 N--CA 1.471 0.62 0 C-N-CA 124.575 1.15 . . . . 0.0 109.562 170.013 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo -61.86 128.72 25.16 Favored 'Trans proline' 0 CA--C 1.538 0.704 0 C-N-CA 123.016 2.478 . . . . 0.0 113.135 -178.44 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 45.2 mmtm -92.47 151.41 20.22 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 124.506 1.122 . . . . 0.0 113.686 -172.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -66.39 142.2 57.68 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 126.471 1.908 . . . . 0.0 112.338 172.854 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 9.7 ptm180 -83.84 8.14 15.8 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 115.944 1.831 . . . . 0.0 115.944 -174.237 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 35.1 t -131.33 -37.88 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 124.857 1.263 . . . . 0.0 111.494 -173.761 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 63.5 p -116.34 -17.53 10.71 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 125.411 1.484 . . . . 0.0 112.555 -176.236 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.77 9.27 65.4 Favored Glycine 0 CA--C 1.539 1.542 0 C-N-CA 124.77 1.176 . . . . 0.0 114.944 -178.369 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 39.2 mt-30 -70.63 162.91 28.09 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 125.205 1.402 . . . . 0.0 110.934 173.149 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 12.8 p80 -72.38 155.19 40.41 Favored 'General case' 0 N--CA 1.473 0.693 0 O-C-N 120.727 -1.233 . . . . 0.0 111.525 169.694 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 37.8 mt-30 -95.92 22.14 7.77 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 124.225 1.01 . . . . 0.0 113.715 -171.361 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.94 3.4 83.1 Favored Glycine 0 CA--C 1.533 1.206 0 C-N-CA 125.018 1.294 . . . . 0.0 115.148 179.199 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 46.3 p90 -144.25 160.37 41.09 Favored 'General case' 0 CA--C 1.54 0.596 0 CA-C-N 118.795 1.298 . . . . 0.0 112.934 178.682 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -154.63 -177.37 27.9 Favored Glycine 0 CA--C 1.532 1.112 0 C-N-CA 125.889 1.709 . . . . 0.0 113.456 -178.777 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 89.5 m-85 -143.16 149.39 37.99 Favored 'General case' 0 C--O 1.236 0.378 0 C-N-CA 126.107 1.763 . . . . 0.0 111.617 -178.312 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 16.4 t -132.25 126.47 55.89 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 C-N-CA 124.564 1.146 . . . . 0.0 110.211 174.785 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 72.0 tt0 -102.34 123.16 45.64 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 125.383 1.473 . . . . 0.0 110.575 -176.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -100.81 161.5 13.56 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 125.226 1.411 . . . . 0.0 112.335 178.374 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.6 tp -62.33 -34.17 76.1 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 123.216 0.606 . . . . 0.0 112.351 177.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.2 m -142.17 155.64 45.31 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 124.499 1.12 . . . . 0.0 112.016 -177.141 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 13.6 tm-20 -64.12 -33.42 75.74 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.401 1.081 . . . . 0.0 113.28 -177.828 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -69.26 -26.5 64.8 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 113.189 0.811 . . . . 0.0 113.189 176.851 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 42.0 m-20 -76.93 -33.89 57.7 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 123.71 0.804 . . . . 0.0 111.375 173.202 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.9 -43.82 70.98 Favored 'General case' 0 CA--C 1.54 0.567 0 O-C-N 121.955 -0.466 . . . . 0.0 111.454 173.697 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -61.48 -30.27 70.5 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 123.888 0.875 . . . . 0.0 112.706 178.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 61.8 t80 -77.99 -35.03 50.54 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.047 0.939 . . . . 0.0 113.063 173.905 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.8 -37.8 88.15 Favored 'General case' 0 CA--C 1.537 0.46 0 O-C-N 121.053 -1.03 . . . . 0.0 111.155 175.543 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 53.7 mt -64.11 -35.73 74.66 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 124.808 1.243 . . . . 0.0 111.185 173.825 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -65.81 -40.52 91.94 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 123.961 0.904 . . . . 0.0 112.473 176.774 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 46.3 pt -92.06 -35.88 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 N-CA-C 114.85 1.426 . . . . 0.0 114.85 -175.95 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' MET . . . . . 0.477 ' HA ' HD12 ' A' ' 80' ' ' ILE . 9.9 mmt -91.77 0.75 57.47 Favored 'General case' 0 N--CA 1.479 1.025 0 N-CA-C 115.134 1.531 . . . . 0.0 115.134 -171.675 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -84.82 136.82 33.51 Favored 'General case' 0 CA--C 1.538 0.519 0 O-C-N 121.391 -0.818 . . . . 0.0 112.249 179.426 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 25.5 ttm 59.71 12.25 2.83 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 126.184 1.794 . . . . 0.0 114.729 -172.103 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.477 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.3 mt -69.81 151.68 9.57 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 C-N-CA 125.149 1.379 . . . . 0.0 109.927 168.941 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 47.4 mtpt -111.54 69.5 0.69 Allowed 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 124.994 1.317 . . . . 0.0 112.472 -175.521 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 31.4 tp -57.69 125.1 21.5 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 124.103 0.961 . . . . 0.0 109.99 174.808 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 54.3 m-85 46.21 27.93 0.61 Allowed 'General case' 0 CA--C 1.561 1.378 0 N-CA-C 116.366 1.987 . . . . 0.0 116.366 -168.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 80.11 25.59 57.25 Favored Glycine 0 CA--C 1.541 1.709 0 O-C-N 120.176 -1.577 . . . . 0.0 115.998 176.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -135.94 120.44 13.06 Favored Pre-proline 0 CA--C 1.543 0.694 0 C-N-CA 128.293 2.637 . . . . 0.0 107.814 -179.79 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -70.54 125.01 11.29 Favored 'Trans proline' 0 CA--C 1.538 0.684 0 C-N-CA 122.897 2.398 . . . . 0.0 112.381 -171.337 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 18.9 pt -95.33 144.72 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 C-N-CA 125.168 1.387 . . . . 0.0 111.848 176.187 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 44.9 tpt85 -111.41 128.04 55.86 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 126.145 1.778 . . . . 0.0 109.19 176.827 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.7 t -127.88 138.99 53.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 124.175 0.99 . . . . 0.0 111.34 -170.569 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 31.7 t-20 -157.48 175.96 13.28 Favored 'General case' 0 CA--C 1.549 0.911 0 C-N-CA 125.467 1.507 . . . . 0.0 111.125 -179.242 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 4.8 mmmm -62.61 141.93 58.26 Favored 'General case' 0 N--CA 1.477 0.919 0 O-C-N 120.945 -1.097 . . . . 0.0 109.719 169.984 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -73.82 -11.41 60.37 Favored 'General case' 0 CA--C 1.55 0.952 0 N-CA-C 112.33 0.492 . . . . 0.0 112.33 170.04 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 64.5 p -89.03 -73.63 0.5 Allowed 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.49 1.516 . . . . 0.0 110.739 168.593 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . 52.55 30.04 7.96 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 126.593 1.957 . . . . 0.0 113.618 -173.046 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 20.9 m170 -78.17 143.97 36.77 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 125.696 1.598 . . . . 0.0 111.775 -178.139 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 48.0 t30 -85.35 81.88 8.57 Favored 'General case' 0 CA--C 1.545 0.75 0 O-C-N 121.142 -0.974 . . . . 0.0 110.165 170.794 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 56.8 pttt -131.92 -7.97 3.51 Favored 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 116.824 2.157 . . . . 0.0 116.824 -169.505 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 44.6 t30 -70.84 148.81 47.44 Favored 'General case' 0 CA--C 1.548 0.872 0 CA-C-N 119.554 1.07 . . . . 0.0 111.256 171.348 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.2 pp -146.45 165.0 30.7 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.957 1.303 . . . . 0.0 113.523 -177.969 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 30.8 p -85.89 -37.43 19.14 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 124.972 1.309 . . . . 0.0 113.545 -179.069 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 54.64 50.46 57.41 Favored Glycine 0 CA--C 1.545 1.915 0 C-N-CA 125.511 1.529 . . . . 0.0 115.997 175.76 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -68.05 152.27 76.74 Favored 'Trans proline' 0 CA--C 1.541 0.831 0 C-N-CA 123.498 2.799 . . . . 0.0 113.029 -177.204 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 19.7 m -80.55 -17.55 51.15 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 124.391 1.076 . . . . 0.0 113.9 178.424 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 27.0 m -71.87 149.26 45.34 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 125.051 1.34 . . . . 0.0 113.325 -176.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.278 0 C-N-CA 125.241 1.4 . . . . 0.0 113.44 175.141 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.602 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.4 m 53.05 35.54 19.8 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 124.983 1.313 . . . . 0.0 113.157 -171.505 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 12.5 m -73.84 157.04 37.09 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 125.825 1.65 . . . . 0.0 113.697 -169.843 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -159.51 142.35 8.22 Favored Glycine 0 CA--C 1.533 1.217 0 C-N-CA 124.879 1.228 . . . . 0.0 112.362 174.375 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 73.9 p -116.07 -1.93 12.36 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 125.554 1.542 . . . . 0.0 115.087 -169.86 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 12.2 m -69.77 -26.15 64.15 Favored 'General case' 0 N--CA 1.475 0.801 0 N-CA-C 115.1 1.518 . . . . 0.0 115.1 -169.635 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 47.48 51.48 16.22 Favored Glycine 0 CA--C 1.544 1.868 0 C-N-CA 126.045 1.783 . . . . 0.0 116.692 -178.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_exo -68.63 115.72 4.06 Favored 'Trans proline' 0 C--N 1.354 0.867 0 CA-C-N 121.66 2.73 . . . . 0.0 113.088 -169.862 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 46.1 pt -140.58 155.22 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 125.921 1.688 . . . . 0.0 111.746 174.782 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 71.5 p -105.48 0.65 26.92 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 125.587 1.555 . . . . 0.0 114.108 177.785 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -68.59 -38.82 80.96 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.847 1.259 . . . . 0.0 113.757 -171.045 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 35.9 mtm180 -138.31 149.03 45.26 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.895 1.678 . . . . 0.0 111.981 -171.45 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 10.3 p-10 -75.85 -4.37 40.39 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 114.653 1.353 . . . . 0.0 114.653 -177.542 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.2 mp0 -70.66 -9.07 56.24 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 124.333 1.053 . . . . 0.0 113.609 174.533 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -99.73 -20.75 16.1 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 124.6 1.16 . . . . 0.0 112.607 168.39 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -83.78 -17.47 41.01 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.525 1.13 . . . . 0.0 112.381 168.635 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.9 m -95.68 137.44 34.73 Favored 'General case' 0 N--CA 1.466 0.344 0 C-N-CA 125.312 1.445 . . . . 0.0 109.414 170.643 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.9 m -106.71 147.93 11.58 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 C-N-CA 124.77 1.228 . . . . 0.0 110.225 171.287 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 9.5 t80 -95.19 143.03 26.94 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 125.879 1.672 . . . . 0.0 108.639 169.142 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 25.4 t -130.77 109.82 17.43 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 C-N-CA 125.139 1.375 . . . . 0.0 109.204 174.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -102.76 151.4 18.09 Favored Glycine 0 CA--C 1.53 1.008 0 C-N-CA 124.647 1.118 . . . . 0.0 112.691 175.723 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.45 35.4 6.97 Favored Glycine 0 CA--C 1.533 1.171 0 C-N-CA 124.474 1.035 . . . . 0.0 113.985 174.603 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 90.2 mt -82.93 146.48 28.8 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.382 1.473 . . . . 0.0 111.94 -173.076 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -83.96 157.1 22.01 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 123.872 0.869 . . . . 0.0 112.355 175.779 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -58.4 -21.03 49.14 Favored 'General case' 0 CA--C 1.547 0.839 0 N-CA-C 114.718 1.377 . . . . 0.0 114.718 178.392 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.8 mtmm -80.66 -10.2 59.75 Favored 'General case' 0 N--CA 1.477 0.901 0 N-CA-C 114.269 1.211 . . . . 0.0 114.269 175.055 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 93.2 t -75.18 138.94 19.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 C-N-CA 124.429 1.092 . . . . 0.0 111.56 178.873 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 92.5 p -136.99 162.09 34.26 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 125.178 1.391 . . . . 0.0 112.414 178.672 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -54.73 -46.38 99.4 Favored Pre-proline 0 N--CA 1.478 0.969 0 O-C-N 120.786 -1.196 . . . . 0.0 113.158 174.652 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_exo -57.78 -33.2 96.54 Favored 'Trans proline' 0 C--N 1.354 0.819 0 C-N-CA 122.406 2.071 . . . . 0.0 114.058 173.196 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 28.1 tp -67.43 -51.08 55.95 Favored 'General case' 0 C--N 1.343 0.291 0 CA-C-N 118.687 0.676 . . . . 0.0 110.163 173.491 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 21.2 mt -61.7 -23.06 65.87 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 113.338 0.866 . . . . 0.0 113.338 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.3 t90 -74.41 -66.16 0.77 Allowed 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 123.01 0.524 . . . . 0.0 110.965 170.857 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -65.02 -30.35 71.32 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 114.172 1.175 . . . . 0.0 114.172 -172.543 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.2 tp -68.81 -34.37 75.41 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 123.673 0.789 . . . . 0.0 111.655 175.114 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -90.03 -10.66 44.04 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 125.156 1.382 . . . . 0.0 113.812 -174.786 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 47.7 mt -56.23 -17.69 8.22 Favored 'General case' 0 CA--C 1.545 0.765 0 N-CA-C 113.873 1.064 . . . . 0.0 113.873 169.031 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 -64.03 -34.84 78.93 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 125.177 1.391 . . . . 0.0 112.624 171.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -77.84 -46.26 21.99 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.371 0.669 . . . . 0.0 112.451 179.31 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.27 -172.06 44.03 Favored Glycine 0 CA--C 1.537 1.411 0 C-N-CA 125.013 1.292 . . . . 0.0 112.594 -178.899 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -68.03 110.21 2.13 Favored 'Trans proline' 0 CA--C 1.537 0.655 0 C-N-CA 123.608 2.872 . . . . 0.0 111.698 -179.319 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 61.8 t -84.86 133.64 28.84 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 124.872 1.269 . . . . 0.0 109.785 173.766 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 5.2 t -109.44 -33.65 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 C-N-CA 126.38 1.872 . . . . 0.0 111.923 -171.767 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 17.4 t30 -160.52 161.35 32.71 Favored 'General case' 0 CA--C 1.553 1.072 0 C-N-CA 125.974 1.71 . . . . 0.0 110.968 -173.554 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 7.7 p -140.98 154.59 46.11 Favored 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 126.409 1.883 . . . . 0.0 111.343 174.563 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 42.0 t-80 -142.38 134.45 27.37 Favored 'General case' 0 N--CA 1.473 0.678 0 C-N-CA 123.386 0.674 . . . . 0.0 112.478 175.362 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 36.4 mmm -132.34 102.54 14.15 Favored Pre-proline 0 CA--C 1.543 0.676 0 C-N-CA 125.139 1.375 . . . . 0.0 110.471 175.191 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -60.11 144.31 99.49 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 123.533 2.822 . . . . 0.0 113.46 177.763 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 26.1 mmtp -113.47 159.84 19.09 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 125.313 1.445 . . . . 0.0 113.545 -174.046 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -87.95 136.82 32.79 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.751 1.62 . . . . 0.0 112.332 170.973 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 10.0 ptp180 -82.7 8.85 10.96 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 115.649 1.722 . . . . 0.0 115.649 -173.672 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 39.3 t -130.67 -37.1 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 C-N-CA 125.066 1.346 . . . . 0.0 111.265 -175.051 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 66.9 p -114.27 -15.82 12.11 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 125.502 1.521 . . . . 0.0 112.569 -176.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 71.06 6.39 60.43 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 124.933 1.254 . . . . 0.0 115.151 176.405 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 74.4 mm-40 -79.97 162.71 24.76 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.99 1.316 . . . . 0.0 110.777 177.673 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 10.0 p80 -71.46 155.15 40.93 Favored 'General case' 0 CA--C 1.539 0.534 0 O-C-N 121.317 -0.865 . . . . 0.0 112.381 176.077 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 28.0 mm-40 -84.63 13.54 5.56 Favored 'General case' 0 CA--C 1.548 0.876 0 N-CA-C 114.431 1.271 . . . . 0.0 114.431 -170.256 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.0 -0.13 87.51 Favored Glycine 0 CA--C 1.536 1.355 0 C-N-CA 125.165 1.364 . . . . 0.0 114.701 -178.156 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 45.2 p90 -144.2 157.67 44.16 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 125.19 1.396 . . . . 0.0 112.299 177.283 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -144.98 -179.53 21.38 Favored Glycine 0 CA--C 1.534 1.243 0 C-N-CA 126.996 2.236 . . . . 0.0 112.317 -176.444 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -142.58 150.14 39.96 Favored 'General case' 0 C--O 1.237 0.438 0 C-N-CA 125.594 1.558 . . . . 0.0 112.114 179.557 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.3 t -134.6 129.5 52.33 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 125.05 1.34 . . . . 0.0 109.825 176.641 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 62.1 tt0 -108.85 123.3 48.84 Favored 'General case' 0 N--CA 1.466 0.37 0 C-N-CA 124.414 1.086 . . . . 0.0 111.575 -177.038 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -97.5 161.51 13.75 Favored 'General case' 0 C--O 1.234 0.277 0 C-N-CA 125.209 1.404 . . . . 0.0 112.51 178.128 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 14.7 tp -62.51 -33.8 75.6 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 123.199 0.6 . . . . 0.0 112.32 177.115 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 17.0 m -141.88 155.5 45.52 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 124.422 1.089 . . . . 0.0 112.049 -177.751 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 13.9 tm-20 -62.85 -33.38 75.14 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 124.487 1.115 . . . . 0.0 113.119 -179.565 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -68.4 -25.75 65.21 Favored 'General case' 0 CA--C 1.541 0.633 0 N-CA-C 113.208 0.818 . . . . 0.0 113.208 177.27 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 46.6 m-20 -78.46 -33.1 48.61 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 123.895 0.878 . . . . 0.0 111.491 173.526 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -70.63 -44.07 67.95 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 123.197 0.599 . . . . 0.0 111.474 173.916 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -62.94 -27.57 69.47 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 124.157 0.983 . . . . 0.0 112.846 178.396 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 67.9 t80 -79.73 -35.37 38.99 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 124.3 1.04 . . . . 0.0 112.801 172.351 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.22 -38.99 93.34 Favored 'General case' 0 CA--C 1.538 0.499 0 O-C-N 121.054 -1.029 . . . . 0.0 111.072 177.736 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 70.4 mt -58.24 -38.64 69.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 C-N-CA 125.481 1.512 . . . . 0.0 111.372 172.792 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -67.84 -34.7 77.22 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.314 1.046 . . . . 0.0 113.168 179.249 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 20.2 pt -101.62 -14.22 8.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 115.899 1.815 . . . . 0.0 115.899 -173.889 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 7.9 mmt -111.6 -3.39 15.11 Favored 'General case' 0 N--CA 1.483 1.195 0 N-CA-C 115.453 1.649 . . . . 0.0 115.453 -176.037 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -82.49 142.23 32.04 Favored 'General case' 0 N--CA 1.475 0.795 0 O-C-N 120.674 -1.266 . . . . 0.0 113.9 -173.4 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 26.4 ttm 60.65 16.98 7.06 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 127.801 2.44 . . . . 0.0 115.21 -176.133 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 23.1 mt -91.39 142.04 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 126.453 1.901 . . . . 0.0 111.999 -174.685 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 40.6 mtpt -93.67 67.58 3.9 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.466 1.106 . . . . 0.0 113.003 -168.102 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 38.5 tp -58.46 121.25 10.44 Favored 'General case' 0 CA--C 1.542 0.662 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 173.755 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 52.9 m-85 44.77 30.04 0.5 Allowed 'General case' 0 CA--C 1.56 1.358 0 N-CA-C 116.152 1.908 . . . . 0.0 116.152 -168.688 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 87.38 12.4 67.46 Favored Glycine 0 CA--C 1.543 1.806 0 N-CA-C 117.345 1.698 . . . . 0.0 117.345 174.433 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 60.3 mttp -125.01 121.92 25.44 Favored Pre-proline 0 CA--C 1.541 0.62 0 C-N-CA 127.569 2.348 . . . . 0.0 108.57 176.571 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -72.86 112.82 3.6 Favored 'Trans proline' 0 CA--C 1.533 0.471 0 C-N-CA 123.957 3.104 . . . . 0.0 111.599 -171.239 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 8.2 pt -80.72 145.89 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 C-N-CA 123.861 0.865 . . . . 0.0 111.3 -177.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -114.45 127.97 56.1 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 125.665 1.586 . . . . 0.0 109.482 177.707 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 6.3 t -127.68 134.89 64.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 124.095 0.958 . . . . 0.0 111.838 -169.258 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -158.58 172.39 18.38 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.872 1.669 . . . . 0.0 111.565 179.472 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 4.2 mmmm -58.28 140.92 52.42 Favored 'General case' 0 N--CA 1.483 1.212 0 O-C-N 121.346 -0.846 . . . . 0.0 109.371 171.068 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -61.6 -30.21 70.54 Favored 'General case' 0 CA--C 1.544 0.741 0 N-CA-C 114.524 1.305 . . . . 0.0 114.524 -169.17 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 17.9 m -134.86 57.92 1.79 Allowed 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 124.514 1.126 . . . . 0.0 110.748 169.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -51.8 142.97 13.96 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 124.934 1.293 . . . . 0.0 113.918 -175.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 16.2 p80 -142.95 143.6 32.04 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 125.564 1.546 . . . . 0.0 112.001 -174.573 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 6.8 t-20 -152.63 9.71 0.47 Allowed 'General case' 0 CA--C 1.552 1.025 0 N-CA-C 114.191 1.182 . . . . 0.0 114.191 -178.017 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -80.68 141.23 35.11 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 124.878 1.271 . . . . 0.0 113.1 -169.836 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 12.5 p-10 -145.37 152.01 39.18 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 126.357 1.863 . . . . 0.0 110.78 169.91 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 7.8 tt -76.08 -47.29 25.12 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.721 0.808 . . . . 0.0 111.504 -178.737 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 8.1 t -152.88 174.71 13.75 Favored 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 125.803 1.641 . . . . 0.0 110.867 176.688 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -77.82 169.33 54.61 Favored Glycine 0 CA--C 1.543 1.832 0 C-N-CA 124.346 0.974 . . . . 0.0 113.594 172.33 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -69.71 155.71 65.39 Favored 'Trans proline' 0 CA--C 1.541 0.831 0 C-N-CA 123.637 2.891 . . . . 0.0 112.533 176.614 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 22.9 m -68.88 148.97 49.44 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 124.325 1.05 . . . . 0.0 112.837 178.732 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 40.5 m -69.01 150.96 47.08 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 124.401 1.08 . . . . 0.0 112.871 178.026 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.28 0 C-N-CA 125.146 1.355 . . . . 0.0 113.643 175.802 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.576 0 N-CA-C 111.95 -0.46 . . . . 0.0 111.95 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 53.2 p -76.87 160.53 29.16 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 124.865 1.266 . . . . 0.0 113.22 177.539 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 46.2 t -70.52 145.75 50.65 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 124.025 0.93 . . . . 0.0 112.554 178.156 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.44 -12.04 60.57 Favored Glycine 0 CA--C 1.539 1.554 0 C-N-CA 124.257 0.932 . . . . 0.0 114.516 173.321 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 45.8 m -80.8 5.25 16.48 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 125.06 1.344 . . . . 0.0 114.182 177.09 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 89.7 p -68.92 -21.56 64.2 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 114.864 1.431 . . . . 0.0 114.864 -176.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 174.72 -171.33 44.49 Favored Glycine 0 CA--C 1.539 1.56 0 C-N-CA 124.756 1.169 . . . . 0.0 113.794 178.756 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -65.31 -23.91 58.53 Favored 'Trans proline' 0 CA--C 1.54 0.795 0 C-N-CA 123.591 2.86 . . . . 0.0 115.124 -176.513 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 16.8 tt -145.23 129.05 11.87 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 125.363 1.465 . . . . 0.0 111.697 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 21.7 m -100.9 -15.25 17.62 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 124.914 1.286 . . . . 0.0 112.888 170.246 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 21.4 tt0 -85.0 33.54 0.54 Allowed 'General case' 0 CA--C 1.55 0.943 0 C-N-CA 125.97 1.708 . . . . 0.0 112.526 -178.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 17.8 ptp180 -80.15 44.0 0.65 Allowed 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 126.944 2.098 . . . . 0.0 114.012 -172.107 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 64.4 t-20 -65.83 107.39 1.8 Allowed 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 124.898 1.279 . . . . 0.0 112.094 -174.397 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 31.4 tp60 -85.22 -20.78 29.63 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.142 0.977 . . . . 0.0 113.031 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -69.88 -24.69 63.45 Favored 'General case' 0 N--CA 1.474 0.765 0 O-C-N 120.726 -1.234 . . . . 0.0 112.489 172.486 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -75.24 -0.01 18.06 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 123.959 0.904 . . . . 0.0 113.082 168.904 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 37.4 m -105.18 134.75 47.76 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 124.806 1.243 . . . . 0.0 109.298 169.284 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.0 m -99.05 147.93 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 123.915 0.886 . . . . 0.0 110.327 171.895 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 28.4 t80 -95.29 142.14 28.05 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.737 1.615 . . . . 0.0 109.067 169.193 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 31.3 t -133.21 108.65 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 C-N-CA 125.602 1.561 . . . . 0.0 109.443 178.331 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -102.75 151.78 18.14 Favored Glycine 0 CA--C 1.53 1.024 0 C-N-CA 124.475 1.036 . . . . 0.0 112.997 175.393 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.66 35.26 6.95 Favored Glycine 0 CA--C 1.532 1.143 0 C-N-CA 124.347 0.975 . . . . 0.0 113.924 172.485 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 91.1 mt -79.11 145.39 33.78 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 125.398 1.479 . . . . 0.0 111.542 -174.024 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -82.25 156.41 24.37 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 123.444 0.698 . . . . 0.0 112.184 175.052 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.59 -20.5 47.61 Favored 'General case' 0 CA--C 1.546 0.807 0 N-CA-C 114.632 1.345 . . . . 0.0 114.632 178.126 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.8 mtmm -81.59 -9.69 59.61 Favored 'General case' 0 N--CA 1.476 0.87 0 C-N-CA 124.919 1.288 . . . . 0.0 114.279 174.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 84.9 t -74.78 138.61 20.68 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.908 0 C-N-CA 124.404 1.082 . . . . 0.0 111.437 177.664 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 51.8 m -135.14 162.64 31.92 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 124.782 1.233 . . . . 0.0 111.698 173.473 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -57.32 -38.9 73.03 Favored Pre-proline 0 CA--C 1.546 0.821 0 N-CA-C 114.6 1.333 . . . . 0.0 114.6 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -64.76 -28.49 59.69 Favored 'Trans proline' 0 C--N 1.353 0.786 0 C-N-CA 122.281 1.987 . . . . 0.0 113.605 173.066 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 27.1 tp -68.22 -50.43 54.14 Favored 'General case' 0 C--N 1.343 0.309 0 CA-C-N 118.626 0.648 . . . . 0.0 109.791 172.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 20.6 mt -61.36 -23.01 65.46 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 112.972 0.73 . . . . 0.0 112.972 178.529 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.7 t90 -74.22 -66.15 0.76 Allowed 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 123.281 0.632 . . . . 0.0 111.002 171.038 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -64.82 -30.3 71.3 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 114.222 1.193 . . . . 0.0 114.222 -172.726 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.0 tp -69.23 -34.16 74.41 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 123.842 0.857 . . . . 0.0 111.799 175.504 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -90.1 -10.71 43.67 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.124 1.37 . . . . 0.0 113.337 -175.1 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 46.5 mt -55.21 -19.35 7.81 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 113.853 1.057 . . . . 0.0 113.853 169.313 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 41.0 mt-30 -64.96 -32.57 74.35 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 125.269 1.427 . . . . 0.0 112.592 173.163 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -78.36 -44.08 26.0 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 123.311 0.645 . . . . 0.0 112.639 177.629 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 177.34 -173.68 46.39 Favored Glycine 0 CA--C 1.538 1.517 0 C-N-CA 125.181 1.372 . . . . 0.0 112.498 -179.733 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -66.89 111.22 2.12 Favored 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 123.651 2.9 . . . . 0.0 111.827 -179.431 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 67.1 t -86.51 135.57 24.82 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 C-N-CA 125.12 1.368 . . . . 0.0 109.78 173.8 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 7.8 t -110.32 -33.64 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 C-N-CA 126.172 1.789 . . . . 0.0 111.939 -171.657 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 21.6 t30 -160.92 161.24 31.64 Favored 'General case' 0 CA--C 1.553 1.072 0 C-N-CA 125.752 1.621 . . . . 0.0 111.074 -175.381 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 4.7 p -137.36 155.18 49.71 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 125.938 1.695 . . . . 0.0 111.801 171.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 51.2 t-80 -142.15 132.69 25.28 Favored 'General case' 0 N--CA 1.466 0.357 0 C-N-CA 123.67 0.788 . . . . 0.0 110.838 176.105 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 89.5 mtp -133.89 107.61 11.65 Favored Pre-proline 0 N--CA 1.469 0.515 0 C-N-CA 124.113 0.965 . . . . 0.0 109.493 169.842 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_exo -57.57 142.64 95.59 Favored 'Trans proline' 0 CA--C 1.537 0.661 0 C-N-CA 123.082 2.521 . . . . 0.0 112.897 176.234 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 43.3 mmtm -114.59 159.41 20.47 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 125.218 1.407 . . . . 0.0 113.247 -172.598 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -77.33 141.48 39.87 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.797 1.639 . . . . 0.0 111.418 169.357 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 53.1 ptt85 -83.72 6.39 21.25 Favored 'General case' 0 N--CA 1.479 0.98 0 N-CA-C 115.982 1.845 . . . . 0.0 115.982 -173.582 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 32.4 t -131.31 -37.54 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 124.95 1.3 . . . . 0.0 111.471 -174.128 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 68.5 p -113.42 -14.01 12.79 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 125.764 1.626 . . . . 0.0 112.54 -176.679 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.26 5.67 55.02 Favored Glycine 0 CA--C 1.536 1.403 0 C-N-CA 125.09 1.328 . . . . 0.0 115.452 175.223 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 72.1 mm-40 -76.43 159.36 30.51 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 124.701 1.2 . . . . 0.0 110.717 176.727 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 22.7 p80 -72.23 155.56 40.09 Favored 'General case' 0 N--CA 1.473 0.715 0 O-C-N 120.931 -1.106 . . . . 0.0 113.023 179.841 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 81.9 mt-30 -80.68 11.91 3.5 Favored 'General case' 0 CA--C 1.552 1.052 0 N-CA-C 114.492 1.293 . . . . 0.0 114.492 -174.846 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.76 1.59 79.99 Favored Glycine 0 CA--C 1.538 1.489 0 C-N-CA 125.122 1.344 . . . . 0.0 114.912 -178.049 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 40.2 p90 -144.74 162.03 37.74 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.035 1.334 . . . . 0.0 112.341 178.459 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -153.04 -176.2 25.3 Favored Glycine 0 CA--C 1.532 1.114 0 C-N-CA 125.947 1.737 . . . . 0.0 113.186 -177.943 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 81.9 m-85 -144.03 149.73 37.14 Favored 'General case' 0 C--O 1.237 0.437 0 C-N-CA 126.073 1.749 . . . . 0.0 111.585 -178.29 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 14.9 t -132.99 126.41 53.58 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 124.582 1.153 . . . . 0.0 110.13 176.416 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -102.83 122.42 44.49 Favored 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 125.218 1.407 . . . . 0.0 110.718 -175.643 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -101.33 159.63 15.1 Favored 'General case' 0 C--O 1.234 0.258 0 C-N-CA 124.839 1.256 . . . . 0.0 112.613 179.206 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 14.6 tp -62.63 -35.12 78.58 Favored 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 123.442 0.697 . . . . 0.0 112.504 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.4 m -140.96 157.03 45.92 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.659 1.183 . . . . 0.0 110.944 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 58.5 tt0 -64.72 -35.33 80.72 Favored 'General case' 0 N--CA 1.471 0.58 0 O-C-N 121.499 -0.75 . . . . 0.0 112.863 -176.519 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -64.67 -24.57 67.62 Favored 'General case' 0 N--CA 1.473 0.721 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 177.657 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 52.1 m-20 -78.24 -33.78 49.54 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 123.9 0.88 . . . . 0.0 111.73 173.298 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -70.07 -43.21 71.64 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 123.075 0.55 . . . . 0.0 111.379 171.706 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -60.35 -32.02 70.87 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 124.669 1.188 . . . . 0.0 112.505 179.499 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 63.4 t80 -78.82 -35.22 44.44 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 124.213 1.005 . . . . 0.0 113.036 173.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.38 -36.74 84.7 Favored 'General case' 0 CA--C 1.537 0.466 0 O-C-N 120.978 -1.076 . . . . 0.0 111.211 176.553 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 56.2 mt -62.74 -36.92 77.58 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 124.718 1.207 . . . . 0.0 111.318 172.813 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -66.51 -40.07 89.01 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 124.274 1.029 . . . . 0.0 112.255 178.639 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 21.9 pt -91.41 -40.72 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 N-CA-C 114.409 1.263 . . . . 0.0 114.409 -176.934 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' MET . . . . . 0.487 ' HA ' HD12 ' A' ' 80' ' ' ILE . 12.5 mmt -88.16 1.46 54.35 Favored 'General case' 0 N--CA 1.48 1.063 0 N-CA-C 115.144 1.535 . . . . 0.0 115.144 -169.708 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -83.43 134.63 34.86 Favored 'General case' 0 CA--C 1.539 0.548 0 O-C-N 121.316 -0.865 . . . . 0.0 112.311 -179.064 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 24.6 ttm 58.8 15.0 3.52 Favored 'General case' 0 CA--C 1.549 0.914 0 C-N-CA 126.985 2.114 . . . . 0.0 114.686 -169.58 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.487 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.9 mt -72.54 137.9 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 C-N-CA 124.33 1.052 . . . . 0.0 111.189 173.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 41.6 mtpt -95.03 64.43 2.79 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 124.566 1.146 . . . . 0.0 112.395 -169.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 28.0 tp -58.99 120.39 9.01 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 123.595 0.758 . . . . 0.0 109.167 174.878 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 57.7 m-85 44.75 31.17 0.62 Allowed 'General case' 0 CA--C 1.562 1.411 0 N-CA-C 115.949 1.833 . . . . 0.0 115.949 -168.286 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 87.87 8.81 72.24 Favored Glycine 0 CA--C 1.542 1.76 0 N-CA-C 117.461 1.744 . . . . 0.0 117.461 173.88 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 60.1 mttp -119.42 119.38 31.71 Favored Pre-proline 0 CA--C 1.54 0.585 0 C-N-CA 127.497 2.319 . . . . 0.0 108.78 177.698 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -72.65 98.46 0.97 Allowed 'Trans proline' 0 CA--C 1.538 0.723 0 C-N-CA 124.152 3.234 . . . . 0.0 111.672 -173.409 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 6.5 pt -66.65 148.51 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 C-N-CA 124.44 1.096 . . . . 0.0 111.124 -177.266 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 33.5 mmt-85 -111.68 127.67 55.84 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.571 1.148 . . . . 0.0 109.95 178.826 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 17.0 t -128.0 137.21 58.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 124.054 0.942 . . . . 0.0 111.501 -169.518 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 30.6 t-20 -159.76 174.97 13.71 Favored 'General case' 0 CA--C 1.55 0.96 0 C-N-CA 125.501 1.52 . . . . 0.0 111.051 177.549 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 6.5 mmmm -62.0 141.04 58.29 Favored 'General case' 0 N--CA 1.48 1.052 0 O-C-N 120.849 -1.157 . . . . 0.0 109.704 172.191 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -70.75 -13.26 61.99 Favored 'General case' 0 CA--C 1.552 1.032 0 N-CA-C 113.699 1.0 . . . . 0.0 113.699 178.417 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 74.0 m -123.33 39.6 3.92 Favored 'General case' 0 N--CA 1.479 0.983 0 C-N-CA 126.328 1.851 . . . . 0.0 112.501 173.088 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -61.39 -25.32 67.1 Favored 'General case' 0 CA--C 1.548 0.882 0 N-CA-C 115.269 1.581 . . . . 0.0 115.269 -174.12 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 97.2 m-70 -83.49 132.52 34.94 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.037 0.935 . . . . 0.0 112.045 179.455 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 56.6 t30 -80.97 158.3 25.24 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 123.941 0.896 . . . . 0.0 112.582 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 63.9 tttm -65.56 -26.62 67.95 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 124.845 1.258 . . . . 0.0 113.732 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -137.8 149.92 46.77 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.325 1.45 . . . . 0.0 111.779 176.472 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 35.8 tp -95.78 -19.55 19.55 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 114.217 1.191 . . . . 0.0 114.217 -173.377 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 50.8 m -74.25 141.2 45.38 Favored 'General case' 0 N--CA 1.473 0.72 0 O-C-N 121.233 -0.917 . . . . 0.0 113.263 -172.342 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -78.88 170.43 54.72 Favored Glycine 0 CA--C 1.543 1.788 0 C-N-CA 124.327 0.965 . . . . 0.0 113.989 174.492 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -75.63 -18.19 17.61 Favored 'Trans proline' 0 CA--C 1.543 0.961 0 C-N-CA 123.863 3.042 . . . . 0.0 113.828 -179.777 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 85.3 p -149.7 176.05 11.03 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 125.998 1.719 . . . . 0.0 112.025 -178.726 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 58.4 p -74.96 -5.9 46.41 Favored 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 114.616 1.339 . . . . 0.0 114.616 175.44 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.298 0 C-N-CA 125.734 1.635 . . . . 0.0 113.721 -179.885 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.604 0 N-CA-C 111.438 -0.665 . . . . 0.0 111.438 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.7 m -69.99 151.43 45.59 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 124.523 1.129 . . . . 0.0 113.301 -178.468 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 67.5 p -90.23 -1.07 57.89 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 125.426 1.49 . . . . 0.0 114.988 -177.613 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -69.41 172.12 39.07 Favored Glycine 0 CA--C 1.539 1.55 0 C-N-CA 124.962 1.268 . . . . 0.0 114.98 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 47.3 t -144.89 154.19 42.36 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 125.501 1.52 . . . . 0.0 112.325 -177.503 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 18.0 m -81.03 -4.59 55.68 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 125.132 1.373 . . . . 0.0 113.468 172.04 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.2 -179.2 46.1 Favored Glycine 0 CA--C 1.544 1.853 0 C-N-CA 124.455 1.026 . . . . 0.0 113.683 170.481 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -69.82 143.33 50.2 Favored 'Trans proline' 0 CA--C 1.542 0.886 0 C-N-CA 123.183 2.589 . . . . 0.0 111.348 175.879 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.0 tp -80.94 148.14 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 124.096 0.959 . . . . 0.0 112.019 -177.762 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 17.4 m -66.56 -12.91 59.99 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 114.342 1.238 . . . . 0.0 114.342 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -79.69 -12.85 59.79 Favored 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 124.596 1.159 . . . . 0.0 113.405 176.381 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 23.8 mmt180 -90.63 153.39 20.35 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 125.378 1.471 . . . . 0.0 111.492 177.019 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 64.3 t-20 -81.18 84.27 6.6 Favored 'General case' 0 CA--C 1.537 0.459 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 175.34 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -66.62 -17.03 64.62 Favored 'General case' 0 CA--C 1.539 0.557 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -171.762 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -85.71 -25.23 26.59 Favored 'General case' 0 CA--C 1.543 0.68 0 CA-C-N 119.308 0.958 . . . . 0.0 112.939 174.136 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -94.59 2.04 55.64 Favored 'General case' 0 CA--C 1.546 0.802 0 C-N-CA 124.756 1.222 . . . . 0.0 112.704 168.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 36.0 m -101.94 136.96 40.87 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 124.988 1.315 . . . . 0.0 109.374 172.365 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.2 m -101.52 148.05 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 C-N-CA 123.96 0.904 . . . . 0.0 110.362 171.788 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 25.3 t80 -95.34 141.33 29.03 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 126.018 1.727 . . . . 0.0 108.848 169.019 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 20.2 t -129.07 115.87 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 C-N-CA 125.532 1.533 . . . . 0.0 108.875 175.667 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -113.37 145.63 18.36 Favored Glycine 0 CA--C 1.531 1.034 0 C-N-CA 124.573 1.082 . . . . 0.0 112.793 178.854 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.7 33.27 6.8 Favored Glycine 0 CA--C 1.533 1.213 0 C-N-CA 124.404 1.002 . . . . 0.0 113.738 176.541 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 84.4 mt -72.36 151.96 42.36 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 125.482 1.513 . . . . 0.0 111.405 -174.526 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -91.75 157.3 16.99 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 123.561 0.744 . . . . 0.0 111.967 174.426 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -58.38 -20.93 48.06 Favored 'General case' 0 N--CA 1.475 0.824 0 O-C-N 120.607 -1.308 . . . . 0.0 114.478 179.124 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 27.3 mtpp -76.27 -15.52 59.99 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 124.77 1.228 . . . . 0.0 114.233 174.479 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 93.8 t -73.19 141.56 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 124.553 1.141 . . . . 0.0 111.868 -177.137 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 96.4 p -136.74 162.72 32.41 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.316 1.447 . . . . 0.0 112.36 175.268 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -59.65 -40.41 79.01 Favored Pre-proline 0 CA--C 1.546 0.817 0 O-C-N 120.79 -1.194 . . . . 0.0 113.59 177.519 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_exo -62.04 -30.52 83.04 Favored 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 122.474 2.116 . . . . 0.0 113.839 170.872 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 26.4 tp -68.57 -50.57 50.74 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 119.031 0.832 . . . . 0.0 109.906 173.91 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 20.5 mt -60.91 -22.35 64.26 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 113.026 0.75 . . . . 0.0 113.026 178.341 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.7 t90 -74.42 -66.87 0.68 Allowed 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 123.123 0.569 . . . . 0.0 110.863 170.854 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -65.14 -29.7 70.56 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 114.218 1.192 . . . . 0.0 114.218 -172.239 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.7 tp -69.99 -33.31 71.88 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 123.692 0.797 . . . . 0.0 111.845 175.586 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -90.24 -10.96 42.35 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 124.945 1.298 . . . . 0.0 113.409 -175.067 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 49.4 mt -55.13 -18.14 5.2 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 124.437 1.095 . . . . 0.0 113.889 169.21 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 75.4 mt-30 -63.52 -34.4 77.71 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 125.785 1.634 . . . . 0.0 112.606 172.948 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.92 -45.15 19.07 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 123.657 0.783 . . . . 0.0 112.61 178.421 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.71 -172.98 44.76 Favored Glycine 0 CA--C 1.535 1.286 0 C-N-CA 124.595 1.093 . . . . 0.0 112.932 178.491 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -67.09 111.17 2.15 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 123.719 2.946 . . . . 0.0 111.715 -179.101 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 82.9 t -84.99 134.8 26.19 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 124.96 1.304 . . . . 0.0 109.67 173.364 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 4.1 t -108.04 -33.96 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 126.222 1.809 . . . . 0.0 111.656 -173.202 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 4.7 t30 -161.61 158.27 25.92 Favored 'General case' 0 CA--C 1.553 1.063 0 C-N-CA 125.956 1.702 . . . . 0.0 111.465 -174.468 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 5.9 p -133.8 153.88 51.41 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 125.773 1.629 . . . . 0.0 112.389 171.122 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 2.6 t60 -141.03 130.83 24.27 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.283 1.033 . . . . 0.0 111.088 178.939 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 86.4 mtp -134.57 102.51 11.51 Favored Pre-proline 0 N--CA 1.472 0.655 0 C-N-CA 124.336 1.054 . . . . 0.0 109.461 169.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -60.95 127.36 22.09 Favored 'Trans proline' 0 CA--C 1.537 0.634 0 C-N-CA 123.172 2.581 . . . . 0.0 113.076 -178.703 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 44.9 mmtm -92.47 150.45 20.77 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 124.596 1.158 . . . . 0.0 113.124 -174.867 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -65.25 138.0 57.94 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 125.49 1.516 . . . . 0.0 112.018 172.343 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 16.6 ptm180 -80.41 8.73 7.02 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 116.013 1.857 . . . . 0.0 116.013 -173.121 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 35.0 t -132.47 -37.26 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.116 0 C-N-CA 124.954 1.302 . . . . 0.0 111.447 -175.136 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.8 p -115.84 -14.17 11.34 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 125.736 1.614 . . . . 0.0 112.641 -175.583 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 69.84 8.2 60.37 Favored Glycine 0 CA--C 1.536 1.391 0 C-N-CA 125.039 1.304 . . . . 0.0 115.483 175.841 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 74.0 mm-40 -80.92 162.82 23.75 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.79 1.236 . . . . 0.0 110.994 176.989 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 6.9 p80 -70.17 153.65 42.86 Favored 'General case' 0 N--CA 1.473 0.7 0 O-C-N 120.883 -1.135 . . . . 0.0 111.866 174.126 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 37.7 mt-30 -98.09 21.88 10.19 Favored 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 124.414 1.086 . . . . 0.0 113.618 -170.332 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.77 3.14 86.17 Favored Glycine 0 CA--C 1.535 1.286 0 C-N-CA 124.938 1.256 . . . . 0.0 115.089 179.835 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -141.92 158.93 43.2 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 118.794 1.297 . . . . 0.0 113.077 177.437 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -154.63 -178.32 28.85 Favored Glycine 0 CA--C 1.53 1.007 0 C-N-CA 125.797 1.665 . . . . 0.0 113.016 -178.616 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -144.34 151.57 39.52 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 125.622 1.569 . . . . 0.0 112.036 -178.265 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 13.6 t -134.34 121.08 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 124.796 1.239 . . . . 0.0 110.052 176.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -97.1 118.6 33.88 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 124.901 1.28 . . . . 0.0 110.705 -178.503 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 -95.54 162.08 13.79 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 125.034 1.334 . . . . 0.0 112.252 176.957 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 12.8 tp -64.31 -33.99 77.11 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 123.37 0.668 . . . . 0.0 112.369 177.62 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.6 m -140.58 154.8 46.63 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 124.681 1.193 . . . . 0.0 112.495 -177.495 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -65.38 -30.56 71.4 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 124.693 1.197 . . . . 0.0 112.643 -176.486 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -72.07 -26.33 62.13 Favored 'General case' 0 CA--C 1.542 0.668 0 O-C-N 121.352 -0.843 . . . . 0.0 113.262 175.037 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 61.6 m-20 -75.74 -34.05 60.28 Favored 'General case' 0 N--CA 1.469 0.511 0 O-C-N 121.569 -0.707 . . . . 0.0 111.009 172.86 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -67.51 -45.84 74.63 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 123.341 0.656 . . . . 0.0 111.227 171.873 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -56.67 -36.38 69.5 Favored 'General case' 0 CA--C 1.543 0.697 0 O-C-N 121.259 -0.901 . . . . 0.0 112.772 174.867 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -69.46 -38.76 77.9 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 123.441 0.697 . . . . 0.0 111.915 174.882 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.4 -36.83 83.83 Favored 'General case' 0 CA--C 1.538 0.499 0 O-C-N 120.631 -1.293 . . . . 0.0 111.82 176.242 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 55.9 mt -64.33 -32.31 57.07 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 123.85 0.86 . . . . 0.0 110.752 172.738 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -67.02 -47.84 70.21 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 124.228 1.011 . . . . 0.0 112.301 175.217 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 19.3 pt -90.09 -37.24 9.36 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 114.884 1.438 . . . . 0.0 114.884 -172.071 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' MET . . . . . 0.475 ' HA ' HD12 ' A' ' 80' ' ' ILE . 14.3 mmt -92.22 0.43 57.46 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 114.52 1.304 . . . . 0.0 114.52 -170.192 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -83.83 136.97 33.92 Favored 'General case' 0 CA--C 1.54 0.565 0 O-C-N 121.605 -0.684 . . . . 0.0 111.98 178.845 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 22.8 mtp 58.67 14.07 2.95 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 126.106 1.763 . . . . 0.0 115.405 -171.487 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.475 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.4 mt -72.25 152.47 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.625 0 C-N-CA 125.197 1.399 . . . . 0.0 110.193 169.195 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.2 mtpt -111.33 69.63 0.69 Allowed 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 124.975 1.31 . . . . 0.0 112.456 -176.11 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 29.1 tp -57.71 124.39 18.96 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 124.05 0.94 . . . . 0.0 110.062 175.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 44.5 m-85 45.62 30.04 0.73 Allowed 'General case' 0 CA--C 1.559 1.314 0 N-CA-C 116.321 1.971 . . . . 0.0 116.321 -169.136 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.73 26.69 55.82 Favored Glycine 0 CA--C 1.542 1.723 0 O-C-N 120.188 -1.57 . . . . 0.0 115.94 175.857 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -137.4 120.94 11.74 Favored Pre-proline 0 CA--C 1.542 0.644 0 C-N-CA 128.222 2.609 . . . . 0.0 107.783 179.603 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -69.92 122.4 9.03 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 122.864 2.376 . . . . 0.0 112.223 -172.142 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 18.2 pt -94.2 146.27 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 125.259 1.424 . . . . 0.0 111.264 174.08 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 38.1 mmm-85 -110.43 139.27 45.82 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 124.699 1.2 . . . . 0.0 110.596 170.054 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 25.7 t -130.2 138.73 53.18 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 C-N-CA 124.523 1.129 . . . . 0.0 111.035 -175.042 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 41.2 t-20 -159.5 -179.14 7.66 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 126.247 1.819 . . . . 0.0 110.057 178.737 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 12.1 mmmm -58.78 148.23 30.48 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 124.928 1.291 . . . . 0.0 111.28 170.867 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.02 -24.07 43.91 Favored 'General case' 0 CA--C 1.547 0.861 0 O-C-N 121.893 -0.504 . . . . 0.0 112.034 168.733 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 40.4 p -71.21 -70.15 0.33 Allowed 'General case' 0 N--CA 1.47 0.568 0 C-N-CA 125.691 1.596 . . . . 0.0 111.615 171.349 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . 55.61 -21.51 0.01 OUTLIER 'General case' 0 CA--C 1.553 1.08 0 C-N-CA 130.492 3.517 . . . . 0.0 119.21 172.649 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -78.88 -4.92 52.07 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 125.078 1.351 . . . . 0.0 113.789 177.009 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 46.0 t30 -131.76 147.66 52.51 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.33 1.852 . . . . 0.0 110.421 173.661 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -74.29 -49.08 24.59 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 125.077 1.351 . . . . 0.0 112.434 -179.878 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -158.09 158.68 35.19 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 125.04 1.336 . . . . 0.0 112.347 -179.329 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 10.4 mp -82.19 155.96 24.67 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 123.985 0.914 . . . . 0.0 109.716 168.627 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 68.4 m -138.54 144.56 39.97 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 124.795 1.238 . . . . 0.0 112.079 -177.743 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -80.1 173.89 54.99 Favored Glycine 0 CA--C 1.543 1.785 0 C-N-CA 124.39 0.995 . . . . 0.0 114.034 174.366 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -69.57 159.83 52.06 Favored 'Trans proline' 0 CA--C 1.542 0.889 0 C-N-CA 123.899 3.066 . . . . 0.0 112.638 176.334 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 29.3 t -148.03 156.34 42.53 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.037 1.335 . . . . 0.0 112.06 178.272 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.6 t -78.31 -19.83 52.74 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 124.702 1.201 . . . . 0.0 112.722 172.216 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.27 0 C-N-CA 125.66 1.6 . . . . 0.0 113.744 178.879 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.564 0 N-CA-C 111.554 -0.619 . . . . 0.0 111.554 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 36.3 m -70.02 155.38 40.68 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 124.611 1.164 . . . . 0.0 113.213 -179.449 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 73.0 m -71.37 151.36 44.17 Favored 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 123.684 0.794 . . . . 0.0 112.17 174.306 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -153.42 156.71 26.92 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 124.359 0.98 . . . . 0.0 113.553 178.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 82.0 p -143.88 162.71 35.41 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 126.669 1.988 . . . . 0.0 111.744 -173.268 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 21.9 m -65.74 107.0 1.64 Allowed 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 123.476 0.711 . . . . 0.0 112.604 -179.076 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.86 -177.22 51.89 Favored Glycine 0 CA--C 1.542 1.729 0 C-N-CA 125.181 1.372 . . . . 0.0 112.965 169.191 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -65.87 150.99 85.38 Favored 'Trans proline' 0 CA--C 1.54 0.783 0 C-N-CA 123.096 2.531 . . . . 0.0 111.959 173.905 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 21.5 pt -73.76 152.36 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 123.799 0.84 . . . . 0.0 112.328 178.654 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 77.9 p -112.68 -36.99 5.02 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 124.221 1.008 . . . . 0.0 113.675 177.065 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -143.14 -21.81 0.63 Allowed 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 115.54 1.682 . . . . 0.0 115.54 -173.29 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 15.6 tpt180 -149.86 170.62 18.36 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 125.027 1.331 . . . . 0.0 110.873 -172.155 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 8.7 m120 -69.57 70.16 0.29 Allowed 'General case' 0 CA--C 1.545 0.76 0 CA-C-O 122.523 1.154 . . . . 0.0 112.542 172.83 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 35.8 mt-30 -68.3 -6.52 24.51 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 126.257 1.823 . . . . 0.0 113.088 177.036 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 14.0 p-10 -79.61 -24.98 41.6 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 126.997 2.119 . . . . 0.0 112.838 169.201 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -116.77 -1.43 12.07 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.863 1.665 . . . . 0.0 113.324 175.662 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 24.2 m -98.41 134.08 41.91 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 124.8 1.24 . . . . 0.0 109.779 172.019 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.3 m -100.84 148.57 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 124.595 1.158 . . . . 0.0 110.282 172.86 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 22.0 t80 -95.4 142.38 27.85 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 126.542 1.937 . . . . 0.0 109.243 169.505 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 23.4 t -131.45 108.88 15.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 C-N-CA 125.778 1.631 . . . . 0.0 109.07 177.172 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -106.19 144.69 15.86 Favored Glycine 0 CA--C 1.529 0.947 0 C-N-CA 124.44 1.019 . . . . 0.0 112.856 178.648 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 97.36 32.79 6.19 Favored Glycine 0 CA--C 1.533 1.205 0 C-N-CA 124.488 1.042 . . . . 0.0 113.936 175.207 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 84.6 mt -73.45 152.52 40.73 Favored 'General case' 0 C--O 1.234 0.269 0 C-N-CA 125.431 1.493 . . . . 0.0 111.352 -175.346 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -92.15 157.87 16.49 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 123.842 0.857 . . . . 0.0 112.004 174.812 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -58.68 -20.94 52.75 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 114.489 1.292 . . . . 0.0 114.489 178.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 60.2 mtpt -76.17 -15.53 60.04 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 114.222 1.193 . . . . 0.0 114.222 174.201 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 64.8 t -73.85 141.68 15.87 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 C-N-CA 124.471 1.108 . . . . 0.0 111.763 -177.506 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 95.1 p -136.66 163.09 31.39 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.537 1.535 . . . . 0.0 111.851 174.01 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -58.79 -44.61 99.17 Favored Pre-proline 0 CA--C 1.547 0.85 0 O-C-N 120.949 -1.094 . . . . 0.0 113.119 177.352 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_exo -59.29 -30.69 93.54 Favored 'Trans proline' 0 C--N 1.355 0.896 0 C-N-CA 122.38 2.053 . . . . 0.0 114.108 172.088 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 21.2 tp -66.67 -53.84 29.56 Favored 'General case' 0 C--N 1.345 0.37 0 CA-C-N 119.076 0.853 . . . . 0.0 109.655 173.919 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 28.0 mt -54.74 -42.33 71.49 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 122.518 0.327 . . . . 0.0 111.475 -179.221 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 3.0 t90 -57.48 -62.29 1.88 Allowed 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 123.283 0.633 . . . . 0.0 111.173 178.056 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -65.04 -29.5 70.4 Favored 'General case' 0 N--CA 1.471 0.575 0 N-CA-C 113.835 1.05 . . . . 0.0 113.835 -177.272 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.5 tp -72.23 -36.22 69.05 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 124.215 1.006 . . . . 0.0 111.96 176.628 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 12.0 m-85 -88.58 -10.43 48.79 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.842 1.257 . . . . 0.0 113.334 -176.51 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 24.2 mt -53.71 -21.72 7.65 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 124.323 1.049 . . . . 0.0 113.795 168.923 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 41.4 mt-30 -63.51 -32.11 73.47 Favored 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 125.167 1.387 . . . . 0.0 112.623 174.164 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -78.52 -44.32 24.63 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 123.218 0.607 . . . . 0.0 112.58 176.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 177.52 -172.47 45.22 Favored Glycine 0 CA--C 1.536 1.391 0 C-N-CA 124.609 1.099 . . . . 0.0 112.851 -179.51 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -67.25 109.29 1.73 Allowed 'Trans proline' 0 CA--C 1.537 0.652 0 C-N-CA 123.722 2.948 . . . . 0.0 111.646 -178.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 72.3 t -84.81 133.33 29.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 C-N-CA 124.805 1.242 . . . . 0.0 109.826 173.584 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 4.5 t -107.71 -34.53 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 C-N-CA 126.248 1.819 . . . . 0.0 111.761 -172.723 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 17.0 t30 -161.34 164.17 30.25 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 126.057 1.743 . . . . 0.0 111.357 -174.035 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 4.2 p -141.62 154.42 45.38 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 126.39 1.876 . . . . 0.0 111.86 176.165 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 3.4 t60 -142.38 135.51 28.66 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 123.955 0.902 . . . . 0.0 111.179 175.055 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 83.9 mtp -136.52 103.08 9.45 Favored Pre-proline 0 N--CA 1.471 0.585 0 C-N-CA 124.435 1.094 . . . . 0.0 109.433 169.525 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_exo -55.74 130.31 39.75 Favored 'Trans proline' 0 CA--C 1.535 0.572 0 C-N-CA 123.277 2.651 . . . . 0.0 113.639 -179.352 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 45.1 mmtm -96.23 147.9 23.28 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 125.015 1.326 . . . . 0.0 111.981 -177.762 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -76.82 141.9 40.5 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.338 1.455 . . . . 0.0 112.938 -178.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 33.1 ptt-85 -81.34 4.03 22.13 Favored 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 115.686 1.736 . . . . 0.0 115.686 -176.616 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 20.3 t -132.29 -39.61 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.989 0 C-N-CA 125.285 1.434 . . . . 0.0 111.261 -174.69 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 33.2 p -107.24 -17.26 14.19 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 124.42 1.088 . . . . 0.0 112.523 -178.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 71.1 1.91 44.12 Favored Glycine 0 CA--C 1.539 1.541 0 C-N-CA 124.947 1.26 . . . . 0.0 115.538 178.395 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 67.4 mm-40 -82.1 168.33 17.86 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 124.911 1.285 . . . . 0.0 110.905 177.324 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 18.3 p80 -67.85 148.74 50.76 Favored 'General case' 0 N--CA 1.473 0.681 0 O-C-N 120.772 -1.205 . . . . 0.0 111.459 171.111 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 86.3 mt-30 -88.31 25.53 1.62 Allowed 'General case' 0 CA--C 1.548 0.874 0 N-CA-C 114.254 1.205 . . . . 0.0 114.254 -174.874 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.57 4.54 82.94 Favored Glycine 0 CA--C 1.534 1.259 0 C-N-CA 124.901 1.239 . . . . 0.0 115.253 176.295 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -144.52 159.61 42.49 Favored 'General case' 0 CA--C 1.538 0.501 0 CA-C-N 118.686 1.243 . . . . 0.0 112.652 177.527 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -150.82 -175.94 23.26 Favored Glycine 0 CA--C 1.53 0.983 0 C-N-CA 125.943 1.735 . . . . 0.0 113.039 -178.2 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -145.98 150.73 36.58 Favored 'General case' 0 C--O 1.237 0.421 0 C-N-CA 125.894 1.678 . . . . 0.0 111.62 -178.538 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.3 t -134.24 126.29 49.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.724 1.21 . . . . 0.0 109.805 176.376 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.9 tt0 -101.88 120.59 40.63 Favored 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 124.622 1.169 . . . . 0.0 111.086 -177.363 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -96.9 162.19 13.51 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 124.756 1.223 . . . . 0.0 112.367 177.593 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 12.9 tp -63.4 -34.9 78.75 Favored 'General case' 0 CA--C 1.542 0.662 0 CA-C-N 115.903 -0.59 . . . . 0.0 112.337 176.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 6.6 m -144.17 156.24 44.24 Favored 'General case' 0 N--CA 1.472 0.625 0 CA-C-O 122.587 1.184 . . . . 0.0 112.674 -177.304 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -62.52 -31.98 72.84 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.208 1.403 . . . . 0.0 113.51 -176.236 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -72.05 -27.04 62.44 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 113.2 0.815 . . . . 0.0 113.2 176.793 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 47.4 m-20 -75.98 -34.51 59.77 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 123.732 0.813 . . . . 0.0 111.077 172.511 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -68.24 -47.12 68.64 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 123.936 0.894 . . . . 0.0 111.426 172.857 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -57.21 -35.72 69.99 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 124.284 1.034 . . . . 0.0 112.642 175.499 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 54.1 t80 -73.8 -35.15 64.88 Favored 'General case' 0 CA--C 1.536 0.41 0 O-C-N 121.736 -0.603 . . . . 0.0 112.584 175.645 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -65.31 -37.84 88.36 Favored 'General case' 0 CA--C 1.539 0.522 0 O-C-N 121.118 -0.989 . . . . 0.0 111.211 174.483 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 65.0 mt -63.25 -34.28 66.05 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 124.404 1.082 . . . . 0.0 110.965 172.377 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 41.5 ttmt -68.43 -44.12 75.66 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 123.835 0.854 . . . . 0.0 112.636 176.411 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 43.4 pt -91.05 -34.86 6.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 N-CA-C 115.063 1.505 . . . . 0.0 115.063 -173.644 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' MET . . . . . 0.461 ' HA ' HD12 ' A' ' 80' ' ' ILE . 9.9 mmt -93.51 1.32 56.81 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 114.834 1.42 . . . . 0.0 114.834 -172.279 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -85.22 137.24 33.12 Favored 'General case' 0 CA--C 1.54 0.565 0 O-C-N 121.614 -0.679 . . . . 0.0 111.927 178.776 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 22.4 mtp 58.92 14.44 3.32 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 126.111 1.764 . . . . 0.0 115.358 -171.107 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.461 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.2 mt -72.37 153.85 7.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 C-N-CA 125.285 1.434 . . . . 0.0 110.053 168.815 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.6 mtpt -113.89 70.04 0.72 Allowed 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 125.008 1.323 . . . . 0.0 112.619 -175.46 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 30.1 tp -57.75 124.93 20.85 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 124.1 0.96 . . . . 0.0 110.135 175.59 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 47.7 m-85 45.45 30.02 0.67 Allowed 'General case' 0 CA--C 1.559 1.322 0 N-CA-C 116.21 1.93 . . . . 0.0 116.21 -169.054 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.02 26.93 57.28 Favored Glycine 0 CA--C 1.542 1.726 0 O-C-N 120.139 -1.601 . . . . 0.0 115.916 176.13 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -136.93 120.43 11.98 Favored Pre-proline 0 CA--C 1.541 0.608 0 C-N-CA 128.264 2.626 . . . . 0.0 107.792 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -69.66 124.2 10.89 Favored 'Trans proline' 0 CA--C 1.537 0.646 0 C-N-CA 122.923 2.415 . . . . 0.0 112.35 -171.802 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 18.1 pt -95.84 145.05 9.03 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 C-N-CA 125.468 1.507 . . . . 0.0 111.404 174.859 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 37.3 mmm-85 -111.51 138.05 48.54 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 124.692 1.197 . . . . 0.0 110.75 170.993 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 23.7 t -130.63 137.46 56.05 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 124.376 1.071 . . . . 0.0 111.198 -172.82 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 32.0 t-20 -161.16 -178.89 7.04 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 126.347 1.859 . . . . 0.0 110.073 177.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 11.8 mmmm -63.77 145.73 55.22 Favored 'General case' 0 N--CA 1.477 0.905 0 O-C-N 120.577 -1.327 . . . . 0.0 111.433 175.211 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -74.33 0.36 14.62 Favored 'General case' 0 CA--C 1.551 1.006 0 N-CA-C 113.58 0.956 . . . . 0.0 113.58 171.568 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 15.3 p -110.13 3.53 20.28 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 127.618 2.367 . . . . 0.0 113.605 176.288 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -65.96 19.46 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.153 0 N-CA-C 117.105 2.261 . . . . 0.0 117.105 -168.643 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 24.2 m80 -87.59 -10.36 51.73 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 125.947 1.699 . . . . 0.0 114.517 -170.172 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 27.6 t30 -79.88 126.57 31.17 Favored 'General case' 0 CA--C 1.54 0.586 0 CA-C-N 119.124 0.875 . . . . 0.0 111.075 178.323 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 65.4 pttt -73.33 150.51 41.81 Favored 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 123.696 0.798 . . . . 0.0 112.473 177.937 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -141.44 158.48 43.81 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.829 1.251 . . . . 0.0 112.491 -178.928 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 88.4 mt -81.06 163.07 23.48 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 124.497 1.119 . . . . 0.0 111.2 169.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 59.1 p -75.23 -21.98 58.22 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 124.344 1.057 . . . . 0.0 113.774 175.557 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 171.62 175.74 40.15 Favored Glycine 0 CA--C 1.54 1.656 0 C-N-CA 125.305 1.431 . . . . 0.0 113.508 177.348 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_endo -73.05 166.69 29.35 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 124.18 3.253 . . . . 0.0 112.787 176.877 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 83.1 p -145.29 170.24 16.69 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 125.049 1.34 . . . . 0.0 112.53 175.567 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 64.7 p -82.28 -1.09 48.35 Favored 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 125.339 1.456 . . . . 0.0 114.65 177.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.304 0 C-N-CA 125.677 1.608 . . . . 0.0 114.113 -179.552 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 1.458 0 N-CA-C 111.792 -0.523 . . . . 0.0 111.792 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 38.2 m -72.67 157.76 36.92 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.406 1.082 . . . . 0.0 112.985 176.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 42.8 p -79.52 -21.9 44.65 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 125.381 1.472 . . . . 0.0 114.693 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 81.02 12.08 82.99 Favored Glycine 0 CA--C 1.54 1.612 0 C-N-CA 124.143 0.878 . . . . 0.0 114.362 -169.579 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 59.8 m -61.37 155.62 21.01 Favored 'General case' 0 N--CA 1.476 0.839 0 CA-C-N 118.708 1.254 . . . . 0.0 112.808 175.015 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 60.7 p -68.42 -23.19 64.6 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 114.842 1.423 . . . . 0.0 114.842 -174.749 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 173.22 178.88 43.52 Favored Glycine 0 CA--C 1.539 1.561 0 C-N-CA 124.727 1.156 . . . . 0.0 113.817 174.602 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -61.45 150.11 86.6 Favored 'Trans proline' 0 CA--C 1.539 0.755 0 C-N-CA 123.971 3.114 . . . . 0.0 113.698 177.867 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 29.8 pt -84.98 142.34 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 124.266 1.026 . . . . 0.0 112.304 174.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 22.6 m -74.89 -28.65 60.72 Favored 'General case' 0 N--CA 1.475 0.819 0 N-CA-C 113.839 1.051 . . . . 0.0 113.839 -173.606 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -85.15 143.72 28.64 Favored 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 124.254 1.022 . . . . 0.0 111.829 174.181 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 10.4 mmp_? -97.88 123.36 41.82 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 124.533 1.133 . . . . 0.0 111.342 -173.323 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 75.5 m-20 -102.99 86.65 2.75 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 124.382 1.073 . . . . 0.0 111.92 -172.285 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 57.5 tt0 -61.41 -33.79 74.29 Favored 'General case' 0 N--CA 1.476 0.854 0 O-C-N 121.136 -0.978 . . . . 0.0 112.47 178.568 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -72.34 -12.65 61.22 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 113.782 1.03 . . . . 0.0 113.782 175.412 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -110.39 11.73 23.21 Favored 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 125.234 1.414 . . . . 0.0 111.654 168.75 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 59.1 m -99.12 133.54 43.26 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 124.307 1.043 . . . . 0.0 109.431 173.32 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 13.9 m -100.17 146.58 8.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 C-N-CA 124.114 0.966 . . . . 0.0 109.938 170.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 12.0 t80 -95.0 142.42 27.5 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 125.496 1.518 . . . . 0.0 108.53 169.08 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.5 t -131.75 106.48 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 C-N-CA 125.383 1.473 . . . . 0.0 109.063 179.176 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -102.91 144.56 16.07 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 124.216 0.912 . . . . 0.0 112.593 177.885 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 97.84 32.03 6.4 Favored Glycine 0 CA--C 1.534 1.23 0 C-N-CA 124.48 1.038 . . . . 0.0 113.863 174.853 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 83.3 mt -73.97 145.27 44.78 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 125.222 1.409 . . . . 0.0 111.203 -175.277 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -84.38 157.3 21.48 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 123.063 0.545 . . . . 0.0 112.45 174.864 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -58.51 -20.41 45.66 Favored 'General case' 0 CA--C 1.546 0.809 0 N-CA-C 114.591 1.33 . . . . 0.0 114.591 178.766 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.4 mtmm -79.7 -12.05 59.82 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 114.341 1.238 . . . . 0.0 114.341 174.044 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.6 t -76.2 142.46 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 C-N-CA 124.815 1.246 . . . . 0.0 111.588 178.023 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 6.3 t -144.24 166.79 24.05 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 124.067 0.947 . . . . 0.0 111.71 169.061 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -52.78 -43.01 92.33 Favored Pre-proline 0 CA--C 1.547 0.842 0 N-CA-C 115.495 1.665 . . . . 0.0 115.495 -179.146 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -70.64 -25.12 24.88 Favored 'Trans proline' 0 C--N 1.353 0.792 0 CA-C-N 121.921 1.722 . . . . 0.0 113.024 176.848 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 17.6 tp -65.04 -54.07 35.93 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 170.159 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 26.5 mt -54.91 -42.73 72.55 Favored 'General case' 0 C--O 1.224 -0.259 0 O-C-N 123.305 0.378 . . . . 0.0 111.316 -178.675 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.8 t90 -57.64 -62.7 1.6 Allowed 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 123.272 0.629 . . . . 0.0 111.349 178.692 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -64.44 -30.42 71.46 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 113.857 1.058 . . . . 0.0 113.857 -177.392 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.0 tp -71.11 -35.27 71.72 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 124.173 0.989 . . . . 0.0 112.106 176.433 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 -89.51 -10.77 44.99 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 124.863 1.265 . . . . 0.0 113.361 -176.291 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 26.9 mt -53.96 -20.92 6.93 Favored 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 113.92 1.081 . . . . 0.0 113.92 169.172 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 45.0 mt-30 -59.54 -40.16 86.34 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 124.845 1.258 . . . . 0.0 111.89 173.242 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -74.63 -45.45 44.76 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 123.772 0.829 . . . . 0.0 112.899 179.566 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -177.71 -173.09 42.87 Favored Glycine 0 CA--C 1.537 1.44 0 C-N-CA 124.158 0.885 . . . . 0.0 113.595 -177.567 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -67.66 108.65 1.68 Allowed 'Trans proline' 0 CA--C 1.535 0.565 0 C-N-CA 124.072 3.181 . . . . 0.0 111.505 178.392 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 67.3 t -83.99 132.33 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 C-N-CA 124.195 0.998 . . . . 0.0 109.863 173.579 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 15.6 t -107.05 -35.43 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.72 0 C-N-CA 126.797 2.039 . . . . 0.0 111.725 -171.927 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 14.7 t30 -161.13 157.87 26.64 Favored 'General case' 0 CA--C 1.552 1.029 0 C-N-CA 125.917 1.687 . . . . 0.0 110.777 -171.697 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 11.1 p -136.82 155.59 49.6 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 125.844 1.658 . . . . 0.0 111.584 171.834 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 4.1 t60 -141.74 130.36 22.71 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 124.116 0.967 . . . . 0.0 110.484 177.802 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 86.3 mtp -135.54 107.18 10.01 Favored Pre-proline 0 N--CA 1.468 0.451 0 C-N-CA 123.991 0.916 . . . . 0.0 109.292 169.388 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_exo -55.89 146.18 69.32 Favored 'Trans proline' 0 CA--C 1.539 0.763 0 C-N-CA 123.709 2.939 . . . . 0.0 113.217 173.196 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 21.6 mmtp -121.95 159.77 26.24 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 125.318 1.447 . . . . 0.0 113.483 -168.922 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -79.85 152.27 29.78 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 126.403 1.881 . . . . 0.0 112.066 170.299 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 11.9 ptp85 -92.85 0.18 57.36 Favored 'General case' 0 N--CA 1.478 0.945 0 N-CA-C 116.551 2.056 . . . . 0.0 116.551 -173.07 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 3.3 m -135.29 -31.63 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.22 0 C-N-CA 124.488 1.115 . . . . 0.0 113.456 -178.501 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 80.7 p -104.96 -20.51 13.52 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 124.781 1.233 . . . . 0.0 111.65 179.067 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 69.92 7.71 59.7 Favored Glycine 0 CA--C 1.54 1.607 0 C-N-CA 125.113 1.34 . . . . 0.0 115.262 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 58.3 mm-40 -70.11 161.32 30.41 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 124.682 1.193 . . . . 0.0 111.12 173.787 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 25.4 p80 -75.7 158.74 31.93 Favored 'General case' 0 N--CA 1.472 0.636 0 O-C-N 120.997 -1.064 . . . . 0.0 112.765 175.449 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 82.2 mt-30 -81.3 12.62 3.43 Favored 'General case' 0 CA--C 1.551 1.008 0 N-CA-C 114.595 1.332 . . . . 0.0 114.595 -174.658 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.02 1.48 82.09 Favored Glycine 0 CA--C 1.536 1.362 0 C-N-CA 125.138 1.351 . . . . 0.0 114.941 -178.7 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -144.91 160.73 40.85 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 125.193 1.397 . . . . 0.0 112.138 178.271 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -151.61 -175.03 22.96 Favored Glycine 0 CA--C 1.529 0.942 0 C-N-CA 125.591 1.567 . . . . 0.0 112.918 -179.465 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -144.5 151.73 39.56 Favored 'General case' 0 C--O 1.238 0.452 0 C-N-CA 125.573 1.549 . . . . 0.0 111.582 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 17.1 t -134.22 125.05 47.21 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 124.639 1.176 . . . . 0.0 110.073 175.437 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 78.3 tt0 -100.69 124.88 46.91 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 124.756 1.222 . . . . 0.0 111.298 -178.415 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -98.87 161.42 13.65 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 125.258 1.423 . . . . 0.0 112.274 174.667 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.5 tp -63.38 -33.53 75.75 Favored 'General case' 0 CA--C 1.541 0.63 0 CA-C-N 116.0 -0.545 . . . . 0.0 112.267 176.742 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 12.8 m -143.31 154.46 43.81 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 124.467 1.107 . . . . 0.0 112.129 -175.23 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -63.69 -35.73 81.52 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.565 1.146 . . . . 0.0 113.215 -176.052 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 2.9 pm0 -65.01 -26.12 68.14 Favored 'General case' 0 CA--C 1.541 0.625 0 N-CA-C 113.693 0.997 . . . . 0.0 113.693 174.837 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 46.9 m-20 -79.51 -31.9 42.28 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.639 0.776 . . . . 0.0 111.783 173.336 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.89 -43.67 71.32 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 123.203 0.601 . . . . 0.0 111.337 172.274 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -57.71 -34.26 69.27 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 124.334 1.054 . . . . 0.0 112.583 174.641 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 20.2 t80 -71.93 -37.68 69.98 Favored 'General case' 0 CA--C 1.537 0.479 0 O-C-N 121.597 -0.689 . . . . 0.0 111.985 174.827 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.77 -36.12 81.68 Favored 'General case' 0 CA--C 1.537 0.477 0 O-C-N 120.843 -1.161 . . . . 0.0 111.452 176.388 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 74.8 mt -62.88 -34.33 65.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 C-N-CA 124.085 0.954 . . . . 0.0 111.022 171.633 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 63.3 tttp -68.4 -42.67 78.68 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 124.007 0.923 . . . . 0.0 112.498 176.937 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 18.8 pt -91.78 -39.71 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 N-CA-C 114.771 1.397 . . . . 0.0 114.771 -175.258 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' MET . . . . . 0.482 ' HA ' HD12 ' A' ' 80' ' ' ILE . 15.1 mmt -90.06 1.01 56.82 Favored 'General case' 0 N--CA 1.48 1.051 0 N-CA-C 114.808 1.41 . . . . 0.0 114.808 -169.512 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -86.15 133.65 33.85 Favored 'General case' 0 CA--C 1.537 0.46 0 O-C-N 121.5 -0.75 . . . . 0.0 112.52 -178.301 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 86.2 mmm 56.79 16.67 2.81 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 126.482 1.913 . . . . 0.0 114.968 -170.048 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.482 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.0 mt -69.51 150.78 10.2 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 C-N-CA 124.707 1.203 . . . . 0.0 109.534 167.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 44.6 mtpt -108.72 70.04 0.73 Allowed 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 124.719 1.207 . . . . 0.0 112.163 -177.241 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 30.5 tp -57.48 125.1 21.37 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 124.104 0.961 . . . . 0.0 109.665 174.222 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 63.6 m-85 46.81 29.44 1.0 Allowed 'General case' 0 CA--C 1.56 1.354 0 N-CA-C 116.253 1.946 . . . . 0.0 116.253 -168.714 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 78.71 28.31 55.16 Favored Glycine 0 CA--C 1.54 1.631 0 O-C-N 120.224 -1.547 . . . . 0.0 115.689 176.447 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 33.9 ttmt -144.06 120.06 6.31 Favored Pre-proline 0 CA--C 1.544 0.74 0 C-N-CA 128.157 2.583 . . . . 0.0 107.853 -174.736 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -71.05 130.16 17.34 Favored 'Trans proline' 0 CA--C 1.537 0.649 0 C-N-CA 122.894 2.396 . . . . 0.0 113.294 -168.741 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 17.8 pt -102.06 143.91 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 C-N-CA 125.623 1.569 . . . . 0.0 111.966 175.828 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 46.0 tpt85 -112.58 130.09 56.14 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.967 1.707 . . . . 0.0 109.738 178.738 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 17.5 t -129.3 132.69 66.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 C-N-CA 124.342 1.057 . . . . 0.0 112.167 -170.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 52.5 p-10 -156.48 -178.85 7.65 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 126.27 1.828 . . . . 0.0 111.251 174.77 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 11.5 mmmm -67.5 138.83 56.85 Favored 'General case' 0 N--CA 1.478 0.959 0 O-C-N 121.068 -1.02 . . . . 0.0 111.078 178.011 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -71.92 -5.7 36.57 Favored 'General case' 0 CA--C 1.551 0.994 0 N-CA-C 113.595 0.961 . . . . 0.0 113.595 173.819 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 84.2 p -115.59 11.78 15.93 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 126.768 2.027 . . . . 0.0 113.927 175.564 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -56.2 138.04 50.82 Favored 'General case' 0 CA--C 1.545 0.784 0 N-CA-C 114.493 1.294 . . . . 0.0 114.493 -170.212 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 7.9 p80 -157.06 -36.37 0.08 Allowed 'General case' 0 N--CA 1.476 0.865 0 C-N-CA 125.039 1.336 . . . . 0.0 113.601 177.602 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 14.5 p-10 -90.57 152.88 20.72 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.591 1.556 . . . . 0.0 113.321 -175.43 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -130.48 11.29 5.32 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 125.699 1.6 . . . . 0.0 113.941 -176.866 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 13.3 p-10 -73.86 146.26 44.25 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 125.031 1.332 . . . . 0.0 113.473 -175.511 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 59.8 tp -96.89 -43.11 7.62 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.74 1.216 . . . . 0.0 111.794 170.296 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 46.4 m 58.57 179.21 0.07 Allowed 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 126.865 2.066 . . . . 0.0 115.45 177.349 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -170.3 178.91 42.79 Favored Glycine 0 CA--C 1.541 1.703 0 C-N-CA 125.371 1.462 . . . . 0.0 112.906 -178.431 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -69.02 144.65 58.73 Favored 'Trans proline' 0 CA--C 1.539 0.772 0 C-N-CA 123.682 2.921 . . . . 0.0 112.814 -177.115 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 64.3 p -83.28 -7.3 59.61 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 125.052 1.341 . . . . 0.0 114.436 -179.634 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 18.2 m -74.45 -12.74 60.58 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 114.721 1.378 . . . . 0.0 114.721 -176.791 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.266 0 C-N-CA 125.492 1.52 . . . . 0.0 113.718 -179.779 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.613 0 N-CA-C 111.463 -0.655 . . . . 0.0 111.463 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.7 m -60.09 -23.26 63.66 Favored 'General case' 0 N--CA 1.48 1.052 0 N-CA-C 114.879 1.437 . . . . 0.0 114.879 -171.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 14.7 m -60.7 -23.73 65.1 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.539 1.135 . . . . 0.0 113.427 174.744 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -85.88 -7.08 81.62 Favored Glycine 0 CA--C 1.538 1.484 0 C-N-CA 125.038 1.304 . . . . 0.0 115.169 176.46 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 50.6 m -78.44 -8.9 59.02 Favored 'General case' 0 N--CA 1.478 0.93 0 CA-C-N 119.048 1.424 . . . . 0.0 114.7 -173.533 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 9.2 t -148.42 155.7 41.55 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 125.275 1.43 . . . . 0.0 111.513 175.099 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -74.43 155.1 48.32 Favored Glycine 0 CA--C 1.543 1.838 0 C-N-CA 124.09 0.852 . . . . 0.0 114.054 -179.411 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -72.56 161.2 44.72 Favored 'Trans proline' 0 CA--C 1.54 0.805 0 C-N-CA 123.821 3.014 . . . . 0.0 112.627 176.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.406 HG13 ' H ' ' A' ' 11' ' ' GLU . 10.2 tp -145.64 147.97 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 C-N-CA 124.871 1.269 . . . . 0.0 111.359 175.242 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 22.9 m -72.6 -23.33 60.93 Favored 'General case' 0 N--CA 1.474 0.739 0 C-N-CA 123.928 0.891 . . . . 0.0 113.356 178.596 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.406 ' H ' HG13 ' A' ' 9' ' ' ILE . 38.7 tt0 -63.84 133.16 52.87 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 125.032 1.333 . . . . 0.0 113.396 -172.487 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 5.9 mmp_? -88.92 150.74 22.71 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 125.525 1.53 . . . . 0.0 111.142 175.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 25.0 t-20 -140.05 130.9 26.0 Favored 'General case' 0 CA--C 1.547 0.832 0 N-CA-C 113.776 1.028 . . . . 0.0 113.776 -175.51 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 40.4 mt-30 -80.9 -10.64 59.69 Favored 'General case' 0 N--CA 1.476 0.838 0 N-CA-C 115.387 1.625 . . . . 0.0 115.387 -175.625 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 47.7 m-20 -91.96 -34.04 14.62 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-N 119.828 1.195 . . . . 0.0 111.645 171.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -77.7 -13.85 59.78 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 124.389 1.076 . . . . 0.0 112.832 169.475 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 29.9 m -94.56 136.07 35.29 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 124.36 1.064 . . . . 0.0 110.002 169.158 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 4.7 m -103.13 147.67 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 C-N-CA 124.765 1.226 . . . . 0.0 109.912 170.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 30.3 t80 -95.11 142.22 27.81 Favored 'General case' 0 C--N 1.327 -0.404 0 C-N-CA 126.265 1.826 . . . . 0.0 109.277 169.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 22.8 t -132.18 107.05 12.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.492 0 C-N-CA 125.699 1.6 . . . . 0.0 109.15 176.352 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -103.4 145.47 16.22 Favored Glycine 0 CA--C 1.529 0.923 0 C-N-CA 124.452 1.025 . . . . 0.0 112.747 177.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.12 32.14 6.91 Favored Glycine 0 CA--C 1.534 1.225 0 C-N-CA 124.489 1.042 . . . . 0.0 113.897 175.209 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 85.2 mt -74.06 145.57 44.34 Favored 'General case' 0 C--O 1.234 0.267 0 C-N-CA 125.382 1.473 . . . . 0.0 111.312 -175.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -85.02 158.05 20.57 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 123.14 0.576 . . . . 0.0 112.479 174.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -58.51 -20.85 49.44 Favored 'General case' 0 CA--C 1.545 0.785 0 N-CA-C 114.462 1.282 . . . . 0.0 114.462 178.127 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.4 mtmm -79.66 -11.69 59.85 Favored 'General case' 0 N--CA 1.476 0.839 0 N-CA-C 114.36 1.244 . . . . 0.0 114.36 174.16 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 67.0 t -74.48 142.82 14.2 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.94 0 C-N-CA 124.583 1.153 . . . . 0.0 111.519 178.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 90.6 p -137.82 162.96 32.6 Favored 'General case' 0 N--CA 1.472 0.658 0 C-N-CA 125.418 1.487 . . . . 0.0 111.941 174.116 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -58.15 -44.45 99.27 Favored Pre-proline 0 CA--C 1.548 0.874 0 O-C-N 121.0 -1.062 . . . . 0.0 112.963 176.625 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_exo -58.9 -31.82 96.18 Favored 'Trans proline' 0 C--N 1.354 0.856 0 C-N-CA 122.544 2.163 . . . . 0.0 114.275 171.483 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 21.1 tp -65.85 -53.58 38.08 Favored 'General case' 0 C--N 1.344 0.361 0 CA-C-N 119.261 0.937 . . . . 0.0 109.67 173.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 24.7 mt -55.47 -42.3 74.14 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 119.497 -0.287 . . . . 0.0 111.458 -178.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.8 t90 -57.68 -62.49 1.76 Allowed 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.221 0.608 . . . . 0.0 111.176 177.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -65.03 -30.03 70.97 Favored 'General case' 0 N--CA 1.471 0.598 0 N-CA-C 113.881 1.067 . . . . 0.0 113.881 -176.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.2 tp -71.06 -37.32 72.5 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.123 0.969 . . . . 0.0 111.823 176.086 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.3 m-85 -87.71 -10.6 50.71 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 124.861 1.264 . . . . 0.0 113.439 -175.801 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 24.4 mt -54.03 -21.96 9.5 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 124.373 1.069 . . . . 0.0 113.847 169.23 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 41.8 mt-30 -64.11 -31.15 72.24 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 125.224 1.41 . . . . 0.0 112.608 174.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -78.17 -46.13 21.35 Favored 'General case' 0 CA--C 1.541 0.609 0 C-N-CA 123.509 0.723 . . . . 0.0 112.362 176.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 178.81 -172.64 44.93 Favored Glycine 0 CA--C 1.536 1.404 0 C-N-CA 124.835 1.207 . . . . 0.0 112.969 -179.086 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -67.86 110.84 2.24 Favored 'Trans proline' 0 CA--C 1.537 0.632 0 C-N-CA 123.689 2.926 . . . . 0.0 111.736 -178.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 87.7 t -85.7 134.04 28.14 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.62 0 C-N-CA 124.962 1.305 . . . . 0.0 110.016 174.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 4.4 t -109.12 -33.86 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.807 0 C-N-CA 126.458 1.903 . . . . 0.0 112.068 -172.48 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 10.9 t30 -160.38 157.65 28.21 Favored 'General case' 0 CA--C 1.552 1.028 0 C-N-CA 125.91 1.684 . . . . 0.0 110.975 -171.034 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 7.5 p -140.03 152.53 46.31 Favored 'General case' 0 N--CA 1.481 1.086 0 C-N-CA 126.314 1.846 . . . . 0.0 111.37 174.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 47.3 t-80 -142.46 133.88 26.41 Favored 'General case' 0 N--CA 1.468 0.443 0 C-N-CA 123.467 0.707 . . . . 0.0 111.424 174.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 82.9 mtp -133.73 106.21 11.76 Favored Pre-proline 0 N--CA 1.471 0.615 0 C-N-CA 124.215 1.006 . . . . 0.0 109.338 169.501 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 81.9 Cg_exo -57.27 140.95 94.42 Favored 'Trans proline' 0 CA--C 1.538 0.704 0 C-N-CA 123.278 2.652 . . . . 0.0 113.292 178.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 44.3 mmtm -111.48 145.01 39.78 Favored 'General case' 0 N--CA 1.476 0.827 0 C-N-CA 125.204 1.402 . . . . 0.0 112.812 -173.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -67.82 144.0 55.53 Favored 'General case' 0 CA--C 1.544 0.743 0 C-N-CA 125.952 1.701 . . . . 0.0 112.636 174.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 18.0 ptp180 -86.86 7.53 26.76 Favored 'General case' 0 N--CA 1.478 0.967 0 N-CA-C 115.927 1.825 . . . . 0.0 115.927 -174.117 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 38.2 t -131.31 -37.36 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 124.972 1.309 . . . . 0.0 111.389 -174.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 73.0 p -115.04 -14.58 11.82 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 125.791 1.637 . . . . 0.0 112.555 -176.259 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.43 4.09 50.11 Favored Glycine 0 CA--C 1.538 1.493 0 C-N-CA 125.117 1.341 . . . . 0.0 115.502 176.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 71.9 mm-40 -77.37 162.79 26.98 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 124.677 1.191 . . . . 0.0 110.846 177.21 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 17.8 p80 -68.96 152.89 44.7 Favored 'General case' 0 N--CA 1.472 0.637 0 O-C-N 120.853 -1.154 . . . . 0.0 112.343 176.417 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 47.5 mt-30 -85.3 18.01 2.84 Favored 'General case' 0 CA--C 1.549 0.907 0 N-CA-C 114.355 1.242 . . . . 0.0 114.355 -172.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.6 2.69 84.55 Favored Glycine 0 CA--C 1.535 1.305 0 C-N-CA 125.022 1.296 . . . . 0.0 115.002 179.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -144.74 159.74 42.36 Favored 'General case' 0 CA--C 1.537 0.478 0 C-N-CA 124.732 1.213 . . . . 0.0 112.443 177.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -150.95 -178.13 25.48 Favored Glycine 0 CA--C 1.529 0.953 0 C-N-CA 125.853 1.692 . . . . 0.0 113.264 -176.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -144.78 148.22 33.82 Favored 'General case' 0 C--O 1.236 0.37 0 C-N-CA 126.026 1.73 . . . . 0.0 111.595 -176.586 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 20.2 t -134.65 127.91 50.16 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 C-N-CA 124.841 1.256 . . . . 0.0 109.762 175.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 44.8 tt0 -108.51 127.25 53.76 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 124.252 1.021 . . . . 0.0 111.765 -177.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -100.24 162.69 12.8 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 125.552 1.541 . . . . 0.0 112.493 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.6 tp -62.22 -32.64 73.33 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 123.02 0.528 . . . . 0.0 112.398 177.282 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.0 m -144.99 157.26 44.19 Favored 'General case' 0 N--CA 1.47 0.525 0 C-N-CA 124.104 0.962 . . . . 0.0 111.768 -178.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 88.4 tt0 -61.55 -36.78 81.56 Favored 'General case' 0 N--CA 1.472 0.671 0 O-C-N 121.576 -0.703 . . . . 0.0 112.777 -178.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -64.9 -23.51 67.25 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 113.592 0.96 . . . . 0.0 113.592 179.221 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -80.55 -33.62 36.08 Favored 'General case' 0 CA--C 1.541 0.632 0 C-N-CA 124.215 1.006 . . . . 0.0 111.668 172.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -71.26 -44.75 64.68 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 123.835 0.854 . . . . 0.0 111.741 174.468 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -61.39 -30.19 70.4 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.826 1.25 . . . . 0.0 112.253 179.269 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 59.9 t80 -78.24 -36.45 47.0 Favored 'General case' 0 CA--C 1.535 0.398 0 C-N-CA 124.336 1.054 . . . . 0.0 113.044 173.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.15 -38.4 88.85 Favored 'General case' 0 CA--C 1.539 0.544 0 O-C-N 121.115 -0.991 . . . . 0.0 111.211 176.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 59.7 mt -61.24 -35.91 69.22 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 C-N-CA 124.988 1.315 . . . . 0.0 111.308 173.475 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 85.0 tttt -69.01 -37.34 78.63 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 124.138 0.975 . . . . 0.0 113.102 176.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 19.1 pt -99.16 -14.74 7.67 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 N-CA-C 116.143 1.905 . . . . 0.0 116.143 -172.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 12.2 mmt -112.28 -2.66 14.78 Favored 'General case' 0 N--CA 1.483 1.203 0 N-CA-C 115.149 1.537 . . . . 0.0 115.149 -176.37 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 38.5 t70 -81.88 145.25 30.46 Favored 'General case' 0 N--CA 1.475 0.812 0 O-C-N 120.863 -1.148 . . . . 0.0 113.863 -176.562 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 28.5 ttm 60.33 13.42 3.98 Favored 'General case' 0 N--CA 1.479 0.979 0 C-N-CA 127.316 2.246 . . . . 0.0 115.115 -179.237 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 18.0 mt -87.3 152.04 3.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 C-N-CA 127.96 2.504 . . . . 0.0 111.645 -179.297 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 43.6 mtpt -104.64 72.07 1.02 Allowed 'General case' 0 N--CA 1.473 0.678 0 C-N-CA 124.467 1.107 . . . . 0.0 112.634 -171.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 31.4 tp -57.34 125.01 20.9 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.747 0.819 . . . . 0.0 109.73 173.3 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 63.6 m-85 46.44 28.69 0.77 Allowed 'General case' 0 CA--C 1.561 1.381 0 N-CA-C 116.326 1.973 . . . . 0.0 116.326 -168.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.77 27.46 53.77 Favored Glycine 0 CA--C 1.541 1.709 0 O-C-N 120.124 -1.61 . . . . 0.0 115.751 177.047 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 33.0 ttmt -143.4 120.41 6.75 Favored Pre-proline 0 CA--C 1.543 0.709 0 C-N-CA 128.453 2.701 . . . . 0.0 107.646 -175.739 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 55.2 Cg_endo -71.27 127.66 13.68 Favored 'Trans proline' 0 CA--C 1.537 0.636 0 C-N-CA 123.059 2.506 . . . . 0.0 113.458 -168.227 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 21.5 pt -97.91 143.28 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 125.127 1.371 . . . . 0.0 112.156 174.663 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 47.9 tpt85 -108.38 127.68 54.1 Favored 'General case' 0 N--CA 1.473 0.716 0 C-N-CA 126.246 1.818 . . . . 0.0 109.013 173.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 19.7 t -124.81 135.47 63.88 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 C-N-CA 124.418 1.087 . . . . 0.0 111.064 -173.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 38.5 t-20 -159.29 175.42 13.41 Favored 'General case' 0 CA--C 1.55 0.959 0 C-N-CA 125.182 1.393 . . . . 0.0 111.122 -179.18 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.9 mmmm -62.9 140.16 58.8 Favored 'General case' 0 N--CA 1.48 1.055 0 O-C-N 120.614 -1.304 . . . . 0.0 109.99 172.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -72.33 -4.27 28.85 Favored 'General case' 0 CA--C 1.55 0.95 0 N-CA-C 113.652 0.982 . . . . 0.0 113.652 177.174 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 62.6 p -86.72 -5.61 59.07 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 127.029 2.132 . . . . 0.0 113.361 169.408 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -134.66 177.9 7.42 Favored 'General case' 0 CA--C 1.548 0.878 0 C-N-CA 126.312 1.845 . . . . 0.0 112.404 -175.008 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -120.49 -69.99 0.81 Allowed 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 124.75 1.22 . . . . 0.0 111.467 176.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 49.4 t30 -142.79 160.78 39.66 Favored 'General case' 0 CA--C 1.547 0.846 0 C-N-CA 125.247 1.419 . . . . 0.0 111.329 177.534 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 36.1 ttpt -71.74 134.12 46.03 Favored 'General case' 0 N--CA 1.475 0.776 0 C-N-CA 124.426 1.091 . . . . 0.0 111.526 -178.755 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 21.9 t-20 -103.21 -25.52 13.32 Favored 'General case' 0 CA--C 1.546 0.812 0 N-CA-C 114.355 1.243 . . . . 0.0 114.355 -175.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 96.0 mt -132.78 157.24 45.46 Favored 'General case' 0 N--CA 1.474 0.745 0 C-N-CA 125.781 1.632 . . . . 0.0 111.782 -175.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 2.5 t -149.71 165.41 32.46 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 124.472 1.109 . . . . 0.0 112.022 176.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -177.79 178.37 48.43 Favored Glycine 0 CA--C 1.54 1.625 0 C-N-CA 124.455 1.026 . . . . 0.0 114.224 -178.46 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 98.7 Cg_endo -71.31 160.41 48.88 Favored 'Trans proline' 0 CA--C 1.541 0.855 0 C-N-CA 124.125 3.217 . . . . 0.0 112.975 -179.284 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 20.2 m -71.94 -16.71 62.1 Favored 'General case' 0 N--CA 1.477 0.887 0 N-CA-C 114.422 1.268 . . . . 0.0 114.422 -177.16 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.3 t -150.51 161.44 42.54 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 125.7 1.6 . . . . 0.0 111.466 177.049 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.299 0 C-N-CA 125.632 1.587 . . . . 0.0 113.864 -179.573 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.638 0 N-CA-C 112.089 -0.404 . . . . 0.0 112.089 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 66.7 p -63.17 -14.62 51.0 Favored 'General case' 0 N--CA 1.479 0.998 0 N-CA-C 115.123 1.527 . . . . 0.0 115.123 -174.74 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.1 m -67.35 -14.9 63.34 Favored 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 125.219 1.408 . . . . 0.0 114.055 171.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -64.47 152.52 49.79 Favored Glycine 0 CA--C 1.536 1.401 0 C-N-CA 124.011 0.815 . . . . 0.0 112.995 174.241 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 19.8 m -59.59 -25.99 65.07 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 114.997 1.48 . . . . 0.0 114.997 -169.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 17.2 m -83.4 -6.83 59.58 Favored 'General case' 0 N--CA 1.475 0.815 0 C-N-CA 124.878 1.271 . . . . 0.0 114.123 177.178 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 57.96 50.53 65.11 Favored Glycine 0 CA--C 1.542 1.749 0 C-N-CA 124.956 1.265 . . . . 0.0 113.986 -171.35 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -68.81 150.81 74.15 Favored 'Trans proline' 0 CA--C 1.54 0.795 0 C-N-CA 123.237 2.625 . . . . 0.0 113.738 -169.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 18.6 tt -87.69 152.62 3.38 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.681 0 C-N-CA 125.645 1.578 . . . . 0.0 111.623 175.398 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 52.4 p -81.67 -1.25 46.12 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 125.286 1.434 . . . . 0.0 114.787 179.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . 0.292 10.8 pt-20 50.26 29.74 3.93 Favored 'General case' 0 N--CA 1.478 0.958 0 C-N-CA 127.706 2.402 . . . . 0.0 116.416 174.038 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -125.93 156.54 39.59 Favored 'General case' 0 N--CA 1.477 0.903 0 C-N-CA 126.348 1.859 . . . . 0.0 112.5 -179.103 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 33.8 t-20 50.07 52.6 14.38 Favored 'General case' 0 CA--C 1.546 0.815 0 C-N-CA 126.125 1.77 . . . . 0.0 114.062 177.534 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 24.0 mp0 -58.9 -24.36 62.24 Favored 'General case' 0 CA--C 1.544 0.749 0 C-N-CA 124.683 1.193 . . . . 0.0 112.838 177.345 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -69.04 -23.63 64.08 Favored 'General case' 0 N--CA 1.471 0.619 0 O-C-N 120.982 -1.074 . . . . 0.0 113.501 174.062 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -85.42 1.75 47.37 Favored 'General case' 0 CA--C 1.546 0.812 0 C-N-CA 123.966 0.906 . . . . 0.0 112.702 169.282 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 25.2 m -100.68 135.44 42.12 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.424 1.09 . . . . 0.0 109.699 170.049 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.9 m -102.59 148.28 8.12 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 C-N-CA 124.355 1.062 . . . . 0.0 110.53 172.186 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 32.5 t80 -95.44 142.77 27.42 Favored 'General case' 0 C--N 1.328 -0.356 0 C-N-CA 126.374 1.869 . . . . 0.0 109.3 169.319 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 22.1 t -131.96 113.12 21.43 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 C-N-CA 125.75 1.62 . . . . 0.0 109.147 177.073 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -110.65 145.78 17.39 Favored Glycine 0 CA--C 1.531 1.037 0 C-N-CA 124.494 1.045 . . . . 0.0 113.104 178.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 97.23 30.75 7.21 Favored Glycine 0 CA--C 1.534 1.238 0 C-N-CA 124.763 1.173 . . . . 0.0 113.905 176.313 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 86.9 mt -73.67 145.39 45.32 Favored 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 125.316 1.446 . . . . 0.0 111.345 -173.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 29.7 t70 -84.53 157.58 21.23 Favored 'General case' 0 CA--C 1.542 0.64 0 N-CA-C 112.441 0.534 . . . . 0.0 112.441 175.288 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -58.71 -20.59 50.22 Favored 'General case' 0 CA--C 1.545 0.779 0 N-CA-C 114.485 1.291 . . . . 0.0 114.485 178.05 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.1 mtmm -81.25 -7.86 59.65 Favored 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 114.42 1.267 . . . . 0.0 114.42 174.463 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 85.7 t -77.3 138.55 20.28 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 C-N-CA 124.519 1.128 . . . . 0.0 111.498 178.086 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 52.6 m -135.07 163.25 30.31 Favored 'General case' 0 N--CA 1.477 0.884 0 C-N-CA 124.876 1.27 . . . . 0.0 111.522 172.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -56.15 -42.64 97.22 Favored Pre-proline 0 CA--C 1.548 0.881 0 O-C-N 120.774 -1.204 . . . . 0.0 114.038 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 66.7 Cg_exo -60.92 -28.54 86.49 Favored 'Trans proline' 0 C--N 1.354 0.831 0 C-N-CA 122.236 1.958 . . . . 0.0 114.099 174.005 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 27.2 tp -67.88 -51.49 47.48 Favored 'General case' 0 C--N 1.344 0.328 0 CA-C-N 118.591 0.632 . . . . 0.0 109.981 172.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 20.6 mt -61.54 -23.17 65.76 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 112.801 0.667 . . . . 0.0 112.801 178.952 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.5 t90 -73.2 -66.13 0.72 Allowed 'General case' 0 C--N 1.329 -0.283 0 C-N-CA 123.348 0.659 . . . . 0.0 111.101 171.208 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 39.0 mt-10 -66.12 -29.99 70.4 Favored 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 114.061 1.134 . . . . 0.0 114.061 -172.313 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.1 tp -69.13 -33.22 73.11 Favored 'General case' 0 CA--C 1.541 0.602 0 C-N-CA 123.794 0.837 . . . . 0.0 111.872 175.325 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 19.1 m-85 -90.98 -11.2 39.68 Favored 'General case' 0 CA--C 1.538 0.508 0 C-N-CA 124.996 1.318 . . . . 0.0 113.422 -175.101 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 47.2 mt -55.46 -18.51 7.2 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 114.024 1.12 . . . . 0.0 114.024 169.501 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 40.8 mt-30 -65.18 -32.81 74.68 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 125.261 1.424 . . . . 0.0 112.684 173.464 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.23 -45.48 19.74 Favored 'General case' 0 CA--C 1.539 0.536 0 C-N-CA 123.581 0.752 . . . . 0.0 112.608 177.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.86 -172.33 43.94 Favored Glycine 0 CA--C 1.537 1.438 0 C-N-CA 124.759 1.171 . . . . 0.0 112.997 179.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.2 Cg_endo -67.71 110.68 2.17 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 123.745 2.964 . . . . 0.0 111.58 -179.076 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 65.2 t -86.33 131.85 33.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 C-N-CA 124.848 1.259 . . . . 0.0 109.667 174.01 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 7.8 t -107.3 -33.71 2.69 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 C-N-CA 126.58 1.952 . . . . 0.0 111.715 -171.248 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 19.9 t30 -160.89 165.51 29.97 Favored 'General case' 0 CA--C 1.553 1.088 0 C-N-CA 126.135 1.774 . . . . 0.0 111.016 -175.323 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 4.4 p -141.15 156.61 45.93 Favored 'General case' 0 N--CA 1.482 1.152 0 C-N-CA 126.233 1.813 . . . . 0.0 111.348 174.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 2.6 t60 -142.32 136.7 29.96 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 123.952 0.901 . . . . 0.0 110.886 174.755 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 88.2 mtp -138.98 102.82 7.5 Favored Pre-proline 0 N--CA 1.472 0.645 0 C-N-CA 124.117 0.967 . . . . 0.0 109.273 169.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_exo -55.73 137.39 78.22 Favored 'Trans proline' 0 CA--C 1.537 0.671 0 C-N-CA 123.412 2.741 . . . . 0.0 113.301 177.341 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 44.4 mmtm -107.72 146.77 31.66 Favored 'General case' 0 N--CA 1.476 0.834 0 C-N-CA 125.251 1.421 . . . . 0.0 112.681 -174.31 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -71.36 150.44 45.06 Favored 'General case' 0 CA--C 1.546 0.822 0 C-N-CA 125.527 1.531 . . . . 0.0 112.672 175.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 39.9 ptt180 -89.58 -1.5 58.04 Favored 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 116.571 2.063 . . . . 0.0 116.571 -173.002 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 3.5 m -135.01 -31.55 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.484 1.249 0 C-N-CA 124.687 1.195 . . . . 0.0 113.289 -178.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.4 p -103.72 -20.32 14.0 Favored 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 125.021 1.329 . . . . 0.0 111.905 179.302 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.99 0.52 35.05 Favored Glycine 0 CA--C 1.539 1.586 0 C-N-CA 125.431 1.491 . . . . 0.0 116.094 172.15 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 4.1 pt20 -75.67 170.57 15.92 Favored 'General case' 0 N--CA 1.469 0.504 0 C-N-CA 124.654 1.182 . . . . 0.0 111.257 171.46 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 24.7 p80 -67.46 156.92 35.43 Favored 'General case' 0 CA--C 1.54 0.585 0 O-C-N 121.085 -1.009 . . . . 0.0 112.141 170.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 47.1 mt-30 -86.54 18.41 3.33 Favored 'General case' 0 CA--C 1.549 0.94 0 N-CA-C 114.277 1.214 . . . . 0.0 114.277 -173.704 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.59 0.96 81.35 Favored Glycine 0 CA--C 1.536 1.355 0 C-N-CA 125.263 1.411 . . . . 0.0 114.977 -179.439 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 47.3 p90 -145.3 161.25 40.04 Favored 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 124.963 1.305 . . . . 0.0 112.616 179.247 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -152.62 -176.09 24.84 Favored Glycine 0 CA--C 1.531 1.035 0 C-N-CA 126.013 1.768 . . . . 0.0 112.801 -178.19 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 62.9 m-85 -144.59 151.47 39.09 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.809 1.644 . . . . 0.0 111.536 -179.402 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 17.9 t -132.93 128.23 56.4 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 124.666 1.187 . . . . 0.0 109.802 176.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 50.9 tt0 -102.69 119.8 39.47 Favored 'General case' 0 N--CA 1.464 0.246 0 C-N-CA 124.658 1.183 . . . . 0.0 110.552 -176.11 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 79.7 m-85 -97.02 162.24 13.47 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 124.745 1.218 . . . . 0.0 112.256 175.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.9 tp -63.34 -34.66 78.18 Favored 'General case' 0 CA--C 1.54 0.585 0 N-CA-C 112.55 0.574 . . . . 0.0 112.55 176.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 16.8 m -144.28 157.62 44.18 Favored 'General case' 0 N--CA 1.471 0.623 0 C-N-CA 124.577 1.151 . . . . 0.0 111.927 -176.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -62.85 -33.42 75.21 Favored 'General case' 0 N--CA 1.473 0.708 0 O-C-N 121.503 -0.748 . . . . 0.0 112.872 -179.58 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -67.45 -23.96 65.57 Favored 'General case' 0 N--CA 1.473 0.694 0 O-C-N 121.102 -0.998 . . . . 0.0 113.558 177.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 51.0 m-20 -81.4 -33.25 32.37 Favored 'General case' 0 CA--C 1.54 0.572 0 C-N-CA 124.16 0.984 . . . . 0.0 111.552 172.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.18 -44.97 71.1 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 123.83 0.852 . . . . 0.0 111.395 173.285 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 34.6 t70 -56.99 -36.4 70.34 Favored 'General case' 0 CA--C 1.542 0.652 0 C-N-CA 124.781 1.232 . . . . 0.0 112.44 175.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 26.5 t80 -70.91 -38.14 72.98 Favored 'General case' 0 CA--C 1.536 0.427 0 O-C-N 121.891 -0.505 . . . . 0.0 111.979 175.32 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -65.94 -36.51 83.55 Favored 'General case' 0 CA--C 1.538 0.504 0 O-C-N 120.896 -1.127 . . . . 0.0 111.621 176.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 61.9 mt -63.35 -34.88 69.84 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 124.129 0.971 . . . . 0.0 110.74 172.309 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 63.5 tttp -67.89 -42.92 80.45 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 123.996 0.918 . . . . 0.0 112.681 176.661 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 16.5 pt -90.42 -38.39 10.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -175.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' MET . . . . . 0.488 ' HA ' HD12 ' A' ' 80' ' ' ILE . 15.7 mmt -90.2 0.15 57.33 Favored 'General case' 0 N--CA 1.479 0.995 0 N-CA-C 114.642 1.349 . . . . 0.0 114.642 -169.853 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -84.43 136.07 34.0 Favored 'General case' 0 CA--C 1.541 0.596 0 O-C-N 121.442 -0.786 . . . . 0.0 112.045 178.271 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 1.7 mmt 59.03 13.97 3.16 Favored 'General case' 0 N--CA 1.476 0.844 0 C-N-CA 126.087 1.755 . . . . 0.0 115.25 -170.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.488 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.3 mt -71.21 154.02 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 C-N-CA 124.671 1.188 . . . . 0.0 109.777 168.132 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 47.2 mtpt -113.7 71.01 0.73 Allowed 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 125.125 1.37 . . . . 0.0 112.154 -175.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 25.2 tp -57.99 126.91 29.5 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 123.978 0.911 . . . . 0.0 109.888 174.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 70.0 m-85 46.89 28.55 0.86 Allowed 'General case' 0 CA--C 1.56 1.358 0 N-CA-C 116.268 1.951 . . . . 0.0 116.268 -168.708 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 77.57 29.09 56.19 Favored Glycine 0 CA--C 1.54 1.6 0 O-C-N 120.071 -1.643 . . . . 0.0 115.418 177.101 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 34.8 ttmt -143.21 119.77 6.69 Favored Pre-proline 0 CA--C 1.543 0.708 0 C-N-CA 128.267 2.627 . . . . 0.0 107.842 -175.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -70.18 132.86 23.5 Favored 'Trans proline' 0 CA--C 1.536 0.613 0 C-N-CA 122.972 2.448 . . . . 0.0 113.528 -168.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 17.8 pt -105.72 151.91 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 C-N-CA 125.722 1.609 . . . . 0.0 112.163 175.376 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 24.2 mmt180 -115.11 140.33 49.15 Favored 'General case' 0 N--CA 1.473 0.717 0 C-N-CA 125.307 1.443 . . . . 0.0 110.512 169.585 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 30.4 t -133.34 139.08 49.95 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 C-N-CA 125.253 1.421 . . . . 0.0 110.718 -173.877 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 40.2 t-20 -161.65 179.2 8.35 Favored 'General case' 0 CA--C 1.546 0.826 0 C-N-CA 125.952 1.701 . . . . 0.0 110.252 179.59 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 13.8 mmmm -55.92 147.82 18.61 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 125.373 1.469 . . . . 0.0 111.298 170.016 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -76.08 -33.08 59.54 Favored 'General case' 0 CA--C 1.549 0.909 0 O-C-N 121.973 -0.455 . . . . 0.0 111.967 169.059 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 20.4 m -77.33 -44.07 30.79 Favored 'General case' 0 N--CA 1.479 1.016 0 C-N-CA 124.149 0.98 . . . . 0.0 113.374 176.642 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . 40.64 75.76 0.08 Allowed 'General case' 0 CA--C 1.551 0.999 0 C-N-CA 128.284 2.634 . . . . 0.0 115.759 176.233 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 14.7 p80 -130.74 16.17 5.3 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 126.427 1.891 . . . . 0.0 113.743 -174.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -61.65 141.04 58.07 Favored 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 124.538 1.135 . . . . 0.0 112.579 -174.764 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 62.3 tttp -147.77 146.01 29.01 Favored 'General case' 0 N--CA 1.474 0.766 0 C-N-CA 126.272 1.829 . . . . 0.0 110.968 -175.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 79.4 m-20 -79.93 54.52 1.9 Allowed 'General case' 0 CA--C 1.549 0.91 0 C-N-CA 124.879 1.272 . . . . 0.0 111.259 173.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 41.5 tp -72.98 147.58 45.04 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 125.601 1.56 . . . . 0.0 112.147 -174.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 87.1 p -135.32 167.32 21.24 Favored 'General case' 0 N--CA 1.473 0.69 0 C-N-CA 125.948 1.699 . . . . 0.0 112.513 -179.385 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -170.4 -171.64 36.01 Favored Glycine 0 CA--C 1.539 1.544 0 C-N-CA 124.73 1.157 . . . . 0.0 113.554 -179.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -59.93 152.57 63.46 Favored 'Trans proline' 0 CA--C 1.539 0.752 0 C-N-CA 124.119 3.213 . . . . 0.0 114.36 -178.353 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 35.4 m -67.07 149.8 50.07 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 124.69 1.196 . . . . 0.0 113.039 179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 61.3 p -78.69 -15.37 58.55 Favored 'General case' 0 N--CA 1.476 0.857 0 N-CA-C 114.467 1.284 . . . . 0.0 114.467 179.859 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.209 0 C-N-CA 126.026 1.774 . . . . 0.0 113.05 177.672 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.642 0 N-CA-C 111.836 -0.506 . . . . 0.0 111.836 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 77.0 p -145.82 159.05 43.75 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.292 1.437 . . . . 0.0 112.481 -179.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 38.8 m -72.76 147.43 45.57 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 124.411 1.084 . . . . 0.0 113.136 -177.233 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -178.8 156.33 18.54 Favored Glycine 0 CA--C 1.534 1.271 0 C-N-CA 124.99 1.281 . . . . 0.0 112.805 176.339 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 50.8 p -84.72 -27.93 26.66 Favored 'General case' 0 N--CA 1.476 0.825 0 N-CA-C 114.105 1.15 . . . . 0.0 114.105 -176.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 90.8 p -156.27 161.8 40.19 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.423 1.489 . . . . 0.0 112.585 177.747 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 170.4 171.17 35.54 Favored Glycine 0 CA--C 1.54 1.641 0 C-N-CA 125.049 1.309 . . . . 0.0 113.175 174.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_exo -61.56 133.99 48.73 Favored 'Trans proline' 0 CA--C 1.537 0.646 0 C-N-CA 123.425 2.75 . . . . 0.0 112.7 178.408 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.0 tp -154.29 154.21 7.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 124.941 1.296 . . . . 0.0 111.324 -178.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 59.3 p -85.25 3.0 41.49 Favored 'General case' 0 N--CA 1.476 0.875 0 C-N-CA 125.683 1.593 . . . . 0.0 114.496 177.193 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 30.0 tt0 -72.52 158.48 35.62 Favored 'General case' 0 CA--C 1.548 0.885 0 C-N-CA 125.755 1.622 . . . . 0.0 113.126 -177.215 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 89.9 mtt180 -64.32 163.23 13.37 Favored 'General case' 0 N--CA 1.478 0.961 0 C-N-CA 126.007 1.723 . . . . 0.0 113.243 -178.451 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 77.9 m-20 -69.31 98.19 1.03 Allowed 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.752 1.221 . . . . 0.0 112.785 -169.994 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 20.4 tt0 -70.04 -18.87 63.31 Favored 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 124.091 0.956 . . . . 0.0 113.005 -179.395 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -63.21 -34.66 78.13 Favored 'General case' 0 N--CA 1.472 0.666 0 O-C-N 120.908 -1.12 . . . . 0.0 112.963 174.343 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -95.28 10.77 34.91 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.517 1.527 . . . . 0.0 112.661 173.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 53.1 m -99.55 136.48 39.41 Favored 'General case' 0 N--CA 1.47 0.548 0 O-C-N 121.272 -0.893 . . . . 0.0 109.598 172.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.2 m -102.21 147.74 8.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 C-N-CA 124.418 1.087 . . . . 0.0 110.283 171.337 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 16.5 t80 -95.66 141.98 28.51 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 126.354 1.862 . . . . 0.0 109.097 169.18 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 22.6 t -132.01 108.78 14.46 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 125.626 1.57 . . . . 0.0 109.143 178.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -103.77 145.62 16.18 Favored Glycine 0 CA--C 1.529 0.956 0 C-N-CA 124.436 1.017 . . . . 0.0 112.87 177.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 97.5 33.41 5.91 Favored Glycine 0 CA--C 1.533 1.192 0 C-N-CA 124.677 1.132 . . . . 0.0 113.899 174.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 83.0 mt -76.49 145.97 38.8 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 125.286 1.434 . . . . 0.0 111.346 -174.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 30.4 t70 -85.23 157.8 20.51 Favored 'General case' 0 CA--C 1.543 0.687 0 C-N-CA 123.506 0.723 . . . . 0.0 112.196 174.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.44 -20.7 47.11 Favored 'General case' 0 CA--C 1.547 0.83 0 N-CA-C 114.599 1.333 . . . . 0.0 114.599 178.317 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.0 mtmm -80.45 -11.03 59.73 Favored 'General case' 0 N--CA 1.476 0.846 0 N-CA-C 114.374 1.25 . . . . 0.0 114.374 174.255 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 59.3 t -75.01 138.12 21.63 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.863 0 C-N-CA 124.31 1.044 . . . . 0.0 111.324 177.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 56.7 m -136.42 162.64 32.49 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 125.169 1.388 . . . . 0.0 111.36 172.765 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -55.8 -43.21 99.09 Favored Pre-proline 0 CA--C 1.549 0.916 0 N-CA-C 114.022 1.119 . . . . 0.0 114.022 179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -62.67 -28.26 76.6 Favored 'Trans proline' 0 C--N 1.355 0.873 0 C-N-CA 122.224 1.95 . . . . 0.0 113.999 174.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 20.6 tp -66.31 -54.15 28.1 Favored 'General case' 0 C--N 1.345 0.374 0 CA-C-N 118.634 0.652 . . . . 0.0 109.461 172.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 25.8 mt -55.33 -42.09 73.32 Favored 'General case' 0 N--CA 1.464 0.273 0 O-C-N 123.218 0.324 . . . . 0.0 111.37 -178.429 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 3.0 t90 -57.31 -62.79 1.52 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.379 0.672 . . . . 0.0 111.262 178.418 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 -65.22 -29.04 69.81 Favored 'General case' 0 N--CA 1.47 0.559 0 N-CA-C 113.801 1.037 . . . . 0.0 113.801 -176.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.8 tp -72.03 -36.96 69.81 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 124.229 1.012 . . . . 0.0 111.863 175.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 11.0 m-85 -87.3 -10.5 52.13 Favored 'General case' 0 CA--C 1.539 0.555 0 C-N-CA 124.779 1.231 . . . . 0.0 113.378 -176.082 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 25.5 mt -53.91 -20.47 6.08 Favored 'General case' 0 CA--C 1.546 0.791 0 C-N-CA 124.53 1.132 . . . . 0.0 113.899 168.878 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 76.3 mt-30 -62.42 -33.45 74.81 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 125.672 1.589 . . . . 0.0 112.581 173.824 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.71 -46.11 17.68 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 123.777 0.831 . . . . 0.0 112.715 178.135 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -179.51 -171.86 43.0 Favored Glycine 0 CA--C 1.535 1.341 0 C-N-CA 124.279 0.943 . . . . 0.0 113.16 -179.588 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -67.97 108.75 1.77 Allowed 'Trans proline' 0 CA--C 1.537 0.648 0 C-N-CA 123.757 2.971 . . . . 0.0 111.463 -179.033 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 75.4 t -84.33 132.84 30.62 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.5 0 C-N-CA 124.746 1.218 . . . . 0.0 109.831 174.202 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.8 t -109.3 -33.6 2.47 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.661 0 C-N-CA 126.329 1.852 . . . . 0.0 111.922 -171.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 18.6 t30 -161.0 164.74 30.76 Favored 'General case' 0 CA--C 1.555 1.135 0 C-N-CA 126.028 1.731 . . . . 0.0 111.037 -174.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 3.7 p -141.92 153.79 44.63 Favored 'General case' 0 N--CA 1.481 1.124 0 C-N-CA 126.339 1.856 . . . . 0.0 111.636 175.746 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 3.7 t60 -142.43 133.34 25.71 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 123.815 0.846 . . . . 0.0 111.109 175.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 84.9 mtp -135.29 103.28 10.52 Favored Pre-proline 0 N--CA 1.472 0.651 0 C-N-CA 124.072 0.949 . . . . 0.0 109.257 169.273 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 81.1 Cg_exo -54.58 138.12 74.42 Favored 'Trans proline' 0 CA--C 1.536 0.585 0 C-N-CA 123.276 2.651 . . . . 0.0 112.832 176.275 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 45.0 mmtm -104.3 154.26 20.02 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 125.018 1.327 . . . . 0.0 112.439 -176.301 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -80.51 143.67 33.12 Favored 'General case' 0 CA--C 1.544 0.726 0 C-N-CA 125.843 1.657 . . . . 0.0 112.017 175.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 39.7 ptt180 -86.67 5.2 37.19 Favored 'General case' 0 N--CA 1.48 1.046 0 N-CA-C 116.019 1.859 . . . . 0.0 116.019 -174.211 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 23.8 t -132.16 -37.88 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 124.91 1.284 . . . . 0.0 111.479 -175.047 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 74.9 p -107.95 -21.5 12.8 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 126.052 1.741 . . . . 0.0 112.511 -177.487 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 73.63 1.87 59.18 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 125.072 1.32 . . . . 0.0 116.034 173.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 3.4 pt20 -76.06 172.38 12.88 Favored 'General case' 0 N--CA 1.472 0.638 0 CA-C-N 118.506 1.153 . . . . 0.0 110.871 169.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 29.0 p80 -68.04 158.43 32.95 Favored 'General case' 0 N--CA 1.471 0.577 0 O-C-N 120.946 -1.096 . . . . 0.0 112.355 171.29 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 82.4 mt-30 -80.51 14.04 2.22 Favored 'General case' 0 CA--C 1.552 1.027 0 C-N-CA 124.872 1.269 . . . . 0.0 114.424 -176.082 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.54 0.91 81.53 Favored Glycine 0 CA--C 1.537 1.444 0 C-N-CA 125.207 1.384 . . . . 0.0 114.884 -177.134 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 42.0 p90 -144.4 161.01 40.09 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.1 1.36 . . . . 0.0 112.249 178.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -150.7 -175.38 22.63 Favored Glycine 0 CA--C 1.528 0.882 0 C-N-CA 125.718 1.628 . . . . 0.0 113.176 -179.258 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -145.08 151.67 38.88 Favored 'General case' 0 C--O 1.236 0.391 0 C-N-CA 125.767 1.627 . . . . 0.0 111.937 -178.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 20.5 t -133.89 128.15 53.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 124.716 1.206 . . . . 0.0 110.001 175.301 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 51.3 tt0 -101.18 122.36 43.49 Favored 'General case' 0 N--CA 1.466 0.337 0 C-N-CA 125.03 1.332 . . . . 0.0 110.731 -177.511 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 81.9 m-85 -98.42 162.11 13.33 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 125.058 1.343 . . . . 0.0 112.306 175.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.6 tp -62.39 -34.2 76.25 Favored 'General case' 0 CA--C 1.541 0.622 0 CA-C-N 115.86 -0.609 . . . . 0.0 112.56 176.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.8 m -144.06 155.67 44.07 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 124.497 1.119 . . . . 0.0 112.164 -176.934 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -63.26 -31.12 72.19 Favored 'General case' 0 N--CA 1.474 0.725 0 C-N-CA 123.958 0.903 . . . . 0.0 113.107 -178.596 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -69.63 -23.87 63.55 Favored 'General case' 0 N--CA 1.473 0.705 0 O-C-N 121.119 -0.988 . . . . 0.0 113.535 175.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 46.7 m-20 -81.34 -32.4 33.02 Favored 'General case' 0 CA--C 1.54 0.589 0 C-N-CA 123.822 0.849 . . . . 0.0 111.401 172.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -67.69 -44.03 78.72 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 123.436 0.694 . . . . 0.0 111.076 172.057 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -57.43 -34.31 68.81 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.482 1.113 . . . . 0.0 112.933 173.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 17.3 t80 -72.43 -37.35 68.61 Favored 'General case' 0 CA--C 1.537 0.449 0 O-C-N 121.554 -0.716 . . . . 0.0 111.963 175.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.5 -36.3 82.39 Favored 'General case' 0 CA--C 1.536 0.441 0 O-C-N 120.731 -1.23 . . . . 0.0 111.529 176.356 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 64.8 mt -62.95 -34.23 65.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 124.003 0.921 . . . . 0.0 111.004 172.138 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -68.47 -43.14 77.62 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 124.054 0.942 . . . . 0.0 112.584 176.586 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 19.5 pt -91.73 -38.39 10.35 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.687 0 N-CA-C 114.926 1.454 . . . . 0.0 114.926 -174.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' MET . . . . . 0.482 ' HA ' HD12 ' A' ' 80' ' ' ILE . 15.1 mmt -90.84 0.73 57.39 Favored 'General case' 0 N--CA 1.479 0.984 0 N-CA-C 114.768 1.396 . . . . 0.0 114.768 -169.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -85.04 135.87 33.82 Favored 'General case' 0 CA--C 1.538 0.49 0 O-C-N 121.528 -0.733 . . . . 0.0 112.203 179.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 26.3 ttm 59.88 11.81 2.75 Favored 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 126.149 1.779 . . . . 0.0 114.848 -171.547 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.482 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.5 mt -69.96 150.7 9.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 C-N-CA 124.874 1.27 . . . . 0.0 109.793 168.673 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 44.7 mtpt -108.86 70.52 0.74 Allowed 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 124.713 1.205 . . . . 0.0 112.364 -174.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 25.3 tp -58.55 124.1 18.49 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 123.789 0.835 . . . . 0.0 109.659 174.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 66.4 m-85 45.38 31.09 0.79 Allowed 'General case' 0 CA--C 1.56 1.358 0 N-CA-C 116.082 1.882 . . . . 0.0 116.082 -168.5 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 82.23 17.55 69.01 Favored Glycine 0 CA--C 1.542 1.726 0 O-C-N 120.272 -1.517 . . . . 0.0 116.691 173.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 94.3 mttt -131.96 123.94 19.32 Favored Pre-proline 0 CA--C 1.54 0.569 0 C-N-CA 128.22 2.608 . . . . 0.0 108.088 -179.796 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -71.49 123.09 9.2 Favored 'Trans proline' 0 CA--C 1.538 0.679 0 C-N-CA 123.343 2.695 . . . . 0.0 112.351 -169.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 15.6 pt -91.12 147.92 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.583 0 C-N-CA 125.135 1.374 . . . . 0.0 111.818 175.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 9.6 mmm180 -114.72 132.42 56.43 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 125.412 1.485 . . . . 0.0 110.379 175.363 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.2 t -128.19 137.18 58.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 C-N-CA 124.278 1.031 . . . . 0.0 111.135 -170.976 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 5.7 p30 -157.2 175.32 14.2 Favored 'General case' 0 N--CA 1.472 0.665 0 C-N-CA 126.526 1.93 . . . . 0.0 110.536 176.617 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.5 mmmp? -64.63 138.83 58.62 Favored 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 123.864 0.866 . . . . 0.0 110.298 174.473 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -67.4 -32.14 72.84 Favored 'General case' 0 CA--C 1.55 0.97 0 O-C-N 121.837 -0.539 . . . . 0.0 110.565 168.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 37.4 m -118.23 95.94 5.11 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 126.105 1.762 . . . . 0.0 108.982 166.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -90.96 150.76 21.35 Favored 'General case' 0 CA--C 1.544 0.747 0 C-N-CA 124.721 1.208 . . . . 0.0 112.051 178.521 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 11.1 p80 -147.82 176.31 10.24 Favored 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 125.173 1.389 . . . . 0.0 112.486 -178.168 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 59.6 t-20 -59.82 134.47 57.06 Favored 'General case' 0 CA--C 1.547 0.854 0 C-N-CA 125.501 1.521 . . . . 0.0 112.761 -172.815 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 45.0 mmtm -86.8 -17.35 33.67 Favored 'General case' 0 N--CA 1.476 0.873 0 C-N-CA 125.215 1.406 . . . . 0.0 113.851 -178.533 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 58.4 t30 -73.22 146.41 45.5 Favored 'General case' 0 CA--C 1.547 0.857 0 C-N-CA 123.779 0.832 . . . . 0.0 112.571 -177.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 47.6 tp -92.83 -28.35 16.59 Favored 'General case' 0 CA--C 1.545 0.777 0 C-N-CA 125.561 1.544 . . . . 0.0 113.118 177.011 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 84.3 p -84.43 166.51 17.26 Favored 'General case' 0 N--CA 1.474 0.731 0 N-CA-C 113.729 1.011 . . . . 0.0 113.729 -178.177 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -166.38 176.33 41.63 Favored Glycine 0 CA--C 1.54 1.642 0 C-N-CA 125.299 1.428 . . . . 0.0 112.982 178.838 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -69.5 146.95 63.43 Favored 'Trans proline' 0 CA--C 1.539 0.757 0 C-N-CA 123.684 2.923 . . . . 0.0 112.907 -176.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 19.1 m -92.79 -4.18 53.47 Favored 'General case' 0 N--CA 1.478 0.953 0 C-N-CA 124.872 1.269 . . . . 0.0 114.36 -177.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 9.1 t -72.84 152.87 41.31 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.47 1.108 . . . . 0.0 112.924 -177.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.174 0 C-N-CA 125.693 1.616 . . . . 0.0 112.79 -178.721 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.52 0 N-CA-C 111.734 -0.546 . . . . 0.0 111.734 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 37.2 m -69.19 153.44 43.69 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 124.581 1.153 . . . . 0.0 113.333 -179.033 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 8.6 t -73.16 162.01 29.92 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 124.126 0.971 . . . . 0.0 112.406 173.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -171.3 -178.1 41.53 Favored Glycine 0 CA--C 1.534 1.261 0 C-N-CA 124.86 1.219 . . . . 0.0 113.723 -178.363 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.7 m 55.38 27.82 10.58 Favored 'General case' 0 N--CA 1.48 1.033 0 C-N-CA 125.787 1.635 . . . . 0.0 114.998 179.513 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 13.2 t -151.27 153.51 34.99 Favored 'General case' 0 N--CA 1.472 0.627 0 C-N-CA 125.321 1.448 . . . . 0.0 111.945 -179.01 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 83.99 133.64 2.46 Favored Glycine 0 CA--C 1.545 1.926 0 C-N-CA 125.923 1.725 . . . . 0.0 113.91 -179.182 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_endo -79.8 168.45 19.3 Favored 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 123.888 3.059 . . . . 0.0 112.676 177.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -69.2 147.96 11.8 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 123.997 0.919 . . . . 0.0 112.233 170.242 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.6 m -74.72 -26.66 59.95 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 113.509 0.929 . . . . 0.0 113.509 -179.161 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 40.0 tt0 -151.98 146.18 25.4 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 125.783 1.633 . . . . 0.0 110.599 178.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 4.0 tpm_? -138.37 139.68 39.1 Favored 'General case' 0 N--CA 1.475 0.807 0 C-N-CA 124.956 1.302 . . . . 0.0 111.012 179.084 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 83.8 m-20 -87.49 146.35 25.86 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 124.217 1.007 . . . . 0.0 112.766 -177.372 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 31.8 tp60 -145.78 -40.79 0.22 Allowed 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 125.123 1.369 . . . . 0.0 111.368 169.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -69.33 -33.45 73.15 Favored 'General case' 0 N--CA 1.474 0.727 0 N-CA-C 113.471 0.915 . . . . 0.0 113.471 178.006 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.3 5.54 34.03 Favored 'General case' 0 CA--C 1.545 0.77 0 C-N-CA 124.795 1.238 . . . . 0.0 113.055 171.206 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 18.7 m -99.57 137.57 37.88 Favored 'General case' 0 N--CA 1.469 0.496 0 C-N-CA 124.293 1.037 . . . . 0.0 109.185 172.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 14.3 m -105.66 148.56 9.96 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 C-N-CA 124.685 1.194 . . . . 0.0 110.322 173.24 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 32.1 t80 -95.43 141.77 28.58 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 126.245 1.818 . . . . 0.0 109.392 169.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 22.0 t -131.53 109.9 16.61 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.559 0 C-N-CA 125.636 1.574 . . . . 0.0 109.166 175.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -105.47 147.78 16.34 Favored Glycine 0 CA--C 1.53 0.972 0 C-N-CA 124.445 1.021 . . . . 0.0 112.714 177.056 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.36 31.37 7.21 Favored Glycine 0 CA--C 1.534 1.277 0 C-N-CA 124.767 1.175 . . . . 0.0 114.24 173.837 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 89.1 mt -73.95 150.21 40.92 Favored 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 125.511 1.525 . . . . 0.0 111.598 -172.101 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -89.74 156.38 18.57 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 123.784 0.833 . . . . 0.0 111.973 175.594 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.53 -20.39 45.69 Favored 'General case' 0 CA--C 1.546 0.795 0 N-CA-C 114.818 1.414 . . . . 0.0 114.818 -179.799 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.6 mtmm -81.17 -11.23 59.48 Favored 'General case' 0 N--CA 1.476 0.853 0 C-N-CA 124.666 1.186 . . . . 0.0 114.15 175.132 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 75.4 t -72.15 140.98 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.89 0 C-N-CA 124.395 1.078 . . . . 0.0 111.632 179.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 92.3 p -135.27 162.08 33.58 Favored 'General case' 0 N--CA 1.472 0.642 0 C-N-CA 125.188 1.395 . . . . 0.0 112.16 175.111 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -59.82 -39.86 73.83 Favored Pre-proline 0 CA--C 1.547 0.831 0 O-C-N 120.814 -1.179 . . . . 0.0 113.551 177.43 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -61.96 -30.9 84.08 Favored 'Trans proline' 0 C--N 1.352 0.754 0 C-N-CA 122.537 2.158 . . . . 0.0 113.94 170.369 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 27.1 tp -68.07 -50.37 55.52 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 119.114 0.87 . . . . 0.0 109.893 174.009 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 19.9 mt -61.1 -23.05 65.21 Favored 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 112.985 0.735 . . . . 0.0 112.985 178.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.6 t90 -73.54 -66.62 0.67 Allowed 'General case' 0 C--N 1.329 -0.319 0 C-N-CA 123.159 0.584 . . . . 0.0 111.006 170.745 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -65.01 -30.33 71.3 Favored 'General case' 0 N--CA 1.472 0.668 0 N-CA-C 114.221 1.193 . . . . 0.0 114.221 -172.365 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.9 tp -69.53 -32.56 71.45 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 123.762 0.825 . . . . 0.0 111.917 175.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -91.18 -10.83 40.29 Favored 'General case' 0 CA--C 1.538 0.516 0 C-N-CA 125.194 1.397 . . . . 0.0 113.313 -175.175 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 50.7 mt -55.12 -18.63 5.9 Favored 'General case' 0 N--CA 1.475 0.808 0 C-N-CA 124.477 1.111 . . . . 0.0 113.945 169.377 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 41.2 mt-30 -64.82 -33.06 75.09 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 125.367 1.467 . . . . 0.0 112.737 173.272 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.25 -45.1 20.46 Favored 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 123.543 0.737 . . . . 0.0 112.624 177.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.46 -172.78 44.71 Favored Glycine 0 CA--C 1.535 1.284 0 C-N-CA 124.672 1.13 . . . . 0.0 112.996 179.321 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -67.48 111.28 2.27 Favored 'Trans proline' 0 CA--C 1.537 0.626 0 C-N-CA 123.658 2.905 . . . . 0.0 111.633 -179.197 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 67.0 t -86.25 134.23 27.85 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.598 0 C-N-CA 124.863 1.265 . . . . 0.0 109.856 174.187 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 8.0 t -109.32 -33.37 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.703 0 C-N-CA 126.633 1.973 . . . . 0.0 111.959 -171.416 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 20.0 t30 -160.8 161.35 31.99 Favored 'General case' 0 CA--C 1.554 1.128 0 C-N-CA 125.926 1.691 . . . . 0.0 111.205 -175.265 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 5.0 p -137.97 155.1 49.22 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 125.928 1.691 . . . . 0.0 111.864 171.569 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 47.3 t-80 -142.33 133.72 26.42 Favored 'General case' 0 N--CA 1.467 0.399 0 C-N-CA 123.848 0.859 . . . . 0.0 111.197 175.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 87.5 mtp -134.21 107.24 11.27 Favored Pre-proline 0 N--CA 1.471 0.613 0 C-N-CA 124.04 0.936 . . . . 0.0 109.638 169.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 86.0 Cg_exo -57.82 140.34 93.39 Favored 'Trans proline' 0 CA--C 1.539 0.746 0 C-N-CA 123.305 2.67 . . . . 0.0 113.179 177.384 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 43.3 mmtm -112.89 146.82 38.27 Favored 'General case' 0 N--CA 1.476 0.871 0 C-N-CA 125.249 1.42 . . . . 0.0 113.076 -172.624 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 27.3 t70 -67.14 143.46 56.6 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 125.827 1.651 . . . . 0.0 112.447 172.479 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 9.7 ptm180 -85.84 6.66 27.18 Favored 'General case' 0 N--CA 1.479 1.02 0 N-CA-C 116.0 1.852 . . . . 0.0 116.0 -174.018 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 35.6 t -131.36 -37.48 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.104 0 C-N-CA 124.942 1.297 . . . . 0.0 111.405 -174.307 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 72.5 p -113.97 -14.66 12.42 Favored 'General case' 0 N--CA 1.471 0.584 0 C-N-CA 125.846 1.659 . . . . 0.0 112.544 -176.574 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.21 4.96 52.34 Favored Glycine 0 CA--C 1.538 1.489 0 C-N-CA 125.146 1.355 . . . . 0.0 115.393 176.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 72.9 mm-40 -77.49 162.14 27.39 Favored 'General case' 0 CA--C 1.539 0.539 0 C-N-CA 124.611 1.165 . . . . 0.0 110.805 177.226 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 18.7 p80 -69.18 153.54 43.53 Favored 'General case' 0 N--CA 1.473 0.681 0 O-C-N 120.948 -1.095 . . . . 0.0 112.473 177.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 46.3 mt-30 -84.94 17.36 2.9 Favored 'General case' 0 CA--C 1.549 0.927 0 N-CA-C 114.344 1.239 . . . . 0.0 114.344 -173.456 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 87.12 1.69 84.22 Favored Glycine 0 CA--C 1.535 1.289 0 C-N-CA 125.071 1.32 . . . . 0.0 114.953 -179.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 41.3 p90 -144.79 161.01 40.31 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 124.917 1.287 . . . . 0.0 112.427 177.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -152.12 -178.15 26.53 Favored Glycine 0 CA--C 1.531 1.092 0 C-N-CA 125.968 1.747 . . . . 0.0 113.003 -177.467 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 84.4 m-85 -142.81 149.03 38.08 Favored 'General case' 0 C--O 1.237 0.421 0 C-N-CA 126.025 1.73 . . . . 0.0 111.573 -178.5 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 14.4 t -132.91 127.81 55.91 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 124.637 1.175 . . . . 0.0 109.953 176.488 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 57.3 tt0 -103.63 120.2 40.42 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 124.789 1.236 . . . . 0.0 110.845 -175.842 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -96.83 161.95 13.63 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 124.638 1.175 . . . . 0.0 112.387 176.001 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.8 tp -63.25 -34.42 77.63 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 123.224 0.61 . . . . 0.0 112.448 176.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.0 m -143.65 156.27 44.5 Favored 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 124.393 1.077 . . . . 0.0 112.012 -177.391 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 49.6 tt0 -64.09 -30.85 71.89 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 123.847 0.859 . . . . 0.0 113.27 -178.302 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -69.58 -24.55 63.71 Favored 'General case' 0 N--CA 1.474 0.733 0 O-C-N 121.173 -0.955 . . . . 0.0 113.396 176.159 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 52.5 m-20 -79.83 -33.57 40.15 Favored 'General case' 0 CA--C 1.54 0.569 0 C-N-CA 123.925 0.89 . . . . 0.0 111.333 172.326 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -67.55 -45.2 76.34 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 123.57 0.748 . . . . 0.0 111.491 172.725 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -56.86 -36.0 69.54 Favored 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 124.474 1.11 . . . . 0.0 112.672 175.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 24.0 t80 -71.56 -37.83 71.03 Favored 'General case' 0 CA--C 1.538 0.493 0 O-C-N 121.719 -0.613 . . . . 0.0 111.973 175.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.0 -36.93 84.63 Favored 'General case' 0 CA--C 1.537 0.452 0 O-C-N 120.916 -1.115 . . . . 0.0 111.696 176.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 55.8 mt -63.81 -33.99 65.36 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.649 0 C-N-CA 124.053 0.941 . . . . 0.0 110.783 172.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -67.62 -43.62 79.96 Favored 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 123.865 0.866 . . . . 0.0 112.713 175.546 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 18.2 pt -91.09 -34.38 6.34 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 N-CA-C 115.282 1.586 . . . . 0.0 115.282 -174.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' MET . . . . . 0.477 ' HA ' HD12 ' A' ' 80' ' ' ILE . 15.0 mmt -95.05 -1.16 52.8 Favored 'General case' 0 N--CA 1.479 1.023 0 N-CA-C 114.615 1.339 . . . . 0.0 114.615 -171.257 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -82.84 146.27 29.01 Favored 'General case' 0 CA--C 1.539 0.553 0 O-C-N 121.395 -0.815 . . . . 0.0 111.206 174.159 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 84.6 mmm 60.24 5.96 0.92 Allowed 'General case' 0 N--CA 1.479 1.012 0 C-N-CA 125.929 1.692 . . . . 0.0 115.468 -172.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.477 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.4 mt -71.78 157.42 6.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.61 0 C-N-CA 125.862 1.665 . . . . 0.0 111.236 172.72 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 50.8 mtpt -118.83 71.23 0.84 Allowed 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 125.815 1.646 . . . . 0.0 112.028 -179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 32.9 tp -57.65 126.75 28.72 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.049 0.939 . . . . 0.0 110.301 176.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 53.6 m-85 46.27 27.58 0.59 Allowed 'General case' 0 CA--C 1.559 1.311 0 N-CA-C 116.398 1.999 . . . . 0.0 116.398 -168.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 78.78 27.56 56.51 Favored Glycine 0 CA--C 1.542 1.768 0 O-C-N 120.103 -1.623 . . . . 0.0 115.715 177.542 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -135.71 121.03 13.61 Favored Pre-proline 0 CA--C 1.542 0.64 0 C-N-CA 128.316 2.647 . . . . 0.0 107.63 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -68.61 127.91 16.27 Favored 'Trans proline' 0 CA--C 1.536 0.577 0 C-N-CA 123.002 2.468 . . . . 0.0 112.745 -171.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 27.5 pt -101.39 159.21 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 125.418 1.487 . . . . 0.0 112.051 175.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 86.9 mmt-85 -127.48 134.95 49.79 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 125.747 1.619 . . . . 0.0 110.167 174.003 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 30.9 t -130.01 138.58 53.65 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 124.257 1.023 . . . . 0.0 111.366 -172.605 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 40.8 t-20 -159.0 177.29 11.3 Favored 'General case' 0 CA--C 1.548 0.883 0 C-N-CA 125.987 1.715 . . . . 0.0 110.228 178.039 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.3 mmmp? -58.11 146.91 31.62 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 124.715 1.206 . . . . 0.0 110.69 169.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -80.01 -16.09 55.87 Favored 'General case' 0 CA--C 1.55 0.958 0 N-CA-C 112.494 0.553 . . . . 0.0 112.494 169.485 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 59.7 p -88.84 -55.26 3.77 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 125.322 1.449 . . . . 0.0 112.317 170.519 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . 56.85 40.49 28.92 Favored 'General case' 0 CA--C 1.549 0.928 0 C-N-CA 127.413 2.285 . . . . 0.0 115.495 176.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 84.1 m-70 -114.61 145.85 41.51 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 125.215 1.406 . . . . 0.0 111.122 169.156 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 26.2 m120 -82.91 152.74 25.41 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 124.147 0.979 . . . . 0.0 112.353 -177.246 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 66.1 mttm -81.98 44.63 0.85 Allowed 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 125.752 1.621 . . . . 0.0 112.291 177.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 51.3 t30 -76.4 158.65 31.19 Favored 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 125.303 1.441 . . . . 0.0 112.734 -172.1 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 64.5 tp -141.6 135.23 29.82 Favored 'General case' 0 CA--C 1.542 0.646 0 C-N-CA 126.14 1.776 . . . . 0.0 110.397 177.655 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 17.4 m -69.52 -27.17 64.94 Favored 'General case' 0 N--CA 1.476 0.872 0 N-CA-C 114.207 1.188 . . . . 0.0 114.207 -174.524 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 160.16 -172.68 36.67 Favored Glycine 0 CA--C 1.54 1.617 0 C-N-CA 125.174 1.368 . . . . 0.0 113.354 178.083 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -67.76 -23.53 41.81 Favored 'Trans proline' 0 CA--C 1.54 0.8 0 C-N-CA 123.578 2.852 . . . . 0.0 114.645 178.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 44.2 m 54.4 28.19 9.16 Favored 'General case' 0 N--CA 1.479 1.023 0 C-N-CA 126.197 1.799 . . . . 0.0 114.899 -178.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 59.1 p -89.06 -13.18 39.26 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.519 1.528 . . . . 0.0 114.524 -177.51 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.24 0 C-N-CA 125.705 1.622 . . . . 0.0 113.656 178.096 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.563 0 N-CA-C 111.582 -0.607 . . . . 0.0 111.582 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 69.5 p -152.65 159.6 43.2 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.825 1.25 . . . . 0.0 112.655 178.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 20.2 m 50.63 48.46 22.61 Favored 'General case' 0 N--CA 1.475 0.779 0 N-CA-C 116.14 1.904 . . . . 0.0 116.14 169.238 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -72.02 130.79 17.12 Favored Glycine 0 CA--C 1.534 1.226 0 O-C-N 120.978 -1.076 . . . . 0.0 110.98 168.614 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 68.6 p -88.45 -6.13 57.83 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 124.845 1.258 . . . . 0.0 114.116 -178.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 25.8 m -60.29 140.31 57.15 Favored 'General case' 0 N--CA 1.47 0.572 0 C-N-CA 125.371 1.468 . . . . 0.0 112.775 -178.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 68.15 59.45 6.35 Favored Glycine 0 CA--C 1.542 1.777 0 CA-C-O 118.739 -1.034 . . . . 0.0 113.602 -174.266 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo -63.33 155.43 62.03 Favored 'Trans proline' 0 CA--C 1.539 0.76 0 C-N-CA 123.61 2.874 . . . . 0.0 112.62 178.638 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 71.1 mt -95.76 131.07 43.52 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.612 0 C-N-CA 125.346 1.458 . . . . 0.0 110.742 -175.429 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 67.6 p -97.75 -10.38 24.97 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 124.894 1.277 . . . . 0.0 113.966 174.884 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -94.25 -20.29 19.95 Favored 'General case' 0 N--CA 1.475 0.789 0 N-CA-C 114.477 1.288 . . . . 0.0 114.477 -169.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 32.8 ttp-105 -140.1 143.07 36.07 Favored 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 124.781 1.232 . . . . 0.0 112.832 -169.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 15.9 p-10 -65.14 -8.14 15.59 Favored 'General case' 0 CA--C 1.545 0.775 0 C-N-CA 125.565 1.546 . . . . 0.0 114.997 -179.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 65.0 tt0 -57.26 -29.56 63.93 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.264 1.025 . . . . 0.0 111.932 169.534 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -79.99 -26.95 39.71 Favored 'General case' 0 CA--C 1.543 0.706 0 O-C-N 121.358 -0.839 . . . . 0.0 112.91 174.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -78.09 -5.79 52.63 Favored 'General case' 0 CA--C 1.545 0.768 0 C-N-CA 124.596 1.159 . . . . 0.0 112.627 169.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 26.4 m -102.64 134.58 45.77 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 125.036 1.335 . . . . 0.0 110.18 177.009 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 18.1 m -100.73 147.79 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.64 0 C-N-CA 124.361 1.064 . . . . 0.0 110.368 170.729 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 51.8 t80 -95.49 141.3 29.18 Favored 'General case' 0 C--N 1.328 -0.351 0 C-N-CA 126.419 1.888 . . . . 0.0 109.676 169.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 23.1 t -132.01 107.07 12.28 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 C-N-CA 125.521 1.529 . . . . 0.0 109.123 176.147 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -103.26 147.17 16.74 Favored Glycine 0 CA--C 1.53 0.974 0 C-N-CA 124.58 1.086 . . . . 0.0 112.813 177.174 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 92.76 36.93 5.92 Favored Glycine 0 N--CA 1.472 1.071 0 C-N-CA 124.13 0.871 . . . . 0.0 113.64 173.637 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 83.7 mt -75.06 150.28 38.92 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 125.44 1.496 . . . . 0.0 111.424 -175.09 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -88.84 156.27 19.04 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 123.786 0.834 . . . . 0.0 111.783 174.126 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.28 -20.28 41.4 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 114.774 1.398 . . . . 0.0 114.774 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.5 mtmm -82.02 -11.27 58.91 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 124.758 1.223 . . . . 0.0 114.135 175.028 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 62.4 t -74.0 141.03 16.69 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.926 0 C-N-CA 124.337 1.055 . . . . 0.0 111.265 176.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 9.4 t -144.11 167.2 22.97 Favored 'General case' 0 N--CA 1.473 0.725 0 C-N-CA 124.358 1.063 . . . . 0.0 111.612 170.42 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -56.17 -43.28 99.19 Favored Pre-proline 0 CA--C 1.549 0.918 0 O-C-N 120.996 -1.065 . . . . 0.0 113.816 -177.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -62.52 -29.42 78.54 Favored 'Trans proline' 0 C--N 1.354 0.828 0 C-N-CA 122.311 2.008 . . . . 0.0 113.719 174.387 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 18.5 tp -67.08 -53.69 28.58 Favored 'General case' 0 C--N 1.344 0.355 0 CA-C-N 118.574 0.625 . . . . 0.0 109.54 173.264 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 22.6 mt -55.37 -42.14 73.53 Favored 'General case' 0 C--O 1.224 -0.277 0 O-C-N 123.216 0.322 . . . . 0.0 111.38 -178.303 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.9 t90 -58.35 -62.56 1.75 Allowed 'General case' 0 CA--C 1.531 0.224 0 C-N-CA 123.089 0.555 . . . . 0.0 111.397 178.346 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -65.34 -29.41 70.14 Favored 'General case' 0 CA--C 1.539 0.557 0 N-CA-C 113.851 1.056 . . . . 0.0 113.851 -176.75 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.2 tp -71.76 -36.85 70.52 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.023 0.929 . . . . 0.0 111.762 175.458 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -87.0 -10.38 53.29 Favored 'General case' 0 N--CA 1.469 0.516 0 C-N-CA 124.731 1.212 . . . . 0.0 113.679 -176.18 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 25.5 mt -54.13 -20.57 6.88 Favored 'General case' 0 CA--C 1.547 0.851 0 N-CA-C 113.941 1.089 . . . . 0.0 113.941 168.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 43.2 mt-30 -63.35 -33.75 76.22 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 125.072 1.349 . . . . 0.0 112.682 173.416 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -77.32 -46.78 21.83 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 123.511 0.724 . . . . 0.0 112.443 178.487 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -179.93 -172.66 44.17 Favored Glycine 0 CA--C 1.535 1.337 0 C-N-CA 124.926 1.251 . . . . 0.0 112.675 -179.157 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -67.58 110.79 2.17 Favored 'Trans proline' 0 CA--C 1.538 0.678 0 C-N-CA 123.584 2.856 . . . . 0.0 111.526 -179.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 66.1 t -85.79 133.38 29.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.805 1.242 . . . . 0.0 109.975 174.846 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.1 t -109.78 -33.6 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.712 0 C-N-CA 126.43 1.892 . . . . 0.0 111.899 -171.573 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 17.8 t30 -160.6 162.4 32.8 Favored 'General case' 0 CA--C 1.552 1.045 0 C-N-CA 126.005 1.722 . . . . 0.0 111.056 -174.332 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 7.2 p -140.75 153.24 45.8 Favored 'General case' 0 N--CA 1.48 1.07 0 C-N-CA 126.453 1.901 . . . . 0.0 111.33 174.736 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 49.2 t-80 -142.39 131.14 22.76 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 123.261 0.624 . . . . 0.0 111.355 174.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 81.5 mtp -132.45 106.35 13.22 Favored Pre-proline 0 N--CA 1.471 0.583 0 C-N-CA 124.041 0.936 . . . . 0.0 109.614 169.67 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_exo -56.99 143.05 93.72 Favored 'Trans proline' 0 CA--C 1.537 0.632 0 C-N-CA 123.233 2.622 . . . . 0.0 112.837 176.464 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 45.4 mmtm -108.8 153.87 22.88 Favored 'General case' 0 N--CA 1.477 0.88 0 C-N-CA 124.78 1.232 . . . . 0.0 113.421 -172.478 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -79.41 144.35 34.19 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 126.944 2.098 . . . . 0.0 112.436 178.356 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 53.6 ptt85 -87.23 8.2 25.1 Favored 'General case' 0 N--CA 1.479 1.015 0 N-CA-C 115.722 1.749 . . . . 0.0 115.722 -174.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 32.2 t -132.06 -37.94 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 124.767 1.227 . . . . 0.0 111.391 -173.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 61.0 p -116.67 -18.3 10.33 Favored 'General case' 0 N--CA 1.472 0.626 0 C-N-CA 125.62 1.568 . . . . 0.0 112.647 -175.669 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.71 8.74 64.17 Favored Glycine 0 CA--C 1.54 1.633 0 C-N-CA 124.864 1.221 . . . . 0.0 114.999 -177.44 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 39.4 mt-30 -67.01 171.29 5.64 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.118 1.367 . . . . 0.0 110.801 170.014 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 26.8 p80 -73.94 157.76 35.65 Favored 'General case' 0 N--CA 1.473 0.717 0 O-C-N 120.351 -1.468 . . . . 0.0 112.202 169.859 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 81.8 mt-30 -79.05 12.53 2.18 Favored 'General case' 0 CA--C 1.552 1.029 0 N-CA-C 114.488 1.292 . . . . 0.0 114.488 -177.65 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 87.87 1.52 82.41 Favored Glycine 0 CA--C 1.535 1.303 0 C-N-CA 124.987 1.28 . . . . 0.0 114.89 -177.084 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -144.65 160.72 40.71 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.952 1.301 . . . . 0.0 112.323 178.177 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -151.29 -178.24 25.89 Favored Glycine 0 CA--C 1.529 0.951 0 C-N-CA 125.955 1.74 . . . . 0.0 113.377 -178.231 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 87.6 m-85 -143.29 149.45 37.86 Favored 'General case' 0 C--O 1.236 0.353 0 C-N-CA 126.141 1.776 . . . . 0.0 111.631 -178.329 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 26.1 t -132.93 128.56 56.86 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.762 0 C-N-CA 124.593 1.157 . . . . 0.0 109.612 174.986 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 85.6 tt0 -104.45 122.43 45.51 Favored 'General case' 0 N--CA 1.466 0.338 0 C-N-CA 124.507 1.123 . . . . 0.0 110.977 -178.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 83.0 m-85 -96.26 163.81 12.93 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 125.066 1.347 . . . . 0.0 112.176 176.229 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.5 tp -63.38 -33.47 75.6 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 112.276 0.473 . . . . 0.0 112.276 175.005 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 8.8 m -142.48 158.03 44.12 Favored 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 122.843 1.306 . . . . 0.0 112.655 -176.727 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 53.5 mp0 -67.99 -29.67 68.75 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 125.735 1.614 . . . . 0.0 113.505 -174.123 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -74.35 -26.95 60.45 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 124.001 0.92 . . . . 0.0 112.811 175.469 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 47.9 m-20 -73.47 -34.0 65.13 Favored 'General case' 0 CA--C 1.538 0.498 0 O-C-N 121.49 -0.757 . . . . 0.0 111.003 172.001 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -66.87 -47.65 71.2 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 123.022 0.529 . . . . 0.0 111.205 170.411 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 31.3 t70 -56.31 -35.87 68.03 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 123.877 0.871 . . . . 0.0 112.899 176.135 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 60.8 t80 -75.69 -36.79 59.94 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 123.413 0.685 . . . . 0.0 112.829 176.5 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -61.81 -38.81 89.5 Favored 'General case' 0 CA--C 1.539 0.538 0 O-C-N 121.056 -1.027 . . . . 0.0 111.549 177.3 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 57.4 mt -61.85 -37.93 79.36 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.573 0 C-N-CA 124.92 1.288 . . . . 0.0 111.042 175.018 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 61.4 tttp -65.45 -35.5 81.09 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 124.312 1.045 . . . . 0.0 113.144 177.315 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 19.7 pt -102.1 -14.18 8.23 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 N-CA-C 115.908 1.818 . . . . 0.0 115.908 -172.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 6.0 mmt -113.13 -4.08 13.85 Favored 'General case' 0 N--CA 1.485 1.286 0 N-CA-C 115.518 1.673 . . . . 0.0 115.518 -176.013 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 26.1 t0 -80.9 145.75 31.16 Favored 'General case' 0 N--CA 1.477 0.904 0 O-C-N 120.818 -1.176 . . . . 0.0 113.699 -174.47 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 25.5 mmt 58.26 9.58 1.05 Allowed 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 127.938 2.495 . . . . 0.0 115.832 -175.114 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 17.8 mt -83.2 148.16 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 C-N-CA 126.964 2.106 . . . . 0.0 111.983 -176.294 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 42.3 mtpt -99.93 69.77 1.57 Allowed 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 124.369 1.068 . . . . 0.0 112.448 -169.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 35.7 tp -57.42 123.39 15.31 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 123.64 0.776 . . . . 0.0 109.427 173.66 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 49.3 m-85 45.97 27.18 0.47 Allowed 'General case' 0 CA--C 1.562 1.419 0 N-CA-C 116.473 2.027 . . . . 0.0 116.473 -168.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 84.97 18.12 61.83 Favored Glycine 0 CA--C 1.544 1.871 0 O-C-N 120.222 -1.549 . . . . 0.0 116.743 176.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -131.52 122.11 18.67 Favored Pre-proline 0 CA--C 1.545 0.778 0 C-N-CA 128.34 2.656 . . . . 0.0 107.991 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -72.51 110.06 2.9 Favored 'Trans proline' 0 CA--C 1.538 0.681 0 C-N-CA 123.212 2.608 . . . . 0.0 112.614 -169.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 19.1 pt -78.72 141.29 15.63 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 C-N-CA 124.079 0.952 . . . . 0.0 111.085 174.47 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 4.8 mpt_? -108.97 128.57 55.06 Favored 'General case' 0 N--CA 1.47 0.574 0 C-N-CA 125.712 1.605 . . . . 0.0 108.809 175.07 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 19.3 t -125.5 137.34 57.99 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.718 0 C-N-CA 124.419 1.088 . . . . 0.0 110.979 -171.663 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 8.7 t-20 -163.14 177.85 8.75 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 125.18 1.392 . . . . 0.0 110.97 -177.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 26.3 mmmt -69.4 140.92 54.2 Favored 'General case' 0 N--CA 1.475 0.817 0 O-C-N 120.826 -1.171 . . . . 0.0 110.138 175.011 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -72.7 -11.1 60.49 Favored 'General case' 0 CA--C 1.551 1.005 0 O-C-N 121.41 -0.806 . . . . 0.0 112.472 169.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 70.7 p -87.9 -1.87 58.25 Favored 'General case' 0 CA--C 1.545 0.752 0 C-N-CA 126.857 2.063 . . . . 0.0 114.436 170.351 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -64.97 149.73 49.25 Favored 'General case' 0 CA--C 1.547 0.833 0 CA-C-N 119.171 0.896 . . . . 0.0 113.07 -177.714 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 25.0 p80 -150.94 176.15 11.38 Favored 'General case' 0 N--CA 1.477 0.899 0 C-N-CA 125.126 1.371 . . . . 0.0 112.649 -170.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -136.83 36.91 2.62 Favored 'General case' 0 CA--C 1.549 0.918 0 C-N-CA 124.011 0.925 . . . . 0.0 110.675 168.144 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -92.69 -41.88 9.92 Favored 'General case' 0 N--CA 1.476 0.843 0 C-N-CA 125.14 1.376 . . . . 0.0 112.626 -174.248 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 -112.52 141.79 45.85 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.029 1.332 . . . . 0.0 111.258 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 59.9 tp -152.72 -45.94 0.1 Allowed 'General case' 0 N--CA 1.475 0.792 0 C-N-CA 124.979 1.312 . . . . 0.0 112.263 177.615 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 23.9 m -70.37 159.27 34.45 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.985 1.314 . . . . 0.0 113.275 179.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -160.5 174.15 37.16 Favored Glycine 0 CA--C 1.541 1.675 0 C-N-CA 124.812 1.196 . . . . 0.0 113.684 177.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 96.4 Cg_endo -73.56 161.41 42.27 Favored 'Trans proline' 0 CA--C 1.541 0.84 0 C-N-CA 124.116 3.21 . . . . 0.0 113.438 -176.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 6.8 t 62.0 169.4 0.12 Allowed 'General case' 0 N--CA 1.476 0.864 0 C-N-CA 126.945 2.098 . . . . 0.0 115.457 -178.117 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 79.8 p -129.23 -0.14 5.14 Favored 'General case' 0 N--CA 1.474 0.742 0 C-N-CA 126.823 2.049 . . . . 0.0 113.746 -179.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.252 1.264 0 C-N-CA 125.612 1.577 . . . . 0.0 113.806 178.64 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.66 0 N-CA-C 112.101 -0.4 . . . . 0.0 112.101 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 35.8 t -138.36 148.28 44.37 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 125.328 1.451 . . . . 0.0 112.024 -179.424 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 41.2 m -125.89 45.25 2.66 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 126.161 1.784 . . . . 0.0 109.217 169.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 73.04 35.51 57.65 Favored Glycine 0 CA--C 1.533 1.21 0 N-CA-C 110.814 -0.915 . . . . 0.0 110.814 -167.384 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 17.1 p -120.21 -33.1 3.99 Favored 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 125.981 1.713 . . . . 0.0 112.888 -172.036 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 48.2 m -79.3 -9.12 59.51 Favored 'General case' 0 N--CA 1.479 1.017 0 C-N-CA 123.948 0.899 . . . . 0.0 113.096 169.141 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 176.82 166.39 33.78 Favored Glycine 0 CA--C 1.541 1.672 0 C-N-CA 125.513 1.53 . . . . 0.0 112.847 173.385 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -88.26 174.0 4.55 Favored 'Trans proline' 0 CA--C 1.54 0.783 0 C-N-CA 124.429 3.419 . . . . 0.0 114.345 -169.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 7.0 tp -88.15 154.95 3.21 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.846 0 C-N-CA 124.724 1.21 . . . . 0.0 110.776 168.307 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 16.4 m -72.65 -7.79 52.06 Favored 'General case' 0 N--CA 1.477 0.919 0 N-CA-C 114.216 1.191 . . . . 0.0 114.216 174.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 9.1 tp10 -79.57 79.83 6.01 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 125.625 1.57 . . . . 0.0 111.555 -177.505 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 38.8 ttm180 48.64 -94.55 0.03 OUTLIER 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 127.411 2.284 . . . . 0.0 113.769 175.023 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 23.0 m120 -136.16 27.6 3.18 Favored 'General case' 0 CA--C 1.549 0.916 0 C-N-CA 126.205 1.802 . . . . 0.0 112.311 179.444 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 4.9 tp-100 -62.97 -17.24 61.82 Favored 'General case' 0 N--CA 1.478 0.941 0 O-C-N 120.635 -1.29 . . . . 0.0 113.545 -175.658 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -55.96 -27.14 51.21 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 124.893 1.277 . . . . 0.0 112.82 168.402 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -79.58 -3.74 48.37 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 113.654 0.983 . . . . 0.0 113.654 177.696 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.2 m -103.39 133.48 48.37 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 124.175 0.99 . . . . 0.0 109.903 173.069 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 13.9 m -104.76 148.38 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.729 0 C-N-CA 124.69 1.196 . . . . 0.0 110.697 172.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 34.9 t80 -95.82 143.08 27.35 Favored 'General case' 0 CA--C 1.535 0.395 0 C-N-CA 126.642 1.977 . . . . 0.0 109.81 169.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.7 t -131.43 111.71 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 125.523 1.529 . . . . 0.0 109.222 173.378 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -106.29 149.33 16.63 Favored Glycine 0 CA--C 1.528 0.902 0 C-N-CA 124.623 1.106 . . . . 0.0 112.649 176.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.24 35.46 7.03 Favored Glycine 0 CA--C 1.532 1.112 0 C-N-CA 124.192 0.901 . . . . 0.0 113.644 174.423 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 85.9 mt -74.87 150.15 39.29 Favored 'General case' 0 C--O 1.234 0.289 0 C-N-CA 125.505 1.522 . . . . 0.0 111.273 -174.89 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -88.89 156.81 18.69 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 123.739 0.816 . . . . 0.0 111.802 174.588 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.74 -20.38 48.63 Favored 'General case' 0 CA--C 1.546 0.827 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 179.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.5 mtmm -81.73 -11.89 58.84 Favored 'General case' 0 N--CA 1.476 0.832 0 C-N-CA 124.717 1.207 . . . . 0.0 114.172 174.882 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 88.2 t -72.17 137.2 24.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.916 0 C-N-CA 124.191 0.996 . . . . 0.0 111.113 177.004 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 57.0 m -134.36 163.77 28.92 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 124.811 1.244 . . . . 0.0 111.501 172.218 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -56.0 -42.78 97.9 Favored Pre-proline 0 CA--C 1.549 0.909 0 O-C-N 120.888 -1.132 . . . . 0.0 113.846 179.306 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 76.7 Cg_exo -60.59 -28.82 87.3 Favored 'Trans proline' 0 C--N 1.354 0.825 0 C-N-CA 122.252 1.968 . . . . 0.0 114.046 173.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 26.2 tp -68.21 -50.93 50.9 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 118.82 0.737 . . . . 0.0 110.135 172.502 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 20.5 mt -62.04 -22.12 65.47 Favored 'General case' 0 N--CA 1.466 0.363 0 N-CA-C 112.891 0.7 . . . . 0.0 112.891 178.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.5 t90 -74.27 -66.8 0.68 Allowed 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 123.255 0.622 . . . . 0.0 110.949 170.006 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.8 mt-10 -65.37 -29.95 70.73 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 114.386 1.254 . . . . 0.0 114.386 -171.91 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.7 tp -69.04 -35.22 76.35 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.535 0.734 . . . . 0.0 111.579 175.117 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -89.34 -10.85 45.13 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.123 1.369 . . . . 0.0 113.444 -174.208 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 44.5 mt -54.86 -19.8 7.34 Favored 'General case' 0 CA--C 1.545 0.761 0 C-N-CA 124.529 1.132 . . . . 0.0 113.874 169.393 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 40.5 mt-30 -66.4 -31.54 72.36 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 125.413 1.485 . . . . 0.0 112.638 173.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -77.08 -46.55 23.24 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.23 0.612 . . . . 0.0 112.182 176.504 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.45 -173.68 45.55 Favored Glycine 0 CA--C 1.537 1.416 0 C-N-CA 125.399 1.476 . . . . 0.0 112.492 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -66.76 112.62 2.49 Favored 'Trans proline' 0 CA--C 1.538 0.68 0 C-N-CA 123.579 2.852 . . . . 0.0 111.766 -179.302 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 75.6 t -87.14 134.46 27.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 C-N-CA 125.006 1.322 . . . . 0.0 109.794 174.602 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.9 t -109.14 -33.8 2.51 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.73 0 C-N-CA 126.527 1.931 . . . . 0.0 111.847 -171.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 21.3 t30 -160.84 163.24 32.23 Favored 'General case' 0 CA--C 1.554 1.107 0 C-N-CA 125.851 1.66 . . . . 0.0 111.05 -175.08 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 4.0 p -140.06 154.54 47.1 Favored 'General case' 0 N--CA 1.481 1.079 0 C-N-CA 126.429 1.892 . . . . 0.0 111.295 174.173 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 47.9 t-80 -142.18 132.0 24.28 Favored 'General case' 0 N--CA 1.467 0.41 0 C-N-CA 123.445 0.698 . . . . 0.0 111.142 175.531 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 87.6 mtp -133.28 106.61 12.22 Favored Pre-proline 0 N--CA 1.472 0.671 0 C-N-CA 123.876 0.871 . . . . 0.0 109.649 169.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_exo -57.8 140.28 93.15 Favored 'Trans proline' 0 CA--C 1.538 0.689 0 C-N-CA 123.283 2.655 . . . . 0.0 113.101 177.535 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 43.4 mmtm -112.86 146.18 39.36 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 125.209 1.404 . . . . 0.0 112.822 -173.371 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -66.66 139.12 57.84 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 125.479 1.512 . . . . 0.0 111.618 170.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 34.0 ptt-85 -82.74 5.56 20.98 Favored 'General case' 0 N--CA 1.48 1.034 0 N-CA-C 115.908 1.818 . . . . 0.0 115.908 -173.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 23.3 t -131.4 -38.79 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.961 0 C-N-CA 125.558 1.543 . . . . 0.0 111.277 -173.894 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 33.7 p -106.24 -16.79 14.49 Favored 'General case' 0 N--CA 1.474 0.75 0 C-N-CA 124.771 1.228 . . . . 0.0 112.321 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 71.39 3.52 53.78 Favored Glycine 0 CA--C 1.537 1.448 0 C-N-CA 124.811 1.196 . . . . 0.0 115.221 177.753 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 71.9 mm-40 -80.08 162.65 24.68 Favored 'General case' 0 CA--C 1.539 0.537 0 C-N-CA 124.703 1.201 . . . . 0.0 110.947 178.253 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 18.0 p80 -68.91 153.21 44.2 Favored 'General case' 0 N--CA 1.471 0.602 0 O-C-N 120.986 -1.071 . . . . 0.0 112.621 177.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 45.9 mt-30 -85.06 17.04 3.11 Favored 'General case' 0 CA--C 1.549 0.92 0 N-CA-C 114.251 1.204 . . . . 0.0 114.251 -173.638 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 87.52 1.5 83.35 Favored Glycine 0 CA--C 1.535 1.333 0 C-N-CA 125.06 1.314 . . . . 0.0 114.97 -179.933 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 42.1 p90 -145.13 161.66 38.93 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 124.899 1.279 . . . . 0.0 112.603 178.19 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -153.54 -177.36 26.96 Favored Glycine 0 CA--C 1.531 1.039 0 C-N-CA 125.963 1.744 . . . . 0.0 113.065 -177.417 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 80.8 m-85 -144.22 150.79 38.52 Favored 'General case' 0 C--O 1.237 0.438 0 C-N-CA 126.048 1.739 . . . . 0.0 111.574 -178.116 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 20.1 t -132.51 130.11 59.52 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.746 0 C-N-CA 124.889 1.276 . . . . 0.0 109.642 176.085 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 63.2 tt0 -106.72 119.67 39.94 Favored 'General case' 0 N--CA 1.465 0.324 0 C-N-CA 124.814 1.246 . . . . 0.0 110.582 -176.858 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -96.17 162.58 13.47 Favored 'General case' 0 C--O 1.234 0.272 0 C-N-CA 124.959 1.304 . . . . 0.0 112.441 177.353 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.5 tp -64.13 -34.81 78.91 Favored 'General case' 0 CA--C 1.54 0.594 0 C-N-CA 123.052 0.541 . . . . 0.0 112.298 176.636 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 11.7 m -141.76 157.89 44.48 Favored 'General case' 0 N--CA 1.468 0.472 0 CA-C-O 122.601 1.191 . . . . 0.0 112.324 -177.23 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 60.3 mp0 -65.18 -35.75 82.07 Favored 'General case' 0 CA--C 1.539 0.556 0 C-N-CA 125.117 1.367 . . . . 0.0 112.871 -175.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -67.89 -25.77 65.67 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 113.218 0.822 . . . . 0.0 113.218 177.035 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 55.2 m-20 -76.02 -33.9 59.66 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 123.781 0.832 . . . . 0.0 111.357 173.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -70.83 -45.85 63.8 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 123.841 0.857 . . . . 0.0 111.386 173.213 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -55.91 -34.83 65.94 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 124.134 0.974 . . . . 0.0 112.31 174.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 60.3 t80 -78.09 -36.44 48.17 Favored 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 123.756 0.823 . . . . 0.0 112.902 177.117 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.11 -36.58 82.16 Favored 'General case' 0 CA--C 1.539 0.554 0 O-C-N 120.921 -1.112 . . . . 0.0 111.485 176.829 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 57.9 mt -63.23 -34.23 65.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 124.732 1.213 . . . . 0.0 111.31 174.022 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 62.1 tttp -70.03 -36.59 75.17 Favored 'General case' 0 N--CA 1.472 0.645 0 C-N-CA 124.354 1.061 . . . . 0.0 113.023 176.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 14.1 pt -101.58 -13.97 8.2 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.837 0 N-CA-C 116.135 1.902 . . . . 0.0 116.135 -171.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 13.5 mmt -113.12 -2.28 14.19 Favored 'General case' 0 N--CA 1.484 1.25 0 N-CA-C 115.247 1.573 . . . . 0.0 115.247 -176.228 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -82.53 140.89 33.05 Favored 'General case' 0 N--CA 1.476 0.844 0 O-C-N 120.868 -1.145 . . . . 0.0 114.037 -174.353 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . 0.253 7.9 mmt 56.33 22.26 6.16 Favored 'General case' 0 N--CA 1.479 1.006 0 C-N-CA 127.537 2.335 . . . . 0.0 115.201 -177.44 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 20.9 mt -90.0 149.32 4.08 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.321 0 C-N-CA 127.786 2.435 . . . . 0.0 111.257 177.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 42.9 mtpt -100.61 70.54 1.45 Allowed 'General case' 0 N--CA 1.473 0.68 0 C-N-CA 124.188 0.995 . . . . 0.0 112.498 -169.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 31.3 tp -57.43 123.55 15.87 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.723 0.809 . . . . 0.0 109.709 174.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 59.0 m-85 45.85 27.44 0.47 Allowed 'General case' 0 CA--C 1.561 1.387 0 N-CA-C 116.487 2.032 . . . . 0.0 116.487 -168.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 83.58 21.5 57.97 Favored Glycine 0 CA--C 1.544 1.858 0 O-C-N 120.068 -1.645 . . . . 0.0 116.522 177.038 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -135.02 121.71 14.77 Favored Pre-proline 0 CA--C 1.544 0.731 0 C-N-CA 128.546 2.738 . . . . 0.0 107.803 -179.981 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -72.2 119.57 6.24 Favored 'Trans proline' 0 CA--C 1.537 0.641 0 C-N-CA 123.055 2.504 . . . . 0.0 112.207 -169.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 18.4 pt -88.33 141.41 14.34 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 C-N-CA 124.341 1.056 . . . . 0.0 111.696 176.199 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 36.6 tpt85 -104.32 127.79 52.02 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 125.828 1.651 . . . . 0.0 108.948 173.441 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.8 t -122.55 136.33 59.72 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 123.818 0.847 . . . . 0.0 110.697 -175.495 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -160.44 -178.53 6.98 Favored 'General case' 0 CA--C 1.541 0.615 0 C-N-CA 123.987 0.915 . . . . 0.0 112.122 177.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 7.8 mmmm -63.62 141.88 58.6 Favored 'General case' 0 N--CA 1.477 0.903 0 O-C-N 121.186 -0.946 . . . . 0.0 110.37 172.9 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -66.13 -30.7 71.24 Favored 'General case' 0 CA--C 1.545 0.755 0 O-C-N 121.807 -0.558 . . . . 0.0 111.947 172.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 38.2 m -119.3 83.16 1.99 Allowed 'General case' 0 N--CA 1.469 0.505 0 C-N-CA 126.07 1.748 . . . . 0.0 109.392 168.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -78.38 46.13 0.61 Allowed 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 125.172 1.389 . . . . 0.0 113.321 -177.227 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 11.7 m-70 -123.62 146.32 48.27 Favored 'General case' 0 N--CA 1.467 0.397 0 C-N-CA 126.859 2.063 . . . . 0.0 111.444 -175.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 35.8 t30 -116.87 119.49 35.53 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 124.865 1.266 . . . . 0.0 110.322 173.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 12.5 mptt -110.03 9.94 24.17 Favored 'General case' 0 N--CA 1.478 0.951 0 C-N-CA 126.205 1.802 . . . . 0.0 113.486 178.291 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 47.6 t30 -66.82 154.64 40.36 Favored 'General case' 0 CA--C 1.55 0.958 0 C-N-CA 124.142 0.977 . . . . 0.0 111.642 172.052 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 83.9 mt -79.9 154.48 28.31 Favored 'General case' 0 CA--C 1.543 0.689 0 C-N-CA 124.655 1.182 . . . . 0.0 112.908 -176.405 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 11.8 t -151.79 159.0 44.06 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 125.554 1.542 . . . . 0.0 111.484 175.778 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 65.74 73.68 0.58 Allowed Glycine 0 CA--C 1.541 1.688 0 C-N-CA 125.533 1.539 . . . . 0.0 114.322 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_exo -61.17 153.07 67.46 Favored 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 123.697 2.931 . . . . 0.0 114.242 -179.452 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 10.6 t -76.0 154.58 35.67 Favored 'General case' 0 N--CA 1.474 0.727 0 C-N-CA 124.132 0.973 . . . . 0.0 112.249 175.025 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.5 t -150.09 157.94 43.65 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 125.372 1.469 . . . . 0.0 111.861 178.823 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.33 0 C-N-CA 125.738 1.637 . . . . 0.0 113.734 -179.145 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.428 0 N-CA-C 111.125 -0.79 . . . . 0.0 111.125 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 8.0 t -139.67 172.33 12.95 Favored 'General case' 0 N--CA 1.474 0.771 0 C-N-CA 125.344 1.458 . . . . 0.0 111.343 178.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 40.4 m 52.26 34.01 13.79 Favored 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 125.443 1.497 . . . . 0.0 113.987 -176.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 81.0 1.55 90.0 Favored Glycine 0 CA--C 1.538 1.524 0 C-N-CA 125.168 1.366 . . . . 0.0 115.707 -177.619 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 36.3 t -75.99 134.35 40.18 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 119.349 1.574 . . . . 0.0 112.386 177.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.0 p -81.96 -7.0 59.58 Favored 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 125.344 1.458 . . . . 0.0 113.827 173.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -68.73 153.44 52.93 Favored Glycine 0 CA--C 1.543 1.783 0 C-N-CA 124.171 0.891 . . . . 0.0 114.291 -177.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 64.3 Cg_endo -79.12 170.87 17.12 Favored 'Trans proline' 0 CA--C 1.542 0.908 0 C-N-CA 124.128 3.219 . . . . 0.0 112.972 177.535 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 20.6 tt -139.29 146.39 25.79 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.789 0 C-N-CA 125.533 1.533 . . . . 0.0 110.607 169.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 19.0 m -77.93 -13.95 59.71 Favored 'General case' 0 N--CA 1.474 0.743 0 N-CA-C 114.221 1.193 . . . . 0.0 114.221 -177.277 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 41.5 mt-10 58.63 -28.93 0.03 OUTLIER 'General case' 0 N--CA 1.486 1.35 0 C-N-CA 128.798 2.839 . . . . 0.0 117.884 -177.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 13.6 ptm180 -61.03 139.95 57.95 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 125.402 1.481 . . . . 0.0 114.265 -173.22 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . 0.26 0.7 OUTLIER 46.1 27.88 0.58 Allowed 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 127.803 2.441 . . . . 0.0 116.821 174.347 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.5 tp-100 -67.74 -19.25 65.11 Favored 'General case' 0 CA--C 1.544 0.746 0 O-C-N 120.81 -1.181 . . . . 0.0 113.512 -172.259 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 18.5 m-20 -67.32 -23.05 65.6 Favored 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 124.342 1.057 . . . . 0.0 113.117 169.912 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.43 1.51 51.06 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 124.874 1.269 . . . . 0.0 113.03 171.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 17.5 m -100.63 137.0 39.61 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 124.427 1.091 . . . . 0.0 109.258 169.661 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.9 m -106.2 145.83 13.59 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 124.556 1.142 . . . . 0.0 110.349 172.229 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 19.4 t80 -95.81 142.7 27.77 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 126.083 1.753 . . . . 0.0 109.527 169.575 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 24.2 t -130.02 115.91 35.07 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.607 0 C-N-CA 125.553 1.541 . . . . 0.0 109.094 174.274 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -109.56 150.28 17.3 Favored Glycine 0 CA--C 1.531 1.037 0 C-N-CA 124.511 1.053 . . . . 0.0 113.045 176.557 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 93.04 32.99 7.54 Favored Glycine 0 CA--C 1.533 1.177 0 C-N-CA 124.782 1.182 . . . . 0.0 114.01 175.488 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 87.0 mt -78.72 153.26 31.03 Favored 'General case' 0 C--O 1.234 0.256 0 C-N-CA 125.219 1.408 . . . . 0.0 112.029 -170.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 18.5 t70 -90.97 155.66 18.55 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 124.151 0.98 . . . . 0.0 111.997 176.453 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.51 -20.23 44.17 Favored 'General case' 0 CA--C 1.547 0.832 0 N-CA-C 114.988 1.477 . . . . 0.0 114.988 -179.112 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.4 mtmm -81.6 -9.04 59.77 Favored 'General case' 0 N--CA 1.477 0.879 0 C-N-CA 124.763 1.225 . . . . 0.0 114.119 175.194 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 57.3 t -78.99 138.65 19.7 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 C-N-CA 124.857 1.263 . . . . 0.0 111.275 178.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 6.7 t -147.05 167.75 23.29 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 123.601 0.76 . . . . 0.0 112.43 171.058 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -48.81 -45.56 72.32 Favored Pre-proline 0 CA--C 1.545 0.751 0 N-CA-C 115.923 1.823 . . . . 0.0 115.923 178.753 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 60.8 Cg_endo -69.55 -26.64 28.36 Favored 'Trans proline' 0 C--N 1.354 0.831 0 CA-C-N 122.021 1.757 . . . . 0.0 112.978 177.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 18.3 tp -66.46 -53.86 30.62 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 118.589 0.631 . . . . 0.0 109.486 170.001 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 25.9 mt -55.42 -42.12 73.7 Favored 'General case' 0 N--CA 1.464 0.257 0 C-N-CA 122.769 0.428 . . . . 0.0 111.601 -176.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.8 t90 -57.96 -61.81 2.27 Favored 'General case' 0 C--N 1.331 -0.236 0 C-N-CA 123.236 0.614 . . . . 0.0 111.109 179.328 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 36.7 mt-10 -64.41 -30.19 71.23 Favored 'General case' 0 N--CA 1.469 0.52 0 N-CA-C 113.699 1.0 . . . . 0.0 113.699 -178.487 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 7.4 tp -70.73 -35.91 72.93 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 123.95 0.9 . . . . 0.0 111.879 176.037 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 14.8 m-85 -89.2 -10.64 46.3 Favored 'General case' 0 N--CA 1.471 0.575 0 C-N-CA 124.816 1.247 . . . . 0.0 113.596 -175.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 27.8 mt -54.38 -20.73 7.91 Favored 'General case' 0 CA--C 1.547 0.844 0 N-CA-C 113.805 1.039 . . . . 0.0 113.805 168.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 43.1 mt-30 -61.85 -34.14 75.44 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 125.055 1.342 . . . . 0.0 112.566 173.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -78.9 -45.6 20.23 Favored 'General case' 0 CA--C 1.539 0.529 0 C-N-CA 123.559 0.744 . . . . 0.0 112.666 178.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 178.48 -172.46 44.85 Favored Glycine 0 CA--C 1.536 1.403 0 C-N-CA 124.815 1.197 . . . . 0.0 112.813 -178.377 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.8 Cg_endo -67.81 110.22 2.08 Favored 'Trans proline' 0 CA--C 1.538 0.68 0 C-N-CA 123.663 2.908 . . . . 0.0 111.783 -178.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 63.9 t -85.18 134.3 27.39 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.604 0 C-N-CA 124.916 1.287 . . . . 0.0 109.825 174.07 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 5.7 t -108.69 -34.31 2.63 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.779 0 C-N-CA 126.235 1.814 . . . . 0.0 111.805 -172.611 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 21.3 t30 -160.79 160.82 31.69 Favored 'General case' 0 CA--C 1.55 0.974 0 C-N-CA 125.995 1.718 . . . . 0.0 110.863 -174.343 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 12.2 p -137.31 156.42 48.27 Favored 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 125.9 1.68 . . . . 0.0 111.535 172.644 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 47.3 t-80 -142.11 134.25 27.58 Favored 'General case' 0 N--CA 1.469 0.488 0 C-N-CA 123.461 0.704 . . . . 0.0 111.442 175.493 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 29.5 mmm -133.41 105.56 12.1 Favored Pre-proline 0 N--CA 1.471 0.604 0 C-N-CA 124.57 1.148 . . . . 0.0 109.336 172.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 71.4 Cg_exo -59.24 134.95 62.43 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 123.177 2.585 . . . . 0.0 112.523 176.259 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 41.4 mmtm -109.9 148.63 31.22 Favored 'General case' 0 N--CA 1.478 0.945 0 C-N-CA 125.225 1.41 . . . . 0.0 112.65 -173.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -66.93 148.61 51.72 Favored 'General case' 0 CA--C 1.547 0.848 0 C-N-CA 125.231 1.412 . . . . 0.0 112.395 170.15 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 17.6 ptp180 -87.12 -1.35 57.82 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 116.645 2.091 . . . . 0.0 116.645 -172.568 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 3.5 m -135.54 -31.53 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.295 0 C-N-CA 124.619 1.168 . . . . 0.0 113.355 -178.697 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 69.2 p -103.9 -18.41 14.63 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 124.995 1.318 . . . . 0.0 111.898 179.336 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 71.43 -0.54 32.9 Favored Glycine 0 CA--C 1.539 1.59 0 C-N-CA 125.381 1.467 . . . . 0.0 116.243 170.911 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 6.4 pt20 -79.33 164.16 24.3 Favored 'General case' 0 N--CA 1.47 0.563 0 C-N-CA 125.305 1.442 . . . . 0.0 111.412 173.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 24.4 p80 -69.69 157.03 38.05 Favored 'General case' 0 N--CA 1.471 0.607 0 O-C-N 121.216 -0.928 . . . . 0.0 113.199 -178.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 45.2 mt-30 -85.71 16.8 3.7 Favored 'General case' 0 CA--C 1.551 1.007 0 N-CA-C 114.518 1.303 . . . . 0.0 114.518 -173.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 89.49 0.24 79.69 Favored Glycine 0 CA--C 1.536 1.352 0 C-N-CA 125.395 1.474 . . . . 0.0 115.112 179.536 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 47.4 p90 -145.63 156.72 43.84 Favored 'General case' 0 CA--C 1.541 0.611 0 C-N-CA 125.411 1.484 . . . . 0.0 112.235 179.126 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -145.87 178.18 23.76 Favored Glycine 0 CA--C 1.532 1.124 0 C-N-CA 126.437 1.97 . . . . 0.0 112.92 -175.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 76.0 m-85 -141.85 150.27 41.38 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 125.537 1.535 . . . . 0.0 112.251 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 22.6 t -134.32 130.64 54.39 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.833 0 C-N-CA 125.043 1.337 . . . . 0.0 109.977 175.704 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 86.3 tt0 -107.96 122.67 47.31 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 124.917 1.287 . . . . 0.0 111.073 -176.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -99.05 161.07 13.82 Favored 'General case' 0 CA--C 1.532 0.251 0 C-N-CA 125.29 1.436 . . . . 0.0 112.581 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 14.4 tp -62.84 -34.44 77.34 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 123.305 0.642 . . . . 0.0 112.206 178.395 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.7 m -141.07 154.94 46.19 Favored 'General case' 0 N--CA 1.467 0.408 0 C-N-CA 124.453 1.101 . . . . 0.0 111.831 -178.185 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 12.5 tm-20 -64.42 -31.96 73.38 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 124.479 1.111 . . . . 0.0 113.221 -177.703 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -69.42 -26.26 64.53 Favored 'General case' 0 N--CA 1.472 0.672 0 N-CA-C 113.154 0.798 . . . . 0.0 113.154 176.046 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 41.6 m-20 -77.26 -33.22 55.98 Favored 'General case' 0 CA--C 1.538 0.482 0 C-N-CA 123.707 0.803 . . . . 0.0 111.412 173.405 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.7 -43.67 71.96 Favored 'General case' 0 CA--C 1.539 0.545 0 O-C-N 121.832 -0.543 . . . . 0.0 111.355 172.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -61.58 -28.76 69.57 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 124.088 0.955 . . . . 0.0 112.853 178.082 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 61.6 t80 -79.88 -34.21 39.34 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 124.172 0.989 . . . . 0.0 112.9 173.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -64.57 -37.15 86.56 Favored 'General case' 0 CA--C 1.537 0.457 0 O-C-N 121.119 -0.988 . . . . 0.0 111.091 176.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 65.2 mt -61.31 -39.85 84.09 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 C-N-CA 125.159 1.384 . . . . 0.0 111.224 172.707 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 62.4 tttp -62.88 -38.16 89.79 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 124.051 0.94 . . . . 0.0 112.618 178.184 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 44.9 pt -96.07 -29.5 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.817 0 N-CA-C 115.334 1.605 . . . . 0.0 115.334 -175.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' MET . . . . . 0.481 ' HA ' HD12 ' A' ' 80' ' ' ILE . 5.7 mmt -98.07 -0.75 43.93 Favored 'General case' 0 N--CA 1.482 1.156 0 N-CA-C 115.194 1.553 . . . . 0.0 115.194 -173.24 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -83.9 140.29 32.06 Favored 'General case' 0 CA--C 1.539 0.546 0 O-C-N 121.066 -1.021 . . . . 0.0 111.7 178.396 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 28.1 ttm 60.05 13.41 3.75 Favored 'General case' 0 CA--C 1.552 1.021 0 C-N-CA 125.448 1.499 . . . . 0.0 114.84 -173.316 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.481 HD12 ' HA ' ' A' ' 77' ' ' MET . 1.5 mt -71.04 159.38 5.75 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 C-N-CA 125.659 1.583 . . . . 0.0 110.46 169.014 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 50.8 mtpt -119.9 69.52 0.85 Allowed 'General case' 0 N--CA 1.47 0.566 0 C-N-CA 125.69 1.596 . . . . 0.0 112.214 -179.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 40.2 tp -57.49 127.17 30.66 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 124.113 0.965 . . . . 0.0 109.949 174.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 64.1 m-85 46.17 27.37 0.54 Allowed 'General case' 0 CA--C 1.561 1.384 0 N-CA-C 116.325 1.972 . . . . 0.0 116.325 -168.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 78.99 23.56 63.57 Favored Glycine 0 CA--C 1.542 1.745 0 O-C-N 120.096 -1.627 . . . . 0.0 116.053 176.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -131.12 120.01 18.04 Favored Pre-proline 0 CA--C 1.542 0.654 0 C-N-CA 128.154 2.581 . . . . 0.0 107.915 179.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -69.78 130.33 19.13 Favored 'Trans proline' 0 CA--C 1.536 0.602 0 C-N-CA 122.979 2.452 . . . . 0.0 112.891 -171.397 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 27.3 pt -103.95 161.8 4.4 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.654 0 C-N-CA 125.498 1.519 . . . . 0.0 112.27 179.301 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 89.6 mmt-85 -128.82 139.29 52.24 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 125.292 1.437 . . . . 0.0 110.714 170.343 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.4 t -133.74 136.31 54.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 124.404 1.082 . . . . 0.0 111.386 -169.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -157.07 172.9 17.84 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 125.795 1.638 . . . . 0.0 111.49 179.269 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.9 mmmm -60.26 142.27 54.86 Favored 'General case' 0 N--CA 1.481 1.115 0 O-C-N 121.323 -0.861 . . . . 0.0 109.225 171.432 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -67.94 -20.21 65.04 Favored 'General case' 0 CA--C 1.548 0.883 0 N-CA-C 113.302 0.853 . . . . 0.0 113.302 -179.906 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 70.8 m -122.76 46.72 2.09 Favored 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 126.276 1.831 . . . . 0.0 111.729 173.582 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -67.72 156.62 36.54 Favored 'General case' 0 CA--C 1.547 0.838 0 N-CA-C 114.098 1.147 . . . . 0.0 114.098 179.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 75.9 m-70 -138.44 158.37 44.4 Favored 'General case' 0 N--CA 1.474 0.756 0 C-N-CA 126.294 1.838 . . . . 0.0 111.368 177.247 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 91.5 m-20 -77.26 146.93 36.58 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 123.59 0.756 . . . . 0.0 111.076 171.356 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -75.84 118.85 19.07 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.884 0.874 . . . . 0.0 111.3 179.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 24.5 t-20 -93.41 -22.65 18.78 Favored 'General case' 0 CA--C 1.547 0.862 0 C-N-CA 124.661 1.185 . . . . 0.0 112.929 173.425 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 47.1 tp -69.78 150.19 47.15 Favored 'General case' 0 CA--C 1.545 0.771 0 C-N-CA 125.275 1.43 . . . . 0.0 112.293 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 20.4 m -67.02 167.28 12.1 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 125.502 1.521 . . . . 0.0 114.1 178.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -74.9 -169.58 24.33 Favored Glycine 0 CA--C 1.546 1.978 0 C-N-CA 124.703 1.145 . . . . 0.0 113.413 168.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 63.6 Cg_endo -64.79 152.17 83.07 Favored 'Trans proline' 0 CA--C 1.541 0.839 0 C-N-CA 123.463 2.775 . . . . 0.0 112.613 178.317 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 85.5 p -79.26 -21.74 45.71 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -176.029 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 34.2 m 54.18 27.7 8.11 Favored 'General case' 0 N--CA 1.478 0.941 0 C-N-CA 125.766 1.626 . . . . 0.0 114.433 -174.205 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.251 0 C-N-CA 125.655 1.598 . . . . 0.0 113.84 178.789 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.588 0 N-CA-C 111.741 -0.543 . . . . 0.0 111.741 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 49.6 m -63.59 141.72 58.66 Favored 'General case' 0 N--CA 1.476 0.836 0 C-N-CA 124.634 1.174 . . . . 0.0 112.837 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 21.0 m -72.07 -27.37 62.63 Favored 'General case' 0 N--CA 1.476 0.868 0 N-CA-C 113.563 0.949 . . . . 0.0 113.563 -178.851 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 154.62 -175.63 32.66 Favored Glycine 0 CA--C 1.535 1.314 0 C-N-CA 125.319 1.438 . . . . 0.0 113.215 178.322 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.2 t -152.63 133.72 14.19 Favored 'General case' 0 N--CA 1.473 0.679 0 C-N-CA 125.602 1.561 . . . . 0.0 109.928 174.225 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 92.5 p -131.73 150.91 52.0 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 124.492 1.117 . . . . 0.0 113.869 -175.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 75.24 93.18 0.17 Allowed Glycine 0 CA--C 1.54 1.625 0 C-N-CA 124.904 1.24 . . . . 0.0 113.637 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -57.83 150.33 63.62 Favored 'Trans proline' 0 CA--C 1.538 0.685 0 C-N-CA 123.809 3.006 . . . . 0.0 113.177 174.654 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 8.1 tt -72.92 152.63 7.61 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 N-CA-C 113.496 0.924 . . . . 0.0 113.496 -171.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 64.4 p -98.88 -0.94 41.35 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 125.969 1.708 . . . . 0.0 114.634 176.495 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 45.0 mt-10 -126.14 133.75 51.51 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 125.413 1.485 . . . . 0.0 112.108 -176.308 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 28.2 mtm180 45.35 -136.68 0.6 Allowed 'General case' 0 N--CA 1.48 1.054 0 C-N-CA 125.865 1.666 . . . . 0.0 111.835 -171.493 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 18.6 m120 -131.6 40.76 3.37 Favored 'General case' 0 CA--C 1.544 0.714 0 C-N-CA 126.242 1.817 . . . . 0.0 110.43 177.128 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 16.7 mm100 -58.54 -22.96 57.13 Favored 'General case' 0 CA--C 1.547 0.841 0 N-CA-C 114.693 1.368 . . . . 0.0 114.693 -168.906 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 70.5 m-20 -75.48 -19.19 59.57 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 114.025 1.12 . . . . 0.0 114.025 175.497 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -117.67 12.45 13.99 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 126.097 1.759 . . . . 0.0 112.062 172.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 31.8 m -109.18 137.13 47.55 Favored 'General case' 0 N--CA 1.468 0.428 0 C-N-CA 125.165 1.386 . . . . 0.0 108.664 173.472 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.3 m -98.26 146.56 7.86 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.569 0 C-N-CA 123.348 0.659 . . . . 0.0 110.193 171.056 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 12.0 t80 -95.08 141.8 28.29 Favored 'General case' 0 C--N 1.327 -0.41 0 C-N-CA 125.561 1.544 . . . . 0.0 108.42 168.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.6 t -130.63 111.99 21.67 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.525 0 C-N-CA 125.37 1.468 . . . . 0.0 109.059 177.575 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -107.36 145.81 16.1 Favored Glycine 0 CA--C 1.53 1.022 0 C-N-CA 124.368 0.985 . . . . 0.0 112.681 177.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 99.54 30.17 6.66 Favored Glycine 0 CA--C 1.537 1.411 0 C-N-CA 124.985 1.278 . . . . 0.0 114.352 176.019 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 85.2 mt -77.3 144.69 37.91 Favored 'General case' 0 CA--C 1.532 0.263 0 C-N-CA 125.415 1.486 . . . . 0.0 111.699 -172.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -85.07 158.91 20.31 Favored 'General case' 0 CA--C 1.544 0.732 0 C-N-CA 123.721 0.809 . . . . 0.0 112.519 176.063 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.48 -21.63 52.27 Favored 'General case' 0 CA--C 1.547 0.832 0 N-CA-C 114.534 1.309 . . . . 0.0 114.534 177.687 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.0 mtmm -80.0 -12.73 59.68 Favored 'General case' 0 N--CA 1.477 0.898 0 N-CA-C 114.271 1.212 . . . . 0.0 114.271 174.474 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 66.8 t -71.4 140.16 18.68 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.842 0 C-N-CA 124.056 0.942 . . . . 0.0 111.235 178.329 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 91.3 p -134.57 161.43 35.1 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 125.093 1.357 . . . . 0.0 112.135 175.728 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -59.59 -39.63 72.89 Favored Pre-proline 0 CA--C 1.546 0.8 0 O-C-N 120.878 -1.139 . . . . 0.0 113.512 177.484 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_exo -62.29 -31.17 81.94 Favored 'Trans proline' 0 C--N 1.353 0.798 0 C-N-CA 122.587 2.192 . . . . 0.0 114.005 170.337 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 27.5 tp -67.38 -50.46 59.61 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 119.199 0.909 . . . . 0.0 109.862 173.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 20.2 mt -61.32 -22.6 65.04 Favored 'General case' 0 N--CA 1.464 0.268 0 N-CA-C 113.118 0.785 . . . . 0.0 113.118 178.616 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.6 t90 -74.02 -66.69 0.68 Allowed 'General case' 0 C--N 1.328 -0.335 0 C-N-CA 123.153 0.581 . . . . 0.0 110.851 171.293 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 39.0 mt-10 -64.74 -30.78 71.8 Favored 'General case' 0 N--CA 1.473 0.707 0 N-CA-C 114.064 1.135 . . . . 0.0 114.064 -172.631 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.0 tp -69.13 -31.88 70.87 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 123.687 0.795 . . . . 0.0 112.148 175.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -92.59 -10.47 37.37 Favored 'General case' 0 CA--C 1.537 0.481 0 C-N-CA 125.227 1.411 . . . . 0.0 113.465 -175.102 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 50.4 mt -55.33 -18.07 5.88 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.395 1.078 . . . . 0.0 113.852 169.268 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 40.7 mt-30 -64.43 -33.24 75.41 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 125.456 1.502 . . . . 0.0 112.764 172.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.25 -45.88 18.89 Favored 'General case' 0 CA--C 1.537 0.471 0 C-N-CA 123.469 0.707 . . . . 0.0 112.661 177.68 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.93 -171.6 43.08 Favored Glycine 0 CA--C 1.535 1.334 0 C-N-CA 124.307 0.956 . . . . 0.0 113.098 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -67.96 107.88 1.6 Allowed 'Trans proline' 0 CA--C 1.537 0.658 0 C-N-CA 123.698 2.932 . . . . 0.0 111.441 -179.586 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 64.3 t -82.62 133.63 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 C-N-CA 124.717 1.207 . . . . 0.0 109.602 172.678 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 9.1 t -109.03 -33.25 2.45 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 C-N-CA 126.238 1.815 . . . . 0.0 111.71 -171.789 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 20.6 t30 -161.59 160.91 29.48 Favored 'General case' 0 CA--C 1.552 1.031 0 C-N-CA 126.095 1.758 . . . . 0.0 110.926 -175.134 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 4.0 p -136.74 153.92 50.72 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 125.709 1.603 . . . . 0.0 111.845 171.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 15.9 t-80 -142.36 132.31 24.41 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 123.699 0.8 . . . . 0.0 111.301 177.672 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 88.6 mtp -134.39 104.2 11.26 Favored Pre-proline 0 N--CA 1.473 0.693 0 C-N-CA 124.149 0.979 . . . . 0.0 109.509 171.438 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_exo -55.62 129.7 36.48 Favored 'Trans proline' 0 CA--C 1.536 0.579 0 C-N-CA 123.31 2.673 . . . . 0.0 113.581 -179.507 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 45.6 mmtm -94.44 148.6 22.07 Favored 'General case' 0 N--CA 1.473 0.678 0 C-N-CA 124.937 1.295 . . . . 0.0 112.162 -177.181 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 29.4 t70 -80.79 147.39 30.51 Favored 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 125.922 1.689 . . . . 0.0 113.55 -175.275 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 17.4 ptp180 -89.01 6.33 40.17 Favored 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 115.729 1.751 . . . . 0.0 115.729 -175.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 26.3 t -131.51 -38.56 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.1 0 C-N-CA 124.958 1.303 . . . . 0.0 111.256 -175.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.0 p -113.06 -20.76 11.38 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 125.569 1.548 . . . . 0.0 112.704 -176.779 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 74.01 0.57 56.65 Favored Glycine 0 CA--C 1.54 1.596 0 C-N-CA 124.977 1.275 . . . . 0.0 115.66 179.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 21.8 mm100 -74.67 170.95 14.78 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 124.945 1.298 . . . . 0.0 111.062 172.867 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 22.2 p80 -70.45 151.48 45.1 Favored 'General case' 0 N--CA 1.473 0.693 0 O-C-N 120.523 -1.36 . . . . 0.0 111.453 169.774 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 83.0 mt-30 -88.12 25.56 1.57 Allowed 'General case' 0 CA--C 1.549 0.906 0 N-CA-C 114.498 1.296 . . . . 0.0 114.498 -174.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.74 4.93 84.7 Favored Glycine 0 CA--C 1.535 1.298 0 C-N-CA 124.771 1.176 . . . . 0.0 115.289 175.539 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 39.3 p90 -144.36 161.17 39.66 Favored 'General case' 0 CA--C 1.538 0.51 0 C-N-CA 124.623 1.169 . . . . 0.0 112.422 176.676 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -152.45 -177.29 25.95 Favored Glycine 0 CA--C 1.53 0.97 0 C-N-CA 125.578 1.561 . . . . 0.0 113.136 -177.518 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -142.37 149.01 38.82 Favored 'General case' 0 CA--C 1.535 0.389 0 C-N-CA 126.12 1.768 . . . . 0.0 111.717 -178.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 14.9 t -132.53 122.26 47.1 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.854 0 C-N-CA 124.448 1.099 . . . . 0.0 110.215 175.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 47.6 tt0 -97.39 120.64 38.12 Favored 'General case' 0 N--CA 1.467 0.386 0 C-N-CA 125.083 1.353 . . . . 0.0 110.399 -175.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 77.9 m-85 -99.0 159.8 14.71 Favored 'General case' 0 C--O 1.235 0.295 0 C-N-CA 124.702 1.201 . . . . 0.0 112.298 176.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 14.3 tp -61.87 -34.38 75.91 Favored 'General case' 0 CA--C 1.542 0.641 0 C-N-CA 123.302 0.641 . . . . 0.0 112.383 177.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 19.4 m -143.32 155.42 44.45 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.635 1.174 . . . . 0.0 112.071 -177.312 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -60.78 -34.01 73.84 Favored 'General case' 0 N--CA 1.473 0.706 0 C-N-CA 124.501 1.12 . . . . 0.0 113.142 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -68.49 -22.89 64.52 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 113.527 0.936 . . . . 0.0 113.527 177.011 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 53.2 m-20 -82.62 -31.16 28.98 Favored 'General case' 0 CA--C 1.538 0.499 0 C-N-CA 123.926 0.891 . . . . 0.0 111.577 172.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -68.89 -42.52 76.83 Favored 'General case' 0 CA--C 1.544 0.721 0 O-C-N 121.654 -0.654 . . . . 0.0 111.09 170.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -59.8 -28.08 67.14 Favored 'General case' 0 N--CA 1.474 0.738 0 C-N-CA 124.307 1.043 . . . . 0.0 112.942 173.206 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 6.8 t80 -73.6 -41.42 62.89 Favored 'General case' 0 CA--C 1.536 0.432 0 O-C-N 121.232 -0.918 . . . . 0.0 111.635 172.46 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -68.46 -37.17 79.95 Favored 'General case' 0 CA--C 1.535 0.404 0 O-C-N 120.885 -1.134 . . . . 0.0 112.109 -178.651 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 77.8 mt -59.26 -37.35 68.41 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 124.063 0.945 . . . . 0.0 110.793 171.38 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 3.3 ttmp? -70.11 -37.58 75.38 Favored 'General case' 0 N--CA 1.467 0.417 0 C-N-CA 124.969 1.308 . . . . 0.0 113.275 -177.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 19.5 pt -94.99 -36.38 6.81 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 N-CA-C 115.423 1.638 . . . . 0.0 115.423 -179.447 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' MET . . . . . 0.48 ' HA ' HD12 ' A' ' 80' ' ' ILE . 14.2 mmt -94.05 -0.25 55.54 Favored 'General case' 0 N--CA 1.481 1.098 0 N-CA-C 114.931 1.456 . . . . 0.0 114.931 -169.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -82.69 139.76 33.49 Favored 'General case' 0 CA--C 1.539 0.55 0 O-C-N 121.206 -0.934 . . . . 0.0 111.799 177.242 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 28.0 ttm 60.35 12.26 3.33 Favored 'General case' 0 CA--C 1.55 0.962 0 C-N-CA 125.555 1.542 . . . . 0.0 114.99 -173.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.48 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.1 mt -72.02 158.63 6.1 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.598 0 C-N-CA 125.64 1.576 . . . . 0.0 110.311 169.017 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 49.7 mtpt -117.91 71.52 0.83 Allowed 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 125.379 1.472 . . . . 0.0 112.125 -177.564 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 27.7 tp -58.65 126.97 29.86 Favored 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 123.819 0.848 . . . . 0.0 109.961 175.413 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 67.2 m-85 45.82 29.9 0.78 Allowed 'General case' 0 CA--C 1.561 1.393 0 N-CA-C 116.105 1.891 . . . . 0.0 116.105 -168.669 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.94 19.95 69.0 Favored Glycine 0 CA--C 1.541 1.67 0 O-C-N 120.271 -1.518 . . . . 0.0 116.308 174.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -132.36 124.57 19.29 Favored Pre-proline 0 CA--C 1.54 0.587 0 C-N-CA 128.186 2.595 . . . . 0.0 108.036 179.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -70.57 131.09 19.41 Favored 'Trans proline' 0 CA--C 1.537 0.645 0 C-N-CA 123.364 2.71 . . . . 0.0 113.074 -169.772 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 21.2 pt -102.0 162.77 3.53 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.618 1.567 . . . . 0.0 112.218 176.608 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 89.4 mmt-85 -129.02 140.39 51.65 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 125.342 1.457 . . . . 0.0 111.035 170.509 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 20.9 t -132.58 136.58 55.77 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 C-N-CA 124.598 1.159 . . . . 0.0 111.494 -172.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -158.05 174.14 15.67 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 126.189 1.796 . . . . 0.0 111.068 179.12 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 11.8 mmmm -59.25 139.54 56.87 Favored 'General case' 0 N--CA 1.476 0.865 0 C-N-CA 123.644 0.778 . . . . 0.0 109.781 171.883 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -73.9 -5.39 40.83 Favored 'General case' 0 CA--C 1.553 1.086 0 N-CA-C 112.996 0.739 . . . . 0.0 112.996 175.176 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 88.3 p -112.33 13.59 20.35 Favored 'General case' 0 CA--C 1.544 0.72 0 C-N-CA 127.47 2.308 . . . . 0.0 114.121 172.18 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -54.04 -25.73 22.92 Favored 'General case' 0 N--CA 1.476 0.835 0 N-CA-C 115.357 1.614 . . . . 0.0 115.357 -169.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 21.4 m80 -62.85 -17.84 62.02 Favored 'General case' 0 CA--C 1.543 0.703 0 C-N-CA 125.388 1.475 . . . . 0.0 113.828 176.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 17.2 t30 -66.97 -14.87 63.3 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 124.78 1.232 . . . . 0.0 114.127 -179.371 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 80.8 tttt -51.23 -22.73 2.86 Favored 'General case' 0 N--CA 1.481 1.078 0 C-N-CA 126.482 1.913 . . . . 0.0 114.377 176.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -56.32 -28.43 58.88 Favored 'General case' 0 CA--C 1.55 0.95 0 C-N-CA 124.804 1.242 . . . . 0.0 113.728 171.717 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 93.7 mt -108.07 104.92 14.46 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 125.688 1.595 . . . . 0.0 108.769 170.28 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 80.2 p -96.81 -11.81 24.43 Favored 'General case' 0 N--CA 1.474 0.75 0 N-CA-C 115.453 1.649 . . . . 0.0 115.453 -169.451 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -163.05 174.77 39.4 Favored Glycine 0 CA--C 1.537 1.441 0 C-N-CA 124.57 1.081 . . . . 0.0 113.5 -179.087 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 54.5 Cg_exo -57.69 134.58 63.88 Favored 'Trans proline' 0 CA--C 1.536 0.617 0 C-N-CA 123.194 2.596 . . . . 0.0 112.845 -178.409 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 23.2 m 53.11 32.39 12.99 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 125.394 1.478 . . . . 0.0 114.806 -178.973 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 23.3 t -60.39 139.31 57.74 Favored 'General case' 0 N--CA 1.474 0.767 0 C-N-CA 124.242 1.017 . . . . 0.0 112.184 177.657 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.256 0 C-N-CA 125.561 1.553 . . . . 0.0 113.907 -178.93 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.654 0 N-CA-C 111.683 -0.567 . . . . 0.0 111.683 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 31.6 m -67.74 154.08 42.3 Favored 'General case' 0 N--CA 1.477 0.889 0 C-N-CA 124.518 1.127 . . . . 0.0 113.276 -179.308 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 26.2 m -63.8 143.27 57.98 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 124.68 1.192 . . . . 0.0 112.584 178.104 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 163.83 -151.79 21.36 Favored Glycine 0 CA--C 1.534 1.265 0 C-N-CA 124.23 0.919 . . . . 0.0 113.304 -177.445 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 20.0 m 57.99 26.44 13.47 Favored 'General case' 0 N--CA 1.479 1.008 0 N-CA-C 115.639 1.718 . . . . 0.0 115.639 175.081 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 9.9 t -149.81 145.28 26.51 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 124.994 1.318 . . . . 0.0 111.581 175.662 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -93.94 -166.57 37.27 Favored Glycine 0 CA--C 1.541 1.695 0 C-N-CA 125.298 1.428 . . . . 0.0 114.204 178.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -59.31 150.0 77.39 Favored 'Trans proline' 0 CA--C 1.538 0.697 0 C-N-CA 123.863 3.042 . . . . 0.0 113.169 173.508 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 1.7 pp -131.55 160.17 42.55 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.794 0 C-N-CA 125.423 1.489 . . . . 0.0 112.98 -176.112 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 57.3 p -79.56 -16.21 56.32 Favored 'General case' 0 N--CA 1.474 0.73 0 C-N-CA 124.887 1.275 . . . . 0.0 114.086 178.645 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -79.78 58.8 2.92 Favored 'General case' 0 CA--C 1.548 0.869 0 C-N-CA 125.648 1.579 . . . . 0.0 111.623 178.391 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 63.7 ttt180 -70.1 119.82 14.87 Favored 'General case' 0 N--CA 1.471 0.617 0 C-N-CA 125.522 1.529 . . . . 0.0 110.796 -177.133 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -119.29 142.1 48.39 Favored 'General case' 0 N--CA 1.471 0.588 0 C-N-CA 124.86 1.264 . . . . 0.0 111.952 -173.592 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 25.6 tp60 -60.24 -31.09 69.86 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 124.112 0.965 . . . . 0.0 112.205 176.525 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 21.3 m-20 -67.35 -17.55 64.8 Favored 'General case' 0 CA--C 1.543 0.691 0 C-N-CA 125.206 1.402 . . . . 0.0 113.903 178.017 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -85.52 -4.58 59.2 Favored 'General case' 0 CA--C 1.545 0.763 0 C-N-CA 123.88 0.872 . . . . 0.0 113.062 173.205 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 31.5 m -102.74 138.23 39.92 Favored 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 124.679 1.192 . . . . 0.0 109.429 170.679 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 8.0 m -104.14 146.61 11.35 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.686 0 C-N-CA 124.528 1.131 . . . . 0.0 109.899 170.156 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 18.9 t80 -95.68 143.6 26.81 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 125.85 1.66 . . . . 0.0 109.607 169.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 24.3 t -130.97 111.37 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 C-N-CA 125.68 1.592 . . . . 0.0 109.04 176.659 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -108.39 146.01 16.42 Favored Glycine 0 CA--C 1.53 1.015 0 C-N-CA 124.487 1.041 . . . . 0.0 112.762 177.82 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 98.57 31.31 6.46 Favored Glycine 0 CA--C 1.534 1.278 0 C-N-CA 124.571 1.082 . . . . 0.0 114.223 175.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 76.2 mt -73.17 171.37 13.09 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 125.678 1.591 . . . . 0.0 111.977 -176.597 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 7.9 t70 -130.96 164.41 25.4 Favored 'General case' 0 CA--C 1.539 0.544 0 C-N-CA 124.117 0.967 . . . . 0.0 112.186 179.031 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -59.81 -17.7 38.06 Favored 'General case' 0 N--CA 1.479 0.988 0 N-CA-C 115.699 1.74 . . . . 0.0 115.699 -169.541 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 3.0 mppt? -84.18 -16.08 44.71 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 125.211 1.404 . . . . 0.0 113.637 176.141 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 60.1 t -71.72 139.3 20.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.8 0 C-N-CA 124.655 1.182 . . . . 0.0 110.892 178.358 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 89.4 p -137.06 161.91 34.8 Favored 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 124.964 1.306 . . . . 0.0 112.216 176.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -59.48 -39.93 75.83 Favored Pre-proline 0 CA--C 1.546 0.806 0 O-C-N 120.854 -1.154 . . . . 0.0 113.346 177.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 75.4 Cg_exo -61.76 -31.57 85.86 Favored 'Trans proline' 0 C--N 1.351 0.688 0 C-N-CA 122.577 2.184 . . . . 0.0 113.959 169.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 27.8 tp -67.81 -50.69 55.46 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-N 119.24 0.927 . . . . 0.0 109.959 174.252 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 18.0 mt -61.08 -24.39 66.19 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 112.856 0.687 . . . . 0.0 112.856 178.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.7 t90 -72.79 -66.03 0.72 Allowed 'General case' 0 C--N 1.329 -0.29 0 C-N-CA 123.16 0.584 . . . . 0.0 111.123 171.074 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -64.78 -30.56 71.57 Favored 'General case' 0 N--CA 1.473 0.675 0 N-CA-C 114.189 1.181 . . . . 0.0 114.189 -172.624 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.6 tp -69.28 -33.2 72.86 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 123.81 0.844 . . . . 0.0 111.934 175.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -90.87 -10.51 42.37 Favored 'General case' 0 CA--C 1.538 0.494 0 C-N-CA 125.227 1.411 . . . . 0.0 113.397 -175.493 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 47.6 mt -55.77 -18.68 8.95 Favored 'General case' 0 CA--C 1.544 0.749 0 N-CA-C 113.807 1.04 . . . . 0.0 113.807 169.307 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 40.9 mt-30 -64.24 -32.74 74.44 Favored 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 125.264 1.425 . . . . 0.0 112.634 172.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -78.89 -44.54 22.54 Favored 'General case' 0 CA--C 1.539 0.545 0 C-N-CA 123.205 0.602 . . . . 0.0 112.593 177.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 177.34 -172.67 45.51 Favored Glycine 0 CA--C 1.537 1.414 0 C-N-CA 124.678 1.132 . . . . 0.0 112.868 -178.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.1 Cg_endo -67.85 109.26 1.86 Allowed 'Trans proline' 0 CA--C 1.539 0.749 0 C-N-CA 123.768 2.979 . . . . 0.0 111.764 -179.037 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 70.3 t -84.89 135.23 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.609 0 C-N-CA 124.974 1.31 . . . . 0.0 109.907 173.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.2 t -110.5 -33.4 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 126.356 1.862 . . . . 0.0 111.931 -171.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 19.9 t30 -160.78 159.73 30.36 Favored 'General case' 0 CA--C 1.553 1.067 0 C-N-CA 125.826 1.65 . . . . 0.0 111.217 -174.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 6.1 p -136.93 155.61 49.52 Favored 'General case' 0 N--CA 1.481 1.08 0 C-N-CA 125.942 1.697 . . . . 0.0 111.882 171.495 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 -142.36 133.8 26.47 Favored 'General case' 0 N--CA 1.468 0.426 0 C-N-CA 123.734 0.814 . . . . 0.0 111.122 175.295 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 86.0 mtp -134.7 105.59 10.76 Favored Pre-proline 0 N--CA 1.47 0.566 0 C-N-CA 124.171 0.989 . . . . 0.0 109.561 169.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_exo -57.53 137.81 83.15 Favored 'Trans proline' 0 CA--C 1.537 0.627 0 C-N-CA 123.153 2.568 . . . . 0.0 112.64 177.61 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 45.3 mmtm -103.21 152.45 21.46 Favored 'General case' 0 N--CA 1.478 0.948 0 C-N-CA 124.967 1.307 . . . . 0.0 112.726 -174.612 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -78.11 143.66 37.14 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 126.164 1.786 . . . . 0.0 111.768 176.177 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 40.3 ptt180 -84.46 3.41 36.38 Favored 'General case' 0 N--CA 1.479 1.003 0 N-CA-C 115.91 1.819 . . . . 0.0 115.91 -176.041 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 19.9 t -132.91 -40.3 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.958 0 C-N-CA 125.546 1.539 . . . . 0.0 111.184 -174.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 68.8 p -102.19 -20.67 14.59 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 124.837 1.255 . . . . 0.0 112.438 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 73.62 -1.58 44.07 Favored Glycine 0 CA--C 1.54 1.624 0 C-N-CA 124.735 1.16 . . . . 0.0 115.94 172.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 7.7 pt20 -83.67 174.53 10.43 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.983 1.313 . . . . 0.0 110.824 169.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 33.1 p80 -68.08 157.23 35.72 Favored 'General case' 0 N--CA 1.473 0.688 0 O-C-N 120.827 -1.17 . . . . 0.0 113.471 -179.172 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 -81.07 15.93 1.7 Allowed 'General case' 0 CA--C 1.552 1.055 0 C-N-CA 124.942 1.297 . . . . 0.0 114.296 -177.295 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 87.54 2.67 82.01 Favored Glycine 0 CA--C 1.536 1.381 0 O-C-N 120.651 -1.281 . . . . 0.0 115.056 -178.529 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 39.8 p90 -143.6 161.37 38.67 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 124.778 1.231 . . . . 0.0 112.739 176.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -151.61 -177.86 25.8 Favored Glycine 0 CA--C 1.53 0.992 0 C-N-CA 125.956 1.741 . . . . 0.0 113.128 -177.756 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 85.6 m-85 -143.63 149.51 37.42 Favored 'General case' 0 C--O 1.237 0.407 0 C-N-CA 126.034 1.733 . . . . 0.0 111.655 -178.286 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 15.8 t -133.74 127.95 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.826 0 C-N-CA 124.923 1.289 . . . . 0.0 109.974 175.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -106.53 125.33 50.87 Favored 'General case' 0 N--CA 1.465 0.323 0 C-N-CA 124.703 1.201 . . . . 0.0 111.31 -175.894 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 78.0 m-85 -101.92 160.43 14.5 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 125.083 1.353 . . . . 0.0 112.549 179.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.7 tp -61.37 -35.46 77.52 Favored 'General case' 0 CA--C 1.539 0.557 0 C-N-CA 123.391 0.676 . . . . 0.0 112.242 177.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 13.2 m -141.41 154.56 45.68 Favored 'General case' 0 N--CA 1.468 0.446 0 C-N-CA 124.749 1.22 . . . . 0.0 111.877 -178.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 54.7 mt-10 -62.38 -33.99 75.82 Favored 'General case' 0 CA--C 1.537 0.449 0 C-N-CA 124.361 1.065 . . . . 0.0 113.025 -176.636 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -68.22 -25.6 65.28 Favored 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 113.381 0.882 . . . . 0.0 113.381 176.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 46.8 m-20 -77.67 -33.55 53.33 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 123.814 0.845 . . . . 0.0 111.354 173.563 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.61 -43.67 72.27 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 123.331 0.652 . . . . 0.0 111.362 172.103 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -60.04 -31.17 69.72 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 124.369 1.067 . . . . 0.0 112.648 178.308 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 63.1 t80 -79.9 -34.59 38.9 Favored 'General case' 0 CA--C 1.536 0.412 0 C-N-CA 124.225 1.01 . . . . 0.0 113.114 174.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.45 -37.61 87.96 Favored 'General case' 0 CA--C 1.535 0.398 0 O-C-N 121.084 -1.01 . . . . 0.0 111.149 176.499 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 61.9 mt -61.48 -41.28 89.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 C-N-CA 124.834 1.254 . . . . 0.0 111.074 172.627 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 25.6 ttmm -61.73 -38.67 88.81 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.99 0.916 . . . . 0.0 112.448 179.09 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 45.9 pt -94.24 -32.72 4.77 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.684 0 N-CA-C 115.183 1.549 . . . . 0.0 115.183 -177.124 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' MET . . . . . 0.474 ' HA ' HD12 ' A' ' 80' ' ' ILE . 10.7 mmt -96.72 -0.69 47.87 Favored 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 115.351 1.612 . . . . 0.0 115.351 -171.874 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 26.5 t0 -83.78 139.08 32.93 Favored 'General case' 0 CA--C 1.538 0.512 0 O-C-N 121.341 -0.849 . . . . 0.0 111.943 178.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 23.6 mtp 58.21 13.38 2.3 Favored 'General case' 0 CA--C 1.546 0.818 0 C-N-CA 126.177 1.791 . . . . 0.0 115.318 -171.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.474 HD12 ' HA ' ' A' ' 77' ' ' MET . 1.7 mt -70.13 155.24 7.74 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 C-N-CA 125.429 1.492 . . . . 0.0 110.002 168.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 46.2 mtpt -113.28 71.42 0.74 Allowed 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.916 1.286 . . . . 0.0 112.568 -176.011 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 23.4 tp -58.47 127.48 32.34 Favored 'General case' 0 CA--C 1.544 0.748 0 C-N-CA 123.888 0.875 . . . . 0.0 109.905 174.647 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 84.4 m-85 47.01 28.61 0.91 Allowed 'General case' 0 CA--C 1.561 1.378 0 N-CA-C 116.217 1.932 . . . . 0.0 116.217 -168.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 76.32 32.55 51.44 Favored Glycine 0 CA--C 1.54 1.594 0 O-C-N 120.153 -1.592 . . . . 0.0 115.013 177.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 80.0 tttt -145.57 118.91 5.34 Favored Pre-proline 0 CA--C 1.542 0.638 0 C-N-CA 128.274 2.63 . . . . 0.0 107.848 -172.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -69.79 123.35 10.0 Favored 'Trans proline' 0 CA--C 1.537 0.638 0 C-N-CA 122.623 2.216 . . . . 0.0 112.521 -169.52 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 17.7 pt -95.92 146.75 6.7 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 C-N-CA 125.371 1.468 . . . . 0.0 111.379 173.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 38.9 mmm-85 -111.14 137.87 48.27 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 124.51 1.124 . . . . 0.0 110.797 170.743 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 26.5 t -131.46 136.42 57.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.69 0 C-N-CA 124.407 1.083 . . . . 0.0 111.13 -173.077 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 1.6 p-10 -156.05 171.64 19.77 Favored 'General case' 0 N--CA 1.473 0.721 0 C-N-CA 125.81 1.644 . . . . 0.0 111.509 178.339 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.0 mmmm -59.55 140.83 55.97 Favored 'General case' 0 N--CA 1.479 0.978 0 O-C-N 121.449 -0.782 . . . . 0.0 109.035 171.48 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -70.69 -4.13 22.05 Favored 'General case' 0 CA--C 1.55 0.971 0 CA-C-N 119.317 0.962 . . . . 0.0 113.398 177.722 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 37.3 p -89.83 -16.8 29.38 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 127.149 2.18 . . . . 0.0 113.707 169.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -71.74 -10.67 60.12 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 114.584 1.327 . . . . 0.0 114.584 -170.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 27.5 m80 -72.15 -16.45 61.98 Favored 'General case' 0 CA--C 1.543 0.688 0 C-N-CA 124.213 1.005 . . . . 0.0 113.236 174.395 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 41.7 t-20 -81.64 152.72 27.01 Favored 'General case' 0 CA--C 1.549 0.926 0 C-N-CA 124.818 1.247 . . . . 0.0 112.309 179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 73.5 mmtt 60.97 166.89 0.09 Allowed 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 128.133 2.573 . . . . 0.0 115.385 -178.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 48.4 t30 -149.27 161.38 42.15 Favored 'General case' 0 CA--C 1.547 0.865 0 C-N-CA 126.119 1.767 . . . . 0.0 110.608 177.332 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 62.5 tp -79.02 130.48 35.57 Favored 'General case' 0 CA--C 1.542 0.659 0 C-N-CA 124.413 1.085 . . . . 0.0 111.204 175.324 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 48.0 m -124.08 -0.09 8.42 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 124.826 1.25 . . . . 0.0 114.351 -179.237 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -73.93 153.13 46.63 Favored Glycine 0 CA--C 1.542 1.746 0 O-C-N 121.365 -0.835 . . . . 0.0 113.62 179.222 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -72.58 151.23 52.39 Favored 'Trans proline' 0 CA--C 1.54 0.781 0 C-N-CA 123.667 2.912 . . . . 0.0 112.628 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 68.3 p -87.45 -18.57 29.61 Favored 'General case' 0 N--CA 1.475 0.799 0 C-N-CA 124.805 1.242 . . . . 0.0 114.253 179.049 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 9.3 t -153.07 162.66 41.06 Favored 'General case' 0 N--CA 1.471 0.601 0 C-N-CA 125.798 1.639 . . . . 0.0 111.654 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.147 0 C-N-CA 125.633 1.587 . . . . 0.0 112.843 -179.077 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.636 0 N-CA-C 112.085 -0.406 . . . . 0.0 112.085 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 38.2 t -148.58 152.56 36.99 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.179 1.392 . . . . 0.0 111.809 178.166 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 72.3 p -75.67 -23.33 56.23 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 124.728 1.211 . . . . 0.0 113.175 170.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 69.35 7.39 57.4 Favored Glycine 0 CA--C 1.539 1.593 0 C-N-CA 124.805 1.193 . . . . 0.0 115.069 -175.084 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 72.3 m -57.16 126.95 29.53 Favored 'General case' 0 N--CA 1.472 0.634 0 CA-C-N 118.73 1.265 . . . . 0.0 112.642 -173.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 7.4 m 59.31 13.53 3.17 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 125.951 1.7 . . . . 0.0 115.293 -178.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -72.84 135.68 21.97 Favored Glycine 0 CA--C 1.543 1.797 0 O-C-N 121.209 -0.932 . . . . 0.0 113.43 -176.678 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -78.88 -23.82 7.64 Favored 'Trans proline' 0 CA--C 1.541 0.861 0 C-N-CA 123.406 2.738 . . . . 0.0 114.217 -177.599 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.4 HG13 ' H ' ' A' ' 11' ' ' GLU . 8.3 tp -148.74 145.41 18.18 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.771 0 C-N-CA 125.43 1.492 . . . . 0.0 111.364 178.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 67.8 p -111.73 -8.89 14.14 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 125.696 1.599 . . . . 0.0 113.95 177.609 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.4 ' H ' HG13 ' A' ' 9' ' ' ILE . 40.9 mt-10 -87.1 -22.91 25.1 Favored 'General case' 0 N--CA 1.478 0.93 0 N-CA-C 113.96 1.096 . . . . 0.0 113.96 -173.516 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 10.0 mmm180 -143.1 154.16 43.65 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 126.877 2.071 . . . . 0.0 110.553 178.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 2.0 p-10 -75.46 43.09 0.23 Allowed 'General case' 0 CA--C 1.549 0.912 0 C-N-CA 125.683 1.593 . . . . 0.0 113.194 174.328 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 35.9 tt0 -67.52 -16.23 64.09 Favored 'General case' 0 CA--C 1.545 0.757 0 C-N-CA 124.862 1.265 . . . . 0.0 113.391 -170.241 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -72.71 -23.05 60.81 Favored 'General case' 0 CA--C 1.543 0.708 0 C-N-CA 124.587 1.155 . . . . 0.0 113.018 169.45 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.7 -2.82 58.84 Favored 'General case' 0 CA--C 1.545 0.75 0 C-N-CA 124.156 0.982 . . . . 0.0 112.37 170.36 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 20.4 m -100.17 142.6 31.42 Favored 'General case' 0 N--CA 1.47 0.536 0 C-N-CA 124.595 1.158 . . . . 0.0 109.64 171.029 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 18.1 m -110.41 148.35 13.96 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 124.871 1.268 . . . . 0.0 110.415 171.155 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 22.1 t80 -95.82 143.11 27.33 Favored 'General case' 0 CA--C 1.533 0.32 0 C-N-CA 126.012 1.725 . . . . 0.0 109.346 169.298 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.8 t -132.26 106.48 11.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 C-N-CA 125.724 1.61 . . . . 0.0 109.086 177.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -101.22 145.99 17.17 Favored Glycine 0 CA--C 1.53 1.023 0 C-N-CA 124.296 0.95 . . . . 0.0 112.543 176.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.88 33.66 5.99 Favored Glycine 0 CA--C 1.533 1.203 0 C-N-CA 124.474 1.035 . . . . 0.0 113.936 173.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 85.3 mt -74.98 151.28 38.81 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 125.312 1.445 . . . . 0.0 111.402 -174.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -90.48 157.44 17.56 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 123.979 0.912 . . . . 0.0 111.955 175.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -59.06 -20.13 50.45 Favored 'General case' 0 CA--C 1.547 0.851 0 N-CA-C 114.712 1.375 . . . . 0.0 114.712 179.404 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.4 mtmm -82.46 -7.48 59.64 Favored 'General case' 0 N--CA 1.477 0.886 0 C-N-CA 124.861 1.264 . . . . 0.0 114.183 174.691 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.9 t -77.93 138.82 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 C-N-CA 124.461 1.105 . . . . 0.0 111.479 177.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 51.8 m -136.55 162.12 34.0 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 125.212 1.405 . . . . 0.0 111.459 173.039 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -56.54 -40.03 81.99 Favored Pre-proline 0 CA--C 1.547 0.856 0 N-CA-C 114.572 1.323 . . . . 0.0 114.572 179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_exo -65.75 -28.5 51.61 Favored 'Trans proline' 0 C--N 1.353 0.798 0 C-N-CA 122.28 1.987 . . . . 0.0 113.617 173.752 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 20.4 tp -66.28 -53.08 41.02 Favored 'General case' 0 C--N 1.343 0.321 0 CA-C-N 118.645 0.657 . . . . 0.0 109.33 173.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 22.7 mt -55.47 -41.49 73.03 Favored 'General case' 0 N--CA 1.464 0.252 0 O-C-N 123.315 0.384 . . . . 0.0 111.281 -179.039 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.8 t90 -58.16 -62.96 1.45 Allowed 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 123.373 0.669 . . . . 0.0 111.32 177.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.8 mt-10 -64.62 -29.52 70.53 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 113.892 1.071 . . . . 0.0 113.892 -176.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.5 tp -72.37 -35.86 68.58 Favored 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 124.174 0.989 . . . . 0.0 112.101 176.416 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 11.2 m-85 -88.51 -10.66 48.21 Favored 'General case' 0 CA--C 1.539 0.528 0 C-N-CA 124.86 1.264 . . . . 0.0 113.446 -176.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 25.1 mt -52.69 -21.23 3.78 Favored 'General case' 0 N--CA 1.475 0.821 0 N-CA-C 114.125 1.157 . . . . 0.0 114.125 169.161 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 42.2 mt-30 -63.61 -32.6 74.12 Favored 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 125.389 1.476 . . . . 0.0 112.756 174.524 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.02 -45.82 19.41 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 123.501 0.72 . . . . 0.0 112.559 176.817 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -178.57 -174.54 44.9 Favored Glycine 0 CA--C 1.535 1.319 0 C-N-CA 124.356 0.979 . . . . 0.0 113.176 178.394 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_endo -66.68 113.12 2.62 Favored 'Trans proline' 0 CA--C 1.538 0.677 0 C-N-CA 123.651 2.901 . . . . 0.0 111.549 -179.277 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 85.1 t -87.64 134.92 26.61 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 C-N-CA 125.046 1.338 . . . . 0.0 109.959 175.984 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.3 t -110.03 -33.54 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 C-N-CA 126.81 2.044 . . . . 0.0 111.94 -171.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 19.6 t30 -160.63 159.65 30.68 Favored 'General case' 0 CA--C 1.552 1.039 0 C-N-CA 125.961 1.704 . . . . 0.0 110.911 -174.503 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 6.7 p -137.45 154.81 49.86 Favored 'General case' 0 N--CA 1.481 1.116 0 C-N-CA 125.812 1.645 . . . . 0.0 111.614 171.652 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 43.1 t-80 -142.43 133.94 26.55 Favored 'General case' 0 N--CA 1.467 0.392 0 C-N-CA 123.599 0.76 . . . . 0.0 111.291 175.643 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 84.0 mtp -134.52 105.45 10.95 Favored Pre-proline 0 N--CA 1.47 0.575 0 C-N-CA 124.136 0.974 . . . . 0.0 109.137 169.615 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 81.2 Cg_exo -58.09 139.98 92.42 Favored 'Trans proline' 0 CA--C 1.536 0.579 0 C-N-CA 122.882 2.388 . . . . 0.0 113.017 178.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 44.0 mmtm -108.7 149.74 28.55 Favored 'General case' 0 N--CA 1.474 0.746 0 C-N-CA 125.228 1.411 . . . . 0.0 112.468 -174.568 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -67.87 138.33 55.98 Favored 'General case' 0 CA--C 1.543 0.683 0 C-N-CA 125.525 1.53 . . . . 0.0 111.917 172.419 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 53.6 ptt85 -80.02 7.87 8.2 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 115.947 1.832 . . . . 0.0 115.947 -173.106 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 31.8 t -132.13 -37.44 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.072 0 C-N-CA 124.942 1.297 . . . . 0.0 111.433 -174.802 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 65.6 p -114.91 -14.23 11.91 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 125.69 1.596 . . . . 0.0 112.697 -175.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.29 6.54 57.92 Favored Glycine 0 CA--C 1.537 1.453 0 C-N-CA 125.075 1.322 . . . . 0.0 115.542 174.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 71.1 mm-40 -79.18 159.33 27.43 Favored 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 124.67 1.188 . . . . 0.0 110.662 176.121 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 15.9 p80 -68.03 150.89 47.88 Favored 'General case' 0 N--CA 1.473 0.699 0 O-C-N 120.892 -1.13 . . . . 0.0 112.266 177.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 28.8 mt-30 -86.23 19.05 2.84 Favored 'General case' 0 CA--C 1.549 0.94 0 N-CA-C 114.316 1.228 . . . . 0.0 114.316 -172.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.27 3.3 78.96 Favored Glycine 0 CA--C 1.534 1.254 0 C-N-CA 125.097 1.332 . . . . 0.0 115.131 179.478 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 46.4 p90 -145.59 159.84 42.54 Favored 'General case' 0 CA--C 1.539 0.523 0 C-N-CA 124.822 1.249 . . . . 0.0 112.566 178.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -150.78 -176.25 23.53 Favored Glycine 0 CA--C 1.529 0.946 0 C-N-CA 125.792 1.663 . . . . 0.0 113.396 -178.176 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -144.71 149.02 34.88 Favored 'General case' 0 C--O 1.237 0.414 0 C-N-CA 126.21 1.804 . . . . 0.0 111.63 -178.106 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.3 t -132.8 127.01 55.16 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.697 0 C-N-CA 124.42 1.088 . . . . 0.0 110.028 175.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 77.6 tt0 -103.45 119.71 39.42 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 124.784 1.234 . . . . 0.0 111.049 -177.031 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 88.8 m-85 -95.54 163.13 13.34 Favored 'General case' 0 C--O 1.235 0.319 0 C-N-CA 125.111 1.364 . . . . 0.0 112.366 176.459 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 12.7 tp -63.37 -32.79 74.31 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 123.325 0.65 . . . . 0.0 112.376 175.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.6 m -145.08 157.6 44.06 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-O 122.662 1.22 . . . . 0.0 112.903 -175.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -64.46 -32.66 74.39 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 124.872 1.269 . . . . 0.0 113.404 -175.413 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -70.31 -26.87 63.98 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 123.848 0.859 . . . . 0.0 113.036 176.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 59.6 m-20 -75.74 -33.42 60.26 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 123.849 0.86 . . . . 0.0 111.129 173.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -67.11 -45.86 75.94 Favored 'General case' 0 CA--C 1.54 0.587 0 C-N-CA 122.932 0.493 . . . . 0.0 111.359 170.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -55.29 -36.23 65.92 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 123.599 0.76 . . . . 0.0 112.592 174.229 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 21.4 t80 -73.93 -37.8 64.48 Favored 'General case' 0 CA--C 1.535 0.388 0 O-C-N 121.669 -0.644 . . . . 0.0 112.163 177.718 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -65.17 -35.95 82.71 Favored 'General case' 0 CA--C 1.537 0.446 0 O-C-N 120.682 -1.261 . . . . 0.0 111.52 176.525 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 63.6 mt -63.77 -34.53 68.61 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.693 0 C-N-CA 124.277 1.031 . . . . 0.0 111.033 172.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 63.1 tttp -67.95 -41.71 82.04 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 124.062 0.945 . . . . 0.0 112.523 176.784 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 19.2 pt -92.69 -38.28 9.86 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.701 0 N-CA-C 115.041 1.497 . . . . 0.0 115.041 -175.29 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' MET . . . . . 0.481 ' HA ' HD12 ' A' ' 80' ' ' ILE . 15.2 mmt -91.51 0.56 57.49 Favored 'General case' 0 N--CA 1.48 1.055 0 N-CA-C 114.863 1.431 . . . . 0.0 114.863 -169.794 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -85.82 137.34 32.85 Favored 'General case' 0 CA--C 1.538 0.514 0 O-C-N 121.44 -0.787 . . . . 0.0 112.057 179.64 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 24.1 mmt 59.61 9.59 1.63 Allowed 'General case' 0 CA--C 1.55 0.945 0 C-N-CA 126.238 1.815 . . . . 0.0 115.059 -170.794 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.481 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.5 mt -68.01 152.42 9.59 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 C-N-CA 124.981 1.312 . . . . 0.0 110.061 169.291 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.0 mtpt -112.78 70.21 0.71 Allowed 'General case' 0 N--CA 1.472 0.639 0 C-N-CA 125.05 1.34 . . . . 0.0 112.289 -176.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 31.9 tp -57.64 125.02 21.1 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 124.068 0.947 . . . . 0.0 109.926 175.194 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 57.2 m-85 46.0 28.77 0.66 Allowed 'General case' 0 CA--C 1.561 1.382 0 N-CA-C 116.289 1.959 . . . . 0.0 116.289 -168.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.5 26.71 56.39 Favored Glycine 0 CA--C 1.542 1.745 0 O-C-N 120.183 -1.573 . . . . 0.0 115.903 176.688 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -137.18 120.44 11.74 Favored Pre-proline 0 CA--C 1.542 0.673 0 C-N-CA 128.268 2.627 . . . . 0.0 107.813 -179.364 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -70.19 127.1 13.79 Favored 'Trans proline' 0 CA--C 1.536 0.615 0 C-N-CA 122.878 2.385 . . . . 0.0 112.497 -170.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 17.1 pt -98.86 145.34 10.31 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.472 0 C-N-CA 125.496 1.519 . . . . 0.0 112.215 177.082 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 46.4 tpt85 -114.02 129.18 56.62 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 126.389 1.876 . . . . 0.0 109.522 178.515 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.5 t -128.15 135.79 61.84 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 124.156 0.983 . . . . 0.0 111.787 -171.03 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -153.93 173.73 15.56 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 126.135 1.774 . . . . 0.0 110.613 175.904 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 22.6 mmmt -57.75 143.33 42.33 Favored 'General case' 0 N--CA 1.479 1.014 0 C-N-CA 123.809 0.844 . . . . 0.0 109.298 170.86 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -70.27 -13.74 62.3 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 113.106 0.78 . . . . 0.0 113.106 179.312 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 23.1 t -139.6 128.84 23.94 Favored 'General case' 0 N--CA 1.467 0.38 0 C-N-CA 125.967 1.707 . . . . 0.0 108.338 166.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -134.26 22.46 3.76 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 124.688 1.195 . . . . 0.0 112.607 -171.369 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 92.6 m-70 -89.0 38.86 0.91 Allowed 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 125.271 1.429 . . . . 0.0 113.575 -172.185 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 49.5 p-10 -76.41 47.59 0.48 Allowed 'General case' 0 CA--C 1.551 1.009 0 C-N-CA 125.615 1.566 . . . . 0.0 112.73 176.134 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 97.5 mttt -69.52 -15.35 63.23 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 126.769 2.028 . . . . 0.0 114.354 -169.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 28.4 t-20 -133.73 137.57 45.3 Favored 'General case' 0 CA--C 1.543 0.692 0 C-N-CA 126.031 1.732 . . . . 0.0 109.927 169.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 10.7 mp -99.9 141.06 33.23 Favored 'General case' 0 CA--C 1.538 0.517 0 C-N-CA 124.419 1.088 . . . . 0.0 111.426 -177.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 11.0 t -85.47 154.22 21.95 Favored 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 124.599 1.16 . . . . 0.0 112.704 177.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 178.08 49.16 0.07 OUTLIER Glycine 0 CA--C 1.542 1.729 0 CA-C-O 118.485 -1.175 . . . . 0.0 115.235 175.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 80.0 Cg_endo -66.85 -21.41 50.64 Favored 'Trans proline' 0 CA--C 1.542 0.889 0 C-N-CA 123.206 2.604 . . . . 0.0 113.934 -176.038 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 19.6 m -78.01 -13.14 59.98 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 124.867 1.267 . . . . 0.0 114.161 -179.634 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 55.5 m -73.94 148.15 42.44 Favored 'General case' 0 N--CA 1.473 0.708 0 C-N-CA 124.45 1.1 . . . . 0.0 112.953 -178.171 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.178 0 CA-C-O 118.214 -1.326 . . . . 0.0 112.772 179.429 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.684 0 N-CA-C 112.041 -0.424 . . . . 0.0 112.041 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 47.1 p -76.0 156.17 34.31 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 124.617 1.167 . . . . 0.0 113.243 177.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 63.4 p -86.95 161.67 18.11 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 125.337 1.455 . . . . 0.0 112.975 177.166 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 72.26 -161.02 54.25 Favored Glycine 0 CA--C 1.537 1.458 0 C-N-CA 124.191 0.9 . . . . 0.0 114.033 -178.273 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 56.0 p -74.47 152.32 39.45 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 124.807 1.243 . . . . 0.0 113.152 179.703 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 88.5 p -145.33 164.47 31.36 Favored 'General case' 0 N--CA 1.474 0.74 0 C-N-CA 125.155 1.382 . . . . 0.0 112.549 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -177.91 173.02 45.66 Favored Glycine 0 CA--C 1.539 1.571 0 C-N-CA 124.579 1.085 . . . . 0.0 113.491 179.161 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -73.97 163.52 36.67 Favored 'Trans proline' 0 CA--C 1.539 0.771 0 C-N-CA 123.828 3.019 . . . . 0.0 113.266 -178.505 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.3 tp -72.35 152.68 7.9 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 124.238 1.015 . . . . 0.0 111.867 173.595 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 15.5 m -75.54 -9.74 58.84 Favored 'General case' 0 N--CA 1.472 0.638 0 N-CA-C 114.869 1.433 . . . . 0.0 114.869 -177.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 80.5 mm-40 -132.89 129.67 38.68 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 124.364 1.066 . . . . 0.0 112.984 -172.256 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 21.1 mtm180 55.34 -168.88 0.08 Allowed 'General case' 0 N--CA 1.482 1.127 0 C-N-CA 126.763 2.025 . . . . 0.0 114.07 177.793 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 43.4 p-10 -85.95 30.09 0.69 Allowed 'General case' 0 CA--C 1.546 0.819 0 C-N-CA 126.025 1.73 . . . . 0.0 113.38 176.375 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -66.32 -13.72 60.96 Favored 'General case' 0 CA--C 1.542 0.65 0 N-CA-C 115.58 1.696 . . . . 0.0 115.58 -169.329 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.4 m-20 -71.03 -22.62 62.12 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-N 119.604 1.093 . . . . 0.0 112.729 168.436 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -88.65 -1.18 57.93 Favored 'General case' 0 CA--C 1.548 0.883 0 C-N-CA 125.077 1.351 . . . . 0.0 112.658 169.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.5 m -100.09 134.78 42.51 Favored 'General case' 0 N--CA 1.473 0.688 0 C-N-CA 124.346 1.058 . . . . 0.0 110.212 171.66 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.6 m -106.11 147.42 11.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 124.468 1.107 . . . . 0.0 110.333 171.236 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 33.5 t80 -95.42 143.71 26.54 Favored 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 125.833 1.653 . . . . 0.0 109.324 169.546 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 20.0 t -130.61 112.68 23.21 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 C-N-CA 125.531 1.532 . . . . 0.0 109.127 175.62 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -110.52 145.49 17.29 Favored Glycine 0 CA--C 1.53 0.972 0 C-N-CA 124.493 1.044 . . . . 0.0 112.805 178.576 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 95.73 33.51 6.38 Favored Glycine 0 CA--C 1.533 1.163 0 C-N-CA 124.471 1.034 . . . . 0.0 113.843 175.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 84.0 mt -73.68 152.83 40.34 Favored 'General case' 0 C--O 1.234 0.271 0 C-N-CA 125.496 1.518 . . . . 0.0 111.428 -174.49 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -92.33 157.48 16.61 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 123.677 0.791 . . . . 0.0 111.953 174.018 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -58.6 -20.82 50.54 Favored 'General case' 0 CA--C 1.546 0.823 0 O-C-N 120.543 -1.348 . . . . 0.0 114.58 179.112 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 60.5 mtpt -77.42 -12.89 60.01 Favored 'General case' 0 N--CA 1.475 0.784 0 N-CA-C 114.302 1.223 . . . . 0.0 114.302 174.4 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 78.9 t -74.62 141.19 16.34 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.911 0 C-N-CA 124.509 1.124 . . . . 0.0 111.689 -178.655 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 94.1 p -136.08 163.51 30.16 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 125.315 1.446 . . . . 0.0 111.969 175.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -59.27 -43.63 97.0 Favored Pre-proline 0 CA--C 1.546 0.807 0 O-C-N 120.745 -1.222 . . . . 0.0 113.025 176.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 80.4 Cg_exo -57.64 -31.03 90.78 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 122.509 2.139 . . . . 0.0 114.146 171.232 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 27.7 tp -68.71 -51.28 43.32 Favored 'General case' 0 C--N 1.343 0.322 0 CA-C-N 119.072 0.851 . . . . 0.0 110.261 173.459 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 21.3 mt -61.29 -22.56 64.97 Favored 'General case' 0 N--CA 1.467 0.381 0 N-CA-C 113.094 0.776 . . . . 0.0 113.094 178.633 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.6 t90 -73.61 -67.5 0.59 Allowed 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 123.233 0.613 . . . . 0.0 110.83 170.404 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.8 mt-10 -64.72 -30.13 71.14 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 114.206 1.187 . . . . 0.0 114.206 -172.11 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.0 tp -69.65 -33.3 72.4 Favored 'General case' 0 CA--C 1.541 0.629 0 C-N-CA 123.711 0.804 . . . . 0.0 111.969 175.46 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 18.3 m-85 -90.43 -10.96 41.88 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.048 1.339 . . . . 0.0 113.306 -175.125 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 49.2 mt -54.89 -19.11 5.88 Favored 'General case' 0 CA--C 1.545 0.772 0 C-N-CA 124.517 1.127 . . . . 0.0 114.038 169.648 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 41.2 mt-30 -65.0 -32.72 74.59 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 125.443 1.497 . . . . 0.0 112.678 173.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -78.91 -45.49 20.44 Favored 'General case' 0 CA--C 1.539 0.526 0 C-N-CA 123.44 0.696 . . . . 0.0 112.451 176.897 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.18 -173.8 45.84 Favored Glycine 0 CA--C 1.536 1.354 0 C-N-CA 124.852 1.215 . . . . 0.0 112.855 177.776 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 55.5 Cg_endo -66.1 113.83 2.77 Favored 'Trans proline' 0 CA--C 1.537 0.656 0 C-N-CA 123.614 2.876 . . . . 0.0 111.795 -179.005 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 93.9 t -87.32 135.23 25.76 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.602 0 C-N-CA 125.179 1.391 . . . . 0.0 109.792 174.753 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.2 t -109.71 -34.13 2.5 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 C-N-CA 126.614 1.965 . . . . 0.0 111.746 -171.691 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 20.4 t30 -160.68 163.35 32.51 Favored 'General case' 0 CA--C 1.554 1.119 0 C-N-CA 126.023 1.729 . . . . 0.0 111.066 -175.05 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 2.7 p -142.04 153.58 44.32 Favored 'General case' 0 N--CA 1.48 1.075 0 C-N-CA 126.484 1.913 . . . . 0.0 111.207 175.534 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -142.06 129.74 21.55 Favored 'General case' 0 N--CA 1.47 0.537 0 C-N-CA 123.642 0.777 . . . . 0.0 111.528 177.861 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 87.9 mtp -134.79 102.2 11.38 Favored Pre-proline 0 N--CA 1.472 0.669 0 C-N-CA 124.15 0.98 . . . . 0.0 109.482 169.614 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_exo -61.86 126.82 19.78 Favored 'Trans proline' 0 CA--C 1.537 0.675 0 C-N-CA 122.948 2.432 . . . . 0.0 113.307 -178.432 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 44.2 mmtm -92.67 150.78 20.47 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 124.77 1.228 . . . . 0.0 113.054 -175.358 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 19.9 t70 -67.67 137.92 55.93 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 124.839 1.256 . . . . 0.0 111.317 169.164 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 39.3 ptt180 -80.76 6.52 12.71 Favored 'General case' 0 N--CA 1.479 0.982 0 N-CA-C 116.107 1.892 . . . . 0.0 116.107 -172.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 30.5 t -131.12 -37.2 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.068 0 C-N-CA 125.068 1.347 . . . . 0.0 111.424 -175.38 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 69.7 p -107.8 -17.26 14.12 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 125.732 1.613 . . . . 0.0 112.484 -178.444 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 72.48 7.45 68.61 Favored Glycine 0 CA--C 1.538 1.512 0 C-N-CA 124.963 1.268 . . . . 0.0 115.8 171.197 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 -94.91 163.54 13.29 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 125.589 1.555 . . . . 0.0 111.477 176.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 14.9 p80 -68.74 157.53 36.15 Favored 'General case' 0 N--CA 1.472 0.632 0 O-C-N 121.391 -0.818 . . . . 0.0 112.712 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 37.9 mt-30 -99.41 23.9 8.75 Favored 'General case' 0 CA--C 1.547 0.836 0 C-N-CA 124.797 1.239 . . . . 0.0 113.473 -170.963 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.65 3.65 77.28 Favored Glycine 0 CA--C 1.535 1.301 0 C-N-CA 125.199 1.38 . . . . 0.0 115.251 178.408 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 44.0 p90 -145.86 161.17 40.61 Favored 'General case' 0 CA--C 1.539 0.551 0 CA-C-N 118.713 1.257 . . . . 0.0 112.994 179.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -154.4 -175.74 25.92 Favored Glycine 0 CA--C 1.531 1.088 0 C-N-CA 125.983 1.754 . . . . 0.0 113.118 -179.779 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 71.1 m-85 -144.4 152.49 40.77 Favored 'General case' 0 C--O 1.236 0.381 0 C-N-CA 126.101 1.76 . . . . 0.0 111.471 179.219 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 15.9 t -132.64 131.57 59.85 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 124.864 1.266 . . . . 0.0 109.73 175.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 61.3 tt0 -107.81 120.21 41.63 Favored 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 124.831 1.252 . . . . 0.0 110.674 -177.512 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -96.65 162.94 13.23 Favored 'General case' 0 C--N 1.329 -0.289 0 C-N-CA 125.012 1.325 . . . . 0.0 112.412 177.478 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.8 tp -64.02 -35.25 80.09 Favored 'General case' 0 CA--C 1.54 0.583 0 C-N-CA 123.107 0.563 . . . . 0.0 112.224 176.391 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 20.1 m -140.12 153.82 46.81 Favored 'General case' 0 N--CA 1.468 0.426 0 C-N-CA 124.649 1.18 . . . . 0.0 112.152 -176.549 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 45.9 mt-10 -58.42 -32.42 68.64 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 125.443 1.497 . . . . 0.0 112.785 178.186 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 14.1 mm-40 -67.97 -34.3 76.29 Favored 'General case' 0 N--CA 1.47 0.546 0 C-N-CA 124.659 1.184 . . . . 0.0 112.437 178.244 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 58.4 m-20 -75.75 -31.08 59.42 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 124.105 0.962 . . . . 0.0 111.353 176.559 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -70.64 -46.57 63.06 Favored 'General case' 0 CA--C 1.538 0.511 0 C-N-CA 123.708 0.803 . . . . 0.0 111.16 173.239 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -56.52 -36.11 68.82 Favored 'General case' 0 CA--C 1.542 0.651 0 C-N-CA 124.002 0.921 . . . . 0.0 112.558 174.726 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 25.6 t80 -71.51 -38.23 71.14 Favored 'General case' 0 CA--C 1.537 0.448 0 O-C-N 121.777 -0.577 . . . . 0.0 112.145 175.703 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -65.6 -36.56 84.09 Favored 'General case' 0 CA--C 1.537 0.462 0 O-C-N 120.784 -1.197 . . . . 0.0 111.72 176.517 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 59.4 mt -63.77 -34.0 65.33 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 123.991 0.916 . . . . 0.0 110.858 172.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -68.17 -42.9 79.33 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 123.966 0.906 . . . . 0.0 112.616 176.208 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 18.0 pt -91.22 -37.51 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 N-CA-C 114.916 1.451 . . . . 0.0 114.916 -175.045 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' MET . . . . . 0.48 ' HA ' HD12 ' A' ' 80' ' ' ILE . 15.4 mmt -91.76 0.12 57.51 Favored 'General case' 0 N--CA 1.479 1.02 0 N-CA-C 114.705 1.372 . . . . 0.0 114.705 -169.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -84.72 139.63 31.86 Favored 'General case' 0 CA--C 1.539 0.545 0 O-C-N 121.571 -0.705 . . . . 0.0 111.918 178.218 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 20.4 mmt 58.31 10.47 1.31 Allowed 'General case' 0 CA--C 1.55 0.946 0 N-CA-C 115.408 1.633 . . . . 0.0 115.408 -170.291 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.48 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.5 mt -70.28 152.44 8.98 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.637 0 C-N-CA 124.638 1.175 . . . . 0.0 110.285 169.403 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.1 mtpt -112.06 69.98 0.7 Allowed 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 125.145 1.378 . . . . 0.0 112.345 -176.666 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 29.6 tp -57.73 124.2 18.33 Favored 'General case' 0 CA--C 1.543 0.697 0 C-N-CA 124.156 0.982 . . . . 0.0 110.092 176.302 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 44.3 m-85 45.33 31.06 0.77 Allowed 'General case' 0 CA--C 1.56 1.354 0 N-CA-C 116.2 1.926 . . . . 0.0 116.2 -168.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 78.96 27.77 55.72 Favored Glycine 0 CA--C 1.54 1.64 0 O-C-N 120.234 -1.541 . . . . 0.0 115.811 175.58 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -138.84 120.6 10.2 Favored Pre-proline 0 CA--C 1.541 0.62 0 C-N-CA 128.325 2.65 . . . . 0.0 107.82 -179.575 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -69.65 123.42 10.12 Favored 'Trans proline' 0 CA--C 1.536 0.597 0 C-N-CA 122.964 2.443 . . . . 0.0 112.202 -171.649 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 17.8 pt -95.71 146.53 6.94 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 C-N-CA 125.314 1.445 . . . . 0.0 111.524 175.361 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 43.2 mmm-85 -109.88 137.24 47.95 Favored 'General case' 0 N--CA 1.471 0.598 0 C-N-CA 124.858 1.263 . . . . 0.0 110.73 170.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 24.4 t -130.65 137.56 55.8 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.788 0 C-N-CA 124.6 1.16 . . . . 0.0 111.063 -175.884 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 38.0 t-20 -161.42 178.0 9.56 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 126.1 1.76 . . . . 0.0 110.247 179.09 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 12.5 mmmm -57.17 140.84 48.35 Favored 'General case' 0 N--CA 1.474 0.763 0 C-N-CA 125.337 1.455 . . . . 0.0 110.666 171.437 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -67.36 -25.74 66.13 Favored 'General case' 0 CA--C 1.546 0.811 0 N-CA-C 113.491 0.923 . . . . 0.0 113.491 178.517 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 67.3 m -123.93 52.06 1.49 Allowed 'General case' 0 N--CA 1.474 0.769 0 C-N-CA 125.835 1.654 . . . . 0.0 111.529 176.127 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -62.13 154.76 26.16 Favored 'General case' 0 CA--C 1.547 0.858 0 C-N-CA 124.248 1.019 . . . . 0.0 113.563 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 73.5 m-70 -77.97 152.64 33.05 Favored 'General case' 0 N--CA 1.472 0.643 0 C-N-CA 124.54 1.136 . . . . 0.0 112.766 178.212 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 51.6 p-10 -121.78 21.28 10.79 Favored 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 126.2 1.8 . . . . 0.0 113.149 178.575 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 64.6 mtpt -66.64 145.22 55.82 Favored 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 125.51 1.524 . . . . 0.0 112.339 -174.316 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 50.7 p-10 -133.32 21.64 4.03 Favored 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 125.687 1.595 . . . . 0.0 113.89 -173.017 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 52.8 tp -63.33 137.78 58.3 Favored 'General case' 0 CA--C 1.545 0.766 0 C-N-CA 124.654 1.182 . . . . 0.0 112.131 -177.382 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 58.2 p -86.16 7.36 25.29 Favored 'General case' 0 N--CA 1.475 0.805 0 C-N-CA 125.811 1.644 . . . . 0.0 115.053 -175.753 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 84.28 -176.06 51.42 Favored Glycine 0 CA--C 1.542 1.729 0 C-N-CA 125.114 1.34 . . . . 0.0 114.022 -175.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 74.7 Cg_endo -71.25 154.42 61.56 Favored 'Trans proline' 0 CA--C 1.539 0.773 0 C-N-CA 123.794 2.996 . . . . 0.0 112.97 -177.213 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 51.8 p -80.65 -22.32 40.62 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 124.76 1.224 . . . . 0.0 113.933 176.275 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 46.9 m 60.87 166.43 0.08 Allowed 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 127.458 2.303 . . . . 0.0 115.582 -177.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.213 0 C-N-CA 125.259 1.409 . . . . 0.0 112.825 -178.718 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.648 0 N-CA-C 111.835 -0.506 . . . . 0.0 111.835 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 58.2 p -78.64 -15.89 57.98 Favored 'General case' 0 N--CA 1.477 0.908 0 N-CA-C 114.514 1.302 . . . . 0.0 114.514 -178.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 89.4 p -144.05 160.58 40.63 Favored 'General case' 0 N--CA 1.473 0.678 0 C-N-CA 125.877 1.671 . . . . 0.0 112.188 176.289 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 170.24 -177.39 43.53 Favored Glycine 0 CA--C 1.535 1.32 0 C-N-CA 124.874 1.226 . . . . 0.0 113.08 -179.466 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 46.7 m -72.3 145.86 47.55 Favored 'General case' 0 N--CA 1.474 0.731 0 C-N-CA 124.187 0.995 . . . . 0.0 112.467 177.661 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 67.5 m -137.89 153.01 49.58 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 125.435 1.494 . . . . 0.0 111.926 -179.515 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -73.93 171.22 52.45 Favored Glycine 0 CA--C 1.543 1.806 0 C-N-CA 124.015 0.817 . . . . 0.0 113.829 174.462 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 77.0 Cg_endo -78.43 70.34 7.29 Favored 'Trans proline' 0 CA--C 1.545 1.052 0 C-N-CA 124.427 3.418 . . . . 0.0 111.854 -179.179 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -72.85 -22.94 20.17 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.897 0 N-CA-C 114.12 1.156 . . . . 0.0 114.12 -178.849 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.6 m 59.79 -38.68 0.08 Allowed 'General case' 0 N--CA 1.481 1.123 0 C-N-CA 129.159 2.984 . . . . 0.0 117.232 -178.724 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -80.9 31.73 0.31 Allowed 'General case' 0 N--CA 1.477 0.911 0 C-N-CA 126.089 1.756 . . . . 0.0 113.838 -173.46 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 91.4 mmt-85 -140.16 -55.41 0.54 Allowed 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 125.913 1.685 . . . . 0.0 111.979 177.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . 0.276 1.0 OUTLIER 48.79 24.33 0.81 Allowed 'General case' 0 CA--C 1.55 0.955 0 C-N-CA 127.573 2.349 . . . . 0.0 116.862 178.325 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 84.2 mt-30 -68.27 -14.85 63.29 Favored 'General case' 0 N--CA 1.476 0.83 0 N-CA-C 114.096 1.147 . . . . 0.0 114.096 -174.541 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 25.9 m-20 -88.82 -24.37 22.6 Favored 'General case' 0 CA--C 1.541 0.617 0 N-CA-C 113.369 0.877 . . . . 0.0 113.369 172.187 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.71 -14.06 43.58 Favored 'General case' 0 CA--C 1.545 0.781 0 O-C-N 121.398 -0.814 . . . . 0.0 112.383 170.624 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 27.4 m -90.55 137.93 31.96 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 124.372 1.069 . . . . 0.0 109.863 168.29 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 16.9 m -103.98 149.09 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.657 0 C-N-CA 124.536 1.135 . . . . 0.0 110.334 169.699 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 9.8 t80 -94.97 143.3 26.59 Favored 'General case' 0 CA--C 1.535 0.385 0 C-N-CA 126.192 1.797 . . . . 0.0 108.595 168.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 23.2 t -132.49 109.59 14.97 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 C-N-CA 125.629 1.572 . . . . 0.0 109.231 178.328 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -106.72 143.23 15.76 Favored Glycine 0 CA--C 1.53 0.98 0 C-N-CA 124.274 0.94 . . . . 0.0 113.014 179.372 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 100.87 32.15 5.45 Favored Glycine 0 CA--C 1.535 1.294 0 C-N-CA 124.921 1.248 . . . . 0.0 114.135 175.303 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 83.0 mt -76.49 145.33 39.23 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 125.322 1.449 . . . . 0.0 111.508 -173.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -85.06 157.54 20.7 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 123.486 0.715 . . . . 0.0 112.342 175.597 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -57.79 -20.92 38.89 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 114.749 1.389 . . . . 0.0 114.749 178.576 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.8 mtmm -81.39 -8.22 59.7 Favored 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 124.711 1.204 . . . . 0.0 114.232 174.46 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.6 t -78.31 141.37 15.56 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.948 0 C-N-CA 124.537 1.135 . . . . 0.0 111.241 176.554 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 43.4 m -144.08 165.16 28.57 Favored 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 125.225 1.41 . . . . 0.0 110.676 169.36 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -54.74 -41.18 88.65 Favored Pre-proline 0 CA--C 1.547 0.836 0 N-CA-C 114.839 1.422 . . . . 0.0 114.839 -177.028 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -62.45 -28.02 77.64 Favored 'Trans proline' 0 C--N 1.354 0.843 0 C-N-CA 122.187 1.925 . . . . 0.0 113.608 175.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 20.5 tp -66.82 -55.19 15.97 Favored 'General case' 0 C--N 1.344 0.343 0 CA-C-N 118.393 0.542 . . . . 0.0 109.586 171.919 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 34.1 mt -55.89 -42.61 76.22 Favored 'General case' 0 N--CA 1.464 0.256 0 O-C-N 123.241 0.338 . . . . 0.0 111.388 -176.672 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 3.1 t90 -56.39 -62.32 1.8 Allowed 'General case' 0 CA--C 1.53 0.199 0 C-N-CA 123.552 0.741 . . . . 0.0 111.27 178.959 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 -65.25 -29.53 70.32 Favored 'General case' 0 N--CA 1.471 0.593 0 N-CA-C 113.645 0.98 . . . . 0.0 113.645 -177.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.8 tp -72.22 -36.26 69.09 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 124.081 0.952 . . . . 0.0 112.104 176.535 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 10.3 m-85 -88.32 -10.82 48.23 Favored 'General case' 0 CA--C 1.539 0.54 0 C-N-CA 124.904 1.281 . . . . 0.0 113.286 -176.241 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 23.3 mt -52.89 -21.7 4.6 Favored 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 114.041 1.126 . . . . 0.0 114.041 169.138 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 41.9 mt-30 -64.2 -32.08 73.53 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 125.338 1.455 . . . . 0.0 112.738 175.287 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.23 -45.53 19.62 Favored 'General case' 0 CA--C 1.538 0.502 0 C-N-CA 123.45 0.7 . . . . 0.0 112.521 176.654 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -179.05 -173.65 44.52 Favored Glycine 0 CA--C 1.536 1.378 0 C-N-CA 124.538 1.066 . . . . 0.0 113.008 177.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.5 Cg_endo -66.57 112.6 2.44 Favored 'Trans proline' 0 CA--C 1.537 0.675 0 C-N-CA 123.647 2.898 . . . . 0.0 111.616 -179.302 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 74.5 t -87.84 133.91 29.27 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 125.098 1.359 . . . . 0.0 109.901 175.649 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.7 t -111.88 -32.58 2.19 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 C-N-CA 126.314 1.845 . . . . 0.0 112.329 -169.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 14.6 t30 -160.21 162.08 33.69 Favored 'General case' 0 CA--C 1.553 1.083 0 C-N-CA 126.171 1.788 . . . . 0.0 110.68 -174.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 1.5 p -143.28 153.18 42.51 Favored 'General case' 0 N--CA 1.482 1.159 0 C-N-CA 126.313 1.845 . . . . 0.0 111.417 176.492 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 4.3 t60 -142.91 134.48 26.44 Favored 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 123.914 0.886 . . . . 0.0 111.187 175.358 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 82.2 mtp -136.07 105.15 9.56 Favored Pre-proline 0 N--CA 1.469 0.484 0 C-N-CA 124.099 0.959 . . . . 0.0 108.776 168.672 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_exo -53.62 139.92 66.31 Favored 'Trans proline' 0 CA--C 1.537 0.657 0 C-N-CA 123.397 2.732 . . . . 0.0 112.965 176.5 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 44.7 mmtm -112.22 157.96 20.27 Favored 'General case' 0 N--CA 1.476 0.833 0 C-N-CA 125.069 1.348 . . . . 0.0 113.294 -172.499 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -76.52 151.98 36.19 Favored 'General case' 0 CA--C 1.546 0.792 0 C-N-CA 127.024 2.13 . . . . 0.0 112.225 174.094 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 40.4 ptt180 -90.7 0.86 57.27 Favored 'General case' 0 N--CA 1.476 0.859 0 N-CA-C 116.462 2.023 . . . . 0.0 116.462 -172.666 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 3.6 m -136.28 -31.66 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.217 0 C-N-CA 124.362 1.065 . . . . 0.0 113.461 -178.756 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.3 p -106.97 -20.36 13.34 Favored 'General case' 0 N--CA 1.468 0.437 0 C-N-CA 124.7 1.2 . . . . 0.0 111.866 179.23 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 69.09 8.86 59.19 Favored Glycine 0 CA--C 1.541 1.682 0 C-N-CA 124.674 1.131 . . . . 0.0 115.329 -178.73 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 39.5 mt-30 -65.99 160.76 22.94 Favored 'General case' 0 N--CA 1.47 0.557 0 C-N-CA 125.253 1.421 . . . . 0.0 110.683 171.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 25.2 p80 -74.82 156.86 36.04 Favored 'General case' 0 N--CA 1.474 0.77 0 O-C-N 120.569 -1.332 . . . . 0.0 112.514 173.364 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 78.8 mt-30 -81.55 14.55 2.49 Favored 'General case' 0 CA--C 1.552 1.035 0 N-CA-C 114.59 1.33 . . . . 0.0 114.59 -174.672 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 87.85 0.46 83.6 Favored Glycine 0 CA--C 1.535 1.333 0 C-N-CA 125.256 1.407 . . . . 0.0 115.011 -179.34 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 39.3 p90 -143.43 161.37 38.58 Favored 'General case' 0 CA--C 1.538 0.512 0 C-N-CA 125.063 1.345 . . . . 0.0 112.273 177.276 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -149.21 -174.93 21.15 Favored Glycine 0 CA--C 1.528 0.874 0 C-N-CA 125.737 1.637 . . . . 0.0 113.109 -178.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -145.88 149.98 35.27 Favored 'General case' 0 C--O 1.236 0.364 0 C-N-CA 125.973 1.709 . . . . 0.0 111.402 -179.378 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.2 t -134.4 126.42 48.83 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.704 0 C-N-CA 124.672 1.189 . . . . 0.0 109.981 176.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -100.66 121.39 41.56 Favored 'General case' 0 N--CA 1.467 0.376 0 C-N-CA 124.791 1.236 . . . . 0.0 110.935 -176.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -97.33 160.81 14.11 Favored 'General case' 0 C--O 1.235 0.299 0 C-N-CA 124.246 1.018 . . . . 0.0 112.465 175.783 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 14.6 tp -62.13 -34.3 76.11 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 123.325 0.65 . . . . 0.0 112.478 176.435 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 18.4 m -143.23 156.36 44.73 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 124.515 1.126 . . . . 0.0 112.139 -177.448 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 74.8 tt0 -62.91 -32.84 74.21 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 124.122 0.969 . . . . 0.0 113.092 -179.422 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -68.4 -23.86 64.69 Favored 'General case' 0 N--CA 1.474 0.728 0 O-C-N 121.23 -0.919 . . . . 0.0 113.439 176.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 51.7 m-20 -80.99 -32.6 34.22 Favored 'General case' 0 CA--C 1.54 0.595 0 C-N-CA 123.932 0.893 . . . . 0.0 111.438 172.564 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -68.26 -44.56 75.33 Favored 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 123.47 0.708 . . . . 0.0 111.447 172.525 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -57.6 -33.47 68.25 Favored 'General case' 0 CA--C 1.542 0.66 0 C-N-CA 124.438 1.095 . . . . 0.0 112.659 174.128 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 16.0 t80 -72.72 -36.78 67.87 Favored 'General case' 0 CA--C 1.536 0.442 0 O-C-N 121.638 -0.664 . . . . 0.0 111.912 175.329 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -68.11 -35.0 77.44 Favored 'General case' 0 CA--C 1.54 0.572 0 O-C-N 120.622 -1.299 . . . . 0.0 111.445 175.561 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 70.8 mt -64.24 -29.71 48.08 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 C-N-CA 124.189 0.995 . . . . 0.0 111.384 171.171 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 25.1 ttmm -71.95 -48.02 48.15 Favored 'General case' 0 N--CA 1.471 0.586 0 C-N-CA 124.213 1.005 . . . . 0.0 112.322 174.059 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 19.7 pt -89.34 -39.84 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 N-CA-C 115.156 1.539 . . . . 0.0 115.156 -172.998 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' MET . . . . . 0.478 ' HA ' HD12 ' A' ' 80' ' ' ILE . 15.2 mmt -89.38 0.81 56.55 Favored 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 114.407 1.262 . . . . 0.0 114.407 -170.359 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -86.94 136.26 33.0 Favored 'General case' 0 CA--C 1.538 0.504 0 C-N-CA 123.399 0.68 . . . . 0.0 111.717 178.392 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 21.0 mtp 60.36 10.62 2.5 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 126.084 1.754 . . . . 0.0 115.494 -169.545 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.478 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.8 mt -70.6 151.26 9.33 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 C-N-CA 124.639 1.176 . . . . 0.0 109.9 168.727 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 46.7 mtpt -110.58 70.74 0.73 Allowed 'General case' 0 N--CA 1.47 0.567 0 C-N-CA 124.982 1.313 . . . . 0.0 112.194 -175.692 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 25.3 tp -58.34 124.13 18.45 Favored 'General case' 0 N--CA 1.472 0.675 0 C-N-CA 123.878 0.871 . . . . 0.0 109.618 175.158 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 61.5 m-85 45.39 31.26 0.83 Allowed 'General case' 0 CA--C 1.561 1.38 0 N-CA-C 116.058 1.873 . . . . 0.0 116.058 -168.486 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 82.36 17.4 69.04 Favored Glycine 0 CA--C 1.541 1.685 0 O-C-N 120.268 -1.52 . . . . 0.0 116.655 173.719 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 94.0 mttt -131.58 123.31 19.3 Favored Pre-proline 0 CA--C 1.542 0.639 0 C-N-CA 128.113 2.565 . . . . 0.0 108.081 -179.572 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -71.34 127.06 12.89 Favored 'Trans proline' 0 CA--C 1.535 0.559 0 C-N-CA 123.329 2.686 . . . . 0.0 112.524 -169.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 16.7 pt -97.08 150.51 4.48 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 C-N-CA 125.272 1.429 . . . . 0.0 112.149 176.605 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 23.9 mmt180 -115.4 140.58 49.01 Favored 'General case' 0 N--CA 1.474 0.737 0 C-N-CA 124.948 1.299 . . . . 0.0 111.17 170.323 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 19.8 t -131.5 135.15 59.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.575 0 C-N-CA 124.974 1.31 . . . . 0.0 111.063 -172.647 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 1.3 p-10 -154.68 174.52 14.89 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.061 1.344 . . . . 0.0 111.968 177.243 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 11.9 mmmm -56.34 136.78 53.36 Favored 'General case' 0 N--CA 1.479 1.007 0 C-N-CA 124.021 0.929 . . . . 0.0 109.599 171.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -69.92 -16.9 63.29 Favored 'General case' 0 CA--C 1.547 0.864 0 CA-C-N 119.847 1.203 . . . . 0.0 112.889 177.29 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 75.4 p -70.36 -10.03 57.9 Favored 'General case' 0 CA--C 1.542 0.67 0 C-N-CA 126.53 1.932 . . . . 0.0 114.028 169.571 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -126.14 162.27 25.75 Favored 'General case' 0 CA--C 1.545 0.758 0 C-N-CA 125.838 1.655 . . . . 0.0 112.977 -176.239 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 94.2 m-70 -95.3 -8.71 35.11 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 124.619 1.168 . . . . 0.0 113.68 178.47 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 3.1 p-10 -152.13 165.14 35.71 Favored 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 126.055 1.742 . . . . 0.0 111.525 -176.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 74.7 tttt -70.96 147.82 48.3 Favored 'General case' 0 N--CA 1.474 0.755 0 C-N-CA 124.538 1.135 . . . . 0.0 111.072 171.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 53.8 t30 -74.53 149.53 40.18 Favored 'General case' 0 CA--C 1.549 0.904 0 C-N-CA 123.769 0.828 . . . . 0.0 112.223 177.796 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 23.9 tp -134.15 -0.99 2.97 Favored 'General case' 0 CA--C 1.553 1.089 0 C-N-CA 126.176 1.79 . . . . 0.0 112.968 175.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 52.3 m -122.71 159.84 27.13 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 125.464 1.506 . . . . 0.0 113.392 -169.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -165.78 178.57 40.48 Favored Glycine 0 CA--C 1.54 1.635 0 C-N-CA 124.888 1.232 . . . . 0.0 113.34 178.817 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 88.8 Cg_endo -70.59 159.4 52.91 Favored 'Trans proline' 0 CA--C 1.541 0.829 0 C-N-CA 123.907 3.071 . . . . 0.0 112.973 -178.279 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 67.2 p -76.54 -14.48 60.01 Favored 'General case' 0 N--CA 1.475 0.78 0 N-CA-C 114.539 1.311 . . . . 0.0 114.539 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 9.9 t -148.89 159.78 43.86 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 125.853 1.661 . . . . 0.0 111.572 177.854 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.198 0 C-N-CA 125.542 1.544 . . . . 0.0 112.823 -178.382 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.585 0 N-CA-C 111.601 -0.6 . . . . 0.0 111.601 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 18.3 m -64.04 -13.99 51.07 Favored 'General case' 0 N--CA 1.481 1.085 0 N-CA-C 115.106 1.521 . . . . 0.0 115.106 -173.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 43.0 p -73.28 -14.11 61.25 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 125.797 1.639 . . . . 0.0 114.295 171.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -69.4 155.13 53.4 Favored Glycine 0 CA--C 1.537 1.467 0 C-N-CA 124.519 1.057 . . . . 0.0 113.994 178.05 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 92.9 p -149.02 165.71 30.84 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 125.331 1.452 . . . . 0.0 112.565 -178.039 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 22.8 m -77.3 -9.83 59.06 Favored 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 124.437 1.095 . . . . 0.0 113.891 176.084 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 170.65 -174.46 44.55 Favored Glycine 0 CA--C 1.539 1.538 0 C-N-CA 125.552 1.548 . . . . 0.0 112.783 -178.356 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -78.32 46.6 2.15 Favored 'Trans proline' 0 CA--C 1.549 1.232 0 C-N-CA 125.065 3.843 . . . . 0.0 112.79 -178.422 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 1.6 pp -96.85 158.94 3.1 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.668 0 C-N-CA 126.123 1.769 . . . . 0.0 113.376 -175.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 18.8 m -89.98 11.27 21.07 Favored 'General case' 0 N--CA 1.477 0.902 0 C-N-CA 125.004 1.322 . . . . 0.0 114.451 -174.023 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 16.7 tt0 56.96 36.48 27.83 Favored 'General case' 0 CA--C 1.551 1.017 0 C-N-CA 126.147 1.779 . . . . 0.0 114.036 179.749 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 17.7 ptp180 -146.22 160.01 42.55 Favored 'General case' 0 N--CA 1.48 1.031 0 C-N-CA 125.877 1.671 . . . . 0.0 112.465 178.092 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 12.2 p30 -144.26 162.61 35.95 Favored 'General case' 0 CA--C 1.543 0.71 0 C-N-CA 125.415 1.486 . . . . 0.0 112.53 -173.469 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 85.4 mt-30 -136.08 6.39 3.1 Favored 'General case' 0 CA--C 1.548 0.886 0 C-N-CA 125.116 1.367 . . . . 0.0 113.673 176.438 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 23.8 p-10 -105.72 -37.29 6.78 Favored 'General case' 0 N--CA 1.472 0.632 0 C-N-CA 126.175 1.79 . . . . 0.0 112.287 176.279 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.13 -2.9 58.77 Favored 'General case' 0 CA--C 1.547 0.863 0 C-N-CA 124.68 1.192 . . . . 0.0 112.833 169.188 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 79.0 m -105.8 132.06 52.38 Favored 'General case' 0 N--CA 1.471 0.593 0 C-N-CA 125.027 1.331 . . . . 0.0 109.381 169.134 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.0 m -101.85 149.89 6.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 C-N-CA 124.953 1.301 . . . . 0.0 110.792 174.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 13.6 t80 -95.6 144.57 25.93 Favored 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 126.255 1.822 . . . . 0.0 109.487 169.398 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 24.0 t -132.01 113.47 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 125.618 1.567 . . . . 0.0 109.332 174.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -109.06 149.31 17.06 Favored Glycine 0 CA--C 1.53 1.031 0 C-N-CA 124.554 1.073 . . . . 0.0 113.334 178.054 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 92.9 34.61 6.75 Favored Glycine 0 CA--C 1.533 1.206 0 C-N-CA 124.718 1.151 . . . . 0.0 113.794 175.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 88.4 mt -83.47 144.97 29.21 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 125.275 1.43 . . . . 0.0 112.005 -172.23 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 28.6 t70 -82.86 157.32 23.16 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 123.94 0.896 . . . . 0.0 112.444 177.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -58.29 -21.18 47.93 Favored 'General case' 0 CA--C 1.546 0.799 0 N-CA-C 114.66 1.355 . . . . 0.0 114.66 178.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.0 mtmm -79.49 -13.07 59.81 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 114.258 1.207 . . . . 0.0 114.258 174.509 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 58.1 t -75.4 138.56 20.65 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.898 0 C-N-CA 124.426 1.09 . . . . 0.0 111.302 179.572 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 9.4 t -144.39 167.22 23.0 Favored 'General case' 0 N--CA 1.475 0.824 0 C-N-CA 123.973 0.909 . . . . 0.0 112.151 173.198 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 5.3 mt-10 -54.17 -43.84 97.71 Favored Pre-proline 0 CA--C 1.549 0.908 0 N-CA-C 114.137 1.162 . . . . 0.0 114.137 -179.253 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -62.93 -29.98 76.53 Favored 'Trans proline' 0 C--N 1.353 0.808 0 C-N-CA 122.23 1.953 . . . . 0.0 113.463 175.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 21.3 tp -67.4 -54.43 20.53 Favored 'General case' 0 C--N 1.343 0.311 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 172.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 24.6 mt -56.11 -42.01 76.17 Favored 'General case' 0 N--CA 1.463 0.204 0 C-N-CA 122.692 0.397 . . . . 0.0 111.737 -176.383 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.8 t90 -57.96 -62.05 2.09 Favored 'General case' 0 CA--C 1.53 0.189 0 C-N-CA 123.211 0.605 . . . . 0.0 111.276 178.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -64.61 -29.84 70.86 Favored 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 113.685 0.995 . . . . 0.0 113.685 -177.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.2 tp -70.72 -36.32 73.15 Favored 'General case' 0 CA--C 1.541 0.601 0 C-N-CA 124.021 0.928 . . . . 0.0 112.065 176.187 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 11.6 m-85 -88.86 -10.91 46.26 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 124.92 1.288 . . . . 0.0 113.512 -175.709 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 26.4 mt -53.77 -20.97 6.37 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 114.03 1.122 . . . . 0.0 114.03 169.324 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 -64.14 -32.28 73.79 Favored 'General case' 0 N--CA 1.472 0.635 0 C-N-CA 125.284 1.433 . . . . 0.0 112.712 175.176 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.66 -44.55 20.7 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 123.525 0.73 . . . . 0.0 112.684 177.129 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.54 -172.78 44.66 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 124.485 1.041 . . . . 0.0 113.07 -179.499 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 59.1 Cg_endo -67.92 109.38 1.9 Allowed 'Trans proline' 0 CA--C 1.537 0.664 0 C-N-CA 123.704 2.936 . . . . 0.0 111.663 -179.082 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 68.9 t -84.48 133.63 28.83 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 C-N-CA 124.896 1.278 . . . . 0.0 109.8 174.199 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 5.6 t -109.85 -33.65 2.43 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 126.162 1.785 . . . . 0.0 111.968 -171.683 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 19.5 t30 -160.64 163.23 32.71 Favored 'General case' 0 CA--C 1.55 0.947 0 C-N-CA 125.962 1.705 . . . . 0.0 110.929 -173.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 5.2 p -140.2 156.94 46.31 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 126.449 1.9 . . . . 0.0 111.295 175.59 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 4.8 t60 -141.66 142.37 33.38 Favored 'General case' 0 N--CA 1.47 0.53 0 C-N-CA 123.832 0.853 . . . . 0.0 111.111 171.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 30.7 mmm -139.55 102.84 7.13 Favored Pre-proline 0 N--CA 1.469 0.521 0 C-N-CA 125.127 1.371 . . . . 0.0 108.356 170.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_exo -56.28 132.38 51.52 Favored 'Trans proline' 0 CA--C 1.537 0.632 0 C-N-CA 123.105 2.537 . . . . 0.0 112.701 177.234 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 42.8 mmtm -104.63 141.68 36.0 Favored 'General case' 0 N--CA 1.474 0.748 0 C-N-CA 124.959 1.304 . . . . 0.0 111.698 -177.396 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -69.48 140.1 53.97 Favored 'General case' 0 CA--C 1.544 0.721 0 C-N-CA 125.212 1.405 . . . . 0.0 112.261 177.424 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 53.2 ptt85 -83.98 6.14 23.01 Favored 'General case' 0 N--CA 1.48 1.048 0 N-CA-C 115.887 1.81 . . . . 0.0 115.887 -173.688 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 25.0 t -132.41 -37.7 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.094 0 C-N-CA 124.988 1.315 . . . . 0.0 111.41 -175.207 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 73.4 p -108.4 -20.67 13.04 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 126.05 1.74 . . . . 0.0 112.614 -177.491 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 74.07 1.85 60.72 Favored Glycine 0 CA--C 1.539 1.568 0 C-N-CA 125.018 1.294 . . . . 0.0 116.003 172.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 3.5 pt20 -78.54 168.99 18.96 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-N 118.513 1.156 . . . . 0.0 111.315 171.195 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 18.5 p80 -67.64 156.04 37.77 Favored 'General case' 0 CA--C 1.54 0.581 0 O-C-N 121.029 -1.044 . . . . 0.0 112.037 170.664 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 46.6 mt-30 -87.88 17.04 5.15 Favored 'General case' 0 CA--C 1.55 0.978 0 N-CA-C 114.493 1.294 . . . . 0.0 114.493 -172.047 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.3 1.12 81.86 Favored Glycine 0 CA--C 1.536 1.371 0 C-N-CA 125.223 1.392 . . . . 0.0 115.002 -179.782 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 45.6 p90 -145.66 156.28 43.55 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 125.268 1.427 . . . . 0.0 112.19 178.165 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -142.87 -178.17 18.52 Favored Glycine 0 CA--C 1.532 1.1 0 C-N-CA 126.784 2.135 . . . . 0.0 112.755 -176.918 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 65.4 m-85 -144.03 151.71 40.04 Favored 'General case' 0 CA--C 1.536 0.406 0 C-N-CA 125.705 1.602 . . . . 0.0 111.896 177.364 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 19.4 t -134.84 131.99 53.58 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 C-N-CA 124.72 1.208 . . . . 0.0 110.132 176.518 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -108.35 127.35 53.8 Favored 'General case' 0 N--CA 1.467 0.377 0 C-N-CA 124.772 1.229 . . . . 0.0 111.613 -176.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 79.1 m-85 -103.73 160.67 14.57 Favored 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 125.241 1.416 . . . . 0.0 112.475 178.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 14.8 tp -61.97 -32.61 73.07 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 123.361 0.664 . . . . 0.0 112.387 178.29 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.4 m -143.8 155.3 44.1 Favored 'General case' 0 N--CA 1.468 0.45 0 C-N-CA 124.258 1.023 . . . . 0.0 111.868 -179.435 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 12.8 tm-20 -62.66 -32.06 73.05 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 124.388 1.075 . . . . 0.0 113.221 -178.321 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -69.3 -25.23 64.14 Favored 'General case' 0 CA--C 1.542 0.648 0 N-CA-C 113.346 0.869 . . . . 0.0 113.346 176.52 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 44.6 m-20 -79.75 -32.53 41.07 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 123.875 0.87 . . . . 0.0 111.465 173.416 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.68 -42.83 73.61 Favored 'General case' 0 CA--C 1.539 0.545 0 O-C-N 121.875 -0.516 . . . . 0.0 111.263 172.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -62.16 -26.8 68.53 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 123.929 0.891 . . . . 0.0 112.704 176.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 30.3 t80 -78.68 -34.54 46.13 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 123.705 0.802 . . . . 0.0 112.838 173.657 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -65.38 -34.23 77.81 Favored 'General case' 0 CA--C 1.536 0.434 0 O-C-N 120.541 -1.349 . . . . 0.0 111.146 175.261 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 61.8 mt -65.42 -33.85 66.47 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.622 0 C-N-CA 124.605 1.162 . . . . 0.0 111.625 173.27 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 50.5 tttm -65.03 -41.97 94.78 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.207 1.003 . . . . 0.0 112.053 174.576 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 20.0 pt -93.98 -37.77 8.62 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.629 0 N-CA-C 114.809 1.411 . . . . 0.0 114.809 -174.318 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' MET . . . . . 0.488 ' HA ' HD12 ' A' ' 80' ' ' ILE . 13.8 mmt -90.85 -1.25 57.86 Favored 'General case' 0 N--CA 1.479 1.011 0 N-CA-C 114.948 1.462 . . . . 0.0 114.948 -169.742 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 33.5 t70 -81.17 138.86 35.84 Favored 'General case' 0 CA--C 1.54 0.565 0 O-C-N 120.929 -1.107 . . . . 0.0 111.863 178.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 22.3 mmt 61.5 5.45 1.22 Allowed 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 126.443 1.897 . . . . 0.0 115.345 -170.55 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.488 HD12 ' HA ' ' A' ' 77' ' ' MET . 1.6 mt -68.69 142.36 16.34 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.595 0 C-N-CA 124.405 1.082 . . . . 0.0 111.894 178.711 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 42.5 mtpt -98.27 64.89 1.65 Allowed 'General case' 0 N--CA 1.469 0.519 0 C-N-CA 125.0 1.32 . . . . 0.0 112.35 -171.478 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 27.1 tp -59.35 123.74 17.75 Favored 'General case' 0 CA--C 1.542 0.663 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 174.233 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 63.0 m-85 45.27 31.65 0.85 Allowed 'General case' 0 CA--C 1.562 1.418 0 N-CA-C 115.848 1.796 . . . . 0.0 115.848 -168.022 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 84.61 12.66 74.68 Favored Glycine 0 CA--C 1.542 1.753 0 N-CA-C 117.045 1.578 . . . . 0.0 117.045 173.175 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 93.5 mttt -127.27 117.85 21.72 Favored Pre-proline 0 CA--C 1.54 0.575 0 C-N-CA 127.892 2.477 . . . . 0.0 108.49 -178.026 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -71.89 121.86 7.98 Favored 'Trans proline' 0 CA--C 1.536 0.609 0 C-N-CA 123.617 2.878 . . . . 0.0 111.761 -171.623 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 4.9 pt -86.94 168.49 1.58 Allowed 'Isoleucine or valine' 0 N--CA 1.478 0.955 0 C-N-CA 125.681 1.592 . . . . 0.0 112.524 -176.804 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 73.6 mmt-85 -120.82 132.92 55.28 Favored 'General case' 0 N--CA 1.477 0.909 0 C-N-CA 125.571 1.548 . . . . 0.0 109.961 171.348 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 15.2 t -131.07 133.94 62.1 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.806 0 C-N-CA 123.95 0.9 . . . . 0.0 111.376 -176.659 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -157.65 171.73 19.8 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 125.888 1.675 . . . . 0.0 111.252 179.658 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 5.1 mmmm -58.82 144.04 45.47 Favored 'General case' 0 N--CA 1.48 1.072 0 O-C-N 121.3 -0.875 . . . . 0.0 109.444 170.58 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -66.85 -29.89 69.92 Favored 'General case' 0 CA--C 1.547 0.848 0 CA-C-N 119.142 0.883 . . . . 0.0 112.862 -178.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 5.9 t -85.16 -61.19 1.83 Allowed 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 124.69 1.196 . . . . 0.0 111.505 169.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . 53.28 18.57 1.29 Allowed 'General case' 0 CA--C 1.552 1.034 0 C-N-CA 126.05 1.74 . . . . 0.0 114.921 -169.657 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -139.68 18.62 2.51 Favored 'General case' 0 N--CA 1.474 0.757 0 C-N-CA 125.067 1.347 . . . . 0.0 113.388 -174.549 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 58.8 t-20 -65.93 134.72 53.58 Favored 'General case' 0 CA--C 1.547 0.832 0 C-N-CA 124.898 1.279 . . . . 0.0 112.015 -177.202 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 57.5 mtmt -94.1 -6.73 44.37 Favored 'General case' 0 N--CA 1.478 0.967 0 C-N-CA 125.785 1.634 . . . . 0.0 114.157 -179.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 25.2 t-20 -62.22 149.17 42.48 Favored 'General case' 0 CA--C 1.549 0.922 0 C-N-CA 124.557 1.143 . . . . 0.0 112.672 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 16.9 tp 53.62 47.66 23.36 Favored 'General case' 0 CA--C 1.548 0.897 0 C-N-CA 125.98 1.712 . . . . 0.0 113.173 -179.267 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 56.8 p -71.14 -36.25 72.01 Favored 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 124.282 1.033 . . . . 0.0 112.688 173.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -89.62 173.97 40.81 Favored Glycine 0 CA--C 1.542 1.748 0 C-N-CA 125.221 1.391 . . . . 0.0 113.3 169.69 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_exo -62.33 148.52 93.12 Favored 'Trans proline' 0 CA--C 1.537 0.655 0 C-N-CA 123.539 2.826 . . . . 0.0 113.73 179.164 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 60.8 p -67.82 -18.91 64.99 Favored 'General case' 0 N--CA 1.477 0.889 0 C-N-CA 124.183 0.993 . . . . 0.0 113.649 173.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 61.5 p -85.84 -4.16 59.09 Favored 'General case' 0 CA--C 1.542 0.673 0 C-N-CA 126.271 1.828 . . . . 0.0 114.295 173.449 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.236 0 C-N-CA 125.596 1.57 . . . . 0.0 114.082 -179.544 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.548 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 27.8 m 53.03 38.0 26.18 Favored 'General case' 0 N--CA 1.48 1.065 0 C-N-CA 125.026 1.33 . . . . 0.0 113.439 -174.462 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 60.9 p -140.28 162.93 34.12 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 126.489 1.916 . . . . 0.0 112.043 -171.075 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 61.64 25.38 65.34 Favored Glycine 0 CA--C 1.538 1.517 0 C-N-CA 123.919 0.771 . . . . 0.0 114.648 178.287 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.2 m 56.91 22.17 6.89 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 126.158 1.783 . . . . 0.0 114.826 -170.21 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 8.3 t -79.76 162.65 25.02 Favored 'General case' 0 CA--C 1.541 0.605 0 C-N-CA 124.78 1.232 . . . . 0.0 112.122 174.518 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 77.77 -128.81 9.08 Favored Glycine 0 CA--C 1.543 1.787 0 CA-C-O 118.578 -1.123 . . . . 0.0 112.609 -176.637 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -68.82 157.83 60.27 Favored 'Trans proline' 0 CA--C 1.541 0.826 0 C-N-CA 123.454 2.769 . . . . 0.0 113.507 -175.244 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . 0.418 HD13 ' H ' ' A' ' 9' ' ' ILE . 0.2 OUTLIER -69.81 153.65 8.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 C-N-CA 125.102 1.361 . . . . 0.0 113.401 179.34 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 64.5 p -92.47 -4.21 53.99 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 125.575 1.55 . . . . 0.0 115.018 -175.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.5 tp10 -138.57 147.77 43.41 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 125.678 1.591 . . . . 0.0 111.303 -178.657 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 26.6 mmt85 -78.68 86.36 4.65 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.191 1.396 . . . . 0.0 110.166 177.209 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 10.9 m120 55.7 -94.47 0.04 OUTLIER 'General case' 0 CA--C 1.542 0.657 0 C-N-CA 126.29 1.836 . . . . 0.0 113.71 -171.44 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 1.2 tp-100 61.69 -4.27 0.18 Allowed 'General case' 0 CA--C 1.552 1.028 0 C-N-CA 126.575 1.95 . . . . 0.0 115.228 -170.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 24.6 p-10 -92.43 -41.08 10.51 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 127.667 2.387 . . . . 0.0 111.845 172.92 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -80.18 -3.34 48.6 Favored 'General case' 0 CA--C 1.546 0.82 0 C-N-CA 124.66 1.184 . . . . 0.0 112.991 169.649 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 6.2 m -92.47 133.28 36.07 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 124.158 0.983 . . . . 0.0 109.734 169.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 17.4 m -105.38 147.32 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.611 0 C-N-CA 124.948 1.299 . . . . 0.0 110.768 172.948 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 28.1 t80 -95.4 142.43 27.78 Favored 'General case' 0 CA--C 1.534 0.358 0 C-N-CA 126.16 1.784 . . . . 0.0 109.644 169.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 25.0 t -133.34 108.22 12.13 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 C-N-CA 125.812 1.645 . . . . 0.0 109.374 178.161 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -102.96 150.97 17.95 Favored Glycine 0 CA--C 1.53 1.023 0 C-N-CA 124.353 0.978 . . . . 0.0 112.942 175.889 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.54 34.25 7.52 Favored Glycine 0 CA--C 1.532 1.152 0 C-N-CA 124.591 1.091 . . . . 0.0 113.959 173.216 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 88.9 mt -81.29 144.93 31.18 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 125.394 1.478 . . . . 0.0 111.763 -173.112 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 20.8 t70 -82.43 156.14 24.29 Favored 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 123.821 0.848 . . . . 0.0 112.246 177.413 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.84 -20.28 49.22 Favored 'General case' 0 CA--C 1.546 0.823 0 N-CA-C 114.804 1.409 . . . . 0.0 114.804 179.038 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.5 mtmm -82.24 -8.53 59.64 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 124.883 1.273 . . . . 0.0 114.178 174.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 55.1 t -78.23 140.07 17.54 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.917 0 C-N-CA 124.884 1.274 . . . . 0.0 111.13 177.508 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 9.5 t -144.49 167.29 22.85 Favored 'General case' 0 N--CA 1.476 0.847 0 C-N-CA 123.912 0.885 . . . . 0.0 112.104 171.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 7.8 mt-10 -54.29 -43.9 98.02 Favored Pre-proline 0 CA--C 1.547 0.838 0 CA-C-O 117.682 -1.152 . . . . 0.0 114.106 -179.292 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -62.69 -30.85 79.02 Favored 'Trans proline' 0 C--N 1.354 0.82 0 C-N-CA 122.216 1.944 . . . . 0.0 113.389 175.144 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 20.8 tp -67.29 -54.24 22.57 Favored 'General case' 0 C--N 1.343 0.322 0 CA-C-N 118.218 0.463 . . . . 0.0 109.754 173.197 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 34.4 mt -55.18 -42.99 73.9 Favored 'General case' 0 N--CA 1.466 0.33 0 C-N-CA 122.62 0.368 . . . . 0.0 111.567 -177.365 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.7 t90 -57.22 -61.34 2.54 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 123.407 0.683 . . . . 0.0 111.348 178.684 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -65.54 -29.86 70.54 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 113.745 1.017 . . . . 0.0 113.745 -177.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.6 tp -71.53 -36.18 70.94 Favored 'General case' 0 CA--C 1.541 0.627 0 C-N-CA 124.162 0.985 . . . . 0.0 111.873 176.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 11.9 m-85 -88.57 -11.9 44.26 Favored 'General case' 0 CA--C 1.54 0.578 0 C-N-CA 124.746 1.218 . . . . 0.0 113.299 -176.245 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 24.1 mt -52.84 -22.37 5.35 Favored 'General case' 0 N--CA 1.477 0.904 0 N-CA-C 114.058 1.133 . . . . 0.0 114.058 169.037 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 41.4 mt-30 -63.29 -32.04 73.35 Favored 'General case' 0 N--CA 1.473 0.701 0 C-N-CA 125.225 1.41 . . . . 0.0 112.662 175.584 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.54 -44.88 20.3 Favored 'General case' 0 CA--C 1.54 0.559 0 C-N-CA 123.563 0.745 . . . . 0.0 112.677 176.873 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.64 -173.56 45.33 Favored Glycine 0 CA--C 1.536 1.377 0 C-N-CA 124.631 1.11 . . . . 0.0 112.97 179.099 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -66.71 112.13 2.34 Favored 'Trans proline' 0 CA--C 1.538 0.676 0 C-N-CA 123.66 2.907 . . . . 0.0 111.677 -178.939 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 69.3 t -87.28 131.92 33.92 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 C-N-CA 124.953 1.301 . . . . 0.0 109.686 174.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.8 t -106.44 -34.11 2.87 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.663 0 C-N-CA 126.671 1.988 . . . . 0.0 111.746 -171.961 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 24.3 t30 -160.66 165.83 29.89 Favored 'General case' 0 CA--C 1.554 1.109 0 C-N-CA 125.973 1.709 . . . . 0.0 110.832 -174.741 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 8.4 p -139.69 160.36 40.06 Favored 'General case' 0 N--CA 1.481 1.095 0 C-N-CA 126.391 1.876 . . . . 0.0 111.026 173.619 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 5.6 t60 -142.23 143.17 32.77 Favored 'General case' 0 N--CA 1.467 0.424 0 C-N-CA 123.688 0.795 . . . . 0.0 111.047 171.734 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 2.6 mmm -141.39 104.42 5.99 Favored Pre-proline 0 N--CA 1.468 0.469 0 C-N-CA 125.321 1.448 . . . . 0.0 108.673 170.555 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 79.2 Cg_exo -56.18 134.93 67.25 Favored 'Trans proline' 0 CA--C 1.539 0.768 0 C-N-CA 123.181 2.588 . . . . 0.0 112.049 171.451 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 42.7 mmtm -110.45 146.3 36.16 Favored 'General case' 0 N--CA 1.477 0.918 0 C-N-CA 124.83 1.252 . . . . 0.0 113.19 -172.149 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -68.82 144.87 54.17 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 125.822 1.649 . . . . 0.0 112.324 171.458 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 11.9 ptp85 -88.87 7.24 35.32 Favored 'General case' 0 N--CA 1.48 1.032 0 N-CA-C 115.995 1.85 . . . . 0.0 115.995 -174.449 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 39.3 t -130.24 -37.38 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.15 0 C-N-CA 125.008 1.323 . . . . 0.0 111.291 -174.68 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 73.1 p -113.29 -15.44 12.69 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 125.888 1.675 . . . . 0.0 112.437 -177.212 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.83 4.35 53.94 Favored Glycine 0 CA--C 1.537 1.422 0 C-N-CA 125.041 1.305 . . . . 0.0 115.412 177.067 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 72.6 mm-40 -78.22 164.89 24.53 Favored 'General case' 0 N--CA 1.47 0.527 0 C-N-CA 124.705 1.202 . . . . 0.0 110.945 177.615 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 25.4 p80 -68.04 154.68 41.14 Favored 'General case' 0 N--CA 1.471 0.608 0 O-C-N 120.922 -1.111 . . . . 0.0 112.338 175.247 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 47.7 mt-30 -84.54 20.72 1.64 Allowed 'General case' 0 CA--C 1.55 0.977 0 N-CA-C 114.396 1.258 . . . . 0.0 114.396 -173.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.95 -1.21 86.72 Favored Glycine 0 CA--C 1.535 1.283 0 C-N-CA 125.257 1.408 . . . . 0.0 114.936 -179.331 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 43.4 p90 -144.89 152.26 39.98 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 125.209 1.404 . . . . 0.0 111.949 177.44 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -142.31 -178.94 18.81 Favored Glycine 0 CA--C 1.534 1.244 0 C-N-CA 126.846 2.165 . . . . 0.0 112.284 -176.652 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 51.7 m-85 -142.94 152.72 42.32 Favored 'General case' 0 C--O 1.236 0.371 0 C-N-CA 125.321 1.449 . . . . 0.0 111.688 178.588 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.3 t -133.55 133.87 57.04 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.764 0 C-N-CA 124.714 1.205 . . . . 0.0 109.561 176.135 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 59.8 tt0 -109.77 119.71 40.21 Favored 'General case' 0 N--CA 1.468 0.432 0 C-N-CA 124.687 1.195 . . . . 0.0 110.896 -176.056 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -96.01 163.15 13.25 Favored 'General case' 0 C--O 1.234 0.25 0 C-N-CA 124.688 1.195 . . . . 0.0 112.693 177.163 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.9 tp -64.44 -34.7 78.79 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 123.246 0.618 . . . . 0.0 112.415 177.055 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 18.6 m -144.03 156.83 44.54 Favored 'General case' 0 N--CA 1.47 0.554 0 C-N-CA 124.629 1.172 . . . . 0.0 112.042 -176.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 50.3 tt0 -62.58 -33.31 74.71 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 124.003 0.921 . . . . 0.0 113.027 -179.094 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -68.44 -24.47 64.73 Favored 'General case' 0 CA--C 1.542 0.67 0 O-C-N 121.23 -0.919 . . . . 0.0 113.469 177.343 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 52.0 m-20 -80.24 -33.27 38.09 Favored 'General case' 0 CA--C 1.539 0.533 0 C-N-CA 123.848 0.859 . . . . 0.0 111.376 172.591 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -68.64 -44.76 73.49 Favored 'General case' 0 CA--C 1.54 0.558 0 C-N-CA 123.305 0.642 . . . . 0.0 111.521 172.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 33.6 t70 -57.27 -35.19 69.45 Favored 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 124.515 1.126 . . . . 0.0 112.524 175.635 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 23.6 t80 -71.42 -38.41 71.4 Favored 'General case' 0 CA--C 1.536 0.439 0 O-C-N 121.725 -0.609 . . . . 0.0 111.985 175.052 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -65.8 -37.08 85.3 Favored 'General case' 0 CA--C 1.537 0.466 0 O-C-N 120.795 -1.19 . . . . 0.0 111.537 176.537 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 64.5 mt -63.42 -33.26 60.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.714 0 C-N-CA 124.097 0.959 . . . . 0.0 110.936 172.484 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 63.2 tttp -69.66 -43.68 72.08 Favored 'General case' 0 N--CA 1.47 0.565 0 C-N-CA 124.117 0.967 . . . . 0.0 112.478 176.635 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 18.3 pt -89.21 -42.67 14.63 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 N-CA-C 114.5 1.296 . . . . 0.0 114.5 -175.574 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' MET . . . . . 0.491 ' HA ' HD12 ' A' ' 80' ' ' ILE . 15.3 mmt -86.69 0.82 53.88 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 114.772 1.397 . . . . 0.0 114.772 -169.254 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -84.37 132.27 34.61 Favored 'General case' 0 CA--C 1.538 0.5 0 O-C-N 121.433 -0.792 . . . . 0.0 112.336 -178.338 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 24.4 ttm 59.01 17.7 5.66 Favored 'General case' 0 CA--C 1.549 0.921 0 C-N-CA 126.698 1.999 . . . . 0.0 114.539 -169.87 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.491 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.8 mt -73.71 140.66 17.35 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 C-N-CA 124.52 1.128 . . . . 0.0 111.072 171.814 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 42.7 mtpt -97.63 63.99 1.77 Allowed 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 124.58 1.152 . . . . 0.0 112.622 -172.153 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 37.3 tp -58.14 122.23 12.61 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 123.899 0.88 . . . . 0.0 109.422 174.55 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 57.8 m-85 44.91 31.69 0.72 Allowed 'General case' 0 CA--C 1.56 1.345 0 N-CA-C 116.008 1.855 . . . . 0.0 116.008 -168.578 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 83.49 15.53 70.98 Favored Glycine 0 CA--C 1.541 1.705 0 O-C-N 120.168 -1.583 . . . . 0.0 116.957 173.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 59.3 mttp -126.45 121.1 23.49 Favored Pre-proline 0 CA--C 1.539 0.54 0 C-N-CA 127.638 2.375 . . . . 0.0 108.457 176.857 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -71.14 108.83 2.42 Favored 'Trans proline' 0 CA--C 1.537 0.643 0 C-N-CA 123.807 3.005 . . . . 0.0 111.27 -174.201 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 5.8 pt -77.61 147.12 7.46 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 C-N-CA 124.694 1.197 . . . . 0.0 110.245 179.124 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 40.1 mmm-85 -113.2 133.36 55.1 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 123.947 0.899 . . . . 0.0 110.671 175.064 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.8 t -128.46 136.78 59.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 124.2 1.0 . . . . 0.0 111.326 -169.737 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 2.1 t-20 -158.66 -178.21 7.09 Favored 'General case' 0 CA--C 1.545 0.78 0 C-N-CA 124.853 1.261 . . . . 0.0 111.281 173.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 10.1 mmmm -60.89 144.14 53.51 Favored 'General case' 0 N--CA 1.475 0.819 0 C-N-CA 124.499 1.12 . . . . 0.0 110.167 172.505 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -68.24 -29.33 68.13 Favored 'General case' 0 CA--C 1.549 0.937 0 O-C-N 121.615 -0.678 . . . . 0.0 112.07 174.511 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 26.3 m -117.98 119.15 33.95 Favored 'General case' 0 N--CA 1.472 0.655 0 C-N-CA 125.743 1.617 . . . . 0.0 109.252 167.387 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -134.51 175.22 9.73 Favored 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 125.302 1.441 . . . . 0.0 112.62 -170.292 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 90.4 m-70 56.82 40.0 29.26 Favored 'General case' 0 N--CA 1.479 1.009 0 C-N-CA 125.969 1.707 . . . . 0.0 114.395 178.407 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 46.6 t30 -69.27 160.46 31.17 Favored 'General case' 0 CA--C 1.551 1.018 0 C-N-CA 124.513 1.125 . . . . 0.0 112.094 175.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 40.0 ttpt -61.89 142.77 57.19 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 125.496 1.518 . . . . 0.0 112.127 179.323 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 4.9 p-10 -117.07 166.89 11.68 Favored 'General case' 0 CA--C 1.545 0.765 0 C-N-CA 125.782 1.633 . . . . 0.0 112.766 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 54.8 tp -114.92 145.42 42.23 Favored 'General case' 0 CA--C 1.542 0.667 0 C-N-CA 125.925 1.69 . . . . 0.0 110.496 174.519 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 25.0 m -69.89 -31.47 69.29 Favored 'General case' 0 N--CA 1.478 0.97 0 C-N-CA 123.84 0.856 . . . . 0.0 113.213 179.484 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 170.06 154.96 9.74 Favored Glycine 0 CA--C 1.539 1.569 0 C-N-CA 125.969 1.747 . . . . 0.0 112.243 172.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -67.76 143.53 61.96 Favored 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 123.098 2.532 . . . . 0.0 111.799 178.058 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 22.5 m 53.41 28.2 7.24 Favored 'General case' 0 N--CA 1.479 0.991 0 C-N-CA 125.441 1.496 . . . . 0.0 114.935 -179.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 68.4 p -79.3 -11.38 59.94 Favored 'General case' 0 N--CA 1.477 0.889 0 N-CA-C 114.857 1.429 . . . . 0.0 114.857 -175.671 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.265 0 C-N-CA 125.699 1.619 . . . . 0.0 113.816 177.775 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.632 0 N-CA-C 111.821 -0.512 . . . . 0.0 111.821 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.4 m 61.89 167.75 0.11 Allowed 'General case' 0 N--CA 1.481 1.114 0 C-N-CA 126.676 1.99 . . . . 0.0 115.401 -176.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 71.5 m -74.83 158.87 32.7 Favored 'General case' 0 N--CA 1.475 0.817 0 C-N-CA 124.435 1.094 . . . . 0.0 112.505 175.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.34 164.53 44.56 Favored Glycine 0 CA--C 1.537 1.432 0 CA-C-O 121.791 0.662 . . . . 0.0 113.478 172.71 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 13.3 p -68.0 -22.06 65.01 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 116.119 1.896 . . . . 0.0 116.119 -169.974 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 60.4 p 55.34 -175.27 0.04 OUTLIER 'General case' 0 N--CA 1.481 1.118 0 C-N-CA 127.128 2.171 . . . . 0.0 113.818 -174.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -165.59 156.65 28.73 Favored Glycine 0 CA--C 1.538 1.51 0 O-C-N 120.343 -1.473 . . . . 0.0 115.801 174.468 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -80.51 54.07 5.06 Favored 'Trans proline' 0 CA--C 1.547 1.146 0 C-N-CA 124.984 3.789 . . . . 0.0 112.772 -177.294 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 17.3 tt -69.34 141.19 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 C-N-CA 125.102 1.361 . . . . 0.0 111.709 176.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 61.7 m -109.56 -12.81 14.64 Favored 'General case' 0 N--CA 1.476 0.859 0 C-N-CA 125.068 1.347 . . . . 0.0 112.927 174.424 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 21.9 mp0 -83.06 -14.99 52.71 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 125.352 1.461 . . . . 0.0 112.907 -177.13 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 27.4 ttm180 -143.8 141.17 30.25 Favored 'General case' 0 N--CA 1.473 0.7 0 C-N-CA 127.482 2.313 . . . . 0.0 108.525 170.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 55.9 m-20 -89.12 10.66 21.03 Favored 'General case' 0 CA--C 1.545 0.773 0 N-CA-C 113.576 0.954 . . . . 0.0 113.576 -178.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 63.4 tt0 -66.26 -38.04 86.89 Favored 'General case' 0 N--CA 1.472 0.627 0 O-C-N 120.707 -1.245 . . . . 0.0 112.977 -173.689 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -73.89 -24.41 59.71 Favored 'General case' 0 N--CA 1.473 0.714 0 O-C-N 121.309 -0.869 . . . . 0.0 112.197 173.243 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -84.89 5.06 30.45 Favored 'General case' 0 CA--C 1.547 0.828 0 C-N-CA 125.513 1.525 . . . . 0.0 113.106 169.631 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 53.7 m -112.02 139.39 47.57 Favored 'General case' 0 N--CA 1.468 0.47 0 C-N-CA 125.089 1.355 . . . . 0.0 109.172 174.578 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 4.3 m -104.94 146.17 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 C-N-CA 124.152 0.981 . . . . 0.0 110.012 174.214 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 50.3 t80 -95.44 140.36 30.42 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 125.784 1.634 . . . . 0.0 109.318 169.464 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 26.1 t -131.68 110.96 17.96 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.542 0 C-N-CA 125.673 1.589 . . . . 0.0 109.208 178.507 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -107.23 149.04 16.56 Favored Glycine 0 CA--C 1.531 1.032 0 C-N-CA 124.572 1.082 . . . . 0.0 112.826 176.125 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.65 33.6 6.67 Favored Glycine 0 CA--C 1.533 1.213 0 C-N-CA 124.482 1.039 . . . . 0.0 113.953 174.2 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 84.9 mt -74.41 152.06 39.57 Favored 'General case' 0 C--O 1.234 0.259 0 C-N-CA 125.459 1.504 . . . . 0.0 111.505 -174.522 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -90.69 156.31 18.19 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 123.885 0.874 . . . . 0.0 111.854 174.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.3 -20.53 43.65 Favored 'General case' 0 CA--C 1.546 0.819 0 N-CA-C 114.823 1.416 . . . . 0.0 114.823 -179.543 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.5 mtmm -81.38 -12.18 59.06 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 124.687 1.195 . . . . 0.0 114.093 175.067 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 64.4 t -73.36 141.92 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 124.576 1.15 . . . . 0.0 111.572 178.316 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 6.2 t -144.29 166.88 23.82 Favored 'General case' 0 N--CA 1.473 0.694 0 C-N-CA 123.949 0.899 . . . . 0.0 111.671 169.237 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -53.15 -42.68 92.27 Favored Pre-proline 0 CA--C 1.545 0.786 0 N-CA-C 115.498 1.666 . . . . 0.0 115.498 -179.37 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 67.0 Cg_endo -70.53 -25.01 25.5 Favored 'Trans proline' 0 C--N 1.353 0.804 0 CA-C-N 122.142 1.801 . . . . 0.0 112.997 176.487 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 17.6 tp -65.74 -53.83 35.38 Favored 'General case' 0 C--N 1.343 0.32 0 CA-C-N 118.707 0.685 . . . . 0.0 109.273 170.265 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 25.8 mt -54.94 -41.95 71.7 Favored 'General case' 0 N--CA 1.464 0.269 0 O-C-N 123.265 0.353 . . . . 0.0 111.261 -179.067 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 3.0 t90 -57.87 -62.42 1.82 Allowed 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 123.371 0.669 . . . . 0.0 111.35 177.823 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.6 mt-10 -64.67 -29.48 70.47 Favored 'General case' 0 N--CA 1.471 0.59 0 N-CA-C 113.844 1.053 . . . . 0.0 113.844 -177.33 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.0 tp -71.79 -36.61 70.35 Favored 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 124.328 1.051 . . . . 0.0 111.918 176.425 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 13.7 m-85 -88.36 -10.42 49.43 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.071 1.349 . . . . 0.0 113.424 -176.392 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 25.0 mt -53.66 -21.42 6.89 Favored 'General case' 0 CA--C 1.546 0.804 0 N-CA-C 113.948 1.092 . . . . 0.0 113.948 168.884 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 42.3 mt-30 -63.25 -32.28 73.65 Favored 'General case' 0 N--CA 1.472 0.652 0 C-N-CA 125.182 1.393 . . . . 0.0 112.618 174.02 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -78.58 -44.35 24.3 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.36 0.664 . . . . 0.0 112.519 177.151 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 177.36 -173.02 45.86 Favored Glycine 0 CA--C 1.535 1.316 0 C-N-CA 124.578 1.085 . . . . 0.0 113.04 -178.584 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.5 Cg_endo -67.63 110.08 2.01 Favored 'Trans proline' 0 CA--C 1.537 0.671 0 C-N-CA 123.774 2.983 . . . . 0.0 111.719 -178.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 80.8 t -85.72 135.11 25.66 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 C-N-CA 124.896 1.278 . . . . 0.0 109.973 174.363 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 6.9 t -110.17 -34.01 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.753 0 C-N-CA 126.262 1.825 . . . . 0.0 111.897 -172.038 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 21.3 t30 -160.94 160.88 31.37 Favored 'General case' 0 CA--C 1.553 1.064 0 C-N-CA 125.775 1.63 . . . . 0.0 110.978 -174.864 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 6.7 p -137.57 154.41 49.8 Favored 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 125.816 1.647 . . . . 0.0 111.875 172.124 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 18.1 t-80 -142.29 130.58 22.23 Favored 'General case' 0 N--CA 1.469 0.506 0 C-N-CA 123.659 0.784 . . . . 0.0 111.553 177.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 83.3 mtp -134.09 102.49 12.06 Favored Pre-proline 0 N--CA 1.471 0.62 0 C-N-CA 124.575 1.15 . . . . 0.0 109.562 170.013 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_exo -61.86 128.72 25.16 Favored 'Trans proline' 0 CA--C 1.538 0.704 0 C-N-CA 123.016 2.478 . . . . 0.0 113.135 -178.44 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 45.2 mmtm -92.47 151.41 20.22 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 124.506 1.122 . . . . 0.0 113.686 -172.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 25.7 t70 -66.39 142.2 57.68 Favored 'General case' 0 CA--C 1.544 0.74 0 C-N-CA 126.471 1.908 . . . . 0.0 112.338 172.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 9.7 ptm180 -83.84 8.14 15.8 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 115.944 1.831 . . . . 0.0 115.944 -174.237 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 35.1 t -131.33 -37.88 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.105 0 C-N-CA 124.857 1.263 . . . . 0.0 111.494 -173.761 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 63.5 p -116.34 -17.53 10.71 Favored 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 125.411 1.484 . . . . 0.0 112.555 -176.236 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.77 9.27 65.4 Favored Glycine 0 CA--C 1.539 1.542 0 C-N-CA 124.77 1.176 . . . . 0.0 114.944 -178.369 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 39.2 mt-30 -70.63 162.91 28.09 Favored 'General case' 0 CA--C 1.538 0.519 0 C-N-CA 125.205 1.402 . . . . 0.0 110.934 173.149 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 12.8 p80 -72.38 155.19 40.41 Favored 'General case' 0 N--CA 1.473 0.693 0 O-C-N 120.727 -1.233 . . . . 0.0 111.525 169.694 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 37.8 mt-30 -95.92 22.14 7.77 Favored 'General case' 0 CA--C 1.547 0.856 0 C-N-CA 124.225 1.01 . . . . 0.0 113.715 -171.361 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.94 3.4 83.1 Favored Glycine 0 CA--C 1.533 1.206 0 C-N-CA 125.018 1.294 . . . . 0.0 115.148 179.199 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 46.3 p90 -144.25 160.37 41.09 Favored 'General case' 0 CA--C 1.54 0.596 0 CA-C-N 118.795 1.298 . . . . 0.0 112.934 178.682 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -154.63 -177.37 27.9 Favored Glycine 0 CA--C 1.532 1.112 0 C-N-CA 125.889 1.709 . . . . 0.0 113.456 -178.777 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 89.5 m-85 -143.16 149.39 37.99 Favored 'General case' 0 C--O 1.236 0.378 0 C-N-CA 126.107 1.763 . . . . 0.0 111.617 -178.312 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 16.4 t -132.25 126.47 55.89 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.797 0 C-N-CA 124.564 1.146 . . . . 0.0 110.211 174.785 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 72.0 tt0 -102.34 123.16 45.64 Favored 'General case' 0 N--CA 1.467 0.383 0 C-N-CA 125.383 1.473 . . . . 0.0 110.575 -176.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 78.9 m-85 -100.81 161.5 13.56 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 125.226 1.411 . . . . 0.0 112.335 178.374 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.6 tp -62.33 -34.17 76.1 Favored 'General case' 0 CA--C 1.54 0.571 0 C-N-CA 123.216 0.606 . . . . 0.0 112.351 177.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 15.2 m -142.17 155.64 45.31 Favored 'General case' 0 N--CA 1.468 0.471 0 C-N-CA 124.499 1.12 . . . . 0.0 112.016 -177.141 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 13.6 tm-20 -64.12 -33.42 75.74 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.401 1.081 . . . . 0.0 113.28 -177.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -69.26 -26.5 64.8 Favored 'General case' 0 N--CA 1.472 0.652 0 N-CA-C 113.189 0.811 . . . . 0.0 113.189 176.851 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 42.0 m-20 -76.93 -33.89 57.7 Favored 'General case' 0 CA--C 1.538 0.486 0 C-N-CA 123.71 0.804 . . . . 0.0 111.375 173.202 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.9 -43.82 70.98 Favored 'General case' 0 CA--C 1.54 0.567 0 O-C-N 121.955 -0.466 . . . . 0.0 111.454 173.697 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 2.8 t70 -61.48 -30.27 70.5 Favored 'General case' 0 CA--C 1.544 0.736 0 C-N-CA 123.888 0.875 . . . . 0.0 112.706 178.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 61.8 t80 -77.99 -35.03 50.54 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.047 0.939 . . . . 0.0 113.063 173.905 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -62.8 -37.8 88.15 Favored 'General case' 0 CA--C 1.537 0.46 0 O-C-N 121.053 -1.03 . . . . 0.0 111.155 175.543 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 53.7 mt -64.11 -35.73 74.66 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 124.808 1.243 . . . . 0.0 111.185 173.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -65.81 -40.52 91.94 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 123.961 0.904 . . . . 0.0 112.473 176.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 46.3 pt -92.06 -35.88 7.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.735 0 N-CA-C 114.85 1.426 . . . . 0.0 114.85 -175.95 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' MET . . . . . 0.477 ' HA ' HD12 ' A' ' 80' ' ' ILE . 9.9 mmt -91.77 0.75 57.47 Favored 'General case' 0 N--CA 1.479 1.025 0 N-CA-C 115.134 1.531 . . . . 0.0 115.134 -171.675 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -84.82 136.82 33.51 Favored 'General case' 0 CA--C 1.538 0.519 0 O-C-N 121.391 -0.818 . . . . 0.0 112.249 179.426 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 25.5 ttm 59.71 12.25 2.83 Favored 'General case' 0 CA--C 1.549 0.924 0 C-N-CA 126.184 1.794 . . . . 0.0 114.729 -172.103 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.477 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.3 mt -69.81 151.68 9.57 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 C-N-CA 125.149 1.379 . . . . 0.0 109.927 168.941 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 47.4 mtpt -111.54 69.5 0.69 Allowed 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 124.994 1.317 . . . . 0.0 112.472 -175.521 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 31.4 tp -57.69 125.1 21.5 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 124.103 0.961 . . . . 0.0 109.99 174.808 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 54.3 m-85 46.21 27.93 0.61 Allowed 'General case' 0 CA--C 1.561 1.378 0 N-CA-C 116.366 1.987 . . . . 0.0 116.366 -168.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 80.11 25.59 57.25 Favored Glycine 0 CA--C 1.541 1.709 0 O-C-N 120.176 -1.577 . . . . 0.0 115.998 176.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -135.94 120.44 13.06 Favored Pre-proline 0 CA--C 1.543 0.694 0 C-N-CA 128.293 2.637 . . . . 0.0 107.814 -179.79 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -70.54 125.01 11.29 Favored 'Trans proline' 0 CA--C 1.538 0.684 0 C-N-CA 122.897 2.398 . . . . 0.0 112.381 -171.337 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 18.9 pt -95.33 144.72 9.42 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 C-N-CA 125.168 1.387 . . . . 0.0 111.848 176.187 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 44.9 tpt85 -111.41 128.04 55.86 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 126.145 1.778 . . . . 0.0 109.19 176.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 21.7 t -127.88 138.99 53.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 C-N-CA 124.175 0.99 . . . . 0.0 111.34 -170.569 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 31.7 t-20 -157.48 175.96 13.28 Favored 'General case' 0 CA--C 1.549 0.911 0 C-N-CA 125.467 1.507 . . . . 0.0 111.125 -179.242 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 4.8 mmmm -62.61 141.93 58.26 Favored 'General case' 0 N--CA 1.477 0.919 0 O-C-N 120.945 -1.097 . . . . 0.0 109.719 169.984 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -73.82 -11.41 60.37 Favored 'General case' 0 CA--C 1.55 0.952 0 N-CA-C 112.33 0.492 . . . . 0.0 112.33 170.04 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 64.5 p -89.03 -73.63 0.5 Allowed 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.49 1.516 . . . . 0.0 110.739 168.593 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . 52.55 30.04 7.96 Favored 'General case' 0 CA--C 1.551 0.993 0 C-N-CA 126.593 1.957 . . . . 0.0 113.618 -173.046 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 20.9 m170 -78.17 143.97 36.77 Favored 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 125.696 1.598 . . . . 0.0 111.775 -178.139 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 48.0 t30 -85.35 81.88 8.57 Favored 'General case' 0 CA--C 1.545 0.75 0 O-C-N 121.142 -0.974 . . . . 0.0 110.165 170.794 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 56.8 pttt -131.92 -7.97 3.51 Favored 'General case' 0 N--CA 1.482 1.133 0 N-CA-C 116.824 2.157 . . . . 0.0 116.824 -169.505 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 44.6 t30 -70.84 148.81 47.44 Favored 'General case' 0 CA--C 1.548 0.872 0 CA-C-N 119.554 1.07 . . . . 0.0 111.256 171.348 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 1.2 pp -146.45 165.0 30.7 Favored 'General case' 0 CA--C 1.544 0.715 0 C-N-CA 124.957 1.303 . . . . 0.0 113.523 -177.969 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 30.8 p -85.89 -37.43 19.14 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 124.972 1.309 . . . . 0.0 113.545 -179.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 54.64 50.46 57.41 Favored Glycine 0 CA--C 1.545 1.915 0 C-N-CA 125.511 1.529 . . . . 0.0 115.997 175.76 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 90.2 Cg_endo -68.05 152.27 76.74 Favored 'Trans proline' 0 CA--C 1.541 0.831 0 C-N-CA 123.498 2.799 . . . . 0.0 113.029 -177.204 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 19.7 m -80.55 -17.55 51.15 Favored 'General case' 0 N--CA 1.477 0.904 0 C-N-CA 124.391 1.076 . . . . 0.0 113.9 178.424 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 27.0 m -71.87 149.26 45.34 Favored 'General case' 0 N--CA 1.473 0.689 0 C-N-CA 125.051 1.34 . . . . 0.0 113.325 -176.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.278 0 C-N-CA 125.241 1.4 . . . . 0.0 113.44 175.141 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.602 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 28.4 m 53.05 35.54 19.8 Favored 'General case' 0 N--CA 1.482 1.162 0 C-N-CA 124.983 1.313 . . . . 0.0 113.157 -171.505 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 12.5 m -73.84 157.04 37.09 Favored 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 125.825 1.65 . . . . 0.0 113.697 -169.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -159.51 142.35 8.22 Favored Glycine 0 CA--C 1.533 1.217 0 C-N-CA 124.879 1.228 . . . . 0.0 112.362 174.375 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 73.9 p -116.07 -1.93 12.36 Favored 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 125.554 1.542 . . . . 0.0 115.087 -169.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 12.2 m -69.77 -26.15 64.15 Favored 'General case' 0 N--CA 1.475 0.801 0 N-CA-C 115.1 1.518 . . . . 0.0 115.1 -169.635 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 47.48 51.48 16.22 Favored Glycine 0 CA--C 1.544 1.868 0 C-N-CA 126.045 1.783 . . . . 0.0 116.692 -178.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_exo -68.63 115.72 4.06 Favored 'Trans proline' 0 C--N 1.354 0.867 0 CA-C-N 121.66 2.73 . . . . 0.0 113.088 -169.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 46.1 pt -140.58 155.22 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 C-N-CA 125.921 1.688 . . . . 0.0 111.746 174.782 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 71.5 p -105.48 0.65 26.92 Favored 'General case' 0 N--CA 1.478 0.927 0 C-N-CA 125.587 1.555 . . . . 0.0 114.108 177.785 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 38.2 tt0 -68.59 -38.82 80.96 Favored 'General case' 0 CA--C 1.543 0.695 0 C-N-CA 124.847 1.259 . . . . 0.0 113.757 -171.045 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 35.9 mtm180 -138.31 149.03 45.26 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.895 1.678 . . . . 0.0 111.981 -171.45 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 10.3 p-10 -75.85 -4.37 40.39 Favored 'General case' 0 CA--C 1.544 0.737 0 N-CA-C 114.653 1.353 . . . . 0.0 114.653 -177.542 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 3.2 mp0 -70.66 -9.07 56.24 Favored 'General case' 0 N--CA 1.474 0.772 0 C-N-CA 124.333 1.053 . . . . 0.0 113.609 174.533 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -99.73 -20.75 16.1 Favored 'General case' 0 CA--C 1.543 0.679 0 C-N-CA 124.6 1.16 . . . . 0.0 112.607 168.39 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -83.78 -17.47 41.01 Favored 'General case' 0 CA--C 1.544 0.746 0 C-N-CA 124.525 1.13 . . . . 0.0 112.381 168.635 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.9 m -95.68 137.44 34.73 Favored 'General case' 0 N--CA 1.466 0.344 0 C-N-CA 125.312 1.445 . . . . 0.0 109.414 170.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 11.9 m -106.71 147.93 11.58 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 C-N-CA 124.77 1.228 . . . . 0.0 110.225 171.287 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 9.5 t80 -95.19 143.03 26.94 Favored 'General case' 0 C--N 1.328 -0.363 0 C-N-CA 125.879 1.672 . . . . 0.0 108.639 169.142 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 25.4 t -130.77 109.82 17.43 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.482 0 C-N-CA 125.139 1.375 . . . . 0.0 109.204 174.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -102.76 151.4 18.09 Favored Glycine 0 CA--C 1.53 1.008 0 C-N-CA 124.647 1.118 . . . . 0.0 112.691 175.723 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.45 35.4 6.97 Favored Glycine 0 CA--C 1.533 1.171 0 C-N-CA 124.474 1.035 . . . . 0.0 113.985 174.603 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 90.2 mt -82.93 146.48 28.8 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.382 1.473 . . . . 0.0 111.94 -173.076 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -83.96 157.1 22.01 Favored 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 123.872 0.869 . . . . 0.0 112.355 175.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -58.4 -21.03 49.14 Favored 'General case' 0 CA--C 1.547 0.839 0 N-CA-C 114.718 1.377 . . . . 0.0 114.718 178.392 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.8 mtmm -80.66 -10.2 59.75 Favored 'General case' 0 N--CA 1.477 0.901 0 N-CA-C 114.269 1.211 . . . . 0.0 114.269 175.055 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 93.2 t -75.18 138.94 19.94 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.918 0 C-N-CA 124.429 1.092 . . . . 0.0 111.56 178.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 92.5 p -136.99 162.09 34.26 Favored 'General case' 0 N--CA 1.475 0.779 0 C-N-CA 125.178 1.391 . . . . 0.0 112.414 178.672 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -54.73 -46.38 99.4 Favored Pre-proline 0 N--CA 1.478 0.969 0 O-C-N 120.786 -1.196 . . . . 0.0 113.158 174.652 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_exo -57.78 -33.2 96.54 Favored 'Trans proline' 0 C--N 1.354 0.819 0 C-N-CA 122.406 2.071 . . . . 0.0 114.058 173.196 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 28.1 tp -67.43 -51.08 55.95 Favored 'General case' 0 C--N 1.343 0.291 0 CA-C-N 118.687 0.676 . . . . 0.0 110.163 173.491 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 21.2 mt -61.7 -23.06 65.87 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 113.338 0.866 . . . . 0.0 113.338 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.3 t90 -74.41 -66.16 0.77 Allowed 'General case' 0 C--N 1.328 -0.364 0 C-N-CA 123.01 0.524 . . . . 0.0 110.965 170.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -65.02 -30.35 71.32 Favored 'General case' 0 N--CA 1.473 0.695 0 N-CA-C 114.172 1.175 . . . . 0.0 114.172 -172.543 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.2 tp -68.81 -34.37 75.41 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 123.673 0.789 . . . . 0.0 111.655 175.114 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -90.03 -10.66 44.04 Favored 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 125.156 1.382 . . . . 0.0 113.812 -174.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 47.7 mt -56.23 -17.69 8.22 Favored 'General case' 0 CA--C 1.545 0.765 0 N-CA-C 113.873 1.064 . . . . 0.0 113.873 169.031 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 42.0 mt-30 -64.03 -34.84 78.93 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 125.177 1.391 . . . . 0.0 112.624 171.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -77.84 -46.26 21.99 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.371 0.669 . . . . 0.0 112.451 179.31 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.27 -172.06 44.03 Favored Glycine 0 CA--C 1.537 1.411 0 C-N-CA 125.013 1.292 . . . . 0.0 112.594 -178.899 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.9 Cg_endo -68.03 110.21 2.13 Favored 'Trans proline' 0 CA--C 1.537 0.655 0 C-N-CA 123.608 2.872 . . . . 0.0 111.698 -179.319 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 61.8 t -84.86 133.64 28.84 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 124.872 1.269 . . . . 0.0 109.785 173.766 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 5.2 t -109.44 -33.65 2.46 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.743 0 C-N-CA 126.38 1.872 . . . . 0.0 111.923 -171.767 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 17.4 t30 -160.52 161.35 32.71 Favored 'General case' 0 CA--C 1.553 1.072 0 C-N-CA 125.974 1.71 . . . . 0.0 110.968 -173.554 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 7.7 p -140.98 154.59 46.11 Favored 'General case' 0 N--CA 1.48 1.028 0 C-N-CA 126.409 1.883 . . . . 0.0 111.343 174.563 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 42.0 t-80 -142.38 134.45 27.37 Favored 'General case' 0 N--CA 1.473 0.678 0 C-N-CA 123.386 0.674 . . . . 0.0 112.478 175.362 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 36.4 mmm -132.34 102.54 14.15 Favored Pre-proline 0 CA--C 1.543 0.676 0 C-N-CA 125.139 1.375 . . . . 0.0 110.471 175.191 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -60.11 144.31 99.49 Favored 'Trans proline' 0 C--N 1.35 0.606 0 C-N-CA 123.533 2.822 . . . . 0.0 113.46 177.763 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 26.1 mmtp -113.47 159.84 19.09 Favored 'General case' 0 N--CA 1.474 0.762 0 C-N-CA 125.313 1.445 . . . . 0.0 113.545 -174.046 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -87.95 136.82 32.79 Favored 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.751 1.62 . . . . 0.0 112.332 170.973 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 10.0 ptp180 -82.7 8.85 10.96 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 115.649 1.722 . . . . 0.0 115.649 -173.672 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 39.3 t -130.67 -37.1 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.48 1.046 0 C-N-CA 125.066 1.346 . . . . 0.0 111.265 -175.051 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 66.9 p -114.27 -15.82 12.11 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 125.502 1.521 . . . . 0.0 112.569 -176.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 71.06 6.39 60.43 Favored Glycine 0 CA--C 1.535 1.312 0 C-N-CA 124.933 1.254 . . . . 0.0 115.151 176.405 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 74.4 mm-40 -79.97 162.71 24.76 Favored 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 124.99 1.316 . . . . 0.0 110.777 177.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 10.0 p80 -71.46 155.15 40.93 Favored 'General case' 0 CA--C 1.539 0.534 0 O-C-N 121.317 -0.865 . . . . 0.0 112.381 176.077 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 28.0 mm-40 -84.63 13.54 5.56 Favored 'General case' 0 CA--C 1.548 0.876 0 N-CA-C 114.431 1.271 . . . . 0.0 114.431 -170.256 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.0 -0.13 87.51 Favored Glycine 0 CA--C 1.536 1.355 0 C-N-CA 125.165 1.364 . . . . 0.0 114.701 -178.156 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 45.2 p90 -144.2 157.67 44.16 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 125.19 1.396 . . . . 0.0 112.299 177.283 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -144.98 -179.53 21.38 Favored Glycine 0 CA--C 1.534 1.243 0 C-N-CA 126.996 2.236 . . . . 0.0 112.317 -176.444 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 83.2 m-85 -142.58 150.14 39.96 Favored 'General case' 0 C--O 1.237 0.438 0 C-N-CA 125.594 1.558 . . . . 0.0 112.114 179.557 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.3 t -134.6 129.5 52.33 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 C-N-CA 125.05 1.34 . . . . 0.0 109.825 176.641 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 62.1 tt0 -108.85 123.3 48.84 Favored 'General case' 0 N--CA 1.466 0.37 0 C-N-CA 124.414 1.086 . . . . 0.0 111.575 -177.038 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -97.5 161.51 13.75 Favored 'General case' 0 C--O 1.234 0.277 0 C-N-CA 125.209 1.404 . . . . 0.0 112.51 178.128 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 14.7 tp -62.51 -33.8 75.6 Favored 'General case' 0 CA--C 1.541 0.619 0 C-N-CA 123.199 0.6 . . . . 0.0 112.32 177.115 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 17.0 m -141.88 155.5 45.52 Favored 'General case' 0 N--CA 1.467 0.422 0 C-N-CA 124.422 1.089 . . . . 0.0 112.049 -177.751 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 13.9 tm-20 -62.85 -33.38 75.14 Favored 'General case' 0 N--CA 1.472 0.65 0 C-N-CA 124.487 1.115 . . . . 0.0 113.119 -179.565 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -68.4 -25.75 65.21 Favored 'General case' 0 CA--C 1.541 0.633 0 N-CA-C 113.208 0.818 . . . . 0.0 113.208 177.27 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 46.6 m-20 -78.46 -33.1 48.61 Favored 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 123.895 0.878 . . . . 0.0 111.491 173.526 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -70.63 -44.07 67.95 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 123.197 0.599 . . . . 0.0 111.474 173.916 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -62.94 -27.57 69.47 Favored 'General case' 0 CA--C 1.542 0.643 0 C-N-CA 124.157 0.983 . . . . 0.0 112.846 178.396 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 67.9 t80 -79.73 -35.37 38.99 Favored 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 124.3 1.04 . . . . 0.0 112.801 172.351 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.22 -38.99 93.34 Favored 'General case' 0 CA--C 1.538 0.499 0 O-C-N 121.054 -1.029 . . . . 0.0 111.072 177.736 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 70.4 mt -58.24 -38.64 69.8 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.601 0 C-N-CA 125.481 1.512 . . . . 0.0 111.372 172.792 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 84.3 tttt -67.84 -34.7 77.22 Favored 'General case' 0 N--CA 1.472 0.641 0 C-N-CA 124.314 1.046 . . . . 0.0 113.168 179.249 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 20.2 pt -101.62 -14.22 8.13 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.865 0 N-CA-C 115.899 1.815 . . . . 0.0 115.899 -173.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' MET . . . . . . . . . . . . . 7.9 mmt -111.6 -3.39 15.11 Favored 'General case' 0 N--CA 1.483 1.195 0 N-CA-C 115.453 1.649 . . . . 0.0 115.453 -176.037 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -82.49 142.23 32.04 Favored 'General case' 0 N--CA 1.475 0.795 0 O-C-N 120.674 -1.266 . . . . 0.0 113.9 -173.4 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 26.4 ttm 60.65 16.98 7.06 Favored 'General case' 0 N--CA 1.478 0.928 0 C-N-CA 127.801 2.44 . . . . 0.0 115.21 -176.133 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 23.1 mt -91.39 142.04 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 C-N-CA 126.453 1.901 . . . . 0.0 111.999 -174.685 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 40.6 mtpt -93.67 67.58 3.9 Favored 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 124.466 1.106 . . . . 0.0 113.003 -168.102 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 38.5 tp -58.46 121.25 10.44 Favored 'General case' 0 CA--C 1.542 0.662 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 173.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 52.9 m-85 44.77 30.04 0.5 Allowed 'General case' 0 CA--C 1.56 1.358 0 N-CA-C 116.152 1.908 . . . . 0.0 116.152 -168.688 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 87.38 12.4 67.46 Favored Glycine 0 CA--C 1.543 1.806 0 N-CA-C 117.345 1.698 . . . . 0.0 117.345 174.433 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 60.3 mttp -125.01 121.92 25.44 Favored Pre-proline 0 CA--C 1.541 0.62 0 C-N-CA 127.569 2.348 . . . . 0.0 108.57 176.571 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -72.86 112.82 3.6 Favored 'Trans proline' 0 CA--C 1.533 0.471 0 C-N-CA 123.957 3.104 . . . . 0.0 111.599 -171.239 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 8.2 pt -80.72 145.89 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 C-N-CA 123.861 0.865 . . . . 0.0 111.3 -177.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -114.45 127.97 56.1 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 125.665 1.586 . . . . 0.0 109.482 177.707 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 6.3 t -127.68 134.89 64.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 124.095 0.958 . . . . 0.0 111.838 -169.258 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 1.7 p-10 -158.58 172.39 18.38 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.872 1.669 . . . . 0.0 111.565 179.472 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 4.2 mmmm -58.28 140.92 52.42 Favored 'General case' 0 N--CA 1.483 1.212 0 O-C-N 121.346 -0.846 . . . . 0.0 109.371 171.068 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -61.6 -30.21 70.54 Favored 'General case' 0 CA--C 1.544 0.741 0 N-CA-C 114.524 1.305 . . . . 0.0 114.524 -169.17 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 17.9 m -134.86 57.92 1.79 Allowed 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 124.514 1.126 . . . . 0.0 110.748 169.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -51.8 142.97 13.96 Favored 'General case' 0 CA--C 1.547 0.852 0 C-N-CA 124.934 1.293 . . . . 0.0 113.918 -175.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 16.2 p80 -142.95 143.6 32.04 Favored 'General case' 0 N--CA 1.473 0.698 0 C-N-CA 125.564 1.546 . . . . 0.0 112.001 -174.573 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 6.8 t-20 -152.63 9.71 0.47 Allowed 'General case' 0 CA--C 1.552 1.025 0 N-CA-C 114.191 1.182 . . . . 0.0 114.191 -178.017 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -80.68 141.23 35.11 Favored 'General case' 0 N--CA 1.475 0.823 0 C-N-CA 124.878 1.271 . . . . 0.0 113.1 -169.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 12.5 p-10 -145.37 152.01 39.18 Favored 'General case' 0 CA--C 1.545 0.762 0 C-N-CA 126.357 1.863 . . . . 0.0 110.78 169.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 7.8 tt -76.08 -47.29 25.12 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 123.721 0.808 . . . . 0.0 111.504 -178.737 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 8.1 t -152.88 174.71 13.75 Favored 'General case' 0 N--CA 1.471 0.618 0 C-N-CA 125.803 1.641 . . . . 0.0 110.867 176.688 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -77.82 169.33 54.61 Favored Glycine 0 CA--C 1.543 1.832 0 C-N-CA 124.346 0.974 . . . . 0.0 113.594 172.33 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_endo -69.71 155.71 65.39 Favored 'Trans proline' 0 CA--C 1.541 0.831 0 C-N-CA 123.637 2.891 . . . . 0.0 112.533 176.614 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 22.9 m -68.88 148.97 49.44 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 124.325 1.05 . . . . 0.0 112.837 178.732 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 40.5 m -69.01 150.96 47.08 Favored 'General case' 0 N--CA 1.473 0.713 0 C-N-CA 124.401 1.08 . . . . 0.0 112.871 178.026 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.28 0 C-N-CA 125.146 1.355 . . . . 0.0 113.643 175.802 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.576 0 N-CA-C 111.95 -0.46 . . . . 0.0 111.95 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 53.2 p -76.87 160.53 29.16 Favored 'General case' 0 N--CA 1.475 0.781 0 C-N-CA 124.865 1.266 . . . . 0.0 113.22 177.539 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 46.2 t -70.52 145.75 50.65 Favored 'General case' 0 N--CA 1.473 0.695 0 C-N-CA 124.025 0.93 . . . . 0.0 112.554 178.156 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.44 -12.04 60.57 Favored Glycine 0 CA--C 1.539 1.554 0 C-N-CA 124.257 0.932 . . . . 0.0 114.516 173.321 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 45.8 m -80.8 5.25 16.48 Favored 'General case' 0 N--CA 1.475 0.811 0 C-N-CA 125.06 1.344 . . . . 0.0 114.182 177.09 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 89.7 p -68.92 -21.56 64.2 Favored 'General case' 0 N--CA 1.475 0.806 0 N-CA-C 114.864 1.431 . . . . 0.0 114.864 -176.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 174.72 -171.33 44.49 Favored Glycine 0 CA--C 1.539 1.56 0 C-N-CA 124.756 1.169 . . . . 0.0 113.794 178.756 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -65.31 -23.91 58.53 Favored 'Trans proline' 0 CA--C 1.54 0.795 0 C-N-CA 123.591 2.86 . . . . 0.0 115.124 -176.513 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 16.8 tt -145.23 129.05 11.87 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 125.363 1.465 . . . . 0.0 111.697 179.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 21.7 m -100.9 -15.25 17.62 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 124.914 1.286 . . . . 0.0 112.888 170.246 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 21.4 tt0 -85.0 33.54 0.54 Allowed 'General case' 0 CA--C 1.55 0.943 0 C-N-CA 125.97 1.708 . . . . 0.0 112.526 -178.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 17.8 ptp180 -80.15 44.0 0.65 Allowed 'General case' 0 N--CA 1.478 0.932 0 C-N-CA 126.944 2.098 . . . . 0.0 114.012 -172.107 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 64.4 t-20 -65.83 107.39 1.8 Allowed 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 124.898 1.279 . . . . 0.0 112.094 -174.397 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 31.4 tp60 -85.22 -20.78 29.63 Favored 'General case' 0 CA--C 1.542 0.65 0 C-N-CA 124.142 0.977 . . . . 0.0 113.031 179.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -69.88 -24.69 63.45 Favored 'General case' 0 N--CA 1.474 0.765 0 O-C-N 120.726 -1.234 . . . . 0.0 112.489 172.486 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -75.24 -0.01 18.06 Favored 'General case' 0 CA--C 1.548 0.884 0 C-N-CA 123.959 0.904 . . . . 0.0 113.082 168.904 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 37.4 m -105.18 134.75 47.76 Favored 'General case' 0 N--CA 1.471 0.592 0 C-N-CA 124.806 1.243 . . . . 0.0 109.298 169.284 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.0 m -99.05 147.93 6.63 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 123.915 0.886 . . . . 0.0 110.327 171.895 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 28.4 t80 -95.29 142.14 28.05 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.737 1.615 . . . . 0.0 109.067 169.193 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 31.3 t -133.21 108.65 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 C-N-CA 125.602 1.561 . . . . 0.0 109.443 178.331 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -102.75 151.78 18.14 Favored Glycine 0 CA--C 1.53 1.024 0 C-N-CA 124.475 1.036 . . . . 0.0 112.997 175.393 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 91.66 35.26 6.95 Favored Glycine 0 CA--C 1.532 1.143 0 C-N-CA 124.347 0.975 . . . . 0.0 113.924 172.485 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 91.1 mt -79.11 145.39 33.78 Favored 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 125.398 1.479 . . . . 0.0 111.542 -174.024 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -82.25 156.41 24.37 Favored 'General case' 0 CA--C 1.542 0.665 0 C-N-CA 123.444 0.698 . . . . 0.0 112.184 175.052 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -58.59 -20.5 47.61 Favored 'General case' 0 CA--C 1.546 0.807 0 N-CA-C 114.632 1.345 . . . . 0.0 114.632 178.126 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 37.8 mtmm -81.59 -9.69 59.61 Favored 'General case' 0 N--CA 1.476 0.87 0 C-N-CA 124.919 1.288 . . . . 0.0 114.279 174.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 84.9 t -74.78 138.61 20.68 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.908 0 C-N-CA 124.404 1.082 . . . . 0.0 111.437 177.664 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 51.8 m -135.14 162.64 31.92 Favored 'General case' 0 N--CA 1.477 0.888 0 C-N-CA 124.782 1.233 . . . . 0.0 111.698 173.473 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -57.32 -38.9 73.03 Favored Pre-proline 0 CA--C 1.546 0.821 0 N-CA-C 114.6 1.333 . . . . 0.0 114.6 -179.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -64.76 -28.49 59.69 Favored 'Trans proline' 0 C--N 1.353 0.786 0 C-N-CA 122.281 1.987 . . . . 0.0 113.605 173.066 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 27.1 tp -68.22 -50.43 54.14 Favored 'General case' 0 C--N 1.343 0.309 0 CA-C-N 118.626 0.648 . . . . 0.0 109.791 172.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 20.6 mt -61.36 -23.01 65.46 Favored 'General case' 0 N--CA 1.465 0.298 0 N-CA-C 112.972 0.73 . . . . 0.0 112.972 178.529 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.7 t90 -74.22 -66.15 0.76 Allowed 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 123.281 0.632 . . . . 0.0 111.002 171.038 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -64.82 -30.3 71.3 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 114.222 1.193 . . . . 0.0 114.222 -172.726 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.0 tp -69.23 -34.16 74.41 Favored 'General case' 0 CA--C 1.541 0.608 0 C-N-CA 123.842 0.857 . . . . 0.0 111.799 175.504 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 19.9 m-85 -90.1 -10.71 43.67 Favored 'General case' 0 N--CA 1.469 0.52 0 C-N-CA 125.124 1.37 . . . . 0.0 113.337 -175.1 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 46.5 mt -55.21 -19.35 7.81 Favored 'General case' 0 N--CA 1.475 0.777 0 N-CA-C 113.853 1.057 . . . . 0.0 113.853 169.313 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 41.0 mt-30 -64.96 -32.57 74.35 Favored 'General case' 0 N--CA 1.472 0.637 0 C-N-CA 125.269 1.427 . . . . 0.0 112.592 173.163 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -78.36 -44.08 26.0 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 123.311 0.645 . . . . 0.0 112.639 177.629 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 177.34 -173.68 46.39 Favored Glycine 0 CA--C 1.538 1.517 0 C-N-CA 125.181 1.372 . . . . 0.0 112.498 -179.733 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -66.89 111.22 2.12 Favored 'Trans proline' 0 CA--C 1.539 0.731 0 C-N-CA 123.651 2.9 . . . . 0.0 111.827 -179.431 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 67.1 t -86.51 135.57 24.82 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 C-N-CA 125.12 1.368 . . . . 0.0 109.78 173.8 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 7.8 t -110.32 -33.64 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.759 0 C-N-CA 126.172 1.789 . . . . 0.0 111.939 -171.657 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 21.6 t30 -160.92 161.24 31.64 Favored 'General case' 0 CA--C 1.553 1.072 0 C-N-CA 125.752 1.621 . . . . 0.0 111.074 -175.381 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 4.7 p -137.36 155.18 49.71 Favored 'General case' 0 N--CA 1.481 1.084 0 C-N-CA 125.938 1.695 . . . . 0.0 111.801 171.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 51.2 t-80 -142.15 132.69 25.28 Favored 'General case' 0 N--CA 1.466 0.357 0 C-N-CA 123.67 0.788 . . . . 0.0 110.838 176.105 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 89.5 mtp -133.89 107.61 11.65 Favored Pre-proline 0 N--CA 1.469 0.515 0 C-N-CA 124.113 0.965 . . . . 0.0 109.493 169.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 85.9 Cg_exo -57.57 142.64 95.59 Favored 'Trans proline' 0 CA--C 1.537 0.661 0 C-N-CA 123.082 2.521 . . . . 0.0 112.897 176.234 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 43.3 mmtm -114.59 159.41 20.47 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 125.218 1.407 . . . . 0.0 113.247 -172.598 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -77.33 141.48 39.87 Favored 'General case' 0 CA--C 1.544 0.737 0 C-N-CA 125.797 1.639 . . . . 0.0 111.418 169.357 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 53.1 ptt85 -83.72 6.39 21.25 Favored 'General case' 0 N--CA 1.479 0.98 0 N-CA-C 115.982 1.845 . . . . 0.0 115.982 -173.582 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 32.4 t -131.31 -37.54 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.128 0 C-N-CA 124.95 1.3 . . . . 0.0 111.471 -174.128 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 68.5 p -113.42 -14.01 12.79 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 125.764 1.626 . . . . 0.0 112.54 -176.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 70.26 5.67 55.02 Favored Glycine 0 CA--C 1.536 1.403 0 C-N-CA 125.09 1.328 . . . . 0.0 115.452 175.223 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 72.1 mm-40 -76.43 159.36 30.51 Favored 'General case' 0 CA--C 1.538 0.489 0 C-N-CA 124.701 1.2 . . . . 0.0 110.717 176.727 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 22.7 p80 -72.23 155.56 40.09 Favored 'General case' 0 N--CA 1.473 0.715 0 O-C-N 120.931 -1.106 . . . . 0.0 113.023 179.841 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 81.9 mt-30 -80.68 11.91 3.5 Favored 'General case' 0 CA--C 1.552 1.052 0 N-CA-C 114.492 1.293 . . . . 0.0 114.492 -174.846 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.76 1.59 79.99 Favored Glycine 0 CA--C 1.538 1.489 0 C-N-CA 125.122 1.344 . . . . 0.0 114.912 -178.049 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 40.2 p90 -144.74 162.03 37.74 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.035 1.334 . . . . 0.0 112.341 178.459 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -153.04 -176.2 25.3 Favored Glycine 0 CA--C 1.532 1.114 0 C-N-CA 125.947 1.737 . . . . 0.0 113.186 -177.943 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 81.9 m-85 -144.03 149.73 37.14 Favored 'General case' 0 C--O 1.237 0.437 0 C-N-CA 126.073 1.749 . . . . 0.0 111.585 -178.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 14.9 t -132.99 126.41 53.58 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 124.582 1.153 . . . . 0.0 110.13 176.416 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 59.2 tt0 -102.83 122.42 44.49 Favored 'General case' 0 N--CA 1.466 0.361 0 C-N-CA 125.218 1.407 . . . . 0.0 110.718 -175.643 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -101.33 159.63 15.1 Favored 'General case' 0 C--O 1.234 0.258 0 C-N-CA 124.839 1.256 . . . . 0.0 112.613 179.206 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 14.6 tp -62.63 -35.12 78.58 Favored 'General case' 0 CA--C 1.539 0.538 0 C-N-CA 123.442 0.697 . . . . 0.0 112.504 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 14.4 m -140.96 157.03 45.92 Favored 'General case' 0 N--CA 1.468 0.456 0 C-N-CA 124.659 1.183 . . . . 0.0 110.944 -179.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 58.5 tt0 -64.72 -35.33 80.72 Favored 'General case' 0 N--CA 1.471 0.58 0 O-C-N 121.499 -0.75 . . . . 0.0 112.863 -176.519 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -64.67 -24.57 67.62 Favored 'General case' 0 N--CA 1.473 0.721 0 N-CA-C 113.459 0.911 . . . . 0.0 113.459 177.657 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 52.1 m-20 -78.24 -33.78 49.54 Favored 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 123.9 0.88 . . . . 0.0 111.73 173.298 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -70.07 -43.21 71.64 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 123.075 0.55 . . . . 0.0 111.379 171.706 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -60.35 -32.02 70.87 Favored 'General case' 0 CA--C 1.543 0.68 0 C-N-CA 124.669 1.188 . . . . 0.0 112.505 179.499 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 63.4 t80 -78.82 -35.22 44.44 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 124.213 1.005 . . . . 0.0 113.036 173.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -63.38 -36.74 84.7 Favored 'General case' 0 CA--C 1.537 0.466 0 O-C-N 120.978 -1.076 . . . . 0.0 111.211 176.553 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 56.2 mt -62.74 -36.92 77.58 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.674 0 C-N-CA 124.718 1.207 . . . . 0.0 111.318 172.813 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -66.51 -40.07 89.01 Favored 'General case' 0 N--CA 1.471 0.583 0 C-N-CA 124.274 1.029 . . . . 0.0 112.255 178.639 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 21.9 pt -91.41 -40.72 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.572 0 N-CA-C 114.409 1.263 . . . . 0.0 114.409 -176.934 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' MET . . . . . 0.487 ' HA ' HD12 ' A' ' 80' ' ' ILE . 12.5 mmt -88.16 1.46 54.35 Favored 'General case' 0 N--CA 1.48 1.063 0 N-CA-C 115.144 1.535 . . . . 0.0 115.144 -169.708 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -83.43 134.63 34.86 Favored 'General case' 0 CA--C 1.539 0.548 0 O-C-N 121.316 -0.865 . . . . 0.0 112.311 -179.064 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 24.6 ttm 58.8 15.0 3.52 Favored 'General case' 0 CA--C 1.549 0.914 0 C-N-CA 126.985 2.114 . . . . 0.0 114.686 -169.58 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.487 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.9 mt -72.54 137.9 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.562 0 C-N-CA 124.33 1.052 . . . . 0.0 111.189 173.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 41.6 mtpt -95.03 64.43 2.79 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 124.566 1.146 . . . . 0.0 112.395 -169.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 28.0 tp -58.99 120.39 9.01 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 123.595 0.758 . . . . 0.0 109.167 174.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 57.7 m-85 44.75 31.17 0.62 Allowed 'General case' 0 CA--C 1.562 1.411 0 N-CA-C 115.949 1.833 . . . . 0.0 115.949 -168.286 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 87.87 8.81 72.24 Favored Glycine 0 CA--C 1.542 1.76 0 N-CA-C 117.461 1.744 . . . . 0.0 117.461 173.88 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 60.1 mttp -119.42 119.38 31.71 Favored Pre-proline 0 CA--C 1.54 0.585 0 C-N-CA 127.497 2.319 . . . . 0.0 108.78 177.698 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -72.65 98.46 0.97 Allowed 'Trans proline' 0 CA--C 1.538 0.723 0 C-N-CA 124.152 3.234 . . . . 0.0 111.672 -173.409 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 6.5 pt -66.65 148.51 12.06 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.554 0 C-N-CA 124.44 1.096 . . . . 0.0 111.124 -177.266 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 33.5 mmt-85 -111.68 127.67 55.84 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.571 1.148 . . . . 0.0 109.95 178.826 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 17.0 t -128.0 137.21 58.17 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.803 0 C-N-CA 124.054 0.942 . . . . 0.0 111.501 -169.518 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 30.6 t-20 -159.76 174.97 13.71 Favored 'General case' 0 CA--C 1.55 0.96 0 C-N-CA 125.501 1.52 . . . . 0.0 111.051 177.549 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 6.5 mmmm -62.0 141.04 58.29 Favored 'General case' 0 N--CA 1.48 1.052 0 O-C-N 120.849 -1.157 . . . . 0.0 109.704 172.191 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -70.75 -13.26 61.99 Favored 'General case' 0 CA--C 1.552 1.032 0 N-CA-C 113.699 1.0 . . . . 0.0 113.699 178.417 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 74.0 m -123.33 39.6 3.92 Favored 'General case' 0 N--CA 1.479 0.983 0 C-N-CA 126.328 1.851 . . . . 0.0 112.501 173.088 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -61.39 -25.32 67.1 Favored 'General case' 0 CA--C 1.548 0.882 0 N-CA-C 115.269 1.581 . . . . 0.0 115.269 -174.12 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 97.2 m-70 -83.49 132.52 34.94 Favored 'General case' 0 N--CA 1.472 0.638 0 C-N-CA 124.037 0.935 . . . . 0.0 112.045 179.455 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 56.6 t30 -80.97 158.3 25.24 Favored 'General case' 0 CA--C 1.546 0.809 0 C-N-CA 123.941 0.896 . . . . 0.0 112.582 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 63.9 tttm -65.56 -26.62 67.95 Favored 'General case' 0 N--CA 1.478 0.954 0 C-N-CA 124.845 1.258 . . . . 0.0 113.732 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 21.7 t-20 -137.8 149.92 46.77 Favored 'General case' 0 CA--C 1.547 0.853 0 C-N-CA 125.325 1.45 . . . . 0.0 111.779 176.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 35.8 tp -95.78 -19.55 19.55 Favored 'General case' 0 CA--C 1.547 0.843 0 N-CA-C 114.217 1.191 . . . . 0.0 114.217 -173.377 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 50.8 m -74.25 141.2 45.38 Favored 'General case' 0 N--CA 1.473 0.72 0 O-C-N 121.233 -0.917 . . . . 0.0 113.263 -172.342 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -78.88 170.43 54.72 Favored Glycine 0 CA--C 1.543 1.788 0 C-N-CA 124.327 0.965 . . . . 0.0 113.989 174.492 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -75.63 -18.19 17.61 Favored 'Trans proline' 0 CA--C 1.543 0.961 0 C-N-CA 123.863 3.042 . . . . 0.0 113.828 -179.777 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 85.3 p -149.7 176.05 11.03 Favored 'General case' 0 N--CA 1.472 0.647 0 C-N-CA 125.998 1.719 . . . . 0.0 112.025 -178.726 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 58.4 p -74.96 -5.9 46.41 Favored 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 114.616 1.339 . . . . 0.0 114.616 175.44 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.298 0 C-N-CA 125.734 1.635 . . . . 0.0 113.721 -179.885 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.604 0 N-CA-C 111.438 -0.665 . . . . 0.0 111.438 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 33.7 m -69.99 151.43 45.59 Favored 'General case' 0 N--CA 1.475 0.806 0 C-N-CA 124.523 1.129 . . . . 0.0 113.301 -178.468 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 67.5 p -90.23 -1.07 57.89 Favored 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 125.426 1.49 . . . . 0.0 114.988 -177.613 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -69.41 172.12 39.07 Favored Glycine 0 CA--C 1.539 1.55 0 C-N-CA 124.962 1.268 . . . . 0.0 114.98 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 47.3 t -144.89 154.19 42.36 Favored 'General case' 0 N--CA 1.473 0.677 0 C-N-CA 125.501 1.52 . . . . 0.0 112.325 -177.503 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 18.0 m -81.03 -4.59 55.68 Favored 'General case' 0 N--CA 1.476 0.841 0 C-N-CA 125.132 1.373 . . . . 0.0 113.468 172.04 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -76.2 -179.2 46.1 Favored Glycine 0 CA--C 1.544 1.853 0 C-N-CA 124.455 1.026 . . . . 0.0 113.683 170.481 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 88.4 Cg_endo -69.82 143.33 50.2 Favored 'Trans proline' 0 CA--C 1.542 0.886 0 C-N-CA 123.183 2.589 . . . . 0.0 111.348 175.879 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 10.0 tp -80.94 148.14 5.79 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 124.096 0.959 . . . . 0.0 112.019 -177.762 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 17.4 m -66.56 -12.91 59.99 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 114.342 1.238 . . . . 0.0 114.342 -178.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -79.69 -12.85 59.79 Favored 'General case' 0 CA--C 1.544 0.75 0 C-N-CA 124.596 1.159 . . . . 0.0 113.405 176.381 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 23.8 mmt180 -90.63 153.39 20.35 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 125.378 1.471 . . . . 0.0 111.492 177.019 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 64.3 t-20 -81.18 84.27 6.6 Favored 'General case' 0 CA--C 1.537 0.459 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 175.34 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -66.62 -17.03 64.62 Favored 'General case' 0 CA--C 1.539 0.557 0 N-CA-C 113.876 1.065 . . . . 0.0 113.876 -171.762 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -85.71 -25.23 26.59 Favored 'General case' 0 CA--C 1.543 0.68 0 CA-C-N 119.308 0.958 . . . . 0.0 112.939 174.136 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -94.59 2.04 55.64 Favored 'General case' 0 CA--C 1.546 0.802 0 C-N-CA 124.756 1.222 . . . . 0.0 112.704 168.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 36.0 m -101.94 136.96 40.87 Favored 'General case' 0 N--CA 1.468 0.453 0 C-N-CA 124.988 1.315 . . . . 0.0 109.374 172.365 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 15.2 m -101.52 148.05 7.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.546 0 C-N-CA 123.96 0.904 . . . . 0.0 110.362 171.788 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 25.3 t80 -95.34 141.33 29.03 Favored 'General case' 0 C--N 1.327 -0.371 0 C-N-CA 126.018 1.727 . . . . 0.0 108.848 169.019 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 20.2 t -129.07 115.87 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 C-N-CA 125.532 1.533 . . . . 0.0 108.875 175.667 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -113.37 145.63 18.36 Favored Glycine 0 CA--C 1.531 1.034 0 C-N-CA 124.573 1.082 . . . . 0.0 112.793 178.854 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 94.7 33.27 6.8 Favored Glycine 0 CA--C 1.533 1.213 0 C-N-CA 124.404 1.002 . . . . 0.0 113.738 176.541 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 84.4 mt -72.36 151.96 42.36 Favored 'General case' 0 CA--C 1.531 0.237 0 C-N-CA 125.482 1.513 . . . . 0.0 111.405 -174.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -91.75 157.3 16.99 Favored 'General case' 0 CA--C 1.543 0.677 0 C-N-CA 123.561 0.744 . . . . 0.0 111.967 174.426 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -58.38 -20.93 48.06 Favored 'General case' 0 N--CA 1.475 0.824 0 O-C-N 120.607 -1.308 . . . . 0.0 114.478 179.124 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 27.3 mtpp -76.27 -15.52 59.99 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 124.77 1.228 . . . . 0.0 114.233 174.479 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 93.8 t -73.19 141.56 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.944 0 C-N-CA 124.553 1.141 . . . . 0.0 111.868 -177.137 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 96.4 p -136.74 162.72 32.41 Favored 'General case' 0 N--CA 1.472 0.656 0 C-N-CA 125.316 1.447 . . . . 0.0 112.36 175.268 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.2 mt-10 -59.65 -40.41 79.01 Favored Pre-proline 0 CA--C 1.546 0.817 0 O-C-N 120.79 -1.194 . . . . 0.0 113.59 177.519 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_exo -62.04 -30.52 83.04 Favored 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 122.474 2.116 . . . . 0.0 113.839 170.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 26.4 tp -68.57 -50.57 50.74 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 119.031 0.832 . . . . 0.0 109.906 173.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 20.5 mt -60.91 -22.35 64.26 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 113.026 0.75 . . . . 0.0 113.026 178.341 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.7 t90 -74.42 -66.87 0.68 Allowed 'General case' 0 C--N 1.328 -0.338 0 C-N-CA 123.123 0.569 . . . . 0.0 110.863 170.854 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.7 mt-10 -65.14 -29.7 70.56 Favored 'General case' 0 N--CA 1.471 0.619 0 N-CA-C 114.218 1.192 . . . . 0.0 114.218 -172.239 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.7 tp -69.99 -33.31 71.88 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 123.692 0.797 . . . . 0.0 111.845 175.586 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 21.7 m-85 -90.24 -10.96 42.35 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 124.945 1.298 . . . . 0.0 113.409 -175.067 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 49.4 mt -55.13 -18.14 5.2 Favored 'General case' 0 CA--C 1.547 0.844 0 C-N-CA 124.437 1.095 . . . . 0.0 113.889 169.21 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 75.4 mt-30 -63.52 -34.4 77.71 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 125.785 1.634 . . . . 0.0 112.606 172.948 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -79.92 -45.15 19.07 Favored 'General case' 0 CA--C 1.539 0.532 0 C-N-CA 123.657 0.783 . . . . 0.0 112.61 178.421 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.71 -172.98 44.76 Favored Glycine 0 CA--C 1.535 1.286 0 C-N-CA 124.595 1.093 . . . . 0.0 112.932 178.491 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -67.09 111.17 2.15 Favored 'Trans proline' 0 CA--C 1.538 0.708 0 C-N-CA 123.719 2.946 . . . . 0.0 111.715 -179.101 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 82.9 t -84.99 134.8 26.19 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.57 0 C-N-CA 124.96 1.304 . . . . 0.0 109.67 173.364 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 4.1 t -108.04 -33.96 2.65 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 126.222 1.809 . . . . 0.0 111.656 -173.202 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 4.7 t30 -161.61 158.27 25.92 Favored 'General case' 0 CA--C 1.553 1.063 0 C-N-CA 125.956 1.702 . . . . 0.0 111.465 -174.468 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 5.9 p -133.8 153.88 51.41 Favored 'General case' 0 N--CA 1.481 1.097 0 C-N-CA 125.773 1.629 . . . . 0.0 112.389 171.122 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 2.6 t60 -141.03 130.83 24.27 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 124.283 1.033 . . . . 0.0 111.088 178.939 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 86.4 mtp -134.57 102.51 11.51 Favored Pre-proline 0 N--CA 1.472 0.655 0 C-N-CA 124.336 1.054 . . . . 0.0 109.461 169.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -60.95 127.36 22.09 Favored 'Trans proline' 0 CA--C 1.537 0.634 0 C-N-CA 123.172 2.581 . . . . 0.0 113.076 -178.703 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 44.9 mmtm -92.47 150.45 20.77 Favored 'General case' 0 N--CA 1.474 0.747 0 C-N-CA 124.596 1.158 . . . . 0.0 113.124 -174.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.9 t70 -65.25 138.0 57.94 Favored 'General case' 0 CA--C 1.544 0.712 0 C-N-CA 125.49 1.516 . . . . 0.0 112.018 172.343 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 16.6 ptm180 -80.41 8.73 7.02 Favored 'General case' 0 N--CA 1.478 0.971 0 N-CA-C 116.013 1.857 . . . . 0.0 116.013 -173.121 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 35.0 t -132.47 -37.26 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.116 0 C-N-CA 124.954 1.302 . . . . 0.0 111.447 -175.136 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 67.8 p -115.84 -14.17 11.34 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 125.736 1.614 . . . . 0.0 112.641 -175.583 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 69.84 8.2 60.37 Favored Glycine 0 CA--C 1.536 1.391 0 C-N-CA 125.039 1.304 . . . . 0.0 115.483 175.841 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 74.0 mm-40 -80.92 162.82 23.75 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.79 1.236 . . . . 0.0 110.994 176.989 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 6.9 p80 -70.17 153.65 42.86 Favored 'General case' 0 N--CA 1.473 0.7 0 O-C-N 120.883 -1.135 . . . . 0.0 111.866 174.126 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 37.7 mt-30 -98.09 21.88 10.19 Favored 'General case' 0 CA--C 1.547 0.834 0 C-N-CA 124.414 1.086 . . . . 0.0 113.618 -170.332 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 85.77 3.14 86.17 Favored Glycine 0 CA--C 1.535 1.286 0 C-N-CA 124.938 1.256 . . . . 0.0 115.089 179.835 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -141.92 158.93 43.2 Favored 'General case' 0 CA--C 1.54 0.562 0 CA-C-N 118.794 1.297 . . . . 0.0 113.077 177.437 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -154.63 -178.32 28.85 Favored Glycine 0 CA--C 1.53 1.007 0 C-N-CA 125.797 1.665 . . . . 0.0 113.016 -178.616 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -144.34 151.57 39.52 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 125.622 1.569 . . . . 0.0 112.036 -178.265 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 13.6 t -134.34 121.08 35.84 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 C-N-CA 124.796 1.239 . . . . 0.0 110.052 176.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 41.5 tt0 -97.1 118.6 33.88 Favored 'General case' 0 N--CA 1.468 0.439 0 C-N-CA 124.901 1.28 . . . . 0.0 110.705 -178.503 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 -95.54 162.08 13.79 Favored 'General case' 0 C--O 1.234 0.27 0 C-N-CA 125.034 1.334 . . . . 0.0 112.252 176.957 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 12.8 tp -64.31 -33.99 77.11 Favored 'General case' 0 CA--C 1.541 0.628 0 C-N-CA 123.37 0.668 . . . . 0.0 112.369 177.62 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 3.6 m -140.58 154.8 46.63 Favored 'General case' 0 N--CA 1.47 0.556 0 C-N-CA 124.681 1.193 . . . . 0.0 112.495 -177.495 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -65.38 -30.56 71.4 Favored 'General case' 0 CA--C 1.542 0.645 0 C-N-CA 124.693 1.197 . . . . 0.0 112.643 -176.486 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -72.07 -26.33 62.13 Favored 'General case' 0 CA--C 1.542 0.668 0 O-C-N 121.352 -0.843 . . . . 0.0 113.262 175.037 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 61.6 m-20 -75.74 -34.05 60.28 Favored 'General case' 0 N--CA 1.469 0.511 0 O-C-N 121.569 -0.707 . . . . 0.0 111.009 172.86 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -67.51 -45.84 74.63 Favored 'General case' 0 CA--C 1.539 0.546 0 C-N-CA 123.341 0.656 . . . . 0.0 111.227 171.873 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 32.2 t70 -56.67 -36.38 69.5 Favored 'General case' 0 CA--C 1.543 0.697 0 O-C-N 121.259 -0.901 . . . . 0.0 112.772 174.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -69.46 -38.76 77.9 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 123.441 0.697 . . . . 0.0 111.915 174.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.4 -36.83 83.83 Favored 'General case' 0 CA--C 1.538 0.499 0 O-C-N 120.631 -1.293 . . . . 0.0 111.82 176.242 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 55.9 mt -64.33 -32.31 57.07 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 123.85 0.86 . . . . 0.0 110.752 172.738 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 38.7 ttpt -67.02 -47.84 70.21 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 124.228 1.011 . . . . 0.0 112.301 175.217 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 19.3 pt -90.09 -37.24 9.36 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 114.884 1.438 . . . . 0.0 114.884 -172.071 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' MET . . . . . 0.475 ' HA ' HD12 ' A' ' 80' ' ' ILE . 14.3 mmt -92.22 0.43 57.46 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 114.52 1.304 . . . . 0.0 114.52 -170.192 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -83.83 136.97 33.92 Favored 'General case' 0 CA--C 1.54 0.565 0 O-C-N 121.605 -0.684 . . . . 0.0 111.98 178.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 22.8 mtp 58.67 14.07 2.95 Favored 'General case' 0 CA--C 1.546 0.813 0 C-N-CA 126.106 1.763 . . . . 0.0 115.405 -171.487 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.475 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.4 mt -72.25 152.47 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.625 0 C-N-CA 125.197 1.399 . . . . 0.0 110.193 169.195 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.2 mtpt -111.33 69.63 0.69 Allowed 'General case' 0 N--CA 1.473 0.703 0 C-N-CA 124.975 1.31 . . . . 0.0 112.456 -176.11 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 29.1 tp -57.71 124.39 18.96 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 124.05 0.94 . . . . 0.0 110.062 175.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 44.5 m-85 45.62 30.04 0.73 Allowed 'General case' 0 CA--C 1.559 1.314 0 N-CA-C 116.321 1.971 . . . . 0.0 116.321 -169.136 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.73 26.69 55.82 Favored Glycine 0 CA--C 1.542 1.723 0 O-C-N 120.188 -1.57 . . . . 0.0 115.94 175.857 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -137.4 120.94 11.74 Favored Pre-proline 0 CA--C 1.542 0.644 0 C-N-CA 128.222 2.609 . . . . 0.0 107.783 179.603 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -69.92 122.4 9.03 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 122.864 2.376 . . . . 0.0 112.223 -172.142 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 18.2 pt -94.2 146.27 6.88 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 C-N-CA 125.259 1.424 . . . . 0.0 111.264 174.08 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 38.1 mmm-85 -110.43 139.27 45.82 Favored 'General case' 0 N--CA 1.472 0.666 0 C-N-CA 124.699 1.2 . . . . 0.0 110.596 170.054 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 25.7 t -130.2 138.73 53.18 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.777 0 C-N-CA 124.523 1.129 . . . . 0.0 111.035 -175.042 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 41.2 t-20 -159.5 -179.14 7.66 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 126.247 1.819 . . . . 0.0 110.057 178.737 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 12.1 mmmm -58.78 148.23 30.48 Favored 'General case' 0 N--CA 1.476 0.872 0 C-N-CA 124.928 1.291 . . . . 0.0 111.28 170.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -79.02 -24.07 43.91 Favored 'General case' 0 CA--C 1.547 0.861 0 O-C-N 121.893 -0.504 . . . . 0.0 112.034 168.733 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 40.4 p -71.21 -70.15 0.33 Allowed 'General case' 0 N--CA 1.47 0.568 0 C-N-CA 125.691 1.596 . . . . 0.0 111.615 171.349 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . 55.61 -21.51 0.01 OUTLIER 'General case' 0 CA--C 1.553 1.08 0 C-N-CA 130.492 3.517 . . . . 0.0 119.21 172.649 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -78.88 -4.92 52.07 Favored 'General case' 0 N--CA 1.477 0.907 0 C-N-CA 125.078 1.351 . . . . 0.0 113.789 177.009 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 46.0 t30 -131.76 147.66 52.51 Favored 'General case' 0 CA--C 1.545 0.786 0 C-N-CA 126.33 1.852 . . . . 0.0 110.421 173.661 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -74.29 -49.08 24.59 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 125.077 1.351 . . . . 0.0 112.434 -179.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 3.7 p-10 -158.09 158.68 35.19 Favored 'General case' 0 CA--C 1.54 0.588 0 C-N-CA 125.04 1.336 . . . . 0.0 112.347 -179.329 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 10.4 mp -82.19 155.96 24.67 Favored 'General case' 0 CA--C 1.544 0.739 0 C-N-CA 123.985 0.914 . . . . 0.0 109.716 168.627 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 68.4 m -138.54 144.56 39.97 Favored 'General case' 0 N--CA 1.476 0.849 0 C-N-CA 124.795 1.238 . . . . 0.0 112.079 -177.743 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -80.1 173.89 54.99 Favored Glycine 0 CA--C 1.543 1.785 0 C-N-CA 124.39 0.995 . . . . 0.0 114.034 174.366 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 94.8 Cg_endo -69.57 159.83 52.06 Favored 'Trans proline' 0 CA--C 1.542 0.889 0 C-N-CA 123.899 3.066 . . . . 0.0 112.638 176.334 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 29.3 t -148.03 156.34 42.53 Favored 'General case' 0 N--CA 1.472 0.664 0 C-N-CA 125.037 1.335 . . . . 0.0 112.06 178.272 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 8.6 t -78.31 -19.83 52.74 Favored 'General case' 0 CA--C 1.545 0.785 0 C-N-CA 124.702 1.201 . . . . 0.0 112.722 172.216 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.27 0 C-N-CA 125.66 1.6 . . . . 0.0 113.744 178.879 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.564 0 N-CA-C 111.554 -0.619 . . . . 0.0 111.554 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 36.3 m -70.02 155.38 40.68 Favored 'General case' 0 N--CA 1.476 0.866 0 C-N-CA 124.611 1.164 . . . . 0.0 113.213 -179.449 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 73.0 m -71.37 151.36 44.17 Favored 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 123.684 0.794 . . . . 0.0 112.17 174.306 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -153.42 156.71 26.92 Favored Glycine 0 CA--C 1.533 1.199 0 C-N-CA 124.359 0.98 . . . . 0.0 113.553 178.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 82.0 p -143.88 162.71 35.41 Favored 'General case' 0 N--CA 1.472 0.64 0 C-N-CA 126.669 1.988 . . . . 0.0 111.744 -173.268 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 21.9 m -65.74 107.0 1.64 Allowed 'General case' 0 N--CA 1.473 0.685 0 C-N-CA 123.476 0.711 . . . . 0.0 112.604 -179.076 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -82.86 -177.22 51.89 Favored Glycine 0 CA--C 1.542 1.729 0 C-N-CA 125.181 1.372 . . . . 0.0 112.965 169.191 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -65.87 150.99 85.38 Favored 'Trans proline' 0 CA--C 1.54 0.783 0 C-N-CA 123.096 2.531 . . . . 0.0 111.959 173.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 21.5 pt -73.76 152.36 7.24 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.694 0 C-N-CA 123.799 0.84 . . . . 0.0 112.328 178.654 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 77.9 p -112.68 -36.99 5.02 Favored 'General case' 0 N--CA 1.474 0.752 0 C-N-CA 124.221 1.008 . . . . 0.0 113.675 177.065 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -143.14 -21.81 0.63 Allowed 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 115.54 1.682 . . . . 0.0 115.54 -173.29 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 15.6 tpt180 -149.86 170.62 18.36 Favored 'General case' 0 N--CA 1.48 1.026 0 C-N-CA 125.027 1.331 . . . . 0.0 110.873 -172.155 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 8.7 m120 -69.57 70.16 0.29 Allowed 'General case' 0 CA--C 1.545 0.76 0 CA-C-O 122.523 1.154 . . . . 0.0 112.542 172.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 35.8 mt-30 -68.3 -6.52 24.51 Favored 'General case' 0 CA--C 1.545 0.756 0 C-N-CA 126.257 1.823 . . . . 0.0 113.088 177.036 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 14.0 p-10 -79.61 -24.98 41.6 Favored 'General case' 0 CA--C 1.545 0.782 0 C-N-CA 126.997 2.119 . . . . 0.0 112.838 169.201 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -116.77 -1.43 12.07 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 125.863 1.665 . . . . 0.0 113.324 175.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 24.2 m -98.41 134.08 41.91 Favored 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 124.8 1.24 . . . . 0.0 109.779 172.019 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 10.3 m -100.84 148.57 6.87 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 124.595 1.158 . . . . 0.0 110.282 172.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 22.0 t80 -95.4 142.38 27.85 Favored 'General case' 0 C--N 1.328 -0.326 0 C-N-CA 126.542 1.937 . . . . 0.0 109.243 169.505 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 23.4 t -131.45 108.88 15.21 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 C-N-CA 125.778 1.631 . . . . 0.0 109.07 177.172 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -106.19 144.69 15.86 Favored Glycine 0 CA--C 1.529 0.947 0 C-N-CA 124.44 1.019 . . . . 0.0 112.856 178.648 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 97.36 32.79 6.19 Favored Glycine 0 CA--C 1.533 1.205 0 C-N-CA 124.488 1.042 . . . . 0.0 113.936 175.207 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 84.6 mt -73.45 152.52 40.73 Favored 'General case' 0 C--O 1.234 0.269 0 C-N-CA 125.431 1.493 . . . . 0.0 111.352 -175.346 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 28.4 t70 -92.15 157.87 16.49 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 123.842 0.857 . . . . 0.0 112.004 174.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -58.68 -20.94 52.75 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 114.489 1.292 . . . . 0.0 114.489 178.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 60.2 mtpt -76.17 -15.53 60.04 Favored 'General case' 0 N--CA 1.476 0.87 0 N-CA-C 114.222 1.193 . . . . 0.0 114.222 174.201 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 64.8 t -73.85 141.68 15.87 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.905 0 C-N-CA 124.471 1.108 . . . . 0.0 111.763 -177.506 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 95.1 p -136.66 163.09 31.39 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 125.537 1.535 . . . . 0.0 111.851 174.01 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -58.79 -44.61 99.17 Favored Pre-proline 0 CA--C 1.547 0.85 0 O-C-N 120.949 -1.094 . . . . 0.0 113.119 177.352 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 75.9 Cg_exo -59.29 -30.69 93.54 Favored 'Trans proline' 0 C--N 1.355 0.896 0 C-N-CA 122.38 2.053 . . . . 0.0 114.108 172.088 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 21.2 tp -66.67 -53.84 29.56 Favored 'General case' 0 C--N 1.345 0.37 0 CA-C-N 119.076 0.853 . . . . 0.0 109.655 173.919 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 28.0 mt -54.74 -42.33 71.49 Favored 'General case' 0 N--CA 1.466 0.349 0 C-N-CA 122.518 0.327 . . . . 0.0 111.475 -179.221 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 3.0 t90 -57.48 -62.29 1.88 Allowed 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 123.283 0.633 . . . . 0.0 111.173 178.056 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -65.04 -29.5 70.4 Favored 'General case' 0 N--CA 1.471 0.575 0 N-CA-C 113.835 1.05 . . . . 0.0 113.835 -177.272 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 8.5 tp -72.23 -36.22 69.05 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 124.215 1.006 . . . . 0.0 111.96 176.628 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 12.0 m-85 -88.58 -10.43 48.79 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.842 1.257 . . . . 0.0 113.334 -176.51 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 24.2 mt -53.71 -21.72 7.65 Favored 'General case' 0 CA--C 1.546 0.81 0 C-N-CA 124.323 1.049 . . . . 0.0 113.795 168.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 41.4 mt-30 -63.51 -32.11 73.47 Favored 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 125.167 1.387 . . . . 0.0 112.623 174.164 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -78.52 -44.32 24.63 Favored 'General case' 0 CA--C 1.541 0.603 0 C-N-CA 123.218 0.607 . . . . 0.0 112.58 176.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 177.52 -172.47 45.22 Favored Glycine 0 CA--C 1.536 1.391 0 C-N-CA 124.609 1.099 . . . . 0.0 112.851 -179.51 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -67.25 109.29 1.73 Allowed 'Trans proline' 0 CA--C 1.537 0.652 0 C-N-CA 123.722 2.948 . . . . 0.0 111.646 -178.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 72.3 t -84.81 133.33 29.55 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.574 0 C-N-CA 124.805 1.242 . . . . 0.0 109.826 173.584 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 4.5 t -107.71 -34.53 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.645 0 C-N-CA 126.248 1.819 . . . . 0.0 111.761 -172.723 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 17.0 t30 -161.34 164.17 30.25 Favored 'General case' 0 CA--C 1.554 1.104 0 C-N-CA 126.057 1.743 . . . . 0.0 111.357 -174.035 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 4.2 p -141.62 154.42 45.38 Favored 'General case' 0 N--CA 1.48 1.052 0 C-N-CA 126.39 1.876 . . . . 0.0 111.86 176.165 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 3.4 t60 -142.38 135.51 28.66 Favored 'General case' 0 N--CA 1.47 0.558 0 C-N-CA 123.955 0.902 . . . . 0.0 111.179 175.055 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 83.9 mtp -136.52 103.08 9.45 Favored Pre-proline 0 N--CA 1.471 0.585 0 C-N-CA 124.435 1.094 . . . . 0.0 109.433 169.525 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_exo -55.74 130.31 39.75 Favored 'Trans proline' 0 CA--C 1.535 0.572 0 C-N-CA 123.277 2.651 . . . . 0.0 113.639 -179.352 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 45.1 mmtm -96.23 147.9 23.28 Favored 'General case' 0 N--CA 1.472 0.644 0 C-N-CA 125.015 1.326 . . . . 0.0 111.981 -177.762 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -76.82 141.9 40.5 Favored 'General case' 0 CA--C 1.543 0.681 0 C-N-CA 125.338 1.455 . . . . 0.0 112.938 -178.796 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 33.1 ptt-85 -81.34 4.03 22.13 Favored 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 115.686 1.736 . . . . 0.0 115.686 -176.616 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 20.3 t -132.29 -39.61 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.989 0 C-N-CA 125.285 1.434 . . . . 0.0 111.261 -174.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 33.2 p -107.24 -17.26 14.19 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 124.42 1.088 . . . . 0.0 112.523 -178.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 71.1 1.91 44.12 Favored Glycine 0 CA--C 1.539 1.541 0 C-N-CA 124.947 1.26 . . . . 0.0 115.538 178.395 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 67.4 mm-40 -82.1 168.33 17.86 Favored 'General case' 0 CA--C 1.539 0.549 0 C-N-CA 124.911 1.285 . . . . 0.0 110.905 177.324 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 18.3 p80 -67.85 148.74 50.76 Favored 'General case' 0 N--CA 1.473 0.681 0 O-C-N 120.772 -1.205 . . . . 0.0 111.459 171.111 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 86.3 mt-30 -88.31 25.53 1.62 Allowed 'General case' 0 CA--C 1.548 0.874 0 N-CA-C 114.254 1.205 . . . . 0.0 114.254 -174.874 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 86.57 4.54 82.94 Favored Glycine 0 CA--C 1.534 1.259 0 C-N-CA 124.901 1.239 . . . . 0.0 115.253 176.295 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 38.0 p90 -144.52 159.61 42.49 Favored 'General case' 0 CA--C 1.538 0.501 0 CA-C-N 118.686 1.243 . . . . 0.0 112.652 177.527 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -150.82 -175.94 23.26 Favored Glycine 0 CA--C 1.53 0.983 0 C-N-CA 125.943 1.735 . . . . 0.0 113.039 -178.2 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -145.98 150.73 36.58 Favored 'General case' 0 C--O 1.237 0.421 0 C-N-CA 125.894 1.678 . . . . 0.0 111.62 -178.538 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 21.3 t -134.24 126.29 49.17 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.761 0 C-N-CA 124.724 1.21 . . . . 0.0 109.805 176.376 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 49.9 tt0 -101.88 120.59 40.63 Favored 'General case' 0 N--CA 1.467 0.404 0 C-N-CA 124.622 1.169 . . . . 0.0 111.086 -177.363 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 80.4 m-85 -96.9 162.19 13.51 Favored 'General case' 0 C--O 1.233 0.234 0 C-N-CA 124.756 1.223 . . . . 0.0 112.367 177.593 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 12.9 tp -63.4 -34.9 78.75 Favored 'General case' 0 CA--C 1.542 0.662 0 CA-C-N 115.903 -0.59 . . . . 0.0 112.337 176.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 6.6 m -144.17 156.24 44.24 Favored 'General case' 0 N--CA 1.472 0.625 0 CA-C-O 122.587 1.184 . . . . 0.0 112.674 -177.304 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -62.52 -31.98 72.84 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.208 1.403 . . . . 0.0 113.51 -176.236 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -72.05 -27.04 62.44 Favored 'General case' 0 N--CA 1.471 0.618 0 N-CA-C 113.2 0.815 . . . . 0.0 113.2 176.793 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 47.4 m-20 -75.98 -34.51 59.77 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 123.732 0.813 . . . . 0.0 111.077 172.511 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -68.24 -47.12 68.64 Favored 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 123.936 0.894 . . . . 0.0 111.426 172.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 33.1 t70 -57.21 -35.72 69.99 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 124.284 1.034 . . . . 0.0 112.642 175.499 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 54.1 t80 -73.8 -35.15 64.88 Favored 'General case' 0 CA--C 1.536 0.41 0 O-C-N 121.736 -0.603 . . . . 0.0 112.584 175.645 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -65.31 -37.84 88.36 Favored 'General case' 0 CA--C 1.539 0.522 0 O-C-N 121.118 -0.989 . . . . 0.0 111.211 174.483 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 65.0 mt -63.25 -34.28 66.05 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.71 0 C-N-CA 124.404 1.082 . . . . 0.0 110.965 172.377 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 41.5 ttmt -68.43 -44.12 75.66 Favored 'General case' 0 N--CA 1.471 0.611 0 C-N-CA 123.835 0.854 . . . . 0.0 112.636 176.411 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 43.4 pt -91.05 -34.86 6.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.773 0 N-CA-C 115.063 1.505 . . . . 0.0 115.063 -173.644 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' MET . . . . . 0.461 ' HA ' HD12 ' A' ' 80' ' ' ILE . 9.9 mmt -93.51 1.32 56.81 Favored 'General case' 0 N--CA 1.481 1.111 0 N-CA-C 114.834 1.42 . . . . 0.0 114.834 -172.279 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -85.22 137.24 33.12 Favored 'General case' 0 CA--C 1.54 0.565 0 O-C-N 121.614 -0.679 . . . . 0.0 111.927 178.776 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 22.4 mtp 58.92 14.44 3.32 Favored 'General case' 0 CA--C 1.546 0.793 0 C-N-CA 126.111 1.764 . . . . 0.0 115.358 -171.107 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.461 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.2 mt -72.37 153.85 7.6 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 C-N-CA 125.285 1.434 . . . . 0.0 110.053 168.815 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 48.6 mtpt -113.89 70.04 0.72 Allowed 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 125.008 1.323 . . . . 0.0 112.619 -175.46 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 30.1 tp -57.75 124.93 20.85 Favored 'General case' 0 N--CA 1.474 0.751 0 C-N-CA 124.1 0.96 . . . . 0.0 110.135 175.59 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 47.7 m-85 45.45 30.02 0.67 Allowed 'General case' 0 CA--C 1.559 1.322 0 N-CA-C 116.21 1.93 . . . . 0.0 116.21 -169.054 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.02 26.93 57.28 Favored Glycine 0 CA--C 1.542 1.726 0 O-C-N 120.139 -1.601 . . . . 0.0 115.916 176.13 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -136.93 120.43 11.98 Favored Pre-proline 0 CA--C 1.541 0.608 0 C-N-CA 128.264 2.626 . . . . 0.0 107.792 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -69.66 124.2 10.89 Favored 'Trans proline' 0 CA--C 1.537 0.646 0 C-N-CA 122.923 2.415 . . . . 0.0 112.35 -171.802 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 18.1 pt -95.84 145.05 9.03 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 C-N-CA 125.468 1.507 . . . . 0.0 111.404 174.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 37.3 mmm-85 -111.51 138.05 48.54 Favored 'General case' 0 N--CA 1.473 0.682 0 C-N-CA 124.692 1.197 . . . . 0.0 110.75 170.993 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 23.7 t -130.63 137.46 56.05 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 124.376 1.071 . . . . 0.0 111.198 -172.82 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 32.0 t-20 -161.16 -178.89 7.04 Favored 'General case' 0 CA--C 1.548 0.893 0 C-N-CA 126.347 1.859 . . . . 0.0 110.073 177.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 11.8 mmmm -63.77 145.73 55.22 Favored 'General case' 0 N--CA 1.477 0.905 0 O-C-N 120.577 -1.327 . . . . 0.0 111.433 175.211 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -74.33 0.36 14.62 Favored 'General case' 0 CA--C 1.551 1.006 0 N-CA-C 113.58 0.956 . . . . 0.0 113.58 171.568 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 15.3 p -110.13 3.53 20.28 Favored 'General case' 0 N--CA 1.472 0.66 0 C-N-CA 127.618 2.367 . . . . 0.0 113.605 176.288 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -65.96 19.46 0.02 OUTLIER 'General case' 0 CA--C 1.555 1.153 0 N-CA-C 117.105 2.261 . . . . 0.0 117.105 -168.643 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 24.2 m80 -87.59 -10.36 51.73 Favored 'General case' 0 CA--C 1.539 0.535 0 C-N-CA 125.947 1.699 . . . . 0.0 114.517 -170.172 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 27.6 t30 -79.88 126.57 31.17 Favored 'General case' 0 CA--C 1.54 0.586 0 CA-C-N 119.124 0.875 . . . . 0.0 111.075 178.323 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 65.4 pttt -73.33 150.51 41.81 Favored 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 123.696 0.798 . . . . 0.0 112.473 177.937 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 3.6 p-10 -141.44 158.48 43.81 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 124.829 1.251 . . . . 0.0 112.491 -178.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 88.4 mt -81.06 163.07 23.48 Favored 'General case' 0 CA--C 1.541 0.63 0 C-N-CA 124.497 1.119 . . . . 0.0 111.2 169.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 59.1 p -75.23 -21.98 58.22 Favored 'General case' 0 N--CA 1.474 0.77 0 C-N-CA 124.344 1.057 . . . . 0.0 113.774 175.557 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 171.62 175.74 40.15 Favored Glycine 0 CA--C 1.54 1.656 0 C-N-CA 125.305 1.431 . . . . 0.0 113.508 177.348 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_endo -73.05 166.69 29.35 Favored 'Trans proline' 0 CA--C 1.542 0.888 0 C-N-CA 124.18 3.253 . . . . 0.0 112.787 176.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 83.1 p -145.29 170.24 16.69 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 125.049 1.34 . . . . 0.0 112.53 175.567 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 64.7 p -82.28 -1.09 48.35 Favored 'General case' 0 N--CA 1.475 0.778 0 C-N-CA 125.339 1.456 . . . . 0.0 114.65 177.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 1.304 0 C-N-CA 125.677 1.608 . . . . 0.0 114.113 -179.552 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 1.458 0 N-CA-C 111.792 -0.523 . . . . 0.0 111.792 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 38.2 m -72.67 157.76 36.92 Favored 'General case' 0 N--CA 1.475 0.777 0 C-N-CA 124.406 1.082 . . . . 0.0 112.985 176.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' SER . . . . . . . . . . . . . 42.8 p -79.52 -21.9 44.65 Favored 'General case' 0 N--CA 1.475 0.803 0 C-N-CA 125.381 1.472 . . . . 0.0 114.693 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . 81.02 12.08 82.99 Favored Glycine 0 CA--C 1.54 1.612 0 C-N-CA 124.143 0.878 . . . . 0.0 114.362 -169.579 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 59.8 m -61.37 155.62 21.01 Favored 'General case' 0 N--CA 1.476 0.839 0 CA-C-N 118.708 1.254 . . . . 0.0 112.808 175.015 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' SER . . . . . . . . . . . . . 60.7 p -68.42 -23.19 64.6 Favored 'General case' 0 N--CA 1.476 0.861 0 N-CA-C 114.842 1.423 . . . . 0.0 114.842 -174.749 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . 173.22 178.88 43.52 Favored Glycine 0 CA--C 1.539 1.561 0 C-N-CA 124.727 1.156 . . . . 0.0 113.817 174.602 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -61.45 150.11 86.6 Favored 'Trans proline' 0 CA--C 1.539 0.755 0 C-N-CA 123.971 3.114 . . . . 0.0 113.698 177.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ILE . . . . . . . . . . . . . 29.8 pt -84.98 142.34 13.4 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.728 0 C-N-CA 124.266 1.026 . . . . 0.0 112.304 174.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 22.6 m -74.89 -28.65 60.72 Favored 'General case' 0 N--CA 1.475 0.819 0 N-CA-C 113.839 1.051 . . . . 0.0 113.839 -173.606 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -85.15 143.72 28.64 Favored 'General case' 0 N--CA 1.472 0.63 0 C-N-CA 124.254 1.022 . . . . 0.0 111.829 174.181 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 10.4 mmp_? -97.88 123.36 41.82 Favored 'General case' 0 N--CA 1.475 0.821 0 C-N-CA 124.533 1.133 . . . . 0.0 111.342 -173.323 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 75.5 m-20 -102.99 86.65 2.75 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 124.382 1.073 . . . . 0.0 111.92 -172.285 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLN . . . . . . . . . . . . . 57.5 tt0 -61.41 -33.79 74.29 Favored 'General case' 0 N--CA 1.476 0.854 0 O-C-N 121.136 -0.978 . . . . 0.0 112.47 178.568 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 47.5 m-20 -72.34 -12.65 61.22 Favored 'General case' 0 N--CA 1.474 0.77 0 N-CA-C 113.782 1.03 . . . . 0.0 113.782 175.412 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -110.39 11.73 23.21 Favored 'General case' 0 CA--C 1.547 0.841 0 C-N-CA 125.234 1.414 . . . . 0.0 111.654 168.75 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 59.1 m -99.12 133.54 43.26 Favored 'General case' 0 N--CA 1.468 0.444 0 C-N-CA 124.307 1.043 . . . . 0.0 109.431 173.32 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 13.9 m -100.17 146.58 8.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 C-N-CA 124.114 0.966 . . . . 0.0 109.938 170.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' TYR . . . . . . . . . . . . . 12.0 t80 -95.0 142.42 27.5 Favored 'General case' 0 C--N 1.327 -0.382 0 C-N-CA 125.496 1.518 . . . . 0.0 108.53 169.08 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . . . . . . . . . 21.5 t -131.75 106.48 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.505 0 C-N-CA 125.383 1.473 . . . . 0.0 109.063 179.176 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . -102.91 144.56 16.07 Favored Glycine 0 CA--C 1.529 0.943 0 C-N-CA 124.216 0.912 . . . . 0.0 112.593 177.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 97.84 32.03 6.4 Favored Glycine 0 CA--C 1.534 1.23 0 C-N-CA 124.48 1.038 . . . . 0.0 113.863 174.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' LEU . . . . . . . . . . . . . 83.3 mt -73.97 145.27 44.78 Favored 'General case' 0 C--O 1.235 0.294 0 C-N-CA 125.222 1.409 . . . . 0.0 111.203 -175.277 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -84.38 157.3 21.48 Favored 'General case' 0 CA--C 1.542 0.637 0 C-N-CA 123.063 0.545 . . . . 0.0 112.45 174.864 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -58.51 -20.41 45.66 Favored 'General case' 0 CA--C 1.546 0.809 0 N-CA-C 114.591 1.33 . . . . 0.0 114.591 178.766 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 38.4 mtmm -79.7 -12.05 59.82 Favored 'General case' 0 N--CA 1.476 0.853 0 N-CA-C 114.341 1.238 . . . . 0.0 114.341 174.044 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 61.6 t -76.2 142.46 14.37 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.947 0 C-N-CA 124.815 1.246 . . . . 0.0 111.588 178.023 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' SER . . . . . . . . . . . . . 6.3 t -144.24 166.79 24.05 Favored 'General case' 0 N--CA 1.473 0.675 0 C-N-CA 124.067 0.947 . . . . 0.0 111.71 169.061 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 1.6 mt-10 -52.78 -43.01 92.33 Favored Pre-proline 0 CA--C 1.547 0.842 0 N-CA-C 115.495 1.665 . . . . 0.0 115.495 -179.146 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -70.64 -25.12 24.88 Favored 'Trans proline' 0 C--N 1.353 0.792 0 CA-C-N 121.921 1.722 . . . . 0.0 113.024 176.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' LEU . . . . . . . . . . . . . 17.6 tp -65.04 -54.07 35.93 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 109.182 -0.673 . . . . 0.0 109.182 170.159 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . . . . . . . . . 26.5 mt -54.91 -42.73 72.55 Favored 'General case' 0 C--O 1.224 -0.259 0 O-C-N 123.305 0.378 . . . . 0.0 111.316 -178.675 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' TRP . . . . . . . . . . . . . 2.8 t90 -57.64 -62.7 1.6 Allowed 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 123.272 0.629 . . . . 0.0 111.349 178.692 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 -64.44 -30.42 71.46 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 113.857 1.058 . . . . 0.0 113.857 -177.392 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' LEU . . . . . . . . . . . . . 9.0 tp -71.11 -35.27 71.72 Favored 'General case' 0 CA--C 1.542 0.662 0 C-N-CA 124.173 0.989 . . . . 0.0 112.106 176.433 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' PHE . . . . . . . . . . . . . 12.4 m-85 -89.51 -10.77 44.99 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 124.863 1.265 . . . . 0.0 113.361 -176.291 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' LEU . . . . . . . . . . . . . 26.9 mt -53.96 -20.92 6.93 Favored 'General case' 0 N--CA 1.476 0.833 0 N-CA-C 113.92 1.081 . . . . 0.0 113.92 169.172 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' GLN . . . . . . . . . . . . . 45.0 mt-30 -59.54 -40.16 86.34 Favored 'General case' 0 N--CA 1.47 0.544 0 C-N-CA 124.845 1.258 . . . . 0.0 111.89 173.242 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -74.63 -45.45 44.76 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 123.772 0.829 . . . . 0.0 112.899 179.566 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -177.71 -173.09 42.87 Favored Glycine 0 CA--C 1.537 1.44 0 C-N-CA 124.158 0.885 . . . . 0.0 113.595 -177.567 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' PRO . . . . . . . . . . . . . 61.0 Cg_endo -67.66 108.65 1.68 Allowed 'Trans proline' 0 CA--C 1.535 0.565 0 C-N-CA 124.072 3.181 . . . . 0.0 111.505 178.392 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' VAL . . . . . . . . . . . . . 67.3 t -83.99 132.33 31.78 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 C-N-CA 124.195 0.998 . . . . 0.0 109.863 173.579 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 15.6 t -107.05 -35.43 3.06 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.72 0 C-N-CA 126.797 2.039 . . . . 0.0 111.725 -171.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ASN . . . . . . . . . . . . . 14.7 t30 -161.13 157.87 26.64 Favored 'General case' 0 CA--C 1.552 1.029 0 C-N-CA 125.917 1.687 . . . . 0.0 110.777 -171.697 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' THR . . . . . . . . . . . . . 11.1 p -136.82 155.59 49.6 Favored 'General case' 0 N--CA 1.48 1.039 0 C-N-CA 125.844 1.658 . . . . 0.0 111.584 171.834 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 4.1 t60 -141.74 130.36 22.71 Favored 'General case' 0 N--CA 1.466 0.342 0 C-N-CA 124.116 0.967 . . . . 0.0 110.484 177.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' MET . . . . . . . . . . . . . 86.3 mtp -135.54 107.18 10.01 Favored Pre-proline 0 N--CA 1.468 0.451 0 C-N-CA 123.991 0.916 . . . . 0.0 109.292 169.388 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' PRO . . . . . . . . . . . . . 91.9 Cg_exo -55.89 146.18 69.32 Favored 'Trans proline' 0 CA--C 1.539 0.763 0 C-N-CA 123.709 2.939 . . . . 0.0 113.217 173.196 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 21.6 mmtp -121.95 159.77 26.24 Favored 'General case' 0 N--CA 1.478 0.942 0 C-N-CA 125.318 1.447 . . . . 0.0 113.483 -168.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -79.85 152.27 29.78 Favored 'General case' 0 CA--C 1.548 0.867 0 C-N-CA 126.403 1.881 . . . . 0.0 112.066 170.299 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 11.9 ptp85 -92.85 0.18 57.36 Favored 'General case' 0 N--CA 1.478 0.945 0 N-CA-C 116.551 2.056 . . . . 0.0 116.551 -173.07 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 3.3 m -135.29 -31.63 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.22 0 C-N-CA 124.488 1.115 . . . . 0.0 113.456 -178.501 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' THR . . . . . . . . . . . . . 80.7 p -104.96 -20.51 13.52 Favored 'General case' 0 N--CA 1.468 0.445 0 C-N-CA 124.781 1.233 . . . . 0.0 111.65 179.067 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . 69.92 7.71 59.7 Favored Glycine 0 CA--C 1.54 1.607 0 C-N-CA 125.113 1.34 . . . . 0.0 115.262 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' GLN . . . . . . . . . . . . . 58.3 mm-40 -70.11 161.32 30.41 Favored 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 124.682 1.193 . . . . 0.0 111.12 173.787 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' HIS . . . . . . . . . . . . . 25.4 p80 -75.7 158.74 31.93 Favored 'General case' 0 N--CA 1.472 0.636 0 O-C-N 120.997 -1.064 . . . . 0.0 112.765 175.449 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' GLN . . . . . . . . . . . . . 82.2 mt-30 -81.3 12.62 3.43 Favored 'General case' 0 CA--C 1.551 1.008 0 N-CA-C 114.595 1.332 . . . . 0.0 114.595 -174.658 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 88.02 1.48 82.09 Favored Glycine 0 CA--C 1.536 1.362 0 C-N-CA 125.138 1.351 . . . . 0.0 114.941 -178.7 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 41.9 p90 -144.91 160.73 40.85 Favored 'General case' 0 CA--C 1.537 0.48 0 C-N-CA 125.193 1.397 . . . . 0.0 112.138 178.271 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -151.61 -175.03 22.96 Favored Glycine 0 CA--C 1.529 0.942 0 C-N-CA 125.591 1.567 . . . . 0.0 112.918 -179.465 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' PHE . . . . . . . . . . . . . 59.9 m-85 -144.5 151.73 39.56 Favored 'General case' 0 C--O 1.238 0.452 0 C-N-CA 125.573 1.549 . . . . 0.0 111.582 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' VAL . . . . . . . . . . . . . 17.1 t -134.22 125.05 47.21 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 C-N-CA 124.639 1.176 . . . . 0.0 110.073 175.437 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 78.3 tt0 -100.69 124.88 46.91 Favored 'General case' 0 N--CA 1.465 0.304 0 C-N-CA 124.756 1.222 . . . . 0.0 111.298 -178.415 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -98.87 161.42 13.65 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 125.258 1.423 . . . . 0.0 112.274 174.667 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' LEU . . . . . . . . . . . . . 13.5 tp -63.38 -33.53 75.75 Favored 'General case' 0 CA--C 1.541 0.63 0 CA-C-N 116.0 -0.545 . . . . 0.0 112.267 176.742 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' SER . . . . . . . . . . . . . 12.8 m -143.31 154.46 43.81 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 124.467 1.107 . . . . 0.0 112.129 -175.23 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' GLU . . . . . . . . . . . . . 38.4 tt0 -63.69 -35.73 81.52 Favored 'General case' 0 N--CA 1.472 0.628 0 C-N-CA 124.565 1.146 . . . . 0.0 113.215 -176.052 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' GLU . . . . . . . . . . . . . 2.9 pm0 -65.01 -26.12 68.14 Favored 'General case' 0 CA--C 1.541 0.625 0 N-CA-C 113.693 0.997 . . . . 0.0 113.693 174.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ASP . . . . . . . . . . . . . 46.9 m-20 -79.51 -31.9 42.28 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.639 0.776 . . . . 0.0 111.783 173.336 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ALA . . . . . . . . . . . . . . . -69.89 -43.67 71.32 Favored 'General case' 0 CA--C 1.54 0.561 0 C-N-CA 123.203 0.601 . . . . 0.0 111.337 172.274 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -57.71 -34.26 69.27 Favored 'General case' 0 CA--C 1.542 0.654 0 C-N-CA 124.334 1.054 . . . . 0.0 112.583 174.641 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' TYR . . . . . . . . . . . . . 20.2 t80 -71.93 -37.68 69.98 Favored 'General case' 0 CA--C 1.537 0.479 0 O-C-N 121.597 -0.689 . . . . 0.0 111.985 174.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ALA . . . . . . . . . . . . . . . -66.77 -36.12 81.68 Favored 'General case' 0 CA--C 1.537 0.477 0 O-C-N 120.843 -1.161 . . . . 0.0 111.452 176.388 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 74.8 mt -62.88 -34.33 65.43 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.646 0 C-N-CA 124.085 0.954 . . . . 0.0 111.022 171.633 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 63.3 tttp -68.4 -42.67 78.68 Favored 'General case' 0 N--CA 1.471 0.596 0 C-N-CA 124.007 0.923 . . . . 0.0 112.498 176.937 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 18.8 pt -91.78 -39.71 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 N-CA-C 114.771 1.397 . . . . 0.0 114.771 -175.258 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' MET . . . . . 0.482 ' HA ' HD12 ' A' ' 80' ' ' ILE . 15.1 mmt -90.06 1.01 56.82 Favored 'General case' 0 N--CA 1.48 1.051 0 N-CA-C 114.808 1.41 . . . . 0.0 114.808 -169.512 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ASP . . . . . . . . . . . . . 38.8 t70 -86.15 133.65 33.85 Favored 'General case' 0 CA--C 1.537 0.46 0 O-C-N 121.5 -0.75 . . . . 0.0 112.52 -178.301 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' MET . . . . . . . . . . . . . 86.2 mmm 56.79 16.67 2.81 Favored 'General case' 0 CA--C 1.546 0.796 0 C-N-CA 126.482 1.913 . . . . 0.0 114.968 -170.048 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.482 HD12 ' HA ' ' A' ' 77' ' ' MET . 2.0 mt -69.51 150.78 10.2 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 C-N-CA 124.707 1.203 . . . . 0.0 109.534 167.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' LYS . . . . . . . . . . . . . 44.6 mtpt -108.72 70.04 0.73 Allowed 'General case' 0 N--CA 1.471 0.614 0 C-N-CA 124.719 1.207 . . . . 0.0 112.163 -177.241 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' LEU . . . . . . . . . . . . . 30.5 tp -57.48 125.1 21.37 Favored 'General case' 0 CA--C 1.543 0.69 0 C-N-CA 124.104 0.961 . . . . 0.0 109.665 174.222 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 63.6 m-85 46.81 29.44 1.0 Allowed 'General case' 0 CA--C 1.56 1.354 0 N-CA-C 116.253 1.946 . . . . 0.0 116.253 -168.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 78.71 28.31 55.16 Favored Glycine 0 CA--C 1.54 1.631 0 O-C-N 120.224 -1.547 . . . . 0.0 115.689 176.447 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' LYS . . . . . . . . . . . . . 33.9 ttmt -144.06 120.06 6.31 Favored Pre-proline 0 CA--C 1.544 0.74 0 C-N-CA 128.157 2.583 . . . . 0.0 107.853 -174.736 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -71.05 130.16 17.34 Favored 'Trans proline' 0 CA--C 1.537 0.649 0 C-N-CA 122.894 2.396 . . . . 0.0 113.294 -168.741 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ILE . . . . . . . . . . . . . 17.8 pt -102.06 143.91 14.1 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.544 0 C-N-CA 125.623 1.569 . . . . 0.0 111.966 175.828 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' ARG . . . . . . . . . . . . . 46.0 tpt85 -112.58 130.09 56.14 Favored 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.967 1.707 . . . . 0.0 109.738 178.738 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 17.5 t -129.3 132.69 66.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.87 0 C-N-CA 124.342 1.057 . . . . 0.0 112.167 -170.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' ASN . . . . . . . . . . . . . 52.5 p-10 -156.48 -178.85 7.65 Favored 'General case' 0 CA--C 1.548 0.887 0 C-N-CA 126.27 1.828 . . . . 0.0 111.251 174.77 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 11.5 mmmm -67.5 138.83 56.85 Favored 'General case' 0 N--CA 1.478 0.959 0 O-C-N 121.068 -1.02 . . . . 0.0 111.078 178.011 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' ALA . . . . . . . . . . . . . . . -71.92 -5.7 36.57 Favored 'General case' 0 CA--C 1.551 0.994 0 N-CA-C 113.595 0.961 . . . . 0.0 113.595 173.819 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' SER . . . . . . . . . . . . . 84.2 p -115.59 11.78 15.93 Favored 'General case' 0 CA--C 1.545 0.784 0 C-N-CA 126.768 2.027 . . . . 0.0 113.927 175.564 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' ALA . . . . . . . . . . . . . . . -56.2 138.04 50.82 Favored 'General case' 0 CA--C 1.545 0.784 0 N-CA-C 114.493 1.294 . . . . 0.0 114.493 -170.212 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' HIS . . . . . . . . . . . . . 7.9 p80 -157.06 -36.37 0.08 Allowed 'General case' 0 N--CA 1.476 0.865 0 C-N-CA 125.039 1.336 . . . . 0.0 113.601 177.602 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' ASN . . . . . . . . . . . . . 14.5 p-10 -90.57 152.88 20.72 Favored 'General case' 0 CA--C 1.544 0.741 0 C-N-CA 125.591 1.556 . . . . 0.0 113.321 -175.43 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' LYS . . . . . . . . . . . . . 29.8 mtpp -130.48 11.29 5.32 Favored 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 125.699 1.6 . . . . 0.0 113.941 -176.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 13.3 p-10 -73.86 146.26 44.25 Favored 'General case' 0 CA--C 1.544 0.723 0 C-N-CA 125.031 1.332 . . . . 0.0 113.473 -175.511 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' LEU . . . . . . . . . . . . . 59.8 tp -96.89 -43.11 7.62 Favored 'General case' 0 N--CA 1.473 0.709 0 C-N-CA 124.74 1.216 . . . . 0.0 111.794 170.296 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 46.4 m 58.57 179.21 0.07 Allowed 'General case' 0 N--CA 1.477 0.901 0 C-N-CA 126.865 2.066 . . . . 0.0 115.45 177.349 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -170.3 178.91 42.79 Favored Glycine 0 CA--C 1.541 1.703 0 C-N-CA 125.371 1.462 . . . . 0.0 112.906 -178.431 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' PRO . . . . . . . . . . . . . 70.4 Cg_endo -69.02 144.65 58.73 Favored 'Trans proline' 0 CA--C 1.539 0.772 0 C-N-CA 123.682 2.921 . . . . 0.0 112.814 -177.115 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' SER . . . . . . . . . . . . . 64.3 p -83.28 -7.3 59.61 Favored 'General case' 0 N--CA 1.475 0.798 0 C-N-CA 125.052 1.341 . . . . 0.0 114.436 -179.634 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 18.2 m -74.45 -12.74 60.58 Favored 'General case' 0 N--CA 1.475 0.799 0 N-CA-C 114.721 1.378 . . . . 0.0 114.721 -176.791 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.266 0 C-N-CA 125.492 1.52 . . . . 0.0 113.718 -179.779 . . . . . . . . 0 0 . 1 stop_ save_